<SEC-DOCUMENT>0000950170-22-007877.txt : 20220506
<SEC-HEADER>0000950170-22-007877.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505163225
ACCESSION NUMBER:		0000950170-22-007877
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Longboard Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001832168
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				845009619
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40192
		FILM NUMBER:		22896930

	BUSINESS ADDRESS:	
		STREET 1:		4275 EXECUTIVE SQUARE
		STREET 2:		SUITE 950
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		619-592-9775

	MAIL ADDRESS:	
		STREET 1:		4275 EXECUTIVE SQUARE
		STREET 2:		SUITE 950
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lbph-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-05-05T15:43:56.6084+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:lbph="http://www.longboardpharma.com/20220331" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_1f13ee31-05a2-420a-b85b-665c04190587" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_c97da89c-c235-411e-8d1d-ca53c0034968">P1Y</ix:nonNumeric><ix:nonNumeric id="F_5ce25b0a-c8b6-4a6e-9441-b443568f228e" name="dei:CurrentFiscalYearEndDate" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7">--12-31</ix:nonNumeric><ix:nonFraction id="F_5a0988e8-75d5-4bd3-b7bb-e0565dc26350" name="lbph:AccruedTaxes" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ebed43d0-0a92-4d67-8082-ae25c97d4cd4" name="us-gaap:AccruedInsuranceCurrentAndNoncurrent" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_df5dbf7b-b950-49f3-abc4-43f13bddedd6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_bc658670-58ad-420e-91d0-3c0fdd6210c0" name="dei:DocumentFiscalPeriodFocus" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7">Q1</ix:nonNumeric><ix:nonFraction id="F_31aa28bf-c96d-414d-a22e-8d815c9560c0" name="lbph:InitialPublicOfferingCostsInAccruedOtherExpenses" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3e9290f2-0b2a-4695-a7d0-847c4bef8c92" name="lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_c95df60b-4fb8-4cd0-9d53-ee8d8e733b63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_02266e54-4c73-4ddd-a755-5e6bb9805b74">P1Y</ix:nonNumeric><ix:nonFraction id="F_d22cadd7-b2aa-40bc-acf9-36f7dc858eea" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_552e6b6d-c6a6-46a7-bb88-6954cc69799d" name="dei:EntityCentralIndexKey" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"> 0001832168</ix:nonNumeric><ix:nonFraction id="F_6bdb1ba3-dfad-4058-a0be-7b7aed903997" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9231d077-945d-410b-8307-6c7553574eee" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_95ed34e6-5f20-47df-b65f-8340f754d540" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ebc61d5c-536a-481b-9217-70d9a5350593" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_bd9f2f72-a0af-4338-a21a-6b79219310b1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1f0d255a-768e-477d-b6ea-fede3d5836b8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4436940e-61d1-4fc1-835e-8100582ca39f" name="lbph:InitialPublicOfferingCostsInAccountsPayable" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_7367b3af-9865-48bd-99a3-78098bb4ce66" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_1564051c-6da9-4837-b61b-5f6a25fdd6d3" name="dei:AmendmentFlag" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7">false</ix:nonNumeric><ix:nonFraction id="F_447350e3-6678-4d9f-8965-dfcca260ed3b" name="lbph:AccruedRecruitmentFeesCurrent" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lbph-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_2655fe60-4d25-4284-b79f-1967edee3839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdcd3f71-38fa-42e6-9add-cb16918179ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31170f32-a22f-4352-849d-e35afea40908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11b0fef0-018f-4b6f-ab46-c55488de2309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29313d8d-0ffb-41be-8fa7-c20863221e1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e86bcfe1-5eb0-4d7b-989e-1f9935ce49ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0628a4d5-b09e-41bf-a2ee-edcd9f32b55b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0722e749-c954-4ce9-ab39-444c58dc2881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffc4f5e6-0263-492e-ad25-dcc5b98597cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03502668-69d3-4b66-87e8-922d0b9abce4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:RestrictedStockAwardsIssuedButUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dec870ee-6073-4897-923d-80d2a6b03504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02020b7d-b208-4c2c-a733-42569e5d08dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fda728c6-7230-445d-bb2d-a1d2a175a4dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdeeb5db-054e-4a0c-86cf-6ce2edf523ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81e2be07-54b9-4bae-bda9-6422aa68dcac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lbph:NonVotingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a89fc91-d506-45f3-8bba-599c41b01b99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8bb7596-5e83-40a5-bc09-180d4c07bdb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f014e8f-22fe-4b60-8044-d462c1e03e5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_111122f4-280d-463c-9ab4-63bd2975497a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5471e841-ee26-4cc9-9b66-05a2aa664d47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0f2460f-20c4-446c-ac60-5e0355d60e9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c97da89c-c235-411e-8d1d-ca53c0034968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e184fe9-70db-4b51-8f51-e7daee0646e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0898e6aa-40e5-4b23-a631-d1afea0062f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44a745b1-8590-4c56-a3ed-0c09f28a94c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0af9bf0f-83d2-47dd-b34f-f5ff391ab8e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab26e8fc-4dd9-4f09-b2f7-0485e626668f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3089195e-628b-4987-a83b-ebdfac8204f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ca15a2e-29d2-44a0-806a-b15a96250afe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e062ff4-cbda-4e3e-8fa7-05c3aade08b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_549ce4bd-686d-442f-bec8-cff814bcf0e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22339958-3266-42a9-b2a0-2291d1710f50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6986e0f3-27b9-4230-8099-f7546e5d6aec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec438a36-4ab4-4833-ab54-531b4294a419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7d798c6-2583-44f6-b7aa-21e646fcc6e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dac1763-1355-4e75-8a87-b645f330a7a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d514ad7-d0d1-4543-a8ee-033cdb99e31e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lbph:VotingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81a29217-af44-4634-b86a-6f8e9b5cd41f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d30731d9-ffd1-4fb3-a5cb-af59f3e75e1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c8296e4-a716-439c-9900-3c7b633eae24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26a7cd1a-59b8-401c-a12e-bb0756e81c89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_747a9757-4637-484e-8f82-bcf37809bb1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8efd140d-3127-4cdd-8ac9-f08d5e61b9af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a531a6b1-934f-48b8-b028-def438b4f83e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bcd0cd4-3850-4908-83de-d934090eb79e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be132c83-e4b1-424e-8599-c831e7ef8f25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72b0ea79-5b1c-4a38-a65e-54b9a5e8d3fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9cb68ea-1f8f-406a-aac6-ca4b08dfabf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a879bf7-5305-4aed-a15a-0c23a2c40c3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_463e3347-cf52-4239-9f7a-da1011c1a577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16281141-6238-424a-a692-584efe899d06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb620d64-a9b5-4688-82e4-277ff6804f79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_efe47525-2ddf-4af4-b89b-dd45c135f753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5569f3b9-e8d6-4f09-abb0-3e4cf23b60af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ed6747a-4df3-4e56-9206-ca5d99f749b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e96d89c-3510-4a01-bed8-8670aa664af7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08f1e619-22db-4701-aac9-d440535be96c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d24a6fd-40bc-4a7d-b253-daa51fdda1a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd422146-05ed-41df-a129-56bc4396484d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_641c2769-ddbe-423d-9412-3a70a2e24ef9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e77ce52b-d6f2-4eed-8fd9-5a23050d2e60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba57d460-9816-4359-a3ef-f6f9cb97b646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02266e54-4c73-4ddd-a755-5e6bb9805b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43c46d9e-b7fb-42d5-9413-a5ff23430785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36111630-4e04-42da-b57e-0f75ad0cc30a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36a1f79c-d3cd-46af-8004-96e6e76ca20d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f110eb6-6397-4682-9e46-c1939e77c0ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_839615d0-1a34-4d54-ab89-c7fcaed43c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b0cdbe2-b835-49c9-bc65-56f719043e55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4eca72ce-0189-4f47-8a5c-532366ac8a15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_232f4315-8657-4869-b33e-7c126f32a8ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e80a750-d3a7-4459-84c3-c56a5568c616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93010243-3fe5-453c-9416-305b5ced4e85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5abf3b7d-dfe1-4131-b569-1ba2bbc191cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_506976c5-dd13-46a5-8cfa-503cc70a41d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40e8580c-c3e8-4c87-a553-b371d230dd76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f71add10-710e-4bf5-b5f6-4fff7c798c9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eef36757-226e-47ff-beb4-5d13c0c46eab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ce3d74a-3f84-471d-9e5c-04ef7df96e27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-25</xbrli:startDate><xbrli:endDate>2020-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a030be25-78e1-4090-9c78-9f4811f1e055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-03</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaa76b6a-d6e8-4190-83d0-cdcd0bfea44e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f8cf839-c503-41f8-9e31-ce86ee57e5b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf78c477-8c49-4b52-b598-45ec83827cde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6903f08f-6a69-4542-a56f-570e58669425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82778bab-76e7-48f5-8b9e-88f94d43736a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93a82a9b-a4cd-49de-9617-b82cd4e5a356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5a4e72f-cf27-46e2-ab49-3355ed77023e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_317bfead-8157-4725-b85c-7b445e78eecf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20c59b03-2524-402d-b021-af6520d107e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2c10102-6c97-4154-85bb-f3bae871ff64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_151f28bf-56b2-4205-b6b7-87fdd9e3d327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75d9b63f-7f04-4f56-b23d-3c79af44d34c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:RestrictedStockAwardsIssuedButUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_699a037f-4e23-4963-91de-5ec47a942247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68129ee5-d5db-40e7-8ebc-9736893ecaab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dcaf53c-8e87-4231-9cdf-cbd59cbb3dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56ad1eec-83c4-4eb6-9d05-df599a3ebed5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ab315bc-d0fd-45e4-8748-3fffcde6b7bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84dde4dc-9258-407b-9e70-2284d1860ed8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fca0cf8b-0c7e-4480-9275-35cb0b51c5ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c837c3fa-195b-40fa-9996-1c5976eb2157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f191f3e-5732-495f-a6d2-07b3bf590202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bf2e3e8-5766-4a8d-a320-22cfde28e6ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_447a2d48-43c5-47de-9129-d4546af4a637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb752fef-8648-4131-978b-8d72d633b477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Securities"><xbrli:measure>lbph:Securities</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_764e77a5-513a-4fb3-9f05-eb63b1931457" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31a5673b-c7b7-4bf4-84f3-a411f4eac832" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92b391d2-5b75-429c-94d8-57576fab2463" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21f572df-cf4f-4c5c-baf7-ed77fb0fb518" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cc8bdaa-81b0-4762-b67e-ae34d55636bf" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from __________ to ___________</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81d464e5-861c-462f-b86e-96e634727458" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">001-40192</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e24cbf7-be56-48d0-a2f2-6cc4c5e26f89" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf2cb209-02a8-4e26-94af-14b4c7ded830" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6b8df17-af22-4f59-ad2e-e065714d1261" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">84-5009619</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">(I.R.S. Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d08dda9-a3c8-4769-9dc1-324e13fb3a08" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4275 Executive Square</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ccbc9f4-6cf7-4c2c-98bc-d93ea5d28036" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Suite 950</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbd15cb3-3ac8-4146-b668-19bfe4400ce8" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">La Jolla</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_368c9157-a22d-4c9e-91d5-f3eea9534825" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee61252e-1507-4ac4-8ce0-a20b4f4fb49a" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">92037</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7785f77c-6638-4de8-8887-5800fffae3c8" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">619</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d22da009-6a35-456d-b791-43428436fe60" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">592-9775</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3925b4a-da93-4fc1-8f0b-2eff96b65a13" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0aa17aa-aba4-4ed6-a449-c34f5124dea5" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">LBPH</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91a4718e-bab3-4f6d-8f1f-6f8a2e512233" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2dc84b0d-09a9-4903-b83c-da0caab22c87" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a846a6d1-7d64-4a11-adda-c6941991412b" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.296%;"></td>
    <td style="width:0.602%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.5%;"></td>
    <td style="width:0.602%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c08da267-c19b-4c62-8ffc-6cc30f1d06c4" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4359f6fe-b364-4f76-8046-a69578ddcff6" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b83b82e-cdf0-490c-b99f-04c19047595f" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1ffeaab-b4c6-495d-b5fb-67f7aa4a3c2f" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4959a3d3-4500-4334-bf2c-988f7ca8ddfa" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">    No  &#9746;</span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of May 2, 2022, the registrant had </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_87c7f04a-3f98-4288-95d9-428ca13cefe3" contextRef="C_0a879bf7-5305-4aed-a15a-0c23a2c40c3f" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,215,350</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding, comprised of 13,585,950 shares of voting common stock, $0.0001 par value per share, and 3,629,400 shares of non-voting common stock, $0.0001 par value per share.</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.101%;"></td>
    <td style="width:82.816%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#special_note_regarding_forward"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#summary_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY RISK FACTORS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PART I.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#parti_fininfo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#i_item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements (Unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Condensed Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_operations_and_comprehensive"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Condensed Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Condensed Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_unaudited_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Condensed Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_mda"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_qualitativeandquantitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#ii_item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PART II.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#ii_item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#ii_item1a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#ii_item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#ii_item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#ii_item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#ii_item5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#ii_item6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="special_note_regarding_forward"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report on Form 10-Q (this &#x201c;Quarterly Report&#x201d;) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; or the negative of these words or other comparable terminology. These forward-looking statements may include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our plans to research, develop and commercialize our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the initiation, progress, success, cost and timing of our clinical trials and product development activities;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the therapeutic potential of our product candidates, and the disease indications for which we intend to develop our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability and timing to advance our product candidates into, and to successfully initiate, conduct, enroll and complete, clinical trials;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and costs of such manufacture;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the performance of third parties in connection with the development and manufacture of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain funding for our operations, including funding necessary to initiate and complete clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the potential scope, duration and value of our intellectual property rights;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability, and the ability of our licensors, to obtain, maintain, defend and enforce intellectual property rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing the proprietary rights of third parties;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit and retain key personnel;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the effects of the COVID-19 pandemic on our operations; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">other risks and uncertainties, including those described under Part II, Item 1A, &#x201c;Risk Factors&#x201d; of this Quarterly Report.</span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part II, Item 1A, &#x201c;Risk Factors&#x201d; of this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unless the context otherwise indicates, references in this Quarterly Report to the terms, &#34;Longboard&#34;, &#34;the Company&#34;, &#34;we&#34;, &#34;our&#34;, and &#34;us&#34; refer to Longboard Pharmaceuticals, Inc. and references to our &#34;common stock&#34; refers to our voting common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="summary_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY OF RISKS AS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SOCIATED WITH OUR BUSINESS</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part II, Item 1A, &#x201c;Risk Factors&#x201d; in this Quarterly Report. Some of the material risks associated with our business include the following:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Arena was acquired by Pfizer, Inc. on March 11, 2022, and Arena's acquisition may negatively impact our development programs and stock price.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have a very limited operating history, and we have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We will need substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are early in our development efforts and have only one product candidate, LP352, in early clinical development. All of our other product candidates are in the preclinical stage. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Clinical and preclinical drug development involves a lengthy and expensive process with an uncertain outcome. The results of prior clinical trials and early preclinical studies and clinical trials of our product candidates are not necessarily predictive of future results.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The regulatory approval processes of the U.S. Food and Drug Administration (&#34;FDA&#34;) and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Because we have multiple product candidates in our clinical pipeline and are considering a variety of target indications, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we estimate, even assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 has impacted and could continue to adversely impact our business. </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. Our stock market price may be negatively affected if our principal stockholders and management sell some or all of their stock.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We depend on intellectual property licensed from Arena, the termination of which could result in the loss of significant rights, which would harm our business. </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our current or any future product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="parti_fininfo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PART I&#x2014;FINANC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">IAL INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="i_item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Financial Statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Condensed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Balance Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.626%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.079%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.079%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_54b88eea-9695-4ed9-a409-2510855eaa5e" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45452a93-2f1b-47b3-8ee5-cc37aa60d90f" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,346</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ca531450-8dc9-426b-9112-b28744f3704f" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,087</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a095c129-e981-4099-8fd5-8a6a8e68a56f" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b7708e90-3d99-49b8-883c-1300c045ab63" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,035</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ca1e5f66-3e37-4eac-b74c-5493bcf348bb" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,659</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0cd1bf50-4cac-4c30-a133-fdb8e700ceb8" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c33ebbde-7dc5-464c-8ed5-42e89c716523" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b19897a6-7a8d-4272-9d09-ed40ac0ad3b4" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5015901e-82cb-4a14-9cfe-8758528d5662" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fee2ed5c-710e-453f-a371-edd6a0d851f5" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_64d1f666-fcb2-403e-9f35-a4c352ae8a74" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf759891-c4a6-4ba8-938d-9b557b6b3417" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OtherLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03cb9436-7f78-44ef-8a9a-5c96201533cc" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:OtherLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4fd90f8b-934b-4e98-a108-eb3f758073d3" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_40a6fe4f-83dc-44d4-90cc-10265a1a58f0" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,952</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LIABILITIES AND EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a7d712c8-718c-41cf-9676-7441dfd87ba5" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,357</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4e99edcd-9ecf-48d3-8d82-ad737cbf7aa1" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7aec7d4b-565d-41dc-ac90-292daf4fb058" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="lbph:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_646728b5-b62a-4a2e-ad3b-adb3acc9404f" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="lbph:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a0bb330e-2964-4821-a778-84b6c8d8fda3" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">443</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_82f54535-866b-4297-8da8-f05b4157b69b" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued other expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_10c6f502-e8d3-48e1-8c95-6262f730bfc2" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2cb92e02-1a00-4432-8164-5dc470c5ee64" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use liabilities, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f4b2f4e-d9a2-4ae9-a3d4-62e512f9e771" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7a727993-c95b-458a-bc92-5b4e0830397d" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bd01dbe3-e34d-4844-ab70-2bf6b5a119e7" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,684</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7b936457-4d8e-4032-aaf7-477f8aad2c77" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bfaac795-ac19-4000-9d4e-2f3a5bc352ce" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d89d6df-50f6-4b76-8eb0-7cc8e99b0835" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9231d077-945d-410b-8307-6c7553574eee;"><span style="-sec-ix-hidden:F_1f0d255a-768e-477d-b6ea-fede3d5836b8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commitments and contingencies (see Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_18fc72ed-d32e-4606-9a93-ee6ada8ca2ad" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_c5f0a5d2-d952-4805-ac9d-7320db3b6dd2" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; authorized shares - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d29848e9-3ae9-4924-8132-689a440b14ad" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_49ac1a4d-56d0-49cc-b8e7-ebef97be8bfd" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;at March 31, 2022 and December 31, 2021; issued and outstanding shares - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e85b4ce4-e29c-4978-9b46-e2f16dc6f675" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8970246f-96a1-4401-b762-210115414ad5" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4d2f9361-3706-4e31-b876-acf8b86de34d" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0422d049-ee9d-48c5-85f7-df91145c5de1" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;at March 31, 2022 and December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_333a1558-1d50-4161-b02e-20c052064754" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5c404260-139b-4f92-93b3-61a47072b2cb" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Voting common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_812d2b52-94cf-4702-8dae-6546a9caa46a" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_bc0c51ea-0b27-4dc0-8282-7e025aa0f328" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; authorized shares - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_16a05661-6473-48e7-b64c-dc9992736e42" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_67e197ce-a518-4f65-9034-f3173d418857" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;at March 31, 2022 and December 31, 2021; issued and outstanding shares - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_852fb288-4b56-432c-b2fc-e1f05f2e917f" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e8f7625d-5486-4340-82fd-2c68fa862af0" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,484,315</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f594b89-0f75-4e8e-b2b3-ff7c2a267f5e" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e7db14d7-1e23-476b-b324-b0209fbd07f3" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,440,761</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;at March 31, 2022 and December 31, 2021, respectively, excluding </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_152c5055-cd1d-47bb-b652-24cde95b00c5" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">101,635</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fbe75a19-1a9d-4db9-8a6f-f34d7d3c82cb" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">145,189</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively, subject to repurchase</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60a50584-00f1-46d9-91ab-71e35b936e53" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5498c207-b1d2-4b8c-90d8-46e79d096da7" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Non-voting common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e0930587-58a0-422d-9946-1868eb161ddd" contextRef="C_31170f32-a22f-4352-849d-e35afea40908" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_1f885dc3-241c-4fc7-9eb8-1b513cfbd0b6" contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; authorized shares - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bd26ec26-aa85-4ff7-944d-4d2315193484" contextRef="C_31170f32-a22f-4352-849d-e35afea40908" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_20ce6e0c-8f17-459e-9ceb-80c569e0f2ef" contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;at March 31, 2022 and December 31, 2021; issued and outstanding shares - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_afee300c-bac0-4f12-b1cf-5e5893c6035c" contextRef="C_31170f32-a22f-4352-849d-e35afea40908" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_19c24883-fd45-4699-b029-c2c4657bbd99" contextRef="C_31170f32-a22f-4352-849d-e35afea40908" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4a6a8cb0-96ad-4297-8e39-f3d49b25cc72" contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d254ef4f-6d2d-4ca8-a143-cbf0ba48cba6" contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;at March 31, 2022 and December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_22d7620c-4f3a-4993-bec3-e26b8d06d8f2" contextRef="C_31170f32-a22f-4352-849d-e35afea40908" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dd2d0ac8-843d-46c7-aad1-741be0abc3cf" contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_068e9439-cce4-4a7f-b1bc-7959fad7cbd4" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146,254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b83a06a3-770a-45de-a1b1-e62a73211eec" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ab45f0d9-92ed-406b-a049-44e16be563cd" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">596</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_87af739d-f1fd-49d0-8432-193d055293bd" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_72ac5d4b-ce43-42e7-8238-6260ce0e17a5" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dd5ebbd1-63f5-4946-ad23-012063bba7db" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,197</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b500b54e-6bb7-4b25-b4b7-5e9b0462baee" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_11b859a9-a7ec-4e31-8431-05b5f80e90c5" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3d65a4d7-8c68-4955-a79b-49901d0137cf" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf0c7ec9-992c-4c8d-962a-050d3bc7e01e" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,952</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_operations_and_comprehensive"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Condensed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.124%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:16.603%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:17.262%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b9ef8b3e-a970-41ad-a8d8-7ce0773162a4" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fe1e75be-2a30-44f1-bfb7-b55bee66dccc" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,398</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0549a859-6032-4f74-86a0-1e0fcbc40f94" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,499</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6da3711b-a0eb-482f-a30f-5d99bf7c0b87" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bfb6f579-b97d-4eb5-aecf-948e7c2d2b60" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,620</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5f213688-e17c-4a05-ac11-8da0c8baa5e2" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,703</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_67297c67-9e5a-4095-826d-ffa05e6f4edf" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,620</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9594741a-7c26-4f52-ae02-926d8531c2f3" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,703</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_86861c5e-1cff-4182-b2d5-bc60b1c9e67e" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7e58f4b6-34d2-41d4-830b-7ffa131e524e" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9484df02-2ae9-467f-a15d-b378e501c7de" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_251770ba-4452-4318-b91f-5b53657f9d1d" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ab4fe14d-ea4b-4b05-8e55-84f256b3d9a1" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,597</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9dc6f280-c100-429d-ae11-a0ea63f476cc" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af2e83d5-f703-46df-99e7-47b032ee2388" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_19f89f61-2ddb-48e1-9742-605b675e541c" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.84</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_354475f1-5204-4b98-bb67-7ed6d9957512" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">17,086,615</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f326b89e-a411-4c84-ad5b-59ca201cf724" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,810,407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b37d224f-6a51-4b88-9df6-6686910a5c32" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,597</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2aff8e45-e10e-46da-bc20-c6d1c89b3cfb" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized loss on short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_079f94c1-4daf-4d7b-afb7-b5e903f6a0dd" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">432</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_422298b6-1af7-4a55-8526-6c4906896ce5" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f6b2d7e6-ef5e-4c1e-9c3f-b079e6044201" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,029</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aaeb68fd-b57e-43f1-a977-479aa0766f9f" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Condensed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Statements of Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.327%;"></td>
    <td style="width:1.53%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:12.298%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.53%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:12.308%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7f38b5aa-1288-48bb-9287-dc17af2c05fd" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,597</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2ac01ca4-88aa-4393-91ac-1c5c0ad2cc6d" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dd19c030-90f5-4274-ba4d-f1ad2ebe7231" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_38803ebc-8809-4b98-946f-e91937e0e0ff" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Depreciation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_240adac5-28ac-41e7-bfee-b3c23b685423" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortization of premiums on investments, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f9a8882d-b3fd-4596-b9b6-c3d5f0b8443b" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6bdb1ba3-dfad-4058-a0be-7b7aed903997;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_65fc8cd0-8726-4bb7-8da9-55dfd7ea0e4a" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_84e33b54-3745-45ac-8949-c8c4a95cf38c" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da608668-c510-4ccf-a7ae-e431bdd1270c" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_51d730f1-796e-44f9-adfb-8e75a363e938" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">275</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_588304c3-88a0-4445-ae9b-4c5e5c346eaf" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">753</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e8904c46-6a2f-4cb7-8dab-739c810556cb" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">135</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f0611029-6107-43fa-baff-a01b36dfb4af" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:IncreaseDecreaseInAccruedSalaries" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3769833f-01e0-4010-92f6-49d5cb8ffdeb" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:IncreaseDecreaseInAccruedSalaries" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued other expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_496d4a26-f2cc-40cc-a2f3-1ca624e79988" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3182a4cd-2bb3-4bb2-99c5-3e6bda14890b" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">172</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating right-of-use assets and lease liabilities, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_001ca912-2a20-4c5d-8d55-b0f81c4eff4d" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3e9290f2-0b2a-4695-a7d0-847c4bef8c92;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2f468bc6-0e4a-428f-905b-2f807ca15b94" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ff80e552-252f-4336-9d58-b09b09b18321" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,746</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Purchases of short-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6aeed1dd-a7df-4f13-aa50-80a1a805f833" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,284</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_95ed34e6-5f20-47df-b65f-8340f754d540;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_556f1389-8e40-4892-92ec-57600aa215b8" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21,284</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bd9f2f72-a0af-4338-a21a-6b79219310b1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Series A convertible preferred stock financing costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ebc61d5c-536a-481b-9217-70d9a5350593;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_591d29fb-f896-4445-b4de-1949d109f15f" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d22cadd7-b2aa-40bc-acf9-36f7dc858eea;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_02acdbee-4a65-4ab9-8d57-0c9dbde62e49" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Initial public offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7367b3af-9865-48bd-99a3-78098bb4ce66;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a2140983-90f0-446a-aa50-1833ad7056c4" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_df5dbf7b-b950-49f3-abc4-43f13bddedd6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d2c9e4af-bf75-46e6-b64b-c53334b674d8" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,281</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_793e99af-879a-4e32-80c3-1335e16eb19d" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,309</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c57bedab-3fa2-4f28-aba0-1e08254e4f46" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents at the beginning of the period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ff307f55-910a-4b13-af07-ec9423e29c57" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,346</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_58cfccc1-3b9c-4f7b-9c8f-29917cbbfdd1" contextRef="C_f71add10-710e-4bf5-b5f6-4fff7c798c9a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents at the end of the period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5d3cf4b2-3621-4dfb-a7fa-8ed6a9c730f3" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4c27d11e-0f6c-4588-b596-4b1107e0fbe6" contextRef="C_cf78c477-8c49-4b52-b598-45ec83827cde" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Initial public offering costs in accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4436940e-61d1-4fc1-835e-8100582ca39f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d703a96f-77b6-47f8-8b5e-0e26997063f1" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="lbph:InitialPublicOfferingCostsInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Initial public offering costs in accrued other expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_31aa28bf-c96d-414d-a22e-8d815c9560c0;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5d464ea6-72ff-4433-bc8c-eab2badea880" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="lbph:InitialPublicOfferingCostsInAccruedOtherExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_unaudited_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae2de305-fa63-4a5f-aa0b-34954ce802e5" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Organization and Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc. (the &#34;Company&#34;), formerly Arena Neuroscience, Inc., was incorporated in the state of Delaware on January 3, 2020, and is based in San Diego, California. The Company was organized and initially wholly-owned by Arena Pharmaceuticals, Inc. (&#34;Arena&#34;), until the closing of its Series A convertible preferred stock (&#34;Series A Preferred Stock&#34;) financing in October 2020. The Company is a clinical stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The Company&#x2019;s most advanced product candidate, LP352, is being developed for the treatment of seizures associated with developmental and epileptic encephalopathies and is currently in a Phase 1b/2a clinical trial (&#34;the PACIFIC Study&#34;). The Company&#x2019;s preclinical product candidates include LP659 and LP143, which are potential therapies for multiple neurological diseases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On March 16, 2021, the Company completed the initial public offering (&#x201c;IPO&#x201d;) of its common stock. In connection with the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fc3333f2-e5e5-43e7-848d-4377346b6341" contextRef="C_84dde4dc-9258-407b-9e70-2284d1860ed8" name="lbph:NumberOfCommonStockSharesIssuedAndSold" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,298,360</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock, which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d4236b36-becf-4015-a622-5612ef510e08" contextRef="C_84dde4dc-9258-407b-9e70-2284d1860ed8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">298,360</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of its voting common stock issued pursuant to the option granted to the underwriters to purchase additional shares in April 2021, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_64560fe5-8138-47ac-950d-55be13a893eb" contextRef="C_84dde4dc-9258-407b-9e70-2284d1860ed8" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">16.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Company raised $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_978a6fdb-358e-4889-b861-6220da14dc0e" contextRef="C_5471e841-ee26-4cc9-9b66-05a2aa664d47" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">76.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds from the IPO after deducting underwriters&#x2019; discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ef31dd85-aa2b-492e-ab6c-dab2afce1e95" contextRef="C_40e8580c-c3e8-4c87-a553-b371d230dd76" name="us-gaap:CommonStockDiscountOnShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and issuance costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ce1b37d-e95e-4825-969f-47674f04e07f" contextRef="C_5471e841-ee26-4cc9-9b66-05a2aa664d47" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. Unless otherwise noted, all references in the financial statements and related footnotes to the Company's &#34;common stock&#34; refers to the Company's voting common stock.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the closing of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9dfb4f06-6d10-4127-8c8d-d8a83b090713" contextRef="C_eef36757-226e-47ff-beb4-5d13c0c46eab" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,630,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A Preferred Stock were exchanged for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_688c02cd-32a8-4afe-97f9-8ff8302a976c" contextRef="C_81e2be07-54b9-4bae-bda9-6422aa68dcac" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of non-voting common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_555bb312-1ca3-44ec-99eb-32e931ea4665" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,970,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_efddb313-dc17-4ca2-91bc-b6a7f6dbe47f" contextRef="C_8d514ad7-d0d1-4543-a8ee-033cdb99e31e" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,098,600</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock. Following the IPO, there were no shares of Series A Preferred Stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Forward Stock Splits</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b53616e-77d0-47c8-b9eb-4a6c13e534fd" contextRef="C_4ce3d74a-3f84-471d-9e5c-04ef7df96e27" name="us-gaap:StockholdersEquityNoteStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2020, the Company filed an amendment to the Company&#x2019;s certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a4e7ce5f-3470-4531-b325-02ddce415423" contextRef="C_4ce3d74a-3f84-471d-9e5c-04ef7df96e27" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" decimals="0" format="ixt:numdotdecimal">2,783</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-for-1 basis (the &#34;October 2020 Forward Stock Split&#34;). The par value of the common stock was not adjusted as a result of the October 2020 Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the October 2020 Forward Stock Split for the periods presented.</span></ix:nonNumeric></span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bce0d40c-aae4-4f7f-aa7b-fa3aaef58776" contextRef="C_a030be25-78e1-4090-9c78-9f4811f1e055" name="us-gaap:StockholdersEquityNoteStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On March 5, 2021, the Company filed an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_379a9440-4385-4e7b-86fa-0dc68dd87b54" contextRef="C_a030be25-78e1-4090-9c78-9f4811f1e055" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">1.38</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-for-1 basis (the &#34;March 2021 Forward Stock Split&#34;). Adjustments corresponding to the March 2021 Forward Stock Split were made to the ratio at which the Company&#x2019;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March 2021 Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March 2021 Forward Stock Split for all periods presented.</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eaf22d25-1ab5-4b4b-bcc6-8185bed59c61" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and applicable regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, the accompanying unaudited condensed financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The balance sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. The operating results presented in these unaudited condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. The Company&#x2019;s unaudited condensed financial statements should be read in conjunction with the audited financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 3, 2022.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">its inception, the Company has devoted substantially all of its resources to research and development (&#34;R&amp;D&#34;) activities, organizing and staffing, business planning, raising capital, in-licensing intellectual property rights and establishing its intellectual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">property </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">portfolio, and providing general and administrative (&#34;G&amp;A&#34;) support for these operations and has funded its operations primarily with the net proceeds from the issuance of Series A Preferred Stock and common stock. The Company has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b4e9a922-5596-4c28-a510-84ae94022fc0" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">51.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_114970e9-d381-48fe-9da4-759dd17b1f40" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">42.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as of March 31, 2022, and December 31, 2021, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Management expects the Company will incur substantial operating losses for the foreseeable future in order to complete preclinical studies and clinical trials, seek regulatory approval, and launch and commercialize any product candidates for which it receives regulatory approval. The Company will need to raise additional capital through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic continues to evolve and has resulted in a significant disruption of global financial markets. The Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the pandemic. If the disruption persists or deepens, the Company could experience an inability to access additional capital.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, the Company had available cash, cash equivalents and investments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_279cfe80-abad-4b67-9006-7fd82d8d0034" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">96.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and working capital of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_47cd4984-e381-43d2-92bb-08882fa4896e" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="lbph:WorkingCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">93.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million to fund future operations. Management believes that its capital resources as of March 31, 2022, will be sufficient to fund the Company&#x2019;s operations for at least 12 months after the date these unaudited condensed financial statements are issued.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_040c8b52-3484-4cf6-b1ef-551e2147d136" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44f0cf70-5ca0-45ef-b2d6-7bd570d08280" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Estimates are based on the Company&#x2019;s historical experience, knowledge of current events and actions it may undertake in the future, and actual results may materially differ from these estimates and assumptions.</span></p></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb7c8387-d6e9-4c29-b749-c017d3f65c3a" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.</span></p></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ace3a6da-82d3-477b-a59a-52f0c1030b7d" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a38135f-1947-4205-84ae-e4380f73067c" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. government-sponsored enterprises. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99196370-2321-499b-b424-443961d24e17" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="lbph:ShortTermInvestmentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97932192-fe40-4ace-93ea-ad824bcfdbea" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">R&amp;D Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#x2019;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;D expenses amounted to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_efda0a7f-adfa-4993-ab05-86b976461e24" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_470eeeaf-499f-4148-8421-59f81c6fb05f" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, for the three months ended March 31, 2022 and 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be872577-4f6f-4cbf-8def-6893fac7645b" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based awards are measured at fair value and compensation expense is recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.</span></p></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7599dc5-1298-4b35-9023-f554621edc53" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease or contains lease components at inception. Lease terms are determined at the commencement date by considering whether renewal options and termination options, if any, are reasonably assured of exercise. For long-term operating leases, the Company recognizes a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset on its balance sheets and recognizes lease expense on a straight-line basis over the lease term. The lease liability is determined as the present value of future lease payments using the discount rate implicit in the lease or, if the implicit rate is not readily determinable, an estimate of the Company&#x2019;s incremental borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. The Company does not have any financing leases.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8192b82e-2b8e-41b4-8a38-6ead361f339b" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_22b0612f-c852-428a-a64f-36d300c8f763" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;" id="bkmk_278"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.622%;"></td>
          <td style="width:0.664%;"></td>
          <td style="width:17.99%;"></td>
          <td style="width:0.664%;"></td>
          <td style="width:1.74%;"></td>
          <td style="width:0.664%;"></td>
          <td style="width:17.99%;"></td>
          <td style="width:0.664%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cb59130d-bdf9-4cd2-b671-fb89fdb81a8d" contextRef="C_8b0cdbe2-b835-49c9-bc65-56f719043e55" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,350,934</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fb7b44e8-12b5-48c9-868d-1a8c1582e0af" contextRef="C_ec438a36-4ab4-4833-ab54-531b4294a419" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,248,156</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock awards, issued but unvested</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2776f918-e701-4e96-abca-d493f6296138" contextRef="C_03502668-69d3-4b66-87e8-922d0b9abce4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">101,635</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_37395533-6c95-42e8-b025-3c8fd460c9d2" contextRef="C_75d9b63f-7f04-4f56-b23d-3c79af44d34c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">348,450</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8c8c66ac-882b-49d6-904c-dd8088ee5fad" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,452,569</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_55c0c26e-c0b9-4acb-9544-a3552651df8d" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,596,606</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44c01a0c-953d-4b8a-8063-e5dfbda691d3" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2016-13), to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance will become effective for the Company beginning January 1, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on its financial statements.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92dc7851-fd93-4189-b9e9-55554e7cb637" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="lbph:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Potential impacts to the Company&#x2019;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#x2019;s ability to raise capital and conduct business development activities.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7020939b-52f9-487b-bcb5-f7fa48a62eaa" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 3. Fair Value Measurements</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> &#x2014; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> &#x2014; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> &#x2014; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_e7732527-320b-471b-aefa-82ffa360e788" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.14%;"></td>
        <td style="width:3.229%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:11.45%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:3.229%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:10.578%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:3.229%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:10.615%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:3.229%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.128%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements at <br />Reporting Date Using</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets <br />(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Other Observable Inputs <br />(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Unobservable Inputs <br />(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_866a8e51-99cc-4aed-ae49-8977d815185b" contextRef="C_02020b7d-b208-4c2c-a733-42569e5d08dd" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,904</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4da00532-5d4e-4300-8802-2d14e6ca2fbc" contextRef="C_8efd140d-3127-4cdd-8ac9-f08d5e61b9af" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,904</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be73908b-34af-4340-a6f2-9486c6372a37" contextRef="C_82778bab-76e7-48f5-8b9e-88f94d43736a" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a08ebc7d-09b0-450e-8519-93ca59fa70a4" contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1008a247-2fbe-4007-b140-2d34e9d9c96f" contextRef="C_232f4315-8657-4869-b33e-7c126f32a8ca" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ced1e3e5-f0b5-4cea-8e5b-5e436cf1bef8" contextRef="C_72b0ea79-5b1c-4a38-a65e-54b9a5e8d3fc" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e7757150-88b7-4307-b9ce-c11c814c5a0a" contextRef="C_5abf3b7d-dfe1-4131-b569-1ba2bbc191cf" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,456</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bde02af6-dd22-400c-9554-cb23774c6a5b" contextRef="C_747a9757-4637-484e-8f82-bcf37809bb1b" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_647b3ac4-7a4d-4905-bc79-29e8640241f3" contextRef="C_6986e0f3-27b9-4230-8099-f7546e5d6aec" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,456</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_80d19bc3-5417-47c5-a337-d6122843fcd9" contextRef="C_a531a6b1-934f-48b8-b028-def438b4f83e" name="lbph:ShortTermInvestmentsAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,647</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_651de634-280c-4649-a065-2ab237ee76aa" contextRef="C_2ca15a2e-29d2-44a0-806a-b15a96250afe" name="lbph:ShortTermInvestmentsAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,862</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bef0886e-aa68-4c04-9a5c-5ecff1d51e61" contextRef="C_81a29217-af44-4634-b86a-6f8e9b5cd41f" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,785</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d93ce9ac-a31d-4a71-bf03-dff5ebed0a43" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,990</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_efbd2cca-bb5e-4864-81d9-0a0841e24998" contextRef="C_56ad1eec-83c4-4eb6-9d05-df599a3ebed5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_44687d33-dc97-4b68-817e-fb2c0cb62923" contextRef="C_463e3347-cf52-4239-9f7a-da1011c1a577" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6e602020-a127-436d-af2b-f8aba96885e0" contextRef="C_eaa76b6a-d6e8-4190-83d0-cdcd0bfea44e" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_442cc76f-1cab-4971-8f2d-47aa7667e439" contextRef="C_4f191f3e-5732-495f-a6d2-07b3bf590202" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b8114535-89fe-484e-a7c0-0cdfe0759fe6" contextRef="C_6ed6747a-4df3-4e56-9206-ca5d99f749b6" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2a3a747d-ca96-4d13-8eec-44326fff201f" contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4ba8a277-ea6f-479f-ac45-6e03cbb87e33" contextRef="C_0722e749-c954-4ce9-ab39-444c58dc2881" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_080d1432-7bb7-4975-a661-684a96cb657d" contextRef="C_5569f3b9-e8d6-4f09-abb0-3e4cf23b60af" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f5998b3c-e160-4852-a582-afcb5d069b02" contextRef="C_c0f2460f-20c4-446c-ac60-5e0355d60e9d" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ec1b850-c0a1-4a8a-9a1e-8f0782dfafbe" contextRef="C_6903f08f-6a69-4542-a56f-570e58669425" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_904b85a1-a241-4126-96a7-6f96b0ccb746" contextRef="C_b9cb68ea-1f8f-406a-aac6-ca4b08dfabf4" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_608276b2-349c-49a6-8003-d9f9c24f8308" contextRef="C_111122f4-280d-463c-9ab4-63bd2975497a" name="lbph:ShortTermInvestmentsAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ccab7d3e-6c13-47ba-8145-33c7bdb5efb3" contextRef="C_be132c83-e4b1-424e-8599-c831e7ef8f25" name="lbph:ShortTermInvestmentsAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f188f641-5a13-421b-8012-9e383f392b97" contextRef="C_44a745b1-8590-4c56-a3ed-0c09f28a94c7" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,816</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c25c598-527e-4ced-9918-f79085ef2ad3" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4b375f34-9985-4b04-aa93-b32644aaee22" contextRef="C_11b0fef0-018f-4b6f-ab46-c55488de2309" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bac3a538-0ad0-45f6-beca-f697fc1e6e50" contextRef="C_08f1e619-22db-4701-aac9-d440535be96c" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a3ae066d-e30a-4ec8-9543-8cb28b669a96" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4f518dd3-c6b0-4c4e-9245-ffca847042cb" contextRef="C_11b0fef0-018f-4b6f-ab46-c55488de2309" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8b25d242-a2d2-4b0f-b2a8-6d6ebcdec9ee" contextRef="C_08f1e619-22db-4701-aac9-d440535be96c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92c64068-09b5-49e9-b174-88ae6d857822" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 4. Short-Term Investments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_93aec26d-cf42-4196-b21f-d90a907ce136" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes short-term investments:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.427%;"></td>
        <td style="width:3.349%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.02%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:3.349%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.955%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:3.349%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.788%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:3.349%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.011%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3714981f-0b86-413d-9766-8920df8abd57" contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3f540737-c294-4eec-ab44-d92a019381dc" contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_43922153-4b18-4ce5-bb9b-320af9e359f0" contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8ea0ee2f-05f9-4d94-84d2-639cc388c774" contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_716c429b-9531-4528-b774-6f8c95005d70" contextRef="C_5f110eb6-6397-4682-9e46-c1939e77c0ad" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e5d1b940-8457-4775-8cb5-b4d3a7750c36" contextRef="C_5f110eb6-6397-4682-9e46-c1939e77c0ad" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9a2178df-3194-4f69-9a2d-221eb686f3aa" contextRef="C_5f110eb6-6397-4682-9e46-c1939e77c0ad" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2c9f3c83-3569-4cfd-a0c4-d782ccaebc0a" contextRef="C_5f110eb6-6397-4682-9e46-c1939e77c0ad" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,456</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_46fc8c16-6770-4df1-9fde-885d46208f03" contextRef="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c6f1b0d4-8035-45d5-8c24-390787bf1ab7" contextRef="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da4ba7af-de9c-4d1e-8f0b-c69b5dae3739" contextRef="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1634367b-ff1a-4b5e-8cc7-9c846cf320c1" contextRef="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ad963d03-4981-4572-8182-0a2d3e5058e4" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,683</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_091f6217-d8cb-4cfc-b610-4b78fd322d63" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a38810a5-0868-4b20-83e8-034fb8342cbc" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6087c072-942c-4806-8e71-56822aa8431d" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,087</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dac25b9e-6b53-4051-bf08-30b7c200b947" contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6592fff7-07be-45f0-ab5c-7e9943970a74" contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ac11e672-dbb4-4dc5-9f3a-1f759e19d167" contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_924f2733-2a64-44cf-987c-d0a2e7d91c31" contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_72b7a177-d742-4294-be00-3210bb03027c" contextRef="C_2a89fc91-d506-45f3-8bba-599c41b01b99" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_489b5e2b-9e3e-41fe-bda9-ca2f68452a9e" contextRef="C_2a89fc91-d506-45f3-8bba-599c41b01b99" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9d90714e-8cae-4400-81ca-142592468d93" contextRef="C_2a89fc91-d506-45f3-8bba-599c41b01b99" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5638b825-f728-458e-ad85-4374502fefc7" contextRef="C_2a89fc91-d506-45f3-8bba-599c41b01b99" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_27046d40-bc63-48e7-9a8e-c02f2e88ce99" contextRef="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e91416b5-82ec-465f-8225-e2a6d5191cde" contextRef="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9ad230b1-564d-4726-8e50-7e6950687a58" contextRef="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3394edd4-1646-4c3e-b670-f67ddb1260dc" contextRef="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3be5a011-ed63-47bb-81ee-267cdfe50757" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,543</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d23cdea-1698-4250-8d11-d4ce5dc7f984" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6b1fe47f-da02-44aa-91fb-e42cebd54313" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a84adb13-ad78-4014-a0c5-60cc3e7b3e6d" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. As of March 31, 2022, the Company held </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_38c08b2f-519f-4d74-9e2a-61b518e5ba0d" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="lbph:NumberOfSecurities" unitRef="U_Securities" decimals="INF" format="ixt:numdotdecimal">27</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> securities, with an aggregate fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_049847c5-119e-4b6a-bcb9-1bffe67792b4" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, in an unrealized loss position. These securities have not been in a continuous loss position for more than 12 months and there were no individual securities that were in a significant unrealized loss position as of March 31, 2022. The Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_55e92bcb-8a01-4670-a08b-d715015557a8" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the maturities of the Company's short-term investments at March 31, 2022:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.649%;"></td>
        <td style="width:3.385%;"></td>
        <td style="width:12.594%;"></td>
        <td style="width:3.385%;"></td>
        <td style="width:12.594%;"></td>
        <td style="width:3.385%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.619%;"></td>
        <td style="width:0.992%;"></td>
        <td style="width:3.385%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.609%;"></td>
        <td style="width:0.992%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7f5ae626-6e2a-4b03-81d8-acafb0b61b7f" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_43cfd59d-bb15-451f-bee2-f91dff0b2957" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,878</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Due after one year through three years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2c45700b-b793-4bdb-b8a5-457266210471" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="lbph:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,720</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0c39cb58-9ba5-4a25-98ec-fc8a7f69a5fb" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="lbph:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,209</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7638db67-5e77-4e21-8903-284ff8ccf4ee" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,683</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5a975d3f-c71a-4a4a-925e-55e1aaab7af7" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,087</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_859161a9-0aa6-4b36-aff9-c29a05a6fd1e" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 5. Accrued Other Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_36d36dd2-dc55-4571-9eb3-feffeb7af329" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued other expenses consisted of t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">he following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_281">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.945%;"></td>
        <td style="width:1.794%;"></td>
        <td style="width:1.869%;"></td>
        <td style="width:22.617%;"></td>
        <td style="width:0.803%;"></td>
        <td style="width:3.236%;"></td>
        <td style="width:1.869%;"></td>
        <td style="width:22.065%;"></td>
        <td style="width:0.803%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">As of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Insurance premium finance liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7e12c4ad-f47a-4fd8-9499-1663052df9f3" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AccruedInsuranceCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ebed43d0-0a92-4d67-8082-ae25c97d4cd4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued consulting fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f8772cbc-f1d0-4600-ba4c-f23f79554421" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ce8d69b-bb50-4ca3-8064-b6bc81113175" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued legal and accounting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_090ca4ad-2442-44d2-92a1-123783db3760" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="lbph:AccruedLegalAndAccountingFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_89c1fe31-f3c8-49ee-b06b-40138995bd5c" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="lbph:AccruedLegalAndAccountingFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued computer related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5d93b0c8-0752-415d-8513-64ff86292a9b" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="lbph:AccruedComputerRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1a584be2-26da-4427-aecb-c5e12cb9b853" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="lbph:AccruedComputerRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5a0988e8-75d5-4bd3-b7bb-e0565dc26350;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9a857809-7fca-4a1f-ba5b-048f324cb7de" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="lbph:AccruedTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued recruiting fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_447350e3-6678-4d9f-8965-dfcca260ed3b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3db574e9-84b4-4663-935c-b41339bbcb1d" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="lbph:AccruedRecruitmentFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_64337406-e129-40d1-afbd-676fe815fb64" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1060521b-3d0f-4bac-93ff-e85f72b3b531" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b42a31b2-6207-4b57-b55f-b301dcdedd3c" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,536</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_74a38960-e098-4500-9ee4-85e85b1abbd1" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.231%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company entered into a premium finance agreement in March 2022 in connection with the renewal of its annual directors and officers insurance.  The total amount financed is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6a8401a-9864-4032-8e2d-93259025db60" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million which will be paid over nine months. The total finance charge for the premium finance agreement is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_841a70b6-1158-473d-bf3f-828af9f8fad0" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:InterestPayableCurrentAndNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">15,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> which is recorded to interest expense monthly on a straight-line basis.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1efc30c0-6e4c-4c5d-9193-b1468a519dd3" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock" escape="true" continuedAt="F_1efc30c0-6e4c-4c5d-9193-b1468a519dd3_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 6.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#x2019; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the Company amended and restated the Company&#x2019;s certificate of incorporation to, among other things, increase the authorized shares of voting common stock, non-voting common stock and preferred stock to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_12f759bb-e356-4e0f-9756-9a2debfa9ca3" contextRef="C_36a1f79c-d3cd-46af-8004-96e6e76ca20d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_65dddaf3-b459-4e6a-8979-a68a37b4fef9" contextRef="C_fd422146-05ed-41df-a129-56bc4396484d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2b261a46-d960-4382-98f9-678e8faccb47" contextRef="C_cf78c477-8c49-4b52-b598-45ec83827cde" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Common Stock and Non-Voting Common Stock</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ba2c41a0-8d69-4641-a182-c46ed1e3ee0e" contextRef="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,484,315</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock outstanding, excluding </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_04bf6f32-e147-43c6-9322-afc10fdbb26d" contextRef="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">101,635</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares subject to repurchase, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_75ce02b8-f624-4ebc-b597-948806f99578" contextRef="C_31170f32-a22f-4352-849d-e35afea40908" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of non-voting common stock outstanding. As of December 31, 2021, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_87c206cc-72f4-4724-8573-762cc2b7727a" contextRef="C_e2c10102-6c97-4154-85bb-f3bae871ff64" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,440,761</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock outstanding, excluding </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b74e4b7a-90ea-433b-a71e-42683e12cc68" contextRef="C_e2c10102-6c97-4154-85bb-f3bae871ff64" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">145,189</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares subject to repurchase, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_18ff3e81-7cbd-41df-9291-58b391a5de08" contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of non-voting common stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series A Preferred Stock</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0e30ccfe-070d-4424-86df-ff97a685a948" contextRef="C_7f8cf839-c503-41f8-9e31-ce86ee57e5b3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_32017701-be78-4f48-8b32-8194d5f47b0d" contextRef="C_7f8cf839-c503-41f8-9e31-ce86ee57e5b3" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4e5dd951-b870-4e12-8df4-c7e5d85bc312" contextRef="C_8ab315bc-d0fd-45e4-8748-3fffcde6b7bb" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">56.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, including </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ff06a88e-2fc7-4bbd-91db-c09649e8dea7" contextRef="C_8ab315bc-d0fd-45e4-8748-3fffcde6b7bb" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares purchased by Arena. The Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8fe9f287-1d78-4937-9bf2-15e5d8d23a08" contextRef="C_8ab315bc-d0fd-45e4-8748-3fffcde6b7bb" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in issuance costs related to the Series A Preferred Stock financing. On March 16, 2021, immediately prior to the closing of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_62b53b21-115d-4fae-bd63-977a6ebc5ca4" contextRef="C_20c59b03-2524-402d-b021-af6520d107e6" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,630,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Series A Preferred Stock were exchanged for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8c913013-a416-44aa-a218-2cadf58fb614" contextRef="C_317bfead-8157-4725-b85c-7b445e78eecf" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of non-voting common stock. Upon the closing of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_625fde2a-a98e-4348-a564-77510e8e7713" contextRef="C_151f28bf-56b2-4205-b6b7-87fdd9e3d327" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,970,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Series A Preferred Stock were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6701fc21-9213-4565-bd11-267d2bdbaacb" contextRef="C_506976c5-dd13-46a5-8cfa-503cc70a41d0" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,098,600</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock. Following the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4d93f70b-f4d3-41fc-bfa4-87ad8dceb1e5" contextRef="C_ab26e8fc-4dd9-4f09-b2f7-0485e626668f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A Preferred Stock outstanding.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_1efc30c0-6e4c-4c5d-9193-b1468a519dd3_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reconciliation of Changes in Stockholders&#x2019; Equity</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea51d15a-6d65-42f6-ab2b-24b2e343f27f" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following tables document the changes in stockholders' equity for the three months ended March 31, 2022 and 2021 (unaudited):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.225%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.32%;"></td>
        <td style="width:5.937%;"></td>
        <td style="width:0.417%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.64%;"></td>
        <td style="width:4.86%;"></td>
        <td style="width:0.417%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.32%;"></td>
        <td style="width:6.041%;"></td>
        <td style="width:0.32%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.64%;"></td>
        <td style="width:4.957%;"></td>
        <td style="width:0.32%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.32%;"></td>
        <td style="width:6.041%;"></td>
        <td style="width:0.32%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.64%;"></td>
        <td style="width:4.957%;"></td>
        <td style="width:0.32%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.64%;"></td>
        <td style="width:6.5%;"></td>
        <td style="width:0.32%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.64%;"></td>
        <td style="width:7.919%;"></td>
        <td style="width:0.417%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.64%;"></td>
        <td style="width:7.258%;"></td>
        <td style="width:0.417%;"></td>
        <td style="width:0.66%;"></td>
        <td style="width:0.64%;"></td>
        <td style="width:7.919%;"></td>
        <td style="width:0.417%;"></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Non-Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Additional<br />Paid-in<br />Capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Deficit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ee16f5d0-9fd2-444f-b1ed-b5443ed8626b" contextRef="C_16281141-6238-424a-a692-584efe899d06" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_13c72c0e-2701-43a9-b213-5be6180f31d7" contextRef="C_16281141-6238-424a-a692-584efe899d06" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d4a3bdd2-1d7a-4b8c-922f-b390a187a659" contextRef="C_e2c10102-6c97-4154-85bb-f3bae871ff64" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,440,761</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9a094542-9661-45da-8a74-72b3f64e0aa1" contextRef="C_e2c10102-6c97-4154-85bb-f3bae871ff64" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e3cb197f-b2ef-417e-9ea4-3996e99a1f35" contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7bcbd1a5-d5b1-4025-82fc-939c164d6bd0" contextRef="C_ffc4f5e6-0263-492e-ad25-dcc5b98597cc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,683</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1e83144f-1f11-427c-9eb7-d45b7e13fda4" contextRef="C_2d24a6fd-40bc-4a7d-b253-daa51fdda1a9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3d1b383d-9efe-4a00-8342-6241f858b638" contextRef="C_8c8296e4-a716-439c-9900-3c7b633eae24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,197</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_84b8cd24-88f1-4378-87c9-ef57e7101f3c" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Vesting of restricted stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_337be1fe-e735-4f3f-9c82-8c1e9aedf5bd" contextRef="C_549ce4bd-686d-442f-bec8-cff814bcf0e1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">43,554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a579db34-81d4-4d5d-ba5d-46487499678d" contextRef="C_36111630-4e04-42da-b57e-0f75ad0cc30a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">571</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f23ab182-0890-4327-a81b-928b136197ac" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">571</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized loss on short-term investments, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0d85b60c-5708-477e-a805-dcbeba1ac084" contextRef="C_0628a4d5-b09e-41bf-a2ee-edcd9f32b55b" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da6bcbfb-c7ea-4f8e-bd9a-b8a4b4636127" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d389d884-5f23-4e99-84d8-b5fc35d707c0" contextRef="C_699a037f-4e23-4963-91de-5ec47a942247" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0022564a-f560-411c-8215-a4ebe8e8ec79" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8898faa5-4eaf-427b-a424-ba0939d9d4f6" contextRef="C_fca0cf8b-0c7e-4480-9275-35cb0b51c5ea" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_28023d26-b387-4f63-bf1a-a33242194a65" contextRef="C_fca0cf8b-0c7e-4480-9275-35cb0b51c5ea" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_496b10ff-4571-4ddd-b5c0-9345bf9584d5" contextRef="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,484,315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_794329b7-4fc5-44ca-bc4d-8632059e4227" contextRef="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e2602960-1e98-4e6b-83a4-32445147c445" contextRef="C_31170f32-a22f-4352-849d-e35afea40908" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b0ef2fb6-2f56-4447-922e-c4c6066635c3" contextRef="C_2655fe60-4d25-4284-b79f-1967edee3839" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b3510afe-4b8f-4099-9095-e43010c40962" contextRef="C_6bf2e3e8-5766-4a8d-a320-22cfde28e6ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">596</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_57fcee95-4e0a-49e7-a1a7-161e4f584574" contextRef="C_2e062ff4-cbda-4e3e-8fa7-05c3aade08b3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be2ef4cb-2d2d-45b6-be80-d6c36342add8" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,865</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Non-Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Additional<br />Paid-in<br />Capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Deficit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_acec0ae6-09a9-4589-992b-521710d805e1" contextRef="C_0898e6aa-40e5-4b23-a631-d1afea0062f5" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,600,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b443bdbe-91e3-4de9-87a0-ce9dd10d2828" contextRef="C_0898e6aa-40e5-4b23-a631-d1afea0062f5" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,795</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ce05f30d-fbee-4752-bf86-940e9037eeca" contextRef="C_0e184fe9-70db-4b51-8f51-e7daee0646e2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,840,540</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf4e4d28-e011-4d12-97c8-db3cd16e2b68" contextRef="C_0e184fe9-70db-4b51-8f51-e7daee0646e2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6ca107e5-1b7b-49a8-851d-affc8f270b3c" contextRef="C_641c2769-ddbe-423d-9412-3a70a2e24ef9" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bcae0f27-292f-4d72-8020-9e50153f13d2" contextRef="C_6f014e8f-22fe-4b60-8044-d462c1e03e5f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,708</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3711acae-ba55-46e3-ae65-4272d3b6bddf" contextRef="C_b5a4e72f-cf27-46e2-ab49-3355ed77023e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_87596f74-021d-450e-a0cd-9a23993a82f7" contextRef="C_29313d8d-0ffb-41be-8fa7-c20863221e1e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9dd4dfc1-dab5-4548-9ec3-b39f14ee7438" contextRef="C_f71add10-710e-4bf5-b5f6-4fff7c798c9a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,692</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Conversion of Series A convertible preferred stock to common stock in connection with initial public offering</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7a778e1f-4279-43fc-9b48-c444460c0d0f" contextRef="C_26a7cd1a-59b8-401c-a12e-bb0756e81c89" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,600,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b1819a47-30d0-4c80-926b-13e69ac5c654" contextRef="C_26a7cd1a-59b8-401c-a12e-bb0756e81c89" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,795</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f792b01e-8a53-403d-b8f5-b6c2f89f11a7" contextRef="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">4,098,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_662aca3a-c4d8-44e8-aa7a-5fc8df9dc92e" contextRef="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a64e8f7d-b414-4c7f-8fa7-be8520c3c07a" contextRef="C_fb752fef-8648-4131-978b-8d72d633b477" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3f5f0ded-51a9-4d36-8733-8f767be68ec8" contextRef="C_93010243-3fe5-453c-9416-305b5ced4e85" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,795</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fc90ff12-afd2-4cb3-9629-0ddbbdb71321" contextRef="C_fdeeb5db-054e-4a0c-86cf-6ce2edf523ed" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a3749ceb-1b82-4168-aef8-4c122b2ed4f6" contextRef="C_ba57d460-9816-4359-a3ef-f6f9cb97b646" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_238a452d-06a5-4a36-9fce-68db1122acc4" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,795</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock in initial public offering, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dd7597c5-bcad-4e32-a8c9-309bf9289b19" contextRef="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_937703e6-73b1-438d-b856-0ed823b79b5d" contextRef="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_28fc0e10-0cae-4235-b6de-a662d74a6d3c" contextRef="C_93010243-3fe5-453c-9416-305b5ced4e85" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,848</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bc21368e-ee7f-4a9d-af53-c3927127d799" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,849</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1b3dd147-d51d-42ab-a98c-7940eabc3a23" contextRef="C_93010243-3fe5-453c-9416-305b5ced4e85" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c7412a31-11bc-4612-a1ef-0a6a49fe5b8d" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d0ae51cd-0637-40ac-ba74-490046c53be2" contextRef="C_ba57d460-9816-4359-a3ef-f6f9cb97b646" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,699</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0cec09f2-85aa-4d07-af0a-314b10ffaa20" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,699</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_322456e2-3e38-4e2c-afde-a541374993c6" contextRef="C_22339958-3266-42a9-b2a0-2291d1710f50" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0705ef5c-3ee9-41a9-9a03-1b70734adaa4" contextRef="C_22339958-3266-42a9-b2a0-2291d1710f50" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4f146fd3-30be-4baa-bf21-e58105f202d3" contextRef="C_36a1f79c-d3cd-46af-8004-96e6e76ca20d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,939,140</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9a88d479-fcfd-4c23-a6f2-20699dfc29b3" contextRef="C_36a1f79c-d3cd-46af-8004-96e6e76ca20d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_53e1ac2e-295d-4c0a-b35b-e38b0949f134" contextRef="C_fd422146-05ed-41df-a129-56bc4396484d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3a224d88-49d1-40ae-bb13-e270158fcb8b" contextRef="C_c837c3fa-195b-40fa-9996-1c5976eb2157" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">139,684</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cf1c189e-cf1a-4b08-a569-c598b0ade3b2" contextRef="C_efe47525-2ddf-4af4-b89b-dd45c135f753" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_44447a97-f0e7-4889-8949-c6b091d72586" contextRef="C_4eca72ce-0189-4f47-8a5c-532366ac8a15" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_81897685-e309-4ae5-9a6b-af082ec7030d" contextRef="C_cf78c477-8c49-4b52-b598-45ec83827cde" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119,586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_374db6a7-9e0f-4a0e-8bf7-088319e406f5" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 7. Agreements with Arena Pharmaceuticals, Inc.</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company entered into a license agreement (the &#34;License Agreement&#34;), a services agreement (the &#34;Services Agreement&#34;), and a royalty purchase agreement (the &#34;Royalty Purchase Agreement&#34;) in October 2020 with Arena. The Company amended the License Agreement in January 2022 to add an additional program. The following section summarizes these related party agreements.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the License Agreement, the Company obtained an exclusive, royalty bearing, sublicensable, worldwide license under certain know-how and patents of Arena to develop and commercialize LP352 for any use in humans, LP143 for the treatment of any central nervous system (&#34;CNS&#34;) indication in humans (excluding the treatment, prevention or amelioration of pain or any gastrointestinal, non-CNS autoimmune or cardiovascular disorder), and LP659 for the treatment of selected CNS indications in humans (pharmaceutical products containing any such compounds, Licensed Products). As consideration for the rights granted to the Company under the License Agreement, the Company will be required to pay to Arena a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by the Company, its affiliates or its sublicensees, subject to standard reductions. The Company&#x2019;s royalty obligations continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of the (i) tenth anniversary of the first commercial sale of such product in such country or (ii) expiration of the last-to-expire valid claim of the patents licensed by us under the License Agreement covering the manufacture, use or sale of such product in such country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Services Agreement</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the License Agreement, the Company also entered into a Services Agreement with Arena under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for the Company and receive service fees therefore on an hourly rate based on an annual full time equivalent rate agreed upon by the parties. Arena invoices the Company for services provided on a monthly basis, in arrears. The Services Agreement will continue until December 31, 2022, and will automatically renew for successive </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da7a4966-d1bc-49c2-84c6-25948eb16552" contextRef="C_3bcd0cd4-3850-4908-83de-d934090eb79e" name="lbph:RenewOfSuccessiveAgreementTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> terms. Either party may terminate the Services Agreement for any reason, subject to specified notice periods. Payments for services provided under the Services Agreement are recorded to research and development or general and administrative, on the statement of operations, as appropriate. The Company has been decreasing its activities under the Services Agreement, including as a result of its having hired employees or contracted with third parties with the requisite expertise, and the Company is no longer substantially dependent on such services from Arena.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c0b13fa-7d12-4f8c-9d2d-09e76083f59e" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the services expensed under the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Services Agreement:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.758%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:21.074%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:2.467%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:21.083%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7c203997-372d-4009-80c7-3bd57bea928b" contextRef="C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a494b1f1-dbe6-47c4-8885-0c019ce58454" contextRef="C_a8bb7596-5e83-40a5-bc09-180d4c07bdb0" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">246</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_88f99ddf-e5a2-415c-b16a-697a51b75f48" contextRef="C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c19e9cf8-e37e-4cc1-b069-dfd19b8e61a8" contextRef="C_a8bb7596-5e83-40a5-bc09-180d4c07bdb0" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1425ed5a-0443-4e48-8251-cdb25dccba2f" contextRef="C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_535c0dad-0bae-42a4-8257-7c7d2c7d48cc" contextRef="C_a8bb7596-5e83-40a5-bc09-180d4c07bdb0" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c29b9931-244c-4c0f-b2a6-ec540cfc5df3" contextRef="C_d30731d9-ffd1-4fb3-a5cb-af59f3e75e1c" name="us-gaap:AccountsPayableRelatedPartiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0dcbfb68-c4dd-493b-a142-e3a39ffd9732" contextRef="C_fda728c6-7230-445d-bb2d-a1d2a175a4dd" name="us-gaap:AccountsPayableRelatedPartiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">188,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of related party amounts related to the Services Agreement in accounts payable as of March 31, 2022, and December 31, 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty Purchase Agreement</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company entered into a Royalty Purchase Agreement with 356 Royalty Inc., a wholly owned subsidiary of Arena (&#34;356 Royalty&#34;), and Arena, pursuant to which it purchased the right to receive all milestone payments, royalties, interest and other payments relating to net sales of lorcaserin, owed or otherwise payable to 356 Royalty by Eisai Inc. and Eisai Co., Ltd., pursuant to the Transaction Agreement, dated December 28, 2016, as amended, by and among 356 Royalty, Eisai Inc. and Eisai Co., Ltd. The Company made a one-time payment to Arena of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_13f98f58-c264-4a66-bfe2-f5b7580fc594" contextRef="C_3bcd0cd4-3850-4908-83de-d934090eb79e" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expensed this amount to research and development expense on the statement of operations and comprehensive loss as lorcaserin is subject to regulatory approval and there are risks and uncertainties as to whether royalties will ultimately be paid and collected.</span></p></ix:nonNumeric></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b09ffe90-ed76-4352-9a01-8609aaf74083" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 8. Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company&#x2019;s board of directors and stockholders approved the 2020 Equity Incentive Plan (&#34;2020 Plan&#34;), which provided for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, and stock appreciation rights to its employees, members of its board of directors, and consultants. The Company&#x2019;s board of directors determined the exercise price, vesting and expiration period of the grants under the 2020 Plan.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company's board of directors adopted the 2021 Equity Incentive Plan (&#34;2021 Plan&#34;) in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan became effective on March 11, 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_33c97270-89af-4f20-828d-1758150e34a5" contextRef="C_b7d798c6-2583-44f6-b7aa-21e646fcc6e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> additional awards may be granted under the 2020 Plan and all outstanding awards under the 2020 Plan remain subject to the terms of the 2020 Plan. As of March 31, 2022, the 2021 Plan authorizes and provides for the issuance of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4a547012-1cf2-4a74-abe6-00388f047446" contextRef="C_1e80a750-d3a7-4459-84c3-c56a5568c616" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,694,999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which amount will be increased to the extent that awards granted under the 2021 Plan are forfeited, expire or are settled for cash (except as otherwise provided in the 2021 Plan). The number of shares of common stock reserved for issuance under the 2021 Plan automatically increase on January 1 of each calendar year, through January 1, 2031, in an amount equal to (i) 5% of the total number of shares of common stock outstanding on December 31 of the fiscal year before the date of each automatic increase (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock), or (ii) a lesser number of shares determined by the Company&#x2019;s board of directors prior to the applicable January 1. Recipients of stock options are eligible to purchase shares of the Company&#x2019;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2020 and 2021 Plans (or collectively, the &#x201c;Equity Plans&#x201d;) is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee112f45-8957-46bc-ae6e-40b841015819" contextRef="C_93a82a9b-a4cd-49de-9617-b82cd4e5a356" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_905b7d63-93b0-44ab-860b-5630722a3e69" contextRef="C_e77ce52b-d6f2-4eed-8fd9-5a23050d2e60" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and, in general, the options issued under the Equity Plans vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c95df60b-4fb8-4cd0-9d53-ee8d8e733b63;"><span style="-sec-ix-hidden:F_1f13ee31-05a2-420a-b85b-665c04190587;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one </span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a499acb-1e14-47e2-bc5f-4b3f0f100084" contextRef="C_93a82a9b-a4cd-49de-9617-b82cd4e5a356" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_46b4c2b5-d158-4dfd-8b81-38bf746a36f4" contextRef="C_e77ce52b-d6f2-4eed-8fd9-5a23050d2e60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four year</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> period from the vesting commencement date. There are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3f24c5a2-4de3-46bb-85ac-1672b59b589b" contextRef="C_3dcaf53c-8e87-4231-9cdf-cbd59cbb3dca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,344,065</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares available for grant under the 2021 Plan as of March 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Award Grants under the Equity Plans</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad84cba5-e628-48bb-9047-03024fbaf14a" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#x2019;s Equity Plans stock option activity is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.726%;"></td>
        <td style="width:1.075%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:12.302%;"></td>
        <td style="width:0.97%;"></td>
        <td style="width:1.075%;"></td>
        <td style="width:1.444%;"></td>
        <td style="width:11.311%;"></td>
        <td style="width:0.643%;"></td>
        <td style="width:1.075%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:12.239%;"></td>
        <td style="width:0.643%;"></td>
        <td style="width:1.075%;"></td>
        <td style="width:1.444%;"></td>
        <td style="width:9.92%;"></td>
        <td style="width:0.643%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Aggregate Intrinsic Value<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3efd1d03-2767-4521-b6d7-d76f5b06c51f" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,421,756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6fef4f6-b665-4a7d-a3c2-a27850df8de9" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">6.31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_483861e8-79f4-4ff2-82c6-4df574225b9f" contextRef="C_e86bcfe1-5eb0-4d7b-989e-1f9935ce49ac" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b2982688-ed54-43e9-a739-78af3de829a7" contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1708bb3a-7e03-40f5-952a-a67df3eb8390" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">997,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8e516a37-6bf9-4142-abe4-40a48f2a1c52" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1fffa0b0-dcb0-42ef-a1a0-7d725c215f06" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_072504d8-94e1-49d4-86ca-40f952539f6e" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options forfeited/cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ce5651c-4c9b-4b3d-813c-1654f7ed3fa0" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">68,722</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a1f74928-ea54-4369-afab-9d4fc70b3128" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.55</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e2d8b8fc-419a-4290-b253-6efe6dde53f1" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,350,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0682ae12-23f4-4b9d-9697-20ac8c18f77b" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">5.47</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99ff1c3b-8837-4238-b44d-9e6571942322" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9650d453-a650-408f-b151-69dc0f8eae6f" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,493</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Vested and expected to vest at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_db55255f-a372-4a44-8d5b-0e93dbae09c2" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,350,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_67fa2ef7-7ab6-46d8-9933-1dba4323bde0" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.47</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6aae6b14-44c3-4f56-be0d-6e5917f07450" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_098c3132-f4be-49ad-a080-24af1b71386f" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,493</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options exercisable at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d1f22bf4-1b8e-44cb-8cbf-e387649febac" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">686,889</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cc423b82-c1f5-48a5-9e9d-f76e4c588ead" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">4.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7cfea07-3b39-444e-8cec-1cbc67398aa6" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b79adc72-b211-4861-9b88-c79a8195671f" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options exercisable at March 31, 2022 included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fbe4d8cc-6d39-4f4e-8b51-b3f1eff1c341" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">338,439</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> vested stock options and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2de2bc1b-34d9-4190-856e-2a798339a4be" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="lbph:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">348,450</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> stock options that are subject to an early exercise provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb079f0e-f0b4-4632-8900-804a276adad1" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the weighted-average assumptions used for the stock option grants for the three months ended March 31, 2022 and 2021, along with the related grant date fair value:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.077%;"></td>
        <td style="width:1.334%;"></td>
        <td style="width:1.694%;"></td>
        <td style="width:15.232%;"></td>
        <td style="width:2.831%;"></td>
        <td style="width:1.334%;"></td>
        <td style="width:1.694%;"></td>
        <td style="width:15.974%;"></td>
        <td style="width:2.831%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cce89ceb-f280-4d0e-b3c3-4e3121d329ec" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:SharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_73c74836-74c4-49cb-8056-339570262565" contextRef="C_cf78c477-8c49-4b52-b598-45ec83827cde" name="us-gaap:SharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f38cd22f-488a-43b7-8825-f66d968f4461" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.94</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3af66033-f881-44bd-9d0c-128571f1cce0" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6e676bc8-34b1-40b1-9a21-0b3435616ae1" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_340fec6d-602e-465c-ac42-4ca824f5e6b4" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6e8cca87-f024-4f18-b232-6f950a805146" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">75.21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0a40a134-42cc-4927-94ab-286f51f95f48" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">73.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expected life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_416b8bfb-83d5-4137-84dc-9b17b0d3f9df" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db1223d7-2cd8-4659-a598-df12a24cd364" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated grant date fair value per share of award granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7e1a729a-c186-443e-9bf2-809e18944a74" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5e497a9f-e414-4a35-93db-100a843ec684" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Prior to the IPO, there was no public market for the Company's common stock, and therefore, the estimated fair value of common stock for option grants was determined by the Company&#x2019;s board of directors as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third-party valuations of the Company's equity instruments were performed contemporaneously with identified value inflection points. These third-party valuations were performed in accordance with the guidance outlined in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (&#34;Practice Aid&#34;). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the common stock at each valuation date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition to considering the results of these independent third-party valuations, the Company&#x2019;s board of directors considered various objective and subjective factors to determine the fair value of its common stock as of each grant date, including: the prices of the preferred stock sold to or exchanged between outside investors in arm&#x2019;s length transactions and the rights, preferences and privileges of the preferred stock as compared to those of the Company&#x2019;s common stock including liquidation preferences of the Company&#x2019;s preferred stock; the progress of the Company&#x2019;s research and development programs, including the status and results of preclinical and clinical trials for product candidates; the stage of development and material risks related to the Company&#x2019;s business; external market and other conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; the Company&#x2019;s business conditions and projections; the Company&#x2019;s financial position and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#x2019;s common stock and preferred stock; the likelihood of achieving a liquidity event for the Company&#x2019;s securityholders, such as an initial public offering or a sale of the Company in light of prevailing market conditions; the hiring of key personnel and the experience of management; and the analysis of initial public offerings and the market performance of similar companies in the biopharmaceutical industry, as well as trends and developments in the biopharmaceutical industry.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">After the closing of the IPO in March 2021, the Company began utilizing the closing stock price of the common stock on the Nasdaq Global Market as both the exercise price and an input to the Black Scholes option pricing model to determine stock-based compensation expense.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Since the Company is a newly public company and does not have a trading history for its common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">life</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The expected life represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is equal to the contractual term.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Awards</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ea4d584d-9947-4923-8b19-0a23ca2c110d" contextRef="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">348,450</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> restricted stock awards were granted to an employee under the 2020 Plan, which vest over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5b6ddc0-3297-41b8-b59a-7e1bd295c6f9" contextRef="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and had an estimated fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dacefc21-1797-4753-accb-e4dbb550a625" contextRef="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">3.12</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share at the time of grant. As of March 31, 2022, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6f6a874c-0db6-4b74-91b2-65a50c45103d" contextRef="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">101,635</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> restricted stock awards remained to vest.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ded77d37-2ffb-487d-bd23-cc27def93e6b" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.635%;"></td>
        <td style="width:1.694%;"></td>
        <td style="width:20.682%;"></td>
        <td style="width:0.754%;"></td>
        <td style="width:2.366%;"></td>
        <td style="width:1.694%;"></td>
        <td style="width:22.422%;"></td>
        <td style="width:0.754%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ed20ba3d-9ba0-4418-813c-5a9904daaad1" contextRef="C_dec870ee-6073-4897-923d-80d2a6b03504" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fbab596b-c929-4eb4-abce-830c1546bc8e" contextRef="C_3089195e-628b-4987-a83b-ebdfac8204f0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f45e9b2d-035e-454a-b732-b4637a2608aa" contextRef="C_447a2d48-43c5-47de-9129-d4546af4a637" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">443</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_642a03a1-4b73-49d4-bf4a-9188ffbfb69f" contextRef="C_bdcd3f71-38fa-42e6-9add-cb16918179ef" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af17078c-0662-42d9-965d-1265b3ec556e" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">571</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ff2a7d73-f811-4562-be56-fe69c6d94806" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, unrecognized stock-based compensation expense was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5e449c51-7484-4776-a04e-418999898369" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">which is expected to be recognized over a remaining weighted-average period of approximatel</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">y </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_062bcbac-c94b-4462-ac86-6b0db5d392ae" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3.1</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> y</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ears.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company's board of directors adopted the 2021 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) in February 2021, the Company's stockholders approved the ESPP in March 2021 and it became effective on March 11, 2021. As of March 31, 2022, the ESPP authorizes the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8b51ee36-c6f9-434e-9d78-284bec5ef2db" contextRef="C_0af9bf0f-83d2-47dd-b34f-f5ff391ab8e2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">525,492</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under purchase rights granted to our employees. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, through January 1, 2031, by the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d577bc74-1f92-49bd-9979-aefd0051edac" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="lbph:PercentageOfSharesOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on the last day of the fiscal year before the date of the automatic increase (determining on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock); and (ii) such number of shares of common stock that would cause the aggregate number of shares of common stock then reserved for issuance under the ESPP to equal </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45a019a3-5f80-47fb-814a-31b7e446ddae" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,060,017</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares; provided that before the date of any such increase, the Company&#x2019;s board of directors may determine that such increase will be for a lesser amount of shares. The ESPP permits eligible employees, who elect to participate in an offering under the ESPP, to contribute up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9607cd62-dac6-4978-b837-9f35203fed9b" contextRef="C_bb620d64-a9b5-4688-82e4-277ff6804f79" name="lbph:EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of their eligible earnings (as defined in the ESPP) towards the purchase of shares of common stock. Unless otherwise determined by the Company's board of directors, the price at which stock is purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d1da700-9d3a-437b-8ef3-7d94193ef68f" contextRef="C_bb620d64-a9b5-4688-82e4-277ff6804f79" name="lbph:EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the Company&#x2019;s common stock on the commencement date of each offering period or the relevant purchase date, whichever is lower. There are certain service requirements for an employee to be eligible to participate in the ESPP, and no employee may purchase shares under the ESPP at a rate in excess of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e1ba75d-fe08-47c5-bff8-c220c7cf2ea2" contextRef="C_bb620d64-a9b5-4688-82e4-277ff6804f79" name="lbph:EmployeeStockPurchasePlanMaximumSharesPurchasedValue" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> worth of common stock (as determined in accordance with the ESPP). Offering durations under the ESPP may not be longer than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b99abd4-1acb-497b-99e6-813668cd15d9" contextRef="C_bb620d64-a9b5-4688-82e4-277ff6804f79" name="lbph:EmployeeStockPurchasePlanMaximumOfferingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and the Company may specify shorter purchase periods within each offering. The ESPP is considered a compensatory plan as defined by the authoritative guidance for stock-based compensation. As of March 31, 2022, the ESPP had not yet been implemented.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7af99f4e-3ccd-4c12-8679-20e0c0199c51" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 9. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, the Company entered into a lease agreement for office space located at 4275 Executive Square, Suite 950, La Jolla, California 92037 where it occupies </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c77a1416-44be-4013-91c4-f8aa22976270" contextRef="C_68129ee5-d5db-40e7-8ebc-9736893ecaab" name="lbph:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">8,681</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> square feet. The lease became effective </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d372964-aadd-4191-b9a5-a705a57c4f1d" contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8" name="lbph:EffectiveLeaseDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">July 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and continues through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df5818e3-7ba5-4c92-8245-59bf551a8d2c" contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Rent payments are approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da3dc98b-be09-4bfa-8cc4-f60326146e1b" contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8" name="us-gaap:PaymentsForRent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">29,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per month for the first year and increase by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f1d4feab-c51b-4480-ac36-56c2134f4fc4" contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8" name="lbph:PercentageOfIncreaseInRent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% in the second year. A security deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4937ded1-9e61-469a-b734-ba494e74ba47" contextRef="C_68129ee5-d5db-40e7-8ebc-9736893ecaab" name="us-gaap:SecurityDeposit" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">33,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> was paid in June 2021 and is classified as a long-term asset on the unaudited condensed balance sheets.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Previously, the Company leased certain office space in San Diego, California under a month to month lease. Rent payments were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_66e809fc-8701-4dba-b13c-e28239fa8ee2" contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8" name="lbph:PaymentsForRentHistorical" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per month.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Rent expense totaled approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a14eeef3-c770-4227-8025-9b8676de3f0f" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:OperatingLeasesRentExpenseNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">95,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f324392-782b-4fec-9469-8681d7084e17" contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687" name="us-gaap:OperatingLeasesRentExpenseNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> for the three months ended March 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eaff28f4-ed5e-4135-9c09-ca676196a3b4" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The below table provides supplemental cash flow information related to leases as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.267%;"></td>
        <td style="width:71.243%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:22.681%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4091559a-0d56-4f3a-a8fc-5b3435ff3c7f" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_e29a1c82-06d4-4f69-84cf-ad064872f351" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.341%;"></td>
        <td style="width:72.375%;"></td>
        <td style="width:1.364%;"></td>
        <td style="width:19.898%;"></td>
        <td style="width:2.022%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3c75ab7e-8d0b-4ada-a04d-911b830540ef" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a1fdda6d-2492-4d93-816e-18cd68c77905" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">350</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_98fa058b-3dd1-409c-9962-5d7b876f1610" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c1c2c788-a443-481c-85c2-6408c95d0983" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">444</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66c6591e-8b3b-4d9e-85bb-45114997d4cd" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.25</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_78422ae4-1244-4124-8c7a-f3f919636dfd" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03e7f79a-60cc-4690-b1e1-f061d6a23b54" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease commitments are as follows as of March 31, 2022 (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.267%;"></td>
        <td style="width:71.227%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:22.503%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7928755f-bad2-493c-85b9-eb75de614e42" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">279</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b66f57a0-1273-48e4-85d4-3f9f95ca7de1" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ca32786f-5e6a-4ede-8638-e2a231c1118c" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">468</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7c2f16c3-db1c-4a2d-b31b-7854bd724941" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2581b4aa-6dcc-4732-8b57-dc78cd0a9875" contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">444</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of March 31, 2022, and December 31, 2021, the Company is not a party to any litigation.</span></p></ix:nonNumeric></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3414b415-cb19-4330-ba0e-52bf253987d8" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:PostemploymentBenefitsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 10. Employment Benefits</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Effective in June 2021, the Company established a 401(k) salary deferral plan for its employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company provides a safe harbor contribution of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5241b343-336c-4983-a119-98f739c78685" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the employee's compensation, not to exceed eligible limits, and subject to employee participation. For the three months ended March 31, 2022, the Company incurred approximatel</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">y $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_50278741-d3b4-4763-8fe3-00ff6a071523" contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> in expenses related to the safe harbor contribution.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="i_item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Management&#x2019;s Discuss</span><span id="item_2_mda"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ion and Analysis of Financial Condition and Results of Operations</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes included in the our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (&#34;SEC&#34;) on March 3, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Quarterly Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#x201c;Risk Factors&#x201d; section of this Quarterly Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. We were formed in January 2020 by Arena Pharmaceuticals, Inc. (&#34;Arena&#34;) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (&#34;GPCRs&#34;). Our small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Our pipeline includes:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LP352, an oral, centrally acting, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5-hydroxytryptamine 2c receptor subtype</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (&#x201c;5-HT2c&#x201d;) superagonist, currently in a Phase 1b/2a clinical trial (&#34;the PACIFIC Study&#34;) for the treatment of seizures associated with </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">developmental and epileptic encephalopathies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (&#x201c;DEEs&#x201d;), which may include Dravet syndrome, Lennox-Gastaut syndrome (&#34;LGS&#34;), tuberous sclerosis complex (&#34;TSC&#34;), and CDKL5 deficiency disorder, among others; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LP659, a centrally acting, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">sphingosine-1-phosphate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(&#x201c;S1P&#x201d;) receptor subtypes 1 and 5 (&#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">S1P1,5&#x201d;) receptor modulator in preclinical studies for multiple neurological diseases, for which we anticipate submitting an </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">investigational new drug application</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (&#x201c;IND&#x201d;) to the FDA in the fourth quarter of 2022; and </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LP143,  a centrally acting, full </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">cannabinoid type 2 receptor</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (&#x201c;CB2&#x201d;) agonist in preclinical studies for CNS diseases and disorders.</span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, we entered into a License Agreement with Arena (the &#34;Arena License Agreement&#34;), pursuant to which Arena granted us an exclusive, royalty bearing, sublicensable, worldwide license to develop and commercialize LP352, LP659, LP143 and certain 5-HT2a compounds (pharmaceutical products containing any such compounds, the &#34;Licensed Products&#34;). In January 2022, we amended the Arena License Agreement to add an additional program.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table provides an overview of the current product candidates we are focusing on:</span><img src="img8591006_0.jpg" alt="img8591006_0.jpg" style="width:718px;height:281px;" /></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:11.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">* We hold rights to our product candidates through the Arena License Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:11.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">We are also eligible to receive royalties of 9.5% to 18.5% on sales of lorcaserin if approved for commercialization through the Royalty Purchase Agreement.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in January 2020. Since our inception, we have devoted substantially all of our resources to research and development activities, organizing and staffing our company, business planning, raising capital, in-licensing intellectual property rights and establishing our intellectual property portfolio, and providing general and administrative support for these operations. We have principally financed our operations to date through the private placement of convertible preferred stock and the completion of our initial public offering (the &#34;IPO&#34;) of our common stock in March 2021. To date, we have raised gross proceeds of approximately $56.0 million from the issuance of our convertible preferred stock and $84.8 million from our IPO. As of March 31, 2022, we had cash, cash equivalents and short-term investments of $96.1 million.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have incurred net losses since our inception. Our net losses were $9.6 million and $5.7 million for the three months ended March 31, 2022 and 2021. As of March 31, 2022, we had an accumulated deficit of $51.8 million. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and preclinical studies and our expenditures on other research and development activities. We expect that our expenses and operating losses will increase substantially as product candidates advance through preclinical studies and clinical trials, and as we expand our clinical, regulatory, quality and manufacturing capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and distribution, if we obtain marketing approval for any of our product candidates, and incur additional costs associated with operating as a public company. We expect that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operations for at least the next 12 months. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We base our estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more product candidates, which will not be for many years, if ever. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, reduce or terminate our research and development programs or other operations, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The global COVID-19 pandemic continues to evolve. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials. Specifically, the initiation of the multiple-ascending dose (&#34;MAD&#34;) portion of the Phase 1 clinical trial of LP352 was delayed, in part, as a result of the impact of the COVID-19 pandemic on the clinical site in the United Kingdom that conducted the single-ascending dose (&#34;SAD&#34;) portion of the Phase 1 clinical trial for LP352, and subsequently we modified the protocol and relocated the MAD portion of such trial to a new clinical site in the United States. We completed the MAD portion of the Phase 1 clinical trial of LP352 in September 2021. The extent of the impact of COVID-19 on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our development activities, planned clinical trial enrollment, future trial sites, contract research organizations (&#34;CROs&#34;), third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and work locations. We will continue to actively monitor the evolving situation related to COVID-19 and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which the COVID-19 pandemic may affect our business, operations and development timelines and plans, including the resulting impact on our expenditures and capital needs, remains uncertain.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Agreements with Arena</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Below is a summary of the key terms for our license and other agreements with Arena. On March 11, 2022, Pfizer announced it completed its acquisition of Arena, and Arena became a wholly-owned subsidiary of Pfizer.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, we entered into the Arena License Agreement, pursuant to which we obtained an exclusive, worldwide license of certain intellectual property for the Licensed Products. In January 2022, we amended the Arena License Agreement to add an additional program. The Arena License Agreement imposes various development, regulatory and/or commercial diligence obligations, payment of royalties, including a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by our company, its affiliates or its sublicensees, subject to standard reductions, and other obligations.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty Purchase Agreement</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, we entered into a Royalty Purchase Agreement with Arena and 356 Royalty Inc., a wholly owned subsidiary of Arena (&#34;356 Royalty&#34;), pursuant to which we purchased the right to receive all milestone payments, royalties, interest and other payments relating to net sales of lorcaserin, in all countries and territories of the world owed or otherwise payable to 356 Royalty by Eisai Inc. and Eisai Co., Ltd., pursuant to a Transaction Agreement dated December 28, 2016, as amended, by and among 356 Royalty and Eisai Inc. and Eisai Co., Ltd., for an upfront payment of $0.1 million. Lorcaserin is currently in a Phase 3 clinical trial for Dravet syndrome.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Services Agreement</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, we entered into the Services Agreement under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for us and receive service fees therefore on an hourly rate based on an annual full time equivalent rate agreed upon by the parties. We have been decreasing our activities under the Services Agreement, including as a result of our having hired employees or contracted with third parties with the requisite expertise, and we are no longer substantially dependent on such services from Arena.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Components of Our Results of Operations</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;" id="bkmk_127"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the preclinical and clinical development of our product candidates.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Direct costs include:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">external research and development expenses incurred under agreements with CROs, investigative sites, consultants and other third parties to conduct our preclinical studies and clinical trials; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">costs related to manufacturing our product candidates for preclinical studies and clinical trials, including fees paid to third-party manufacturers.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indirect costs include:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">personnel-related costs, which include salaries, payroll taxes, employee benefits, and other employee-related costs, including stock-based compensation, for personnel engaged in research and development functions; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">facilities and other various expenses.</span></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific or stage of program basis because these costs are deployed across multiple programs and, as such, are not separately classified.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_128"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect that our research and development expenses will increase substantially for the foreseeable future as we continue the development of our product candidates, particularly as product candidates in later stages of development generally have higher development costs than those in earlier stages of development. We cannot determine with certainty the timing of initiation, the duration or the completion costs of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> future clinical trials and preclinical studies of our product candidates due to the inherently unpredictable nature of clinical and preclinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that we will make determinations as to which product candidates and development programs to pursue and how much funding to direct to each product candidate or program on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#x2019;s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements may occur, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses may vary significantly based on a variety of factors, such as:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the scope, rate of progress, expense and results of our preclinical development activities; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the phase of development of our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">per patient clinical trial costs; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the number of clinical trials required for approval;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the number of sites included in our ongoing and planned clinical trials;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the number of patients that participate in our ongoing and planned clinical trials;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the countries in which our clinical trials are conducted; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates, particularly in light of the current COVID-19 pandemic environment; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the duration of patient participation in our ongoing and planned clinical trials and follow-up;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile of our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">significant and changing government regulation and regulatory guidance;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">potential additional trials requested by regulatory agencies;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of manufacturing our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we establish additional strategic collaborations or other arrangements;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the impact of any business interruptions to our operations or to those of the third parties with whom we work, particularly in light of the current COVID-19 pandemic environment; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.</span></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, which include salaries, payroll taxes, employee benefits, and other employee-related costs, including stock-based compensation, for personnel in executive, finance and other administrative functions. Other significant costs include legal fees relating to corporate matters, professional fees for accounting and consulting services and facility-related costs.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect that our ongoing general and administrative expenses will increase modestly for the foreseeable future to support our increased research and development activities and increased costs of operating as a public company and in building our internal resources. These increased costs will include increased expenses related to audit and legal services associated with maintaining compliance with exchange listing and SEC requirements, prosecuting and maintaining our patent portfolio, and investor and public relations activities associated with operating as a public company.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the three months ended March 31, 2022 and 2021:</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_130"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.147%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:18.329%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:2.189%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:18.329%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7,121</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,398</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,499</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,305</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,620</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,703</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(9,620</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(5,703</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(9,597</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(5,699</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;" id="bkmk_131"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses for the three months ended March 31, 2022 and 2021:</span></p>
  <p style="margin-left:6.8%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.963%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:16.713%;"></td>
    <td style="width:0.603%;"></td>
    <td style="width:1.994%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:16.713%;"></td>
    <td style="width:0.603%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Direct costs:</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LP352</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,542</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,508</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Preclinical programs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,547</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,110</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indirect costs:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Personnel-related</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,763</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">646</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">All other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">269</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">134</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7,121</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,398</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $7.1 million for the three months ended March 31, 2022, an increase of $2.7 million, or 62%, compared to $4.4 million for the three months ended March 31, 2021. The net increase of $2.7 million is primarily related to an increase of $2.0 million in clinical trial and preclinical expenses related to LP352 and an increase of $1.1 million in personnel-related expenses, offset by a decrease of $0.6 million in preclinical expenses related to LP659 and LP143.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $2.5 million for the three months ended March 31, 2022, an increase of $1.2 million, or 92%, compared to $1.3 million for the three months ended March 31, 2021. The net increase of $1.2 million is primarily related to an increase of $0.6 million in personnel-related costs, $0.4 million in insurance expense, $0.1 million in professional services and consulting expenses, and $0.1 million in rent expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.311%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have funded our operations primarily through the sale and issuance of common stock and convertible preferred stock. In October 2020, we completed a $56.0 million private placement of our Series A convertible preferred stock. In connection with our IPO in March 2021, we issued and sold 5,298,360 shares of common stock, which included 298,360 shares of our common stock issued pursuant to the over-allotment option granted to the underwriters to purchase additional shares of common stock, at a public offering price of $16.00 per share. We raised $76.2 million in net proceeds from the IPO after deducting underwriters&#x2019; discounts and commissions of $5.9 million and issuance costs of $2.6 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.311%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.311%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, we had cash, cash equivalents and short-term investments of $96.1 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.311%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Material Cash Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.311%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.311%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.311%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.311%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operations for at least the next 12 months. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based our estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the type, number, scope, progress, expansions, results, costs and timing of, our preclinical studies and clinical trials for our current and any future product candidates and the potential indications which we are pursuing or may choose to pursue in the future;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and costs of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of manufacturing for our product candidates, including commercial manufacturing;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> the costs of obtaining, expanding, maintaining and enforcing our patent and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of establishing or securing sales and marketing and distribution capabilities, whether alone or with third parties, to commercialize product candidates for which we may obtain regulatory approval, if any;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the timing and amount of the payments we are obligated to make under the Arena License Agreement;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third- party payors and adequate market share and revenue for any approved products;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">patients&#x2019; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">costs associated with any product candidates, products or technologies that we may in-license or acquire; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">if we experience any delays or encounter any issues with any of the above, including the risk of each of which may be exacerbated by the ongoing COVID-19 pandemic.</span></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any product candidate for which we may obtain marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for at least several years, if ever. As a result, we will need substantial additional financing to support our continuing operations and further the development of and commercialize our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic and otherwise. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams or research programs or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_136"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth a summary of our cash flows for the three months ended March 31, 2022 and 2021:</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.26%;"></td>
    <td style="width:1.929%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:15.937%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.929%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:15.937%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(10,025</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(7,746</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(21,284</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">73,281</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(31,309</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">65,535</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities was $10.0 million and $7.7 million for the three months ended March 31, 2022 and 2021, respectively. Net cash used in operating activities for the three months ended March 31, 2022, was primarily due to our net loss of $9.6 million, adjusted for $0.6 million of stock-based compensation expense and $1.1 million from changes in operating assets and liabilities. Net cash used in operating activities for the three months ended March 31, 2021, was primarily due to our net loss of $5.7 million, adjusted for $0.3 million of stock-based compensation expense and $2.4 million from changes in operating assets and liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities was $21.3 million and none for the three months ended March 31, 2022 and 2021, respectively. Net cash used in investing activities for the three months ended March 31, 2022, was due to $21.3 million of short-term investment purchases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities was none and $73.3 million for the three months ended March 31, 2022 and 2021, respectively. Net cash provided by financing activities during the three months ended March 31, 2021, was comprised of net proceeds of $73.3 million from our IPO, which excludes $1.2 million in issuance costs related to the IPO that were unpaid as of March 31, 2021, and $0.2 million of IPO expenses that were paid in 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on a periodic basis. Our actual results may differ from these estimates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">While our significant accounting policies are described in more detail in the notes to our financial statements appearing in our Annual Report on Form 10-K for the year ended December 31, 2021, we believe that the following accounting policies are critical to understanding our historical and future performance, as the policies relate to the more significant areas involving management&#x2019;s judgments and estimates used in the preparation of our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, based on a pre-determined schedule or when contractual milestones are met, but some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. If timelines or contracts are modified based upon changes in the protocol or scope of work to be performed, we modify our estimates and accruals accordingly on a prospective basis.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We base our expenses related to external research and development services on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material differences between our estimates of such expenses and the amounts actually incurred.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; under the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;), and as such, we can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We will cease to be an emerging growth company prior to the end of December 31, 2026, if certain earlier events occur, including if we become a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Securities Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;), our annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="i_item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Quantitative and Qua</span><span id="item_3_qualitativeandquantitative"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">litative Disclosures About Market Risk.</span></p>
  <p style="margin-left:2.32%;text-indent:4.363%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information required by this item.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="i_item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Con</span><span id="item_4_controlsandprocedures"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">trols and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in the Securities Exchange Act of 1934 (the &#34;Exchange Act&#34;) Rules 13a-15(e) and 15d-15(e) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives. Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2022, the end of the period covered by this Quarterly Report. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting during the quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PART II&#x2014;OTHE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">R INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="ii_item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Legal Proc</span><span id="item_1_legal_proceedings"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">eedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in various legal proceedings and claims that arise in the ordinary course of our business activities. We are not currently a party to any material legal proceedings. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1A</span><span id="ii_item1a"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Risk Factors.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An investment in shares of our common stock is speculative and involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report, including our unaudited condensed financial statements and the related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; before deciding whether to purchase, hold or sell shares in our common stock. The occurrence of any of the risks described below could harm our business, financial condition, results of operations, growth prospects and/or stock price or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. We have marked with an asterisk (*) those risk factors that are new risk factors or ones containing substantive changes from the similarly titled risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (&#34;SEC&#34;), on March 3, 2022 (the &#34;2021 Annual Report&#34;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risk Relating to Arena Having Been Acquired by Pfizer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Arena was acquired by Pfizer, Inc. on March 11, 2022, and Arena&#x2019;s acquisition may negatively impact our development program and stock price.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On March 11, 2022, Pfizer announced it completed its acquisition of Arena, and Arena became a wholly-owned subsidiary of Pfizer. We have licensed our product candidates, including LP352, LP659 and LP143, from Arena, and we rely on Arena to help protect intellectual property relating to our licensed products. As of March 11, 2022, Arena also holds 23.1% of our outstanding shares of voting and non-voting common stock, and provides us certain services pursuant to a Services Agreement. We do not know if Pfizer will cooperate with us in protecting the intellectual property relating to our licensed products, continue to provide us services or hold or sell the shares of our common stock that it owns. We also do not know if Pfizer will view our development programs positively or negatively, or as complimentary or competitive to its development programs. If a disagreement between us and Pfizer were to occur, Pfizer might seek to acquire control of us through ownership of the shares of our common stock that it owns, challenge our rights or default on its obligations in the License Agreement or another agreement between us, or sell its shares, any of which actions could have an adverse impact on our ability to develop our products or on our stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Any of the risks identified herein relating to Arena are also risks relating to Pfizer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Position and Need For Additional Capital</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a very limited operating history, and we have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in January 2020 and we have a very limited operating history upon which you can evaluate our business and prospects. Our operations to date have been primarily focused on organizing and staffing our company, research and development activities, business planning, raising capital, in-licensing intellectual property rights and establishing our intellectual property portfolio, and providing general and administrative support for these operations. LP352, our most advanced product candidate, is in early clinical development, while our other product candidates, including LP659 and LP143, are in the preclinical or research stage. We have not yet demonstrated an ability to overcome many of the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry, including an ability to obtain regulatory approval of a product candidate, manufacture any product candidate at commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. In addition, we have limited experience completing clinical trials as a company. Consequently, any predictions about our future performance may not be as accurate as they would be if we had a history of successfully developing and commercializing biopharmaceutical products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effectiveness in the targeted indication or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses since our inception in January 2020. For the three months ended March 31, 2022, we reported a net loss of $9.6 million. As of March 31, 2022, we had an accumulated deficit of $51.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">continue to invest in our research and development activities, including conducting preclinical studies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">submit INDs and conduct clinical trials for our current and future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">seek marketing approvals for any product candidates that successfully complete the clinical trial process;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing and distribution infrastructure and establish manufacturing capabilities, whether alone or with third parties, to commercialize product candidates for which we may obtain regulatory approval, if any; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">hire additional personnel and build our internal resources, including those related to audit, patent, other legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">obtain, expand, maintain, enforce and protect our intellectual property portfolio; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">operate as a public company.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we continue to develop our product candidates in preclinical studies and clinical trials and expand our organization by hiring additional personnel. Our expenses will increase substantially if our product candidates successfully complete early clinical and other studies, and also could increase beyond expectations if the U.S. Food and Drug Administration (&#34;FDA&#34;) or other regulatory authorities require us to perform clinical and other studies in addition to those that we currently anticipate. In addition, we have incurred and expect to continue to incur additional costs associated with operating as a public company. Furthermore, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related to manufacturing, marketing, sales and distribution.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, our cash, cash equivalents and short-term investments were $96.1 million. We believe, based on our current operating plan, that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operations for at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In any event, we will require substantial additional capital to support our business operations as we pursue additional preclinical and clinical activities and regulatory approval of our current or any future product candidates, and otherwise to support our continuing operations. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Even if we believe we have sufficient</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">capital for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and, if approved, commercialize our current and any future product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additional funding may not be available on acceptable terms, or at all. As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility and disruptions, including those related to liquidity and credit availability, consumer confidence, economic growth, unemployment rates, and economic stability. If the equity and credit markets deteriorate or are otherwise not favorable, it may make any necessary debt or equity financing more difficult, more costly or more dilutive. If we do not raise additional capital in sufficient amounts, we may be prevented from pursuing development and commercialization efforts, which will harm our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital or acquiring or licensing assets by issuing equity or debt securities may cause dilution to our stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Negative U.S. and global economic conditions may create financial risks for us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">From time to time we may maintain a portfolio of investments in marketable debt securities, which are recorded at fair value. Although we have established investment guidelines relative to diversification and maturity with the objectives of maintaining safety of principal and liquidity, we rely on credit rating agencies to help evaluate the riskiness of investments, and such agencies may not accurately predict such risk. In addition, such agencies may reduce the credit quality of our individual holdings, which could adversely affect their value. Lower credit quality and other market events, such as changes in interest rates and deterioration in credit markets, may have an adverse effect on the fair value of our investment holdings and cash position.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Development and Commercialization of Our Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are early in our development efforts and have only one product candidate, LP352, in early clinical development. All of our other product candidates are in the preclinical or research stage. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are in the early stages of our development efforts and have one product candidate, LP352, in clinical development. We have completed the SAD and MAD portions of a Phase 1 clinical trial and have initiated a Phase 1b/2a clinical trial (the &#34;PACIFIC Study&#34;) for this product candidate. Our other product candidates currently in development, including LP659 and LP143, are in the preclinical stage. We will need to progress LP659, LP143 and any other early product candidates through IND-enabling studies and submit INDs to the FDA prior to initiating their clinical development. Moreover, none of our product candidates have advanced into a pivotal study. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">successful enrollment in clinical trials and completion of clinical trials and preclinical studies with favorable results;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">clearance of INDs by the FDA or similar regulatory filings by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">demonstrating the safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities, including new drug applications (&#34;NDAs&#34;) from the FDA and maintaining such approvals;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">making arrangements with third-party manufacturers for, or establishing, clinical and commercial manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">establishing and maintaining of patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">maintaining an acceptable safety profile of our products following approval; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">building and maintaining an organization of people who can successfully develop our product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our most advanced product candidate, LP352, as well as our other product candidates, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter. Given our early stage of development, it will take several years before we can demonstrate the safety and efficacy of a treatment sufficient to warrant approval for commercialization, if we can do so at all. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks associated with the in-licensing or acquisition of product candidates could cause substantial delays in the preclinical and clinical development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prior to October 2020, as a company we had no involvement with or control over the preclinical and early clinical research and development of our product candidates. We have relied on third parties, including Arena, to have conducted such research and development in accordance with the applicable protocol, legal, regulatory and scientific standards prior to the in-licensing of our product candidates. If the research and development processes or the results of the development programs prior to the in-licensing of our product candidates prove to be unreliable, this could result in increased costs and delays in the development of our product candidates, which could adversely affect any future revenue from these product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have licensed our product candidates from Arena. The fields of the licenses for these products contain certain restrictions. For example, the field of license for LP659 is for limited selected CNS indications and other neurological indications that Arena consents to include in the license, which consent shall not be unreasonably withheld. By way of another example, the field of license for LP143 and certain other licensed compounds is for CNS indications. If we make a request to expand the field of our license to include additional indications that we determine are advantageous or necessary for us to develop a licensed compound, Arena may not agree. This could have an adverse impact on our ability to develop our product candidates and could limit the ability to commercialize our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We may also acquire or in-license additional product candidates for preclinical or clinical development in the future as we continue to build our pipeline. The risks associated with acquiring or in-licensing current or future product candidates could result in delays in the commencement or completion of our preclinical studies and clinical trials, if ever, and our ability to generate revenues from our product candidates may be delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical and preclinical drug development involves a lengthy and expensive process with an uncertain outcome. The results of prior clinical trials and early preclinical studies and clinical trials of our product candidates are not necessarily predictive of future results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining marketing approval from the FDA, European Medicines Agency or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical and preclinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high. The results from preclinical studies or early clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Furthermore, product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In particular, while we have results from the SAD and MAD portions of a Phase 1 clinical trial of LP352, we do not know how LP352 will perform in future clinical trials, including the PACIFIC Study. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, or after others, including regulatory authorities, disagreed with such companies&#x2019; views and interpretations of the data and results from earlier preclinical studies or clinical trials. As we investigate LP352 for DEEs and other epileptic diseases, we may encounter difficulties that we have not yet encountered. Furthermore, LP659 and LP143 may not be able to progress from preclinical to Phase 1 clinical development.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials may not be conducted as planned or completed on schedule, if at all. A failure of a clinical trial can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on trial design or implementation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining regulatory authorization to commence a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining approval from one or more institutional review boards (&#34;IRBs&#34;), or IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional participants, or withdrawing their approval of the trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">delays in recruiting suitable patients to participate in our ongoing and planned clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">changes to the clinical trial protocol;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">delays in manufacturing sufficient quantities of our product candidates for use in clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">participants choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding to continue a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">occurrence of adverse events (&#34;AEs&#34;) or serious adverse events (&#34;SAEs&#34;) associated with the product candidate that are viewed to outweigh its potential benefits;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">occurrence of SAEs in trials of the same class of agents conducted by other companies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice (&#34;cGMP&#34;) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol (&#34;GCP&#34;) or other regulatory requirements; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended, terminated or modified by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political, economic and legal risks relevant to such foreign countries.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter difficulties or delays in initiating, screening, enrolling, conducting, or completing our ongoing and planned preclinical studies and clinical trials. Clinical site initiation and patient screening and enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Investigators and patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, could be limited, which in turn could adversely impact our clinical trial operations. Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials. For example, the initiation of the MAD portion of the Phase 1 clinical trial of LP352 was delayed, in part, as a result of the impact of the COVID-19 pandemic on the clinical site in the United Kingdom that conducted the SAD portion of the Phase 1 clinical trial for LP352, and subsequently we modified the protocol and relocated the MAD portion of such trial to a new clinical site in the United States. We completed the MAD portion of such trial in September 2021.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales and regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring comparable products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited experience as a company in conducting clinical trials, have never conducted later-stage clinical trials or submitted an NDA, and may be unable to do so for any of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are early in our development efforts for our product candidates, and we will need to successfully complete Phase 1 clinical trials and later-stage and pivotal clinical trials in order to obtain FDA or comparable foreign regulatory approval to market LP352, LP659, LP143 or any future product candidates. Carrying out clinical trials and the submission of NDAs is complicated. We completed the MAD portion of a Phase 1 clinical trial for LP352 (which was the first clinical trial we conducted as a company) in September 2021 and have not yet conducted any clinical trials for our other product candidates. We have not conducted any later stage or pivotal clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted an NDA or other comparable foreign regulatory submission for any product candidate. We also plan to conduct a number of clinical trials for multiple product candidates in parallel over the next several years. This may be a difficult process to manage with our limited resources and may divert the attention of management. In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of our product candidates will be required or how such trials will have to be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in submitting NDAs for and commercializing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we have multiple product candidates in our clinical pipeline and are considering a variety of target indications, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on specific product candidates, indications and development programs. We may also conduct several clinical trials for our product candidates in parallel over the next several years, which may make our decision as to which product candidates to focus on more difficult. For example, we are currently conducting the PACIFIC Study for LP352 for the treatment of seizures associated with DEEs, which may include Dravet syndrome, LGS and TSC, among others, which we initiated in the first quarter of 2022. Further, we are investigating in preclinical studies LP659 for multiple</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">neurological diseases, LP143 for CNS diseases and disorders and we have other compounds in earlier research. As a result, we may forgo or delay pursuit of opportunities with other product candidates or other indications that could have had greater commercial potential or likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#x2019;s conclusion as required by the FDA or other comparable foreign regulatory authorities. Additionally, certain clinical trials for future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. For example, the number of patients suffering from DEEs, such as Dravet syndrome, LGS and TSC, is small and, in some cases, has not been established with precision. If the actual number of patients with these diseases is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the severity of the disease under investigation, the nature of the trial protocol, the existing body of safety and efficacy data for the product candidate, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the trial, the ability to adequately monitor patients during a trial, clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied, and the risk that patients will drop out of a trial before completing all site visits. There are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner, including due to the fact that the neurological diseases we target are rare.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in clinical trials of our product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible. For example, the impact of public health epidemics, such as the ongoing COVID-19 pandemic, may delay or prevent patients from enrolling or from receiving treatment in accordance with the protocol and the required timelines, which could delay our clinical trials, or prevent us or our partners from completing our clinical trials at all, and harm our ability to obtain approval for such product candidate. Further, if patients drop out of our clinical trials, miss scheduled doses or follow-up visits, or otherwise fail to follow clinical trial protocols, whether as a result of the COVID-19 pandemic and related illness or actions taken to slow the spread of COVID-19 or otherwise, the integrity of data from our clinical trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preliminary, topline and interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other AEs that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by participants. Many times, side effects are only detectable after investigational product candidates are tested in large-scale, Phase 3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. Patients in our ongoing or planned clinical trials may experience similar or other side effects after treatment with one or more of our product candidates. If additional clinical experience indicates that any of our current product candidates and any future product candidates has serious or life-threatening side effects or other side effects that outweigh the potential therapeutic benefit, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LP352, our most advanced product candidate, is an oral, centrally acting, 5-HT2c superagonist with negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes in our preclinical studies to date. 5-HT2b and 5-HT2a receptor subtypes have been known to be associated with significant adverse side effects, including valvular heart disease and pulmonary arterial hypertension in the case of the 5-HT2b receptor, and hallucinations and mild to severe anxiety in the case of the 5-H2Ta receptor. LP352 has the potential to be a clinically differentiated 5-HT2c superagonist for patients with DEEs. For example, fenfluramine, marketed as FINTEPLA, a non-specific 5-HT2 agonist, was approved for the treatment of seizures associated with Dravet syndrome and LGS by the FDA in 2020 and 2022, respectively. Fenfluramine has been associated with significant side effects and FINTEPLA has a REMS program requirement and a boxed warning. Another 5-HT2c agonist, lorcaserin, is also under evaluation for its potential to reduce seizures in patients with Dravet syndrome and refractory epilepsies. Lorcaserin was discovered by Arena and approved by the FDA for chronic weight management, marketed as BELVIQ by Eisai. Lorcaserin was withdrawn from the market at the request of the FDA following the FDA&#x2019;s analysis of the CAMELLIA-TIMI 61 clinical trial, for which patients in the lorcaserin group demonstrated a numerically higher but not a statistically significantly higher rate of total cancer diagnoses (7.7% vs 7.1% placebo). Based on the results of this clinical trial, the FDA concluded that the risks of lorcaserin outweigh the benefits, and requested that lorcaserin be withdrawn from the market for the approved indication of weight management. However, the FDA authorized an expanded access program for patients with Dravet syndrome to continue to receive lorcaserin. LP352 was designed and developed by Arena to be the next generation to lorcaserin, with the goal of being a safer and more effective 5-HT2c agonist. We believe LP352&#x2019;s potential for high selectivity and novel chemistry gives it the potential to reduce seizures in DEE patients and overcome the known or perceived safety limitations of available drugs in the 5-HT2 class. However, we may not be correct, and the selectivity, specificity or other attributes of LP352 may result in similar or less desirable clinical profiles than less selective and specific available drugs or other product candidates. Further, in nonclinical toxicity studies of LP352 in rats and non-human primates (&#34;NHPs&#34;) conducted by Outpost Medicine, LLC prior to returning the product to Arena, certain male rats and NHPs of varying degrees of maturity in the respective high dose groups</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">experienced minimal to slight degeneration/atrophy of the seminiferous tubules with reduced spermatocyte maturation. Although exposure levels for these high dose groups were estimated to be far in excess of planned human exposures in our clinical trials and no similar AEs were observed in our subsequent toxicity studies in sexually mature rats and NHPs, we may see similar findings in the future.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, if any of our product candidates receive marketing approval, the FDA could require us to include a black box warning in our label or adopt REMS to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our product candidates, several other potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">we may need to conduct a recall; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly harm our business, prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may explore strategic collaborations that may never materialize or may fail.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We intend to broaden the global reach of our platform by selectively collaborating with leading biopharmaceutical companies. We intend to retain significant economic and commercial rights to our programs in key geographic areas that are core to our long-term strategy. As a result, we intend to periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we estimate, even assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We focus on developing novel medicines for neurological diseases. Given the small number of patients who have the diseases that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidates. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates that have been derived from a variety of sources, including scientific literature, patient foundations, or market research, and which may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of pharmaceutical products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DEEs are commonly treated with multiple combinations of anti-epileptic drugs (&#34;AEDs&#34;) though physician preference for administered therapies differs across different epilepsy types. Pharmaceutical companies, such as Eisai, Lundbeck, Pfizer, and UCB have approved AEDs for the treatment of epilepsies. There are also non-pharmaceutical therapies for epilepsy patients, such as a ketogenic diet, vagus nerve stimulation, and surgery for some patients. Three companies have obtained FDA approval for the treatment seizures associated with DEEs. For example, fenfluramine was approved for the treatment of seizures associated with Dravet syndrome in June 2020 and LGS in March 2022, and is available for patients through a REMS program.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Epidiolex (cannabidiol) was approved by the FDA for the treatment of seizures associated with Dravet syndrome and LGS in 2018, and the treatment of seizures associated with TSC in 2020, and DIACOMIT (stiripentol) was approved by the FDA in 2018 for seizures associated with Dravet syndrome. In addition, other companies are developing therapeutics for the treatment of epilepsies, including alternative approaches such as gene therapy.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In the S1P receptor modulator space, there are four drugs that have been approved by the FDA for the treatment of certain indications in multiple sclerosis: fingolimod, ozanimod, ponesimod and siponimod. There are multiple additional S1P receptor modulators in development for additional therapeutic indications beyond multiple sclerosis, including in other neurological diseases. There are also numerous other drugs and product candidates in development for indications for which we might develop our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additional, potential competitors include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the indications that we are pursuing. More established companies may have a competitive advantage over us due to their greater size, resources and institutional experience. In particular, these companies have greater experience and expertise in securing reimbursement, government contracts, relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory approvals and distribution relationships to market products, and marketing approved drugs. These companies also have significantly greater research and marketing capabilities than we do. If we are not able to compete effectively against existing and potential competitors, our business and financial condition may be harmed.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The key competitive factors affecting the success of our product candidates are likely to be their efficacy and safety, the scope and limitations of marketing approval, success of regulatory approval, successful protection of our intellectual property, and the availability of funding and reimbursement.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted and cheaper than ours, and may also be more successful than us in manufacturing and marketing their drugs. These appreciable advantages could render our product candidates obsolete or non-competitive before we can recover the expenses of such product candidates&#x2019; development and commercialization.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that any product candidates we may seek to develop in the future will never obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. To demonstrate the safety of our clinical products, we may also be required to conduct extensive clinical trials and nonclinical studies, some of which have not been initiated or completed, and may not be completed for several years. For example, we believe that we will need to conduct additional nonclinical studies in juvenile animals, as well as develop a liquid formulation, to support the evaluation of LP352 in pediatric populations. We also expect that we will need to conduct additional toxicology, long-term carcinogenicity and other nonclinical studies to support the safety evaluation of LP352 and any of our product candidates intended to be administered for an extended period of time. There is no assurance our development or these studies will be successful. In addition, results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional nonclinical or clinical testing or abandon a program for, including the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical studies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA&#x2019;s or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if our current or future product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Even if our current or future product candidates receive marketing approval, they may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If they do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our current or future product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product candidate is approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments and therapies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of the product as well as competitive products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">effectiveness of sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the strength of our relationships with patient communities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to offer such product for sale at competitive prices;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments and therapies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any restrictions on the use of the product together with other medications.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, if approved, LP352 may face challenges in gaining market acceptance by physicians, patients, third-party payors or others in the medical community as a result of it being a 5-HT2c agonist, which is part of an agonist class associated with significant risks and side effects. For example, fenfluramine, marketed as FINTEPLA, is a non-specific 5-HT2 agonist, has been associated with significant side effects and FINTEPLA has a REMS program requirement and a boxed warning. Another 5-HT2c agonist, lorcaserin, is also under evaluation for its potential to reduce seizures in patients with Dravet syndrome and refractory epilepsies. Lorcaserin was discovered by Arena and approved by the FDA for chronic weight management, marketed as BELVIQ by Eisai and withdrawn from the market at the request of the FDA based on a change in the FDA&#x2019;s risk-benefit assessment for the approved indication. However, the FDA authorized an expanded access program for patients with Dravet syndrome to continue to receive lorcaserin.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Although we aim to improve upon current 5-HT2c agonist product profiles with LP352, which was designed to be the next generation to lorcaserin, with the goal of being a safer and more effective 5-HT2c agonist, and which we believe has the potential to overcome the limitations of the currently available 5-HT2 class, if we are unable to do so and to educate physicians, patients, third-party payors and others in the medical community about this product candidate and successfully distinguish the safety profile of this product candidate to those of other products in the 5-HT2c agonist class, we may fail to gain market acceptance of LP352.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates, if approved, to find market acceptance would harm our business and could require us to seek additional financing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for our current or future product candidates, they will remain subject to ongoing regulatory oversight.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain any regulatory approval for our current or any future product candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCPs for any clinical trials that we may conduct post-approval. Any regulatory approvals that we receive for our current or future product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 trials, and surveillance to monitor the quality, safety and efficacy of the drug.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, drug manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a drug, such as AEs of unanticipated severity or frequency, or problems with the facility where the drug is manufactured or if a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with applicable regulatory requirements following approval of our current or future product candidates, a regulatory authority may:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">issue an untitled letter or warning letter asserting that we are in violation of the law;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">suspend or withdraw regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">suspend any ongoing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">refuse to approve a pending NDA or NDA supplement, or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">restrict or suspend the marketing or manufacturing of the drug;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">seize or detain the drug or otherwise require the withdrawal of the drug from the market;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">refuse to permit the import or export of product candidates; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">refuse to allow us to enter into supply contracts, including government contracts.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our current or future product candidates and harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA&#x2019;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could cause changes to or delays in the drug review process, or suspend or restrict regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in the markets that we target, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We currently plan to independently commercialize our product candidates in the United States by establishing a focused sales force and marketing infrastructure. We may opportunistically seek additional strategic collaborations to maximize the commercial opportunities for our product candidates outside of the United States. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our current and any future product candidates in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for any product candidate that we may develop;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">significant time and costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any product candidate that we may develop;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a decline in our share price.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Any product liability insurance coverage that we obtain and maintain may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to obtain or maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may be regulated as controlled substances, the making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration (&#34;DEA&#34;) and other regulatory agencies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may be classified as controlled substances, which are subject to state, federal, and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation, and distribution. Among other things, controlled substances are regulated under the federal Controlled Substances Act of 1970, and regulations of the DEA.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. Prior to commercialization, centrally acting drugs are generally subject to review and potential scheduling by the DEA. It is possible that LP352 or our other product candidates may be regulated by the DEA as a Schedule IV controlled substance, which would subject such product candidates to additional restrictions regarding their manufacture, shipment, storage, sale and use, depending on the scheduling of the active ingredients, and may limit the commercial potential of any of our product candidates, if approved. For example, BELVIQ and FINTEPLA are Schedule IV controlled substances.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Various states also independently regulate controlled substances. Though state controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule drugs as well. While some states automatically schedule a drug when the DEA does so, in other states there must be rulemaking or a legislative action. State scheduling may delay commercial sale of any controlled substance drug product for which we obtain federal regulatory approval and adverse scheduling could impair the commercial attractiveness of such product. We or our collaborators must also obtain separate state registrations in order to be able to obtain, handle and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal law.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For any of our product candidates classified as controlled substances, we and our suppliers, manufacturers, contractors, customers and distributors are required to obtain and maintain applicable registrations from state, federal and foreign law enforcement and regulatory agencies and comply with state, federal and foreign laws and regulations regarding the manufacture, use, sale, importation, exportation and distribution of controlled substances. There is a risk that DEA regulations may limit the supply of the compounds used in clinical trials for our product candidates, and, in the future, the ability to produce and distribute our products in the volume needed to meet commercial demand. Regulations associated with controlled substances govern manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting, handling, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates including controlled substances. The DEA, and some states, conduct periodic inspections of registered establishments that handle controlled substances. Failure to obtain and maintain required registrations or comply with any applicable regulations could delay or preclude us from developing and commercializing our product candidates containing controlled substances and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations or initiate proceedings to revoke those registrations. In some circumstances, violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of any of our product candidates that are classified as controlled substances.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Compliance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with customers, healthcare providers, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, other healthcare laws and regulations and data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, including physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, as well as our proposed sales, marketing and educational programs. In addition, we may be subject to data privacy and security laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to, among other things, arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">federal civil and criminal false claims laws, including, without limitation, the False Claims Act, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (&#34;HIPAA&#34;), which created additional federal criminal statutes that prohibit, among other things, a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private). Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#34;HITECH&#34;) and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform certain services on behalf of a covered entity that involves the use or disclosure of individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services (&#34;CMS&#34;), information related to: (i) payments or other &#x201c;transfers of value&#x201d; made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants and certified nurse midwives, and teaching hospitals during the previous year; and (ii) ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">state and foreign law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and/or information regarding drug pricing, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers, state laws and regulations that require drug manufacturers to file reports relating to drug pricing and marketing information, and state and local laws that require the registration of pharmaceutical sales representatives; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">state and foreign laws that govern the privacy and security of personal information, including health-related information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. By way of example, California enacted the California Consumer Privacy Act (&#34;CCPA&#34;), effective January 1, 2020, which gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Moreover, a new privacy law, the California Privacy Rights Act (&#34;CPRA&#34;) was approved in November 2020 by California voters. The CCPA and CPRA may increase our compliance costs and potential liability. Further, the EU General Data Protection Regulation (&#34;GDPR&#34;) imposes obligations and restrictions on the collection and use of personal data relating to individuals in the European Economic Area (&#34;EEA&#34;) (including health data). The GDPR increases obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data and requiring changes to informed consent practices and more detailed notices for clinical trial participants and investigators.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In Europe, the GDPR, as well as EU and EEA Member State implementing legislations, apply to the collection and processing of personal data, including health-related information. Importantly, the GDPR materially expands the definition of what is expressly provided to constitute &#x201c;personal data&#x201d; including by clarifying that the GDPR applies to pseudonymized (i.e. key-coded) data, which is often processed by sponsors in the context of clinical trials EU and EEA Member States are also able to legislate separately on health and genetic data, and we must comply with these local laws where we operate. Also, notwithstanding the UK&#x2019;s withdrawal from the EU, the data protection obligations of the GDPR continue to apply to UK-related processing of personal data in substantially unvaried form under the so-called &#x201c;UK GDPR&#x201d; (i.e. the GDPR as it continues to form part of law in the UK by virtue of section 3 of the European Union (Withdrawal) Act 2018). The GDPR has &#x201c;extra-territorial&#x201d; reach in that it applies (inter-alia) to any processing of personal data that concerns the offering of goods or services to individuals in the EEA or UK (as applicable) and/or the monitoring of their behavior, regardless of the existence of an establishment in the EEA or UK (as applicable). As such, the GDPR applies to any clinical trials and other operations taking in place in the EEA and UK. The GDPR provides for robust regulatory enforcement and fines of up to 20 million euros (and/or in respect of the UK GDPR, 17.5 million pounds sterling) or up to 4% of annual global revenue (whichever is higher). While the GDPR affords some flexibility in determining how to comply with the various requirements,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">significant effort and expense has been, and will continue to be, invested to ensure continuing compliance. In Switzerland, the Federal Act on Data Protection (&#34;DPA&#34;), also applies to the collection and processing of personal data, including health-related information, by companies located in Switzerland, or in certain circumstances, by companies located outside of Switzerland. The DPA has been revised and adopted by Parliament, and the revised version and its revised ordinances are expected to enter into force in 2022. This revised law may result in an increase of costs of compliance, risks of noncompliance and penalties for noncompliance.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">These data privacy and security laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. This includes several requirements relating to (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal data is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their personal data).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the GDPR prohibits the transfer of personal data from the EEA and the UK to the United States, and other countries in respect of which the European Commission or other relevant regulatory body has not issued a so-called &#x201c;adequacy decision&#x201d; (known as &#x201c;third countries&#x201d;). Switzerland has adopted similar restrictions under the DPA. Although there are legal mechanisms to allow for the transfer of personal data from the EEA, UK and Switzerland to the United States, legal challenges in Europe to these mechanisms have resulted in further limitations on the ability to transfer personal data across borders. In particular, certain governments have been unable to reach agreement on or maintain existing mechanisms designed to support cross-border data transfers, such as the EU-US and Swiss-US Privacy Shield Frameworks (the Privacy Shield). For example, on July 16, 2020, the Court of Justice of the European Union invalidated Decision 2016/1250 on the adequacy of the protection provided by the EU-US Privacy Shield Framework. To the extent that we were able to rely on the Privacy Shield, we will not be able to do so in the future, which could increase our costs and limit our ability to process personal data from the EEA, UK and/or Switzerland. The same decision also cast doubt on the ability to use one of the primary alternatives to the Privacy Shield, namely, the European Commission&#x2019;s &#x201c;Standard Contractual Clauses&#x201d;, to lawfully transfer personal data from the EEA, UK and/or Switzerland to the United States other third countries. On June 4, 2021, the European Commission published new versions of the Standard Contractual Clauses. These must be used for all new transfers of personal data from the EEA to third countries (including the US) starting September 27, 2021, and all existing transfers of personal data from the EEA to third countries relying on the existing versions of the Standard Contractual Clauses must be replaced by December 27, 2022. The implementation of the new Standard Contractual Clauses will necessitate significant contractual overhaul of our data transfer arrangements with our CROs, sub-processors and other vendors. At present, there are few if any viable alternatives to the Privacy Shield and the Standard Contractual Clauses. As such, transfers of personal data from the EEA, UK and/or Switzerland to the United States and other third countries may not fully comply with the cross-border data transfer restrictions set out in the GDPR. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of operating our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, following Brexit, the relationship between the UK and the EEA in relation to certain aspects of data protection law remains somewhat uncertain. On June 28, 2021, the European Commission issued an adequacy decision under the GDPR which allows (subject to some limitations) transfers of personal data from the EEA to the UK to continue without restriction for a period of four years ending June 27, 2025. After that period, the adequacy decision may be renewed only if the UK continues to ensure an adequate level of data protection. During these four years, the European Commission will continue to monitor the legal situation in the UK and could intervene at any point if the UK deviates from the level of data protection in place at the time of issuance of the adequacy decision. If the adequacy decision is withdrawn or not renewed, transfers of personal data from the EEA to the UK will require a valid transfer mechanism and we may be required to implement new processes and put new agreements in place, such as Standard Contractual Clauses, to enable transfers of personal data from the EEA to the UK to continue, which could disrupt our operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Actual or perceived failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial participants, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. The laws and regulations discussed in these risk factors are intended to be examples, and updates to these laws and regulations, as well as other laws and regulations, could have a material effect on our operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which coverage and adequate reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One third-party payor&#x2019;s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each third-party payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a third-party payor&#x2019;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our drugs.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Reform measures that result in decreased physician reimbursement may adversely affect our business. Further, any reduction in reimbursement from Medicare or other governmental programs may result in a similar reduction in payments from private payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Additionally, based on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict what healthcare reform initiatives may be adopted in the future. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs. Further, it is possible that additional governmental action is taken in response to address the ongoing COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our current or future product candidates are approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians prescribe or use any of our current or future product candidates off-label, we may become subject to prohibitions on the sale or marketing of any of our current or future product candidates, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The FDA, Department of Justice (&#34;DOJ&#34;), and comparable foreign authorities strictly regulate the marketing and promotional claims that are made about pharmaceutical products, including our product candidates LP352, LP659 and LP143. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or comparable foreign authorities as reflected in the product&#x2019;s approved labeling. Although physicians may prescribe products for off-label uses as the FDA and other regulatory agencies do not regulate a physician&#x2019;s choice of drug treatment made in the physician&#x2019;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. If we are found to have promoted such off-label uses, we may receive warning letters from the FDA and comparable foreign authorities and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#x2019;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA and other governmental authorities have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve enforcement actions. If we are deemed by the FDA, DOJ, or other governmental authorities to have engaged in the promotion of any current or future product candidates for off-label use, we could be subject to certain prohibitions or other restrictions on the sale or marketing and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to obtain or maintain orphan drug designations or exclusivity for our product candidates, which could limit the potential profitability of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation, however, neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for an indication for which it receives the designation, then the drug is entitled to a period of marketing exclusivity that precludes the applicable regulatory authority from approving another marketing application for the same drug for the same indication for the exclusivity period except in limited situations. For purposes of small molecule drugs, the FDA defines &#x201c;same drug&#x201d; as a drug that contains the same active moiety and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We intend to pursue orphan drug designation for our one or more of our product candidates, as well as for potential other future product candidates. Obtaining orphan drug designations is important to our business strategy; however, obtaining an orphan drug designation can be difficult and we may not be successful in doing so. Even if we were to obtain orphan drug designation for a product candidate, we may not obtain orphan exclusivity and that exclusivity may not effectively protect the drug from the competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any product candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, at times during the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By way of another example, in response to the global COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products through April 2020, and subsequently, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. On July 10, 2020, the FDA announced its intention to restart routine pre-announced surveillance inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on intellectual property licensed from third parties, including Arena, and the failure of our licensors to protect the licensed intellectual property or the termination our license could result in the loss of significant rights, which would harm our business.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on technology, patents, know-how, and proprietary materials, both our own and licensed from Arena. We entered into the Arena License Agreement pursuant to which we acquired an exclusive, royalty bearing, sublicensable, worldwide license to develop and commercialize LP352 for any use in humans, LP659 for the treatment of selected CNS indications and other neurological indications that Arena consents to include in the license (which consent shall not be unreasonably withheld), LP143 for the treatment of any CNS indication, and certain other compounds for CNS indications (pharmaceutical products containing any such compounds, the Licensed Products). Any termination of this license will result in the loss of significant rights and will restrict our ability to develop and commercialize our product candidates. If we or Arena fails to adequately protect this intellectual property, or if we seek to expand the field of our license to include additional indications we determine are advantageous or necessary for us to develop a licensed compound and Arena does not consent our ability to commercialize these compounds could suffer.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Agreements under which we license intellectual property or technology to or from third parties may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Our business also would suffer if any current or future licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the growth of our business will likely depend in part on our ability to acquire or in-license additional proprietary rights, including to advance our research or allow commercialization of our product candidates. In that event, we may be required to expend considerable time and resources to develop or license replacement technology. For example, our programs may involve additional technologies or product candidates that may require the use of additional proprietary rights held by third parties. Furthermore, other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. Our product candidates may also require specific formulations or other technology to work effectively and efficiently. These formulations or technology may be covered by intellectual property rights held by others. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. We may be unable to acquire or in-license any relevant third-party intellectual property rights, including any such intellectual property rights required to manufacture, use or sell our product candidates, that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, and as a result we may be unable to develop or commercialize the affected product candidates, and we may have to abandon development of the relevant research programs or product candidates, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors&#x2019; access to the same technologies licensed to us.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of payments owed under license agreements; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us and if we fail to comply with our obligations under these agreements, including due to the impact of the COVID-19 pandemic on our business operations or our use of the intellectual property licensed to us in an unauthorized manner, or we are subject to a bankruptcy, we may be required to pay damages and the licensor may have the right to terminate the license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend, in part, on our licensors to file, prosecute, maintain, defend, and enforce patents and patent applications that are material to our business.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Patents relating to our product candidates may be controlled by our licensor. Licensors may have rights to file, prosecute, maintain, and defend the patents we have licensed from such licensor. Our ability to settle legal claims may require consent of licensors. If our licensor or any future licensees having rights to file, prosecute, maintain, and defend our patent rights fail to conduct these activities for patents or patent applications covering any of our product candidates, including due to the impact of the COVID-19 pandemic on our licensor&#x2019;s business operations, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, or selling competing products. We cannot be certain that such activities by our licensor has been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. If our licensor has the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and, even if we are permitted to pursue such enforcement or defense, we cannot ensure the cooperation of our licensor. We cannot be certain that our licensor will allocate sufficient resources or prioritize its or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent applications, enforcement of licensed patents, or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions of our licensor and its counsel that took place prior to or after our assuming control. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Arena has the first right to control the prosecution and bring enforcement actions for infringement by third parties with respect to the licensed patents for LP143 licensed to us under the Arena License Agreement, for at least a period of time, with input from us, and we have an obligation to reasonably cooperate with Arena with respect to prosecution and enforcement of the other licensed programs, including LP352, LP659 and the 5HT2a compounds. Unsuccessful actions to prosecute the patent applications or to prosecute such patent applications in our best interest could adversely affect our intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may enter into collaboration agreements and strategic alliances, and we may not realize the anticipated benefits of such collaborations or alliances. We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development collaborations are subject to numerous risks, which may include the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration, and may not commit sufficient efforts and resources, or may misapply those efforts and resources;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of collaboration product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results or changes in their strategic focus;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay, provide insufficient resources to, or modify or stop clinical trials for collaboration product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators could develop or acquire products outside of the collaboration that compete directly or indirectly with our products or product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital and personnel to pursue further development or commercialization of the applicable product candidates; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop, including in territories outside the United States or for certain indications. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#x2019;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or in-license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, or if there are materially adverse impacts on our or the counterparty&#x2019;s operations resulting from COVID-19, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third-party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third-party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As a result of these risks, we may not be able to realize the benefit of our existing collaborations or any future collaborations or licensing agreements we may enter into. In addition, there have been a significant number of recent business combinations among large pharmaceutical and biomedical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">intellectual property rights to other parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our products require specific constituents to work effectively and efficiently, and rights to those constituents are and, in the future, may be held by others. We may be unable to in-license any rights to constituents, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies, which could harm our business prospects, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be dependent on intellectual property licensed or sublicensed to us from, or for which development was funded or otherwise assisted by, government agencies or academic or other institutions, for development of our technology and product candidates. Failure to meet our own obligations to our licensors or upstream licensors, including such government agencies or academic or other institutions, may result in the loss of our rights to such intellectual property, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Government agencies or academic or other institutions may provide funding, facilities, personnel or other assistance in connection with the development of the intellectual property rights owned by or licensed to us. Such government agencies may have retained rights in such intellectual property, including the right to grant or require us to grant mandatory licenses or sublicenses to such intellectual property to third parties under certain specified circumstances, including if it is necessary to meet health and safety needs that we are not reasonably satisfying or if it is necessary to meet requirements for public use specified by federal regulations, or to manufacture products in the United States. Any exercise of such rights, including with respect to any such required sublicense of these licenses could result in the loss of significant rights and could harm our ability to commercialize licensed products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our current or any future product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that we will file additional patent applications both in the United States and in other countries, as appropriate. However, we cannot predict:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">if and when any patents will issue;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the degree and scope of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and patent applications;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which may be costly whether we win or lose; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">whether the patent applications that we own, or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in foreign countries.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current and any future product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner, including as a result of the COVID-19 pandemic impacting our or our licensors&#x2019; operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current or any future product candidates in the United States or in foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our current or any future product candidates, third parties may challenge their scope, validity, or enforceability, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">us could deprive us of rights necessary for the successful commercialization of any product candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate and companion diagnostic under patent protection could be reduced.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If the patent applications we hold or have in-licensed with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future drugs. Any such outcome could have a negative effect on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Composition of matter patents for pharmaceutical products often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (&#34;USPTO&#34;), or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#x201c;off-label&#x201d; for those uses that are covered by our method of use patents. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or enforce against.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to file for patent protection. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. These changes could also increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (&#34;Leahy-Smith Act&#34;) was signed into law. When implemented, the Leahy-Smith Act included several significant changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act also included provisions that switched the United States from a &#x201c;first-to-invent&#x201d; system to a &#x201c;first-to-file&#x201d; system, allowed third party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO-administered post-grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures governing the administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became effective on March 16, 2013. It remains unclear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a negative effect on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Moreover, patents have a limited lifespan. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years from the earliest filing date of a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. For instance, a patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not necessarily extend to all claims, but instead only to claims that read on the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. In addition, although upon issuance in the United States a patent&#x2019;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Without patent protection for our current or future product candidates, including once the patent life has expired even if patents covering our product candidates are obtained, we may be open to competition from generic versions of such drugs. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Even if we have or obtain patents covering our products or methods, we may still be barred from making, using and selling such products or methods because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our ability to successfully develop our technology or to successfully commercialize any approved products alone or with collaborators.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Patent applications in the United States and elsewhere are generally published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our methods and products could have been filed by others without our knowledge. Additionally, pending claims in patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies or related products. These patent applications may have priority over patent applications filed by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our outside counsel, patent annuity service providers, or our licensing partners to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates such as LP352, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business. The following examples are illustrative:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or control;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">we might not have been the first to file patent applications covering certain of the inventions we own or control;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">pending patent applications that we own or control may not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we own or control may be held invalid or unenforceable as a result of legal challenges;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends, in part, upon our ability and the ability of our current or future collaborators to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. Our product candidates and other proprietary technologies we may develop may infringe existing or future patents owned by third parties. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Third parties asserting their patent or other intellectual property rights against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates or force us to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">cease some of our business operations. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, cause development delays, and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible on a cost-effective basis or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are aware of third-party patents and/or patent applications that could adversely affect the potential commercialization of our compounds. For example, we are aware of third-party patents, as well as a third-party patent application, with broad claims to administering an S1P receptor modulator by starting with a lower dose and then increasing to a higher, standard daily dose. Further, we are aware of third-party patent applications with broad claims to administering a 5-HT receptor agonist for epileptic disorders. While we do not believe that any such claims that would cover the potential commercialization of LP659 or LP352 would be valid and enforceable, we may be incorrect in this belief.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive, time-consuming, and unpredictable. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our related patent applications at risk of not issuing. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to, or the correct inventorship of, our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation, interference, derivation or other proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">There may be third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture, or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, our competitors in both the United States and abroad, many of which have made substantial investments in patent portfolios and competing technologies, may obtain patents in the future that may prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates, and may claim that use of our technologies or the manufacture, use, or sale of our product candidates infringes upon these patents. We may also receive, and expect to receive, communications from various industry participants alleging our infringement of their patents, trade secrets or other intellectual property rights and/or offering licenses to such intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patents, or any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action, which typically last for years before they are concluded, may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings and that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in-license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim we infringe their patents or that the patent covering our product candidate is invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#x2019;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#x2019;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates and such an outcome may limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Such a loss of patent protection could have a material adverse impact on our business. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents covering our current and any future product candidates throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than do those in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drugs and, further, may export otherwise infringing drugs to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These drugs may compete with our drugs in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If we rely on third parties to manufacture or commercialize our current or any future product candidates, or if we collaborate with additional third parties for the development of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, services agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any third-party collaborators. A competitor&#x2019;s discovery of our trade secrets could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidates, technology and product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Trade secrets and confidential information, however, may be difficult to protect. We seek to protect our trade secrets, know-how and confidential information, including our proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors, and collaborators. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes, or that any such agreements will be adequate. Although we seek to protect our trade secrets, our employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or inadvertently disclose our trade secret information to competitors or otherwise misappropriate our information, and in certain cases third parties who we may share confidential information have negotiated limits on their liability in their agreements with us. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed trade secrets or other confidential information of their current or former employers or claims asserting inventorship or ownership of what we regard as our own intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other healthcare, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">One aspect of the determination of patentability of our inventions depends on the scope and content of the &#x201c;prior art,&#x201d; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Because patent applications in the United States and most other countries are confidential for typically a period of 18 months after filing, or may not be published at all, we cannot be certain that we were the first to file any patent application related to our product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our trademarks or trade names may be challenged, opposed, infringed, circumvented, invalidated, cancelled, declared generic, determined to be not entitled to registration, or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Any trademark litigation could be expensive. In addition, we could be found liable for significant monetary damages, including treble damages, disgorgement of profits and attorneys&#x2019; fees, if we are found to have willfully infringed a trademark. We may not be able to protect our exclusive right to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential collaborators or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our current and any future product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have no experience in drug formulation or manufacturing and do not own or operate, and we do not expect to own or operate, facilities for drug manufacturing, storage and distribution, or testing. We will be dependent on third parties to manufacture the clinical supplies of our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Further, we also will rely on third-party manufacturers to supply us with sufficient quantities of our product candidates, to be used, if approved, for commercialization. We do not have long-term supply agreements. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">inability to meet our drug specifications and quality requirements consistently;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">delay or inability to procure or expand sufficient manufacturing capacity;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">issues related to scale-up of manufacturing;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">costs and validation of new equipment and facilities required for scale-up;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">failure to comply with cGMP or similar foreign standards;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">reliance on single sources for drug components;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">misappropriation of proprietary information, including our trade secrets and know-how;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or study drug or placebo not being properly identified;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">carrier disruptions or increased costs that are beyond our control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have the ability to independently conduct preclinical studies required to develop our drug candidates or any clinical trials. We intend to rely on CROs, clinical trial sites and other third parties to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs and others to monitor and manage data for our clinical programs, as well as the execution of future nonclinical studies. We expect to control only certain aspects of our CROs&#x2019; and others' activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies or clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs and others does not relieve us of our regulatory responsibilities.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We, our CROs and other third parties we might engage will be required to comply with the good laboratory practices (&#34;GLPs&#34;) and GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we will rely on CROs and others to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs and others does not relieve us of our regulatory responsibilities. If we, our CROs and other third parties we engage fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs or others fail to comply with these regulations or fail to recruit a sufficient number of participants, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">While we will have agreements governing their activities, our CROs and other third parties we engage will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and nonclinical programs. These CROs and others may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs and others, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. In addition, certain of our agreements with CROs and other third parties provide for monetary and other limitations on their liability. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed, decreased or eliminated.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, quarantines, shelter-in-place, and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at our CROs, which could disrupt our clinical timelines, which could have a material adverse impact on our business, prospects, financial condition, and results of operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If our relationship with these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to federal, state, and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical, radioactive and hazardous materials. Although we believe that our manufacturers&#x2019; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical, radioactive or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical radioactive or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development, and production efforts, which could harm our business, prospects, financial condition, or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">COVID-19 has impacted and could continue to adversely impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic continues to evolve. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials. Specifically, the initiation of the MAD portion of the Phase 1 clinical trial of LP352 was delayed, in part, as a result of the impact of the COVID-19 pandemic on the clinical site in the United Kingdom that conducted the SAD portion of the Phase 1 clinical trial for LP352, and subsequently we modified the protocol and relocated the MAD portion of such trial to a new clinical site in the United States. We completed the MAD portion in September 2021. The extent to which the COVID-19 pandemic continues to impacts our business, our clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions, quarantines, social distancing and vaccine mandate requirements and business closures in the United States and other countries, and business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the virus and its variants. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts have previously impacted and could in the future adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#x201c;Risk Factors&#x201d; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are highly dependent on the services of our senior management team and if we are not able to retain these members of our management team and recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on our senior management team. The employment agreements we have with these officers do not prevent such persons from terminating their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, we will need to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract, retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which we can discover and develop product candidates and our business will be limited and we may experience constraints on our development objectives.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations. Additionally, we do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, our ability to commercialize product candidates, develop a scalable infrastructure and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a negative impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. In addition, many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the accessibility and distributed nature of our information technology systems, and the sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks on our technology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">environment. In addition, due to the COVID-19 pandemic, we have enabled all of our employees to work remotely, which may make us more vulnerable to cyberattacks. Potential vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#x201c;hacktivists,&#x201d; nation states and others. In addition to the extraction of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. In addition, the prevalent use of mobile devices increases the risk of data security incidents.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant disruptions of our, our third-party vendors&#x2019; and/or business partners&#x2019; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. If we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of personal or health information, we may have to notify consumers, partners, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our business and reputation.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">There is no way of knowing with certainty whether we have experienced any data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event that leads to unauthorized access, use or disclosure of personal information, including but not limited to personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state breach notification laws and foreign law equivalents, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information. This could result in increased costs to us, and result in significant legal and financial exposure and/or reputational harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality or data security-related legal or other obligations to third parties, or any further security incidents or other inappropriate access events that result in the unauthorized access, release or transfer of sensitive information, which could include personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including clinical sites, regulators or current and potential partners, to lose trust in us or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or security incidents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An active, liquid and orderly trading market for our common stock may not be sustained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have a limited number of shares that trade each day compared to many other companies. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Further, a lesser active market may impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Quarterly Report, these factors include:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the commencement, enrollment or results of our ongoing and planned preclinical studies and clinical trials, or any future pre-clinical studies or clinical trials, we may conduct of our current and any future product candidates, or changes in the development status of our current and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any delay in our regulatory filings for our current and any future product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#x2019;s review of such filings, including without limitation the FDA&#x2019;s issuance of a &#x201c;refusal to file&#x201d; letter or a request for additional information;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">adverse results or delays in our preclinical studies and clinical trials, including as a result of the FDA or comparable foreign regulatory authorities disagreeing with the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval for our current and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">changes in laws or regulations applicable to our current and any future product candidates, including but not limited to clinical trial requirements for approvals;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the failure to obtain coverage and adequate reimbursement of our current and any future product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">changes on the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our inability to establish collaborations if needed;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our failure to commercialize our current and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any termination or loss of rights under the Arena License Agreement or Services Agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key scientific or management personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">unanticipated serious safety concerns related to the use of our current and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">introduction of new products or services offered by us or our competitors, or the release or publication of clinical trial results from competing product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to effectively manage our growth;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated variations in quarterly operating results;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our cash position;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">overall performance of the equity markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">issuances of debt or equity securities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us or our stockholders in the future, including sales of our common stock by Arena, or the perception that such sales may occur;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">changes in accounting practices;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ineffectiveness of our internal controls;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">general political and economic conditions, including the COVID-19 pandemic; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">other events or factors, many of which are beyond our control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. From March 12, 2021, through May 2, 2022,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the closing price of our common stock has ranged between $4.00 and $17.30 per share. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources, which would harm our business, operating results or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders would therefore be limited to the appreciation, if any, of their stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. Our stock market price may be negatively affected if our principal stockholders and management sell some or all of their stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our executive officers, directors, greater than 5% holders, and their affiliates beneficially own shares representing a significant percentage of our common stock. These stockholders will have the ability to influence us through their ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. Nonetheless, each share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation. Consequently, if holders of our non-voting common stock exercise their option to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of our non-voting common stock, and correspondingly decreasing the voting power of the holders of our common stock, which may limit your ability to influence corporate matters. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting common stock, but 10% or less of our common stock, and are not otherwise an insider, may not be required to report changes in their ownership due to transactions in our non-voting common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders, including Arena (or Pfizer), in the public market, or the perception that such sales could occur, could cause our stock price to fall.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of March 31, 2022, there were a total of 13,585,950 shares of common stock outstanding (including 101,635 shares subject to repurchase as of such date), which does not include the shares of our non-voting common stock that may be converted into an aggregate of 3,629,400 shares of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of March 31, 2022, Arena (and Pfizer) owns 3,978,540 shares, or 23.1%, of our outstanding shares of voting and non-voting common stock. The sale by Arena (or Pfizer) of a substantial number of shares, or a perception that such sales could occur, could significantly reduce the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, applicable lock-up agreements, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Further, certain holders of shares of our common stock (including the shares of common stock issuable upon conversion of our non-voting common stock) are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect that we will need significant additional capital in the future to continue our planned operations, including conducting clinical trials, commercialization efforts if we are able to obtain marketing approval of any of our current or future product candidates, research and development activities, and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to our 2021 Plan, our management is authorized to grant stock options to our employees, directors and consultants. Additionally, the number of shares of our common stock reserved for issuance under our 2021 Plan will automatically increase on January 1 of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock), or a lesser number of shares determined by our board of directors.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, pursuant to our ESPP, the number of shares of our common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2022 (through January 1, 2031), by the lesser of (i) 1% of the total number of shares of our common stock outstanding (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock) on the last day of the fiscal year before the date of the automatic increase and (ii) such number of shares of common stock that would cause the aggregate number of shares of common stock then reserved for issuance under the ESPP to equal 1,060,017 shares; provided that before the date of any such increase, our board of directors may determine that such increase will be for a lesser amount of shares. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#34;JOBS Act&#34;). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company until December 31, 2026, although circumstances could cause us to lose that status earlier, including if we become a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act or if we have total annual gross revenue of $1.07 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31 or, if we issue more than $1.0 billion in non-convertible debt during any three year period before that time, we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#x201c;smaller reporting company&#x201d; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors may find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">provide that the authorized number of directors may be changed only by resolution of the board of directors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">provide that our board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then-outstanding common stock;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">divide our board of directors into three classes;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#x2019;s notice;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">provide that special meetings of our stockholders may be called only by the chair of our board of directors, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following types of actions or proceedings under state, statutory and common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#x2019;s having personal jurisdiction over the indispensable parties named as defendants; provided these provisions of our amended and restated certificate of incorporation and amended and restated bylaws do not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law and subject to the court&#x2019;s having personal jurisdiction over the indispensable parties named as defendants, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any derivative action or proceeding brought on our behalf;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any action or proceeding asserting a breach of fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or bylaws;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">This provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred, and expect to continue to incur, significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we have incurred and expect to continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (&#34;Dodd-Frank Act&#34;) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#x201c;say on pay&#x201d; and proxy access. Emerging growth companies and smaller reporting companies are exempted from certain of these requirements, but we may be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect the rules and regulations applicable to public companies to continue to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will continue to decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404 of Sarbanes-Oxley, our management are required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December 31, 2022. When we lose our status as an &#x201c;emerging growth company&#x201d; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to meet Nasdaq&#x2019;s continued listing requirements could result in a delisting of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with the listing requirements of Nasdaq.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, or discontinues coverage, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="ii_item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Unregistered Sales of Equity Securities and Use of Proceeds.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unregistered Sales of Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We commenced our IPO pursuant to a Registration Statement on Form S-1, as amended (File No. 333-253329), that was declared effective on March 11, 2021, and registered an aggregate of 5,750,000 shares of our common stock. On March 16, 2021, we completed our IPO and sold 5,000,000 shares of our common stock at a public offering price of $16.00 per share, for aggregate gross proceeds of $80.0 million. An additional 298,360 shares were sold pursuant to the underwriters&#x2019; option to purchase additional shares in April 2021, at a public offering price of $16.00 per share, for additional gross proceeds of $4.8 million. Citigroup Global Markets Inc., Evercore Group L.L.C., Guggenheim Securities, LLC and Cantor Fitzgerald &amp; Co. acted as joint book-running managers for the IPO.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The underwriting discounts and commissions for the IPO totaled approximately $5.9 million. We incurred additional offering expenses of approximately $2.6 million, which when added to the underwriting discounts and commissions paid by us, amounts to total fees and costs of approximately $8.5 million. Thus, net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were approximately $76.2 million. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents. We are also investing some of the net proceeds from our IPO in a combination of short-term and intermediate-term, interest-bearing obligations, investment grade instruments, certificates of deposit or direct or guaranteed government obligations. We expect to use the net proceeds from our IPO as described under &#x201c;Use of Proceeds&#x201d; in the Prospectus. We cannot predict with certainty all of the particular uses for the net proceeds from our IPO, or the amounts that we will actually spend on the uses described under &#x201c;Use of Proceeds&#x201d; in the Prospectus. The amounts and timing of our actual use of the remaining net proceeds will vary depending on numerous factors, including our ability to access additional financing, the relative success and cost of our research, preclinical and clinical development programs and whether we are able to enter into future licensing arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="ii_item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Defaults Upon Senior Securities.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="ii_item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Mine Safety Disclosures.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="ii_item5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Other Information.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="ii_item6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Exhibits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.083%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:90.898%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000095017021000164/lbph-20210331-ex3_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Form 10-Q (File No. 001-40192) filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000095017021000164/lbph-20210331-ex3_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Form 10-Q (File No. 001-40192) filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521049139/d16883dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Investors&#x2019; Rights Agreement by and among the registrant and certain of its stockholders, dated October 27, 2020 (incorporated by reference to Exhibit 4.2 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253329), filed with the SEC on February 19, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000119312521049139/d16883dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">January 2022 amendment to Arena License Agreement (incorporated by reference to Exhibit 10.14 to the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-40192), filed with the SEC on March 3, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.2*+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Retirement and Consulting Agreement by and between the Registrant and Philip Perera, M.D., dated March 17, 2022</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.3*+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Employment Agreement by and between the Registrant and Randall E. Kaye, M.D., dated March 17, 2022</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">32.1*#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended and 18 U.S.C. Section 1350.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.494%;"></td>
    <td style="width:95.506%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Filed herewith.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indicates management contract or compensatory plan.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The information in Exhibit 32.1 shall not be deemed &#34;filed&#34; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SIG</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">NATURES</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date: May 5, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Kevin R. Lind</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kevin R. Lind</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date: May 5, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Brandi L. Roberts</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Brandi L. Roberts</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>lbph-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img141511159_0.jpg" alt="img141511159_0.jpg" style="width:218px;height:38px;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">                                                                  </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">March 17, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Philip Perera</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Via email</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Re:	Retirement and Consulting Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Dear Philip:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">This letter sets forth the substance of the retirement and consulting agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that Longboard Pharmaceuticals, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) is offering to you in connection with your employment termination.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Retirement and Employment Resignation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  You have informed Longboard that you are retiring and resigning as the Chief Medical Officer of Longboard, as well as from any other positions you may hold as an employee of Longboard, effective as of March 21, 2022 (your &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Retirement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued Salary and Vacation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  On your Retirement Date, Longboard will pay you all accrued salary earned through your Retirement Date, subject to standard payroll deductions and withholdings. You are entitled to this payment by law. Since Longboard has a nonaccrual vacation/PTO policy, you do not have any accrued vacation/PTO or other paid time off and thus will not be paid out for any accrued vacation/PTO or other paid time off.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Health Insurance.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> Your participation in Longboard&#x2019;s group health insurance plan will end March 31, 2022. To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by Longboard&#x2019;s current group health insurance policies, you will be eligible to continue your group health insurance benefits at your own expense following the Separation Date. Later, you may be able to convert to an individual policy through the provider of Longboard&#x2019;s health insurance, if you wish. You will be provided with a separate notice describing your rights and obligations under COBRA. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consulting Relationship.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> Longboard agrees to retain you, and you agree to provide consulting services for Longboard, under the following terms and conditions (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consulting Relationship</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;):</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consulting Period.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The Consulting Relationship will be deemed to have commenced immediately following your Retirement Date and will continue until the six month anniversary of such date (i.e., until September 21, 2022), unless the Consulting Relationship has been terminated earlier pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section 4(h)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consulting Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consulting Services.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">You agree to provide consulting services to Longboard in any area of your expertise, including but not limited to, providing strategic advice and counseling and performing other assignments as requested by your successor Chief Medical </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Officer or Longboard&#x2019;s Chief Executive Officer (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consulting Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  You agree to exercise the highest degree of professionalism and utilize your expertise and creative talents in performing these services.  You agree to make yourself available to perform such Consulting Services throughout the Consulting Period, on an as-needed basis; provided, unless otherwise mutually agreed upon by you and Longboard&#x2019;s Chief Executive Officer, the Consulting Services shall not (i) for the first two months of the Consulting Period, exceed eighty (80) hours per month and (ii) for the remaining months of the Consulting Period, exceed twenty (20) hours per month.  When providing such services, you shall abide by Longboard&#x2019;s policies and procedures.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Independent Contractor Relationship.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> Your relationship with Longboard during the Consulting Period will be that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship after your Retirement Date.  Other than your COBRA rights, you will not be entitled to any of the benefits that Longboard may make available to its employees, including but not limited to, group health or life insurance, profit-sharing or retirement benefits, and you acknowledge and agree that your relationship with Longboard during the Consulting Period will not be subject to the Fair Labor Standards Act or other laws or regulations governing employment relationships.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consideration for Consulting Services. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">During the Consulting Period, you will be compensated at the rate of</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">$400 per hour for your Consulting Services (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consulting Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  You will submit detailed invoices of your Consulting Services on a monthly basis, and Longboard will provide payment of any owed Consulting Fees within 30 calendar days after receipt of such invoices.  Longboard will not withhold from the Consulting Fees any amount for taxes, social security or other payroll deductions.  Longboard will report your Consulting Fees on an IRS Form 1099.  You acknowledge that you will be entirely responsible for payment of any taxes that may be due with regard to the Consulting Fees, and you hereby indemnify, defend and save harmless Longboard, and its officers and directors in their individual capacities, from any liability for any taxes, penalties or interest that may be assessed by any taxing authority with respect to the Consulting Fees (with the exception of the employer&#x2019;s share of social security, if any).  Longboard encourages you to obtain professional advice from an advisor of your choice with respect to the tax treatment of, and any and all tax issues with respect to, the Consulting Fees.</font></div></div>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  You will be responsible for all expenses incurred in connection with the performances of Consulting Services, unless such expenses are reasonable and approved in advance by Longboard.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Limitations on Authority.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  You will have no responsibilities or authority as a consultant to Longboard other than as provided above.  You will have no authority to bind Longboard to any contractual obligations, whether written, oral or implied, except with the written authorization of the Company&#x2019;s Chief Executive Officer.  You agree not to represent or purport to represent the Company in any manner whatsoever to any third party (including but not limited to customers, potential customers, investors, business partners or vendors), unless authorized by Longboard&#x2019;s Chief Executive Officer, in writing, to do so.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information and Inventions. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">You agree that, during the Consulting Period and thereafter, you will not use or disclose, other than in furtherance of the Consulting Services, any confidential or proprietary information or materials of Longboard, including any confidential or proprietary information that you obtain or develop in the course of performing the Consulting Services.  Any and all work product you create in the course and scope of performing the Consulting Services will be the sole and exclusive property of Longboard.  You hereby assign to Longboard all right, title, and interest in and to all inventions, techniques, processes, materials, and other intellectual property developed in the course and scope of performing the Consulting Services. You further acknowledge and reaffirm your continuing obligations under your previously executed Employee Proprietary Information and Inventions Agreement (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;PIAA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), a copy of which is attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding the foregoing nondisclosure obligations, pursuant to 18 U.S.C. Section 1833(b), you will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Early Termination of Consulting Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Either you or Longboard have the right to terminate the Consulting Period at any time and for any reason upon 30 calendar days&#x2019; prior written notice to the other party. Additionally, Longboard has the right to immediately terminate the Consulting Period upon written notice to you if (i) you do not sign the Retirement Date Release attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> on or within twenty-one (21) days after your Retirement Date and allow it to become effective or (ii) you materially breach this Agreement or your continuing obligations owed to the Company (including but not limited to those in the PIAA). </font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Other Work Activities / Representations.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Throughout the Consulting Period, you retain the right to engage in employment, consulting, or other work relationships in addition to your Consulting Services for Longboard, so long as such activities do not present a conflict of interest with Longboard&#x2019;s business, or interfere with your continuing obligations owed to Longboard.  In the event that it is unclear to you whether a particular activity would breach this commitment, you agree to contact Longboard&#x2019;s Chief Executive Officer to seek clarification. </font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Equity Vesting and Extension of Time to Exercise Vested Equity. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard will consider your change of status from an employee to a consultant (effective as of your Retirement Date), and your Consulting Services during the Consulting Period, to constitute &#x201c;Continuous Service&#x201d; for purposes of Longboard&#x2019;s  2021 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Equity Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and therefore your outstanding equity awards will continue to vest in accordance with their terms during the Consulting Period; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> any stock options that are &#x201c;incentive stock options&#x201d; under Section 422 of the Internal Revenue Code shall immediately cease to be &#x201c;incentive stock options&#x201d; upon the execution of this Agreement.  Vesting of your equity awards will cease at the termination of the Consulting Period and your rights to exercise or otherwise acquire any vested shares shall be governed and controlled by the Equity Plan and your applicable grant documents (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Equity Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). All terms, conditions and limitations applicable to your equity awards will continue to be subject to the applicable Equity Documents.  Notwithstanding the foregoing, unless the Consulting Period was terminated early by you or by the Company pursuant to the last </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">sentence of Section 4(h), if you (i) timely have signed the Retirement Date Release and allowed it to become effective, (ii) comply with your obligations hereunder, and (iii) sign a release of claims in substantially the same form as the Retirement Date Release on or within twenty-on (21) days after the end of the Consulting Period, your exercise period for any outstanding equity awards that are vested as the end of the Consulting Period shall be extended until December 31, 2023, but in any event not beyond the original contractual life of the equity awards. For the avoidance of doubt, the vesting in your equity awards will cease as of the end of the Consulting Period, but your right to exercise vested equity awards shall be extended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No Other Compensation or Benefits.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> You acknowledge that, except as expressly provided in this Agreement, you have not earned, will not earn by your Retirement Date or as a result of the termination of your employment with Longboard, and will not receive from Longboard any additional compensation (including base salary, bonus, incentive compensation, or equity, equity acceleration or vesting), severance, or benefits before or after your Retirement Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested options.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Expense Reimbursements.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> You agree that, within 30 calendar days after your Retirement Date, you will submit your final documented expense reimbursement statement reflecting all unreimbursed business expenses you incurred through your Retirement Date in connection with your employment, if any, for which you seek reimbursement. Longboard will reimburse you for these expenses pursuant to its regular business practice.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Return of Longboard Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. On your Retirement Date, you agree to return to Longboard all Longboard documents (and all copies thereof) and other Longboard property which you have in your possession or control, including any materials of any kind which contain or embody any proprietary or confidential information of Longboard (and all reproductions thereof in whole or in part). You agree that you will make a diligent search to locate any such documents, property and information by the close of business on your Retirement Date. If you have used any personally owned computer, server, or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, within five calendar days after your Retirement Date, you shall provide Longboard with a computer-useable copy of such information and then permanently delete and expunge such Longboard confidential or proprietary information from those systems; and you agree to provide Longboard access to your system as requested to verify that the necessary copying and/or deletion is done. Longboard will provide you with access to Longboard documents and other property, as necessary, to the extent needed for you to perform your Consulting Services; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> you must return such Longboard documents and property upon request and not later than the last day of the Consulting Period.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Nondisparagement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">You agree not to disparage Longboard, its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation; provided that you may respond accurately and fully to any question, inquiry, or request for information if required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Agreement is intended to prohibit or restrain you in any manner from making disclosures that are protected under the whistleblower provisions of federal or state law or </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">regulation or under other applicable law or regulation or as set forth in the section of this Agreement entitled &#x201c;Protected Rights.&#x201d;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No Voluntary Adverse Action. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">You agree that you will not voluntarily (except in response to legal compulsion or as permitted under the section of this Agreement entitled &#x201c;Protected Rights&#x201d;) assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against Longboard, its parent or subsidiary entities, affiliates, officers, directors, employees or agents.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cooperation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> You agree to cooperate fully with Longboard in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of your employment by Longboard. Such cooperation includes, without limitation, making yourself available to Longboard upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. Longboard will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding foregone wages) and will make reasonable efforts to accommodate your scheduling needs.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No Admissions. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by Longboard to you or to any other person, and that Longboard makes no such admission.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Protected Rights. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the California Department of Fair Employment and Housing, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Government Agencies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). You further understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to Longboard. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement. Nothing in this Agreement prevents you from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Representations.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> You hereby represent that you have been paid all compensation owed and for all hours worked through the date you sign this Agreement, have received all the leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act, the California Family Rights Act, or otherwise, and have not suffered any on-the-job injury for which you have not already filed a workers&#x2019; compensation claim.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Dispute Resolution</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> You and Longboard agree that any and all disputes, claims, or controversies of any nature whatsoever arising from, or relating to, this Agreement or its interpretation, enforcement, breach, performance or execution, your employment or the termination of such employment (including, but not limited to, any statutory claims) (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;, each a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), shall be resolved, pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration in San Diego, California (or another mutually acceptable location) conducted before a single neutral arbitrator by JAMS, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">JAMS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at http://www.jamsadr.com/rules-employment-arbitration/).  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By agreeing to this arbitration procedure, both you and Longboard waive the right to have any Claim resolved through a trial by jury or judge or an administrative proceeding.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  You will have the right to be represented by legal counsel at any arbitration proceeding, at your own expense.  This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Excluded Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.  The arbitrator shall have sole authority for determining if a Claim is subject to arbitration, and any other procedural questions related to the dispute and bearing on the final disposition.  In addition, the arbitrator shall:  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#x2019;s essential findings and conclusions on which the award is based.  Longboard shall pay all JAMS arbitration fees. Nothing in this Agreement shall prevent you or Longboard from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> This Agreement, including its Exhibits, constitutes the complete, final and exclusive embodiment of the entire agreement between you and Longboard with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of Longboard. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and Longboard, and inure to the benefit of both you and Longboard, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of California without regard to conflict of laws principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall not be </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">deemed to be a waiver of any successive breach. This Agreement may be executed in counterparts and facsimile signatures will suffice as original signatures.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If this Agreement is acceptable to you, please sign below and return the original to me.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Sincerely,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Kevin R. Lind</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Kevin R. Lind</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">I have read, understand and agree fully to the foregoing Agreement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Philip Perera</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Philip Perera, M.D.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Date:  March 17, 2022</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Retirement Date Release</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>lbph-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><img src="img142434680_0.jpg" alt="img142434680_0.jpg" style="width:218px;height:38px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">March 17, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Randall E. Kaye, M.D.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">via email</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Re:	Offer of Employment</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Dear Randall:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is pleased to offer you at-will employment in the position of Chief Medical Officer (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CMO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) under the terms and conditions set forth in this employment agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Employment by the Company.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Your employment with the Company shall commence on March 21, 2022 (your &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Start Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). This is an exempt position, and during your employment with the Company, you will devote your best efforts and substantially all of your business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company&#x2019;s general employment policies. You shall perform such duties as are required by the Company&#x2019;s Chief Executive Officer (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CEO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), to whom you will report. Your principal place of employment shall be your current residence located in New York, New York. The Company reserves the right to reasonably require you to perform your duties at places other than your principal place of employment from time to time, and to require reasonable business travel. The Company may modify your job title and duties as it deems necessary and appropriate in light of the Company&#x2019;s needs and interests from time to time. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Compensation.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">2.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Base Salary.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  For services to be rendered hereunder, you shall receive a base salary at the rate of $450,000 per year (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to standard payroll deductions and withholdings and payable in accordance with the Company&#x2019;s regular payroll schedule. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">2.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Annual Bonus.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  During your employment, you will be eligible for an annual discretionary bonus pursuant to the Company&#x2019;s Performance Bonus Plan (as then in effect) with a target amount of</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">40% of your then current annual Base Salary (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Annual Bonus&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">). Whether you receive an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined by the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (and/or its Compensation Committee) in its discretion based upon the achievement of corporate and/or individual objectives and milestones that are determined in the sole discretion of the Board (and/or its Compensation Committee). You must continue to be employed through the date the Annual Bonus is paid in order to earn such bonus. The Annual Bonus, if any, shall be paid to you in a lump sum no later than March 15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> of the calendar year that follows the performance year, subject to applicable payroll deductions and withholdings. For clarity, the Annual Bonus for 2022, if any, will not be prorated based on the number of days you were employed by the Company in 2022.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">2.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Equity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the approval of the Board, the Company will grant you on or as soon as reasonably practical after your Start Date an option to purchase 206,500 shares of the Company&#x2019;s </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), pursuant to the Company&#x2019;s 2021 Equity Incentive Plan (as may be amended from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), with an exercise price equal to the fair market value on the date of the grant as determined by the Board. The shares subject to the Option will vest over four years, subject to your Continuous Service to the Company (as defined in the Plan), as follows: 25% of the shares shall be fully vested on the first-year anniversary of the date of the grant, and the remaining shares shall vest in thirty-six (36) equal monthly increments thereafter. The Option shall be governed by the terms of the Plan and the grant documents thereunder. You will remain eligible to receive future equity awards at the discretion of the Board or the Compensation Committee.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Reasonable Business Expenses.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  You will be eligible for reimbursement of all reasonable, necessary and documented out-of-pocket business, entertainment, and travel expenses incurred by you in connection with the performance of your duties hereunder in accordance with the Company's expense reimbursement policies and procedures.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Company Policies; Standard Company Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The employment relationship between the parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company&#x2019;s general employment policies or practices, this Agreement shall control. You shall be entitled to participate in all employee benefit programs for which you are eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its employees. The Company reserves the right to cancel or change the benefit plans or programs it offers to its employees at any time.   </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">At-Will Employment.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Your employment relationship is at-will. Either you or the Company may terminate the employment relationship at any time, with or without cause or advance notice. Upon termination of your employment for any reason, you shall resign from all positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date of termination.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Outside Activities During Employment.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Except with the prior written consent of the Company, you will not during the term of your employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. You may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance of your duties hereunder. You agree not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise. Ownership by you in professionally managed funds over which you do not have control or discretion in investment decisions, or, an investment of less than one percent (1%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute a breach of this Section.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Termination; Severance.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">7.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Term and Termination.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The term of this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall be the period commencing on your Start Date and ending on the date that this Agreement is terminated by either party pursuant to the provisions of this Agreement. You are employed at-will, meaning that, subject to the terms and conditions set forth herein, either the Company or you may terminate your employment at any time, with or without Cause.   </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">7.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Compensation upon Termination.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  Upon the termination of your employment for any reason, the Company shall pay you all of your accrued and unpaid wages earned through your last day of employment (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Separation Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">7.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Involuntary Termination Unrelated to a Change in Control.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If you are subject to an Involuntary Termination (that does not occur within the Change in Control Period (as defined below)), and provided that you remain in compliance with the terms of this Agreement (including the conditions described in Section 7.7 below), the Company shall provide you with the following benefits (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Severance Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;): </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cash Severance.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company shall pay you, as severance,</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the equivalent of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">twelve (12) months</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Severance Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of your Base Salary in effect as of the Separation Date, subject to standard payroll deductions and withholdings (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Severance will be paid as a continuation on the Company&#x2019;s regular payroll, beginning no later than the first regularly-scheduled payroll date following the sixtieth (60</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">) day after your Separation from Service, provided the Separation Agreement (as discussed in Section 7.7) has become effective; and </font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">a pro-rata portion of your Annual Bonus for the calendar year in which the Involuntary Termination occurs, based on actual performance results for such year as determined by the Board or the Compensation Committee (determined by multiplying the amount of your Annual Bonus which would be due for the full calendar year by a fraction, (i) the numerator of which is the number of days during the calendar year that you were employed by the Company and (ii) the denominator of which is three hundred sixty-five (365)), if any (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pro-Rata Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), payable at the same time annual bonuses for such year are paid to actively-employed senior executives of the Company, but in no event prior to the effective date of the Separation Agreement and no later than March 15 of the year following the year in which your Separation from Service occurs.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payment of Continued Group Health Plan Benefits. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> If you are eligible for and timely elect continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 or any state law of similar effect (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">COBRA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) following your Involuntary Termination, the Company will pay your COBRA group health insurance premiums for you and your eligible dependents directly to the insurer until the earliest of (A) the end of the period immediately following your Involuntary Termination that is equal to the Severance Period (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">COBRA Payment Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), (B) the expiration of your eligibility for continuation coverage under COBRA, or (C) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment. For purposes of this Section, references to COBRA premiums shall not include any amounts payable by you under a Section 125 health care reimbursement plan under the Code. Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then regardless of whether you elect continued health coverage under COBRA, and in lieu of providing the COBRA premiums, the Company will instead pay you on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings (such amount, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Special Severance Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which payments shall continue until the earlier of expiration of the COBRA Payment Period or the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">self-employment. On the first payroll date following the effectiveness of the Separation Agreement, the Company will make the first payment to the insurer under this clause (and, in the case of the Special Severance Payment, such payment will be to you, in a lump sum) equal to the aggregate amount of payments that the Company would have paid through such date had such payments instead commenced on the Separation Date, with the balance of the payments paid thereafter on the schedule described above. If you become eligible for coverage under another employer&#x2019;s group health plan, you must immediately notify the Company of such event, and all payments and obligations under this subsection shall cease.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Accelerated Vesting. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The vesting and exercisability of all outstanding options, restricted stock unit awards, and other equity awards covering the Company&#x2019;s common stock that are held by you as of immediately prior to the Involuntary Termination, to the extent such equity awards would otherwise have vested solely conditioned on your continued services with the Company, shall accelerate vesting in accordance with their applicable vesting schedules as if you had completed an additional six (6) months of service with the Company as of the Separation Date. For the avoidance of doubt, equity awards which vest wholly or partially subject to the attainment of performance goals are not eligible to accelerate vesting pursuant to this subsection.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">7.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Involuntary Termination in Connection with a Change in Control.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If you are subject to an Involuntary Termination during the Change in Control Period, and provided that you remain in compliance with the terms of this Agreement (including the conditions described in Section 7.7 below), the Company shall provide you with the following benefits (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CIC Severance Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cash Severance.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Company shall pay you, as severance, </font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">an amount equal to 100% of your Base Salary in effect as of the Separation Date, subject to standard payroll deductions and withholdings, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> 100% of your target Annual Bonus amount for the year in which the Involuntary Termination occurs, in a lump sum on the first regularly scheduled payroll date following the Release Deadline, but in no event later than March 15 of the year following the year in which your Separation from Service occurs; and</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pro-Rata Bonus, payable upon the later of (x) the same time annual bonuses for such year are paid to actively-employed senior executives of the Company, (y) the first payroll date following the effective date of the Separation Agreement, but in either case, no later than March 15 of the year following the year in which Separation from Service occurs.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payment of Continued Group Health Plan Benefits. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> You will receive the payment for continued group health plan benefits described in Section 7.3(b) above.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Accelerated Vesting.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The vesting and exercisability of all outstanding time-based stock options and other time-based equity awards covering the Company&#x2019;s common stock and restricted stock units that are held by you as of immediately prior to the Separation Date shall accelerate vesting in full effective as of the later of the Separation Date or the effective date of the Change in Control (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CIC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Acceleration Benefit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). For the avoidance of doubt, the CIC Acceleration Benefit is conditioned upon the actual consummation of a Change in Control.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">7.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Termination due to Death or Disability.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If your employment with the Company terminates due to your death or Disability, then (a) the vesting and exercisability of all outstanding options, restricted stock awards, and other equity awards covering the Company&#x2019;s common stock that are held by you as of immediately prior to your death or Disability, to the extent such equity awards would </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">otherwise have vested solely conditioned on your continued services with the Company, shall accelerate vesting in accordance with their applicable vesting schedules as if you had completed an additional twenty-four (24) months of service with the Company as of the Separation Date, (b) all payments of compensation by the Company to you hereunder will terminate immediately (except as to amounts already earned), and (c) you will not be entitled to any Severance Benefits or CIC Severance Benefits or CIC Acceleration Benefit.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">7.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Termination for Cause; Resignation Without Good Reason.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If you resign without Good Reason, the Company terminates your employment for Cause, or upon dissolution or cessation of the Company, then (a) you will no longer vest in any equity awards, (b) all payments of compensation by the Company to you hereunder will terminate immediately (except as to amounts already earned), and (c) you will not be entitled to any Severance Benefits or CIC Severance Benefits.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">7.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Conditions to Receipt of Severance Benefits.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  The receipt of the Severance Benefits or CIC Severance Benefits will be subject to you signing and not revoking a separation agreement and general release of claims in a form reasonably satisfactory to the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Separation Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) within the time period set forth therein, and allowing such Separation Agreement to become effective pursuant to its terms by no later than the sixtieth (60th) day after the Separation Date (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Release Deadline</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). No Severance Benefits or CIC Severance Benefits will be paid or provided until the Separation Agreement becomes effective. You shall also resign from all positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the Separation Date. Without your written consent (which may be withheld in your discretion), the Separation Agreement shall not release or reduce any indemnification obligations owed to you.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Definitions.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cause.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  For purposes of this Agreement, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Cause&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> for termination means: (a) conviction of, or plea of guilty or nolo contendere to, a felony or any crime involving fraud, dishonesty or moral turpitude; (b) participation in any fraud against the Company; (c) material and intentional damage to any property of the Company; (d) willful misconduct, or any violation of Company policy that causes material harm to the Company; (e) breach of this Agreement, the Confidentiality Agreement (as defined below), or any other written agreement with the Company; or (f) conduct by you which in the good faith and reasonable determination of the Company demonstrates gross unfitness to serve. For a termination of employment to be for Cause, you must (a) receive a written notice from the Company which indicates in reasonable detail the facts and circumstances claimed to provide a basis for the termination of your employment for Cause; and (b) be provided with an opportunity to cure or resolve, no later than 30 days following the receipt of such notice, the behavior in question (if deemed curable by the Company in its sole discretion).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Change in Control.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">   For purposes of this Agreement, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning as set forth in the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Change in Control Period.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> For purposes of this Agreement, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Change in Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period commencing three (3) months prior to a Change in Control and ending eighteen (18) months following a Change in Control.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Code. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Agreement, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Code&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">means the U.S. Internal Revenue Code of 1986 (as it has been and may be amended from time to time) and any regulations and guidance that has been promulgated or may be promulgated from time to time thereunder and any state law of similar effect.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means your inability to perform satisfactorily all of your usual services for the Company because you have become permanently disabled within the meaning of any policy of disability income insurance covering employees of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when you become disabled, then such term shall mean your permanent and total disability within the meaning of Section 22(e)(3) of the Code.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Good Reason.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Agreement, you shall have &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; for resignation from employment with the Company if any of the following actions are taken by the Company without your prior written consent: (a) a material reduction in your Base Salary, which the parties agree is a reduction of at least 10% of your Base Salary (unless pursuant to a salary reduction program applicable generally to the Company&#x2019;s similarly situated employees); (b) a material reduction in your duties (including responsibilities and/or authorities) other than the transition of duties, responsibilities and authorities to others within the Company as the Company&#x2019;s management team evolves (excluding oversight and management of your primary function); or (c) relocation of your principal place of employment to a place that increases your one-way commute by more than fifty (50) miles as compared to your then-current principal place of employment immediately prior to such relocation. In order to resign for Good Reason, you must provide written notice to the Company&#x2019;s CEO within 30 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for your resignation, allow the Company at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably cured within such period, you must resign from all positions you then hold with the Company not later than 90 days after the expiration of the cure period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Involuntary Termination. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Involuntary Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a termination of your employment with the Company pursuant to either (i) a termination initiated by the Company without Cause, or (ii) your resignation for Good Reason, and provided in either case such termination constitutes a Separation from Service. An Involuntary Termination does not include any other termination of your employment, including a termination due to your death or Disability.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s 2021 Equity Incentive Plan (as it may be amended from time to time).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Separation from Service. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Agreement, &#x201c;Separation from Service&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">means a &#x201c;separation from service&#x201d;, as defined under Treasury Regulation Section 1.409A-1(h).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Proprietary Information Obligations.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  As a condition of employment, you shall execute and abide by the Company&#x2019;s standard form of Proprietary Information and Inventions Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">PIIA Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">otherwise provided or developed by the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section 409A.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A 1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For all purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulations Sections 1.409A-2(b)(2)(i) and (iii)), your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of your Separation from Service to be a &#x201c;specified employee&#x201d; for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#x201c;deferred compensation,&#x201d; then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to you prior to the earliest of (i) the first date following expiration of the six-month period following the date of your Separation from Service with the Company, (ii) the date of your death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. If the severance benefits are not covered by one or more exemptions from the application of Section 409A  and the Release Deadline occurs in the calendar year following the calendar year of your Separation from Service, the Separation Agreement will not be deemed effective any earlier than the Release Deadline for purposes of determining the timing of provision of any severance benefits.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section 280G.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If any payment or benefit you will or may receive from the Company or otherwise (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">280G Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Excise Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then any such 280G Payment pursuant to this Agreement or otherwise (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall be equal to the Reduced Amount. The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Reduced Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Reduction</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Reduction Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest  economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Unless you and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control transaction triggering the Payment shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.  The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other reasonable time as requested by you or the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section so that no portion of the remaining Payment is subject to the Excise Tax). For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section, you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Arbitration of All Disputes.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">12.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agreement to Arbitrate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  To ensure the timely and economical resolution of disputes that may arise between you and the Company, both you and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by applicable law, you and the Company will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement; or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> your employment with the Company (including but not limited to all statutory claims); or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> the termination of your employment with the Company (including but not limited to all statutory claims). </font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By agreeing to this arbitration procedure, both you and the Company waive the right to </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">resolve any such disputes through a trial by jury or judge or through an administrative proceeding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">12.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Arbitrator Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">12.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Individual Capacity Only</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  All claims, disputes, or causes of action under this Section, whether by you or the Company, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences in this Section are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.   </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">12.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Arbitration Process</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by JAMS, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">JAMS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in New York, New York, or as otherwise agreed to by you and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">http://www.jamsadr.com/rules-employment-arbitration/</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">). You and the Company both have the right to be represented by legal counsel at any arbitration proceeding. Each party is responsible for its own attorneys&#x2019; fees. The arbitrator shall: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> have the authority to compel adequate discovery for the resolution of the dispute; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> issue a written arbitration decision, to include the arbitrator&#x2019;s essential findings and conclusions and a statement of the award; and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. You and the Company shall equally share all JAMS&#x2019; arbitration fees, or such fees shall be paid in such other manner to the extent required by, and in accordance with, applicable law to effectuate your and the Company&#x2019;s agreement to arbitrate. To the extent JAMS does not collect or you otherwise do not pay to JAMS an equal share of all JAMS&#x2019; arbitration fees for any reason, and the Company pays JAMS your share, you acknowledge and agree that the Company shall be entitled to recover from you half of the JAMS arbitration fees invoiced to the parties (less any amounts you paid to JAMS) in a federal or state court of competent jurisdiction.   </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">12.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Excluded Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  This Section shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, discrimination or sexual harassment claims, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Excluded Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">12.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Injunctive Relief and Final Orders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Nothing in this Section is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">General Provisions.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> This Agreement, together with the PIIA Agreement, constitutes the entire agreement between you and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the parties&#x2019; agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. Modifications or amendments to this Agreement, other than those changes expressly reserved to the Company&#x2019;s discretion in this letter, must be made in a written agreement signed by you and the Company&#x2019;s CEO. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and their respective successors, assigns, heirs, executors and administrators. The Company may freely assign this Agreement, without your prior written consent. You may not assign any of your duties hereunder and you may not assign any of your rights hereunder without the written consent of the Company. This Agreement shall terminate upon your termination of employment with the Company. The obligations as forth under Sections 7, 8, 9, 10, 11, 12, and 13 will survive the termination of this Agreement. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of New York.    </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">This offer is subject to satisfactory proof of your identity and right to work in the United States and other applicable pre-employment screenings, including without limitation, satisfactory clearance of a background check and review of your responses in a directors&#x2019; and officers&#x2019; questionnaire. If you have any questions about this Agreement, please do not hesitate to call me.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Best regards,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Kevin Lind				</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Kevin Lind</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Accepted and agreed:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Randall E. Kaye</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">			</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Randall E. Kaye, M.D.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">March 17, 2022                         </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Employee Proprietary Information and Inventions Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>lbph-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I, Kevin R. Lind, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this quarterly report on Form 10-Q of Longboard Pharmaceuticals, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.459%;"></td>
    <td style="width:4.759%;"></td>
    <td style="width:3.324%;"></td>
    <td style="width:46.459%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:  May 5, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Kevin R. Lind</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kevin R. Lind</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>lbph-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I, Brandi L. Roberts certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this quarterly report on Form 10-Q of Longboard Pharmaceuticals, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.324%;"></td>
    <td style="width:46.176%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:  May 5, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Brandi L. Roberts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Brandi L. Roberts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>lbph-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Longboard Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the three months ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.459%;"></td>
    <td style="width:4.481%;"></td>
    <td style="width:3.602%;"></td>
    <td style="width:46.459%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:  May 5, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Kevin R. Lind</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kevin R. Lind</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.459%;"></td>
    <td style="width:4.342%;"></td>
    <td style="width:3.74%;"></td>
    <td style="width:46.459%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:  May 5, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/s/ Brandi L. Roberts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Brandi L. Roberts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img8591006_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8591006_0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X2+>17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C T.C(U(#$Q.C$W.C,V   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,S,0  DI(  @    ,S,0  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP-#HR-2 Q,3HQ-SHP-  R,#(R.C T.C(U(#$Q.C$W.C T      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  $3$         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 9 $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M&"#P.3^.: +R*515+LY P6;&3^530_?'U_H: )G3?WQ@U']G_P!K]* #[/\
M[7Z4?9_]K]* #[/_ +7Z4?9_]K]* #[/_M?I1]G_ -K]* #[/_M?I1]G_P!K
M]* #[/\ [7Z4?9_]K]* #[/_ +7Z4?9_]K]* #[/_M?I1]G_ -K]* #R/]K]
M*/L_^U^E !]G_P!K]*/L_P#M?I0 ?9_]K]*/L_\ M?I0 >1_M?I1]G_VOTH
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M &3G[I_2C)_NG]* #)_NG]*,G^Z?TH ,G^Z?THR?[I_2@ R?[I_2C)_NG]*
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MK!(++@@\_P!#4-W-(Q41VT9SS^=&WW/YTB@V^Y_.C;[G\Z #;[G\Z-ON?SH
M-ON?SHV^Y_.@ V^Y_.C;[G\Z #;[G\Z-ON?SH -ON?SHV^Y_.@ V^Y_.C;[G
M\Z #;[G\Z-ON?SH -ON?SHV^Y_.@ V^Y_.C;[G\Z #;[G\Z-ON?SH -ON?SH
MV^Y_.@ V^Y_.C;[G\Z #;[G\Z-ON?SH -ON?SHVC.>?SH __V0#_X3'H:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[
MOR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(^/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C
M(CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB
M83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^/'AM<#I#<F5A=&]R5&]O;#Y7:6YD
M;W=S(%!H;W1O($5D:71O<B Q,"XP+C$P,#$Q+C$V,S@T/"]X;7 Z0W)E871O
M<E1O;VP^/'AM<#I#<F5A=&5$871E/C(P,C(M,#0M,C54,3$Z,3<Z,#0N,S$Q
M/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\+W)D9CI21$8^
M/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L 0P # @(#
M @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3
M%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@%
MW@[[ P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _5.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **ANKJ*SA,LTBQ1KU9C@5S-UXZ#2>796K3MZM_@* .LHKCO^$FUUN4T
MSY?^N$A_K2_\))K_ /T#/_):3_&@#L**X_\ X237_P#H&?\ DM)_C1_PDFO_
M /0,_P#):3_&@#L**X__ (237_\ H&?^2TG^-'_"2:__ - S_P EI/\ &@#L
M**X__A)-?_Z!G_DM)_C1_P ))K__ $#/_):3_&@#L**X_P#X237_ /H&?^2T
MG^-'_"2:_P#] S_R6D_QH ["BN/_ .$DU_\ Z!G_ )+2?XT?\))K_P#T#/\
MR6D_QH ["BN/_P"$DU__ *!G_DM)_C1_PDFO_P#0,_\ ):3_ !H ["BN/_X2
M37_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\ ^$DU_P#Z!G_DM)_C1_PD
MFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-'_"2:_\ ] S_ ,EI/\:
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M,_\ ):3_ !H ["BN/_X237_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\
M^$DU_P#Z!G_DM)_C1_PDFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-
M'_"2:_\ ] S_ ,EI/\: .PHKC_\ A)-?_P"@9_Y+2?XT?\))K_\ T#/_ "6D
M_P : .PHKC_^$DU__H&?^2TG^-'_  DFO_\ 0,_\EI/\: .PHKC_ /A)-?\
M^@9_Y+2?XT?\))K_ /T#/_):3_&@#L**X_\ X237_P#H&?\ DM)_C1_PDFO_
M /0,_P#):3_&@#L**X__ (237_\ H&?^2TG^-'_"2:__ - S_P EI/\ &@#L
M**X__A)-?_Z!G_DM)_C1_P ))K__ $#/_):3_&@#L**X_P#X237_ /H&?^2T
MG^-'_"2:_P#] S_R6D_QH ["BN/_ .$DU_\ Z!G_ )+2?XT?\))K_P#T#/\
MR6D_QH ["BN/_P"$DU__ *!G_DM)_C1_PDFO_P#0,_\ ):3_ !H ["BN/_X2
M37_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\ ^$DU_P#Z!G_DM)_C1_PD
MFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-'_"2:_\ ] S_ ,EI/\:
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M,_\ ):3_ !H ["BN/_X237_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\
M^$DU_P#Z!G_DM)_C1_PDFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-
M'_"2:_\ ] S_ ,EI/\: .PHKC_\ A)-?_P"@9_Y+2?XT?\))K_\ T#/_ "6D
M_P : .PHKC_^$DU__H&?^2TG^-'_  DFO_\ 0,_\EI/\: .PHKC_ /A)-?\
M^@9_Y+2?XT?\))K_ /T#/_):3_&@#L**X_\ X237_P#H&?\ DM)_C1_PDFO_
M /0,_P#):3_&@#L**X__ (237_\ H&?^2TG^-'_"2:__ - S_P EI/\ &@#L
M**X__A)-?_Z!G_DM)_C1_P ))K__ $#/_):3_&@#L**X_P#X237_ /H&?^2T
MG^-'_"2:_P#] S_R6D_QH ["BN/_ .$DU_\ Z!G_ )+2?XT?\))K_P#T#/\
MR6D_QH ["BN/_P"$DU__ *!G_DM)_C1_PDFO_P#0,_\ ):3_ !H ["BN/_X2
M37_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\ ^$DU_P#Z!G_DM)_C1_PD
MFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-'_"2:_\ ] S_ ,EI/\:
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M,_\ ):3_ !H ["BN/_X237_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\
M^$DU_P#Z!G_DM)_C1_PDFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-
M'_"2:_\ ] S_ ,EI/\: .PHKC_\ A)-?_P"@9_Y+2?XT?\))K_\ T#/_ "6D
M_P : .PHKC_^$DU__H&?^2TG^-'_  DFO_\ 0,_\EI/\: .PHKC_ /A)-?\
M^@9_Y+2?XT?\))K_ /T#/_):3_&@#L**X_\ X237_P#H&?\ DM)_C1_PDFO_
M /0,_P#):3_&@#L**X__ (237_\ H&?^2TG^-'_"2:__ - S_P EI/\ &@#L
M**X__A)-?_Z!G_DM)_C1_P ))K__ $#/_):3_&@#L**X_P#X237_ /H&?^2T
MG^-'_"2:_P#] S_R6D_QH ["BN/_ .$DU_\ Z!G_ )+2?XT?\))K_P#T#/\
MR6D_QH ["BN/_P"$DU__ *!G_DM)_C1_PDFO_P#0,_\ ):3_ !H ["BN/_X2
M37_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\ ^$DU_P#Z!G_DM)_C1_PD
MFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-'_"2:_\ ] S_ ,EI/\:
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M,_\ ):3_ !H ["BN/_X237_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\
M^$DU_P#Z!G_DM)_C1_PDFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-
M'_"2:_\ ] S_ ,EI/\: .PHKC_\ A)-?_P"@9_Y+2?XT?\))K_\ T#/_ "6D
M_P : .PHKC_^$DU__H&?^2TG^-'_  DFO_\ 0,_\EI/\: .PHKC_ /A)-?\
M^@9_Y+2?XT?\))K_ /T#/_):3_&@#L**X_\ X237_P#H&?\ DM)_C1_PDFO_
M /0,_P#):3_&@#L**X__ (237_\ H&?^2TG^-'_"2:__ - S_P EI/\ &@#L
M**X__A)-?_Z!G_DM)_C1_P ))K__ $#/_):3_&@#L**X_P#X237_ /H&?^2T
MG^-'_"2:_P#] S_R6D_QH ["BN/_ .$DU_\ Z!G_ )+2?XT?\))K_P#T#/\
MR6D_QH ["BN/_P"$DU__ *!G_DM)_C1_PDFO_P#0,_\ ):3_ !H ["BN/_X2
M37_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\ ^$DU_P#Z!G_DM)_C1_PD
MFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-'_"2:_\ ] S_ ,EI/\:
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M,_\ ):3_ !H ["BN/_X237_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\
M^$DU_P#Z!G_DM)_C1_PDFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-
M'_"2:_\ ] S_ ,EI/\: .PHKC_\ A)-?_P"@9_Y+2?XT?\))K_\ T#/_ "6D
M_P : .PHKC_^$DU__H&?^2TG^-'_  DFO_\ 0,_\EI/\: .PHKC_ /A)-?\
M^@9_Y+2?XT?\))K_ /T#/_):3_&@#L**X_\ X237_P#H&?\ DM)_C1_PDFO_
M /0,_P#):3_&@#L**X__ (237_\ H&?^2TG^-'_"2:__ - S_P EI/\ &@#L
M**X__A)-?_Z!G_DM)_C1_P ))K__ $#/_):3_&@#L**X_P#X237_ /H&?^2T
MG^-'_"2:_P#] S_R6D_QH ["BN/_ .$DU_\ Z!G_ )+2?XT?\))K_P#T#/\
MR6D_QH ["BN/_P"$DU__ *!G_DM)_C1_PDFO_P#0,_\ ):3_ !H ["BN/_X2
M37_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\ ^$DU_P#Z!G_DM)_C1_PD
MFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-'_"2:_\ ] S_ ,EI/\:
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M,_\ ):3_ !H ["BN/_X237_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\
M^$DU_P#Z!G_DM)_C1_PDFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-
M'_"2:_\ ] S_ ,EI/\: .PHKC_\ A)-?_P"@9_Y+2?XT?\))K_\ T#/_ "6D
M_P : .PHKC_^$DU__H&?^2TG^-'_  DFO_\ 0,_\EI/\: .PHKC_ /A)-?\
M^@9_Y+2?XT?\))K_ /T#/_):3_&@#L**X_\ X237_P#H&?\ DM)_C1_PDFO_
M /0,_P#):3_&@#L**X__ (237_\ H&?^2TG^-'_"2:__ - S_P EI/\ &@#L
M**X__A)-?_Z!G_DM)_C1_P ))K__ $#/_):3_&@#L**X_P#X237_ /H&?^2T
MG^-'_"2:_P#] S_R6D_QH ["BN/_ .$DU_\ Z!G_ )+2?XT?\))K_P#T#/\
MR6D_QH ["BN/_P"$DU__ *!G_DM)_C1_PDFO_P#0,_\ ):3_ !H ["BN/_X2
M37_^@9_Y+2?XT?\ "2:__P! S_R6D_QH ["BN/\ ^$DU_P#Z!G_DM)_C1_PD
MFO\ _0,_\EI/\: .PHKC_P#A)-?_ .@9_P"2TG^-'_"2:_\ ] S_ ,EI/\:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!" >,5SNO>%8KQ
M&FM%6"Z4$C;PK'WQT/O71TG% '/>$]<>_C>UN,BYA ^]U9??W%=#7&WJ?V7X
MUMVCX6X*DCM\V0?U%=D* %HHHH **** "BBB@ KF_'G_ ""8?^NX_P#06KI*
MYOQY_P @F#_KN/\ T%J -?1?^0/8_P#7"/\ ]!%7:I:+_P @>P_ZX1_^@BKM
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''^(_\ D;M+
M_P"V7_HPUV%<?XC_ .1NTO\ [9?^C#784 %%%% !1110 4444 %<WX\_Y!,'
M_7<?^@M725S?CS_D$P?]=Q_Z"U &OHO_ "![#_KA'_Z"*NU2T7_D#V'_ %PC
M_P#015V@ I*6D- !^-%8VH?\?DGX?RJM0!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[1
M0!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5%<[10!T5
M%<[10!T5%<[10!T5%<[10!T5+63I7_'PW^[_ %%:M '(>(_^1NTO_ME_Z,-=
MA7'^(_\ D;M+_P"V7_HPUV% !1110 4444 %%%% !7-^//\ D$P?]=Q_Z"U=
M)7-^//\ D$P?]=Q_Z"U &OHO_('L/^N$?_H(J[5+1?\ D#V'_7"/_P!!%7:
M"D-+2&@#&U#_ (_)/P_D*K59U#_C\D_#^0JM0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!=TK_CX;_=_J*U:RM*_X^&_W?ZBM6@#D/$?_(W:7_VR_P#1AKL*
MX_Q'_P C=I?_ &R_]&&NPH **** "BBB@ HHHH *YOQY_P @F#_KN/\ T%JZ
M2N;\>?\ ()@_Z[C_ -!:@#7T7_D#V'_7"/\ ]!%7:I:+_P @>P_ZX1_^@BKM
M !2&EI#0!C:A_P ?DGX?R%5JLZA_Q^2?A_(56H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HIK,%906"DYV@GJ<?CTZT[^G^>: "BCIUX_P _6C\* "BBB@ H
MHH]Z "BCIUX_S]:/PH **** "BBB@ HHH]S]?:@ HI&8+C=P<@<GU_Q[4M !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 44=N>,FD5U<95@PR1E2",@X(X]",?A0 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%(3_G_ #_GBA6610RG<IY!]1VH
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***/PH **1F5
M5)9MHZ%CT'I2Y_PZYH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***/\]* "BBC_ #Q_
MGZ4 %%(KJX^4@X)!P<\^E+0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1137D6-69V5549+,0,#_/\J '44?7KWXHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"[I7_'PW^[_45JUE:5_Q\-_N_P!16K0!R'B/_D;M+_[9?^C#785Q_B/_
M )&[2_\ ME_Z,-=A0 4444 %%%% !1110 5S?CS_ )!,'_7<?^@M725S?CS_
M )!,'_7<?^@M0!KZ+_R![#_KA'_Z"*NU2T7_ ) ]A_UPC_\ 015V@ I#2TAH
M QM0_P"/R3\/Y"JU6=0_X_)/P_D*K4 %'I]:*/\ ]5 'R5^U9<?%'X0:+<>,
M-%^)5U)I=SJ7DC26T^%?LJ2!V0+)@[@H7;R.>#GFO-/V>O'GQI^/^N:IIUM\
M39=&6PMUG>6:Q@D+@MM  "#^=>W_ +?G_) V_P"PI;#]'KQ[_@FZH/BOQJQ&
M6^PV_/?[[?X#\J8"_'+Q!^T'^SX]CJ5YX\_MK1[J7RH[V"SA*B7!(C>-H_E)
M"D\$@X;GBO:_V2?VF+KXY:?J>F:[;0V_B+3%24RVZE8[J$G&\*3PP/4#CYEQ
M53]OO6+&Q^!+V=U(OVN^U&W6VC+?,S*2S$#_ '01GW%>2_\ !.;PA>QZWXK\
M62QF+3([1=/25@0LDA=97 ]=H1/^^Q2 ^Z_UHKYW\3_MW?"K087^PWNH:_,O
M'EZ?9.H)^LI3C/<9_&K&N?MD>%_#OPC\/^,[VPN!>:[YIL]#BE5IBL<KQL[-
MP F5'S8ZL ,\T ?0%%<7\)?B;;?%7X:Z7XQ2T?2;:]29VMYY QB$<KQG+8 Q
ME"<XZ$=*\D\3?MO>%X/$O_"/^#-!U;Q]J@=E TJ/]U)MZ[&^9GQR<A=O'4CF
M@#Z/HKY9_P"&\=-\/^(AI/C7P%X@\)2X!/F@2.H)QO*,$)7KAER#VSQ7TIX:
M\2Z7XOT.SUG1KZ'4M,NT\R"Y@;<KC)'IU!!!!Y!!!Y% &E17 _%OXX>$_@GI
M$=[XEOVBFN-PM;&W3S+BY9<9"+[9')('(YKR&_\ VS-3L= 3Q&_PE\31^%Y!
MO75IF")M)PK$;2-IR,'=CT- 'TY17@WA/]MKX4^)-)2ZN];ET"Y)VM8ZA;2>
M8ISCAD#*P/J#GV%=5XF_:8^&_A'PUHVOW_B)1IFL+(VGRQ6L\AN!&P5B $R,
M$X^;'KVH ]/HKY]\"_MH>$/B1\1K#PKHFGZ@L-Q'<2/JFH>7;Q(L43R%L;B2
M,)C)VT_P5^V)X;^(7QDM_ FA:7>74$[7"1ZP\BK&QBB>0E4QN*D1M@G!.0<"
M@#W^BN#^+'QN\(_!C2Q=^)=2$,T@)@T^W_>7,V.NU,]/]IB%'<]*\!L_^"CO
MA.2^*7/A36(K3< LL<L4CGG^YE1T[;J /KJBL/P3XVT7XA^&;+7O#]\FHZ7=
MJ3'.H*\@X*LIY4@Y!!QR/>O*/'7[9_PO\":CJ&G3ZG>:EJ5C*]O/9V%E(S+(
MC%77<X1"0<C.XB@#W.BOG[1_VT/!EU\,;OQGJ<,^DQ+?2V-II;.DMW=LB1N6
M15.T#]X,Y.!W;D"N3\,_\%$/!>K:U#::IH6J:-9S.%6^8I,B9(^9U4A@.N=N
MXCC@T ?5M%>*_&C]K+P5\&9+:TGEDUW5IU$@L=-96,<9&5=V)"J""".I((.,
M$&L;X,_MI^#_ (M>(8- FLKOP]K%SQ;QW962&9L9*+(IX;J & SP!R<4 ?0=
M%'^>** "BBB@ HHHH **** "N/\ B7X1\1>+]+MK?PWXQN/!MY'+O>Y@LX[G
MS5P0%*N1@9(.<C_#L** /RX\3?M/_&3PSXBU71I_'%R]SI]W-9NRVL #/&Y0
MX!C]17WI^S3\5C\8/A'I&LW$RRZM#FSU'H#YZ8!) Z%U*OQQ\U?%>N_"4?$+
M2?CQK%G"9-8\.^)I;R/:,L]OYL_GI]-H#_\ ;/'>K'["/Q;'@;XG/X:OY_*T
MKQ&%@0L?ECNE)\H^V[)3W)7TH _1^O.OV@?B<GPC^$^N^(%D5;]8O(L%8CYK
MA_E3 /7'+GCHAKT7T/08_"ODCXV,?V@/V@M/\ Q,TWA7P?;/J>LA3\DEQM!6
M(GH>L:>HWR^E 'SQX)_:4^,GC;QCH?AZW\=W$$^JWL-DDTEM!M0R.J[B-F>,
MYP#V-?HI\-_"VO>$=!ELO$/BNX\8WSW#2KJ%Q:1VQ5"J@1A$)& 58Y//S'VK
M\MOV<R?^%[> O7^V+;/_ '\%?KGU; ^F*8!17G?Q6^/G@WX.1QKK^H,^HS &
M'2;%/.NY<G Q'G@=>6*@D=>*\C_X;X\,Z7JT5GXB\'^)?#T4VTQS75NN=IX#
ME"P.WGMN]L]T!]045F>&?$VE^,M"L]:T6]BU'2[Q/,@N(2=K#H>#R""""" 0
M0<\U4\;>.] ^'.@SZUXCU.'2M.AZRRG)9NRJH&7/'W1DG!XH WJY#XH>#]<\
M;>'8[#0/%UWX-NEG$CWUG LK.@5AL.XC )*G((/RX[U\\7W_  4:\'PZA)';
M>%]9N+16P)V>)&(]=NX]>W]*^AOA3\4=*^,'@VV\3:+#=VUG,[Q".]C"2JZ-
MA@0"1U'4&@#\U_".O>)]<_:*\(Z7XE\0:AKT]GXHM;9FO+J2905NU5BH8G X
M)_&OU8]_6ORH\#@_\-::3@=/&2_E]LY_+K7V-\1OV[/ 7@77KC1["WOO$UQ;
M-LFN+#RQ;!AU42%LL1[#'OWI@?2-%>7_  3_ &C?"/QV@N5T&2XMM2M5$EQI
MM^@CF1#@;P%+!ER<9W<=\96O3I9DMX6ED94C1=S,S;0 .Y)^GM2 =17S3\1O
MV]/ ?@S5)=/T:WNO%LT)*R7-DRI:Y''RR'[W/=05/9C6Y\'?VRO!/Q<UZ/0T
MAO- UF;'V>WU *4N&QG:CJ3\WL0,]L]* />J*Y7XC?%#PS\)=#CU;Q5J?]F6
M$DRVT;^3)*SR%2=@$:DDD*W..,=<UXW8_MS>"?$/CC0O#6@:=JFI2ZI?0V7V
MR:-;>&+S'"AAN8L>N<$#IUH ^CJ*^;_B1^W7X#\">(+C1[&VOO$UQ;MMFN-/
MV"V#=U60D%B/88]^M>@?!/\ :-\(_':"Y709+BVU*U427&FWZ".9$.!O 4L&
M7)QG=QWQE: .^\2/J$?AW5&T@*=66UE-GOQCSMAV9SQC=MZ_XU^>G[,.M?%2
M?]H:RBN;C7IB)Y%UR'46E,:1;2'\T-\JD'&W(&&P!7W5\2_C%X2^#]G97?BK
M5?[,2\9DM@L$LK2LH!( 121P1R<5Y9X7_;7\'^.OB-H7A+PYINJ7SZC-Y7V^
MX1((D 4L65<ECP.X% 'T,?\ /%%-9A'&S.RQJHRS,<!0.IKY]U7]LK0[[Q!=
M:-X%\+Z]\0KRV&9)='M_W SD?>P3MR/O;<<\$C% 'T)17SYX!_;"TSQ5X_LO
M!FM>$->\)^(+QQ'%!?1 @,02 X.U@.#@[/KBNY^*7[1'@/X.ZA#I_B?6'M=2
MFMQ<Q6<-M++(\9+*#E5*CE&')'([T >E45\__#[]M+P5\0O$NLV44%UHVCZ5
MILFHW&K:LR1+M26./:$4L?F,@(YR2,8YXXN__P""C'@ZWUAX+;PWK%WIZN5^
MU[XD=@&QN$98\8R0"03QT[ 'UI17DVI?M0_#_2_A?;>.GU??IET&2WM%4?:I
M9E(#0B,G(<$X)/ R#G!!/E/A_P#X*(^"]1UM+34M!U72;"1]BWQ*3;1Q\SHI
MR!USLW'CC- 'U?14-C>V^I6=O=VD\=S:7$:S0S1,&21&&592.H((.:FH **:
M\BQ(SNRJJC)+'  [G-?.?BK]M_PK9^)!X?\ !^BZKX]U8N8U72H_W4K 9(C8
M;F?&#RJ8.."1S0!]'45\LR?MX6'AKQ -*\:^ ?$'A.3 8F;:[JI.-Y1@AV>A
M&<^^,5])>%_%.D^--"L]9T2^AU'2[I-\5S"V589P?<$$$$'D$$=<T 4?B!X^
MT;X8^$[_ ,1:]<_9M.LURV!EW8G"HB_Q,QX _P#KFOC2/P?X[_;L74/$LFN6
MWAGPKI]TUKINE.&E&]45BS $9;#+ESGG( P,5T/_  40\;Z3=>%_#_AJUU:W
MN-3AU$W=UI\,@:2)1$RJSJ.5^^>#57]CWX_?#[X7_!N33/$WB2/3-0_M">Y:
MW:":1MI5 &&Q#UV]!S3 ^F/@+X%U#X9_"/PYX9U1X);_ $^%XY'M6+1G,KL-
MI(!(PP["N^K,\->)-.\8:#8ZWI-Q]KTV_B$]O.8GC\Q&Y!VL 1^(K3I %%%%
M !1110 4444 %%%% !1110 4444 >%?MB>+/$_@[X:Z3>>$=4ETK5I=;M[82
M0A29%=)%V$$$$%BGX@5QL7PA_:6:%3)\6M*63'S*L&0#T(S]G^O:OHWQ5X.T
M7QM:6EIKE@NHV]K=1WL,;,PV31YV/P1TR>O!K:Z@YYH _+_QE^TI\9O!/B[6
MO#]YXZGFN=+O)K&22*"'8[1N4++^[!(RN:^F(?A)^TG-"DO_  MK3%5U# &
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M F#P@9B0>.N/I2 ]XZ<44=N!V_'I^5>3?&?]IKP7\$E^S:K=R:CK3#<FDZ<
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MBOGGPG^VOX/\??$?1O"F@Z=J4ZZ@[HVI72K#$@6-GW!=Q)'RXYV]?PJ;P_\
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M-'AUM7\-W3RK&P2YM;A=D]L^"0KKT_$$@^IH [>BBB@ HHHH **** "BBB@
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M3-?JM3 ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRHXX5BB(4#))^9GY))YZ\5X7_P %'M/@TZR^&L-I;16EK#_:")#"@1$'^C$
M*.!T/2O3OV 8PGP$) QNU:Y)_*,?TJ@/I*BBBI **** "BBB@ HHHH ****
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M%/V?]:\;>*Q\5/BZGVOQ#<8DT[0YHSY-A&#E-R'H1QM3^'DME_N_4 SCGTH
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MY#C/)]B>M?I37PE\3?A4/C#^T]\:=$A0-JD6@VM[I['M<1Q614?\"!9/^!T
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M+'9OI\>IVPN%MI'WL@.< G SQ[5\G?\ !2@#[)\/3CD27^#^%O0!ZE^PF/\
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MB%R!]\<9/3K7:>+O&&C> O#UWKGB#4(M,TNU \ZXFR1R<  #DL3@!1DDG@4
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M7$D-W=_V8;F0A96A8RSR [>QP4/JK8/6N;_X)O\ AJU:'QIK[Q!KU7ALHI6
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MG@9]?\^U 'GFN?!WPMJ7Q,'Q UM(KN[M-+&GK;WRQM:P*LC2>=\PX?YB,YP
M37RU^W-JGPM\2>&[&[\/:MHMWXPLKQ8I/[,D1VD@*L&60H-IPP0_,21\P[UY
MG\3O'VH?'7]I2#P[XBU:XM?"R^(%TJ&TCD,<4,"S^47"G@2,.2S<@MZ 5[O^
MV-X#\"_"WX!C2M!T?2]#O+J^@2%8D47-PJ$ELNWSO@8R6/&1DT 2?\$X[Z:;
MX=^*+1I&:"'5%>-23\I>%0<?]\BJ?_!1G2[*+P7X5O8K2&.[;4I(VF5 '*F(
MG&<<C*BK'_!.$*/ /BUP?G.IID>WDC'U[TO_  4<91\/O":;L$ZHY''I$?\
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M0$(&3V&3Q[TS_@H^?^*)\'G_ *B,Q/\ WZKJ_P#@GW/YOP(G7/\ JM8N$_\
M'(F_K3 ^C=-TVUT;3K:PL;>.TLK:-88+>% J1HHPJJ!P !P!5FBBD 4444 %
M%%% !1110 4444 %%%% !1110 >W:CUHHH _(7X_?\EQ\??]AZ\_]'/7ZYV'
M_'E;>T:D?D*_(KX]R"3XX>/V7YA_;U]C\)W%?KGIKK)I]JR'<K1(0?4;1S3
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M&S]EWP-XP^'NJQ:7X:TW0]9M+:26QN],MDMV$BJ65'*J R$C:=PXR2*^7?\
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MP.>,5XQ_P3C5#\2/%)ZR#25 YZCSDSQ^ H _0'N:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\*_;<_Y-M\4_]=+/_P!*HJ]UKPC]MZ0+
M^S;XF!(!:6S ]_\ 28S_ "S^5 'RI^PCH]QX@\>>,-.M-4N-%N[CPY*D6H6N
M/,MW-Q!M=03S@]1W''?CZ(U;]BR;QYK,%YX_^).N^+8X#^[MC$ENJJ<97JP
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MI;!CWC;TW8/85VGQ$LUT_P"#_B>T0 )!H5U$ /18&%=EZY!.>H Y-<M\5O\
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MG2>&?^PK-_Z#)7ZHU^5'[/$AC_:=\+'.TG6&7/UW#_/UK]5Z8!1112 ****
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M4IG C^'L(P7W7[X]/^/<#^9_*O2OV [@3? %$!R(=4N4_1#_ %I@?2%%%%(
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#XQ_X*2_\@3P)_P!?%Y_Z!%6=^Q;X/U?QI\$?$%GH
MGBB]\)7\?B!9A?64:R%E%LH,;*3RISGZJ*T/^"DTBC1_ 29^=I[P@>P6'/\
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MD_V8*JVSN ?)(!R#U."%.".*^+?VY/ GA_X?_$[1+'PYI5MI%I-I"7$D5LN
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M%"97DQEBS?,Q).22>O>MVB@ ZDD]:*** "BBB@ HHHH **** "BBB@ HHHH
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M2-D9556,8!PS$M@ 5]L^!_"-GX!\'Z-X<T_)M-,M8[5&;&7VJ 6..[')/N:
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M@ZM;Z3J\D*P7<%XC&*;9PK[ER0P4!3Q@A1C!Z_3H)'(X-% 'RAX-_85MM/\
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M/))YKD/ G[$?BSX3ZO)J_@[XKC3M3DA-N[OH*,K1G!*E7F=3R!CY>"*^N:*
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M=\#<P';)R<=JGHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ H_#/MT_"BB@#Y1^(7['?C?XQ364W
MC7XNKJ+V(D6T$>@1QI&KE=QPDJ#)VKV[#GIB;X?_ +(WQ ^#ZW<?@OXNIIZ7
MK*US'-H$;J2H.T@/)(!P<$C';GBOJC)HH ..@Z5E^*+/5=0\/:A;:)J,>DZK
M)$5MKV6 3K"^1ABA(W=^./QK4HH ^/\ QI^P=K_Q*\17/B+Q/\45N]8O-HFD
M700$ 50JA0LR@   =/?O7O'P<\!^,OA_8G3/$GC2'Q5I=M;16NGH-.2VE@5
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MT'X9^&[?0O#MA'I^GP\[%Y9V.,N['EF.!DGT[  5T5% !1110 4444 %%%%
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MVB+*G_?3&1O<;:Y+XE_' _M::EH_PP^'MO?Q:9J$R7&MZE<1B/RK=&!( R>
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M?X#Z'\>O#,&GZI,]A?V;--9ZE;@.T#$#<"#PR-A<@XSM!!'6O3:* /D/X<_
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MWV>YL[D#?&VT,"""05(.0?8T >C44>U% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<KXL^%?@[QUJ$5]XB\-Z9K-
MY%&(8YKVW61U0$L%!(X&23^-=510!YU_PSK\+_\ H0M QUS]@3@_7%=UI.DV
M6A:9;:?IUK%96%K&(H+>!0J1H. J@< #TJW[T4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]LO_ $8:["N/\1_\C=I?_;+_ -&&NPH **** "BBB@ HHHH *YOQY_R"8/\
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MTOQ5J7QI^#-AKG@O6$\,ZGJ]NDD%Y-;)="U</B9"C<-@JZ9/UP.E(#T;L?\
M)_STI>><C![C!_R*_*OXW?$3XEZ3\0-7\,>)O&VI:O\ V9=>5(MM.8()0,,&
M\I-JY((Z],GGM7T#\4O ?[0OQITEO%%O=Q>&=': RV7A2SU*6&Y:(C</,"J%
M>0C'#-D=-J\BF!]I?2BOS@_9-_:,\7:%\4-%\,ZQK-]K&A:O<+8M;:A.TSV\
MC_+&T98EDPY&5!P03WQ7Z/\ Z&@ HHHI %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP,84DL26+,%QCUYH ^6/^"C'/Q>\/]Q_82?^E$]?9_P!_P"2'^ #W_L*S_\
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MC@>BYXYK]5_!WC31?B!H,.M>'K^/4M+F9UCN(U902K%6&& /!!'2@#;HHHI
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!=TK_CX;_=_J*U:RM*_P"/AO\ =_J*
MU: .0\1_\C=I?_;+_P!&&NPKC_$?_(W:7_VR_P#1AKL* "BBB@ HHHH ****
M "N;\>?\@F#_ *[C_P!!:NDKF_'G_()@_P"NX_\ 06H U]%_Y ]A_P!<(_\
MT$5=JEHO_('L/^N$?_H(J[0 4AI:0T 8VH?\?DGX?R%5JLZA_P ?DGX?R%5J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ADLX)9TG>"-YD&%D9 67Z'M2?8;;[4+G[/%]H' FV#?TQUZ]*GHH !\N
M,<51.AZ:W73[4_\ ;%?\*O44 5I--LYG1Y+2!W0 *S1J2H'3''%6?\<T44 <
MGK7PD\#^)+YKW5O!VA:E>,=S7%SIL,DC?5F4DY]ZW]'T33O#MBEEI6GVNF6:
MG*V]G"L48SZ*H %7:* (;RRM]1MWM[NWBNK=QAHID#JWU!X/0?E571?#NE>&
MX6ATG3+/2XF.6CLK=(5)]2% K0HH BBM(()))(H8XY).7=4 +?4]Z);2">2.
M22&.22,Y1F0$J?4'M4M% !7):Y\(_ _B6\-YJO@_0M1NRV]KBZTZ%Y&YSRQ4
MDY]*ZVCWH SM#\-Z3X7LQ::-I=EI-IG<(+&W2&/GOM4 ?_JJ[/;Q743131I+
M$V-R2*&!P<C(-244 (J+&H15"JHP% P!BF6]K#:J5AB2%2VXB-0H)]>.]244
M 5?[+LO+:/['!Y;'<R>4N"?4C'6IH+>*UC$<,:11CHD:A0/P%244 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH NZ5_P ?#?[O]16K65I7_'PW^[_45JT
M<AXC_P"1NTO_ +9?^C#785Q_B/\ Y&[2_P#ME_Z,-=A0 4444 %%%% !1110
M 5S?CS_D$P?]=Q_Z"U=)7-^//^03!_UW'_H+4 :^B_\ ('L/^N$?_H(J[5+1
M?^0/8?\ 7"/_ -!%7: "D-+2&@#&U#_C\D_#^0JM5G4/^/R3\/Y"JU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %W2O^/AO]W^HK5K*TK_CX;_=_J*U: .0\
M1_\ (W:7_P!LO_1AKL*X_P 1_P#(W:7_ -LO_1AKL* "BBB@ HHHH **** "
MN;\>?\@F#_KN/_06KI*YOQY_R"8/^NX_]!:@#7T7_D#V'_7"/_T$5=JEHO\
MR![#_KA'_P"@BKM !2&EI* ,;4/^/R3\/Y"JU;DEG#*Q9TW,>^33?[/M_P#G
MG^IH Q:*VO[/M_\ GG^IH_L^W_YY_J: ,6BMK^S[?_GG^IH_L^W_ .>?ZF@#
M%HK:_L^W_P">?ZFC^S[?_GG^IH Q:*VO[/M_^>?ZFC^S[?\ YY_J: ,6BMK^
MS[?_ )Y_J:/[/M_^>?ZF@#%HK:_L^W_YY_J:/[/M_P#GG^IH Q:*VO[/M_\
MGG^IH_L^W_YY_J: ,6BMK^S[?_GG^IH_L^W_ .>?ZF@#%HK:_L^W_P">?ZFC
M^S[?_GG^IH Q:*VO[/M_^>?ZFC^S[?\ YY_J: ,6BMK^S[?_ )Y_J:/[/M_^
M>?ZF@#%HK:_L^W_YY_J:/[/M_P#GG^IH Q:*VO[/M_\ GG^IH_L^W_YY_J:
M,6BMK^S[?_GG^IH_L^W_ .>?ZF@#%HK:_L^W_P">?ZFC^S[?_GG^IH Q:*VO
M[/M_^>?ZFC^S[?\ YY_J: ,6BMG^S[?_ )Y_J:JVMK')<3JRY53P,GUH H45
MM?V?;_\ //\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']GV_\ SS_4T 8M%;7]
MGV__ #S_ %-']GV__//]30!BT5M?V?;_ ///]31_9]O_ ,\_U- &+16U_9]O
M_P \_P!31_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30!BT5M?V?;_\
M//\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']GV_\ SS_4T 8M%;7]GV__ #S_
M %-']GV__//]30!BT5M?V?;_ ///]31_9]O_ ,\_U- &+16U_9]O_P \_P!3
M1_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30!BT5M?V?;_\ //\ 4T?V
M?;_\\_U- &+16U_9]O\ \\_U-']GV_\ SS_4T 8M%;7]GV__ #S_ %-']GV_
M_//]30!BT5M?V?;_ ///]31_9]O_ ,\_U- &+16U_9]O_P \_P!31_9]O_SS
M_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30!BT5M?V?;_\ //\ 4T?V?;_\\_U-
M &+16U_9]O\ \\_U-']GV_\ SS_4T 8M%;7]GV__ #S_ %-']GV__//]30!B
MT5M?V?;_ ///]31_9]O_ ,\_U- &+16U_9]O_P \_P!31_9]O_SS_4T 8M%;
M7]GV_P#SS_4T?V?;_P#//]30!BT5M?V?;_\ //\ 4T?V?;_\\_U- &+16U_9
M]O\ \\_U-5=0M(H8-R+M.>N30!GT5LK80$9,?/U-+_9]O_SS_4T 8M%;7]GV
M_P#SS_4T?V?;_P#//]30!BT5M?V?;_\ //\ 4T?V?;_\\_U- &+16U_9]O\
M\\_U-']GV_\ SS_4T 8M%;7]GV__ #S_ %-']GV__//]30!BT5M?V?;_ ///
M]31_9]O_ ,\_U- &+16U_9]O_P \_P!31_9]O_SS_4T 8M%;7]GV_P#SS_4T
M?V?;_P#//]30!BT5M?V?;_\ //\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']G
MV_\ SS_4T 8M%;7]GV__ #S_ %-']GV__//]30!BT5M?V?;_ ///]31_9]O_
M ,\_U- &+16U_9]O_P \_P!31_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#/
M/]30!BT5M?V?;_\ //\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']GV_\ SS_4
MT 8M%;7]GV__ #S_ %-']GV__//]30!BT5M?V?;_ ///]31_9]O_ ,\_U- &
M+16U_9]O_P \_P!31_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30!BT5
MM?V?;_\ //\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']GV_\ SS_4T 8M%;7]
MGV__ #S_ %-']GV__//]30!BT5M?V?;_ ///]31_9]O_ ,\_U- &+16U_9]O
M_P \_P!31_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30!BT5M?V?;_\
M//\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']GV_\ SS_4T 8M%;7]GV__ #S_
M %-']GV__//]30!BT5M?V?;_ ///]31_9]O_ ,\_U- &+16U_9]O_P \_P!3
M1_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30!BT5M?V?;_\ //\ 4T?V
M?;_\\_U- &+15^WM8GNIE9<J.@YJW_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;
M_P#//]30!BT5M?V?;_\ //\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']GV_\
MSS_4T 8M%;7]GV__ #S_ %-']GV__//]30!BT5M?V?;_ ///]31_9]O_ ,\_
MU- &+16U_9]O_P \_P!31_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30
M!BT5M?V?;_\ //\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']GV_\ SS_4T 8M
M%;7]GV__ #S_ %-']GV__//]30!BT5M?V?;_ ///]31_9]O_ ,\_U- &+16U
M_9]O_P \_P!31_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30!BT5M?V?
M;_\ //\ 4T?V?;_\\_U- &+16U_9]O\ \\_U-']GV_\ SS_4T 8M%;7]GV__
M #S_ %-']GV__//]30!BT5M?V?;_ ///]31_9]O_ ,\_U- &+16U_9]O_P \
M_P!31_9]O_SS_4T 8M%;7]GV_P#SS_4T?V?;_P#//]30!BT5M?V?;_\ //\
M4T?V?;_\\_U- &+16U_9]O\ \\_U-)_9]OD?N_U- &-16A8VL4L;ETW$' Y-
M6O[/M_\ GG^IH Q:*VO[/M_^>?ZFC^S[?_GG^IH Q:*VO[/M_P#GG^IH_L^W
M_P">?ZF@#%HK:_L^W_YY_J:/[/M_^>?ZF@#%HK:_L^W_ .>?ZFC^S[?_ )Y_
MJ: ,6BMK^S[?_GG^IH_L^W_YY_J: ,6BMK^S[?\ YY_J:/[/M_\ GG^IH Q:
M*VO[/M_^>?ZFC^S[?_GG^IH Q:*VO[/M_P#GG^IH_L^W_P">?ZF@#%HK:_L^
MW_YY_J:/[/M_^>?ZF@#%HK:_L^W_ .>?ZFC^S[?_ )Y_J: ,6BMK^S[?_GG^
MIH_L^W_YY_J: ,6BMK^S[?\ YY_J:/[/M_\ GG^IH Q:*VO[/M_^>?ZFC^S[
M?_GG^IH Q:*VO[/M_P#GG^IH_L^W_P">?ZF@#%HK:_L^W_YY_J:/[/M_^>?Z
MF@#%HK:_L^W_ .>?ZFC^S[?_ )Y_J: ,6BMK^S[?_GG^IH_L^W_YY_J: ,6B
MMK^S[?\ YY_J:/[/M_\ GG^IH Q:*VO[/M_^>?ZFC^S[?_GG^IH Q:*VO[/M
M_P#GG^IH_L^W_P">?ZF@#%HK:_L^W_YY_J:BN+&%+>1E3!"DCDT 95%:EI9P
MR6ZLR98YSR?6IO[/M_\ GG^IH Q:*VO[/M_^>?ZFC^S[?_GG^IH Q:*VO[/M
M_P#GG^IH_L^W_P">?ZF@#%HK:_L^W_YY_J:/[/M_^>?ZF@#%HK:_L^W_ .>?
MZFC^S[?_ )Y_J: ,6BMK^S[?_GG^IH_L^W_YY_J: ,6BMK^S[?\ YY_J:/[/
MM_\ GG^IH Q:*VO[/M_^>?ZFC^S[?_GG^IH Q:*VO[/M_P#GG^IH_L^W_P">
M?ZF@#%HK:_L^W_YY_J:/[/M_^>?ZF@#%HK:_L^W_ .>?ZFC^S[?_ )Y_J: ,
M6BMK^S[?_GG^IH_L^W_YY_J: ,6BMK^S[?\ YY_J:/[/M_\ GG^IH Q:*VO[
M/M_^>?ZFC^S[?_GG^IH Q:*VO[/M_P#GG^IH_L^W_P">?ZF@#%HK:_L^W_YY
M_J:/[/M_^>?ZF@#%HK:_L^W_ .>?ZFC^S[?_ )Y_J: ,6BMK^S[?_GG^IH_L
M^W_YY_J: ,6BMK^S[?\ YY_J:/[/M_\ GG^IH Q:*VO[/M_^>?ZFC^S[?_GG
M^IH Q:*VO[/M_P#GG^IH_L^W_P">?ZF@#%HK:_L^W_YY_J:K7UG%#!N1=IR!
MG)H SJ*V(["!HU)CR2 >I]*=_9]O_P \_P!30!BT5M?V?;_\\_U-']GV_P#S
MS_4T 8M%;7]GV_\ SS_4T?V?;_\ //\ 4T 8M%;7]GV__//]31_9]O\ \\_U
M- &+16U_9]O_ ,\_U-']GV__ #S_ %- &+16U_9]O_SS_4T?V?;_ ///]30!
MBT5M?V?;_P#//]31_9]O_P \_P!30!BT5M?V?;_\\_U-']GV_P#SS_4T 8M%
M;7]GV_\ SS_4T?V?;_\ //\ 4T 8M%;7]GV__//]31_9]O\ \\_U- &+16U_
M9]O_ ,\_U-']GV__ #S_ %- &+16U_9]O_SS_4T?V?;_ ///]30!BT5M?V?;
M_P#//]31_9]O_P \_P!30!BT5M?V?;_\\_U-']GV_P#SS_4T 8M%;7]GV_\
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M_P#SS_4T 8M%;7]GV_\ SS_4T?V?;_\ //\ 4T 8M%;7]GV__//]31_9]O\
M\\_U- &+16U_9]O_ ,\_U-']GV__ #S_ %- &+16U_9]O_SS_4T?V?;_ ///
M]30!BT5M?V?;_P#//]31_9]O_P \_P!30!BT5M?V?;_\\_U-']GV_P#SS_4T
M 8M%;7]GV_\ SS_4T?V?;_\ //\ 4T 8M%;7]GV__//]31_9]O\ \\_U- &+
M16U_9]O_ ,\_U-']GV__ #S_ %- &+16U_9]O_SS_4T?V?;_ ///]30!BT5M
M?V?;_P#//]31_9]O_P \_P!30!BT5M?V?;_\\_U-']GV_P#SS_4T 8M%;7]G
MV_\ SS_4T?V?;_\ //\ 4T 8M%;7]GV__//]31_9]O\ \\_U- &+16U_9]O_
M ,\_U-']GV__ #S_ %- &+16U_9]O_SS_4T?V?;_ ///]30!BT5M?V?;_P#/
M/]31_9]O_P \_P!30!BT5M?V?;_\\_U-']GV_P#SS_4T 8M%;7]GV_\ SS_4
MT?V?;_\ //\ 4T 8M%;7]GV__//]31_9]O\ \\_U- &+16U_9]O_ ,\_U-']
MGV__ #S_ %- &+16U_9]O_SS_4T?V?;_ ///]30!BT5M?V?;_P#//]31_9]O
M_P \_P!30!BT5M?V?;_\\_U-']GV_P#SS_4T 8M%;7]GV_\ SS_4T?V?;_\
M//\ 4T 8M%;7]GV__//]31_9]O\ \\_U- &+16U_9]O_ ,\_U-']GV__ #S_
M %- &+16U_9]O_SS_4T?V?;_ ///]30!BT5M?V?;_P#//]31_9]O_P \_P!3
M0!BT5M?V?;_\\_U-']GV_P#SS_4T 8M%;7]GV_\ SS_4T?V?;_\ //\ 4T 8
MM%;7]GV__//]31_9]O\ \\_U- &+16U_9]O_ ,\_U-07MG#%;.Z+M88[GUH
MS**UK>Q@D@1FC^8J">34G]GV_P#SS_4T 8M%;7]GV_\ SS_4T?V?;_\ //\
M4T 8M%;7]GV__//]31_9]O\ \\_U- &+16U_9]O_ ,\_U-']GV__ #S_ %-
M&+16U_9]O_SS_4T?V?;_ ///]30!BT5M?V?;_P#//]31_9]O_P \_P!30!BT
M5M?V?;_\\_U-']GV_P#SS_4T 8M%;7]GV_\ SS_4T?V?;_\ //\ 4T 8M%;7
M]GV__//]31_9]O\ \\_U- &+16U_9]O_ ,\_U-']GV__ #S_ %- &+16U_9]
MO_SS_4T?V?;_ ///]30!BT5M?V?;_P#//]31_9]O_P \_P!30!BT5M?V?;_\
M\_U-']GV_P#SS_4T 8M%;7]GV_\ SS_4T?V?;_\ //\ 4T 8M%;7]GV__//]
M31_9]O\ \\_U- &+16U_9]O_ ,\_U-']GV__ #S_ %- &+16U_9]O_SS_4T?
MV?;_ ///]30!BT5M?V?;_P#//]31_9]O_P \_P!30!BT5M?V?;_\\_U-']GV
M_P#SS_4T 8M%;7]GV_\ SS_4T?V?;_\ //\ 4T 8M%;7]GV__//]31_9]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M6_X]
MA_O5=JEJW_'L/]Z@"XOW12TB_=%+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %&U_X_IZO51M?^/Z>KU !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %(U+2-0!2TG_4R?[]7JHZ3_J9/]^KU !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?_'K+_NG^535
M#=_\>LO^Z?Y4 ,T__CSC_'^9JS5;3_\ CSC_ !_F:LT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 53U3_ (]?^!"KE4]4_P"/7_@0H LP
M_P"J3_=%/ID/^J3_ '13Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *HZA_KK;_>_J*O51U#_ %UM_O?U% %ZBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K:C_QYO\ A_,5
M9JMJ/_'F_P"'\Q0!):_\>T7^Z*EJ*U_X]HO]T5+0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 <?XC_Y&[2_^V7_ *,-=A7'^(_^1NTO_ME_
MZ,-=A0 4444 %%%% !1110 5S?CS_D$P?]=Q_P"@M725S?CS_D$P?]=Q_P"@
MM0!KZ+_R![#_ *X1_P#H(J[5+1?^0/8?]<(__015V@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!*HV7_ !]W/^]_4U>JC9?\?=S_ +W]30!>I:2EH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *I:M_Q[#_>J[5+5O\ CV'^]0!<7[HI:1?NBEH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@"C:_\ ']/5ZJ-K_P ?T]7J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@"EI/^ID_W
MZO51TG_4R?[]7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *AN_\ CUE_W3_*IJAN_P#CUE_W3_*@!FG_ /'G'^/\S5FJVG_\><?X_P S
M5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>J?\>O\
MP(5<JGJG_'K_ ,"% %F'_5)_NBGTR'_5)_NBGT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 51U#_76W^]_45>JCJ'^NMO][^HH O4444
M%%%-;K0 ZBF;C[4Z@!:*;^-.H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "JVH_\>;_ (?S%6:K:C_QYO\ A_,4 26O_'M%_NBI:BM?^/:+
M_=%2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''^(_^1NT
MO_ME_P"C#785Q_B/_D;M+_[9?^C#784 %%%% !1110 4444 %<WX\_Y!,'_7
M<?\ H+5TE<WX\_Y!,'_7<?\ H+4 :^B_\@>P_P"N$?\ Z"*NU2T7_D#V'_7"
M/_T$5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2J-E_P ?=S_O?U-7
MJHV7_'W<_P"]_4T 7J6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "J6K?\>P_WJNU2U;_ (]A_O4 7%^Z
M*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MHVO_ !_3U>JC:_\ ']/5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D:EI&H I:3_J9/]^KU4=)_U,G^_5Z@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "H;O_ (]9?]T_RJ:H;O\ X]9?]T_RH 9I
M_P#QYQ_C_,U9JMI__'G'^/\ ,U9H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C
M_$?_ "-VE_\ ;+_T8:["N/\ $?\ R-VE_P#;+_T8:["@ HHHH **** "BBB@
M KF_'G_()@_Z[C_T%JZ2N;\>?\@F#_KN/_06H U]%_Y ]A_UPC_]!%7:I:+_
M ,@>P_ZX1_\ H(J[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E4;+_C
M[N?][^IJ]5&R_P"/NY_WOZF@"]2TE+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 52U;_CV'^]5VJ6K?\>P_
MWJ +B_=%+2+]T4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 4;7_C^GJ]5&U_X_IZO4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4C4M(U %+2?]3)_OU>JCI/^ID_WZO4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5#=_\>LO^Z?Y5-4-W_QZR_[I_E0
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M(XHUAA;;R23RYY)/7Z :G[3VFV>C_LS>-[*PM8;&S@TMDBM[>,1QHNX<*H&
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M3F)7S;=LE6_NLIP5;V8 T =)12+T]:* %HKGO&OC[P]\.]'?5/$FLVFC6*G
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MH **** "BBB@ HHHH 2J-E_Q]W/^]_4U>JC9?\?=S_O?U- %ZEI*6@ HHHH
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MLTS;F=B<EB?6O R[+<3GE=8[,OA6R[_\#\SZC-LXP?#F&>69,_?>\NU_/O\
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MI\#=,\0_&H^/=;:'5XK?2DT^QTN[@$D5K)YC,\XW$C<00.GJ<]*X']K;P_\
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MXRR:<X^@-S_\50!]Y4M%% !1110 56U'_CS?\/YBK-5M1_X\W_#^8H DM?\
MCVB_W14M16O_ ![1?[HJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4C4M(U %+2?]3)_OU>JCI/^ID_WZO4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5#=_\>LO^Z?Y5-4-W_P >LO\ NG^5
M #-/_P"/./\ '^9JS5;3_P#CSC_'^9JS0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !5/5/^/7_@0JY5/5/^/7_@0H LP_ZI/]T4^F0_ZI
M/]T4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.H?Z^
MV_WOZBKU4=0_UUM_O?U% %MLYXKY=_;"^!L_B2U7QIHEOYM]9Q;+^WC3+30C
MD2#'4KSGN5_W17U)3&4'((X(Z5Z&!QM7+Z\:]+=?BNQY&:9;1S;"RPU9:/9]
MGW/R-9NV,"CC@5]P_&C]C_3?&5U/K'A26+1=4DR\MHZ8MIF]1CF,GN0"/;DF
MOE+Q9\%O&W@F1EU;PY?11J<?:((_.A^N],@?CS["OV[+\\P>/@G&?++L^G^9
M_-&:\-9AE51QG3<H=)+5'%MA>!TI!FI/L\GG>5Y3B7./+VG/TQ78>%/@WXV\
M:3*ND^'+^5#_ ,MYH_)B'_ WPOX UZ]3%8>E'FG-)>IX-/!XFM+DA3;;\F<8
MOS9SVK[+_8]^!L^A1CQOK=OY5S=0%=-@D4[HXFQF4YZ%AT[[?K6A\&?V.=/\
M*W%OK'BVXAUC48\/'8QKFVB8=SG_ %A'O@#T-?2T<:JHP!QQ7YAQ!Q%'$0>$
MP;]U[O\ R/VGA3A"IA:JQV8*TE\,?U8HZ4]:,#THZ5^<G[&<YX\E\60Z/&W@
MZ#1KC5/.7>NN3S10"+:V2#$CL6SMP, 8)YXP?CV__9#^,^H?&7_A9SZSX)7Q
M$NI1ZBMJ)[LVWR  )_J=VW"A3WQG!!K[FI,#TH Y?P+-XRDL)_\ A-+?0[:]
M#XB_L&XFEB9,#);S8T*MG/ SVYKIMQ]#]*=CVHP/2@#P7]I;X=?$WXQ>%M8\
M': /"MEX=OC 3>:C>7(NV".DI&Q8651O0 8)X].@H_LQ?"GXG_ WP_:^%-8'
MA._\.K<RW#W=E?7/VJ/>,X"-;A&^8#^)>OY_1&!Z4M 'GGQ\\!ZI\4/A#XD\
M+Z-/:V^I:E"D44E\SI",2HS;BJL1\JGH.OI7F7[+WPA^*/P'T5/#.JGPIJ?A
MZ2]DNI+JUOKD746]%!"JT 5AE.Y'4\]A]'X'I10 B\BD=L4^DH ^<_C=X!^-
MOQ>\(ZOX3@/@32M'U!PKS_;;R2X,2RJX'^IVJ3M7/7J:Y_X!_!'XS_L]Z#J>
M@Z3/X'UO2KJ[-ZIO;N\BE24QHC?=@(P0B]?3.>:^K,>U'M0!#9-.UI";H1K<
M[%\U86+('P-P4D D9S@D U/110!YC^T!\"=#^/G@O^Q=6D>RNK=S/8ZE"@9[
M63&"<'[R'C<N1G Y! (^:O _P _:6^"Y.B>#O%^C3>'VE8I'<2B2*,''S;)8
MF:/KDB,D9SUZG[CI* /D_P"+?[('B#XC_#HK<>(+/7_B5=W,$E[KNL%H8(X$
M#DV]LD<;>5'N8' 4%B-S'H!Z+^SMX+^)GPQ\+Z1X3\4)X7OM$TV%HHK[2[RX
M-UC+% 8WA53UQD,N .AKVO ]*-H]!0!\;_$+]DWXA^&?C;>_$CX2Z]I]G<ZA
M-)<3VM\^UEDE.9EP8V1XV)+<X()&!P#7H*_ KQU\2/".J#XJ>);'6]5DM94T
MW1-/4Q:5:3F-ECGEPH>9PQ!^8%4(.T$X(^AZ6@#Y=_97^!?Q/_9[CN]'OY?"
M>I^'M0O!=7$EO>W0N8<)M)0& *V<+P2.AY-=Q^U5\ Y?V@OA[#I-C>QZ?K-A
M<?:[.2X!\IVVE6C<@$@$'J <$#@U[3CVHVCTH ^8O@/\*?CQX971](\6^-]/
MM/"6D;$BM--CCGN[B-"NR$R/"-L6!C/+E1MXR")/VL?V5M3^-NK:+XI\*ZM;
MZ5XITN-;?_2V:..6-7,B$2(&975BV.,'=R1CGZ9P/2B@#YO\$_#7XX>,(EL/
MBEXTLK3PZJ;;BS\/*L=YJ XRDDRHOE(>_ED,02..M<7X-_95^(?PE^.NM>-_
M!@\'C1KAKB&UTF\NKJ'R[9R"JGRX&"L-J]-PX[U]B8''%&/:@"*T:9K6(W"H
MEQM'F+$Q9 V.0"0"1GO@5(WK3J3'M0!\;_$/]DWXA^&?C=??$CX2Z[865S?S
MR7$]K?N59))3F50#&R/&Q);YCD$C X!KT%?@5XZ^)'A'5!\5/$MCK>JR6LJ:
M;HFGJ8M*M)S&RQSRX4/,X8@_,"J$':"<$?0^!Z4M 'R[^RO\"_B?^SW'=Z/?
MR^$]3\/:A>"ZN)+>]NA<PX3:2@, 5LX7@D=#R:[C]JKX!R_M!?#V'2;&]CT_
M6;"X^UV<EP#Y3MM*M&Y ) (/4 X('!KVG'M1M'I0!\Q? ?X4_'CPPNCZ1XM\
M<:?:>$M(V)%::;''/=W$:%=D)D>$;8L#&>7*C;QG(^G$.12X'I2T <WXZF\6
MPZ;$?!UGHMWJ)DPXURZF@B5,=1Y43DG....O6OD[X2_LN_&7X3_%;4_'5O>>
M"=1OM36X6YMIKR\1/WT@D.TB XPRKZ\9%?:E&/:@#SSX@I\2-0\-VUIX7L_"
MZ7]U9O'?RZK?7(C@E9 /W.R$EU!+<MM. /EY./GW]F_]FSXP?LZZEK$UE-X*
MU>UU985N(9[^[1E\LN5*D6W!Q(XY![?C]BT8'I0!Q?QB\(ZA\0?A9XH\-Z3+
M;P7^JV,EI#)=LRQ*7&"6*JQQC/8UXI^R[\$?BI^S[8W&AWC^$=5\/WU^+RXD
MAOKI;F'*JCF,& *YVHO!*\CJ*^G\=L44 ?/7[3W[).F?'Q(=6L+M-$\66L?E
M)>&/=%<Q@Y6.4#GCG##D;CUX XWP3I7[5W@6TBT1G\)^);2$&*+4-9N9)&"@
MC!+J4D;CNP8^OI7UO1C'04 >7_"_P7X_LM9FU_Q_XPBU>]D@-O#HND0F#3K4
M$JQ;!PTK_+@,XR 2!U-87[3'[,>C_M#:+:%[LZ1XCT]66SU)8]X*-]Z*5>"R
M'L<Y4\CJP;VW ]** /BSP!\'?VH_AW;VGAS2_&FACP_#\D<]RZW:6\>?X/,A
M\S@=%^[R!QUK1^.W[$>K>/=#T5?#VLV=]XE^T376N:]XBED2XOW946/;Y<;A
M$7#!8QA4!'4Y-?8=)0!Y?\-;+XG^'_!XTOQ':>%+F\L-.6#3Y].O[K9<2H@5
M1,'@RBG&2R[CZ+7SW\6/V7?C+\6/BMI?CRYO?!%C>::ML+:UAO;QHP(9#(,D
MV^3EF)XQQQ7VI@>E% ',^$X_$FI^'[B#QOI^BQWLCO$T.DSRW-M+ 5 ^;S8T
M())8%<$8 Y.3CY(U;]C'X@_"/X@2>*?@OXFM[>!V(_LV_E*.B,1F%B59)HQC
M^+:0 ."PW5]NT4 ?-VBC]I[Q1;I9ZG-X)\&P,@$FI6T$EU=KQC<L9D>-F[X(
M _E6C^T_^S/<?'KP+H=G;:PD7B;0P?LU]?KB.YW!%E$NQ<KN**V5&,CISQ]
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ME1/RV?W&K14?XTHR !7F'N#Z*9FG+0 M%%-_BH =13>:;^E $E%,SGO1SS0
M^BF;NV>:-U #Z*9N-'K_ (T=; /HIO-)DGZ4@'T4S%'/X4P'T4S=QUHW4 /H
MIF3WHYI"'T4P<^W:C%,8^BF=J,XS1Y /HIF?>E_&@!U%1L2P]*#2 DHIG/%
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M HHHH **** "BBB@ HHHH *I:M_Q[#_>J[5+5O\ CV'^]0!<7[HI:1?NBEH
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MS9RRB%0I.>Y&#7PE\3->N?#/[?U]JMGI-UKMS:ZM!(FG6(S-.?LL8PHQUZT
M?I@2,9Z#KS7!>-?AJWBWXE?#[Q1]ICCB\+S7LLD#*2TWGV_E+M(Z8;#<^E>?
M7W[46OVMHTJ?!'XA2N,?)_9P]?\ 9+$_E3_V0?&EU\1=%^(?B*\M+G3IKOQ=
M= :?=,3):JMO; 1MD#!'<8'.: />UY49Y.?RK\W/V7[=6_;JUDA<"*^UEACH
M.91_6OTE[5^7OP=\97G@7]K[Q5JECX<U+Q3,M_JD9T_24#3E6F8%P#V7G\Z
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M &9_P4F@63X%:,YP#'XA@(./6VN1_6O9/V:V_P"+ ?#[G_F"6O\ Z+%>/?\
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MTC4 4M)_U,G^_5ZJ.D_ZF3_?J]0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !4-W_QZR_[I_E4U0W?_'K+_NG^5 #-/_X\X_Q_F:LU6T__
M (\X_P ?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%4]4_P"/7_@0JY5/5/\ CU_X$* +,/\ JD_W13Z9#_JD_P!T4^@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "J.H?ZZV_WOZBKU4=0_P!=
M;?[W]10!>IIZ]*=28H ;Q2%0W4 CWI^T>E%(1#]GBS_JU_*GK&$X &*?BEJK
MLE0C'5(9^%.4Y[8HP/2BD6+1110 4444 %%%% !1110 4444 %%%% !1110
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M&Y20.M &M13"VWJ<'K7(^)OB]X)\$W1M-?\ %VBZ1=CK;W=_&DH[_<+;OTH
M[&BN?\*^//#OCJU:Z\.Z]IVNVZ8#OI]U',$)Z [2<'ZUOJ<]#GM0 M%%% !1
M110 4444 %%%% !5;4?^/-_P_F*LU6U'_CS?\/YB@"2U_P"/:+_=%2U%:_\
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MN:]G"Y6JV"E)P?/*[3Z6CT^>MO0^:QV>O#YI&FJB5.-HR75N77Y=3Z\%</\
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M1D6+5='VW=I=J=LD>&&Y=PYP1V]0I["N^^%^N3^)?AWX;U2Z.ZZN]/@FF8#
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MH N+]T4M(OW12T %)2U6OKJ.QM9KF9BD,,;2.0I;"@9)P 2>!Z4 ?GRDR/\
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MDHRAAD$'!'I3 ^#O^">XQ\9/B=@<>6?_ $H:L_Q5J0E_X*567]JEC;P7]K#
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MP^"/BS7OV)/$^J>#?B187:>"]2N?.LO$%I"\MJDV I<$#[K*%ROWE*C@YS3
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M%/MGUO\ 9+^)6DZM\+?"GA1A?VOB+2],2*YM+S3[B$*$.W(D= C9&"-K'\*
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M4F/>C'O0 M%)CWHQ[T +128]Z,>] "T4F/>C'O0 M%)CWHQ[T +128]Z,>]
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZI_QZ_\
M A5RJ>J?\>O_  (4 68?]4G^Z*?3(?\ 5)_NBGT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9X.2!$"6+(W8<@'US17PM\6-2_:?^!>ECQGJ/C/3/$FC0R)]KAL[6-HH@Q
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M-45\.?"_]I;XH?"WXVV/PU^+KQ:C'?3I;17_ ):"6-I#MAE1HU DB9\#YAN
M.<@J5/V%XZ\;:9\._!^K>)-8E:+3--@:>9D&6/\ =5?5B<*/<B@#H:*^:_A;
MXH^)/[3'AN3Q4GB$?#?PM<320Z=9Z3:Q7-Y<JC;3)+-,&"@,K+A$4G:>G?RK
MXM?%SXQ_LB^,;"+4_$4/Q!\*ZHDC6<FJVZQR;EQN1FC 967<O.2I!!P#D  ^
MZ:*\7^$_C'XP>+/$%O-XL\*Z#X>\*R6OG+=6MZ;B>5F V*N'P,YSDKT7'<&O
M9UZ4 +1110 4444 %8_BS1K7Q!X<U*PO+:&[@FMY$,5P@9#E2.016Q5?4/\
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M-<0Z7IF+/2H&#+_RR49E('1FP>>G<_8F/:O)OVK_ /DW/QZ!Q_Q+6_\ 0EH
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MSL?0(37UMX#\+Q>"?!.@>'H7\R+2;""Q60]6\N-4W'W.,_C0!NT444 %%%%
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MYKP;]FW_ (2&'X\^)+3Q2/\ B=6>D"UFD.29 C0JKY/WMR@'=WSFOJR-=JC
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MTD0C(92.""#D&O$_V@?V:?"_Q)^'>N0Z3X2TF+Q5]G,FGW=M!':R^<O*JT@
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M7W0!G([5^@8?@NI*-\15L_)7/R?%^(U.$FL+0NN\G8_43_A<W@'_ *';P_\
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M?^#2#_XJORZS1FC_ %*H?\_G]R#_ (B1BO\ H'C][/U%_P"%S> ?^AW\/?\
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MJC_A<W@'_H=_#W_@T@_^*K\NLT9H_P!2J'_/Y_<@_P"(D8K_ *!X_>S]1?\
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M:/\ 4JA_S^?W(/\ B)&*_P"@>/WL_47_ (7-X!_Z'?P]_P"#2#_XJH[CXR>
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M\NLT9H_U*H?\_G]R#_B)&*_Z!X_>S]1?^%S> ?\ H=_#W_@T@_\ BJ/^%S>
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MC?$C[INM/4C@[K(9!^F?7^==YX4\>_M"_$30HM=T..R?2YPQA95MD\S:S*P
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MJB.GY*X7_@->Z+7YMBL/+"5YX>6\78_9<NQD<PPE/%16DU<6BBBN0]$****
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M9?V4_BY^SU\1I?$?P<O8=<TR9B/[/N[B..1HB<^5.CLB2*.SJP;N IH ^[U
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MP3A0,D_@* )Z*\J^$'[1OA;XX:YXALO"JWMS9Z*L)EU">(11S-*9,!%8[_\
MEF>6 KU04 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!1M?^/Z>KIJE:_P#']/5QJ /+?VAOB\OPC\"RWMOL?6+P_9[&)N1O
M(Y<CT4<^YVCO7YRZEJ%UJVH7-Y>3R75W<2-)--(<L[$DDGW.?UKVS]L3Q@_B
M3XNS:<CL;;1H$ME3.5\QAO=O;[RC_@ ]*\)^G%?N'#.7PP>#C5:]^>K?ET1_
M,O&6;U,?F$J$7^[IZ)>?5CNV.E--%%?8'P%] HHHH)"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG^Z*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'4/\
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M@((]17944 5=1TZTU:SEM+VVAO+29=DL%Q&'C=3V92""*\Q;]E?X2R:@;P^
M=&$IR=JP8CY[^7G;V]*]8I* *.B:%IOAS3HK#2=/M=+L8O\ 5VMG"L42?15
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M+1_@3X%BT'3&:\NI'^T7^HRKMDNYR "Y&3M'& N>!ZDDGT6@!:*** "BBB@
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MN>/NH1R$]^K9XXSGQ8 # '0<5RO_  L;3AQ]GNA_P%?Q_BI/^%CZ=_S[W/\
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MO]A9E_SXE]Q[/^M.2_\ 03$^D:0U\W_\-T^"?^@/KO\ WZ@_^.T?\-T^"?\
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M2YDCGO;B5[FYFC^ZTCG)QGG &%'LHKPK_ANCP3_T!]=_[]0?_':/^&Z/!/\
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M/7I3M-7Q(UTC:A)IL%LN=T=J)'=S@_Q-@+@X['..U>'_ /#='@G_ * ^N_\
M?J#_ ..T?\-T>"?^@/KO_?J#_P".T?V'F7_/B7W$_P"LF2<W,L4E\W_D>T>)
M-(U2YU?2]2TO[))-:+,C1W;N@(<+T*JW3;Z58L)O$[7<?VVVTI+;)WM!<2,^
M/8% /UKP_P#X;H\$_P#0'UW_ +]0?_':/^&Z/!/_ $!]=_[]0?\ QVC^P\R_
MY\2^X7^L>2<SDL4E\_\ @'N7B'19[ZXL[^QN%MM3LBWEM*I:.1&&&C< CY3A
M3D<@J#Z@U+;1]6U/6+.]UN6V2.R+/!:6>XJ9""OF.S 9(4L  ,#<>O%>,?\
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MZYCX9_\ )./"W_8+MO\ T4M=-7YGB/XT_5_F?LV#_P!VI_X5^2'5%<?ZE_\
M=IX^:F7'^I?Z5BMT=,_@9^3WB3_D8=4_Z^Y?_0S7Z ?LWZW8:5\#_"4=W?6]
MK))!*8TFE5"P$KY(!/.,C\Q7Y_\ B/\ Y&+5/^ON7_T,U]K_  K^#OAOXM_
M'P7#X@MY93:1S-!)#*8W0F5L\CL<#@\<"OUSB94W@L.JKM&ZV]#^?^#76CF>
M*>'BG*ST>B^(YW]KSXW:'?\ A%O!VC:A;ZG>7DB/=O;OO2"-&#@%EXW%E7CL
M <]17EG[+/P9O_'7C2P\07=NT/A[2IEG,T@P+B93E(U]<-@MVXQU-?2WA_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M (S7T?12_MS,O^?\OO#_ %7R;_H&C]Q\W_\ #"O@?I_;/B+'_7>#_P",T?\
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M_P#&:/\ AA7P/_T&?$7_ '_@_P#C-?2%%']N9E_S_E]X?ZL9-_T"Q^X^;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4IOFE%-^B,7_ (0O0%_Y@NGC_MU3_"C_ (0O0.AT33S_ -NJ?X5M457MJO\
M._O(^JT/^?:^Y&;8>'=+TJ9I;+3[6SE8;2\$*HQ'ID#IP/RI+_P[I6ISB:\T
MVTNY=NW?- KMCGC)'N?SK3HQ4>TG?FYG<T]C2Y>3E5NUD9+^%=%>)8CI5FT0
M.1&8%V@^N,5&O@OP_P '^Q-/X_Z=D_PK:Q2U7MJFW,_O(^K4-^1?<ABJJ@ #
M '2@]*=1@5D='D9^K:+8:]9O9ZE9V]_:R##V]S&LB-^!KSVZ_9G^&EW.TK^%
M+16)R1&SHO\ WRK 5ZE@48%=%+$5Z.E*;BO)G'7P6&Q+3K4U)KNDSFO#'P]\
M,^"U;^Q-#L--<C:TEM JNP_VF R?Q-=%QZ<4_:/2C K*<YU'S3;;\S>G1IT8
M\M**BO)$4D:3(T;J&1@05(R"/<5YYK/[//P[UZY:XNO"FGB4G)-NAAR?4A",
MFO2,#THVCTJZ5:K1=Z4G'TT,Z^%H8E6KP4O57.&\,_!GP3X,FCGTGPSI]M<)
MREQY(>5?H[9(_.NU '3CCM4F!Z4;0.@J:E2I5?-4DV_,JCAZ6'7+2@HKR5B&
M:&.XC>*5%DC<%61@"I![$5BV_@#PS:@^3X>TR'=R?+LXUS^0KH**4:DX?"VB
MIT:=1WG%/U1CP^$=#MY!)'H]C&XZ,MN@/IUQ22>#]!D9G;1;!V8Y8M;(2?KQ
M6S1BK]M5WYG][(^JT/\ GVON1D:?X5T71[Q[RQTBRL[N12C3V]NB.RD@D%@,
MXR!^0K67I2X%'2LY2E)WD[LUA3C37+!67D+1114F@4444 %%%% "51LO^/NY
M_P![^IJ]5&R_X^[G_>_J: +U+24M #6KX5_;X^&_B70_B#X;^+'AVWEFBT^*
M%+B:"(O]DGAE,D4K_P"R=P&3P"G)^85]UTQU60,C ,",%3R.?44 ?'W@7_@I
M-X.U#3[:/Q3H>J:/J&T++)8JEQ;;L<D$LK@9SQM..F3UKV_X>_M/?#/XH7T-
MAH'BFWDU.0A4L+Q'MIW;KA5D"[S@9^7-3^*/V:/A;XRDEDU3P-I#2RY$DMK!
M]FD8GJ2\15B??.?>OBS]L3]DO1_@GH]AXQ\&W%U!I;W:VUQ8W$ID:U<@M')&
M_P![;E,'<202I!.30!]D_'+Q]\0? &CWVJ>$O"NEZSI=AI\E]=WNH:@8FCV!
MF=5A"@MA%W9WC.<=JXO]C/XX^*OCMH/BG6/$[6:BUOHX+:&Q@,4<2^7N8#)9
MCU'WB:U_!OC"^\??L;R:[J;M-J-SX6O%N)F^]*\<,L;.?=BFX^Y->6?\$S?^
M2;^+O^PNO_HE: /<_CAX[^(7@71[S4O"/A32]:T^QL);VZN[_4C$T>P,S((0
MOS850<[QG.,<<\#^QS\=?%_QVT3Q?JGB)['S+2[CAL[:UB,,4>49B,_,W/R\
MDMTXKVSXH*)/AKXL1AE&TB\!_P"_+5\M_P#!,N-1\._&#X^<ZI&I'L(1C^9H
M Q_VH/VE/CC\&;RPTZZB\+Z*NI1/+:WND+)=N A 8$S@+D;A_P L_6O5O%'Q
M(^+?Q/AC3X/Z=86>@Q?*WBO7L*+]QP3;1%3^ZR/]84PW\(QR?'?^"FL0FUCX
M:1G(#"^7(/JUM7W59VD-C:PVUO$L,$*"..-% 55 P  .@Q0!\%ZQ^U#\>?V>
M?%=E:_%#1[;6=*N"=LL<440G7N89HAL#+Q\K*3[#((^UO!_CO2?''@G3?%6F
M72MH][;"Y2:4A-BX.X/SA2I!!&>"#SQ7E'[<7AZPUS]FWQ/->QH9--,%[;2D
M<QRB5%R/JKLOT<UX1\,]:U'PO_P3D\67KO(BS/=6]JRYR(IIXX6Q[%WD_.@#
MVGPW\=/$G[0?B;6=,^&,EIH?AG1Y!%=>*]3MFN'GD.<);6Y*C^$DL[<*0=N2
M!7._&#Q5\:OV<M-C\7S>*K#XC^%HIE34;*ZTF.QFME<@*5:'/RYXW'."RY5N
MM>=_L/>+?'WAWX0ZA;^%/AQ:^*].DUB:22^?Q!%8L)?*A!0QO&Q.%5.<X.>G
M%>L?%JZ^,/Q8^'>N>$9/A%8Z4NJPB'[8_BNWE$!W!A(4$0W8*@XR.E 'J7AG
MXK2?$GX1VOC+P/IT>L7EY$#!IE[="VVR;PDD<D@5MI0[CTYVC!P0:^9=4_;&
M^('AGX^V'A#QM:Z'X/T>QF5]5^RAKEFB,/FC$I/.05 ")NR<<G@>V?L>_"/Q
M+\%?A3<>'_%+VIO7U.6[ACM)3(L<31Q *20.=RN>_7K7S5\1=!MO$?\ P4BL
M+&ZBCGMS>6,SQR*&5A'9)( 0>",H* .F\6?M&?'=OB7X8E7PS<>#/!.L:Q:Z
M?:1ZAIRL\J2R!0L[MDI(02=HVXVD#.,GZ,^+WQ9UOPGXB\->$?">@QZUXK\1
M)/):R7LQALK6.$*7DF8 L<!AA5&3^0/IUS9P7D:K<0QSHK*X650P5E((//<$
M CZ5YK\8/C=X&^#-YIESXAW77B"Z5H=/L=/M1<7\JLR[E0?PJS!>I ) ZXH
M\=^(C?M2^!]#N_$L6O\ A;6;:S4W%SI6F6>66-1N;9YD89U !XW[R.F3Q7H7
M[*W[24?[1'A.]FNK./3/$.END=];6[$Q,'!V2QY.0K;6&#D@CJ>";EE\0?BK
MXRA+:1\,[+P]9R@E+CQ9JX20KS]ZW@1V4]>&8?ER?FS_ ()JVAM?&7Q'0LN(
M8;>,JA)7(DE&1GGL>M 'U1^T!\>M%_9_\&KK6J127UY<2&&QTZ%PCW$F,GYC
MG:BCEFP<9'&2!7,0Z!\<O'GAN+5V\<:3\/KZZC$T.BV>B)>^0" 52::9CE^<
M-M0 '.,UXI_P4R\,:K<6?@GQ#;PR3:38M<6]PP7*02.8BA;V;81_P$>N*^LO
MAS\3="^)G@6Q\4:5?P2V,]NLL^)!FU?:"Z2<_*5.<Y],].: /D_PM^V-\5?"
MGQ O/AMXH\$V?C#Q?#=&W@^PWBZ<9?E+@DLC(P9<,I 3@C@FOJ'X1^+?&OC#
M2;^[\9>#D\%SQS^7;6?V\74DJ8R78JH &3@=^#P.*^8-)\,CX^?MP7'C3P\X
MG\(>%W@^T:O#S#<SQ1X$<;#[_P _!(R-J$@\C/TM^T9X@NO"OP+\<:G8N8KN
M'2YEBD7JC.-@8>XW9_"@#@$^/^O_ !B^(FJ>#OA0+".QT?"ZMXNU.)IX8F+,
MH2WA4KYI)4X8L%.&[ $IX^\.?'KP3H=SK_AWXA6?C*XLT\Z30;_0(+=9E498
M1O&=V[KA2W/9LXSQ'_!-&UMU^$OB>X7'VJ36VCD'?8MO"5Y^KO7U\Q_R* /#
MOV9?VHM*_:&T>XA-L-)\36"![O3]^Y7C/ FB)Y*9(!!Y4D Y!!;B/VG/VB/B
MQ\%M.GU&V\):'9Z%-J!T^SU.>]:[D?(=D=HEV;"5C9L$D \$GOX)\*;-_AW_
M ,%!;C2-*3[-92:M?6YMXS\OV>2-Y%7Z#*$?[H]*]Y_X*0_\D#TWC_F/VYQ_
MVPN* #PG\;_BK\7?ACH*_#W3;2^UUK53K/B?54%O8P3GDPPIC]XX!&Y@"J].
M23CS?Q)^TE\??V<?%&GK\3;"P\0:)?.2LL$,:+(H/S+#+$% < _=<$XQZYKZ
MC_9?LX;']GOP!'!&L:-I$,I"@ %G&]C]2S$D]R2:\M_X*+6<-Q\ (I9(PTD.
ML6[1L1RI*2J?T)H ]TO_ !??ZQ\/[7Q%X*L+?Q%/?6\-S8V]U=_98Y8Y I#%
M]K8PI)QC.1CBOF;P?^TY\4->_:FTGX:^(--TCP_!'-,M[:V*&=Y%6U>9?WK,
M<C 4Y0#WKW']E29Y_P!G;P"[L6/]F( 3Z D#] *^8;+_ )2A'_KI)_Z9FH ^
MN?C1\6-.^"OP\U/Q5J<;W*6X"06L9PUQ.QPD8..!GJ2. "<<8/GGAO0_C5\2
MO#%AXBN?B+8>!)-2ACNH='TW0(KQ;:-EW*LDD[EF<J1N P <XK5_:W^#>H_&
M[X/W6B:,4_MBTN8M0M(9&"+.Z!E,98G RKM@GC(&<=1\L^#_ -KSXK_L_:/I
M_ASQYX%FOM/T]%MH9KZ*2SG,:\*HEPT;A0, @$\<DT ?27P7\:_%"W^+7B+P
M'\1)M*U1;#3(]3L]6TZW,37,;R;%.!A<?+("-N04/)')\&_X*'^.]6UO0]&T
M6;PEJ6DZ1;:K(T6M7\L2K=2(C)B*-2S%"&W!VQP!QSFO>_@+^U%X!^/&O2C3
M[)M$\7K;!&M[Z)//F@5BQ6.5<[T4L3M.#R3M[UY5_P %-&/_  @O@OL?[3F_
M]%4 =C\+?BW\6;?PGX.T:U^"4R:;'9V5HNJRZ_#Y?D!$3SO+V9^[\VW.?<U]
M/+TYKF_ADH_X5OX4&./[)M/_ $2E=-0 4444 %%%% !1110 4444 %%%% !5
M+5O^/8?[U7:I:M_Q[#_>H N+]T4M(OW12T %%%% "8]J*6B@!*,#TI:* $P!
MVHI:* $I:** $HP/2EHH 3V[48'/%+10 E%+10 E%+10 E%+10 4444 %)2T
M4 )7GGQ@^.GA7X'QZ)-XINIK6WU6Y:W22&(R^4%0LTC*N6*CY0=H)^8<=:]$
MKFO&GPX\+?$2"WA\3>'M.UU+<DP?;K=9#%G&[:2,KG:N<=<#TH \.L?'>G?M
M6?%+1K;P^L]Y\//!]PNJWNH30-%'?Z@ 1;PH' 8JFYG.0,D#M@GZ47OQCFL_
MP_X<TKPKI<.G:+IEII.GPY\NULH5BC7/)PJ@#DUI4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 4;7_C^GJ[WJE:_\?T]7J $X.:8WWO44^B@#*USPWI7
MB:U:UU;3;74K8_\ +*ZA61?K@BO.K_\ 97^&.H2[Y/"\49SG;;W$T0_)' KU
MJEKJI8JO05J4VO1LX*^ PF)=ZU*,GYI'C0_9&^%G_0MM_P"!]S_\=H_X9%^%
MG_0MO_X'W/\ \=KV6BMO[1QG_/Z7WLY?[&R[_H'C]R/&O^&1?A9_T+;_ /@?
M<_\ QVC_ (9%^%G_ $+;_P#@?<__ !VO9:*/[1QG_/Z7WL/[&R[_ *!X_<CQ
MK_AD7X6?]"V__@?<_P#QVC_AD7X6?]"V_P#X'W/_ ,=KV6BC^T<9_P _I?>P
M_L;+O^@>/W(\:_X9%^%G_0MO_P"!]S_\=H_X9%^%G_0MO_X'W/\ \=KV6BC^
MT<9_S^E][#^QLN_Z!X_<CQK_ (9%^%G_ $+;_P#@?<__ !VC_AD7X6?]"V__
M ('W/_QVO9:*/[1QG_/Z7WL/[&R[_H'C]R/&O^&1?A9_T+;_ /@?<_\ QVC_
M (9%^%G_ $+;_P#@?<__ !VO9:*/[1QG_/Z7WL/[&R[_ *!X_<CQK_AD7X6?
M]"V__@?<_P#QVC_AD7X6?]"V_P#X'W/_ ,=KV6BC^T<9_P _I?>P_L;+O^@>
M/W(\:_X9%^%G_0MO_P"!]S_\=H_X9%^%G_0MO_X'W/\ \=KV6BC^T<9_S^E]
M[#^QLN_Z!X_<CQK_ (9%^%G_ $+;_P#@?<__ !VC_AD7X6?]"V__ ('W/_QV
MO9:*/[1QG_/Z7WL/[&R[_H'C]R/&O^&1?A9_T+;_ /@?<_\ QVC_ (9%^%G_
M $+;_P#@?<__ !VO9:*/[1QG_/Z7WL/[&R[_ *!X_<CQK_AD7X6?]"V__@?<
M_P#QVC_AD7X6?]"V_P#X'W/_ ,=KV6BC^T<9_P _I?>P_L;+O^@>/W(\:_X9
M%^%G_0MO_P"!]S_\=H_X9%^%G_0MO_X'W/\ \=KV6BC^T<9_S^E][#^QLN_Z
M!X_<CQK_ (9%^%G_ $+;_P#@?<__ !VC_AD7X6?]"V__ ('W/_QVO9:*/[1Q
MG_/Z7WL/[&R[_H'C]R/&O^&1?A9_T+;_ /@?<_\ QVC_ (9%^%G_ $+;_P#@
M?<__ !VO9:*/[1QG_/Z7WL/[&R[_ *!X_<CQK_AD7X6?]"V__@?<_P#QVC_A
MD7X6?]"V_P#X'W/_ ,=KV6BC^T<9_P _I?>P_L;+O^@>/W(\:_X9%^%G_0MO
M_P"!]S_\=H_X9%^%G_0MO_X'W/\ \=KV6BC^T<9_S^E][#^QLN_Z!X_<CQK_
M (9%^%G_ $+;_P#@?<__ !VC_AD7X6?]"V__ ('W/_QVO9:*/[1QG_/Z7WL/
M[&R[_H'C]R/&O^&1?A9_T+;_ /@?<_\ QVC_ (9%^%G_ $+;_P#@?<__ !VO
M9:*/[1QG_/Z7WL/[&R[_ *!X_<CQK_AD7X6?]"V__@?<_P#QVC_AD?X6 _\
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M<9_S^E][#^QLN_Z!X_<CQK_AD7X6?]"V_P#X'W/_ ,=H_P"&1?A9_P!"V_\
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M/^A;?_P/N?\ X[7LM%']HXS_ )_2^]A_8V7?] \?N1XU_P ,B_"S_H6W_P#
M^Y_^.T?\,B_"S_H6W_\  ^Y_^.U[+11_:.,_Y_2^]A_8V7?] \?N1XU_PR+\
M+/\ H6W_ / ^Y_\ CM'_  R+\+/^A;?_ ,#[G_X[7LM%']HXS_G]+[V']C9=
M_P! \?N1XU_PR+\+/^A;?_P/N?\ X[5FQ_97^&.G3;X_"\,G?%Q<32C\F<BO
M7*3 ZXH_M#&;>VE][&LGRY.ZH1^Y&5H?AG2/#-J+?2-,M-,@_P">=I L:_D
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MD9P0">1]:XKXT_#1?BWX#F\-M=K8B6ZM;CSFC+@"*>.1EQD?>52O_ J[E>E
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MW.[' 4#N3V%<!#^T%\,[K5&T^/Q[X=:[!V!/[2A 9LD;58MM)R#P"30!\Z?
MO]HSXG>._P!I^Z\%>++O3;2STL7T%WI^D6P\AYH<KD2/ND(!&1\PSW K[-3/
M.?6O@KX#QJW_  4&\=-\K@MJ4B.O((9T((^H-?;6N^./#GABZ2WUCQ#I>D7$
MB>8D-]>Q0NRY(R Y!(R#S[&@#=HKF+'XF>$-6O(;2R\6:)=W4S!8X+?487D<
M],*H;)-7M>\7:)X56W.M:SI^D"<D1&_ND@\PC&0N\C)Y'3UH V:*Y[1OB!X8
M\17BV>E>)-)U.[92P@LKZ*9\#J=JDG%= N><T +1110 4444 %%%% !1110
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M10 4444 %%%% !1110 4444 %%%% !4-W_QZR_[I_E4U0W?_ !ZR_P"Z?Y4
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M^9,>&CDP]G*>@SDJI/8.] 'Z(^(+J:Q\/ZG<VXWW$-M))&OJP4D#\Q7YR_\
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M_;8E^,'B2/PCXMTVUTOQ#-&S6=U9!E@NBBY:,HQ)1]H9OO8.",*<9^LFZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*^O_  _HS>'O FG:5(WF26.FQVK.>2Q2(*3^E?&'_!+]AN^)8)Y_XEI_]*J
M/=_VXO\ DUOQKZ?Z#_Z76]'[#?\ R:WX)Y_Y_?\ TNN*3]N0X_9;\: <9^Q
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M[!ADC.><=".M<]^U#^QW=_&'Q1;>,O"6M1:)XHAC2.1;IG2.;9]R02("R.H
M&<$$ =,9KQC5/&'[5'[.MBU[K7F>(O#]KR]Q=B/4(0H_B>12)D7W<@>] 'V)
M^SK!K]K\$_"47BA[]]?6T_TLZF7-QNWL0'+_ #9 P.?2O1Z\I_9O^.UI^T!\
M/%UZ&R;3;ZVG-G>VA;<JS*JME&ZE2'4C/(R1SC)]54YH 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HVO_ !_3U>JC:_\ ']/5Z@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "D:EI&H I:3_J9/]^KU4=)_U,G^_5Z@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;O_ (]9?]T_RJ:H
M;O\ X]9?]T_RH 9I_P#QYQ_C_,U9JMI__'G'^/\ ,U9H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JGJG_'K_ ,"%7*IZI_QZ_P# A0!9
MA_U2?[HI],A_U2?[HI] !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %4=0_UUM_O?U%7JHZA_KK;_>_J* +U%%% !1110 F!Z4M%% !1110
M 4444 <WXZ\0:WX=TJ*YT'PQ<>*[QIA&UE;W<%LR(58^87F95P"%7 R?G!Q@
M&OAG5/@G\<-0_:('Q7'PW17358;[^R/[;LB3'&%79YGF  E5QNQP2>,5^A-&
M!Z4 <OX#\2Z]XCT^:7Q#X3N/"%RD@2.VN+V"Y\U< [@T3$ 9R,'!XZ5T5Q-)
M%;R/'$9Y50LD2D*7('"Y)P"3^%3TE 'Q=\<- ^-OQ@\?>#=0;X5-#X6\.7T=
M\='GUZQ8WL@D4L782X'RKM P<;F]2!]7^!=?UKQ'HK76O>&;CPI?"4H+&XNX
M+DLH52'#PLRX))&"<_+TY%=%@>E+0!4U.XFM;&YFMK5KVYCB9XK975#*P!(0
M,QPN2 ,GCFO@O]I_X*_%OX]^.M-\1:5\+IM!EM;-;5Y)=<L'EFP[,K$"4 $!
MCW_I7W\0#P1FC:/2@#S#X)^)/B%JVA6]AX_\&2>'M2M+9$?4?[1MKJ*]D VL
MP6-RR$XR0>.>M'QV^ /AGX^^&TT[7(F@OK?+6.IVX'G6S$<^S(<#<IX.!C!P
M1ZA2;1Z>U 'PAX7^%?[1G[+=U/;^#OL?CCPLTGF?8O,#1]>6\IV5XV/?RRPS
MUSBO3])_::^+]QFWN/V?-8>[48#KJ)@B8Y (W/"0!UYR>GIS7U!1@>E '@6F
MS?';XF3V7]J6FD?"[0?/1[J."X^W:G/$&RR(X_=Q[AQN^\,\="*F_:,OOB-X
MF\*^*/!OA7X<SZO;:C:&T37)-8LX(2LB+O*QO)OR,LN"%Y7(."*]WP/2B@#X
ME_94\"_&+]G6W\06%_\ "V76K34Y(I4EM=<L8WC9 P(PTOS!@1W&-O?-?0WQ
M8\7>/+73+K3O"WPWN/$DEYIY'VIM6L[:*"9PRF-@\@9BH*G(&#G ->J;1Z"E
MH ^"?V7?A#\9/V=?%6IZC<_#5M=LM3LUMY([?6[**2)@^X'+28/\0QWR#GL?
MN?0;ZZU+1K.ZOM/DTJ\FB5YK&61)&@<CE"R$J<>JDBKU% %+6;RYT_2[VYL[
M%]2NH8'EALXY$C:=U4E8PSD*I8X&6( R,G%?#G[57PM^,O[1>N:+<VGPRDT6
MSTF"6.-;C7+&1YF=E)/$H"\*,#)]^PK[QI,>U 'DGP3\0>/5T;1= \5_#N?P
MV+#3X[>35!JUI<PR/&BJ,)&Y<;L$XP<=,GK74?%7X3^'/C)X1G\/>)K/[19N
MP>.6,A9;>0<"2-N<,,D<Y!R0002#V=% 'P9I?[.?QW_9EUVZO?AEJEMXKT6<
M[I+"5UC\T#_GI!(P&[&,-&^[@]*],T?]ISXRQ;;;5/@!JEQ=A<&:TO&AA9L9
MXS$X /\ O'KCDU]3X'I10!\\+X@_:!^)EK+;6OAS1?A19R95K[4+L:E>JOK%
M&@"[N?XP.G'8U[_IMJ;'3[:V::6Y:&-8C-.VZ1]H W,>Y.,D^]6,#TI: ,OQ
M/97&I>'=4L[-D6[N+66&)I#A [(0I. >,GTKY#^%/BCX]?L\^';;PAK'POD\
M9:)IZ[;.[TFZ7S5C)SMRH;< 2< JK#Z8K[/HQ[4 ?/,GQL^+OC*U^Q^%/@]>
M:'>2C8=2\4WJ06]J3QO,6 \@'H.?8UT/P'_9YB^%=YJOB;7M4;Q/X^UMB^I:
MQ(N% )!,40[)D#TSM'  "CV:DH ^?/VT?@;K?QN^&]E;^'1%-K6E7?VN*UE<
M)]H4HRLBL2 &Z$9XXK _9[U+]H/['H/AKQ'X:T?P_H&DQQ03:Q?YEN9H8]H$
M21I-@NR@CS"-N.>3U^HMH]*,#KCF@#RS]I3X23_&SX1ZMX:LYX[;4V:.YLII
ML^6)HVR WLPW+GMNSVKYE^"NM?M)_!;PZO@N'X:KK]A:2.MF]W,BBWR2VP3+
M+M9,Y(STSC=T ^[:,>U 'QE^T1^S_P#%3XP?#6SU/5DM]<\;M?Q^1H>EW26^
MGZ5:E)-^WSI!YLK-Y>YB2><+P.?5_P!F.T\;>$/AWH/@GQ;X"NM&&G6\L+:D
MVH6=Q;.N]F4%8Y2^2&QC;CCK7NU&!Z4 ?!?C;]DOXD_!/XG/XT^"TJW=E)*S
M)IZRHDMNCMEX'21@LL/3'.X87C*[J]4\$ZU^T'\8(GTCQ1I%A\,]$==MWK%F
MK#4)5Z&.W5I'\MR./,(^7J#GBOJ# ]** /@SX??L_P#Q(^!_[1VH^*?#GP]D
MU?PC%+<VUK%'K%I'(]LPVHX,DN[=PIPV"><XK[DT#4+O5-'M;N_TR;1KN5=T
MEC<2QR20G^ZS1LR$_P"ZQ%7Z@N+N&UD@CEECB>X<QQ*[!3(^TMM7U.U6./12
M>U 'SS^WE\-!X\^!=]J<$8;4?#CC4HF[F'[LZY[#8=__ &S%:/[&/P_O/"/P
M=L=7UEY9]?\ $*Q7UQ+.29! L:QVT9)YPL*(>>07859^/M]_PL+7O#OPBL)U
MDFUN9;[7O)?YK;2H'5W!QRIE<)&O_ J]PAA2"%(HU5(T 554   =  .U #UX
MI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K:C_P >;_A_
M,59JMJ/_ !YO^'\Q0!):_P#'M%_NBI:BM?\ CVB_W14M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!Q_B/_ )&[2_\ ME_Z,-=A7'^(_P#D
M;M+_ .V7_HPUV% !1110 4444 %%%% !7-^//^03!_UW'_H+5TE<WX\_Y!,'
M_7<?^@M0!KZ+_P @>P_ZX1_^@BKM4M%_Y ]A_P!<(_\ T$5=H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 2J-E_Q]W/^]_4U>JC9?\?=S_O?U- %ZEI*
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCMR8=3UT""YNYMRX6.WY(C W'>3SP .M>G>4GF"38N\ J&QR <9&?3@?E3J
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M4 %%%% !2-2TC4 4M)_U,G^_5ZJ.D_ZF3_?J]0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4-W_QZR_[I_E4U0W?_ !ZR_P"Z?Y4 ,T__
M (\X_P ?YFK-5M/_ ././\?YFK- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %4]4_X]?^!"KE4]4_X]?^!"@"S#_JD_W13Z9#_JD_W13Z
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZA_KK;_>_J
M*O51U#_76W^]_44 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***8S;<>E #Z*X+Q9\=OA[X%$XUSQEH]C-;DK):
MF\22X4C@CRD)<G((Z=173^%?$^G>-/#>G:[I$[7.F:A MQ;3-&R%T89!VL 1
M^(H UJ*** "BBB@ HHICN%903C/2@!]%-4]:=0 4444 %%%% !1110 4444
M%%%% !1136ZT .KQW]HW]G]OCYIVAVJ>)[SPU)I5P]U%):PB4-(0%#$;E.Y1
MG!!&-QSVKT)?'WAC'_(R:3_X'1?_ !536OC+0-0NH[>UUS3;JX<_)%#=QL['
MV //&?RH X'X&_L]Z)\$+;4)[:]N]=U_4RIO]:U%MTTVWHHY.U0><9))ZDX&
M/5U.:;TR?Y5BR>./#EK(\4OB#2XI8V*LCWL892#@@C/!S0!NT5AP^-_#MU/'
M%!K^F332,$2..\C9F8G   ;DD\5LY([T /HJHVI6T=R+9KF%;CM$7&[\LU:6
M@!:*** "BFMU_2J]OJ%K=NZ07,<KK]Y4<$C\* +5%(*1FQ0 ZBLZ37M/AO$L
MY+^VCO&X6!IE$A^BUH+0 M%-8XJLVI6T=R+9KF%;CM$7&[\LT 6Z*1::S8_*
M@!]%9=_XDTK3;I;:\U6RM;AP-L,UPB.<G' )SR>*THY%EC#HP=3R&4Y!H =5
M;4?^/-_P_F*LU6U'_CS?\/YB@"2U_P"/:+_=%2U%:_\ 'M%_NBI: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C_$?_ "-VE_\ ;+_T8:["
MN/\ $?\ R-VE_P#;+_T8:["@ HHHH **** "BBB@ KF_'G_()@_Z[C_T%JZ2
MN;\>?\@F#_KN/_06H U]%_Y ]A_UPC_]!%7:I:+_ ,@>P_ZX1_\ H(J[0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 E4;+_C[N?][^IJ]5&R_P"/NY_W
MOZF@"]2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 52U;_CV'^]5VJ6K?\>P_WJ +B_=%+2+]T4M !111
M0 4444 8WB[4-8TS0KBXT#28=<U5=ODV-Q>?9$DRP#$R['VX4D_=.< <9S7Q
M[;?LZ?&2#]HX_%MK#PR]V;MKC^R_[5E"[#"8=GF>1V3^+'7!QVK[:Z]:,>U
M&3X3O]7U3P_:W.NZ5%HFJR;O.L(;L72188A<2A5W94!NG&<<XS6O24M !111
M0 4444 %%%% #)&*J2.N. 3Q7Q;^TE^S_P#&#]I+5=$OYM%\.^&H=-MY(DLV
MUE[E]SL"S,X@4<[5P!GZU]J4;1TQQ0!Q7PWU+QG=64MKXPT#3]'GM8X4AN=/
MU/[4EVV#YC%3$AC (7CYL[NV*[5<XYHI: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@ HHHH **** "BBB@ HHHH *AN_^/67_=/\JFJ&[_X]9?\ =/\ *@!FG_\
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M'S3OA[_;'PW\972:$YO&FL9;[]VJ3\)-!(3PARH*[L<[AG. 0#[H\6>&M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <?XC_Y&[2_^V7_HPUV%<?XC
M_P"1NTO_ +9?^C#784 %%%% !1110 4444 %<WX\_P"03!_UW'_H+5TE<WX\
M_P"03!_UW'_H+4 :^B_\@>P_ZX1_^@BKM4M%_P"0/8?]<(__ $$5=H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 2J-E_Q]W/^]_4U>JC9?\ 'W<_[W]3
M0!>I:2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *I:M_Q[#_>J[5+5O^/8?[U %Q?NBEI%^Z*6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-K_ ,?T]7JHVO\
MQ_3U>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&I:1J
M *6D_P"ID_WZO51TG_4R?[]7J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *AN_P#CUE_W3_*IJAN_^/67_=/\J &:?_QYQ_C_ #-6:K:?
M_P ><?X_S-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*IZI_P >O_ A5RJ>J?\ 'K_P(4 68?\ 5)_NBGTR'_5)_NBGT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 51U#_76W^]_45>JCJ'^NMO]
M[^HH O4444 %%%% !1110 4444 %%%% "5Y+\4/V6_AO\7-2;4M>T!1JS8WZ
MA8R-;S2?[Y7AS@ 98$@# ->MTGO0!\_^$_V&_A%X4OH[LZ#-K4T?W5U:Y::/
MZF,81O\ @0/YU[VL*1QB)441* H10   .F/2IJ* /#=6_8]^'UUXE?7]%&K^
M#-5ESYDWAC4'L@V>ORC(7Z+@5T_@G]G_ ,(>"=<37EAO->\2*NQ=<\07LE_>
M*N",(\A(3J?N@'DUZ510!0UK2;?7-+N]/N_-^S74;12>3,\#[2,':Z%64^X(
M(KQ^\_8M^#NI7C75WX3FNKIB"T\VLW[N<#@[C/GBO;Z* .(M_@[X8M?!ESX4
MA@U)=$N)?.DA.L7AEW?+P)C*9%4[1E0P7KQR<\,/V+_@\NH?;AX4F6]\SS?M
M/]LW_F[\YW;O/SG/?/->XTE &3X;\.V/A+0[31]-6=+"U!6);BYEN) "2<&2
M1F=ADGJ>!@#@"O+C^R!\)H]<GUF+PS/!JDTKS/=V^LWT4A=SEB"LXQDD]*]G
MP/2CB@#S7X[6<>F_L[^/+2'>8;?PY>11^9(TC;5MV RS$LQP.22237R3^QA^
MSGX#^-?P5U6\\4:,UUJ-OKTT$-]!<20RK&+>V8)E3@C+,>0<9/K7T;^U9\5/
M#?AWX8^,/"UQJ:CQ+J6B3+:Z9%&\DTJRAHE8*H/&X,,GC@UXC_P3]^)WA_P3
MX)U'PGKVH?V1J^H:\'L+>[B=/M)EBBB54.,%BT?3/>F!]&?"K]FCX>?!JZ>]
M\.Z&JZHP*G4+R0SSJI[*S'" _P"R!GO7J?\ %S_*E3[HI=H]*0'D7BC]E/X8
M^/-2GU'7]!NM6NYIGF9KC6KYE#.<G:OG[4!XX4  8&.*W?AW\"_!?PFO#+X6
MTZZTP-"T)A.J7<\(4MNXBEE9 <@G<%SRW/)KT&DH X#XH? OP/\ &2VCC\5Z
M!#J,T2[8;M"T-Q&.N%D0AL9_A)QGM7F>B_L$_!_2;T7,FD7VI@/N6&\U"0QC
M';"%<CKP<U]%X'I2T 9V@Z!IOA?2;?2](L+;3-.MEV0VMI$L<:#V4# KC?BQ
M\!_!'QJCM%\6:.M[-:@K;W,4K0S(#R5W*1E?]DY'M7H=% '!_#'X*^#?@[I5
MU8>$]&33%NB&N)O,>2:8@8&Z1B6('8 @#)(&2:X_5OV-_A)X@N/M.J^&;K4K
MCD>=>:WJ$KX))(RT_J37M=% ''?#_P"%/ASX6V]U;^&K2[LK:Y">9%-J-S=*
M-@8+M$TC[."?N8SQGH*ROBO\ ? _QHB@/BC1H[F\@&V'4+=S#<QC.=HD7DCK
M\IR!DG&:]'I,#TH \2LOV3?"7E06NLZUXL\5:7!CRM*UW7IIK,8.1^Z7:#R!
MP<CVKV+3=-M-&L8+'3[:*RL[=%BAMK= D<:@8"JHX48%7*2@#R7Q=^RS\-/B
M!JEQJ/B'0KK5KJ>9IV:?6;[8&;J403[4'LH  XK7^'OP'\%?">\^T>%=,NM,
M;RFB\G^U+N:':3D_NY)60'/?;GD^M>B4A&>HS0!R7Q(^&/AGXM:"FB>+-._M
M72XYUNA!]HEA'F*&4-NC=3P';@G'.<<5D?#OX!^"/A3>?:?"NF7>E-L9/)_M
M2[FAPQR3Y4DK)G.><9YKT2C ]* $7[M.HHH **** "F2?TQ3Z2@#Q:^_8Z^$
M>JW*7%_X7GOYE! >\UF_F('I\\QXK5\$_LQ_#CX<ZM;:EX<T.YTNZMI#)'Y>
MKWK1[B,$M&TQ1N/[P->J8'I2T 1=ACGC]*\C\0_LF?"WQ=JDNHZUX=N-4NI)
MFG8W.KWS*'8[CA/.V@$GH !TXKV#:/2EH \?\-_LH_"_P;J\.HZ)X?GTRZAG
M2Y4V^L7JJ9%;<I9/.VL 1]T@@XP12^+_ -DWX5^/_$E]K^O^%VU#5[UP]Q<-
MJ5XA<@ #Y5F"@  #  '%>OTG3@4 >$?\,-_!+_H2?_*K??\ Q^D;]AWX)@C_
M (HK@_\ 45OO_CU>\TE ")]VHKRWCO+::WE#&.9#&VQBI(((."""#[@Y%3T4
M >#C]ASX)]3X+R<Y_P"0M??_ !^C_AAOX)?]"5_Y5;[_ ./U[Q10!Y'X)_95
M^%WPU\46/B/PYX7_ +-UFRWF"Z_M"ZEV;T:-OE>5E/RNPY'?(YKNO&G@?0?B
M-X=N-#\1Z7!JVESX+6]P#\I'1E8$%6'9E((S70T4 >%:7^R#X2TG36TF+Q#X
MR;PX['?H/]OS+8LA)^0QI@[>>?FY[YKV#PSX;TKP?HMIH^B6$&EZ9:ILAM;9
M J(/P[GDDGDDG)K5I: /(/%_[)OPK\?>)+[7]?\ "[:AJ]ZX>>X;4KQ"Q  '
MRK,%   &  .*QO\ AAOX)?\ 0D_^56^_^/U[Q10!X*W[#GP2R/\ BBN#Q_R%
M;[_X]_G%>@_%'X,^$/C-I=O8^+=)74H[8LUO*LKQ20E@ Q5E((SM&1TX%=Q1
M0!\^Z+^Q'\/-%7RENO$ESI_/_$MDUF5+<J<Y7;'M.#GGFO:O"?@_1/ ^BQ:3
MH&E6FD:=%RMO9Q!$S@98XZDX&6/)QS6Q2T %5M1_X\W_  _F*LU6U'_CS?\
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M %%%% !1110 E4;+_C[N?][^IJ]5&R_X^[G_ 'OZF@"]2TE+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52
MU;_CV'^]5VJ6K?\ 'L/]Z@"XOW12TB_=%+0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %&U_X_IZO51M?^/Z>KU !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %(U+2-0!2TG_4R?[]7JHZ3_ *F3
M_?J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-W_P >
MLO\ NG^535#=_P#'K+_NG^5 #-/_ ././\?YFK-5M/\ ^/./\?YFK- !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]4_X]?\ @0JY5/5/
M^/7_ ($* +,/^J3_ '13Z9#_ *I/]T4^@ HHHH **** "BBB@ HHHH ****
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M_D$P?]=Q_P"@M0!KZ+_R![#_ *X1_P#H(J[5+1?^0/8?]<(__015V@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!*HV7_ !]W/^]_4U>JC9?\?=S_ +W]
M30!>I:2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *I:M_Q[#_>J[5+5O\ CV'^]0!<7[HI:1?NBEH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C:_\ ']/5ZJ-K
M_P ?T]7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6
MD:@"EI/^ID_WZO51TG_4R?[]7J "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *AN_\ CUE_W3_*IJAN_P#CUE_W3_*@!FG_ /'G'^/\S5FJ
MVG_\><?X_P S5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "J>J?\>O\ P(5<JGJG_'K_ ,"% %F'_5)_NBGTR'_5)_NBGT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 51U#_76W^]_45>JCJ'^NMO
M][^HH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5;4?\ CS?\/YBK-5M1_P"/-_P_F* )+7_CVB_W14M16O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5+5O\ CV'^]5VJ6K?\>P_W
MJ +B_=%+2+]T4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 4;7_C^GJ]5&U_X_IZO4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4C4M(U %+2?]3)_OU>JCI/^ID_WZO4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5#=_\>LO^Z?Y5-4-W_P >LO\ NG^5
M #-/_P"/./\ '^9JS5;3_P#CSC_'^9JS0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !5/5/^/7_@0JY5/5/^/7_@0H LP_ZI/]T4^F0_ZI
M/]T4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.H?ZZ
MV_WOZBKU4=0_UUM_O?U% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *K:C_QYO^'\Q5FJVH_\>;_A_,4 26O_
M ![1?[HJ6HK7_CVB_P!T5+0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <?XC_Y&[2_^V7_HPUV%<?XC_P"1NTO_ +9?^C#784 %%%% !111
M0 4444 %<WX\_P"03!_UW'_H+5TE<WX\_P"03!_UW'_H+4 :^B_\@>P_ZX1_
M^@BKM4M%_P"0/8?]<(__ $$5=H ***0T &?2DY_R*Y;5O#NK7NH3S6UZL4+'
MY4\UQC@=@*J?\(GKO_013_O^_P#A0!VG/^11S_D5Q?\ PB>N_P#013_O^_\
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M3_O^_P#A0!VG/^11S_D5Q?\ PB>N_P#013_O^_\ A1_PB>N_]!%/^_[_ .%
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MG_?]_P#"@#M.?\BCG_(KB_\ A$]=_P"@BG_?]_\ "C_A$]=_Z"*?]_W_ ,*
M.TY_R*.?\BN+_P"$3UW_ *"*?]_W_P */^$3UW_H(I_W_?\ PH [3G_(HY_R
M*XO_ (1/7?\ H(I_W_?_  H_X1/7?^@BG_?]_P#"@#M.?\BCG_(KB_\ A$]=
M_P"@BG_?]_\ "C_A$]=_Z"*?]_W_ ,* .TY_R*.?\BN+_P"$3UW_ *"*?]_W
M_P */^$3UW_H(I_W_?\ PH [3G_(HY_R*XO_ (1/7?\ H(I_W_?_  H_X1/7
M?^@BG_?]_P#"@#M.?\BCG_(KB_\ A$]=_P"@BG_?]_\ "C_A$]=_Z"*?]_W_
M ,* .TY_R*.?\BN+_P"$3UW_ *"*?]_W_P */^$3UW_H(I_W_?\ PH [3G_(
MHY_R*XO_ (1/7?\ H(I_W_?_  H_X1/7?^@BG_?]_P#"@#M.?\BCG_(KB_\
MA$]=_P"@BG_?]_\ "C_A$]=_Z"*?]_W_ ,* .TY_R*.?\BN+_P"$3UW_ *"*
M?]_W_P */^$3UW_H(I_W_?\ PH [3G_(HY_R*XO_ (1/7?\ H(I_W_?_  H_
MX1/7?^@BG_?]_P#"@#M.?\BCG_(KB_\ A$]=_P"@BG_?]_\ "C_A$]=_Z"*?
M]_W_ ,* .TY_R*IZI_Q[#_>_I7+_ /")Z[_T$4_[_O\ X5#=>&-9BC!DOT9<
MXQYS_P"% '=+G:/\*.?\BN*7PIKI&?[17_O_ "?X4O\ PB>N_P#013_O^_\
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M/^_[_P"% ':<_P"11S_D5Q?_  B>N_\ 013_ +_O_A1_PB>N_P#013_O^_\
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M/^_[_P"% ':<_P"11S_D5Q?_  B>N_\ 013_ +_O_A1_PB>N_P#013_O^_\
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M/^_[_P"% ':<_P"11S_D5Q?_  B>N_\ 013_ +_O_A1_PB>N_P#013_O^_\
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M]!%/^_[_ .% ':<_Y%'/^17%_P#")Z[_ -!%/^_[_P"%'_")Z[_T$4_[_O\
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M_P#")Z[_ -!%/^_[_P"%'_")Z[_T$4_[_O\ X4 =IS_D4<_Y%<7_ ,(GKO\
MT$4_[_O_ (4?\(GKO_013_O^_P#A0!VG/^11S_D5Q?\ PB>N_P#013_O^_\
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MW_?_  H [3G_ "*.?\BN+_X1/7?^@BG_ '_?_"C_ (1/7?\ H(I_W_?_  H
M[3G_ "*.?\BN+_X1/7?^@BG_ '_?_"C_ (1/7?\ H(I_W_?_  H [3G_ "*.
M?\BN+_X1/7?^@BG_ '_?_"C_ (1/7?\ H(I_W_?_  H [3G_ "*.?\BN+_X1
M/7?^@BG_ '_?_"C_ (1/7?\ H(I_W_?_  H [3G_ "*.?\BN+_X1/7?^@BG_
M '_?_"C_ (1/7?\ H(I_W_?_  H [3G_ "*.?\BN+_X1/7?^@BG_ '_?_"C_
M (1/7?\ H(I_W_?_  H [3G_ "*.?\BN+_X1/7?^@BG_ '_?_"C_ (1/7?\
MH(I_W_?_  H [3G_ "*.?\BN+_X1/7?^@BG_ '_?_"C_ (1/7?\ H(I_W_?_
M  H [3G_ "*.?\BN+_X1/7?^@BG_ '_?_"C_ (1/7?\ H(I_W_?_  H [3G_
M "*.?\BN+_X1/7?^@BG_ '_?_"C_ (1/7?\ H(I_W_?_  H [3G_ "*.?\BN
M+_X1/7?^@BG_ '_?_"C_ (1/7?\ H(I_W_?_  H [3G_ "*.?\BN+_X1/7?^
M@BG_ '_?_"C_ (1/7?\ H(I_W_?_  H [3G_ "*.?\BN+_X1/7?^@BG_ '_?
M_"C_ (1/7?\ H(I_W_?_  H [3G_ "*BNO\ CWE_W3_*N0_X1/7?^@BG_?\
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M .%'_")Z[_T$4_[_ +_X4 =IS_D53O\ _76V?[W]17+_ /")Z[_T$4_[_O\
MX5!<>&=9C:(/?JQ8X7]\_'Z4 =WS_D4<_P"17%_\(GKO_017_O\ R?X4?\(G
MKO\ T$4_[_O_ (4 =IS_ )%'/^17%_\ ")Z[_P!!%/\ O^_^%'_")Z[_ -!%
M/^_[_P"% ':<_P"11S_D5Q?_  B>N_\ 013_ +_O_A1_PB>N_P#013_O^_\
MA0!VG/\ D4<_Y%<7_P (GKO_ $$4_P"_[_X4?\(GKO\ T$4_[_O_ (4 =IS_
M )%'/^17%_\ ")Z[_P!!%/\ O^_^%'_")Z[_ -!%/^_[_P"% ':<_P"11S_D
M5Q?_  B>N_\ 013_ +_O_A1_PB>N_P#013_O^_\ A0!VG/\ D4<_Y%<7_P (
MGKO_ $$4_P"_[_X4?\(GKO\ T$4_[_O_ (4 =IS_ )%'/^17%_\ ")Z[_P!!
M%/\ O^_^%'_")Z[_ -!%/^_[_P"% ':<_P"11S_D5Q?_  B>N_\ 013_ +_O
M_A1_PB>N_P#013_O^_\ A0!VG/\ D4<_Y%<7_P (GKO_ $$4_P"_[_X4?\(G
MKO\ T$4_[_O_ (4 =IS_ )%'/^17%_\ ")Z[_P!!%/\ O^_^%'_")Z[_ -!%
M/^_[_P"% ':<_P"11S_D5Q?_  B>N_\ 013_ +_O_A1_PB>N_P#013_O^_\
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M/^_[_P"% ':<_P"11S_D5Q?_  B>N_\ 013_ +_O_A1_PB>N_P#013_O^_\
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M/^_[_P"% ':<_P"11S_D5Q?_  B>N_\ 013_ +_O_A1_PB>N_P#013_O^_\
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MJ"A2,@><_P#A3_\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\
M?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\
MA$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@
MBG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\
M"@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\
M(HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO
M_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"
M*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\
M*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=
M_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?
M]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M
M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_
MR*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]
M=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\
M?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\
MA$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@
MBG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\
M"@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\
M(HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO
M_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"
M*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\
M*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=
M_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?
M]_\ "@#M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M
M.?\ (HY_R*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_
MR*XO_A$]=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M.?\ (HY_R*XO_A$]
M=_Z"*?\ ?]_\*/\ A$]=_P"@BG_?]_\ "@#M<TM<UH.AZGIU\9;N\6:+81M$
MK-R<<X(KI%H Y#Q'_P C=I?_ &R_]&&NPKC_ !'_ ,C=I?\ VR_]&&NPH **
M** "BBB@ HHHH *YOQY_R"8/^NX_]!:NDKF_'G_()@_Z[C_T%J -?1?^0/8?
M]<(__015VJ6B_P#('L/^N$?_ *"*NT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 )5&S_ ./NY_WOZU>JC9?\?=S_ +W]30!>I:2EH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:M_Q
M[C_>J[5+5O\ CV'^]0!<7[HI:1?NBEH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"C:_\ ']<5>JC:_P#']/5Z@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H I:3_ *F3_?J]5'2?]3)_
MOU>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&Z_X]I?
M]TU-4-W_ ,>LO^Z?Y4 ,T_\ X\X_Q_F:LU6T_P#X\X_Q_F:LT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 53U3_CU_P"!"KE4]4_X]?\
M@0H LP_ZI/H*?3(?]4G^Z*?0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !5'4/]=;?[W]15ZJ.H?ZZV_WOZB@"]1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5M1_X\W_  _F
M*LU6U'_CS?\ #^8H DM?^/:+_='\JEJ*U_X]HO\ =%2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-K_Q_3U>JC:_\?T]7
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@"EI/
M^ID_WZO51TG_ %,G^_5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "H;O_CUE_P!T_P JFJ&[_P"/67_=/\J &:?_ ,><?X_S-6:K:?\
M\><?X_S-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I
MZI_QZ_\  A5RJ>J?\>O_  (4 68?]4G^Z*?3(?\ 5)_NBGT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 51U#_ %UM_O?U%7JHZA_KK;_>
M_J* +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 56U'_CS?\/YBK-5M1_X\W_#^8H DM?\ CVB_W14M16O_ ![1
M?[HJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%&U_X_IZO51M?^/Z>KU !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %(U+2-0!2TG_4R?[]7JHZ3_J9/]^KU !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %0W?_'K+_NG^535#=_\>LO^Z?Y4 ,T__CSC
M_'^9JS5;3_\ CSC_ !_F:LT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(J[5+1?^0/8?]<(__015V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*
MHV7_ !]W/^]_4U>JC9?\?=S_ +W]30!>I:2EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:M_Q[#_>J[5+
M5O\ CV'^]0!<7[HI:1?NBEH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"C:_\ ']/5ZJ-K_P ?T]7J "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *1J6D:@"EI/^ID_WZO51TG_4R?[]7J "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN_\ CUE_W3_*IJAN
M_P#CUE_W3_*@!FG_ /'G'^/\S5FJVG_\><?X_P S5F@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J>J?\>O\ P(5<JGJG_'K_ ,"% %F'
M_5)_NBGTR'_5)_NBGT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 51U#_76W^]_45>JCJ'^NMO][^HH O4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5+5O\ CV'^]5VJ6K?\>P_WJ +B_=%+2+]T4M !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 4;7_C^GJ]5&U_X_IZO4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C4M(U %+2?]3)_OU>J
MCI/^ID_WZO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M#=_\>LO^Z?Y5-4-W_P >LO\ NG^5 #-/_P"/./\ '^9JS5;3_P#CSC_'^9JS
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/5/^/7_@0J
MY5/5/^/7_@0H LP_ZI/]T4^F0_ZI/]T4^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "J.H?ZZV_WOZBKU4=0_UUM_O?U% %ZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K:
MC_QYO^'\Q5FJVH_\>;_A_,4 26O_ ![1?[HJ6HK7_CVB_P!T5+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <?XC_Y&[2_^V7_HPUV%<?XC
M_P"1NTO_ +9?^C#784 %%%% !1110 4444 %<WX\_P"03!_UW'_H+5TE<WX\
M_P"03!_UW'_H+4 :^B_\@>P_ZX1_^@BKM4M%_P"0/8?]<(__ $$5=H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 2J-E_Q]W/^]_4U>JC9?\ 'W<_[W]3
M0!>I:2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *I:M_Q[#_>J[5+5O^/8?[U %Q?NBEI%^Z*6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-K_ ,?T]7JHVO\
MQ_3U>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&I:1J
M *6D_P"ID_WZO51TG_4R?[]7J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *AN_P#CUE_W3_*IJAN_^/67_=/\J &:?_QYQ_C_ #-6:K:?
M_P ><?X_S-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*IZI_P >O_ A5RJ>J?\ 'K_P(4 68?\ 5)_NBGTR'_5)_NBGT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 51U#_76W^]_45>JCJ'^NMO]
M[^HH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !5;4?^/-_P /YBK-5M1_X\W_  _F* )+7_CVB_W14M16O_'M
M%_NBI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C_$?_(W
M:7_VR_\ 1AKL*X_Q'_R-VE_]LO\ T8:["@ HHHH **** "BBB@ KF_'G_()@
M_P"NX_\ 06KI*YOQY_R"8/\ KN/_ $%J -?1?^0/8?\ 7"/_ -!%7:I:+_R!
M[#_KA'_Z"*NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )5&R_X^[G_>
M_J:O51LO^/NY_P![^IH O4M)2T %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %4M6_X]A_O5=JEJW_ ![#_>H
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M6-:5I3*;G7-0DO9\D*,"1^=ORYP. 2?6@#HJ*** $-133I!$\DLBQ1H,L[L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 4;7_C^GJ]5&U_X_IZO4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4C4M(U %+2?]3)_OU>JCI/\ J9/]^KU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %0W?_ !ZR_P"Z?Y5-4-W_ ,>LO^Z?
MY4 ,T_\ X\X_Q_F:LU6T_P#X\X_Q_F:LT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 53U3_CU_P"!"KE4]4_X]?\ @0H LP_ZI/\ =%/I
MD/\ JD_W13Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MHZA_KK;_ 'OZBKU4=0_UUM_O?U% %ZBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *K:C_P >;_A_,59JMJ/_ !YO
M^'\Q0!):_P#'M%_NBI:BM?\ CVB_W14M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!Q_B/_ )&[2_\ ME_Z,-=A7'^(_P#D;M+_ .V7_HPU
MV% !1110 4444 %%%% !7-^//^03!_UW'_H+5TE<WX\_Y!,'_7<?^@M0!KZ+
M_P @>P_ZX1_^@BKM4M%_Y ]A_P!<(_\ T$5=H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 2J-E_Q]W/^]_4U>JC9?\?=S_O?U- %ZEI*6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUM=1E^U%Q##IUA-=.VT L3L4A1R/O$9SQ7Q1X+_Y287'_82O_P#TWS5^A34
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %&U_X_IZO51M?^/Z>K
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(U+2-0!2TG
M_4R?[]7JHZ3_ *F3_?J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !4-W_P >LO\ NG^535#=_P#'K+_NG^5 #-/_ ././\?YFK-5M/\
M^/./\?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4
M]4_X]?\ @0JY5/5/^/7_ ($* +,/^J3_ '13Z9#_ *I/]T4^@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "J.H?ZZV_P![^HJ]5'4/]=;?
M[W]10!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "JVH_\ 'F_X?S%6:K:C_P >;_A_,4 26O\ Q[1?[HJ6HK7_
M (]HO]T5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <?XC
M_P"1NTO_ +9?^C#785Q_B/\ Y&[2_P#ME_Z,-=A0 4444 %%%% !1110 5S?
MCS_D$P?]=Q_Z"U=)7-^//^03!_UW'_H+4 :^B_\ ('L/^N$?_H(J[5+1?^0/
M8?\ 7"/_ -!%7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $JC9?\?=S
M_O?U-7JHV7_'W<_[W]30!>I:2EH *8[;><X&.2>@IQ]*^,OVU?B)K?B;XD>#
M/@SH6H3:7%KLMO\ VE<PDAG6>4QI&<$'8H5F8=\KZ<@'O'B#]J3X4^&;J2VO
MO'>DB:-F1UMW:X*L"00?+#8Y!%=%X-^,G@?X@S&'PYXKTO5[A>MM;W2^</?R
MR0V/PJ#P'\$_ _PWT*'2]#\-Z?!"D?ER3R6Z///QRTDA&YR?<X[# XKQ?]H[
M]FCPYJ6N>!/$'AGPH+;6!XGL(M0;1[9E1K-I"9994C& %(4F0C@$Y)XP ?4*
MMN&:9-,L",[L$1069F.  .I)[5S7Q'NO%EKX1O9/!-I87WB/=&MM#JCLEN-S
MJ'9RI!PJEC@')QZU\>_M>?#/QQIGP6N?$OC;XBWVN:F;V"+^QM,C%KI42N2"
M/+ S*1QAVP1W% 'VYH>O:;XFTU+_ $G4+;4[%V=%NK.598V96*L RD@X8$?A
M5;Q1XNT/P9917NOZWI^@V<DH@CN=2NH[>-I"&(0,[ %L*QQU.#Z5X_\ L,Q[
M/V7?!IQAG-ZQ_P# V?G\L5[7JVBZ?KUK]FU.PM=1MLY\F[A65,X(SA@1T)'T
M)H X\?'SX9D9_P"%B^$\8S_R'+7_ ..4O_"_/AEMS_PL;PF/?^W+7_XY7Y_^
M(/ &@R?M['PP-)LSH$NN0[]-$0$!5HED9-@& N2W&,=*_0&]^!WPYOK'['/X
M#\-R6^-H0:5 NW/'!"Y4^XI@=%X?\7Z)XLMVGT/6M/UJ!<;I=.NHYU&>F2A-
M;*G(S7YB_M$>#;K]CWX[:3K/@"^GT[3[R 7MK;M(SA,-MEMWSDNG ^]DX?!R
M1FOTJ\.ZLNO:#IVJ)&8DO;:.Y6-CDJ'0,!^&:0$NJ:I::+87%_J%W!8V-O&9
M9KFYD$<<2#DLS$X  [GI7&K\??AEC_DHWA/_ ,'MK_\ '*[FZM8;VWD@N(8Y
MX)%*O%*H96!Z@@\$5^<G_!1SP;HWACQYX5N-(TBRTLWMA*9_L4*0B5UDX9@N
M,GY_O=>GI0!]P3?M ?#&-&<_$7PKM S\NM6QS],/SUK8\/\ Q.\(>++DV^A^
M*]$UJX_YXZ?J,,[_ )*QKE?!GP!^'&F^%=.A_P"$#\./(]I$)GFTN&5Y#L7.
MYF4ELD=S[U\J?MR_LY>&_AEH.E^/_!=I_P (Y.FH);W=M8EDB4LK,DR ']V5
M9<87 ^8'C!R ??:]*=7D7[*/Q'U'XJ? GPWKFL.9M6VR6MS,1_K6BD9 Y]2R
MA2?]HFO7: "BBB@ HHHH **** "BBB@ HHHH ***IZM?-INFWEV(_-^SPO+Y
M><;MJDXSVSB@"Y17SA^R?^TIKG[16N>,Y[[3+/1](TH6BVEK S/)NE,Q8O(<
M!C^['15[<>OT<O2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*K:C_P >;_A_,59JMJ/_ !YO^'\Q0!):_P#'M%_NBI:BM?\ CVB_W14M !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ!17E?\ PU!\*SG_ (KC2\_[[?X55G_:R^$UO)L?QI9,?^F:2N/S"&J]G/\
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M]'^">CV'C'P;<74&EO=K;7%C<2F1K5R"T<D;_>VY3!W$D$J03DT ?I OW?\
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M;JJC+32.P*C#$C:K$[3TKY3_ ."G'AVPCF\#:XD:IJ<PN;.5U',D2;'4'O\
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M]GA?4>8N?YB@#YH_:C^"6K_LU?$:P^*7P^+66BO=B8K"ORZ?.3\T9 X\F3)
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M:3HWAR*6^@2[AL2;IY(74/@2L<?=/90:^S>*^"OB=C_AX]X9]?,LL_\ ?@T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M &!_*OD/]KW]K#4/!^K3>"?!EW]FU&- =1U2(AGM\C/E1^CX();DC.!@\C[
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M[]7JHZ3_ *F3_?J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !4-W_P >LO\ NG^535#=_P#'K+_NG^5 #-/_ ././\?YFK-5M/\ ^/./
M\?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]4_X
M]?\ @0JY5/5/^/7_ ($* +,/^J3_ '13Z9#_ *I/]T4^@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J.H?ZZV_P![^HJ]5'4/]=;?[W]1
M0!>HHHH *2EHH **** "BBB@ HHHH 9(P3DL  .<]*_-7Q-XHL&_X*'Q:I]M
MMQ9+KUK ;G>/+XACAZ^Q!!_&OT)\=?#[PY\2-+ATSQ/I-OK-A#,+A+>Y!*B0
M*RAN.^&;\ZXG_AE+X1E=O_" Z1MSGB-@?YT >J)() K*<JPR".0?0\?YYKYC
M\'>*M/N/V]O&MJMY;L?^$9AMA^\',JM QC![L Q)'^R?0U[+8? WP'H_A/4_
M#-EX7L;?0-2=9+S3T4^5,RX(+<_[*_E6#_PRC\(A_P R%I)/_7-OP[T >LJ/
M6N%^-'PAT7XV>!;SPUK,>P2#?:WB*#):3 ';(N?3N.X)'>NOT72;30=(LM,T
M^!;6PLH4M[>!/NQQHH55'L  *NT ?D/XJUCQM\"="\=_!O7H]^FZD\+B-B3&
MKI/'*ES#ZK(D6".O3.&0BOUB\,3F?PUI4I&W?:1-C/3* ]<5S7Q,^"/@CXOK
M OBS0(-5EMXVCAGW/'+&I() ="&QD9QG%=E8VL.GV<%K -D$$:Q1@G.%   R
M>O H _/[_@II?1R>-/!-H)0TL-A/*R;A\H:10"1GOL/Y5]A^!/B]X(O?!^C>
M7XQ\/F1+*$21IJD!,;"-<J1NR"/>F^(/V<?AKXMUJ[U?6/!VG:AJ=T^^>YG5
MB\C8QD\^E9W_  RC\(E_YD+2!_P!N_\ P*@ \;?M4?"SP'8O<7OC33;Z10=M
MII,RWLS$#.W;$6VGW; ]Q7SM:?#_ ,6_MM?$O3O%OBW2[KPM\,-+&W3]-N25
MFO5R&)7@?ZS W.., *N2"P^I/#WP%^''A6X2XTKP1H5I<QXV3BPC:5<=P[ D
M'WS7?#'I0!%9VL-C:PV]O$D,$*+'''&H544# 4 <  =A4IHHH \BO_C%%H_[
M2H\"ZCJUG9Z=<^'8;RTAN"J-)>FYE1E5SU)C"X7/8UV_Q L?"]_X3U >,8-/
MF\/)$S77]I*IB10#\V3T([8YSC%8/Q$_9]^'OQ6OA>^*?#%MJE\$$8NM\D,P
M49P-\;*<#)XSWKG]'_9%^%FCBW7_ (1V34(K=P\,&I:A<W4$>"#@122%",CN
MIH \?_X)X^ ;K0]-\;^)XXKBV\/:U=QPZ0L^09H86E_>8/)^^%!]5:O./VFM
M>_X5+^W!X>\9:C;2G3-EG=L\2Y+Q!3#(1GJP /&?2OT'MK>.U@2&&-8HHU")
M&BA550,  #H .U<K\1OA/X2^+.FQZ?XLT*VUFWB),1EW))$3UV2(0ZYP,X(S
M@4 <U>?M/_"RST==17QUH]XC#,=M9W*S74A[*(%R^XGC!4<D5\6:UXHU/5OV
M^O#VKZ[IS>'II]1L1'873J98(6B58A+@D*[*02N3M+XS7VIX%_9C^%_PVUB/
M5?#WA&TM-2BYBN9Y9;EXSP,H97?8>.HP1D^IJ]XJ_9_^'?CG7;C6M?\ ".GZ
MIJT^WS;JX4EWV*%7.#V4 ?A0!X]_P46N/(^ ,"$X$NM6R;2/O?)*V/;[OZ=:
MF_9!_:$\!77P?\-^&[KQ+8Z3KNE6WV:>SU29;9G8,2&C+$!P0<X!)'<"O:Q\
M'?!JZ-I6D'P]:2:9I=^-3M+64,T<5R$91)@DY(#MUR,G.,@&N/\ $G[(?P?\
M6:G+J.H>";,7,C;G:SGGLT)/<I#(BY_#K[T <;^T-\3D^+/AV\^%_P ,+BW\
M5>(]:58;Z[L91+9Z9:[QO>>9<J"0"NT9."W&< ^N_!CX6V'P9^&NC>$[%Q.M
MG&3/<8VF>9R6D<_5CQU(  YQ6UX)\!>'OAWHJ:3X:T>TT73T.?)M8PNXX^\S
M=7;_ &F)/O6EK.D6>O:7=Z;?P+<V5U$T,T+9PZL,$'';% 'P'^U1K4$/[<WP
M^G,Z-'83:/YIW#]UB[+D'TX;/XU^@O7 R#GI7E(_9/\ A%T_X0+2<#I\C?\
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M\Z_0%:\H_P"&5_A-Y_G?\(-I?F[MV\(V[=G.>O7->IVT*6MO'#$NR*-0B+Z
M# %("6BBB@ HHHH 2EHHH **** "BBB@ HHHH **** "JVH_\>;_ (?S%6:K
M:C_QYO\ A_,4 26O_'M%_NBI:BM?^/:+_=%2T %%%% !1110 4444 %%%(:
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MHH *YOQY_P @F#_KN/\ T%JZ2N;\>?\ ()@_Z[C_ -!:@#7T7_D#V'_7"/\
M]!%7:I:+_P @>P_ZX1_^@BKM !1110 4444 %(>U+2'M0!SGQ(_Y)[XG_P"P
M7=?^BFK\<._XU^Q_Q(_Y)[XG_P"P7=?^BFK\</\ &O8P&TCY7.?C@?L1\*_^
M28^$/^P/:?\ HE*ZH5ROPI.[X7^$,?\ 0'M/_1*5U/3O7DRW9]+3^"/H.IK_
M '329PQ&:&/RFDBWLS\8_%?_ "-.L?\ 7[-_Z&U?>/PR\:>//!/[-OPXNO!?
MA*/Q;')!<I>0>84DB_?,49<=1]\$8STKX.\5_P#(TZQ_U^S?^AM7Z??LB_\
M)NO@S_KWE_\ 1\E>YC':G&ZN?)9;%RKU$G9_\$^7?B1X3^/O[3NJ64.J>%&T
M'1[9LPVTY%M;PD\&1][;W;'' .!]T#)S]#?LW_LLZ7\#4DU2]N$UCQ5<1^7)
M>*I$5NIZI"#SSQECR<< #(KWS:!T&*-H]*\N=>4H\B5D>]3P-.%3VLFY2[L^
M5_\ @H-XF?2_A-I&D(Y0ZIJ:F;C.Z*)&8C_OLQG\*^2_V:_B)IOPJ^(4_B/4
M+.:_N[;3YH]/L;=27N+J1D14! .WY6?)P>AP"< _2?\ P4>B?_A'_!,G2-;J
MY4_4HF/Y'\J\L_8#\,V>N?&:[O;R%)FTO3)+BW#@'9*TB(''T5G'MD5Z-&T<
M+S,\+%J=3'J*=GI8P?BI\7OCO-.VL:]<>*/".GW#[H([:&?3[9 <X16 7/']
MYB3P:ZK]G/\ ;$\3^'/%FGZ+XSU>;6?#EY*ENUWJ#;I[-F.%D,I^9ESC<&SQ
MR#V/WSXD\.:=XM\/WVCZI;1W>GWT30S0R*""I'OT(SD'L17X]>,/#[>$_%NN
M:&[>8^F7L]D6QC<4D*$_CC]:*#IXB+BXVL/&1K8&I&K&;:?<_9D<K7Y67'Q9
M\8^"OB-\0;?P?J$]E-KNKS><UK"))WVS2E0C$$K_ *QN1@]*_2KX5ZA+JWPQ
M\(WTX*S7.CV<T@)Z,T*$C\S3_"'PQ\+>!+B^N="T.STZYOI7FN9XH\RR,QW$
M%SDXST7.!V%>?1JJCS75SVL3AYXI0<78_*;Q%K_CZQNDGU[4?$EO<]4DU*>X
M1SD9X+^N?6O3/@K^V!XR^&VM6L.M:E=>)O#C.$N+2\E,L\29Y>)V)8%1_"3M
M.,<$@U^C_B;POI/B_1;G2=:T^WU+3KE2LEO<1AE;W]B.Q'(/2OR6^,?@,?#'
MXG>(?#"2-+!I]SMA>3[QB9 \>??8RY/KG'%>G1J0Q*<)1V/!Q-&ME\E5C-M,
M_6_2M4M/$FB6NH6<JW5A?0+/#*!\LD;J"I_$$5^/'C3PY<>#O%VL:'=(T<^G
M7<MLRL.R.5!YZC !SW'K7Z:_LBW%Q=?LZ^#'NMWF+!*BY_N+/(J?AM"UB?M!
M?LDZ%\;KP:S;7C:!XD$8C:\CB\R*X4#Y1*F020  &!! P.0 *XL/4C0J2C+8
M]/&8>>,HPJ4_B6ID? W]L/P7X@\":=!XIUV/1O$-E (;L7V56=D7!E1NAW8S
MM.&SD8Q@GYH_;+^-FE?&#QAI">'VDNM#T>&6*.]="BSS.5,A3/. %C'(!SGV
MKTGP]_P3GN%U*)M?\80_V>I!>'3[5O,D'=0SMA/KAOIZ>>?ML6.B>$_&WASP
M;X=M8K'3-#TI28(1G;+*[,=Q/WF*A&+'D[JZJ,:7M[T]3AQ4L7]5:K))':_\
M$Y(9&\6>,YA_JDLK=&/;+.Q7]%:OO%:^4O\ @GOX)FT7X;ZUXBGB,3ZW>A(2
M1P\,(*AA[;WE'_ <U]6K7!BI*55V/:RZ+AAHIBT445R'I!1110 4444 )5&R
M_P"/NY_WOZFKU4;+_C[N?][^IH O4M)2T %%%% "4M%% !1110 4E+10 E+1
M10 4444 )1@>E+10 E+110 F!Z4M%% "4M%% !1110 4444 )6-XN\6:;X(T
M.YUG6)9H-.M]OFR6]M+<.-S!1B.)68\D= <=>!S6U10!^<]IKNJI^VXWQ*D\
M*^*(_#'VUQ]J_L.Z+B$VAMQ)Y>S=CD'&,@=L\5^@'A/Q1IWC30+76=*DEFL+
MDOY;SVTMN_RL4;*2JKC!4CE1Z]*U]H]**8"TE+12 3 ]*6BB@!**6B@!**6B
M@!*6BB@ HHHH **** "BBB@ HHHH **** "J6K?\>P_WJNU2U;_CV'^]0!<7
M[HI:1?NBEH *Y?XA^&=7\6Z&EAHWBF]\(W/G!WOK&"*61XPK QXD!"@DJ=PP
M?E'.":ZBD- 'YN?"?Q5\2K7]K'7?#]MK-YXRUVQ?4-+L[G7+N0VUN$?:;F1!
MG:@52VQ.2S!<@FO:_'7["=_XW6XU;4OBGKFH>+),RBZNXU6V\S!VA8U.8UR2
M,*2 "<"N!_9Q('[?7Q*!('[W5\?7[6O_ ->OO4=J /B?]B'XP>,;?XC>)?A5
MXTU"XU.;38YFMY;N4RR6\L$BQRQ!VY9#NR,GC9QUKT7]J7]HC6_ GB3PW\.O
M! A'C3Q')#&E[<@.EDDLOE1MM/#,6#=>% R0<C'CWP; '_!1+QH!Q^]U#I]!
M_C7(?M(3:A>?MY:9;0ZDVB3_ &[2K>QU)(DF-N72+;*$?Y3MD=N#QQ0!]<2?
MLD^ M;TQ$\41ZIXLU<C,VL:IJER;AY3R74*X6/GHJ@ # P:\-^$_Q(\2?L__
M +3DWP>UK7+OQ%X2O9DBTR;4)#+-:^9&'@PQZYR$91A=V6 '?W4?"?XL]?\
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M48W75V?K^_<#] * /&?^"H77X9_]Q/\ ]M*^[:^$O^"H1RWPS //_$RX_P#
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M^#O_ .YZ/^'DS_\ 1/!_X.__ +GH^JUOY0_M+"_S'VY17Q'_ ,/)G_Z)X/\
MP=__ '/1_P /)G_Z)X/_  =__<]'U6M_*']I87^8^W**^(_^'DS_ /1/!_X.
M_P#[GH_X>3/_ -$\'_@[_P#N>CZK6_E#^TL+_,?;E%?$?_#R9_\ HG@_\'?_
M -ST?\/)G_Z)X/\ P=__ '/1]5K?RA_:6%_F/MRBOB/_ (>3/_T3P?\ @[_^
MYZ/^'DS_ /1/!_X._P#[GH^JUOY0_M+"_P Q]N45\1_\/)G_ .B>#_P=_P#W
M/1_P\F?_ *)X/_!W_P#<]'U6M_*']I87^8^W**^(_P#AY,__ $3P?^#O_P"Y
MZ/\ AY,__1/!_P"#O_[GH^JUOY0_M+"_S'VY17Q'_P /)G_Z)X/_  =__<]'
M_#R9_P#HG@_\'?\ ]ST?5:W\H?VEA?YC[<HKXC_X>3/_ -$\'_@[_P#N>C_A
MY,__ $3P?^#O_P"YZ/JM;^4/[2PO\Q]N45\7Z?\ \%(;*1O].\"7%NO/-OJ:
MS'IZ&):]'\%_MR?#3Q9,D%]=WGAJY8[5&J0[8R?^NB%E ]VQ4O#U8ZN)I''X
M:;LIGT3156QU"WU*UBN;2XBN[:5=\<T+AT=3T((X(^E617,=R:>PM%%% PHH
MHH **** "BBB@ HHHH *1J6D:@"EI/\ J9/]^KU4=)_U,G^_5Z@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "H;O\ X]9?]T_RJ:H;O_CU
ME_W3_*@!FG_\><?X_P S5FJVG_\ 'G'^/\S5F@ HHHH **** "BBB@ HHHH
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M_B)X?ELM57[)XHTI_L^HVC *VX$CS,>C8/3H01TQ7+>#>?VMO&I//_$IC/\
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MH **** "BBB@#C_$?_(W:7_VR_\ 1AKL*X_Q'_R-VE_]LO\ T8:["@ HHHH
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M2E-G1AQNSP>.E?4E% 'YV?MX>,K;XR:QX1C\(V&L:Q%I45T+BX&E7,2!Y&C
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MG^_5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;O_CU
ME_W3_*IJAN_^/67_ '3_ "H 9I__ !YQ_C_,U9JMI_\ QYQ_C_,U9H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJG_'K_P(5<JGJG_'
MK_P(4 68?]4G^Z*?3(?]4G^Z*?0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5'4/]=;?[W]15ZJ.H?ZZV_P![^HH O4444 %%%% !1110
M 4444 %%%% #6^N/I7C'Q:_:6TSX?>)+7P?H6F7/C3Q[>$+!H6FD#RLC*M-(
M>(QCGO@?,<#FNA_:&^* ^#WPC\0>)DVM?00B&RC;!W7$C!(^#U"D[B/137A'
M_!/?P(UQX3U[XD:P7O?$.OWTL*WUR=TAA1@9&R><O-NW>NQ?2F!Z##I/[17B
MJW%S<^(/!_@KS5REE9V4E])'QD!W<[2V>#MR.XKF?%GB3]I7X3VK:M/:>&OB
M+HUNF^YCT^WD@NPH'+! 1D]_E#]^.]?42]*1NU(#P[]GW]K3PK\>U%A"KZ%X
MG1"\NCW+[]R@<M%( !(!Z85NO&.3[DGW>>M?FS^VQX'G^!_QTT;QUX5=M(.K
MEM0CD@&!%>QN/-('3#!T8KW+N.E?H%\./&4'Q"\ ^'_$MJGE1:I9170ASGRR
MR@LF>^&R/PH W-2U"WTFQN+V\N$M;2WC:6::4A4C102S$]@ .37S3\"OVP;K
MX\?&S4_#.EZ+;V7ABUL+BYANY6=KJ?9+&B.1PL88,3L()_VN.>G^+EQ+\9O'
MUM\*-.ED70;58]1\7W<+$;8"<P608=&F(W-T(1<^HKY]_8XM8;']M#XJ6]M"
MEO;PP:K''%&H"HHU&   #@# ' H ^^EZ4M)0: /'?VAOVE]"^ %E917-G<:U
MX@U('[!I-K\IEP<;F?!VC) X!8GH.I'SKJ_[='Q=T2W75K_X2MIV@DY^T7EI
M>1H5SSB8J%]L[<9-?3E]\*Y=6_:(L_'E^EM+IVEZ -.T^-R3(ET\\C22@8P
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M?%(WDQ2$XVS1N T8!P"V2!GD <U]=:+I%GH.DVFFZ?;1VEC:1+!!!$,+&BC
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MHYAA)1RJ>$I+F:BDO.UCD?C1X-U+P5K5I\4O",6=1L4"ZM9KP+NV  9CCJ0
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MZ[?SV_@:UO8[JYL+&0QR:A=,@"+(X&?+15)VC&68'/RBONGXV?\ )&?'O?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"C:_P#']/5MASUJI:_\?T]7&H _*_\ :X\22^)?
MV@/%+R/OCLI5L85_N+&H!'_?>X_C7CU>D?M(:>VF?'CQS"V[+:I-.-V<XD/F
M#]&_+%>;U]715J:MV/S?$:UIW[A1116ISA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4MG=36-U#<V[F*XA<21R#J
MK @@^W-14?7_ /5S2*C\2L?LUX0UD>(_"FC:L,?Z=9PW7'3YT#?UK86N4^$^
MGOI/PM\'V,@(DM='M('W=<K"BG/XBNKKY*7Q,_2J>L%?L+1114F@4444 %%%
M% !1110 4C4M(U %+2?]3)_OU>JCI/\ J9/]^KU !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %0W?_ !ZR_P"Z?Y5-4-W_ ,>LO^Z?Y4 ,
MT_\ X\X_Q_F:LU6T_P#X\X_Q_F:LT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 53U3_CU_P"!"KE4]4_X]?\ @0H LP_ZI/\ =%/ID/\
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MS3W,I^50/;J23@ #DD@#DUX)X-\%ZG^TAXLL?B'XZL);+P?8OYGACPK=#_6
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MC!XLO?A;\/;QK.&#]WXH\40C<NFQ'[UM"1]Z=^1P?DYZ$$KZ]\.OA[H7PO\
M"5CX=\.V*V.G6J\+U>1R/FD=OXG/<_R  H Z&WACM84AB18XHP%2-1@* . !
MV%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,JY^S6H)07"@\1QCJL0Y!;J3D#DEJ^N))M'\&Z&HDDM=)TNTC"*N5BCC4#@
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MP;K4\3M#/'8SNDB-AD8(Q!!'?-:5G-NM(2S9;8N2><\<TC7VD>;E?8L 8I2
M3TZU@^"[J>\TFX>XD>5UOKN,-(Q)VK<2*H^@  K/\=2WNI36.@Z9=RV-Y=!Y
MY+J$X>&&,#D?61HU]P6IV,Y5DJ7M+7\CK_I3:RO">M-KV@6EXZ>7<%=D\?\
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M%(W"BBB@ HHHH **** "BBB@#C_$?_(W:7_VR_\ 1AKL*X_Q'_R-VE_]LO\
MT8:["@ HHHH **** "BBB@ KF_'G_()@_P"NX_\ 06KI*YOQY_R"8/\ KN/_
M $%J -?1?^0/8?\ 7"/_ -!%7:I:+_R![#_KA'_Z"*NT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMW*D.;>1EX([-L;!]\5\<?"GX8_M-_LY7&H:)X5T31_$&@37'G9N[R$VN\@
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MK\VT<@CC%2_#_P#:6N?$?Q.3X?>*/ FL>#/$\L+W$:331W-L\: EF$JXRO!
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M **** "D:EI&H I:3_J9/]^KU4=)_P!3)_OU>H **** "BBB@ HHHH ****
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M)P!P!SVS0!S'CCQ-X^TJ^,'A;P38^(+7RLB\N];6TPY[>7Y3$@?45\H_ _X
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M7P->2MH\FG7<ADOM+E:RF9N"^T HY_WD*-]2:Z7\*BCMX8YI)4BC263&]U4
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M/^%(_$3_ *$'Q1_X);G_ .(K]?:*/K\OY4']BTOYF?D%_P *1^(G_0@^*/\
MP2W/_P 11_PI'XB?]"#XH_\ !+<__$5^OM%'U^7\J#^Q:7\S/R"_X4C\1/\
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M[]7JHZ3_ *F3_?J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !4-W_P >LO\ NG^535#=_P#'K+_NG^5 #-/_ ././\?YFK-5M/\ ^/./
M\?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]4_X
M]?\ @0JY5/5/^/7_ ($* +,/^J3_ '13Z9#_ *I/]T4^@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J.H?ZZV_P![^HJ]5'4/]=;?[W]1
M0!>HHHH **** "BBB@ HHHH **** "BBB@!*,>U+10 E+110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 54U$?Z*_P"'\ZMU6U'_ (\W_#^8H#T"W/\ H\?^X.*^'OC
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M!M3[S\X=OQO_ .>?C[_OF^HV_&__ )Y^/O\ OF^K]'J*/]:/^H6'W!_J*O\
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MO?Y;W-?>/PG&HCX;^'/[7%T-4^PQ?:?MF[SO,VC=OW<YSZUUF!Z45X^99O\
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MQ]W/^]_4U>JC9?\ 'W<_[W]30!>I:2EH **** "BBB@ HHHH **** "BBB@
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M[]7JHZ3_ *F3_?J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !4-W_P >LO\ NG^535#=_P#'K+_NG^5 #-/_ ././\?YFK-5M/\ ^/./
M\?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]4_X
M]?\ @0JY5/5/^/7_ ($* +,/^J3_ '13Z9#_ *I/]T4^@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J.H?ZZV_P![^HJ]5'4/]=;?[W]1
M0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "JVH_\ 'F_X?S%6:K:C_P >;_A_,4 26O\ Q[1?[HJ6HK7_ (]H
MO]T5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <?XC_P"1
MNTO_ +9?^C#785Q_B/\ Y&[2_P#ME_Z,-=A0 4444 %%%% !1110 5S?CS_D
M$P?]=Q_Z"U=)7-^//^03!_UW'_H+4 :^B_\ ('L/^N$?_H(J[5+1?^0/8?\
M7"/_ -!%7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $JC9?\?=S_O?U
M-7JHV7_'W<_[W]30!>I:2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *I:M_P >P_WJNU2U;_CV'^]0!<7[
MHI:1?NBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"C:_\?T]7JHVO_']/5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "D:EI&H I:3_J9/\ ?J]5'2?]3)_OU>H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J&[_X]9?]T_RJ:H;O_CUE_P!T_P J &:?
M_P ><?X_S-6:K:?_ ,><?X_S-6: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *IZI_QZ_\"%7*IZI_QZ_\"% %F'_5)_NBGTR'_5)_NBGT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U#_76W^]_4
M5>JCJ'^NMO\ >_J* +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 56U'_CS?\/YBK-5M1_X\W_#^8H DM?^/:+_
M '14M16O_'M%_NBI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#C_$?_(W:7_VR_P#1AKL*X_Q'_P C=I?_ &R_]&&NPH **** "BBB@ HH
MHH *YOQY_P @F#_KN/\ T%JZ2N;\>?\ ()@_Z[C_ -!:@#7T7_D#V'_7"/\
M]!%7:I:+_P @>P_ZX1_^@BKM !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "51LO\ C[N?][^IJ]5&R_X^[G_>_J: +U+24M !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+5O^/8?[U7:
MI:M_Q[#_ 'J +B_=%+2+]T4M !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 4;7_ (_IZO51M?\ C^GJ]0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2-2TC4 4M)_P!3)_OU>JCI/^ID_P!^KU !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?\ QZR_[I_E
M4U0W?_'K+_NG^5 #-/\ ^/./\?YFK-5M/_X\X_Q_F:LT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 53U3_CU_X$*N53U3_CU_X$* +,/^
MJ3_=%/ID/^J3_=%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JCJ'^NMO][^HJ]5'4/]=;?[W]10!>HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JVH_P#'F_X?S%6:K:C_
M ,>;_A_,4 26O_'M%_NBI:BM?^/:+_=%2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% ''^(_P#D;M+_ .V7_HPUV%<?XC_Y&[2_^V7_ *,-
M=A0 4444 %%%% !1110 5S?CS_D$P?\ 7<?^@M725S?CS_D$P?\ 7<?^@M0!
MKZ+_ ,@>P_ZX1_\ H(J[5+1?^0/8?]<(_P#T$5=H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 2J-E_Q]W/\ O?U-7JHV7_'W<_[W]30!>I:2EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *I:M_Q[#_ 'JNU2U;_CV'^]0!<7[HI:1?NBEH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"C:_\?T]7JHVO_']/5Z@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H I:3_J9/]^KU4=)
M_P!3)_OU>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&
M[_X]9?\ =/\ *IJAN_\ CUE_W3_*@!FG_P#'G'^/\S5FJVG_ /'G'^/\S5F@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>J?\>O_  (5
M<JGJG_'K_P "% %F'_5)_NBGTR'_ %2?[HI] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %4=0_P!=;?[W]15ZJ.H?ZZV_WOZB@"]1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %5M1_X\W_#^8JS5;4?^/-_P_F* )+7_ (]HO]T5+45K_P >T7^Z*EH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./\1_\ (W:7_P!LO_1A
MKL*X_P 1_P#(W:7_ -LO_1AKL* "BBB@ HHHH **** "N;\>?\@F#_KN/_06
MKI*YOQY_R"8/^NX_]!:@#7T7_D#V'_7"/_T$5=JEHO\ R![#_KA'_P"@BKM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% "51LO^/NY_WOZFKU4;+_ (^[
MG_>_J: +U+24M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !5+5O^/8?[U7:I:M_Q[#_>H N+]T4M(OW12T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1M?^/Z>KU4
M;7_C^GJ]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-2
MTC4 4M)_U,G^_5ZJ.D_ZF3_?J]0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !4-W_QZR_[I_E4U0W?_'K+_NG^5 #-/_X\X_Q_F:LU6T__
M (\X_P ?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_7"/_T$5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2J-E_P ?=S_O
M?U-7JHV7_'W<_P"]_4T 7J6DI: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "J6K?\>P_WJNU2U;_ (]A_O4
M7%^Z*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH HVO_ !_3U>JC:_\ ']/5Z@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "D:EI&H I:3_J9/]^KU4=)_U,G^_5Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "H;O_ (]9?]T_RJ:H;O\ X]9?]T_R
MH 9I_P#QYQ_C_,U9JMI__'G'^/\ ,U9H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ JGJG_'K_ ,"%7*IZI_QZ_P# A0!9A_U2?[HI],A_
MU2?[HI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=0_
MUUM_O?U%7JHZA_KK;_>_J* +U%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P">B?F* )**C\^/_GHGYBCSX_\ GHGYB@"2BH_/C_YZ)^8H\^/_ )Z)^8H
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M?'_ST3\Q0!)14?GQ_P#/1/S%'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\?_/1/S%
M$E%1^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ_P#/1/S%'GQ_\]$_,4 245'Y\?\
MST3\Q1Y\?_/1/S% $E%1^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ_P#/1/S%'GQ_
M\]$_,4 245'Y\?\ ST3\Q1Y\?_/1/S% $E%1^?'_ ,]$_,4>?'_ST3\Q0!)1
M4?GQ_P#/1/S%'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\?_/1/S% $E%1^?'_ ,]$
M_,4>?'_ST3\Q0!)14?GQ_P#/1/S%'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\?_/1
M/S% $E%1^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ_P#/1/S%'GQ_\]$_,4 245'Y
M\?\ ST3\Q1Y\?_/1/S% $E%1^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ_P#/1/S%
M'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\?_/1/S% $E%1^?'_ ,]$_,4>?'_ST3\Q
M0!)14?GQ_P#/1/S%'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\?_/1/S% $E%1^?'_
M ,]$_,4>?'_ST3\Q0!)14?GQ_P#/1/S%'G1_\]$_.@"K:_\ ']/5ZLZUF3[=
M<'>O/O5WSX_^>B?G0!)14?GQ_P#/1/S%'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\
M?_/1/S% $E%1^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ_P#/1/S%'GQ_\]$_,4 2
M45'Y\?\ ST3\Q1Y\?_/1/S% $E%1^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ_P#/
M1/S%'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\?_/1/S% $E%1^?'_ ,]$_,4>?'_S
MT3\Q0!)14?GQ_P#/1/S%'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\?_/1/S% $E%1
M^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ_P#/1/S%'GQ_\]$_,4 245'Y\?\ ST3\
MQ1Y\?_/1/S% $E%1^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ_P#/1/S%'GQ_\]$_
M,4 245'Y\?\ ST3\Q1Y\?_/1/S% $E%1^?'_ ,]$_,4>?'_ST3\Q0!)14?GQ
M_P#/1/S%'GQ_\]$_,4 245'Y\?\ ST3\Q1Y\?_/1/S% $E(U,\^/_GHGYBD:
M:/'^L7\Z *VD_P"ID_WZO5G:7,@CD^=1\Y[U=\^/_GHGYB@"2BH_/C_YZ)^8
MH\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"
M2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8
MH\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"
M2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8
MH\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"
M2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8
MH\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"
M2BH_/C_YZ)^8H\^/_GHGYB@"2BH_/C_YZ)^8H\^/_GHGYB@"2H;O_CUE_P!T
M_P J=Y\?_/1/S%0WDT?V64>8OW3WH 73_P#CSC_'^9JS52QFC6U0;U'7O[FI
M_/C_ .>B?F* )**C\^/_ )Z)^8H\^/\ YZ)^8H DHJ/SX_\ GHGYBCSX_P#G
MHGYB@"2BH_/C_P">B?F*//C_ .>B?F* )**C\^/_ )Z)^8H\^/\ YZ)^8H D
MHJ/SX_\ GHGYBCSX_P#GHGYB@"2BH_/C_P">B?F*//C_ .>B?F* )**C\^/_
M )Z)^8H\^/\ YZ)^8H DHJ/SX_\ GHGYBCSX_P#GHGYB@"2BH_/C_P">B?F*
M//C_ .>B?F* )**C\^/_ )Z)^8H\^/\ YZ)^8H DHJ/SX_\ GHGYBCSX_P#G
MHGYB@"2BH_/C_P">B?F*//C_ .>B?F* )**C\^/_ )Z)^8H\^/\ YZ)^8H D
MHJ/SX_\ GHGYBCSX_P#GHGYB@"2BH_/C_P">B?F*//C_ .>B?F* )**C\^/_
M )Z)^8H\^/\ YZ)^8H DHJ/SX_\ GHGYBCSX_P#GHGYB@"2BH_/C_P">B?F*
M//C_ .>B?F* )**C\^/_ )Z)^8H\^/\ YZ)^8H DHJ/SX_\ GHGYBCSX_P#G
MHGYB@"2J>J?\>O\ P(58\^/_ )Z)^8JIJ<T?V7_6*?F'0T 7(?\ 5)_NBGU!
M#-'Y2?O%^Z._M3_/C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?
MF*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H
M DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?
MF*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H
M DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?
MF*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H
M DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?
MF*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H DHJ/SX_^>B?F*//C_YZ)^8H
M DHJ/SX_^>B?F*//C_YZ)^8H DJCJ'^NMO\ >_J*M>?'_P ]$_,52U"9#+;_
M #J?F['W% &C14?GQ_\ /1/S%'GQ_P#/1/S% $E%1^?'_P ]$_,4>?'_ ,]$
M_,4 245'Y\?_ #T3\Q1Y\?\ ST3\Q0!)14?GQ_\ /1/S%'GQ_P#/1/S% $E%
M1^?'_P ]$_,4>?'_ ,]$_,4 245'Y\?_ #T3\Q1Y\?\ ST3\Q0!)14?GQ_\
M/1/S%'GQ_P#/1/S% $E%1^?'_P ]$_,4>?'_ ,]$_,4 245'Y\?_ #T3\Q1Y
M\?\ ST3\Q0!)14?GQ_\ /1/S%'GQ_P#/1/S% $E%1^?'_P ]$_,4>?'_ ,]$
M_,4 245'Y\?_ #T3\Q1Y\?\ ST3\Q0!)14?GQ_\ /1/S%'GQ_P#/1/S% $E%
M1^?'_P ]$_,4>?'_ ,]$_,4 245'Y\?_ #T3\Q1Y\?\ ST3\Q0!)14?GQ_\
M/1/S%'GQ_P#/1/S% $E%1^?'_P ]$_,4>?'_ ,]$_,4 245'Y\?_ #T3\Q1Y
M\?\ ST3\Q0!)14?GQ_\ /1/S%'GQ_P#/1/S% $E%1^?'_P ]$_,4>?'_ ,]$
M_,4 245'Y\?_ #T3\Q1Y\?\ ST3\Q0!)14?GQ_\ /1/S%'GQ_P#/1/S% $E%
M1^?'_P ]$_,4>?'_ ,]$_,4 245'Y\?_ #T3\Q1Y\?\ ST3\Q0!)14?GQ_\
M/1/S%'GQ_P#/1/S% $E%1^?'_P ]$_,4>?'_ ,]$_,4 245'Y\?_ #T3\Q1Y
M\?\ ST3\Q0!)14?GQ_\ /1/S%'GQ_P#/1/S% $E%1^?'_P ]$_,4>?'_ ,]$
M_,4 245'Y\?_ #T3\Q1Y\?\ ST3\Q0!)14?GQ_\ /1/S%'GQ_P#/1/S% $E%
M1^?'_P ]$_,4>?'_ ,]$_,4 245'Y\?_ #T3\Q1Y\?\ ST3\Q0!)14?GQ_\
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M_P">B?F* )**C\^/_GHGYBCSX_\ GHGYB@"2BH_/C_YZ)^8H\^/_ )Z)^8H
MDHJ/SX_^>B?F*//C_P">B?F* )**C\^/_GHGYBCSX_\ GHGYB@"2BH_/C_YZ
M)^8H\^/_ )Z)^8H DHJ/SX_^>B?F*//C_P">B?F* )**C\^/_GHGYBCSX_\
MGHGYB@"2BH_/C_YZ)^8H\^/_ )Z)^8H DHJ/SX_^>B?F*//C_P">B?F* )**
MC\^/_GHGYBCSX_\ GHGYB@"2BH_/C_YZ)^8H\^/_ )Z)^8H DHJ/SX_^>B?F
M*//C_P">B?F* )**C\^/_GHGYBCSX_\ GHGYB@"2BH_/C_YZ)^8H\^/_ )Z)
M^8H DHJ/SX_^>B?F*//C_P">B?F* )**C\^/_GHGYBCSX_\ GHGYB@"2BH_/
MC_YZ)^8H\^/_ )Z)^8H DHJ/SX_^>B?F*//C_P">B?F* )**8LJ,V%=6/L13
MJ .0\1_\C=I?_;+_ -&&NPKC_$?_ "-VE_\ ;+_T8:["@ HHHH **** "BBB
M@ KF_'G_ ""8/^NX_P#06KI*YOQY_P @F#_KN/\ T%J -?1?^0/8?]<(_P#T
M$5=JEHO_ "![#_KA'_Z"*NT %(:6B@#EM4\$_P!IZA-<_;?*\PYV^5NQQ]15
M3_A7?_41_P#('_V5=I10!Q?_  KO_J(_^0/_ +*C_A7?_41_\@?_ &5=I10!
MQ?\ PKO_ *B/_D#_ .RH_P"%=_\ 41_\@?\ V5=I10!Q?_"N_P#J(_\ D#_[
M*C_A7?\ U$?_ "!_]E7:44 <7_PKO_J(_P#D#_[*C_A7?_41_P#('_V5=I10
M!Q?_  KO_J(_^0/_ +*C_A7?_41_\@?_ &5=I10!Q?\ PKO_ *B/_D#_ .RH
M_P"%=_\ 41_\@?\ V5=I10!Q?_"N_P#J(_\ D#_[*C_A7?\ U$?_ "!_]E7:
M44 <7_PKO_J(_P#D#_[*C_A7?_41_P#('_V5=I10!Q?_  KO_J(_^0/_ +*C
M_A7?_41_\@?_ &5=I10!Q?\ PKO_ *B/_D#_ .RH_P"%=_\ 41_\@?\ V5=I
M10!Q?_"N_P#J(_\ D#_[*C_A7?\ U$?_ "!_]E7:44 <7_PKO_J(_P#D#_[*
MC_A7?_41_P#('_V5=I10!Q?_  KO_J(_^0/_ +*C_A7?_41_\@?_ &5=I10!
MQ?\ PKO_ *B/_D#_ .RH_P"%=_\ 41_\@?\ V5=I10!Q?_"N_P#J(_\ D#_[
M*C_A7?\ U$?_ "!_]E7:44 <7_PKO_J(_P#D#_[*C_A7?_41_P#('_V5=I10
M!Q?_  KO_J(?^0/_ +*H8? GG32I]NV[3_SQ_P#LJ[FJ-G_Q^7/^]_4T <U_
MPKO_ *B/_D'_ .RH_P"%=_\ 41_\@?\ V5=G2T <7_PKO_J(_P#D#_[*C_A7
M?_41_P#('_V5=I10!Q?_  KO_J(_^0/_ +*C_A7?_41_\@?_ &5=I10!Q?\
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M?_41_P#('_V5=I10!Q?_  KO_J(_^0/_ +*C_A7?_41_\@?_ &5=I10!Q?\
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M_P!E7:44 <7_ ,*[_P"HC_Y _P#LJ/\ A7?_ %$?_('_ -E7:44 <7_PKO\
MZB/_ ) _^RH_X5W_ -1'_P @?_95VE% '%_\*[_ZB/\ Y _^RH_X5W_U$?\
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M_P!E7:44 <7_ ,*[_P"HC_Y _P#LJ/\ A7?_ %$?_('_ -E7:44 <7_PKO\
MZB/_ ) _^RH_X5YC/_$PS_VQ_P#LJ[2D:@#AK7P']H5C]NV[3C_4_P#V53_\
M*[_ZB/\ Y _^RKI=*_U,G^_5Z@#B_P#A7?\ U$?_ "!_]E1_PKO_ *B/_D#_
M .RKM** .+_X5W_U$?\ R!_]E1_PKO\ ZB/_ ) _^RKM** .+_X5W_U$?_('
M_P!E1_PKO_J(_P#D#_[*NTHH XO_ (5W_P!1'_R!_P#94?\ "N_^HC_Y _\
MLJ[2B@#B_P#A7?\ U$?_ "!_]E1_PKO_ *B/_D#_ .RKM** .+_X5W_U$?\
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M_P!E1_PKO_J(_P#D#_[*NTHH XO_ (5W_P!1'_R!_P#94?\ "N_^HC_Y _\
MLJ[2B@#B_P#A7?\ U$?_ "!_]E1_PKO_ *B/_D#_ .RKM** .+_X5W_U$?\
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M_P#41_\ ('_V5=I10!Q?_"N_^HC_ .0/_LJ/^%=_]1'_ ,@?_95VE% '%_\
M"N_^HC_Y _\ LJ/^%=_]1'_R!_\ 95VE% '%_P#"N_\ J(_^0/\ [*C_ (5W
M_P!1'_R!_P#95VE% '%_\*[_ .HC_P"0/_LJ/^%=_P#41_\ ('_V5=I10!Q?
M_"N_^HC_ .0/_LJ/^%=_]1'_ ,@?_95VE% '%_\ "N_^HC_Y _\ LJ/^%=_]
M1'_R!_\ 95VE% '%_P#"N_\ J(_^0/\ [*C_ (5W_P!1'_R!_P#95VE% '%_
M\*[_ .HC_P"0/_LJ/^%=_P#41_\ ('_V5=I10!Q?_"N_^HC_ .0/_LJ/^%=_
M]1'_ ,@?_95VE% '%_\ "N_^HC_Y _\ LJ/^%=_]1'_R!_\ 95VE% '%_P#"
MN_\ J(_^0/\ [*C_ (5W_P!1'_R!_P#95VE% '%_\*[_ .HC_P"0/_LJ/^%=
M_P#41_\ ('_V5=I10!Q?_"N_^HC_ .0/_LJ/^%=_]1'_ ,@?_95VE% '%_\
M"N_^HC_Y _\ LJ/^%=_]1'_R!_\ 95VE% '%_P#"N_\ J(_^0/\ [*C_ (5W
M_P!1'_R!_P#95VE% '%_\*[_ .HC_P"0/_LJ/^%=_P#41_\ ('_V5=I10!Q?
M_"N_^HC_ .0/_LJBNO ?V:/?]NW\XQY./_9J[FJ>J?\ 'K_P(4 <LOP]W*&_
MM#&1G_4__94O_"N_^HC_ .0/_LJ[&'_5)_NBGT <7_PKO_J(_P#D#_[*C_A7
M?_41_P#('_V5=I10!Q?_  KO_J(_^0/_ +*C_A7?_41_\@?_ &5=I10!Q?\
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M?_41_P#('_V5=I10!Q?_  KO_J(_^0/_ +*C_A7?_41_\@?_ &5=I10!Q?\
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M]1#_ ,@__94?\*[_ .HC_P"0/_LJ[2B@#B_^%=_]1'_R!_\ 94?\*[_ZB/\
MY _^RKM** .+_P"%=_\ 41_\@?\ V5'_  KO_J(_^0/_ +*NTHH XO\ X5W_
M -1'_P @?_94?\*[_P"HC_Y _P#LJ[2B@#B_^%=_]1'_ ,@?_94?\*[_ .HC
M_P"0/_LJ[2B@#B_^%=_]1'_R!_\ 94?\*[_ZB/\ Y _^RKM** .+_P"%=_\
M41_\@?\ V5'_  KO_J(_^0/_ +*NTHH XO\ X5W_ -1'_P @?_94?\*[_P"H
MC_Y _P#LJ[2B@#B_^%=_]1'_ ,@?_94?\*[_ .HC_P"0/_LJ[2B@#B_^%=_]
M1'_R!_\ 94?\*[_ZB/\ Y _^RKM** .+_P"%=_\ 41_\@?\ V5'_  KO_J(_
M^0/_ +*NTHH XO\ X5W_ -1'_P @?_94?\*[_P"HC_Y _P#LJ[2B@#B_^%=_
M]1'_ ,@?_94?\*[_ .HC_P"0/_LJ[2B@#B_^%=_]1'_R!_\ 94?\*[_ZB/\
MY _^RKM** .+_P"%=_\ 41_\@?\ V5'_  KO_J(_^0/_ +*NTHH XO\ X5W_
M -1'_P @?_94?\*[_P"HC_Y _P#LJ[2B@#B_^%=_]1'_ ,@?_94?\*[_ .HC
M_P"0/_LJ[2B@#B_^%=_]1'_R!_\ 94?\*[_ZB/\ Y _^RKM** .+_P"%=_\
M41_\@?\ V5'_  KO_J(_^0/_ +*NTHH XO\ X5W_ -1'_P @?_94?\*[_P"H
MC_Y _P#LJ[2B@#B_^%=_]1'_ ,@?_94?\*[_ .HC_P"0/_LJ[2B@#B_^%=_]
M1'_R!_\ 94?\*[_ZB/\ Y _^RKM** .+_P"%=_\ 41_\@?\ V5'_  KO_J(_
M^0/_ +*NTHH XO\ X5W_ -1'_P @?_94?\*[_P"HC_Y _P#LJ[2B@#B_^%=_
M]1'_ ,@?_94?\*[_ .HC_P"0/_LJ[2B@#B_^%=_]1'_R!_\ 94?\*[_ZB/\
MY _^RKM** .+_P"%=_\ 41_\@?\ V5'_  KO_J(_^0/_ +*NTHH XO\ X5W_
M -1'_P @?_94?\*[_P"HC_Y _P#LJ[2B@#B_^%=_]1'_ ,@?_94?\*[_ .HC
M_P"0/_LJ[2B@#B_^%=_]1'_R!_\ 94?\*[_ZB/\ Y _^RKM** .+_P"%=_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 E4;+_C[N?][^IJ]5&R_P"/
MNY_WOZF@"]2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 52U;_CV'^]5VJ6K?\>P_WJ +B_=%+2+]T4M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4;7_C^GJ]
M5&U_X_IZO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C
M4M(U %+2?]3)_OU>JCI/^ID_WZO4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5#=_\>LO^Z?Y5-4-W_QZR_[I_E0 S3_^/./\?YFK-5M/
M_P"/./\ '^9JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5/5/\ CU_X$*N53U3_ (]?^!"@"S#_ *I/]T4^F0_ZI/\ =%/H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJ'^NMO][^HJ]5'4/\
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M03!_UW'_ *"U=)7-^//^03!_UW'_ *"U &OHO_('L/\ KA'_ .@BKM4M%_Y
M]A_UPC_]!%7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $JC9?\ 'W<_
M[W]35ZJ-E_Q]W/\ O?U- %ZEI*6@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJW_'L/]ZKM4M6_P"/8?[U
M %Q?NBEI%^Z*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *-K_P ?T]7JHVO_ !_3U>H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ I&I:1J *6D_ZF3_?J]5'2?]3)_OU>H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ J&[_P"/67_=/\JFJ&[_ ./67_=/
M\J &:?\ \><?X_S-6:K:?_QYQ_C_ #-6: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *IZI_QZ_P# A5RJ>J?\>O\ P(4 68?]4G^Z*?3(
M?]4G^Z*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'4
M/]=;?[W]15ZJ.H?ZZV_WOZB@"]1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5M1_P"/-_P_F*LU6U'_ (\W_#^8
MH DM?^/:+_=%2U%:_P#'M%_NBI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#C_ !'_ ,C=I?\ VR_]&&NPKC_$?_(W:7_VR_\ 1AKL* "B
MBB@ HHHH **** "N;\>?\@F#_KN/_06KI*YOQY_R"8/^NX_]!:@#7T7_ ) ]
MA_UPC_\ 015VJ6B_\@>P_P"N$?\ Z"*NT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 )5&R_X^[G_ 'OZFKU4;+_C[N?][^IH O4M)2T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M6
M_P"/8?[U7:I:M_Q[#_>H N+]T4M(OW12T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!1M?^/Z>KU4;7_C^GJ]0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !2-2TC4 4M)_U,G^_5ZJ.D_ZF3_?J
M]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-W_QZR_[I
M_E4U0W?_ !ZR_P"Z?Y4 ,T__ (\X_P ?YFK-5M/_ ././\?YFK- !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4]4_X]?^!"KE4]4_X]?^
M!"@"S#_JD_W13Z9#_JD_W13Z "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *HZA_KK;_>_J*O51U#_76W^]_44 7J*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JMJ/_'F_X?S%
M6:K:C_QYO^'\Q0!):_\ 'M%_NBI:BM?^/:+_ '14M !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Q_B/_D;M+_[9?^C#785Q_B/_ )&[2_\
MME_Z,-=A0 4444 %%%% !1110 5S?CS_ )!,'_7<?^@M725S?CS_ )!,'_7<
M?^@M0!KZ+_R![#_KA'_Z"*NU2T7_ ) ]A_UPC_\ 015V@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!*HV7_'W<_[W]35ZJ-E_P ?=S_O?U- %ZEI*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JEJW_'L/]ZKM4M6_X]A_O4 7%^Z*6D7[HI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH HVO\ Q_3U>JC:_P#']/5Z@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H I:3_ *F3
M_?J]5'2?]3)_OU>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J&[_ ./67_=/\JFJ&[_X]9?]T_RH 9I__'G'^/\ ,U9JMI__ !YQ_C_,
MU9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJG_ !Z_
M\"%7*IZI_P >O_ A0!9A_P!4G^Z*?3(?]4G^Z*?0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5'4/]=;?[W]15ZJ.H?ZZV_WOZB@"]111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^[G_ 'OZF@"]2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 52U;_CV'^]5VJ6K?\ 'L/]Z@"XOW12TB_=
M%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %&U_X_
MIZO51M?^/Z>KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %(U+2-0!2TG_4R?[]7JHZ3_ *F3_?J]0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !4-W_P >LO\ NG^535#=_P#'K+_NG^5 #-/_ ./.
M/\?YFK-5M/\ ^/./\?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %4]4_X]?\ @0JY5/5/^/7_ ($* +,/^J3_ '13Z9#_ *I/]T4^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.H?ZZV_P![
M^HJ]5'4/]=;?[W]10!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "JVH_\ 'F_X?S%6:K:C_P >;_A_,4 26O\
MQ[1?[HJ6HK7_ (]HO]T5+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 <?XC_P"1NTO_ +9?^C#785Q_B/\ Y&[2_P#ME_Z,-=A0 4444 %%
M%% !1110 5S?CS_D$P?]=Q_Z"U=)7-^//^03!_UW'_H+4 :^B_\ ('L/^N$?
M_H(J[5+1?^0/8?\ 7"/_ -!%7: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $JC9?\?=S_O?U-7JHV7_'W<_[W]30!>I:2EH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:M_P >P_WJ
MNU2U;_CV'^]0!<7[HI:1?NBEH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@"C:_\?T]7JHVO_']/5Z@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D:EI&H I:3_J9/\ ?J]5'2?]3)_OU>H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&[_X]9?]T_RJ:H;O
M_CUE_P!T_P J &:?_P ><?X_S-6:K:?_ ,><?X_S-6: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *IZI_QZ_\"%7*IZI_QZ_\"% %F'_5
M)_NBGTR'_5)_NBGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 51U#_76W^]_45>JCJ'^NMO\ >_J* +U%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 56U'_CS?\/YBK-5M1_X
M\W_#^8H DM?^/:+_ '14M16O_'M%_NBI: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#C_$?_(W:7_VR_P#1AKL*X_Q'_P C=I?_ &R_]&&N
MPH **** "BBB@ HHHH *YOQY_P @F#_KN/\ T%JZ2N;\>?\ ()@_Z[C_ -!:
M@#7T7_D#V'_7"/\ ]!%7:I:+_P @>P_ZX1_^@BKM !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "51LO\ C[N?][^IJ]5&R_X^[G_>_J: +U+24M !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !5+5O^/8?[U7:I:M_Q[#_ 'J +B_=%+2+]T4M !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 4;7_ (_IZO51M?\ C^GJ]0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-2TC4 4M)_P!3)_OU
M>JCI/^ID_P!^KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %0W?\ QZR_[I_E4U0W?_'K+_NG^5 #-/\ ^/./\?YFK-5M/_X\X_Q_F:LT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53U3_CU_X$*N
M53U3_CU_X$* +,/^J3_=%/ID/^J3_=%/H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ JCJ'^NMO][^HJ]5'4/]=;?[W]10!>HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JVH
M_P#'F_X?S%6:K:C_ ,>;_A_,4 26O_'M%_NBI:BM?^/:+_=%2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS<Z5H]QJOBZ^MSMDC\.:=)=KGCD.,*PZ\J2.*- _;.^%VL:HNFWVLW'AG4"
M?(\06CVF,@<,Y&Q>N.6H ]SHJ*UN([JWCFAE6:&10Z21L&5E(R""."".]2T
M%%%,8G.!0 ^BO"?B?^V+X#^%-Y>6>HIKEY>VTKP-%;:7*B-(I(*K)+L1AP>5
M)! .":]+^%GCR+XG?#_1/%,-G)80ZI!YZ6\KAV0;B "0!Z?K0!U=%<CXU^+'
M@_X=WVGV?B7Q)I^B7-^=MO%>3!&?MN_V5SQN;"YXS76(P900=P/((H =1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 44QV(88KYR^(G[=OP]\![XDM->U6\(/E0KITEJKXR,[IPAVY&,@'KWH
M ^D**SO#NK?V]H.FZEY)M_MEM'<>4S!BF]0VW(ZXSUK1H **** "BBB@ HHH
MH **** "BBB@ HHHH HVO_']/5ZJ-K_Q_3U>H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ I&I:1J *6D_ZF3_ 'ZO51TG_4R?[]7J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN_^/67_=/\JFJ&
M[_X]9?\ =/\ *@!FG_\ 'G'^/\S5FJVG_P#'G'^/\S5F@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J>J?\>O_ A5RJ>J?\>O_ A0!9A_
MU2?[HI],A_U2?[HI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !5;4?\ CS?\/YBK-5M1_P"/-_P_F* )+7_CVB_W14M16O\
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ML/\ KA'_ .@BKM !1110 4444 %%%)0 M%)S10 M%)2T %%%(: %HI#2?C0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *AN_^/67_ '3_ "J:H;O_ (]9?]T_RH 9I_\ QYQ_C_,U9JMI
M_P#QYQ_C_,U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JGJG_'K_P "%7*IZI_QZ_\  A0!9A_U2?[HI],A_P!4G^Z*?0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*Q?"&O+XG\,Z9JJC9]J@61E_NL1\P_ Y'X5M+4GV\)JI%26S%HHHI%A1110
M4444 )5&R_X^[G_>_J:O51LO^/NY_P![^IH O4M)2T %%%,=MO?':@!]%>#_
M !(_:^\)>"O$:^%]"M-0\=^+7+(NEZ!'YVQP,[7D&0#UR%#%<'(%9T/Q$_:)
MUJ%;FS^&'AW1(Y/F6WU;6/,EVGL=C#GOSCKTH ^B:*^6_%G[3?Q6^$J_:O'/
MP?,FC)_K=5T/4O.BC7CYB C$#M\^WJ.?7T71_C=K/Q"^&FC>,OAWX-D\26^H
M/*K6>J:G'ILL>QBA(.V16RRL.HZ?A0!Z_17QSX/_ &\O$_C[Q8_AC0?@_)?Z
MZAD#6?\ PD<<9&PX?+/ %X/O7:^*/VAOC#X/TV?4]2^ -T-/A0O*;3Q+!=.H
M'5BL,3M@#KQ[T ?2-%>'_L\_M7>&?V@I+JQLK>XT;7[6/SI=-NF5]\>0-\;K
M]X D Y ()Z8Y/J?C'QEH_@'P]>:[X@U&'2]*M$+RW$S8 ]% ZLQZ!0"2>E &
M[17QGK__  4P\+65]+%H_A+5-4M58JMQ<7"6^_T8 !S@]L\UZK\#/VP?!'QR
MU!-(M#<Z'X@92R:;J 4>?@$MY4@)#X'..&P"<8!- 'N]%-7I3J "BBF2,(U+
M,VU0,DD\"@!]%>$_L_\ [46F_';Q=XST6W@CM/['N-U@ZR$F\M-Q3S<'H00O
M'I(OO7NJT +1110 4444 %%%% !1110 4444 %%%<G\4OB)I_P )_ >K^*]4
MCFGL=-C5WBMP#([,ZHBC) Y9E&3TH ZRBO*OV??V@-(_:$\*7>L:78W6F2V=
MQ]FN+6Z*L5;:&!5@<$$-['KQT)]46@!:**2@!:*AFG2.1%:0(SML4$XR<$X'
MJ< \5(O2@!U%%% !1110 4444 %%%% !1110 4444 %4M6_X]A_O5=JEJW_'
ML/\ >H N+]T4M(OW12T %<=\8O"4OCSX5^+/#UN,W6HZ9<009Z>:8SL_\>Q7
M8TR0\@"@#\XO^"=/CR'PG\5M>\*:AFT?7+91$)OE87%N6(C(/0E7EX]5 [U^
MCR]*^'_VJ_V/]:D\5R?$CX912?VF9Q>WFF6K%;A;C=N-Q;\C+$_,4R#NY7.<
M5K_"/_@H'IT<4>A?%73KKP[K]NWDS:A#:N8G([R1 ;XV]0%([_*#@ 'V717D
M4?[67PBDL_M(\>Z7Y?'RLSJ_0G[A7=V/:J?AG]IS1_B/XMT[1_ >C:MXHLY9
M]E[KPM9+?3K., EB9'4%G/15QR>] &%^W$P7X2:.2<8\1Z>?_'FKZ%^O/:OD
M#]O3XM>%6^&MKH5CK^G:EKUOKL#S:=9W:2S0>4)"_F*#E"" OS8.37TSX+^)
M'A;XB6LD_AGQ!IVN)"J-,+&Y25X-X.SS%!)0G:V P&<&@#YV_;>_9?\ ^%F:
M))XV\,VN?%FF0G[3;Q+\U_;J.F!UD09QW(^7G"BG_L3_ +4 ^)^AIX,\37?_
M !5NF18@GF;YM0@48W9[RJ/O#J1\W/S8^J<CDYKX$_;(_9WU+X:>)H_BY\/Q
M+81I<BYOXK(8:QN,Y%R@_N,?O ]">X8@ 'O'[)?_ "'?C=_V/VI?^A"OH*25
M%F6,NHD92RIGYB!C) _$<^]?*/\ P3X\47?C+PS\1-:OA&+S4_$DNH3B(87S
M)45WP.PR>F:M_M%?&*P^"G[2?P_U[6H+AM$;1KNTN)H$+&,22*=V/XL&-21U
MQG'N ?2VK^']+U^W%OJFG6>I0=/+O($E7\F!%?)'[97[*O@JU^%NL>,?"^BV
MWAW6-'5;B2/3T\JWGAWA7!C'R*0&+9 _AP<]O>='_:8^%6N6(NK?X@Z!#'MW
ME;R^CMI0.O,<A5@>.F,UXW\</BQ+^TAI<_PP^$D,FO\ V^2--8\1"-DT^P@5
MU8KYA'S,<#.W.1D*&)X .E_8!UZ]UK]G33XKR1I%T^_N;.W+G)$08.!GT!<@
M>P '&*^CCFN/^$7PVL/A'\.]&\*:<QE@T^+:\[##3R$EI)".VYBQQV&!VKL:
M /S^_;@U3^U/VIOAOHNHR,FC6T5E(P/11+>,)7_[Y11_P&OO]0/3VKX]_P""
M@'P)UCQI8Z1X[\-VTMYJ&BPFWO;>W!,QMPQD21 .3L8N2!SA@>@-1_!O_@H3
MX5N?"=G9>/\ [;I6OVL:PS7D5NT\-V0,>9A/F5C@Y&, ]#S@ '2?\%&,?\,_
MVX]=:MN/7]W-7J/[+9!_9X^'^/\ H$PC]*^5OVTO'6O?%OX3:;XBL-/FTCX>
M0:C$+1]00QW6JS.D@698^=D*J&"EL%M^<8KW_P#8[^(GAG6O@=X.T6RU[3YM
M9L[$QW&FBY3[3'M=MQ,6=V.^<8QTH \'_P""G_\ Q_\ PY[?N]0_G;U]P^(]
M#M/%&@ZEH]Z"]EJ%K+:3*I&3'(A1A^1/:OSZ_P""BWQ \.^-->\%VN@ZYIVN
M?V?;W9N&T^Y6X6)G:(!79"0&_=D[>O'/49^M/&WQ?T;6/V??&>O>%/$]E?7E
MEH$TBW&F7BR2VDSV[&(ML.Y'W<@'!R/:@#Y2T_X0_M$?LK:IJ*^!!)XA\.2R
MF3;9HEPEP!T+6S'S%?& Q0>VYABNW^'G_!0;4;'Q/#H'Q3\)CP]*76*6_MXY
M83;,>AEMY,MMSU(;C&<'M[U\&_VC? OQ!\&Z++'XNTY-7^RQ)=6=_=)#<B8(
M-^4<@MSGYAD'UKP[]J?2](_:@\?>#/!W@9K?6]4L9I'U;7K/$MOIUJP&4DF7
M())!(3).1C@M0!Y__P %(=7ED^+/@RR)7[);Z4+F-Y.8R9+AU;//3$29QV-?
M4\=O^T-M&+SX9'W^RZA_\<KS/]N[]GO4OB+X2T?Q'X8LGO=4\/Q/;S6,.6EG
MM3@C8.K,A&<#DAFZG ,/[/?[='A2_P#"-AH?Q OY- \2:?$MM+>7,+F&\V_*
M'W*#L? &X, ,YP>P (_B_P#LH_$[X_>(M)U7Q9XD\):/-IL7DPOH5G<DE2Q8
MEA*_4'I@XYKZ#^,GQD\/? _P:_B#Q!)(8C(L$%I;J&FN92,A$!('0$DDX !K
MFK#]J7P5XI\3:?X>\'RWGC34[J94E_LBU=H+*(L TT\K *J 9Y&22 ,<BO!O
M^"FGAW4[WP_X(U>"*272K*>Z@N65"1')*(?+9B!P"(V'/?CO0!['X6\=_&7X
MJ:7::OH_AWP[X%T*\02V\NO2S7U[)&PRKB&+RU7(YPS>G7-?-:Z)JFE_\%%-
M"M]=UB+7-4\R&6>_@LQ:+(18':!&&;&  O4YQ7T!X-_;9^'GB?0]*M-'BU74
M/$]Q$B1>%['3I7N/,"CY%<@1;1_>W@ #)P*^;M0\47VA_M]:3K/C^?3-!N%E
MB:Y6.XQ;V:O9D11M*V 2H= S_=+$D<8H ^R?VE/@N/CM\+[OPU'<I9Z@DJ7E
MC/,"8UG0, 'QSM97=21R-V>>A^1M!\0?M0_LUZ;!I;^'Y_$/AVQ&R&*2V&H0
MQQ#@;9(6\Q%'8,0 ,# KZ2_:0^-EA\/-'^&_B*VUICH-UXBB>\NM-D,R7%D(
M)A)]S.],LC$#/W1@'%>AZ5\;/A_K>EMJ5GXVT&:Q4!GF_M*%?+!_O@L"A]FP
M: /&_P!F_P#;5T[XT^(D\+:WHY\.>)W1S;JCL\%T44LZC< T;!0QVG/ /.>*
M^<-#U3Q1JW[?FO2^')=+@\1C5=1MK1M>CD>VVQ0R1\B,AN8T.,'TKV/X<^"[
M3XO_ +8=]\4O#=B(/!.DIL&IF(Q1ZI>&%HF>(8&X L26Z?*#SOK@?VL/AKXH
M^!_QUMOC)X4LVN=+EN4O9WC0NMO< !9$E '$<@S\WJS#CY<@'T[Y/[0W/^F_
M#(Y[&UU#_P".UP/PS_93\6Z'^T,OQ6\2^(M&:]EEN9KG3='MI1$[2PO'A6D;
M( W!N0<E:Z?P/^W!\*/%VBPW5YK_ /PCE]MS-I^J1.KQGI@.JE'![8/(YP.E
M=G\.?CQH/Q:\17=GX5M=2U/1K2%GE\0M:M#9-+N $,;. TCX))P, +U.10!X
M5^U)^S#XYUOXH6GQ0^&-YM\0I'&+BW2=;><21J$62-F^5@8P%96/;N#@<$/V
MQOCE\'VBB^(W@87=FK!3=75F]D\OJ%F0&(GZ*:]R\,_M(>'= _: ^)GA7Q9X
MGCTN&.ZM3I7]I2^7:QJMK&)D61CM0^9EB"1DL:ZCXY?%_P  6/PQUNSOM6TS
M7Y-3LI+>TT>RF2ZFO9)%(C5(T)8C=@[L87&<]* .G^"OQCT/XX^!X?$>A-)'
M'YAM[FUG $EM, "8VP<'AE((Z@CH<@=\*\ _8K^#^J?!_P"#JV^NP_9=7U:[
M;49K5C\]NK1QJD;C'#83)'8MCM7O] '-_$3Q]HWPQ\(:CXEU^Y^RZ98Q[G9>
M78DX5$!ZL6( 'OV%>/>"?C)\4OC=IL>L>"?".C^&O#4S,+;5?%=S)++<*"07
M2WAP>W=@..M8O_!1#0-4UOX#0S:=')-!INJPWEXL:%BL(CE0N<= K.I/;&3V
MK$_9_P#VR/AOI'PA\*>'KR>]MO$>GV,.G#2+73YIY;J1 $'E%%*DOC."PP3C
MWH \B_:>T#Q#I_[3GPM_X2C7[77]1N6L<3V.G"SCB3[<V$5=[D@$N<EL_-[5
M^BXQMXZ5^;O[47B?6[G]I/X<:[XOL8/#=FIL[JWL9) \]I9K>$[[E@=HD.UF
M*KD*,#)()/WAJ/QA\#:5H,>MW/C'0H]*FW^3=_VC"8YF0 LL;!OG8#^$9/(H
M ^.O^":B@^,/B,Y +B&V /?_ %DM?>^/\*_-[_@GG\0M \(>./%R^(-;T_15
MU"TA,4FH7*6Z2.LA^52Y'/S],YK]'8Y5DC5PP92,A@>"/7- 'P;_ ,$]5$/Q
M@^)D2?)&(\!%X Q<,!Q]*K>,-4/B#_@I-I-OJCLMMI]W;6]JKC[NVT$J#\96
M)_X%6'^PQ\0O#WA7XU>.9-<UFRT6WU"WD\B74+A((Y&%P"%#,0-V&Z=ZZG]N
M/X1^(_#?Q"TWXR>$4FECC$#WD]FI9[6>$ 1SD#^ HJ@GH-N"?F% 'WDO05\0
M_P#!3S']@^ !_P!/%[Q[;(J[/P#_ ,%#_AYK7A^WD\2K>^'];" 7%K';/<1%
M^YC9<G:>OS $=.<9/@W[=FN>*?&\?A#Q-JVG/X?\.SO<0:-I%X/]-*@1L]Q.
MH)"%\IA,Y 49P: /T.\('/A/13G/^A0\^O[M:UZ\^^"_Q$\->-_ F@C0M=T_
M5)H=-M_/M[:Y1YH#Y:@B1 =RD'CD"O0%.X9ZT +1110 4444 %%%% !1110
M4444 %%%% %&U_X_IZO51M?^/Z>KU !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %(U+2-0!2TG_4R?[]7JHZ3_ *F3_?J]0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !4-W_P >LO\ NG^535#=_P#'
MK+_NG^5 #-/_ ././\?YFK-5M/\ ^/./\?YFK- !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %4]4_X]?\ @0JY5/5/^/7_ ($* +,/^J3_
M '13Z9#_ *I/]T4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&WU222ZM+*Y2=X L94^8JGY#EOXJ]L^%,W@'X^?L]^&O!]_J&F:ZPT"SCO\
M3H;I&NK22.)%+E0=T;*XX8CT]: /7?!/C;1?B'X9L=?\/W\>HZ9>)OBFC_56
M'56!X(/((-;R\"OSEAG\=?\ !/[XF&%UF\0_#K5ILKU6.8<<KVBN% Y!.& '
M48*_>'PR^)F@?%KPG!XA\-W<EWITK%"TL+1.C@ LA##J-PY&1Z$T =71110
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MK]W%9_B3_D7M3_Z]I/\ T$U!]E6C%4Y-+H_R/@GV[5]^Z6 NFVH P/+7^5?
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M*RNH96&"K#((]*P=+^'OA70]4?4]-\-:/I^I/DM>6MA%%,V1@Y=5!/YUT%%
M&;J7AK2-:F274-*L;Z55VJ]S;I(P&<X!8'CD_G4+^#= DM8;9]#TU[:$LT4+
M6D91"<9*C& 3@9QZ5L44 8/_  @/AC_H7-)_\ 8O_B:W54*H"@  8  Z4M%
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M^/-_P_F*LU6U'_CS?\/YB@"2U_X]HO\ =%2U%:_\>T7^Z*EH **** "BBB@
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MAUKZ]4UZ/\ST-NO:E"_C2*>W>E[]:@_2O4=67XH./#FJ=O\ 19/_ $ UI9K
M\<WT5AX/UJ>5PJI9S'DX_@/%"W,*\E&E)OLSX7]NU?H#9X^R0XP%V#'Y5^?W
M'KUZ=P>W]:^^-#N%NM'LI5(97A1@1[J*IGPO"[7/57H>:_M):_<:-X"%M "H
MU"=;>23L$P6(_';CZ9KQ7PK\<M?\':+;Z7IMOIZ6T()7S(6+$DEB2=_7)/\
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M:XN@ 6W/,V%4 _+A0,\'/4"F!Z'12+2T@"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN[_&#>3X+CC!VC^$=>G//6N\Q1@>E.[)H97A</)3C&[\W<04M%+4GJA1110
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M)P.YYKV?_@H)\4-2\!?"6RTK2+J2RN_$%TUM+/$VUQ;HA:0 ]LDH#_LEAWH
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M HHHH **** "BBB@ HHHH *1J6D:@"EI/^ID_P!^KU4=)_U,G^_5Z@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;O_CUE_W3_*IJAN_^
M/67_ '3_ "H 9I__ !YQ_C_,U9JMI_\ QYQ_C_,U9H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JGJG_'K_P(5<JGJG_'K_P(4 68?]4G
M^Z*?3(?]4G^Z*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !5'4/]=;?[W]15ZJ.H?ZZV_P![^HH O4444 %%%% !1110 4444 %%%% #
M&)R,5YWXU^//A3P3KBZ!)/>:UXF9/,&A:%9O>W@7 ;+1H#M&"#\Q'!STJ#]I
M+XF3_"+X->(_$MGM_M*&%8+/>,@3R.(T;'?:6W8[[37E?[ /A.&'X1W/C*Z\
MR\U_Q'?W$MS?W#;YG5)"@4L>2-RNQR>2QH ZN_\ VP?"?AO4[:S\6Z!XM\$)
M<OMAN]?T@Q02?1D9O;L,=\#->TZ3J]GKVFVNH:;=PW]A<H)8;JWD$D<J'HRL
M#@C'I7-?%OX;Z=\6OAYK'AC44C>.\@803.H)@G _=RKZ%6P?<9'0U\=?\$Y?
MB1J=AXF\1_#C4I7DLXX7O[2-R2()HY%29%SV;<&QZH3WH ^CO%W[8GPE\'Q2
MF?QA::G,APMOI :[9R/1D!7\2P'O5WXF?M0> ?A/I>E7>NZG,+G4[=+FVTVU
MC\VZ,; $.R@X0<X^8@$@XS@X^9O^"E7A?2M&L? -WINFV=A+)+>QR-:P+&9.
M(6&[:!G!W=?[QZ9-?4WPC^"_ASP5X6L9I+&'5]>N[:*34-:U!%FN;IS&!]]@
M2$ X5%PH  ]30!SGPI_;(^&OQ:UB'1]/U*ZTG5K@[;>SUB 0M,?[JL&9=W;;
MNR>P->W[CZX_I7Y^?\%!OACHOP]USPCXQ\,6<6A:E>3RK<"Q3RE:6/RWCF51
M@*PRV2.O'>OL+Q_XXOM#^ >M^++(9U.#P^]_"=N0LOD;E;'H&P<>@H ;XO\
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MQ9_*2:^G6,.^"=BY/+8!X'/%<5X#_::\ ?$[QPWA7POJLFLZA':O=O/#;.L
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MJNJGH0HY!ZCK2 ^@HT6-510%1> JC %?!7_!-.9?^$S^(J=6D@MG!]A)+_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 4;7_ (_IZO51M?\ C^GJXU #J2F[N:\^^)_QBTSX=P^0
MH^WZNXS'9H^-H_O.>P_4_K32.>MB*>'@ZE5V2/0&8*/05FW7BC2--W"[U2SM
M=IY\^=$Q^9KX\\6?%CQ-XQFD:[U*2"V?I:VK&.$#T(!^;\<UR'TY'K5<I\77
MXHA%VHPNO,^X_P#A9'A/_H9M'_\  ^+_ .*I?^%D>$_^AGTC_P #XO\ XJOA
MNBCE1R?ZU5O^?2^]GW)_PLCPG_T,^D?^!\7_ ,51_P +(\)_]#/I'_@?%_\
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M %(U+2-0!2TG_4R?[]7JHZ3_ *F3_?J]0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !4-W_P >LO\ NG^535#=_P#'K+_NG^5 #-/_ ./.
M/\?YFK-5M/\ ^/./\?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %4]4_X]?\ @0JY5/5/^/7_ ($* +,/^J3_ '13Z9#_ *I/]T4^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?X;:!\)_"-IX=\.68L]-MP6);YGE<XW22-_$QQR?3 &  *0'R3_P4\E"Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_7)_$OP[\-ZI=$-=7>GP33,!@%V0%B/;.:RQ5*C.A'%4(\J;LUO9VOH^S.C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV'YA1113/F/0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %0W?_'K+_NG^535#=_\>LO^Z?Y4 ,T__CSC_'^9JS5;3_\
MCSC_ !_F:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M3U3_ (]?^!"KE4]4_P"/7_@0H LP_P"J3_=%/ID/^J3_ '13Z "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN6?K@&OKE>5YH55485=H' &*=0 FT>E&T>E+10 E& >HS2T4 )M'7'-%+10
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M;7/*_B-\,5^(OP3TZ&S0)K-G90WEA*G#>:L8.W(_O#(]C@]JW?@'\2O^%E^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3BGO9"T444&P4444 %%%% !1110 4C4M(U %+2?]3)_OU>JCI/\ J9/]^KU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?_ !ZR_P"Z
M?Y5-4-W_ ,>LO^Z?Y4 ,T_\ X\X_Q_F:LU6T_P#X\X_Q_F:LT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 53U3_CU_P"!"KE4]4_X]?\
M@0H LP_ZI/\ =%/ID/\ JD_W13Z "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "J6K?\>P_WJNU2U;_CV'^]0!<7[HI:1?NBEH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"H;O_CUE_P!T_P JFJ&[_P"/67_=/\J &:?_ ,><?X_S-6:K:?\ \><?X_S-
M6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZI_QZ_\
M A5RJ>J?\>O_  (4 68?]4G^Z*?3(?\ 5)_NBGT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 51U#_ %UM_O?U%7JHZA_KK;_>_J* +U%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW(CW<X]\5X=_PW1X)_Z ^N_]^H/_ ([1_P -T>"?^@/KO_?J#_X[1_8>9?\
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M3E^*P<5+$4W%/N>EE^9Y?CZDHX2MSR2UUV1L4445YQ[X4444 %%%% !1110
M4444 <?XC_Y&[2_^V7_HPUV%<?XC_P"1NTO_ +9?^C#784 %%%% !1110 44
M44 %<WX\_P"03!_UW'_H+5TE<WX\_P"03!_UW'_H+4 :^B_\@>P_ZX1_^@BK
MM4M%_P"0/8?]<(__ $$5=H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 53U3_ (]?^!"KE4]4_P"/7_@0H LP_P"J3_=%/ID/^J3_ '13Z "BBB@
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M#_\ 09\1?]_X/_C-'_#"O@?_ *#/B+_O_!_\9KZ0HH_MS,O^?\OO#_5C)O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJG_'K_P(5<JGJG_'K_P(
M4 68?]4G^Z*?3(?]4G^Z*?0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !5'4/]=;?[W]15ZJ.H?ZZV_P![^HH O4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;4?^/-_P_F*
MLU6U'_CS?\/YB@"2U_X]HO\ =%2U%:_\>T7^Z*EH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ./\1_\C=I?_;+_ -&&NPKC_$?_ "-VE_\
M;+_T8:["@ HHHH **** "BBB@ KF_'G_ ""8/^NX_P#06KI*YOQY_P @F#_K
MN/\ T%J -?1?^0/8?]<(_P#T$5=JEHO_ "![#_KA'_Z"*NT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 )5&R_P"/NY_WOZFKU4;+_C[N?][^IH O4M)2
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %4M6_X]A_O5=JEJW_'L/\ >H N+]T4M(OW12T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!1M?\ C^GJ]5&U_P"/Z>KU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(U+2-0!2TG_
M %,G^_5ZJ.D_ZF3_ 'ZO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5#=_P#'K+_NG^535#=_\>LO^Z?Y4 ,T_P#X\X_Q_F:LU6T__CSC
M_'^9JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/5/^
M/7_@0JY5/5/^/7_@0H LP_ZI/]T4^F0_ZI/]T4^@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "J.H?ZZV_WOZBKU4=0_UUM_O?U% %ZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *K:C_ ,>;_A_,59JMJ/\ QYO^'\Q0!):_\>T7^Z*EJ*U_X]HO]T5+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\?=S_O?U- %ZEI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JEJW_'L/\ >J[5+5O^/8?[U %Q?NBEI%^Z
M*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-K_Q_
M3U>JC:_\?T]7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *1J6D:@"EI/^ID_WZO51TG_ %,G^_5Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "H;O_CUE_P!T_P JFJ&[_P"/67_=/\J &:?_ ,><
M?X_S-6:K:?\ \><?X_S-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *IZI_QZ_\  A5RJ>J?\>O_  (4 68?]4G^Z*?3(?\ 5)_NBGT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U#_ %UM_O?U
M%7JHZA_KK;_>_J* +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 56U'_CS?\/YBK-5M1_X\W_#^8H DM?\ CVB_
MW14M16O_ ![1?[HJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH X_Q'_P C=I?_ &R_]&&NPKC_ !'_ ,C=I?\ VR_]&&NPH **** "BBB@
M HHHH *YOQY_R"8/^NX_]!:NDKF_'G_()@_Z[C_T%J -?1?^0/8?]<(__015
MVJ6B_P#('L/^N$?_ *"*NT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )
M5&R_X^[G_>_J:O51LO\ C[N?][^IH O4M)2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M6_X]A_O5=JEJ
MW_'L/]Z@"XOW12TB_=%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% %&U_X_IZO51M?^/Z>KU !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %(U+2-0!2TG_4R?[]7JHZ3_J9/]^KU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\_UO_P!_!61_P@.G_P#/6Z_[Z7_XFC_A =/_ .>MU_WTO_Q- &O_ ,)!IO\
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M?_A(--_Y_K?_ +^"C_A(--_Y_K?_ +^"LC_A =/_ .>MU_WTO_Q-'_" Z?\
M\];K_OI?_B: -?\ X2#3?^?ZW_[^"C_A(--_Y_K?_OX*R/\ A =/_P">MU_W
MTO\ \31_P@.G_P#/6Z_[Z7_XF@#7_P"$@TW_ )_K?_OX*/\ A(--_P"?ZW_[
M^"LC_A =/_YZW7_?2_\ Q-'_  @.G_\ /6Z_[Z7_ .)H U_^$@TW_G^M_P#O
MX*/^$@TW_G^M_P#OX*R/^$!T_P#YZW7_ 'TO_P 31_P@.G_\];K_ +Z7_P")
MH U_^$@TW_G^M_\ OX*/^$@TW_G^M_\ OX*R/^$!T_\ YZW7_?2__$T?\(#I
M_P#SUNO^^E_^)H U_P#A(--_Y_K?_OX*/^$@TW_G^M_^_@K(_P"$!T__ )ZW
M7_?2_P#Q-'_" Z?_ ,];K_OI?_B: -?_ (2#3?\ G^M_^_@H_P"$@TW_ )_K
M?_OX*R/^$!T__GK=?]]+_P#$T?\ " Z?_P ];K_OI?\ XF@#7_X2#3?^?ZW_
M ._@H_X2#3?^?ZW_ ._@K(_X0'3_ /GK=?\ ?2__ !-'_" Z?_SUNO\ OI?_
M (F@#7_X2#3?^?ZW_P"_@H_X2#3?^?ZW_P"_@K(_X0'3_P#GK=?]]+_\31_P
M@.G_ //6Z_[Z7_XF@#7_ .$@TW_G^M_^_@H_X2#3?^?ZW_[^"LC_ (0'3_\
MGK=?]]+_ /$T?\(#I_\ SUNO^^E_^)H U_\ A(--_P"?ZW_[^"C_ (2#3?\
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M_G^M_P#OX*J:EKFGR6X"WD+'/9P>Q]ZI_P#" Z?_ ,];K_OI?_B:/^$!T_\
MYZW7_?2__$T :R^(--QS>P#_ (&/\:7_ (2#3?\ G^M_^_@K(_X0'3_^>MU_
MWTO_ ,31_P (#I__ #UNO^^E_P#B: -?_A(--_Y_K?\ [^"C_A(--_Y_K?\
M[^"LC_A =/\ ^>MU_P!]+_\ $T?\(#I__/6Z_P"^E_\ B: -?_A(--_Y_K?_
M +^"C_A(--_Y_K?_ +^"LC_A =/_ .>MU_WTO_Q-'_" Z?\ \];K_OI?_B:
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M_OI?_B: -?\ X2#3?^?ZW_[^"C_A(--_Y_K?_OX*R/\ A =/_P">MU_WTO\
M\31_P@.G_P#/6Z_[Z7_XF@#7_P"$@TW_ )_K?_OX*/\ A(--_P"?ZW_[^"LC
M_A =/_YZW7_?2_\ Q-'_  @.G_\ /6Z_[Z7_ .)H U_^$@TW_G^M_P#OX*/^
M$@TW_G^M_P#OX*R/^$!T_P#YZW7_ 'TO_P 31_P@.G_\];K_ +Z7_P")H U_
M^$@TW_G^M_\ OX*/^$@TW_G^M_\ OX*R/^$!T_\ YZW7_?2__$T?\(#I_P#S
MUNO^^E_^)H U_P#A(--_Y_K?_OX*/^$@TW_G^M_^_@K(_P"$!T__ )ZW7_?2
M_P#Q-'_" Z?_ ,];K_OI?_B: -?_ (2#3?\ G^M_^_@H_P"$@TW_ )_K?_OX
M*R/^$!T__GK=?]]+_P#$T?\ " Z?_P ];K_OI?\ XF@#7_X2#3?^?ZW_ ._@
MH_X2#3?^?ZW_ ._@K(_X0'3_ /GK=?\ ?2__ !-'_" Z?_SUNO\ OI?_ (F@
M#7_X2#3?^?ZW_P"_@H_X2#3?^?ZW_P"_@K(_X0'3_P#GK=?]]+_\31_P@.G_
M //6Z_[Z7_XF@#7_ .$@TW_G^M_^_@H_X2#3?^?ZW_[^"LC_ (0'3_\ GK=?
M]]+_ /$T?\(#I_\ SUNO^^E_^)H U_\ A(--_P"?ZW_[^"C_ (2#3?\ G^M_
M^_@K(_X0'3_^>MU_WTO_ ,31_P (#I__ #UNO^^E_P#B: -?_A(--_Y_K?\
M[^"C_A(--_Y_K?\ [^"LC_A =/\ ^>MU_P!]+_\ $T?\(#I__/6Z_P"^E_\
MB: -?_A(--_Y_K?_ +^"C_A(--_Y_K?_ +^"LC_A =/_ .>MU_WTO_Q-'_"
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M_P (#I__ #UNO^^E_P#B:/\ A =/_P">MU_WTO\ \30!K_\ "0:;_P _UO\
M]_!1_P )!IO_ #_6_P#W\%9'_" Z?_SUNO\ OI?_ (FC_A =/_YZW7_?2_\
MQ- &O_PD&F_\_P!;_P#?P4?\)!IO_/\ 6_\ W\%9'_" Z?\ \];K_OI?_B:/
M^$!T_P#YZW7_ 'TO_P 30!K_ /"0:;_S_6__ '\%'_"0:;_S_6__ '\%9'_"
M Z?_ ,];K_OI?_B:/^$!T_\ YZW7_?2__$T :_\ PD&F_P#/];_]_!1_PD&F
M_P#/];_]_!61_P (#I__ #UNO^^E_P#B:/\ A =/_P">MU_WTO\ \30!K_\
M"0:;_P _UO\ ]_!1_P )!IO_ #_6_P#W\%9'_" Z?_SUNO\ OI?_ (FC_A =
M/_YZW7_?2_\ Q- &O_PD&F_\_P!;_P#?P4?\)!IO_/\ 6_\ W\%9'_" Z?\
M\];K_OI?_B:/^$!T_P#YZW7_ 'TO_P 30!K_ /"0:;_S_6__ '\%'_"0:;_S
M_6__ '\%9'_" Z?_ ,];K_OI?_B:/^$!T_\ YZW7_?2__$T :_\ PD&F_P#/
M];_]_!1_PD&F_P#/];_]_!61_P (#I__ #UNO^^E_P#B:/\ A =/_P">MU_W
MTO\ \30!K_\ "0:;_P _UO\ ]_!1_P )!IO_ #_6_P#W\%9'_" Z?_SUNO\
MOI?_ (FC_A =/_YZW7_?2_\ Q- &O_PD&F_\_P!;_P#?P4?\)!IO_/\ 6_\
MW\%9'_" Z?\ \];K_OI?_B:/^$!T_P#YZW7_ 'TO_P 30!K_ /"0:;_S_6__
M '\%'_"0:;_S_6__ '\%9'_" Z?_ ,];K_OI?_B:/^$!T_\ YZW7_?2__$T
M:_\ PD&F_P#/];_]_!1_PD&F_P#/];_]_!61_P (#I__ #UNO^^E_P#B:/\
MA =/_P">MU_WTO\ \30!K_\ "0:;_P _UO\ ]_!1_P )!IO_ #_6_P#W\%9'
M_" Z?_SUNO\ OI?_ (FC_A =/_YZW7_?2_\ Q- &O_PD&F_\_P!;_P#?P4?\
M)!IO_/\ 6_\ W\%9'_" Z?\ \];K_OI?_B:/^$!T_P#YZW7_ 'TO_P 30!K_
M /"0:;_S_6__ '\%'_"0:;_S_6__ '\%9'_" Z?_ ,];K_OI?_B:/^$!T_\
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MO_Q-'_" Z?\ \];K_OI?_B: -?\ X2#3?^?ZW_[^"C_A(--_Y_K?_OX*R/\
MA =/_P">MU_WTO\ \31_P@.G_P#/6Z_[Z7_XF@#7_P"$@TW_ )_K?_OX*/\
MA(--_P"?ZW_[^"LC_A =/_YZW7_?2_\ Q-'_  @.G_\ /6Z_[Z7_ .)H U_^
M$@TW_G^M_P#OX*/^$@TW_G^M_P#OX*R/^$!T_P#YZW7_ 'TO_P 31_P@.G_\
M];K_ +Z7_P")H U_^$@TW_G^M_\ OX*/^$@TW_G^M_\ OX*R/^$!T_\ YZW7
M_?2__$T?\(#I_P#SUNO^^E_^)H U_P#A(--_Y_K?_OX*/^$@TW_G^M_^_@K(
M_P"$!T__ )ZW7_?2_P#Q-'_" Z?_ ,];K_OI?_B: -?_ (2#3?\ G^M_^_@H
M_P"$@TW_ )_K?_OX*R/^$!T__GK=?]]+_P#$T?\ " Z?_P ];K_OI?\ XF@#
M7_X2#3?^?ZW_ ._@H_X2#3?^?ZW_ ._@K(_X0'3_ /GK=?\ ?2__ !-'_" Z
M?_SUNO\ OI?_ (F@#7_X2#3?^?ZW_P"_@H_X2#3?^?ZW_P"_@K(_X0'3_P#G
MK=?]]+_\31_P@.G_ //6Z_[Z7_XF@#7_ .$@TW_G^M_^_@H_X2#3?^?ZW_[^
M"LC_ (0'3_\ GK=?]]+_ /$T?\(#I_\ SUNO^^E_^)H U_\ A(--_P"?ZW_[
M^"C_ (2#3?\ G^M_^_@K(_X0'3_^>MU_WTO_ ,31_P (#I__ #UNO^^E_P#B
M: -?_A(--_Y_K?\ [^"C_A(--_Y_K?\ [^"LC_A =/\ ^>MU_P!]+_\ $T?\
M(#I__/6Z_P"^E_\ B: -?_A(--_Y_K?_ +^"C_A(--_Y_K?_ +^"LC_A =/_
M .>MU_WTO_Q-'_" Z?\ \];K_OI?_B: -?\ X2#3?^?ZW_[^"C_A(--_Y_K?
M_OX*R/\ A =/_P">MU_WTO\ \31_P@.G_P#/6Z_[Z7_XF@#7_P"$@TW_ )_K
M?_OX*/\ A(--_P"?ZW_[^"LC_A =/_YZW7_?2_\ Q-'_  @.G_\ /6Z_[Z7_
M .)H U_^$@TW_G^M_P#OX*/^$@TW_G^M_P#OX*R/^$!T_P#YZW7_ 'TO_P 3
M1_P@.G_\];K_ +Z7_P")H U_^$@TW_G^M_\ OX*/^$@TW_G^M_\ OX*R/^$!
MT_\ YZW7_?2__$T?\(#I_P#SUNO^^E_^)H U_P#A(--_Y_K?_OX*/^$@TW_G
M^M_^_@K(_P"$!T__ )ZW7_?2_P#Q-'_" Z?_ ,];K_OI?_B: -?_ (2#3?\
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MIO\ S_6__?P4?\)!IO\ S_6__?P5D?\ " Z?_P ];K_OI?\ XFC_ (0'3_\
MGK=?]]+_ /$T :__  D&F_\ /];_ /?P4?\ "0:;_P _UO\ ]_!61_P@.G_\
M];K_ +Z7_P")H_X0'3_^>MU_WTO_ ,30!K_\)!IO_/\ 6_\ W\%'_"0:;_S_
M %O_ -_!61_P@.G_ //6Z_[Z7_XFC_A =/\ ^>MU_P!]+_\ $T :_P#PD&F_
M\_UO_P!_!1_PD&F_\_UO_P!_!61_P@.G_P#/6Z_[Z7_XFC_A =/_ .>MU_WT
MO_Q- &O_ ,)!IO\ S_6__?P4?\)!IO\ S_6__?P5D?\ " Z?_P ];K_OI?\
MXFC_ (0'3_\ GK=?]]+_ /$T :__  D&F_\ /];_ /?P4?\ "0:;_P _UO\
M]_!61_P@.G_\];K_ +Z7_P")H_X0'3_^>MU_WTO_ ,30!K_\)!IO_/\ 6_\
MW\%'_"0:;_S_ %O_ -_!61_P@.G_ //6Z_[Z7_XFC_A =/\ ^>MU_P!]+_\
M$T :_P#PD&F_\_UO_P!_!1_PD&F_\_UO_P!_!61_P@.G_P#/6Z_[Z7_XFC_A
M =/_ .>MU_WTO_Q- &O_ ,)!IO\ S_6__?P4?\)!IO\ S_6__?P5D?\ " Z?
M_P ];K_OI?\ XFC_ (0'3_\ GK=?]]+_ /$T :__  D&F_\ /];_ /?P4?\
M"0:;_P _UO\ ]_!61_P@.G_\];K_ +Z7_P")H_X0'3_^>MU_WTO_ ,30!K_\
M)!IO_/\ 6_\ W\%'_"0:;_S_ %O_ -_!61_P@.G_ //6Z_[Z7_XFC_A =/\
M^>MU_P!]+_\ $T :_P#PD&F_\_UO_P!_!1_PD&F_\_UO_P!_!61_P@.G_P#/
M6Z_[Z7_XFC_A =/_ .>MU_WTO_Q- &O_ ,)!IO\ S_6__?P4?\)!IO\ S_6_
M_?P5D?\ " Z?_P ];K_OI?\ XFC_ (0'3_\ GK=?]]+_ /$T :__  D&F_\
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M^M_^_@K(_P"$!T__ )ZW7_?2_P#Q-'_" Z?_ ,];K_OI?_B: -?_ (2#3?\
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M@TW_ )_K?_OX*/\ A(--_P"?ZW_[^"LC_A =/_YZW7_?2_\ Q-'_  @.G_\
M/6Z_[Z7_ .)H U_^$@TW_G^M_P#OX*/^$@TW_G^M_P#OX*R/^$!T_P#YZW7_
M 'TO_P 31_P@.G_\];K_ +Z7_P")H U_^$@TW_G^M_\ OX*IWVN:>\D!6\A;
M:W.'!_K53_A =/\ ^>MU_P!]+_\ $T?\(#I__/6Z_P"^E_\ B: -?_A(--'6
M^@_[^"C_ (2#3?\ G^M_^_@K(_X0'3_^>MU_WTO_ ,31_P (#I__ #UNO^^E
M_P#B: -?_A(--_Y_K?\ [^"C_A(--_Y_K?\ [^"LC_A =/\ ^>MU_P!]+_\
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M;K_OI?\ XF@#7_X2#3?^?ZW_ ._@H_X2#3?^?ZW_ ._@K(_X0'3_ /GK=?\
M?2__ !-'_" Z?_SUNO\ OI?_ (F@#7_X2#3?^?ZW_P"_@H_X2#3?^?ZW_P"_
M@K(_X0'3_P#GK=?]]+_\31_P@.G_ //6Z_[Z7_XF@#7_ .$@TW_G^M_^_@H_
MX2#3?^?ZW_[^"LC_ (0'3_\ GK=?]]+_ /$T?\(#I_\ SUNO^^E_^)H U_\
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M -?_ (2#3?\ G^M_^_@H_P"$@TW_ )_K?_OX*R/^$!T__GK=?]]+_P#$T?\
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M_P (#I__ #UNO^^E_P#B: -?_A(--_Y_K?\ [^"C_A(--_Y_K?\ [^"LC_A
M=/\ ^>MU_P!]+_\ $T?\(#I__/6Z_P"^E_\ B: -?_A(--_Y_K?_ +^"C_A(
M--_Y_K?_ +^"LC_A =/_ .>MU_WTO_Q-'_" Z?\ \];K_OI?_B: -?\ X2#3
M?^?ZW_[^"C_A(--_Y_K?_OX*R/\ A =/_P">MU_WTO\ \31_P@.G_P#/6Z_[
MZ7_XF@#7_P"$@TW_ )_K?_OX*/\ A(--_P"?ZW_[^"LC_A =/_YZW7_?2_\
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M_@H_X2#3?^?ZW_[^"LC_ (0'3_\ GK=?]]+_ /$T?\(#I_\ SUNO^^E_^)H
MU_\ A(--_P"?ZW_[^"C_ (2#3?\ G^M_^_@K(_X0'3_^>MU_WTO_ ,31_P (
M#I__ #UNO^^E_P#B: -?_A(--_Y_K?\ [^"C_A(--_Y_K?\ [^"LC_A =/\
M^>MU_P!]+_\ $T?\(#I__/6Z_P"^E_\ B: -?_A(--_Y_K?_ +^"C_A(--_Y
M_K?_ +^"LC_A =/_ .>MU_WTO_Q-'_" Z?\ \];K_OI?_B: -?\ X2#3?^?Z
MW_[^"C_A(--_Y_K?_OX*R/\ A =/_P">MU_WTO\ \31_P@.G_P#/6Z_[Z7_X
MF@#7_P"$@TW_ )_K?_OX*/\ A(--_P"?ZW_[^"LC_A =/_YZW7_?2_\ Q-'_
M  @.G_\ /6Z_[Z7_ .)H U_^$@TW_G^M_P#OX*/^$@TW_G^M_P#OX*R/^$!T
M_P#YZW7_ 'TO_P 31_P@.G_\];K_ +Z7_P")H U_^$@TW_G^M_\ OX*/^$@T
MW_G^M_\ OX*R/^$!T_\ YZW7_?2__$T?\(#I_P#SUNO^^E_^)H U_P#A(--_
MY_K?_OX*/^$@TW_G^M_^_@K(_P"$!T__ )ZW7_?2_P#Q-'_" Z?_ ,];K_OI
M?_B: -?_ (2#3?\ G^M_^_@H_P"$@TW_ )_K?_OX*R/^$!T__GK=?]]+_P#$
MT?\ " Z?_P ];K_OI?\ XF@#7_X2#3?^?ZW_ ._@H_X2#3?^?ZW_ ._@K(_X
M0'3_ /GK=?\ ?2__ !-'_" Z?_SUNO\ OI?_ (F@#7_X2#3?^?ZW_P"_@H_X
M2#3?^?ZW_P"_@K(_X0'3_P#GK=?]]+_\31_P@.G_ //6Z_[Z7_XF@#7_ .$@
MTW_G^M_^_@H_X2#3?^?ZW_[^"LC_ (0'3_\ GK=?]]+_ /$T?\(#I_\ SUNO
M^^E_^)H U_\ A(--_P"?ZW_[^"C_ (2#3?\ G^M_^_@K(_X0'3_^>MU_WTO_
M ,31_P (#I__ #UNO^^E_P#B: -?_A(--_Y_K?\ [^"C_A(--_Y_K?\ [^"L
MC_A =/\ ^>MU_P!]+_\ $T?\(#I__/6Z_P"^E_\ B: -?_A(--_Y_K?_ +^"
MC_A(--_Y_K?_ +^"LC_A =/_ .>MU_WTO_Q-'_" Z?\ \];K_OI?_B: -?\
MX2#3?^?ZW_[^"C_A(--_Y_K?_OX*R/\ A =/_P">MU_WTO\ \31_P@.G_P#/
M6Z_[Z7_XF@#7_P"$@TW_ )_K?_OX*/\ A(--_P"?ZW_[^"LC_A =/_YZW7_?
M2_\ Q-'_  @.G_\ /6Z_[Z7_ .)H U_^$@TW_G^M_P#OX*/^$@TW_G^M_P#O
MX*R/^$!T_P#YZW7_ 'TO_P 31_P@.G_\];K_ +Z7_P")H U_^$@TW_G^M_\
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MF@"UHN/['L<=/(3_ -!%7:P?!^H+=Z2D1(\V'*%?;/'Z$5O4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\
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M_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\
MQ-'_  @NG_\ /6Y_[[7_ .)H V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK
M'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\ XF@#8_MBP_Y_K;_O\O\
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M_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\ Q-'_  @NG_\
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M V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\
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M;G_OM?\ XF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7_&L?_A!=/_YZW/\
MWVO_ ,31_P (+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\
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M (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\
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M_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\
MQ-'_  @NG_\ /6Y_[[7_ .)H V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK
M'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\ XF@#8_MBP_Y_K;_O\O\
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M_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\ Q-'_  @NG_\
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M V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\
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M;G_OM?\ XF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7_&L?_A!=/_YZW/\
MWVO_ ,31_P (+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\
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M (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\
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M_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\
MQ-'_  @NG_\ /6Y_[[7_ .)H V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK
M'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\ XF@#8_MBP_Y_K;_O\O\
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M_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\ Q-'_  @NG_\
M/6Y_[[7_ .)H V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_
M -]K_P#$T?\ ""Z?_P ];G_OM?\ XF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_
M '^7_&L?_A!=/_YZW/\ WVO_ ,31_P (+I__ #UN?^^U_P#B: -C^V+#_G^M
MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\ Q-'_  @NG_\ /6Y_
M[[7_ .)H V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K
M_P#$T?\ ""Z?_P ];G_OM?\ XF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7
M_&L?_A!=/_YZW/\ WVO_ ,31_P (+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R
M_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\ Q-'_  @NG_\ /6Y_[[7_
M .)H V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$
MT?\ ""Z?_P ];G_OM?\ XF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7_&L?
M_A!=/_YZW/\ WVO_ ,31_P (+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R_P"-
M']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\ Q-'_  @NG_\ /6Y_[[7_ .)H
M V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\
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M;G_OM?\ XF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7_&L?_A!=/_YZW/\
MWVO_ ,31_P (+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\
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M (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\
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M_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\
MQ-'_  @NG_\ /6Y_[[7_ .)H V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK
M'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\ XF@#8_MBP_Y_K;_O\O\
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M_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\ Q-'_  @NG_\
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M V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\
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M;G_OM?\ XF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7_&L?_A!=/_YZW/\
MWVO_ ,31_P (+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\
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M (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\
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M_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\
MQ-'_  @NG_\ /6Y_[[7_ .)H V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK
M'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\ XF@#8_MBP_Y_K;_O\O\
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M_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T__GK<_P#?:_\ Q-'_  @NG_\
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M V/[8L/^?ZV_[_+_ (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\
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M;G_OM?\ XF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7_&L?_A!=/_YZW/\
MWVO_ ,31_P (+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\
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M (T?VQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\
MXF@#8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7_&L?_A!=/_YZW/\ WVO_ ,31
M_P (+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^
M$%T__GK<_P#?:_\ Q-'_  @NG_\ /6Y_[[7_ .)H V/[8L/^?ZV_[_+_ (T?
MVQ8?\_UM_P!_E_QK'_X073_^>MS_ -]K_P#$T?\ ""Z?_P ];G_OM?\ XF@#
M8_MBP_Y_K;_O\O\ C1_;%A_S_6W_ '^7_&L?_A!=/_YZW/\ WVO_ ,31_P (
M+I__ #UN?^^U_P#B: -C^V+#_G^MO^_R_P"-']L6'_/];?\ ?Y?\:Q_^$%T_
M_GK<_P#?:_\ Q-'_  @NG_\ /6Y_[[7_ .)H U9M<T^&,L;V#'?;(&/Y"N=U
M7Q1+JI^Q:9'(QD^4R8P2/;VJ_'X'TY&R7N']BX_H*V;'3;;3HRMO"L>>I Y/
MU- %+P[H:Z-:8.'N'^^W]!6M2T4 %%%% !1110 4444 %%%% "44M% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img141511159_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img141511159_0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (!"UP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/ZUY!17I0R;+J?PT(_<G^9XU3B+-ZOQ8J?RDU^5CT&\_:!^(]]DR>,M67/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8_-L1BJ^+FZN(FYR[MW?XA1116YRA1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ9B22>3ZTE%%?8'Y\%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC*ZBIXA;ZIK9F.3YWA,\HNMA6]'9IZ-?B]^@M%%%>2>\%%%% !1110 4444
M%%>*?M5?$[7_ (6^!],O_#MS':7EQJ"V[RR0K)\GER,0 P(ZJ.<5\M?\-??%
M'_H/0_\ @!!_\17U&7\.XO,J"Q%&45%Z:MWT^3/B,VXOR_)\4\)B(S<DD]$K
M:^LD?HA17P?\/?VJOB/K7CSPYIU]K$%Q97FHV]M/$;*%=R/(JL,JH(X)Z&OO
M"N',\IKY5.,*[3YM=/\ AD>IDN?87/:<ZF%4DHNSYDEOZ-A1117BGT84444
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MY)_<O_DC]"J*_/7_ (;$^)W_ $%K3_P!B_PH_P"&Q/B=_P!!:T_\ 8O\*/\
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M2YFRE_8PCTCL4(_7-+;_ +9?Q+A8%[ZPG']V2R0#_P =Q7H?ZGYC:]X_>_\
M(\K_ (B#E%[<L_\ P%?_ "1^@E%?$&C_ +=GBRV9?[3T'2+Z,=?L_FP,?Q+,
M/TKT_P *_MQ>#]69(];TS4-!D;K(H%S"OU*X;\DKSJ_#>9T%?V7,O)I_AO\
M@>OA>,LEQ3Y56Y7_ 'DU^.WXGTA16!X3\=>'O'-G]JT#6+/58@,M]GE#,G^\
MOWE/U K?KYN<)TY.$U9KHS[&G4A6BITY*2?5:H****@T"BBB@ HHHH ****
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M /#6GQ6_Z&K_ ,IUI_\ &J!^UI\5O^AJ_P#*=:?_ !JC_4W,/YX??+_Y$/\
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MQ%K2Y4S*V;2!O=A_K#[*<?[0Z5\Z_&3]I[Q-\5&FL+=VT/P\V5^PV[G?,O\
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MV'\/<UJZU90A\VW^"M^)^:E2PVLUP<0Q/*?]A2?Y5^JNG^!O#>D "P\/:59
M=/L]E%'C\EK9CC6-0J*$4?PJ,"O+GQM'[&'^^7_ /;I^&TW_ !,4EZ0O_P"W
M(_)]/#.L2<II5\P]5MG/]*1O#>K1YW:7>KCKFW<?TK]9**Q_UUG_ ,^%_P"!
M?\ Z?^(;4_\ H*?_ (!_]L?D=-;RV[8EB>(^CJ145?KHR+(I5E#*>JL,BL34
M/ OAO5MWVWP]I5X#U^T64;Y_-:VAQM'[>'^Z7_ 1S5/#:?\ R[Q2?K"W_MS/
MRFHK]+-6_9O^&NM;OM'A"PBW?\^FZW_]%LM<%KO[$/@34=S:?=ZMI,G\*QSK
M+&/P=2Q_[ZKU*/&& J:5(RC\D_R?Z'B8CP]S6GK2E"?S:?XJWXGPA17U%XD_
M80U^UWOH?B2PU%1R([V)[=OH"N\$_E7D/BK]GWXA>#0[:AX8O9(%Y-Q9*+F/
M'J3&3M'UQ7T.'SC+\7I2K*_9Z/[G9GR6,X>S7 W=?#R2[I77WJZ/.Z*<RE6*
ML"K X((Z4VO9/G@J:UNIK&ZAN;:5X+B%Q)'+&Q5D8'(((Z$&H:*35]&";3NC
M]#/V:OCS%\7/#WV#4I$C\4Z?&/M*# ^TQ]!,H_(,!T)[ BO:J_*/P=XNU/P+
MXDL=<TB<V]_9R;T;^%AT*L.ZD9!'H:_2SX5_$K3?BMX-L]>TX[/,&RXMB<M;
MS #<A_/(/<$'O7XKQ)DO]GU?K%!?NY?^2OMZ=ON/Z1X.XD_M:A]4Q+_?07_@
M2[^JZ_?W.PHHHKXH_20HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\*_
M;/\ ^2(W7_7];_\ H1KW6O"OVS_^2(W7_7];_P#H1KV<F_Y&-#_$OS/G>(O^
M1/BO\$OR/S^HHHK^AS^1C]4OAK_R3KPK_P!@JU_]$K725S?PU_Y)UX5_[!5K
M_P"B5KI*_F;$?QI^K_,_M'"?[O3_ ,*_(****P.H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBO#/VA/VEK#X46\FCZ1Y6H^*I$_U9YBLP1PTF.K=P
MGXG QGLPF#K8ZLJ%"-Y/^KOR/.Q^88;+,/+$XJ7+%?CY+NSO?B9\7O#7PFTO
M[5KM[MGD!,%C" UQ/C^ZOI_M' 'K7Q?\4OVM/&'Q >:UTR9O#.CL<"WLI#Y[
MK_MR\'\%P.<'->1>(O$FI^+-8N=5UB]FU#4+AMTD\S9)]AZ =@.!T%9E?L>5
M<-87 )3K+GJ=WLO1?J]?0_G?/.,\=FDG2P[=*EV6[]7^BT]1SLTC%F)9B<DD
MY)IM%3V=E<:A<);VD$MU.YPL4*%W;V ')K[#2*NS\_2<G9;D%%>DZ'^SC\2O
M$"*]KX1OHD;O>;+7])66NFA_8W^)LBY;3K&(_P!U[Z//Z$UYD\TP--VG7BG_
M (D>S2R/-*RYJ>&FU_A?^1XA17LNH?LB_%"Q4LF@Q787K]GOH2?R+@UP'B;X
M9^+/!RLVM>'-2TZ)?^6TULPB_P"^\;3^=:T<PPF(=J56,GY-&.(RK'X5<U>A
M.*[N+2^^QS-;GA/QMKW@74EO] U6YTNY!&6MY,*^.S+T8>S BL.BNR<(U(N$
MU=/HSSZ=2=&:J4Y--;-:,^S/@_\ MJ6FJ20:7XZACT^Y;"KJULI\EC_TT3JG
M^\,CV45]1VMU#?6\5S;31W%O*H>.6)@R.I&001P0?6OR0KU_X&?M%ZW\(+Z.
MSF,FJ>&9'S-I[-\T6>KPD_=/?;T/L>1^=9QPI3J)UL!I+^7H_3MZ;>A^N\/\
M=U:4HX;-7S1Z3ZK_ !=UY[^I^B]%8OA'Q=I/CG0+76=%O$O=/N%RDB=0>ZL.
MH8'@@]*VJ_*91E3DX35FC]UIU(58*I3=T]4ULPHHHJ30**** "BBB@ HHHH
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M-7Y!7H5<-4=&M&TENC^@L+BJ.-HQQ&'ES0ELT%%%%8'4%%%% !1110 4444
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MIJMT^Z/ZHR3.*.=X..*I:/9KL^J_5>04445Y)[P4444 %%%% !1110 4444
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M[U-]>WD_\]C^A^'.*L/GD?937)66\>C\X_Y;KSW.ZHHHKY4^Z"BBB@ HHHH
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M.N<9]C<[J<^)E[JVBOA7R[^;U"BBBO9/G0HHHH **** "BBB@ HHHH ****
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M?QI^K_,_M'"?[O3_ ,*_(****P.H**** "BBB@ HHHH **** "BBB@ HHHH
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M!_\ V&+/_P!'I7ZFU^67PK_Y*AX/_P"PQ9_^CTK]3:^6XT_CT?1_F?<>&_\
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M0Q2WB[?)_P#!_,^D\.\=*GC*N";]V:NO5?YI_@CWFBBBOR(_?PHHHH ****
M"BBB@ KXA_;O_P"2B^'_ /L%#_T=)7V]7Q#^W?\ \E%\/_\ 8*'_ *.DKZ_A
M3_D:1]'^1^?<=_\ (DG_ (H_F?,]>C?LZ_\ );O!_P#U_+_Z":\YKT;]G7_D
MMW@__K^7_P!!-?L68?[G6_PR_)G\]95_R,,/_CC_ .E(_3"BBBOYN/[&"BBB
M@ J*>".YA>*:-9HG&UDD4%6'H0>M2T4!OHSP[XE?LC^"O',<MQIEO_PC&JMD
MK-8(! S?[</W<?[NT^]?&OQ2^#'B;X1ZD(-:M-UG(VVWU"WRUO-[!NS?[+8/
MX<U^G=9VO:!IWBC2;G2]6LX=0T^X79+;SKE6']".H(Y!Z5]?E?$N+P$E"J^>
MGV>Z]'^CT]#\^SS@W 9I%U,/%4JO=;/U7ZK7UV/R:HKV[]HC]G*\^$=\=5TO
MS+[PK</A)FY>U8](Y#Z>C=^AYZ^(U^RX3%T<=15>A*\7_5GYG\ZX_ 8C+<1+
M#8J/+)?U==TSZ+_9=_:*D\!ZA!X6\17);PW<OMM[B1L_89&/KVC)Z^A.?7/W
M2K!@""""*_(NOMW]COXUMXJT9O!FL3[]4TV+=8RR'YIK<<;/=DX_X"1_=)K\
M\XIR56>88=?XE_[=_G]_<_7.!^))<RRK%RNOL-_^D_\ R/W=CZ9HHHK\N/V\
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***HZUK5AX>TNXU'4[N&
MQL;=-\MQ.P5%'N332<FDE=DRDH)RD[)%ZO _CI^U9H_PW^T:1H/DZWXD&48!
MLV]HW_30C[S#^X#]2.A\;^.O[7E_XL-QHG@R272]&.8Y=1Y2XN1WV]XT/_?1
M[XY%?-7N:_3,FX5<K5\P6G2/_P E_E]_8_&.(N.E'FPN4N[ZS_\ D?\ /[NY
ML^+/&&L^.M:FU;7=0FU&^EZR2GA1V50.%4=@ !6+117ZA"$:<5""LD?B-2I.
MK-SJ.[>[>["BBBK,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V
M?"G@_6?'&L1:5H6G3:E?2=(X5^Z/[S'HJ^Y(%>F?!']FG7OBU+'J%SOT;PT&
M^:^D7YY\'E85/7TW'Y1[D8K[I\ _#?P]\,]%73/#^GI9P\&24_-+.P_B=^K'
M]!V KXW..)*&77I4??J=NB]7^B_ _1.'^#L5F]J^(_=T>_67HNWF].USP_X0
M?L9:/X<6'4O&;QZYJ0PRZ?'G[)$?]KO(?KA?8]:^DK>WAL[>."")((8U")'&
MH554=  .@J:BOR+&YAB<PJ>TQ$[_ )+T1_0&6Y3@\II>RPE-175]7ZO=_P!6
M"BBBO./7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@".2-)HWCD19(W!5D89!!X((]*^=_B_^QSH/BX3:CX3:+P[J[98VNT_8YC_N
MC_5GW48_V>]?1E%=^#QV)P%3VF'GRO\ !^JZGE9CE>#S6E['%TU)?BO1[H_,
M&73?%GP&^(%C<WME-I6L:?,)X?,YCF4'!VL.'1@2IP>A(K](/ _C"Q\?>$]+
MU_3FS:7T(E"DY*-T9#[JP*GW%-\:>!="^(6BR:5K^G1:A:/RN\8>-O[R,.5;
MW%<%\&/ACJ_P9U35/#\=TVK>$+QC=V%Q)CS;27@/%(.X88(8<90Y +#/T>9Y
MG0SK#*I-<E>'W276WFM[/SM<^/R7)<5PWC)4J4O:8:K]\)=+KL]KKRNE8]=H
MHHKXT_10HHHH **** "BBB@ HHHH **** "BBB@ KPK]L_\ Y(C=?]?UO_Z$
M:]UKPK]L_P#Y(C=?]?UO_P"A&O9R;_D8T/\ $OS/G>(O^1/BO\$OR/S^HHHK
M^AS^1C]4OAK_ ,DZ\*_]@JU_]$K725S?PU_Y)UX5_P"P5:_^B5KI*_F;$?QI
M^K_,_M'"?[O3_P *_(****P.H**** "BBB@ HHHH **** "BBB@ HHHH *^#
M?VROB@WB[Q^/#=I-NTO0B8W"GY9+HC]X?^ C">Q#>M?9_P 1/%D?@3P/KFOR
M[2+"T>9%;H\F,(OXL5'XU^6=Y>3ZA>3W5S(TUQ/(TLDC'EF8Y)/U)-?HO!^!
M56M/&36D-%ZO?[E^9^0^(6:.CAZ>7TWK/67HME\W^1!5G3M/N=7U"VL;.%[F
M[N9%AAAC&6=V.%4>Y)%5J^I_V(_A:FJ:M?>-K^'=#8,;6P##@S%?G?\ X"I
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M,X4UM&,F_GI^I[51117XH?TF%%%% !1110 4444 %%%,9EC5F8A5 R23@ 4
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MBO=J:_-;_HS]TX#S/ZYESPLW[U)V_P"W7JONU7R1/1117Q!^F!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1&Z_Z_K?_P!"->SDW_(QH?XE^9\[Q%_R)\5_@E^1^?U%%%?T.?R,?JE\-?\
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MU^I]?.<:8AVHX=;:R?Y+]3Z_PWPBOB,8]U:*_-_H%%%%?EQ^WA1110 4444
M%%%% !1110 4444 ?$O[='@Q=,\9Z-XDACVIJENUO.5'66+&&/N491_P"OF.
MOO3]MK1EU#X/Q7FW]YI^HPR[N^U@T9'YLOY"O@NOW7AC$/$99!2WC>/W;?@T
M?R_QMA%A<ZJN*TFE+[]_Q39T'P_\2-X0\<:#K2L5%C>PSOCN@<;A^*Y'XU^J
MN0PR.17Y%5^JOP\U(ZSX!\,Z@QRUUIEM.3[M$I_K7S7&M%?N*R\U^37ZGV?A
MOB'_ +3AWM[LE^*?Z'0T445^7G[:%%%% !1110 4444 %?#'[=G_ "5;1O\
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M^$2\#Z_K0.&L+&:X3/=E0E1^)P/QK\JW9I'9G8LS')+'))]37Z+?M8:F=-^
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M_LS-:<I.T)^[+Y[/Y.WRN?HG1117X*?U.%%%% !1110 4444 %%%% !1110
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M5\0_MW_\E%\/_P#8*'_HZ2OK^%/^1I'T?Y'Y]QW_ ,B2?^*/YGS/7HW[.O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M33**_;\ORW#Y;2]E07J^K]3^:,VSC%YS7]OBI>BZ)>2_7=A1117J'AA1110
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M&UX](M%8?[7DKG]<UR<:-?5Z*_O/\CT/#B+^N8B73E7YG6T445^2'[X%%%%
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MR9!P&Z<XXC-;.VT%K_X$_P!%IY]""TM(-/M8;6VACM[:%!''#$H544# 4 =
M!4]%%?F6^K/VE))604444#"BBB@ HHHH **** "OB']N_P#Y*+X?_P"P4/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<E\2?B=H/PK\//JNNW7EKRL%M'@S7#X^ZB]SZGH.Y%<[
M\;/CQHGP:TG-P5O]<N$)M=,1\,W;>Y_A3/?J<8&><?GYX^^(6N?$KQ#-K&O7
MC75R_P J(.(X4SPB+_"H_7J23DU]CD?#U7,FJU;W:7XOT_S/SSB;BVCDT7A\
M/:==].D?-^?9??Y]!\8OC=KWQDUCS]0D^R:7"Q-IID3'RHAZG^\^.K'UXP.*
M\[HHK]HH4*6&IJE1C:*Z'\XXK%5L96E7Q$G*<MVPHHHK<Y0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OHG]D_X"CQ]K"^*-=MMWA[3Y/W
M$,B\7DXYP1W1>_8G Y^:O+?@_P##"^^+7CBST.TW16^?-O+H#(@@!&YOKR !
MW)%?I;X>T"P\*Z'9:3I=NMKI]G$(88E[*/7U)ZD]R237PG$^<O!4OJM!_O);
MOLO\WT_X8_4>"N'5F5;Z]B8_NH/1?S2_R77N].YHTM%%?C1_104444 %%%%
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M) 50?@N]O8A:_7LPQ<<#A:F(E]E?CT7S9_/V58">9XVE@X?;?W+J_DKLQ/\
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M?#__ &"A_P"CI*^OX4_Y&D?1_D?GW'?_ "))_P"*/YGS/7HW[.O_ "6[P?\
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MA.%:"G!W3_(_DFI3J4*CIU%:479KLT?I)^S[\8K?XO>"(KB61%UZR"PZC ,
M[\<2 ?W7P3['([5ZE7Y9_#7XCZO\+?%=KKNCR8EC^2:!B=EQ$<;HW'H<?@0#
MU%?HW\+_ (I:)\6/#46KZ/-\PPMS:.1YMM)C[K#^1Z$5^*<0Y)++JKKT5^ZE
M_P"2OMZ=ON/Z2X2XEAF]!8;$2M7BM?[R[KS[_?L=C1117QQ^AA1110 4444
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M/[$P>*IX[#4\32^&:37S_P @HHHKF.P**** "BBB@ HHHH *_)76/^0M>_\
M7=__ $(U^M5?DKK'_(6O?^N[_P#H1K]-X)^+$?\ ;O\ [<?BOB5\&$_[?_\
M;2G7VQ^P;_R(WB7_ +"*_P#HI:^)Z^V/V#?^1&\2_P#817_T4M?2\5?\BN?K
M'\SX[@7_ )'=/TE^3/IZBBBOPT_IL*S/$?A^R\5:#?Z/J47GV-]"T$R?[+#&
M1Z$=0>Q K3HJHR<6I1=FB)QC4BX35T]S\K?B)X(O?ASXSU3P]?@F:SE*K)C
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MJ68A5 R23C%?'W[2'[5IN_M7A;P1=[8.8KS686P9.Q2$CMZN.O;CD\[^T?\
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MSTVRM]/M$^[!:Q+$@^BJ *NT45\PVY.[W/M8Q44HQ5D@HHHI%!1110 4444
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MV_Y&+PC_ ->L_P#Z&M?6<+_\C6GZ2_\ 26?!\<?\B*MZQ_\ 2D?*M=Q\#_\
MDL7@O_L+VW_HQ:X>NE^&WB"U\)_$#P[K5Z)&L]/OX;F41*&?8K@G )&3@>M?
MM6*BYX>I&*NVG^1_-V!G&GBZ4YNR4HM_>C]4:*^?O^&W?AY_SPUK_P !$_\
MCE'_  V[\//^>&M?^ B?_'*_!?[#S+_GQ+[C^I_]9LF_Z"H?>?0-%?/W_#;O
MP\_YX:U_X")_\<H_X;=^'G_/#6O_  $3_P".4?V'F7_/B7W!_K-DW_05#[SZ
M!HKY^_X;=^'G_/#6O_ 1/_CE9>M?MU>$+6%O[,T/6+^?LMP(X$/_  (,Q_\
M':J.19G)V5"7Y?F1/BC)8+F>)C\M?R/I*218XV=V"(HRS,< #U-?#G[5W[0D
M/CZY'A3P[<>;H%K+ONKN,_+=RKT"^L:GO_$>>@!/&_%C]ISQ=\5();!Y$T;1
M'X;3[(G]Z/21SR_TX7VKR&OT#(N&7@YK%8S6:V71>;[O\OR_)^*.,UF-)X++
M[JF_BD]'+R2Z+OU>VBW*<B-(RHBEF8X"J,DGT%-KZ,_9#^"DGC#Q-'XNU6W/
M]AZ3+NME<<7-R.5QZJG#'W"CGFOL\=C*>7X>6(J[+\7T7S/SK*\NK9KBX82@
MM9/[EU;]#ZN^!_@0_#CX7Z#HDJ;+R.'SKKU\Z0[W'O@G;]%%=Y117\Z5JT\1
M5E6GO)MOYG]>X;#PPM"&'I+W8))>B5@HHHK$Z0HHHH **** "BBB@ KYU_:M
M_9_;X@::?%&@6^[Q%91XGMXQS>PCL!W=>W<CCLHKZ*HKOP.-JY?7CB*+U7XK
MLSR\SRVAFN%EA,0KQ?WI]&O-?\#8_(ME*G!&"..:;7VA^TQ^RV?$4EUXL\'6
MP&J-F2^TN,8%R>IDC']_U7^+J/F^]\921O#(T<BLDBDJRL,$$=017[UEN9T,
MTHJK1>O5=4_ZV?4_E?.<EQ628AT,0M/LRZ27];KH=1\.?B9K_P +=>35=!O#
M!(<+-;N-T-PO]V1>X]^HSP17W)\(OVHO"OQ,C@L[N9- U]L*;*[D 25O^F4A
MP&_W3AO8]:_/"BN3-,CPN:KFFN6?\RW^??\ JS._(^)L=D;Y:3YJ;WB]OEV?
M]-,_7:BOS6\!_M'>/OA[''!8:V]Y81C L=1'GQ #L,_,H]E85[7X?_;UD5$3
M7/":N_\ %-I]T5'X1NI_]"K\UQ7">847^Z2FO)V?W.WZG[-@>/,IQ,5[=NE+
MS5U]ZO\ BD?7U%?.5K^W1X%D0>=I.O0OW @A8?GYO]*;=?MT>!XXSY&D:]._
M8-!"B_GYI_E7D_V#F=[>P9[W^M.2VO\ 68_B?1])TY-?'WB+]O2Z>-TT+PI%
M"_\ #-J%T9!^*(%_]"KP_P >_M >.OB-')!JNN2QV#\&QLOW$)'HP7EQ_O$U
MZ^%X2S"LU[:T%YN[^Y?YH^?QW'N58:+^KWJR\E9?-NWX)GU]\8/VL/#'P[CG
ML='DC\1Z\,J(;=\V\+>LD@X./[JY/&#MZU\0>.OB!KGQ(UZ75]?OFO+I^$7I
M'$O9$7HJC_ZYR>:YRBOTO*\DPN51O25Y]9/?Y=E_3/QC.^),=GDK5GRTUM%;
M?/N_7Y)!3XHGGE2.-&DD<A511DL3P !ZTZUM9KVXBM[>)YYY6"1Q1J6=V)P
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M7^9_HNGY^84445\T?9A1110 4444 %%%% !1110 4444 %?#'[=G_)5M&_[
ML?\ Z/GK[GKX8_;K!_X6KHQQQ_8L8S_VWGK['A/_ )&<?1GYYQY_R)9?XH_F
M?.%>]_L4_P#):A_V#;C^:5X)7OG[%*D_&@$ X&FSY]N4K]4SK_D6U_\ "S\+
MX;_Y'&%_QK\S[ZHHHK^>C^MPHHHH **** "BBB@#Y3_;"^!/]J6LOCS0K;_2
MX%_XFMO&O,D8&!.!ZJ.&_P!D _PG/QK7ZYR1K)&R.JNK##*PR"#V-?GW^T]\
M#&^%7BC^T]+A/_",:G(3!M'%M)U,)/IU*^V1_"37ZMPKG7M(K 8AZKX7W7;Y
M=/+T/PCCGASV,GFN%C[K^-=G_-\^OGKU/.?A7_R5#P?_ -ABS_\ 1Z5^IM?E
MG\*06^*'@\ 9/]LV>!_VW2OU,K@XT_CT?1_F>MX;_P"[8C_$OR"BBBOS@_80
MHHHH **** "BBB@ HHHH **** /)/C5^SEX>^,$+W9 TGQ"JXCU*! =^!PLJ
M_P 8]^H]<<5\.?$SX->*?A3?-#KFGL+1FVQ:A "]O+]'QP?]EL'VK]/JKWUC
M;:E:2VMY;Q7=K,NV2&= Z./0J>"*^LRKB/%9:E2E[]/L]UZ/]-CX+/>#\%G#
M=:'[NKW6S_Q+KZZ/U/R1HK[R^(7[%_@_Q0\ESH4TWA>];)V0CSK8G_KF2"O_
M  %@!Z5\_P#BS]CKXB>'&=[*TM?$%LO/F6$X#X]T?:<^RYK].P?$>78Q+]YR
M/M+3\=OQ/Q7,.#\WR]O]USQ[P][\-_P/#:*W]:\ >)O#;,-5\/:IIVWJ;FSD
M0?4$C!K KZ.%2%1<T'=>1\A4ISI2Y:D6GYJP445LZ/X,\0>(F"Z7H>I:D6Z?
M9+227_T$&B4XP5YNR%"G.H^6";?D8U%>S^%?V1_B/XF9#-I46B6[?\MM3G"'
M_OA=SY^H%>]^ /V(_#.AM'<^)[^?Q%<KS]FC!M[?/H<'<WY@>U?/XOB'+L&G
MS5.9]HZ_\#[V?6Y?PGF^8-<M%PCWE[J_'5_),^1_ 'PQ\2_$W5!9>'M,EO"I
M EN#\L,(]7<\#Z=3V!K[=^"/[+VA_"OR=4U%DUOQ*!D73K^ZMC_TR4]_]L\^
MFW)%>PZ/HNG^'M/BL-+LK?3[*(82WM8Q&B_0"KU?F6:\2XG,$Z5+W*?9;OU?
MZ+\3]HR+@W!Y2U7K/VE5=7LO1=_-_*P4445\>?H04444 %%%% !1110 4444
M %?&?[>W_(Q>$?\ KUG_ /0UK[,KXS_;V!_X2#PBV./LMP ?^!I7U?"__(UI
M^DO_ $EGP?''_(BK>L?_ $I'RK1117[J?S %%%% !1110 445)#!)<R+'#&T
MLC?=1%))_ 4#6NA'17HOA']GSX@>-)$^P^&KRW@;_EYOT^S1 >N7QN'^Z#7T
MO\*_V*='\/2PZAXPNUUZ\0AA80 K:*?]HG#2?CM'J#7@8[/,!@$_:5$Y=EJ_
M^!\SZK+.&,TS22]E2<8_S2T7_!^5SPOX!?LX:K\6KZ+4;]9=-\*QO^]NR,/<
MX/*19Z^A;H/<C%??^AZ'8^&])M-+TRUCLK"UC$4,$8PJJ/\ /)ZDG)JS;V\5
MG!'!!$D$$:A$CC4*JJ!@  =![5-7X[FV<5\VJ<T](+:/;_-G]#9!P]ALAH\M
M/WJDOBEU?DNR\OO"BBBO /J@HHHH **** "BBB@ HHHH **** "O$?CA^R_H
MGQ6\[5-.:/1?$Q&3=*O[JY/82J._^V.?7=@"O;J*[,+BZ^"JJMAY<LE_6O<\
M_'9?ALRHO#XJ"E%_U=/H_-'Y9>/?AGXD^&>J&Q\0:9+9.2?*FQNAF [HXX;^
M8SR!7+5^LVM:%IWB33I=/U6QM]1LI1A[>YC$B'\".OO7SOX__8@\.:T\ESX6
MU&;P_.QS]EG!GM_H,G>OYM]*_4<OXOP]5*&-CR2[K5?YK\3\0S;P_P 50;J9
M=+VD?Y7I)?/9_AZ'Q#17LGBK]DOXD>&6<QZ1'K5NO_+;2YA)G_@!VO\ ^.UY
MGK'@_7O#[,NJ:+J.FE>OVNUDBQ_WT!7VU#'8;$J]&HI>C1^;8K+<;@G;$T91
M]4U^.QCT445VGF!16WH_@GQ#XB95TO0M2U$MT^RVDDG\@:].\*?LB_$?Q,R-
M/ID.A6[?\MM2G"G'^XNYL_4"N&OCL+A5>M44?5H]3"Y7CL:[8:C*7HG;[]CQ
M:NP^'/PG\3?%/4A::!IKW"*P$UY)\EO![N_0?09)[ U];?#[]B7PMX?:*Y\2
MWLWB.Z7G[.H,%L#[@'<WXL ?2OH32])LM#L8;'3K."QLX1MCM[:,1H@]E' K
MXC,.,*--.&"CS/N]%]V[_ _2LH\/L36:J9E+DC_*M9??LOQ/*?@C^S7H'PBC
M2_FVZQXD9</J$J86'(Y6%?X1VW?>//0'%>Q445^78G%5L95=:O+FDS]OP6!P
M^745A\+!1BNB_-]WYL****Y3N"BBB@ HHHH **** "BBB@""]O(=/LY[JYD6
M&W@C:661CPBJ"23[  U^7/Q.\;3?$3Q]K7B&;<!>W!:)&ZI$/EC7\$"C\*^U
MOVQ/'DGA'X4R:;;LRW>N2_8]R_PP@;I>?< +CT<^E? %?K/!N!Y*4\9):RT7
MHM_O?Y'X+XAYG[2O3RZ#TA[TO5[?<OS"OJ+]AOX>_P!I>)-4\7W,68--3[):
M,PX,SCYR/=4X_P"VE?,"(TCJB*69C@*HR2?05^G'P3\ K\-/AGHFB,@6\2+S
MKPCO._S/SWP3M'LHKT^*L=]5P/L8OWJFGRZ_Y?,\7@7+/KV9K$37NTO>_P"W
MOL_J_D=W1117XF?TH%%%% !1110 4444 %%%% &3XH\.VGB[PYJ>BWR[K2_M
MWMY..0&!&1[CJ/<5^6?B;P_=^%/$6I:-?)LO+"X>WD';<K$9'L<9'L:_6*OB
M/]N#X>_V/XPT_P 66T6+;5H_(N64<"XC  )_WDQ_W[-??\'X[V.)EA)/2>WJ
MO\U^2/RCQ!RSZQ@H8^"]ZF[/_"_\G;[V?,M?8W[#'Q"^T:?K'@RZE^>W/]H6
M08_P,0LJCV#;3_P-J^.:Z_X2^.I?AO\ $/1/$"%C%:S@7"+_ !PM\LBX]=I.
M/?%?H^<X'^T,#4H+XMUZK;[]OF?C_#N9O*<RI8EOW;VE_A>C^[?Y'ZCT4U6#
MJ&7H1D4ZOYY/ZW"BBB@ HHHH **** "OR5UC_D+7O_7=_P#T(U^M5?DOKD;1
MZU?HZE76XD#*PP00QX-?IO!/Q8C_ +=_]N/Q7Q*^#">L_P#VTHU]L?L&_P#(
MC>)?^PBO_HI:^)Z^V?V#U9? ?B-BI"G4E ..#B):^DXJ_P"17/UC^9\=P+_R
M.Z?I+\F?3M%%%?AQ_384444 %)PPP>12T4 ?G'^TQ\*?^%6_$:X2TA\O1-3W
M7=CM'RH"?GB'^XQ_[Y*UY+7Z2?M%?"M?BM\.+RSMX@VLV.;O3V[F11S']'7*
M_7:>U?FZZ&-F5E*L#@JPP0?2OW;AW,O[1P:4W[\-'^C^?YW/Y=XOR7^R,P;I
MJU.I[T?+NOD_P:-[P#XTOOA[XPTOQ!IS?Z38S!]A.!(G1T/LRD@_6OU \+^)
M+'QAX=T[6M-E\ZQOH5GB;O@CH?0@Y!'8@U^3]?7'[#WQ.E,VH>!KQG>+:U]8
M-R0G($J>P.0P[9W>M>9Q9EOUC#+%TU[T-_./_ W^\]O@/.7@\8\OJOW*NWE+
M_@K3UL?7U%%%?CA_0X4444 %%%% !1110 5\0_MW_P#)1?#_ /V"A_Z.DK[>
MKXA_;N4_\+$\/G'']E8!Q_TVDKZ_A3_D:0]'^1^?<=?\B2?K'\SYGHHHK]Q/
MYE"BBB@ HHHH **LV6GW>I2>7:6LUU)_<AC+G\@*[GP[^S[\1/%#*++PGJ,:
M-_RTO(_LR8]<R;<CZ5SU<11H*]6:BO-I'70PF(Q3Y:%.4GY)O\CSVI;>WEO+
MB."")YII&"I'&I9F8]  .IKZD\$_L*:I=-'-XJUV"PAZM:Z:IEE(]"[ *I^@
M:OI/X=_!3P?\+XP="TB..\V[6O[C][<-Z_.?N@^BX'M7R6.XKP.&35#]Y+RV
M^_\ RN?>Y9P+F>,:EB5[*'GJ_DE^K1\O_!G]C74_$$D&J>-_,TC3>'73$.+F
M8>CG_EF/;[W7[O6OLG0M!T[PSI-MIFE6<-A86Z[8K>!=JJ/\?4GDDY-:-%?E
MN99MBLTGS5Y:+9+9?UW9^XY/D."R2GR8:/O/>3W?_ \EH%%%%>,?1!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<
MWX_^(&B_#7PW<:WKER(+6+Y41>9)G[1HO=C_ $). ":TITYU9JG35V]D95:M
M.A3E5JRM%:MO9$_C+QGI'@'P_=:UK=VMG86XY9N6=NR*/XF/8"OSU^.'QVU?
MXS:YNEW66A6S$V>FAN%[;W_O.1^ S@=R:7QD^-&M?&3Q";R_8VVFPDBRTV-B
M8X%]3_><]V_D,"O/:_9\AX?AET5B,0KU7]T?3S[OY+S_ )QXIXLJ9Q)X7"MQ
MH+[Y>;\NR^;[(HHHK[4_-PHHHH *6NI^'OPQ\1?%#6!IWA_3VNG&/-G;Y88%
M/\3OT'?CJ<< U]O?!G]EGPY\,5@U'4537_$2X;[5.G[J!O\ IDAZ$?WCSZ;>
ME?/9IGF%RM6J/FG_ "K?Y]E_2N?6Y)PSCL\ES4ERT^LGM\N[]/FT?.OP=_9&
M\1>/O(U+Q!YGAS0FPP$B?Z5.O^PA^Z#_ 'F]B :^SO /PR\-_#+2_L/A[3(K
M)& \V?&Z:8CN[GD_3H.P%=517X_F>=XO-':K*T/Y5M\^_P S^A,EX;P&21O1
MCS5.LGO\NR]/G<****\ ^J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT7_92\+CPQ\$=#+)LGU$R:A+[[V^0_\ ?M8Z\CBO$_5\N<%O-I?J_P K'T'
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MXK="<E8D"C/K@58HHJ&V]6:))*R"BBBD,**** "BBB@ HHHH **** "BBB@
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M;:%AWCA53^@J[110Y.6[",5'2*L%%%%(H**** "BBB@ HHHH **** "BBB@
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MKX=TI#N73+-3[6Z#^E:-%+VD^X>RI_RK[AD<:0H%C147LJC I]%%0:A1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT/3_  UI-MIFE6<-C86Z;(K>!=JJ/\?4]2>36A7XIG&?5\TER+W:?1=_7O\
MDOQ/Z1X?X6PN1Q51^_6>\NWE'LO/=_@%%%%?,'VP4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !117GGQI^,ND_!OPR;Z\VW
M6I3Y2QT]6PT[CN?1!QEOPZD5O0H5,34C1HQO)[(Y<5BJ.#HRQ&(ERPCJV6?B
MQ\7]"^#_ (?.H:M+YMU("MII\3#S;AAV'HH[L>![G /Y]_%3XO\ B'XN:X;[
M6;C;;1D_9=/A)$-NOHH[MZL>3], 8WCCQQK'Q$\1W6MZY=-=7LY^B1+V1!_"
MH[#\>22:P*_;LER&CE<%4G[U5[OMY+_/=_@?S3Q)Q5B,[FZ5/W:"V7?SE_EL
MO74****^K/A HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /</V-=
M,%_\<M/GQG[%:7%P/;*>7_[4K]!J^'OV$K/S/B3KMUC/E:2T8_X%-&?_ &2O
MN&OQ/BZISYE;M%+\W^I_2G -/V>3*7\TI/\ )?H%%%%?%GZ.%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ_0#  %=#117XU4J3JR<YN[>[/Z*I4H48*G2C:*T26R"BBBH-0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M7_VXOB$=+\+Z9X1M9=L^J/\ :KI5//D1GY5/LS\_]LS7Q37I?[1GC8^.OC!X
M@O4??:6TWV&VP>/+B^7(]F8,W_ J\TK^@<BP2P. ITVO>:N_5_Y;?(_D_BC,
MGF>:UJJ=XI\L?1:?B[OYA1117OGR@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >U?L?:I_9_QTTB(G O+>XM_P#R$SC]4%?H97Y>
M_!?6AX=^+'A*_9MD<>IP*[>B,X1C_P!\L:_4*OQ[C*ERXRG5[Q_)O_-']"^'
M5?GRZK1ZQG?Y-+_)A1117P!^K!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5X!\?_B3XD\'^,+*QT?4V
MLK9[!)F18D;+F20$Y93V4?E7O]?+?[4G_)0-/_[!<?\ Z-FIK<^;X@JU*.!<
MJ<G%W6SL<S_PO/QS_P!!^3_OQ%_\11_PO/QS_P!!^3_OQ%_\17M/P'\(Z%JW
MPUT^YOM%T^\N6DF#37%K'(YQ(P&21GI7H7_"O_"__0MZ1_X Q?\ Q-.Z/!P^
M4YCB*,*RQ37,D]Y=?F?*G_"\_'/_ $'Y/^_$7_Q%'_"\_'/_ $'Y/^_$7_Q%
M?5?_  K_ ,+_ /0MZ1_X Q?_ !-'_"O_  O_ -"WI'_@#%_\31='1_8>9?\
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MUM_^!2/F3_A?WCS_ *#O_DG;_P#QNC_A?WCS_H._^2=O_P#&Z^F_^%6^$/\
MH6]-_P# =?\ "C_A5OA#_H6]-_\  =?\*+HK^QLU_P"@M_\ @4CYD_X7]X\_
MZ#O_ ))V_P#\;H_X7]X\_P"@[_Y)V_\ \;KZ;_X5;X0_Z%O3?_ =?\*/^%6^
M$/\ H6]-_P# =?\ "BZ#^QLU_P"@M_\ @4CYD_X7]X\_Z#O_ ))V_P#\;K8\
M%?&_QIJGC#0[*[UD3VMU?002QFUA7<C2*I&0@(X)Z&OH/_A5OA#_ *%O3?\
MP'7_  J6S^'/A?3[N&YMO#^GPW$+B2.1+=0R,#D$''!!HNC2GD^:1G&4L4VD
M^\CI****D^W"BBB@#E_B9K5YX<\!ZSJ5A*(;RWAW12%0VT[@,X(P>O>O'O@G
M\6/%/BSQU#IVK:F+NS>"1C']GB3D#(.54&O4_C5_R2[Q#_UP'_H:U\__ +./
M_)3[7_KVF_\ 0:I;'QF9XBM3S7#TX3:B[75W9ZO='UM1114GV84444 %%%%
M')?%37KWPS\/]8U+3I1!>VZ(8Y"@;:2ZJ3@C!X)ZUY1\#OBMXH\8>-O[/U?4
MA>6AMI)/+^SQ)A@5P<JH/<_G7I'QS_Y)3K__ %SC_P#1J5X7^S3_ ,E*'_7G
M+_-:KH?&9CB*U/-\/2A-J+M=7=GJ^A]84445)]F%%%% 'BG[0GQ#\0>";[18
MM%O_ +$EQ'*TN(8WW$%0/O*<=3T]:\C_ .%]>._^@\W_ ("P?_$5]9:UX7T?
MQ&T3:IIEIJ!AR(S<PJY7.,XR..@_*LW_ (5CX1_Z%K2__ 5/\*JZ/DL=E>/Q
M&(E5HXAQB]E>6FGD?+__  OKQW_T'F_\!8/_ (BC_A?7CO\ Z#S?^ L'_P 1
M7U!_PK'PC_T+6E_^ J?X4?\ "L?"/_0M:7_X"I_A1='#_8N:?]!;^^1\O_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!SDK]Y:;IMKH]A;V-C;QVEG;H(XH85"JB@8  '05^?\ $'$2PE\+A'>IU?\
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M_H)J[5+6O^0/?_\ 7"3_ -!-!$_A9\6_#'_DHOAK_L(0_P#H8K[?KX@^&/\
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M\"JHGR_$6,^K8-TX_%/3Y=?\OF=_^S#X1^W:]>^()DS#8KY,!(ZRN.2/HO\
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M:1V5HA)$<>>IZDD\D^YK2HHH%&,8)1BK)!11104%%%% !1110 4444 %%%%
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M?TK[$\,_\BWI/_7I%_Z *^._B[_R4SQ%_P!?;?TK[$\,_P#(MZ3_ ->D7_H
MJGLCX7(/]]Q7K^K-.BBBI/N@HHHH **** .#^.?_ "2G7_\ KG'_ .C4KPO]
MFG_DI0_Z\Y?YK7NGQS_Y)3K_ /USC_\ 1J5X7^S3_P E*'_7G+_-:I;'PF:?
M\CK#?+_TIGUA1114GW84444 %%%% !11368*I). .>: /$?VGO%WV'0K+P_
M^);YO/G ZB)#\H/U;G_@!KG/V7_"/VS5[_Q%,F8[1?LUN2/^6C#YB/<+@?\
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M[#?6[?\ +2%PV/8^A]C6C4GV<91FE*+NF%%%%!04444 %%%% !1110 4444
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M0O\ \31_PU9I_P#T+]S_ .!"_P#Q-'_#*>G_ /0P7/\ X#K_ /%4?\,IZ?\
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M@)??]_$H_P"&JM'_ .@)??\ ?Q*K_P##*-E_T,5Q_P" J_\ Q5'_  RC9?\
M0Q7'_@*O_P 51H5?B+LO_)2Q_P -5:/_ - 2^_[^)7IW@/QI;^/?#L6KVUO+
M;1.[1^7,02"IQVKRG_AE&R_Z&*X_\!5_^*KU/X?^"XO /AJ+2(;I[Q8Y'D\Y
MU"DECGH*3MT/4RUYM[9_7DN2WEO\CIJ***1],%%%% !1110!Q/QJ_P"27>(?
M^N _]#6OG_\ 9Q_Y*?:_]>TW_H-?0'QJ_P"27>(?^N _]#6OG_\ 9Q_Y*?:_
M]>TW_H-4MCX3-O\ D<87Y?\ I3/K:BBBI/NPHHHH **** .#^.?_ "2G7_\
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MPQI&HPJ *H]A3ZCAF2>%)4.4=0RGV/-25)]RMM HHHH&%%%% !1110 4444
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M ^]^A^=]%%%?T(?R6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]?;?TK[$\,_\BWI/_7I%_P"@"J>R/A<@_P!]Q7K^K-.BBBI/N@HHHH ****
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MP_ZX1_\ H(JGLCX3AW_>L5Z_JR[1114GW84444 %%%% !1110 4444 %%%%
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M\:/-@\JE>6SGT7^'N_/;M?=7M?\ $&I>*M7N=4U:\FU#4+EM\MQ,V68_T Z
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M_IU\.HHK38_(<9C:V.JNK6>OX+T"BBB@X HHHH **** "BBB@ HHHH ****
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M97AW_D7],_Z]8O\ T 5HUG>'?^1?TS_KUB_] %:-2?9T_@CZ!1110:!1110
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M%% 'S#^U-_R.FE?]@\?^C'KU+]G7_DEMA_UVF_\ 1AKRW]J;_D=-*_[!X_\
M1CUZE^SK_P DML/^NTW_ *,-4]CX7 _\CZOZ/_VT],HHHJ3[H**** "BBB@
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M5S&KNW9?K]RLAU%%%2?=A1110 4444 <C\4O"0\:>!]2TY$WW03SK;U\U.5
M^O*_\"-?+7PC\7'P5X\T^\E?R[65OLUSG@>6Y )/^Z<-_P !K[3KXY^.7A'_
M (1/X@7HB3;9WW^F0<<#<3N7\&#<>A%4NQ\/Q%1E1G2S"EO%V?YK]4?8U%<)
M\%_%W_"8> ;">1]]Y:C[)<9Z[D PQ^J[3]2:[NI/L:%:.(I1K0VDKA1110;A
M1110!\0?$[_DHOB7_L(3?^AFOM+1?^0/8?\ 7"/_ -!%?%OQ._Y*+XE_["$W
M_H9K[2T7_D#V'_7"/_T$53V1\)P[_O6*]?U9=HHHJ3[L**** "BBB@ HHHH
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MT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /ZBJ9\9D>'K4L7B95(-)O2Z:OJ]B_1114GV84444 %%%% '!_'/_DE.O_\
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M3G[2"G:UU?7<****#0**** .8^)W_).O$O\ V#YO_0#7S%\ ?^2M:%_VW_\
M2>2OJ7QYIMQK'@O7+&TC\ZZN+*6**/(&YBI &3QU]:\$^#GPK\5>'?B-I.I:
MEI$EI90><9)6D0[<PNHX#$]6%4MCXO-J%6IF6%G"#:35VEHO>ZGTU1114GV@
M4444 %%%% !1110!SGQ(_P"2>^)O^P;<_P#HIJ^6O@3_ ,E8T#_>E_\ 1+U]
M6^-M/N-6\&Z[96J>;=7-C/%%'D#<[1L ,GCDFOGWX0_"GQ7X?^(FD:CJ.D26
MME 9#)*TB$+F)U'1L]2*I;'Q><4*M3,<+.$&TFKM)Z>\MSZ=HHHJ3[0****
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MJC_A1_CC_H 3?]_8_P#XJBR#^W,Q_P"@1_=+_(^KO^%@>%_^ADTC_P #HO\
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M['_\51_PH_QQ_P! ";_O['_\519'J_VYF7_0*_NE_D?5G_"Q/"G_ $,VC_\
M@?%_\51_PL3PI_T,VC_^!\7_ ,57RG_PH_QQ_P! ";_O['_\51_PH_QQ_P!
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MPRZOEM9T:Z]'T:[H_J+*<WPN<X=8C#/U75/L_P"K,6BBBO,/;"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_GU'%0U8_7LGS:&84U";M46Z[^:_K0W****D^C"BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI>'_ .?S^Y!_Q$C%_P#0/'[V?J/_ ,+B\!_]#OX<_P#!M;__ !='_"XO ?\
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M1CR/^[M]VWW6/N\OXVS? VC.:J1_O:O[U9_?<_4?_A<7@/\ Z'?PY_X-K?\
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M2\/_ ,_G]R#_ (B1B_\ H'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/^%Q> _\
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M_P"%Q> _^AW\.?\ @VM__BZ_+BBC_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\
MA<7@/_H=_#G_ (-K?_XNC_A<7@/_ *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/
M^(D8O_H'C][/U'_X7%X#_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XN
MORXHH_U+P_\ S^?W(/\ B)&+_P"@>/WL_4?_ (7%X#_Z'?PY_P"#:W_^+H_X
M7%X#_P"AW\.?^#:W_P#BZ_+BBC_4O#_\_G]R#_B)&+_Z!X_>S]1_^%Q> _\
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M_/Y_<@_XB1B_^@>/WL_4?_A<7@/_ *'?PY_X-K?_ .+H_P"%Q> _^AW\.?\
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M .+K\N**/]2\/_S^?W(/^(D8O_H'C][/U'_X7%X#_P"AW\.?^#:W_P#BZ/\
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M (B1B_\ H'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/^%Q> _\ H=_#G_@VM_\
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MG_@VM_\ XNC_ (7%X#_Z'?PY_P"#:W_^+K\N**/]2\/_ ,_G]R#_ (B1B_\
MH'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/^%Q> _\ H=_#G_@VM_\ XNORXHH_
MU+P__/Y_<@_XB1B_^@>/WL_4?_A<7@/_ *'?PY_X-K?_ .+H_P"%Q> _^AW\
M.?\ @VM__BZ_+BBC_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\ A<7@/_H=_#G_
M (-K?_XNC_A<7@/_ *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/^(D8O_H'C][/
MU'_X7%X#_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XNORXHH_U+P_\
MS^?W(/\ B)&+_P"@>/WL_4?_ (7%X#_Z'?PY_P"#:W_^+H_X7%X#_P"AW\.?
M^#:W_P#BZ_+BBC_4O#_\_G]R#_B)&+_Z!X_>S]1_^%Q> _\ H=_#G_@VM_\
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M_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XNORXHH_U+P_\ S^?W(/\
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M_P"#:W_^+K\N**/]2\/_ ,_G]R#_ (B1B_\ H'C][/U'_P"%Q> _^AW\.?\
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M2\/_ ,_G]R#_ (B1B_\ H'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/^%Q> _\
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M_P"%Q> _^AW\.?\ @VM__BZ_+BBC_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\
MA<7@/_H=_#G_ (-K?_XNC_A<7@/_ *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/
M^(D8O_H'C][/U'_X7%X#_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XN
MORXHH_U+P_\ S^?W(/\ B)&+_P"@>/WL_4?_ (7%X#_Z'?PY_P"#:W_^+H_X
M7%X#_P"AW\.?^#:W_P#BZ_+BBC_4O#_\_G]R#_B)&+_Z!X_>S]1_^%Q> _\
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M_/Y_<@_XB1B_^@>/WL_4?_A<7@/_ *'?PY_X-K?_ .+H_P"%Q> _^AW\.?\
M@VM__BZ_+BBC_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\ A<7@/_H=_#G_ (-K
M?_XNC_A<7@/_ *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/^(D8O_H'C][/U'_X
M7%X#_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XNORXHH_U+P_\ S^?W
M(/\ B)&+_P"@>/WL_4NT^*W@G4+J&UM?&&@7%S,ZQQ0PZG SR.3A550V222
M *ZNORT^$O\ R53P9_V&K+_T>E?J77QN?91#**D(0FY<ROJ?HO"_$%7/Z-6I
M5IJ/*TM/-'FW[07Q(D^%WPOU/5K9@NI3%;2R)[3/G#?\!4,W_ :_-:::2XFD
MEF=I99&+N[DEF8G))/<U]Q?MV9_X59HO]W^V8\_]^)O_ *]?#-??<(4(4\ Z
MJ7O2;O\ +;^O,_*?$#%5*N:+#R?NPBK+S>K?Y?<%%%%?='Y@%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-TZL7&2Z-6844459D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '5_"7_ )*IX,_[#5E_Z/2OU+K\M/A+_P E4\&?]AJR_P#1Z5^I=?DW
M&G\>CZ/\S]Z\-_\ =<1_B7Y!1117YP?L)S?Q&_Y$S5/^N5?F9XX_Y&*Z_P!X
MT45^H\&;5#\0\1?BH^A@4445^GGXF%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '5_"7_ )*IX,_[#5E_Z/2OU+HHK\FXT_CT?1_F?O7A
*O_NN(_Q+\C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img142434680_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img142434680_0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (!"UP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/ZUY!17I0R;+J?PT(_<G^9XU3B+-ZOQ8J?RDU^5CT&\_:!^(]]DR>,M67/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8_-L1BJ^+FZN(FYR[MW?XA1116YRA1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ9B22>3ZTE%%?8'Y\%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC*ZBIXA;ZIK9F.3YWA,\HNMA6]'9IZ-?B]^@M%%%>2>\%%%% !1110 4444
M%%>*?M5?$[7_ (6^!],O_#MS':7EQJ"V[RR0K)\GER,0 P(ZJ.<5\M?\-??%
M'_H/0_\ @!!_\17U&7\.XO,J"Q%&45%Z:MWT^3/B,VXOR_)\4\)B(S<DD]$K
M:^LD?HA17P?\/?VJOB/K7CSPYIU]K$%Q97FHV]M/$;*%=R/(JL,JH(X)Z&OO
M"N',\IKY5.,*[3YM=/\ AD>IDN?87/:<ZF%4DHNSYDEOZ-A1117BGT84444
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MY)_<O_DC]"J*_/7_ (;$^)W_ $%K3_P!B_PH_P"&Q/B=_P!!:T_\ 8O\*/\
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M2YFRE_8PCTCL4(_7-+;_ +9?Q+A8%[ZPG']V2R0#_P =Q7H?ZGYC:]X_>_\
M(\K_ (B#E%[<L_\ P%?_ "1^@E%?$&C_ +=GBRV9?[3T'2+Z,=?L_FP,?Q+,
M/TKT_P *_MQ>#]69(];TS4-!D;K(H%S"OU*X;\DKSJ_#>9T%?V7,O)I_AO\
M@>OA>,LEQ3Y56Y7_ 'DU^.WXGTA16!X3\=>'O'-G]JT#6+/58@,M]GE#,G^\
MOWE/U K?KYN<)TY.$U9KHS[&G4A6BITY*2?5:H****@T"BBB@ HHHH ****
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M /#6GQ6_Z&K_ ,IUI_\ &J!^UI\5O^AJ_P#*=:?_ !JC_4W,/YX??+_Y$/\
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MQ%K2Y4S*V;2!O=A_K#[*<?[0Z5\Z_&3]I[Q-\5&FL+=VT/P\V5^PV[G?,O\
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MV'\/<UJZU90A\VW^"M^)^:E2PVLUP<0Q/*?]A2?Y5^JNG^!O#>D "P\/:59
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MH8'@@]*VJ_*91E3DX35FC]UIU(58*I3=T]4ULPHHHJ30**** "BBB@ HHHH
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M-7Y!7H5<-4=&M&TENC^@L+BJ.-HQQ&'ES0ELT%%%%8'4%%%% !1110 4444
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MIJMT^Z/ZHR3.*.=X..*I:/9KL^J_5>04445Y)[P4444 %%%% !1110 4444
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M[U-]>WD_\]C^A^'.*L/GD?937)66\>C\X_Y;KSW.ZHHHKY4^Z"BBB@ HHHH
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M.N<9]C<[J<^)E[JVBOA7R[^;U"BBBO9/G0HHHH **** "BBB@ HHHH ****
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M?QI^K_,_M'"?[O3_ ,*_(****P.H**** "BBB@ HHHH **** "BBB@ HHHH
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M!_\ V&+/_P!'I7ZFU^67PK_Y*AX/_P"PQ9_^CTK]3:^6XT_CT?1_F?<>&_\
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M0Q2WB[?)_P#!_,^D\.\=*GC*N";]V:NO5?YI_@CWFBBBOR(_?PHHHH ****
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M[N9%AAAC&6=V.%4>Y)%5J^I_V(_A:FJ:M?>-K^'=#8,;6P##@S%?G?\ X"I
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M,X4UM&,F_GI^I[51117XH?TF%%%% !1110 4444 %%%,9EC5F8A5 R23@ 4
M?+/[;WQ0;3=)L/!-C-MFO@+N_*GD0AOW:'_>8%C_ +@]:^,J[#XN>-G^(GQ&
MU[7F8M#<W+"WS_#"ORQC_OD#\<UQ]?T+DV!67X*%&WO;OU>_W;?(_DGB+-)9
MMF57$7]V]H_X5M]^_JPK[F_9*^ T?@[18?%^MVV=>U"/=:12#FT@8<''9W'7
MN 0.,M7SO^S#\+5^)WQ,MA>0^;HVE@7MXK#Y9,'"1G_>;J.ZJU?HN*^/XMS:
M5-+ 47J]9>G1?/=^5NY^@\!9#&LWFN(5U%V@O/K+Y;+SOV0M%%%?E1^ZA111
M0 4444 %%%% !1110!\M?M?? :/6=-G\=:%;A=1M4W:G!&O^OB _UP']Y1U]
M5_W>?BZOUSDC6:-D=5=&&UE89!!Z@BOS8_:&^&(^%?Q,O].MT*Z5=#[98'L(
MG)^3_@+!E^@![U^L\)YM*M%X&L]8J\?3M\NGEZ'X)QYD,<-46:8=6C-VFO[W
M1_/KY^IYG7W#^Q3\4&\1^$;KPE?3;[[1L26I8\M:L>G_  !CCZ.H[5\/5Z%\
M _'#?#_XL>']4:3R[1YQ:W>3QY,GR,3_ +N0WU45]1GF!688&=.WO+5>J_SV
M/BN&,T>4YG2JMVA)\LO1_P"3L_D?II1117\_']8!1110 4444 %%%% !1110
M 4444 %5M1U"WTG3[F^NY5@M;:)II9&Z(B@EB?H :LU\_?MF?$+_ (17X9KH
M=O)LO]>D\DA3R+=,-(?QRB_1C7=@<++'8FGAX_:?X=7\D>7FF.AEF"JXN>T%
M?U?1?-V1\7?$;QE<?$+QQK/B&YW*]]<-(B,<E(QQ&G_ 5"C\*YNBGQQM-(J(
MI=V.U549))Z 5_1U.$:,%3@K)*R]$?Q]5J3Q%256H[RDVWZL^HOV&_A[_:'B
M'5?&-S%F'3T^QVC,./.<9D8>ZH0/^VE?7_B+0;3Q1H.HZ/?)YEG?6[V\J]]K
M*02/<9R/>N9^"_@%?AK\-=$T,J%NXX?-NV'\4[_-)SWP3M'LHKN*_ <XS"6.
MQ\\1!Z)VCZ+;_/YG]6<.Y3'+<JIX6I'62O+UENODM/D?E!XL\-W?@_Q-JFB7
MR[;JPN'MY#CAMI(W#V(P1[$5D5]/_MQ?#W^R_%&F>+K:+%OJB?9;IE' GC'R
MD^[1\?\ ;,U\P5^W99C%C\)3Q"ZK7UV?XG\T9UETLJQ]7"/:+T\T]5^!]??L
M+_$+=#K/@RZEY0_VA9!CV.%E4?CL;'NQKZXK\L_A?XWF^'/C[1?$,.XK9W ,
MR+U>(_+(OXJ6_'%?J+9W4-_:075M(LUO.BRQR*<AE89!'L017Y5Q9@?JV-6(
MBO=J:_-;_HS]TX#S/ZYESPLW[U)V_P"W7JONU7R1/1117Q!^F!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1&Z_Z_K?_P!"->SDW_(QH?XE^9\[Q%_R)\5_@E^1^?U%%%?T.?R,?JE\-?\
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MU^I]?.<:8AVHX=;:R?Y+]3Z_PWPBOB,8]U:*_-_H%%%%?EQ^WA1110 4444
M%%%% !1110 4444 ?$O[='@Q=,\9Z-XDACVIJENUO.5'66+&&/N491_P"OF.
MOO3]MK1EU#X/Q7FW]YI^HPR[N^U@T9'YLOY"O@NOW7AC$/$99!2WC>/W;?@T
M?R_QMA%A<ZJN*TFE+[]_Q39T'P_\2-X0\<:#K2L5%C>PSOCN@<;A^*Y'XU^J
MN0PR.17Y%5^JOP\U(ZSX!\,Z@QRUUIEM.3[M$I_K7S7&M%?N*R\U^37ZGV?A
MOB'_ +3AWM[LE^*?Z'0T445^7G[:%%%% !1110 4444 %?#'[=G_ "5;1O\
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M^$2\#Z_K0.&L+&:X3/=E0E1^)P/QK\JW9I'9G8LS')+'))]37Z+?M8:F=-^
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M_LS-:<I.T)^[+Y[/Y.WRN?HG1117X*?U.%%%% !1110 4444 %%%% !1110
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M5\0_MW_\E%\/_P#8*'_HZ2OK^%/^1I'T?Y'Y]QW_ ,B2?^*/YGS/7HW[.O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M33**_;\ORW#Y;2]E07J^K]3^:,VSC%YS7]OBI>BZ)>2_7=A1117J'AA1110
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M&UX](M%8?[7DKG]<UR<:-?5Z*_O/\CT/#B+^N8B73E7YG6T445^2'[X%%%%
M!1110 4444 %?#'[=G_)5M&_[ L?_H^>ON>OAC]NS_DJVC?]@6/_ -'SU]EP
MG_R,X^C/SSCS_D2R_P 4?S/G"O>_V*?^2U#_ +!MQ_-*\$KWO]BG_DM0_P"P
M;<?S2OU3.O\ D6U_\+/POAO_ )'&%_QK\S[[HHHK^>3^MSY7_;"^!']L6<OC
MO0K?-];)_P 32WC',L2C F _O*.#ZJ,_P\_&-?KFZ+(K*RAE88*L,@CTK\_O
MVH?@6WPM\3?VMI4!'AC4Y"80HXM9>283[=2OMD?PY/ZKPKG7M(K 8AZKX7Y=
MOET\M.A^%<<\.>RD\UPL?=?QKL_YOGU\]>K/#:^W?V0_CO\ \)3I<?@O7+G.
ML6,?^@3R-S<P*/N$]W0?FO\ NDU\15<T?5[S0=4M-2T^X>TOK619H9HSAD8'
M((K[+-LMIYIAG1GH]T^S_K<_.\ASFMD>,CB:>L=I+NO\^J\S]:J*\W^!7Q@L
M_C%X,BU!=D.KVVV'4+13_JY,?> _N-@D?B.H->D5^ 8BA4PM65&JK2CHS^K\
M+BJ6-H0Q%"5X25T_Z_$^:OV[O^2:Z#_V%U_]$RU\/5]P_MW?\DUT'_L+K_Z)
MEKX>K]HX4_Y%D?5_F?SAQW_R.Y_X8_D=3\*_^2H>#_\ L,6?_H]*_4VORR^%
M?_)4/!__ &&+/_T>E?J;7RW&G\>CZ/\ ,^X\-_\ =L1_B7Y!1117YP?L(444
M4 %%%% !1110!X/^VD[+\$Y0,X;4+<''_ C_ $KX!K]"OVP[$WGP*U:4#/V:
MXMIC[?O53_V>OSUK]HX/:>7/_$_R1_./B#%K-XM]81_.05^K'@.)8? _AV->
M%33K=0/81+7Y3U^I?PIU!=6^&/A.\4Y\[2K5C_O>4N1^>:\[C5/V-!]+O\D>
MMX;R7UC$QZ\L?S9U=%%%?E!^\!1110 4444 %?/7[3WQ^\1?!W5M"L]"M]/E
M6]@DFE:\B>0Y5@ !AEQW]:^A:^,/V]O^1H\*?]><W_H8KZ3AW#TL5F,*5:/-
M%WT?HSXWB[%U\%E%6OAIN,DXZK?XD<Y_PW!\0O\ GTT/_P !)/\ X[1_PW!\
M0O\ GTT/_P !)/\ X[7SW17[!_8>6_\ /B/W'\^_ZS9S_P!!4OO/H3_AN#XA
M?\^FA_\ @))_\=H_X;@^(7_/IH?_ ("2?_':^>Z*/[#RW_GQ'[@_UFSG_H*E
M]Y]"?\-P?$+_ )]-#_\  63_ ..U]P>'-3?6O#VEZC(BQR7=K%<,B]%+H&('
MMS7Y-U^K'@+_ )$7P[_V#;;_ -%+7P7%F7X7!TZ+P]-1NW>WR/U/@/-<=F-7
M$1Q=5S24;7Z:LWJ***_.#]A"BBB@ HHHH **** "OC/]O;_D8O"/_7K/_P"A
MK7V97QG^WM_R,7A'_KUG_P#0UKZSA?\ Y&M/TE_Z2SX/CC_D15O6/_I2/E6B
MBND^''AVV\7>/O#VB7KRQVFH7T-M*T) <*[@$J2",X/<&OW"I45*#G+9*Y_,
MU&G*M4C2AO)I+YG-T5]V?\,,> ?^@GXA_P# J#_XS1_PPQX!_P"@GXA_\"H/
M_C-?(?ZVY9WE]Q^@?ZA9UVC_ .!'PG17W9_PPQX!_P"@GXA_\"H/_C-'_##'
M@'_H)^(?_ J#_P",T?ZVY9WE]P?ZA9UVC_X$?"=%?=G_  PQX!_Z"?B'_P "
MH/\ XS67K/[!_AF:%AI/B/5K.;'#7B17"_DJI_.JCQ9EDG9R:^3(GP)G45=0
MB_22_6Q\3T5ZQ\5OV:_&'PIADO;F"/5M&7KJ%CEEC'_312-R?7D>]>3U]/A\
M51Q=-5:$E*/D?$XO!8G 571Q4'"2Z/\ K7U1[#\!OVB]7^$.H1V5TTFI>%Y7
M_?6+-EH<GF2+/0]RO1O8\C]!-!UZP\4:-9ZMI=TEYI]W&)(9HSPRG^1[$'D$
M$5^35?1W['WQHD\)^*$\(:G.3HVK28M2YXM[D\ #V?A<?WMI]:^)XER*&(IR
MQF'5IQU:_F7^:_$_2^#>)ZF$K1R[%RO2EI%O[+Z+T?X>ES[HHHHK\?/Z#"BB
MB@ HHHH **** "OFG]NYC_PK705YVG5E)^HAE_Q-?2U?.O[<MD;CX2Z;.HSY
M&L1%O93%,O\ ,K7O9"TLSH7[GRO%,7+)<2E_+^J/A.BBBOZ"/Y./USBC6*-$
M7[J@ ?04^LOPSJ2ZQX;TF_0[ENK2&<-ZAD#?UK4K^891<9.+W1_;$)*<5*.S
M"BBBI+"BBB@ HHHH **** "BBB@ K(\71B3PGK2-RK64P/T\MJUZYCXG:DNC
M_#?Q5>L<>1I=S(/J(FP/SQ6U"+E5@EO=?F<V)DH4)RELD_R/RPHHHK^FC^+3
M[T_8A<M\&[@'HNK3@?\ ?N(_UKZ"KPG]B^R-K\$;>4C N;^XE!]<$)_[)7NU
M?SSG33S*O;^9G];\-Q<<GPJ?\B"BBBO%/I HHHH **** "BBB@ HHK*\4>(K
M7PCX<U+6KYMMI86[W$GJ0H)P/<]![FJC%SDHQ5VR)SC3BYS=DM6?''[<'Q"_
MMCQAIWA.VES;:3'Y]RJG@W$@! /^ZF/^_AKYEK4\3>(+OQ9XBU+6;YM]W?W#
MW$I[;F8G ]AG ]A677]%Y;@U@,)3PZZ+7UZ_B?R#G.82S7'U<7+[3T\DM$ON
M'PLB2HSIYB!@63.,CTS7TS:_MT:[96T-O!X5TF*"%%CCC620!5 P .>@%?,=
M%5C,OPN/Y?K,.:VV_P"A.7YMC<KYOJ=3DYK7T6MMMTSZA_X;S\1?]"QI?_?V
M3_&C_AO/Q%_T+&E_]_9/\:^7J*\[_5W*_P#GPOO?^9['^MV>?]!+^Z/^1]0_
M\-Y^(O\ H6-+_P"_LG^->;_&G]H"\^-5AIL&HZ'96$]A*SQ7-N[EMK !D.>Q
M(4_\!KR:BM\/DN7X6HJU&DE);.[_ ,SDQ7$F:XZC+#XBNY0ENK+U[!3D=HV5
MT8JRG(93@@^HIM%>V?-GZ=_!+Q^OQ+^&>BZVSAKQXO)O .TZ?*_';)&X>S"N
M[KXL_8;^(7]F^)-4\'W,N(-23[7:*3TF0?.H]V3G_ME7VG7\^9W@?[/QU2BE
M[KU7H_\ +;Y']9\-YG_:V64L1)WDO=E_B7^>C^84445X1].%%%% !1110 44
M44 %%%% !7Y*ZQ_R%KW_ *[O_P"A&OUJK\E=8_Y"U[_UW?\ ]"-?IO!/Q8C_
M +=_]N/Q7Q*^#"?]O_\ MI3HHK3TOPSK.N1/+INDWVH1HVUGM;9Y0IZX)4'!
MK]1E*,5>3LC\1C"51\L%=F9170?\*]\5?]"SK'_@!+_\31_PKWQ5_P!"SK'_
M ( 2_P#Q-9>WI?SK[T;_ %6O_P ^W]S.?HK6U/PGK>BVXN-1T;4+" L$$MU:
MO&NX]!E@!G@_E636L91FKQ=S&<)4W::LPHHKUKX1_LV^)OB]IXU/3[FPL=)$
MS0O<W$VYPPQD"-<G/(X;&<@USXG%4<)3]K7DHQ[LZ<'@L1F%54,+!SD^B/):
M^B?V>_V6;_QY<6VO>*8)=/\ #2D21V[Y2:^],#JL9[MU(Z=<CWWX7_LE^#_A
M[+#?7ZMXEU>/#+/?(!#&P[I%R,^[%B.V*]PK\VS?BQ3BZ.7Z7^T_T7ZO[NI^
MR9!P&Z<XXC-;.VT%K_X$_P!%IY]""TM(-/M8;6VACM[:%!''#$H544# 4 =
M!4]%%?F6^K/VE))604444#"BBB@ HHHH **** "OB']N_P#Y*+X?_P"P4/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOLO\WT_X8_4>"N'5F5;Z]B8_NH/1?S2_R77N].YHTM%%?C1_104444 %%%%
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M) 50?@N]O8A:_7LPQ<<#A:F(E]E?CT7S9_/V58">9XVE@X?;?W+J_DKLQ/\
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M?#__ &"A_P"CI*^OX4_Y&D?1_D?GW'?_ "))_P"*/YGS/7HW[.O_ "6[P?\
M]?R_^@FO.:]&_9U_Y+=X/_Z_E_\ 037[%F'^YUO\,OR9_/65?\C##_XX_P#I
M2/TPHHHK^;C^Q@HHHH **** "BBB@ HHKF?B/XVM/ASX)U?Q#=E3'90EDC8X
M\V0\1H/]YB!^-:4Z<JLU3@KMNR^9E6JPH4Y5:CM&*;;\EN?#/[7GBI?$WQJU
M&&)P\&E01Z>I'3<H+O\ D\C#\*\5JUJ>I7&L:E=W]W(9KNZE>>:1NK.S%F/X
MDFJM?T?@L.L)AJ=!?921_'68XQX_&5<5+[<F_O>B^2/7?V4] .O?'+P]\FZ*
MS,MY)[!(VVG_ +[*?G7Z,U\B?L'^#2/^$C\52I@$+IMN_P"4DO\ [2_6OKNO
MQ[BS$*OF+@MH)+]7^9_0W >#>%R=5)+6I)R^6R_*_P PHHHKXT_1 HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\+_:"_:8T_P"%<$NCZ,8M1\5.O^K)W168(X:3'5NX3\3@8SR_[1G[
M54/A7[5X9\'7"7&M<QW6I)ADM.Q5.S2>IZ+[GI\57%Q+>7$L\\KSSRL7>21B
MS.Q.223U)-?HF0\-/$6Q6-5H=(]_-^7Y^F_Y#Q3QDL+S8'+97J;2ETCY+N_/
MIZ[6]=U[4/$^K76J:K>2W^H7+[Y;B9LLQ_H.P X &!6?117ZU&*BE&*LD?@L
MI2G)RD[MA1115$!1110 4444 %%%% !16IH/AC6/%-V+71M+O-5N>\=G TI'
MN=HX'N:]G\(?L7^/?$0274Q9^';=N3]KE\R7'LB9&?9B*\_$YAA<&KXBHH^K
MU^[<]7!95CLQ=L)1E/S2T^_;\3P2BON3PK^PWX1TO8^N:IJ&NS#[R1D6T)_!
M<M_X_7K_ (9^#?@CP?L.D>%]-MI4^[.T EE'_;1\M^M?*8GC# TM*,7-_<OQ
MU_ ^\P?A[F=:SQ$XTU_X$_PT_$_.#P[\-_%7BS:=&\.ZGJ*-TD@M7:/\7Q@?
MB:])T']COXEZUM,^G6>CHW1K^\7I[B/>1^5?H1TI:^:K\98N?\&G&/K=O]/R
M/LL-X=8"GKB*LIORM%?J_P 3XWT7]@G49-IU;Q;:VWJEE:-+^3,R_P J[?2?
MV%_!=K@W^L:S?..H1XHD/X;"?UKZ1HKPZO$>:5MZUO1)?DCZ:AP?DE#;#IOS
M;?YNWX'C>F_LC_"_3\;] DO6'\5S>SG]%<#]*Z2Q^ 'PYT\ 1>#=);_KO;B7
M_P!#S7H%%>9/,L;4^.M)_P#;S_S/:IY/EM'^'AH+_MV/^1S-M\,?!UFN+?PG
MH< _Z9Z;"O\ ):T(?">B6W^IT;3XO]RU0?R%:U%<DJU67Q2;^9WQPU"'PP2^
M2*0T73QP+&V'TA7_  I9-'L)/OV-LW^]"I_I5RBHYY=S;V<.QDS>$]#N5Q-H
MVGRCTDM4/\Q67=?"KP7? BX\(:%-G^_IL)/_ *#7545<:]6/PS:^;,986A4^
M.FG\D>;WW[.?PUU)2)?!^GINZ_9PT/\ Z 17*ZI^QI\--0#""RO],)[VMZ[8
M_P"_F^O<J*[J>:8^E\%>2_[>9YM7(\KK_P 3#0?_ &ZOSL?*VM?L%Z1,K'2/
M%=]:'LM[;)/^&5*?RKSKQ#^Q#XZTP,^FWFEZR@Z(DS0R'\' 7_QZONZBO7H\
M49I1WJ*2\TOTL_Q/G\1P3DF(VI.#_NR?Y.Z_ _+SQ1\&_&_@W>VK^%]1MHD^
M].L)EB'_ &T3*_K7&5^NU<5XP^#/@GQV'.M>'+&XF?K<QQ^5/_W\3#'\37TN
M%XTZ8JC\XO\ 1_YGQN-\.-W@L1\I+]5_\B?E]17V-XY_83LYUDG\(Z[):R=5
ML]47>GT$BC('U5OK7S?X^^#/C'X:2,=>T2>WM0<"]B'FV[>G[Q<@9]#@^U?:
MX+.L#C]*-1<W9Z/[GO\ *Y^;9EPYF>57EB:3Y?YEJOO6WSL<31117MGS0444
M4 %%%% !1110 4444 %/1&E9412S,<!5&23Z"F5]"_L=_"8>,_&K>)=0AWZ1
MH;J\88?++='E!_P ?.??9ZUP8[&4\!AYXBIM%?>^B^;/4RS+ZN:8RG@Z.\G]
MRZOY+4^EOV;?@^GPG\!Q"[A4:_J06XOW(Y3CY(?H@)_X$6]J];HHK^>,5B*F
M+K2KU7>4G<_KK!8.CE^'AA:"M&*LO\_5[OS"BBBN4[0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"OVS_ /DB-U_U
M_6__ *$:]UKPK]L__DB-U_U_6_\ Z$:]G)O^1C0_Q+\SYWB+_D3XK_!+\C\_
MJ***_H<_D8_5+X:_\DZ\*_\ 8*M?_1*UTE<W\-?^2=>%?^P5:_\ HE:Z2OYF
MQ'\:?J_S/[1PG^[T_P#"OR"BBBL#J"BBB@ HHHH **** "BBB@ HHHH ****
M $K\T_V@OAPWPQ^*&JZ;'$8]-N&^V6)QQY+DD*/]T[E_X#7Z6UXM^U)\'V^*
M/@1KG3X?,\0:1NGM0H^:9,?O(OJ0 1[J!W-?5\-YDLOQB51VA/1^79_UT9\)
MQCDSS;+G*DKU*?O+S75?-:^J1^>5=9\+_B%??"_QMIWB"PRYMWVSP9P)H6X=
M#]1T]" >U<HRD'!X(XYI*_<*M.%:#IU%>+5F?S-1K5,/5C6I.THNZ?9H_5_P
MGXIT[QMX=L-;TF<7-A>1B2-QU'JI'9@<@CL0:UZ_._\ 9U_: NO@_K!L;\R7
M7A>\DS<0+RUN_3S4'KC&1W ]0*_0+1M9L?$.EVVI:9=17MA<H)(9X6W*ZGN#
M_G%?@N<Y15RJORO6#^%_H_-?\$_J?AWB"CGN&4D[58_%']5Y/\-B]1117SQ]
M:%%%% !1110 4444 %?-G[8/QL3PKX=?P;I-Q_Q.=4CQ>-&>;>V/53Z,_3_=
MR>XKM_CY^T!IGP=T9H(&COO$URA-K8YR(Q_SUEQT4=AU8C [D?GIKFMWWB35
MKO5-3N9+R_NI#+-/(<EF/^> . !BOT#AG(Y8FI'&XA>Y'9=W_DOQ^\_*.-.)
MH8.C++L)*]26DFOLKMZO\%\BA117HOP(^$]Q\7/'MIIFUUTJ BXU"=>-D(/W
M0?[S?='U)[&OUC$5Z>&I2K57:,5=GX-A<+5QM>&'H*\I.R/JG]B_X;MX5^'T
M_B*[BV7VNN'CW#E;9,A/^^B6;W!6OHBH+2UAL;6&VMXEAMX46..-!A44#  '
MH *GK^=L=BYX[$SQ,]Y/[ET7R1_7F5X"&5X*E@Z>T%][ZOYN["BBBN ]0***
M* "BBB@ HHHH *^&/V[/^2K:-_V!8_\ T?/7W/7PQ^W9_P E6T;_ + L?_H^
M>OLN$_\ D9Q]&?GG'G_(EE_BC^9\X5[W^Q3_ ,EJ'_8-N/YI7@E>]_L4_P#)
M:A_V#;C^:5^J9U_R+:_^%GX7PW_R.,+_ (U^9]]T445_/)_6X4444 %?*O[8
M7P'_ +6M)?'>A6^;RW3_ (FEO&O^MC P)@/51PW^R ?X3GZJICHLB,K*'5A@
MJPR"/0UZ678^KEN(CB*73==UU1XV;Y70SC"2PE?KL^SZ-?UJM#\C**]P_:@^
M!;?"SQ/_ &II4!'AC4Y"8-HXM9>K0GVZE?;(_A)KP^OZ"P>+I8ZA'$47>+_J
MWR/Y.S# U\MQ,\+B%:47]_9KR?0]2\5?&:Y\;?!C2/">K,\VI:/J"/!=-SYM
ML(I%"L?[R$@9[@CN"3Y;115T,/3PT7&DK)MOYO<RQ6+K8R49UY7:25_);?@=
M3\*_^2H>#_\ L,6?_H]*_4VORR^%?_)4/!__ &&+/_T>E?J;7Y?QI_'H^C_,
M_;O#?_=L1_B7Y!1117YP?L(4444 %%%% !1110 5\A?MS?#AMVE>-K2+*X%A
M?%1TZF)S_P"/*3[(*^O:Q?&/A6Q\;^%]2T'4T\RSOH6A?U7/1A[J0&'N!7KY
M5CGEV,AB.BW]'O\ UW/ SW*XYQE]3"/=ZQ?:2V_R?DS\HZEM[B6TN(IX)&BF
MB<.DB'#*P.00>Q!K;\>>"M1^'GBW4?#^J)MNK.0IOQA94ZK(OLPP1]:Y^OZ%
MA.%:"G!W3_(_DFI3J4*CIU%:479KLT?I)^S[\8K?XO>"(KB61%UZR"PZC ,
M[\<2 ?W7P3['([5ZE7Y9_#7XCZO\+?%=KKNCR8EC^2:!B=EQ$<;HW'H<?@0#
MU%?HW\+_ (I:)\6/#46KZ/-\PPMS:.1YMM)C[K#^1Z$5^*<0Y)++JKKT5^ZE
M_P"2OMZ=ON/Z2X2XEAF]!8;$2M7BM?[R[KS[_?L=C1117QQ^AA1110 4444
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M/[$P>*IX[#4\32^&:37S_P @HHHKF.P**** "BBB@ HHHH *_)76/^0M>_\
M7=__ $(U^M5?DKK'_(6O?^N[_P#H1K]-X)^+$?\ ;O\ [<?BOB5\&$_[?_\
M;2G7VQ^P;_R(WB7_ +"*_P#HI:^)Z^V/V#?^1&\2_P#817_T4M?2\5?\BN?K
M'\SX[@7_ )'=/TE^3/IZBBBOPT_IL*S/$?A^R\5:#?Z/J47GV-]"T$R?[+#&
M1Z$=0>Q K3HJHR<6I1=FB)QC4BX35T]S\K?B)X(O?ASXSU3P]?@F:SE*K)C
MEC/*./9E(/XXKFZ^WOVTOA/_ ,)%X7@\8Z?#NU#2%\N["CF2U)^]_P  8Y^C
M,>U?$-?T%DV8K,\'&M]K:7JO\]S^3>(LHEDN83P_V'K%_P!U[?=L_0]6_9O^
M*Q^%?Q&M;BYEV:+J&+2_!/"H3\LG_ &Y^A8=Z_1Y6#*"""I&017Y%U]^?LB?
M%?\ X3SP -$OIM^LZ$%@;<?FEM^D3^Y&"I_W03]ZOC^+\LYHQQ]-;:2_1_I]
MQ^A>'^=<LY956>C]Z'KU7Z_?W/>J***_*S]S"BBB@ HHHH **** "BBB@ KX
MA_;O_P"2B^'_ /L%#_T=)7V]7Q#^W?\ \E%\/_\ 8*'_ *.DKZ_A3_D:1]'^
M1^?<=_\ (DG_ (H_F?,]>C?LZ_\ );O!_P#U_+_Z":\YKT;]G7_DMW@__K^7
M_P!!-?L68?[G6_PR_)G\]95_R,,/_CC_ .E(_3"BBBOYN/[&"BBB@ HHHH *
M*** "OA']KOXV1^//$2>&-'N/,T/29"9I8SE;FY&02#W5 2H/<ECR,5Z'^U%
M^TU'ID%WX.\(W8DOG!BU#4H6X@'1HHV'\?8L/N]!S]WXTK]3X7R.5-K'XE6?
MV5^K_3[^Q^&\;<30K)Y7@Y77VVO+[*_7[NX5/9V<^HWD%K;1-/<SR+%'$@RS
MLQP !ZDD5!7U!^QE\&VUO7#XXU2#_B7Z>QCT]9!Q+<=#)[A <#_:/^S7W>8X
MZGEV&EB*G39=WT1^7Y1EM7-\;#"4OM;OLNK^7YZ'U+\(_ 47PT^'>C>'TVF:
MWAW7,B]'F8[I#]-Q('L!78T45_.U6K.M4E5J.[D[OYG]=T*-/#4H4*2M&*27
MHM HHHK(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***@NKJ&PM9KFYFCM[:%#))-*P5$4#)))Z "GOHA-I*[)&81
MJ68A5 R23C%?'W[2'[5IN_M7A;P1=[8.8KS686P9.Q2$CMZN.O;CD\[^T?\
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MSTVRM]/M$^[!:Q+$@^BJ *NT45\PVY.[W/M8Q44HQ5D@HHHI%!1110 4444
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MV_Y&+PC_ ->L_P#Z&M?6<+_\C6GZ2_\ 26?!\<?\B*MZQ_\ 2D?*M=Q\#_\
MDL7@O_L+VW_HQ:X>NE^&WB"U\)_$#P[K5Z)&L]/OX;F41*&?8K@G )&3@>M?
MM6*BYX>I&*NVG^1_-V!G&GBZ4YNR4HM_>C]4:*^?O^&W?AY_SPUK_P !$_\
MCE'_  V[\//^>&M?^ B?_'*_!?[#S+_GQ+[C^I_]9LF_Z"H?>?0-%?/W_#;O
MP\_YX:U_X")_\<H_X;=^'G_/#6O_  $3_P".4?V'F7_/B7W!_K-DW_05#[SZ
M!HKY^_X;=^'G_/#6O_ 1/_CE9>M?MU>$+6%O[,T/6+^?LMP(X$/_  (,Q_\
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M?/N_7Y)!3XHGGE2.-&DD<A511DL3P !ZTZUM9KVXBM[>)YYY6"1Q1J6=V)P
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M7^9_HNGY^84445\T?9A1110 4444 %%%% !1110 4444 %?#'[=G_)5M&_[
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MCS5.LGO\NR]/G<****\ ^J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT7_92\+CPQ\$=#+)LGU$R:A+[[V^0_\ ?M8Z\CBO$_5\N<%O-I?J_P K'T'
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MXK="<E8D"C/K@58HHJ&V]6:))*R"BBBD,**** "BBB@ HHHH **** "BBB@
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M;:%AWCA53^@J[110Y.6[",5'2*L%%%%(H**** "BBB@ HHHH **** "BBB@
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MKX=TI#N73+-3[6Z#^E:-%+VD^X>RI_RK[AD<:0H%C147LJC I]%%0:A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445Q?Q4^*VB?"/PU)JNL2[I&RMK91G][<R8^ZH[#IEN@'X ZT:-2
MO45*E&\GLC#$8BEA:4JU>2C&.K;+'Q*^)>B?"OPS-K.M7&R,?+#;I@RW$F.$
M0=S[] .37YV_%GXN:W\7O$CZGJLGE6\9*VEA&3Y5LGH/5CQENI]A@"M\3_BA
MK?Q8\32ZOK,_JEO:QD^5;1YX5!_,]2:Y"OVS(LAIY7#VM76J^O;R7ZO]#^:^
M*.*:N=5'0H7C06RZR\W^BZ>H4445]>?GX445K>&/"NK>,]:@TG1;&;4-0G.$
MAA'/N2>B@=R>!4RE&$7*3LD:0A*I)0@KM[);LR:^B?@A^R-JWCD6^L>*A-HF
MA-ATM\;;JZ7V!_U:GU/)[#G->U_ S]D_2?AZ+?6/$@AUKQ$N'1"-UM:-_L _
M?8?WB..P&,GZ"K\PSCBO>AE_SE_\C_G]W<_:^'N!%[N)S9>D/_DG^B^;Z&/X
M7\)Z/X+T:'2M#L(=.L(A\L,*XR>[,>K,>Y.2:V***_,I2E.3E)W;/VF$(4XJ
M$%9+9+8****DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBLGQ-XHTKP;HUQJVM7T.G:? ,O/,<#V '4D]@.3VJHQE.2C%7;(G
M.-.+G-V2W;V-:O+OBG^T5X/^%*R6][>?VCK"]-,L2'E!_P!LYPGX\^@-?-?Q
MG_;$UCQ8T^E^#S-H6D'*->]+N<>H(_U8^GS>XSBOG"21I'9W8N[')9CDD^IK
M]&ROA&=1*KCWRK^5;_-]/1:^A^/YYQ]"BW0RM<S_ )WM\EU]7IY-'M?Q(_:U
M\;^.FEM["Y_X1G2VR!;Z>Q$K#_:F^]G_ '=H]J\5DD>:1WD9G=CN9F.22>I)
M[TRBOTS"X/#X.'L\/!17E^O?YGXQC<PQ>8U/:XNHYOSZ>BV7R"BBBNP\X***
M* "BBB@ HHHH **** -#0_$&I^&=0COM)U"YTV\3[L]K*T;CVR#T]J^C?AG^
MVYK6CM%9^,K(:W:< WUJJQ7*CU*\(_\ XZ?<U\Q45YF,RW"YA'EQ$$_/JOGN
M>UEV<8[*9\^$JN/ET?JMOU/U.\"_$CPW\2]+^V>']3AU"(#][".)8L]G0\K^
M(P>V:^%_VH?@[_PJWQTUS80[/#^K%I[0*/EA;/SP_@2"/]E@.QKROP_XCU/P
MIJD.IZ/?SZ;?PGY)[=RK#V/J#W!X/>OH5_CYIGQT^'UUX-\=+!INO;?-TW6P
M ENURH.SS!_RRW<J6^[AB?EP*^0PV48C(<7[?#-SHRTDNJ7?SMY:VOH??XS/
M\)Q3@/JN,BJ>(CK!_9;[7^SS;6>E[._0^;K.UDOKJ&VA7?-,ZQHOJQ. /S-?
MK!H.DQ:!H6G:7!Q#96T=M'_NHH4?H*_-?X&Z VL?&CPEI\L9RFI1R21L.T1\
MQ@?P0U^G%>7QI6O4HT5T3?WZ?H>YX;X;EI8G$M;M1^Y7?YH****_-3]F"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***\\^,OQHT;X-^'3>WS"ZU*<$66G(V'G
M8=S_ '4'=OYG K>A0J8FI&C1C>3V1RXK%4<'1EB,1+EA'=LG^+OQ?T7X/^&V
MU+4W\Z[ERMGI\; 27+CL/11D9;M[D@'\[/B)\1=:^*'B6?6M;N?-G?Y8H5R(
MX(^R(O8#\R<DY-1>//'NL_$CQ)<ZWKET;F[F.%4<1Q)V1%[*/\2<DDUSM?M^
M1Y'3RJGSSUJO=]O)?UJ?S/Q-Q/6SRK[.G[M&.R[^;\^RZ?B%%%%?5'PP445]
M#? ']E/4/B%]FUWQ,LVE^&SAXH?NSWH[;?[B'^]U(Z==PX<9CJ&7TG6Q$K+\
M7Y(]3+LMQ6:UUA\)#FD_N2[M]$>?_!_X&^(?C%JGEZ?']CTJ%@+K5)U/E1^J
MK_??'\(]1D@<U]]?"_X1^'?A+HHL=$M?W\@'VF^F :>X8=V;T]%' ].IKIM#
MT/3_  UI-MIFE6<-C86Z;(K>!=JJ/\?4]2>36A7XIG&?5\TER+W:?1=_7O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ_0#  %=#117XU4J3JR<YN[>[/Z*I4H48*G2C:*T26R"BBBH-0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M7_VXOB$=+\+Z9X1M9=L^J/\ :KI5//D1GY5/LS\_]LS7Q37I?[1GC8^.OC!X
M@O4??:6TWV&VP>/+B^7(]F8,W_ J\TK^@<BP2P. ITVO>:N_5_Y;?(_D_BC,
MGF>:UJJ=XI\L?1:?B[OYA1117OGR@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >U?L?:I_9_QTTB(G O+>XM_P#R$SC]4%?H97Y>
M_!?6AX=^+'A*_9MD<>IP*[>B,X1C_P!\L:_4*OQ[C*ERXRG5[Q_)O_-']"^'
M5?GRZK1ZQG?Y-+_)A1117P!^K!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5X!\?_B3XD\'^,+*QT?4V
MLK9[!)F18D;+F20$Y93V4?E7O]?+?[4G_)0-/_[!<?\ Z-FIK<^;X@JU*.!<
MJ<G%W6SL<S_PO/QS_P!!^3_OQ%_\11_PO/QS_P!!^3_OQ%_\17M/P'\(Z%JW
MPUT^YOM%T^\N6DF#37%K'(YQ(P&21GI7H7_"O_"__0MZ1_X Q?\ Q-.Z/!P^
M4YCB*,*RQ37,D]Y=?F?*G_"\_'/_ $'Y/^_$7_Q%'_"\_'/_ $'Y/^_$7_Q%
M?5?_  K_ ,+_ /0MZ1_X Q?_ !-'_"O_  O_ -"WI'_@#%_\31='1_8>9?\
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MUM_^!2/F3_A?WCS_ *#O_DG;_P#QNC_A?WCS_H._^2=O_P#&Z^F_^%6^$/\
MH6]-_P# =?\ "C_A5OA#_H6]-_\  =?\*+HK^QLU_P"@M_\ @4CYD_X7]X\_
MZ#O_ ))V_P#\;H_X7]X\_P"@[_Y)V_\ \;KZ;_X5;X0_Z%O3?_ =?\*/^%6^
M$/\ H6]-_P# =?\ "BZ#^QLU_P"@M_\ @4CYD_X7]X\_Z#O_ ))V_P#\;K8\
M%?&_QIJGC#0[*[UD3VMU?002QFUA7<C2*I&0@(X)Z&OH/_A5OA#_ *%O3?\
MP'7_  J6S^'/A?3[N&YMO#^GPW$+B2.1+=0R,#D$''!!HNC2GD^:1G&4L4VD
M^\CI****D^W"BBB@#E_B9K5YX<\!ZSJ5A*(;RWAW12%0VT[@,X(P>O>O'O@G
M\6/%/BSQU#IVK:F+NS>"1C']GB3D#(.54&O4_C5_R2[Q#_UP'_H:U\__ +./
M_)3[7_KVF_\ 0:I;'QF9XBM3S7#TX3:B[75W9ZO='UM1114GV84444 %%%%
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M7U!_PK'PC_T+6E_^ J?X4?\ "L?"/_0M:7_X"I_A1='#_8N:?]!;^^1\O_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!SDK]Y:;IMKH]A;V-C;QVEG;H(XH85"JB@8  '05^?\ $'$2PE\+A'>IU?\
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M_H)J[5+6O^0/?_\ 7"3_ -!-!$_A9\6_#'_DHOAK_L(0_P#H8K[?KX@^&/\
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M\"JHGR_$6,^K8-TX_%/3Y=?\OF=_^S#X1^W:]>^()DS#8KY,!(ZRN.2/HO\
MZ&*U_P!J+PCNCT[Q) G*_P"B7) [<E"?_'A^*UZK\+?"8\%^!]-TUEVW.SSK
MGU\UN6'X<+]%%:7C+PW#XN\,:EI$V MU"45C_"_56_!@#^%%]3.GE*_LGZJU
M[S5_^WM_^ >,?LN>+MT6H^&YWY4_:[8$]C@2#\]IQ[M7T#7PWX2URZ^'_CBS
MO9$:.:QN3'<1=]N2LB_7&1]:^W[>XCNH(IHG$D4BAT=>C*1D$?A1(7#>+=;"
MNA/XH:?+I^J):***D^M"BBB@ HHHH **** /B#XG?\E%\2_]A";_ -#-?:6B
M_P#('L/^N$?_ *"*^+?B=_R47Q+_ -A";_T,U]I:+_R![#_KA'_Z"*I[(^$X
M=_WK%>OZLNT445)]V%%%% !1110 4444 %%%% !7QE\9]<E\1_$S66R76WF^
MQ1+Z"/Y2!]6#'\:^S:^(/$!%C\3M1:Y&%BU>0R;O03'-5$^*XHD_84J=]'+7
M^OF?7_@7PK!X+\*Z?I,"J##&#*RC[\AY=OQ.?PQ704G6EJ3[&G3C2@J<%9+1
M!1110:!5>^L;?4K26UNX([FVF7;)%*H96'H0:L44":35F9N@^'].\,Z;'8:7
M:1V5HA)$<>>IZDD\D^YK2HHH%&,8)1BK)!11104%%%% !1110 4444 %%%%
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M?TK[$\,_\BWI/_7I%_Z *^._B[_R4SQ%_P!?;?TK[$\,_P#(MZ3_ ->D7_H
MJGLCX7(/]]Q7K^K-.BBBI/N@HHHH **** .#^.?_ "2G7_\ KG'_ .C4KPO]
MFG_DI0_Z\Y?YK7NGQS_Y)3K_ /USC_\ 1J5X7^S3_P E*'_7G+_-:I;'PF:?
M\CK#?+_TIGUA1114GW84444 %%%% !11368*I). .>: /$?VGO%WV'0K+P_
M^);YO/G ZB)#\H/U;G_@!KG/V7_"/VS5[_Q%,F8[1?LUN2/^6C#YB/<+@?\
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M[#?6[?\ +2%PV/8^A]C6C4GV<91FE*+NF%%%%!04444 %%%% !1110 4444
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M0O\ \31_PU9I_P#T+]S_ .!"_P#Q-'_#*>G_ /0P7/\ X#K_ /%4?\,IZ?\
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M@)??]_$H_P"&JM'_ .@)??\ ?Q*K_P##*-E_T,5Q_P" J_\ Q5'_  RC9?\
M0Q7'_@*O_P 51H5?B+LO_)2Q_P -5:/_ - 2^_[^)7IW@/QI;^/?#L6KVUO+
M;1.[1^7,02"IQVKRG_AE&R_Z&*X_\!5_^*KU/X?^"XO /AJ+2(;I[Q8Y'D\Y
MU"DECGH*3MT/4RUYM[9_7DN2WEO\CIJ***1],%%%% !1110!Q/QJ_P"27>(?
M^N _]#6OG_\ 9Q_Y*?:_]>TW_H-?0'QJ_P"27>(?^N _]#6OG_\ 9Q_Y*?:_
M]>TW_H-4MCX3-O\ D<87Y?\ I3/K:BBBI/NPHHHH **** .#^.?_ "2G7_\
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MPQI&HPJ *H]A3ZCAF2>%)4.4=0RGV/-25)]RMM HHHH&%%%% !1110 4444
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M ^]^A^=]%%%?T(?R6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]?;?TK[$\,_\BWI/_7I%_P"@"J>R/A<@_P!]Q7K^K-.BBBI/N@HHHH ****
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MP_ZX1_\ H(JGLCX3AW_>L5Z_JR[1114GW84444 %%%% !1110 4444 %%%%
M!1110 4444 4-9T6Q\0:?+8ZE:QWEI*,-%*,CZCT(]1R*^4OC%\()OAY>+>6
M1>XT.X?;'(W+0MUV,?Y'OC\_KRL?Q9X=@\6>'-0TFY4&.ZB9 2/NMU5OJ" ?
MPIIV/#S7+*>847I[ZV?Z>AY;^SK\3)?$6GR>'M2F,M]91[[>5S\TD(P-I]2N
M1^!]J]JKXG^%NH3^'OB9H3C*2?;4MI%]G;RV!_!C^5?;%-G'P]C)XK"<E35P
M=OET_P @HHHJ3Z@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBHIIH[>&2:618HHU+O(Y 55 R22>@Q0&Q+7@GQ_P#VH=-^&,<^
MBZ"8M4\4$;7&=T-E[R8ZOZ)^>.A\Y^/W[7S7'VGP_P" K@I'S'<:XO!;L5@]
M!_TT_P"^>S5\FR2-)(SNQ=V.YF8Y))[FOTG(^%W4MB<>K+I'OZ_Y?>?C?$W&
M\:/-@\JE>6SGT7^'N_/;M?=7M?\ $&I>*M7N=4U:\FU#4+EM\MQ,V68_T Z
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M_IU\.HHK38_(<9C:V.JNK6>OX+T"BBB@X HHHH **** "BBB@ HHHH ****
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M97AW_D7],_Z]8O\ T 5HUG>'?^1?TS_KUB_] %:-2?9T_@CZ!1110:!1110
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M%% 'S#^U-_R.FE?]@\?^C'KU+]G7_DEMA_UVF_\ 1AKRW]J;_D=-*_[!X_\
M1CUZE^SK_P DML/^NTW_ *,-4]CX7 _\CZOZ/_VT],HHHJ3[H**** "BBB@
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M5S&KNW9?K]RLAU%%%2?=A1110 4444 <C\4O"0\:>!]2TY$WW03SK;U\U.5
M^O*_\"-?+7PC\7'P5X\T^\E?R[65OLUSG@>6Y )/^Z<-_P !K[3KXY^.7A'_
M (1/X@7HB3;9WW^F0<<#<3N7\&#<>A%4NQ\/Q%1E1G2S"EO%V?YK]4?8U%<)
M\%_%W_"8> ;">1]]Y:C[)<9Z[D PQ^J[3]2:[NI/L:%:.(I1K0VDKA1110;A
M1110!\0?$[_DHOB7_L(3?^AFOM+1?^0/8?\ 7"/_ -!%?%OQ._Y*+XE_["$W
M_H9K[2T7_D#V'_7"/_T$53V1\)P[_O6*]?U9=HHHJ3[L**** "BBB@ HHHH
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MT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /ZBJ9\9D>'K4L7B95(-)O2Z:OJ]B_1114GV84444 %%%% '!_'/_DE.O_\
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M3G[2"G:UU?7<****#0**** .8^)W_).O$O\ V#YO_0#7S%\ ?^2M:%_VW_\
M2>2OJ7QYIMQK'@O7+&TC\ZZN+*6**/(&YBI &3QU]:\$^#GPK\5>'?B-I.I:
MEI$EI90><9)6D0[<PNHX#$]6%4MCXO-J%6IF6%G"#:35VEHO>ZGTU1114GV@
M4444 %%%% !1110!SGQ(_P"2>^)O^P;<_P#HIJ^6O@3_ ,E8T#_>E_\ 1+U]
M6^-M/N-6\&Z[96J>;=7-C/%%'D#<[1L ,GCDFOGWX0_"GQ7X?^(FD:CJ.D26
MME 9#)*TB$+F)U'1L]2*I;'Q><4*M3,<+.$&TFKM)Z>\MSZ=HHHJ3[0****
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MJC_A1_CC_H 3?]_8_P#XJBR#^W,Q_P"@1_=+_(^KO^%@>%_^ADTC_P #HO\
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M['_\51_PH_QQ_P! ";_O['_\519'J_VYF7_0*_NE_D?5G_"Q/"G_ $,VC_\
M@?%_\51_PL3PI_T,VC_^!\7_ ,57RG_PH_QQ_P! ";_O['_\51_PH_QQ_P!
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MPRZOEM9T:Z]'T:[H_J+*<WPN<X=8C#/U75/L_P"K,6BBBO,/;"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_GU'%0U8_7LGS:&84U";M46Z[^:_K0W****D^C"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH KWUC;ZE:36EW!'=6LR&.6&9 R.I&""#P0:^.?CM
M^Q[<Z4UQKG@2)[RQY>71LEI8O4PD\NO^R?F]-W;[.HKULNS3$Y74]I0>CW3V
M?]=SP,XR3!YW1]EBHZK:2W7I_EL?D9+&\$CQR(T<B$JR,,$$=01VIE?HY\7O
MV;?"WQ:62ZDB_LC7B/EU.T09<]O-3@2#\FXZU\7?%#]GWQA\*9))=1L#>Z2I
M^75+(&2''^UW0_[P'L37['E?$&$S)*-^6?\ *_T?7\_(_GC.^$\PR=N?+STO
MYE_[<NGY>9YI1117TY\4%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %6M-U2\T:_@OK"ZFLKR!M\5Q;N4=&]01R*JT
M4FE)6949.+3B[,^M/A!^VM) (-,\>PF:,85=9M8_G'O+&.O^\G/^R>M?6&@>
M(M,\5:7%J.CW]OJ5C+]RXMI ZGVR.A]0>17Y-UT?@GXA^(OAWJ7V[P]JMQIL
MQQO6,YCE [.ARK#ZBO@LTX3P^);J81\DNWV7_E\ON/U+)>/,5@DJ.8+VL._V
ME_\ )?/7S/U3HKY7^&?[<&FZ@L5GXUT\Z9<<+_:5@ID@/NT?++^&[Z"OI/P[
MXHTCQ=IJ7^BZE:ZI9M_RVM90X!]#CH?8\U^8XW+,7E\K8B#2[]'\]C]LRW.L
M!FT>;"55)]MI+U3U_0U:***\L]L**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI>'_ .?S^Y!_Q$C%_P#0/'[V?J/_ ,+B\!_]#OX<_P#!M;__ !='_"XO ?\
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M1CR/^[M]VWW6/N\OXVS? VC.:J1_O:O[U9_?<_4?_A<7@/\ Z'?PY_X-K?\
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M2\/_ ,_G]R#_ (B1B_\ H'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/^%Q> _\
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M_P"%Q> _^AW\.?\ @VM__BZ_+BBC_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\
MA<7@/_H=_#G_ (-K?_XNC_A<7@/_ *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/
M^(D8O_H'C][/U'_X7%X#_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XN
MORXHH_U+P_\ S^?W(/\ B)&+_P"@>/WL_4?_ (7%X#_Z'?PY_P"#:W_^+H_X
M7%X#_P"AW\.?^#:W_P#BZ_+BBC_4O#_\_G]R#_B)&+_Z!X_>S]1_^%Q> _\
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M_/Y_<@_XB1B_^@>/WL_4?_A<7@/_ *'?PY_X-K?_ .+H_P"%Q> _^AW\.?\
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M .+K\N**/]2\/_S^?W(/^(D8O_H'C][/U'_X7%X#_P"AW\.?^#:W_P#BZ/\
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M (B1B_\ H'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/^%Q> _\ H=_#G_@VM_\
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MG_@VM_\ XNC_ (7%X#_Z'?PY_P"#:W_^+K\N**/]2\/_ ,_G]R#_ (B1B_\
MH'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/^%Q> _\ H=_#G_@VM_\ XNORXHH_
MU+P__/Y_<@_XB1B_^@>/WL_4?_A<7@/_ *'?PY_X-K?_ .+H_P"%Q> _^AW\
M.?\ @VM__BZ_+BBC_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\ A<7@/_H=_#G_
M (-K?_XNC_A<7@/_ *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/^(D8O_H'C][/
MU'_X7%X#_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XNORXHH_U+P_\
MS^?W(/\ B)&+_P"@>/WL_4?_ (7%X#_Z'?PY_P"#:W_^+H_X7%X#_P"AW\.?
M^#:W_P#BZ_+BBC_4O#_\_G]R#_B)&+_Z!X_>S]1_^%Q> _\ H=_#G_@VM_\
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M_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XNORXHH_U+P_\ S^?W(/\
MB)&+_P"@>/WL_4?_ (7%X#_Z'?PY_P"#:W_^+H_X7%X#_P"AW\.?^#:W_P#B
MZ_+BBC_4O#_\_G]R#_B)&+_Z!X_>S]1_^%Q> _\ H=_#G_@VM_\ XNC_ (7%
MX#_Z'?PY_P"#:W_^+K\N**/]2\/_ ,_G]R#_ (B1B_\ H'C][/U'_P"%Q> _
M^AW\.?\ @VM__BZ/^%Q> _\ H=_#G_@VM_\ XNORXHH_U+P__/Y_<@_XB1B_
M^@>/WL_4?_A<7@/_ *'?PY_X-K?_ .+H_P"%Q> _^AW\.?\ @VM__BZ_+BBC
M_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\ A<7@/_H=_#G_ (-K?_XNC_A<7@/_
M *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/^(D8O_H'C][/U'_X7%X#_P"AW\.?
M^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XNORXHH_U+P_\ S^?W(/\ B)&+_P"@
M>/WL_4?_ (7%X#_Z'?PY_P"#:W_^+H_X7%X#_P"AW\.?^#:W_P#BZ_+BBC_4
MO#_\_G]R#_B)&+_Z!X_>S]1_^%Q> _\ H=_#G_@VM_\ XNC_ (7%X#_Z'?PY
M_P"#:W_^+K\N**/]2\/_ ,_G]R#_ (B1B_\ H'C][/U'_P"%Q> _^AW\.?\
M@VM__BZ/^%Q> _\ H=_#G_@VM_\ XNORXHH_U+P__/Y_<@_XB1B_^@>/WL_4
M?_A<7@/_ *'?PY_X-K?_ .+H_P"%Q> _^AW\.?\ @VM__BZ_+BBC_4O#_P#/
MY_<@_P"(D8O_ *!X_>S]1_\ A<7@/_H=_#G_ (-K?_XNC_A<7@/_ *'?PY_X
M-K?_ .+K\N**/]2\/_S^?W(/^(D8O_H'C][/U'_X7%X#_P"AW\.?^#:W_P#B
MZ/\ A<7@/_H=_#G_ (-K?_XNORXHH_U+P_\ S^?W(/\ B)&+_P"@>/WL_4?_
M (7%X#_Z'?PY_P"#:W_^+H_X7%X#_P"AW\.?^#:W_P#BZ_+BBC_4O#_\_G]R
M#_B)&+_Z!X_>S]1_^%Q> _\ H=_#G_@VM_\ XNC_ (7%X#_Z'?PY_P"#:W_^
M+K\N**/]2\/_ ,_G]R#_ (B1B_\ H'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/
M^%Q> _\ H=_#G_@VM_\ XNORXHH_U+P__/Y_<@_XB1B_^@>/WL_4?_A<7@/_
M *'?PY_X-K?_ .+H_P"%Q> _^AW\.?\ @VM__BZ_+BBC_4O#_P#/Y_<@_P"(
MD8O_ *!X_>S]1_\ A<7@/_H=_#G_ (-K?_XNC_A<7@/_ *'?PY_X-K?_ .+K
M\N**/]2\/_S^?W(/^(D8O_H'C][/U'_X7%X#_P"AW\.?^#:W_P#BZ/\ A<7@
M/_H=_#G_ (-K?_XNORXHH_U+P_\ S^?W(/\ B)&+_P"@>/WL_4?_ (7%X#_Z
M'?PY_P"#:W_^+H_X7%X#_P"AW\.?^#:W_P#BZ_+BBC_4O#_\_G]R#_B)&+_Z
M!X_>S]1_^%Q> _\ H=_#G_@VM_\ XNC_ (7%X#_Z'?PY_P"#:W_^+K\N**/]
M2\/_ ,_G]R#_ (B1B_\ H'C][/U'_P"%Q> _^AW\.?\ @VM__BZ/^%Q> _\
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M_P"%Q> _^AW\.?\ @VM__BZ_+BBC_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\
MA<7@/_H=_#G_ (-K?_XNC_A<7@/_ *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/
M^(D8O_H'C][/U'_X7%X#_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XN
MORXHH_U+P_\ S^?W(/\ B)&+_P"@>/WL_4?_ (7%X#_Z'?PY_P"#:W_^+H_X
M7%X#_P"AW\.?^#:W_P#BZ_+BBC_4O#_\_G]R#_B)&+_Z!X_>S]1_^%Q> _\
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M_/Y_<@_XB1B_^@>/WL_4?_A<7@/_ *'?PY_X-K?_ .+H_P"%Q> _^AW\.?\
M@VM__BZ_+BBC_4O#_P#/Y_<@_P"(D8O_ *!X_>S]1_\ A<7@/_H=_#G_ (-K
M?_XNC_A<7@/_ *'?PY_X-K?_ .+K\N**/]2\/_S^?W(/^(D8O_H'C][/U'_X
M7%X#_P"AW\.?^#:W_P#BZ/\ A<7@/_H=_#G_ (-K?_XNORXHH_U+P_\ S^?W
M(/\ B)&+_P"@>/WL_4NT^*W@G4+J&UM?&&@7%S,ZQQ0PZG SR.3A550V222
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-TZL7&2Z-6844459D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '5_"7_ )*IX,_[#5E_Z/2OU+K\M/A+_P E4\&?]AJR_P#1Z5^I=?DW
M&G\>CZ/\S]Z\-_\ =<1_B7Y!1117YP?L)S?Q&_Y$S5/^N5?F9XX_Y&*Z_P!X
MT45^H\&;5#\0\1?BH^A@4445^GGXF%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '5_"7_ )*IX,_[#5E_Z/2OU+HHK\FXT_CT?1_F?O7A
*O_NN(_Q+\C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>lbph-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-05T15:44:00.1519+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.longboardpharma.com/20220331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:lbph="http://www.longboardpharma.com/20220331" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lbph-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lbph-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lbph-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lbph-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" id="StatementCondensedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Condensed Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" id="StatementCondensedBalanceSheetsUnauditedParenthetical">
        <link:definition>100030 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" id="StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100040 - Statement - Condensed Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" id="StatementCondensedStatementsOfCashFlowsUnaudited">
        <link:definition>100050 - Statement - Condensed Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>100060 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure -  Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100080 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestments" id="DisclosureShorttermInvestments">
        <link:definition>100090 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpenses" id="Role_DisclosureAccruedOtherExpenses">
        <link:definition>100100 - Disclosure - Accrued Other Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" id="DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100110 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc" id="Role_DisclosureAgreementsWithArenaPharmaceuticalsInc">
        <link:definition>100120 - Disclosure - Agreements with Arena Pharmaceuticals, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100130 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefits" id="Role_DisclosureEmploymentBenefits">
        <link:definition>100150 - Disclosure - Employment Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100160 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100170 - Disclosure -  Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>100180 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsTables" id="DisclosureShorttermInvestmentsTables">
        <link:definition>100190 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables" id="Role_DisclosureAccruedOtherExpensesTables">
        <link:definition>100200 - Disclosure - Accrued Other Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" id="DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables">
        <link:definition>100210 - Disclosure - Convertible Preferred Stock and Stockholder's Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables" id="DisclosureAgreementsWithArenaPharmaceuticalsIncTables">
        <link:definition>100220 - Disclosure - Agreements with Arena Pharmaceuticals, Inc (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100230 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100240 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100250 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" id="DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails">
        <link:definition>100280 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" id="DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails">
        <link:definition>100290 - Disclosure - Short-Term Investments - Summary of Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" id="DisclosureShorttermInvestmentsAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Short-Term Investments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" id="DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails">
        <link:definition>100310 - Disclosure - Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" id="Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails">
        <link:definition>100320 - Disclosure - Accrued Other Expenses - Summary of Accrued Other Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails" id="DisclosureAccruedOtherExpensesAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Accrued Other Expenses (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta" id="DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta">
        <link:definition>100350 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" id="Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" id="DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails">
        <link:definition>100370 - Disclosure - Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" id="DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions">
        <link:definition>100400 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" id="DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper">
        <link:definition>100410 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails">
        <link:definition>100430 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails">
        <link:definition>100440 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails">
        <link:definition>100450 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" id="Role_DisclosureEmploymentBenefitsAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Employment Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_AccruedComputerRelatedExpenses" name="AccruedComputerRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AccruedLegalAndAccountingFeesCurrent" name="AccruedLegalAndAccountingFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AccruedRecruitmentFeesCurrent" name="AccruedRecruitmentFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AccruedTaxes" name="AccruedTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AreaOfOfficeSpace" name="AreaOfOfficeSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_DefinedContributionPlanArenaMatchingContributions" name="DefinedContributionPlanArenaMatchingContributions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_EffectiveLeaseDate" name="EffectiveLeaseDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" name="EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" name="EmployeeStockPurchasePlanMaximumOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" name="EmployeeStockPurchasePlanMaximumSharesPurchasedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" name="EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" name="IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" name="IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_InitialPublicOfferingCostsInAccountsPayable" name="InitialPublicOfferingCostsInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_InitialPublicOfferingCostsInAccruedOtherExpenses" name="InitialPublicOfferingCostsInAccruedOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_NumberOfCommonStockSharesIssuedAndSold" name="NumberOfCommonStockSharesIssuedAndSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lbph_NumberOfSecurities" name="NumberOfSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_PaymentsForRentHistorical" name="PaymentsForRentHistorical" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_PercentageOfIncreaseInRent" name="PercentageOfIncreaseInRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_PercentageOfSharesOfCommonStockOutstanding" name="PercentageOfSharesOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lbph_RenewOfSuccessiveAgreementTerm" name="RenewOfSuccessiveAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShortTermInvestmentsAndCashEquivalents" name="ShortTermInvestmentsAndCashEquivalents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_ArenaPharmaceuticalsIncMember" name="ArenaPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" name="ArenaTwoThousandSeventeenLongTermIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_NonVotingMember" name="NonVotingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_PostSplitMember" name="PostSplitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_PreSplitMember" name="PreSplitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_RestrictedStockAwardsIssuedButUnvestedMember" name="RestrictedStockAwardsIssuedButUnvestedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" name="SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" name="TwoThousandAndTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_VotingMember" name="VotingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_DeferredFinancingCostsPolicyTextBlock" name="DeferredFinancingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShortTermInvestmentsPolicyTextBlock" name="ShortTermInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" name="TemporaryEquityAndStockholdersEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>lbph-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-05T15:44:02.2734+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShortTermInvestmentsAndCashEquivalents" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="us-gaap_PartnersCapitalAccountContributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" xlink:label="ck0001832168_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedResearchAndDevelopmentExpenses" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_NumberOfSecurities" xlink:label="lbph_NumberOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" xlink:label="ck0001832168_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RenewOfSuccessiveAgreementTerm" xlink:label="lbph_RenewOfSuccessiveAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_InitialPublicOfferingCostsInAccruedOtherExpenses" xlink:label="ck0001832168_InitialPublicOfferingCostsInAccruedOtherExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DeferredFinancingCostsPolicyTextBlock" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_InitialPublicOfferingCostsInAccountsPayable" xlink:label="ck0001832168_InitialPublicOfferingCostsInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_NonVotingMember" xlink:label="ck0001832168_NonVotingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" xlink:label="ck0001832168_EmployeeStockPurchasePlanMaximumSharesPurchasedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PercentageOfSharesOfCommonStockOutstanding" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AreaOfOfficeSpace" xlink:label="lbph_AreaOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RestrictedStockAwardsIssuedButUnvestedMember" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PostSplitMember" xlink:label="lbph_PostSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_VotingMember" xlink:label="ck0001832168_VotingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedRecruitmentFeesCurrent" xlink:label="lbph_AccruedRecruitmentFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_WeightedAverageRemainingLeaseTermAbstract" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedLegalAndAccountingFeesCurrent" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PreSplitMember" xlink:label="lbph_PreSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RisksAndUncertaintiesPolicyTextBlock" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DefinedContributionPlanArenaMatchingContributions" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_WorkingCapital" xlink:label="lbph_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="ck0001832168_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInsuranceCurrentAndNoncurrent" xlink:label="us-gaap_AccruedInsuranceCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedComputerRelatedExpenses" xlink:label="lbph_AccruedComputerRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OptionsToPurchaseCommonStockMember" xlink:label="lbph_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EffectiveLeaseDate" xlink:label="lbph_EffectiveLeaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PercentageOfIncreaseInRent" xlink:label="lbph_PercentageOfIncreaseInRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedTaxes" xlink:label="lbph_AccruedTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PaymentsForRentHistorical" xlink:label="lbph_PaymentsForRentHistorical"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShortTermInvestmentsPolicyTextBlock" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_WeightedAverageDiscountRateAbstract" xlink:label="lbph_WeightedAverageDiscountRateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:label="ck0001832168_NumberOfCommonStockSharesIssuedAndSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" xlink:label="ck0001832168_EmployeeStockPurchasePlanMaximumOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiry date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock award, Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short Term Investments And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employment Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Exchanged During Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending Balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning Balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arena Pharmaceuticals, Inc. capital contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partners' Capital Account, Contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, depreciation method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment Depreciation Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Depreciation Methods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, shares purchase price as a percentage of market fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Shares Purchase Price As Percentage Of Market Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan, shares purchase price as a percentage of market fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remining Contractual Term, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share based payment award, options forfeitures in period, weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, eligible earnings contribution, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Eligible Earnings Contribution Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan, eligible earnings contribution, percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock available for conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arena Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arena Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arena Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Grant Date Fair Values and Weighted Average Assumptions used to calculate Fair Value of Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RenewOfSuccessiveAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Renew of successive agreement term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RenewOfSuccessiveAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Renew Of Successive Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RenewOfSuccessiveAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renew of successive agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_InitialPublicOfferingCostsInAccruedOtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs in accrued other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_InitialPublicOfferingCostsInAccruedOtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Costs In Accrued Other Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_InitialPublicOfferingCostsInAccruedOtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering costs in accrued other expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fixed maturity securities, available for sale, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, liquidation preference, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at the end of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at the beginning of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Financing Costs Policy Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Financing Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Related Party Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable includes related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_InitialPublicOfferingCostsInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_InitialPublicOfferingCostsInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Costs In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_InitialPublicOfferingCostsInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering costs in accounts payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProFormaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pro Forma [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProFormaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro Forma</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_NonVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Voting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_NonVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Voting Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, basis of valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Basis of Valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment Basis of Valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury and Government [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government and agency securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums on investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of premiums on investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future rent payment per month for first year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanMaximumSharesPurchasedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, maximum shares purchased, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanMaximumSharesPurchasedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Maximum Shares Purchased Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanMaximumSharesPurchasedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan, maximum shares purchased, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Other Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Financial Assets Recognized at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of shares of common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares of common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during conversion of convertible securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government and agency securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance , Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, subject to early exercise provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Early Exercise Provision Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options subject to early exercise provision, exercisable number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in-capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Office Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use lease liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Other Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards, Issued But Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock awards, issued but unvested [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards Issued But Unvested [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed maturity securities, available for sale, due after one year through three years, amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed maturity securities, available for sale, due after one year through three years, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per share, Options outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per share, Options outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Options outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Options outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PostSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post split.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PostSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Split [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PostSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Proceeds from Initial Public Offering(IPO)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Contributed Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from contributed capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Unrealized Loss Position, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock in association with initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreements with Arena Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, vested stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholder&#8217;s equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_VotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_VotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Voting Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on short-term investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrealized Gain (Loss) on Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total assets measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total amount financed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total amount financed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Employee-related Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedRecruitmentFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued recruiting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedRecruitmentFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Recruitment Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedRecruitmentFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for recruitment fees received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment Estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company Provides Safe Harbor Contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use assets and lease liabilities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Right-Of-Use Assets and Lease Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in operating right-of-use assets and lease liabilities, net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining lease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity and stockholders equity disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity And Stockholders Equity Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Conversion Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, conversion basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend rate, per-dollar-amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and shareholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed maturity securities, available for sale, due in one year or less, amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arena two thousand seventeen long term incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arena Two Thousand Seventeen Long Term Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arena 2017 LTIP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Legal and Accounting Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for legal and accounting fees received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal and accounting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting rights percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award expiration term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remained to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental balance sheet information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, liquidation preference, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock award, Grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDiscountOnShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount and Commissions Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDiscountOnShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Discount on Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain/(Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PreSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre split.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PreSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Split [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PreSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Voting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvoting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in Years) [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and Uncertainties Policy Text Block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed maturity securities, available for sale, due in one year or less, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock award, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Arena Matching Contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined Contribution Plan Arena Matching Contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for lease obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for lease obligations:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right of Use Assets Obtained in Exchange for Lease Obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Equity Incentive Plan member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInsuranceCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance premium finance liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInsuranceCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedComputerRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued computer related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedComputerRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued computer related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedComputerRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued computer related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated grant date fair value per share of award granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Pension and Other Postretirement Benefits Cost (Reversal of Cost), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses Related To Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining contractual term, options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining contractual term, options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options Vested and Expected to Vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options exercised in period, weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued compensation and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Salaries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturity of the Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forward stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll Taxes, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost not yet recognized, period for recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EffectiveLeaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective lease date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EffectiveLeaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Lease Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EffectiveLeaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective lease date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Series A convertible preferred stock financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Long-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfIncreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfIncreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Increase in Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfIncreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in rent by second year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued consulting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Contractual Term, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining contractual term, options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining contractual term for option awards granted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity, Beginning balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, subject to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and investment securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PaymentsForRentHistorical_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Historical rent paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PaymentsForRentHistorical_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Rent Historical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PaymentsForRentHistorical_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments For Rent Historical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-Term Investments [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Services Expensed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Operating Cost and Expense, by Component [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Income (Expense), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party amounts related to accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Related Parties, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_NumberOfCommonStockSharesIssuedAndSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Stock Shares Issued and Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_NumberOfCommonStockSharesIssuedAndSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock Shares issued and sold.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Preferred Stock (on an as-converted to common stock basis) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock On As Converted To Common Stock Basis [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock On As Converted To Common Stock Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, maximum offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Maximum Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ck0001832168_EmployeeStockPurchasePlanMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan, maximum offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Conversion of convertible preferred stock to common stock in association with initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShortTermInvestmentsAndCashEquivalents" xlink:to="lbph_ShortTermInvestmentsAndCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:to="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountContributions" xlink:to="us-gaap_PartnersCapitalAccountContributions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" xlink:to="ck0001832168_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" xlink:to="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedResearchAndDevelopmentExpenses" xlink:to="lbph_AccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_NumberOfSecurities" xlink:to="lbph_NumberOfSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" xlink:to="ck0001832168_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ArenaPharmaceuticalsIncMember" xlink:to="lbph_ArenaPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_RenewOfSuccessiveAgreementTerm" xlink:to="lbph_RenewOfSuccessiveAgreementTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_InitialPublicOfferingCostsInAccruedOtherExpenses" xlink:to="ck0001832168_InitialPublicOfferingCostsInAccruedOtherExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DeferredFinancingCostsPolicyTextBlock" xlink:to="lbph_DeferredFinancingCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_GrossProceedsFromIssuanceOfCommonStock" xlink:to="lbph_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_InitialPublicOfferingCostsInAccountsPayable" xlink:to="ck0001832168_InitialPublicOfferingCostsInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProFormaMember" xlink:to="srt_ProFormaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_NonVotingMember" xlink:to="ck0001832168_NonVotingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" xlink:to="ck0001832168_EmployeeStockPurchasePlanMaximumSharesPurchasedValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PercentageOfSharesOfCommonStockOutstanding" xlink:to="lbph_PercentageOfSharesOfCommonStockOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" xlink:to="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AreaOfOfficeSpace" xlink:to="lbph_AreaOfOfficeSpace_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_RestrictedStockAwardsIssuedButUnvestedMember" xlink:to="lbph_RestrictedStockAwardsIssuedButUnvestedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:to="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:to="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PostSplitMember" xlink:to="lbph_PostSplitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_VotingMember" xlink:to="ck0001832168_VotingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedRecruitmentFeesCurrent" xlink:to="lbph_AccruedRecruitmentFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:to="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lbph_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" xlink:to="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedLegalAndAccountingFeesCurrent" xlink:to="lbph_AccruedLegalAndAccountingFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDiscountOnShares" xlink:to="us-gaap_CommonStockDiscountOnShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PreSplitMember" xlink:to="lbph_PreSplitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lbph_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:to="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DefinedContributionPlanArenaMatchingContributions" xlink:to="lbph_DefinedContributionPlanArenaMatchingContributions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_WorkingCapital" xlink:to="lbph_WorkingCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="ck0001832168_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInsuranceCurrentAndNoncurrent" xlink:to="us-gaap_AccruedInsuranceCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedComputerRelatedExpenses" xlink:to="lbph_AccruedComputerRelatedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_OptionsToPurchaseCommonStockMember" xlink:to="lbph_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="ck0001832168_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_EffectiveLeaseDate" xlink:to="lbph_EffectiveLeaseDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermInvestments" xlink:to="us-gaap_OtherLongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PercentageOfIncreaseInRent" xlink:to="lbph_PercentageOfIncreaseInRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedTaxes" xlink:to="lbph_AccruedTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PaymentsForRentHistorical" xlink:to="lbph_PaymentsForRentHistorical_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShortTermInvestmentsPolicyTextBlock" xlink:to="lbph_ShortTermInvestmentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_WeightedAverageDiscountRateAbstract" xlink:to="lbph_WeightedAverageDiscountRateAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_NumberOfCommonStockSharesIssuedAndSold" xlink:to="ck0001832168_NumberOfCommonStockSharesIssuedAndSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" xlink:to="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_SeriesAConvertiblePreferredStockMember" xlink:to="lbph_SeriesAConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ck0001832168_EmployeeStockPurchasePlanMaximumOfferingPeriod" xlink:to="ck0001832168_EmployeeStockPurchasePlanMaximumOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>lbph-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-05T15:44:02.7368+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" xlink:href="lbph-20220331.xsd#StatementCondensedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2" xlink:href="lbph-20220331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="lbph-20220331.xsd#StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" xlink:href="lbph-20220331.xsd#StatementCondensedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:href="lbph-20220331.xsd#DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:href="lbph-20220331.xsd#DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="lbph-20220331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:href="lbph-20220331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="lbph_AccruedResearchAndDevelopmentExpenses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherLongTermInvestments" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedResearchAndDevelopmentExpenses" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries" order="11" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lbph_AccruedRecruitmentFeesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lbph_AccruedTaxes" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lbph_AccruedComputerRelatedExpenses" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lbph_AccruedLegalAndAccountingFeesCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedRecruitmentFeesCurrent" xlink:label="lbph_AccruedRecruitmentFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedTaxes" xlink:label="lbph_AccruedTaxes"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedComputerRelatedExpenses" xlink:label="lbph_AccruedComputerRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedLegalAndAccountingFeesCurrent" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>lbph-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-05T15:44:02.4379+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="lbph-20220331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" xlink:href="lbph-20220331.xsd#StatementCondensedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" xlink:href="lbph-20220331.xsd#StatementCondensedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="lbph-20220331.xsd#StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" xlink:href="lbph-20220331.xsd#StatementCondensedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:href="lbph-20220331.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lbph-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="lbph-20220331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestments" xlink:href="lbph-20220331.xsd#DisclosureShorttermInvestments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpenses" xlink:href="lbph-20220331.xsd#Role_DisclosureAccruedOtherExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="lbph-20220331.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc" xlink:href="lbph-20220331.xsd#Role_DisclosureAgreementsWithArenaPharmaceuticalsInc" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="lbph-20220331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="lbph-20220331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefits" xlink:href="lbph-20220331.xsd#Role_DisclosureEmploymentBenefits" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lbph-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="lbph-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="lbph-20220331.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:href="lbph-20220331.xsd#DisclosureShorttermInvestmentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables" xlink:href="lbph-20220331.xsd#Role_DisclosureAccruedOtherExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" xlink:href="lbph-20220331.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables" xlink:href="lbph-20220331.xsd#DisclosureAgreementsWithArenaPharmaceuticalsIncTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="lbph-20220331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="lbph-20220331.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:href="lbph-20220331.xsd#DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:href="lbph-20220331.xsd#DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:href="lbph-20220331.xsd#DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#DisclosureAccruedOtherExpensesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta" xlink:href="lbph-20220331.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:href="lbph-20220331.xsd#DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="lbph-20220331.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:href="lbph-20220331.xsd#DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:href="lbph-20220331.xsd#DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="lbph-20220331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="lbph-20220331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:href="lbph-20220331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedResearchAndDevelopmentExpenses" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lbph_AccruedResearchAndDevelopmentExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherLongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ProFormaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_InitialPublicOfferingCostsInAccountsPayable" xlink:label="lbph_InitialPublicOfferingCostsInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_InitialPublicOfferingCostsInAccruedOtherExpenses" xlink:label="lbph_InitialPublicOfferingCostsInAccruedOtherExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lbph_InitialPublicOfferingCostsInAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lbph_InitialPublicOfferingCostsInAccruedOtherExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefits" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DeferredFinancingCostsPolicyTextBlock" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShortTermInvestmentsPolicyTextBlock" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RisksAndUncertaintiesPolicyTextBlock" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lbph_DeferredFinancingCostsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lbph_ShortTermInvestmentsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lbph_RisksAndUncertaintiesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PostSplitMember" xlink:label="lbph_PostSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PreSplitMember" xlink:label="lbph_PreSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_VotingMember" xlink:label="lbph_VotingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_NonVotingMember" xlink:label="lbph_NonVotingMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_WorkingCapital" xlink:label="lbph_WorkingCapital"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_PostSplitMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_PreSplitMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_VotingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_NonVotingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_NumberOfCommonStockSharesIssuedAndSold" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockDiscountOnShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromContributedCapital" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_WorkingCapital" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OptionsToPurchaseCommonStockMember" xlink:label="lbph_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RestrictedStockAwardsIssuedButUnvestedMember" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_RestrictedStockAwardsIssuedButUnvestedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShortTermInvestmentsAndCashEquivalents" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lbph_ShortTermInvestmentsAndCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_NumberOfSecurities" xlink:label="lbph_NumberOfSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lbph_NumberOfSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInsuranceCurrentAndNoncurrent" xlink:label="us-gaap_AccruedInsuranceCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedLegalAndAccountingFeesCurrent" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedComputerRelatedExpenses" xlink:label="lbph_AccruedComputerRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedTaxes" xlink:label="lbph_AccruedTaxes"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedRecruitmentFeesCurrent" xlink:label="lbph_AccruedRecruitmentFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedInsuranceCurrentAndNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lbph_AccruedLegalAndAccountingFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lbph_AccruedComputerRelatedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lbph_AccruedTaxes" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lbph_AccruedRecruitmentFeesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lbph_GrossProceedsFromIssuanceOfCommonStock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockConversionBasis" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="us-gaap_PartnersCapitalAccountContributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_15"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_18"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PartnersCapitalAccountContributions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RenewOfSuccessiveAgreementTerm" xlink:label="lbph_RenewOfSuccessiveAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lbph_ArenaPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lbph_RenewOfSuccessiveAgreementTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lbph_ArenaPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" xlink:label="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" xlink:label="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" xlink:label="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" xlink:label="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PercentageOfSharesOfCommonStockOutstanding" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_PercentageOfSharesOfCommonStockOutstanding" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PercentageOfIncreaseInRent" xlink:label="lbph_PercentageOfIncreaseInRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EffectiveLeaseDate" xlink:label="lbph_EffectiveLeaseDate"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AreaOfOfficeSpace" xlink:label="lbph_AreaOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PaymentsForRentHistorical" xlink:label="lbph_PaymentsForRentHistorical"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_SecurityDeposit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_PercentageOfIncreaseInRent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_EffectiveLeaseDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_AreaOfOfficeSpace" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_PaymentsForRentHistorical" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PaymentsForRent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_WeightedAverageDiscountRateAbstract" xlink:label="lbph_WeightedAverageDiscountRateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_WeightedAverageRemainingLeaseTermAbstract" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_WeightedAverageRemainingLeaseTermAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_WeightedAverageDiscountRateAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_DefinedContributionPlanArenaMatchingContributions" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="lbph_DefinedContributionPlanArenaMatchingContributions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>lbph-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-05T15:44:02.5969+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" xlink:href="lbph-20220331.xsd#StatementCondensedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" xlink:href="lbph-20220331.xsd#StatementCondensedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="lbph-20220331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:href="lbph-20220331.xsd#DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:href="lbph-20220331.xsd#DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta" xlink:href="lbph-20220331.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:href="lbph-20220331.xsd#DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="lbph-20220331.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:href="lbph-20220331.xsd#DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:href="lbph-20220331.xsd#DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_AccruedResearchAndDevelopmentExpenses" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lbph_AccruedResearchAndDevelopmentExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherLongTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ProFormaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PostSplitMember" xlink:label="lbph_PostSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PreSplitMember" xlink:label="lbph_PreSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_VotingMember" xlink:label="lbph_VotingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_NonVotingMember" xlink:label="lbph_NonVotingMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_WorkingCapital" xlink:label="lbph_WorkingCapital"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_PostSplitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_PreSplitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_VotingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_NonVotingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_NumberOfCommonStockSharesIssuedAndSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockDiscountOnShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromContributedCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_WorkingCapital" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredCostsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_OptionsToPurchaseCommonStockMember" xlink:label="lbph_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RestrictedStockAwardsIssuedButUnvestedMember" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_RestrictedStockAwardsIssuedButUnvestedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShortTermInvestmentsAndCashEquivalents" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lbph_ShortTermInvestmentsAndCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lbph_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockConversionBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="us-gaap_PartnersCapitalAccountContributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PartnersCapitalAccountContributions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_RenewOfSuccessiveAgreementTerm" xlink:label="lbph_RenewOfSuccessiveAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lbph_ArenaPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lbph_RenewOfSuccessiveAgreementTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lbph_ArenaPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" xlink:label="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" xlink:label="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" xlink:label="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" xlink:label="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_PercentageOfSharesOfCommonStockOutstanding" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_PercentageOfSharesOfCommonStockOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20220331.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632071892200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Longboard Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text"> 0001832168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-5009619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4275 Executive Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">592-9775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LBPH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,215,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632071916936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,037<span></span>
</td>
<td class="nump">$ 66,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">61,087<span></span>
</td>
<td class="nump">40,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,035<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">100,159<span></span>
</td>
<td class="nump">108,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">100,643<span></span>
</td>
<td class="nump">108,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">2,998<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use liabilities, current portion</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,684<span></span>
</td>
<td class="nump">5,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use liabilities, net of current portion</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">146,254<span></span>
</td>
<td class="nump">145,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(596)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(51,794)<span></span>
</td>
<td class="num">(42,197)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder&#8217;s equity (deficit)</a></td>
<td class="nump">93,865<span></span>
</td>
<td class="nump">103,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and shareholders&#8217; equity (deficit)</a></td>
<td class="nump">100,643<span></span>
</td>
<td class="nump">108,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632069622664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">13,484,315<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">13,484,315<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, subject to repurchase</a></td>
<td class="nump">101,635<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632069622840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 7,121<span></span>
</td>
<td class="nump">$ 4,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,620<span></span>
</td>
<td class="nump">5,703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,620)<span></span>
</td>
<td class="num">(5,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,597)<span></span>
</td>
<td class="num">$ (5,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">17,086,615<span></span>
</td>
<td class="nump">6,810,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,597)<span></span>
</td>
<td class="num">$ (5,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on short-term investments, net</a></td>
<td class="num">(432)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (10,029)<span></span>
</td>
<td class="num">$ (5,699)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632076907480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (9,597)<span></span>
</td>
<td class="num">$ (5,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on investments, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,377)<span></span>
</td>
<td class="num">(2,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued compensation and related expenses</a></td>
<td class="num">(1,036)<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued other expenses</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet', window );">Operating right-of-use assets and lease liabilities, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,025)<span></span>
</td>
<td class="num">(7,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(21,284)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(21,284)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Series A convertible preferred stock financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Initial public offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,718)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73,281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(31,309)<span></span>
</td>
<td class="nump">65,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">66,346<span></span>
</td>
<td class="nump">55,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">35,037<span></span>
</td>
<td class="nump">120,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_InitialPublicOfferingCostsInAccountsPayable', window );">Initial public offering costs in accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_InitialPublicOfferingCostsInAccruedOtherExpenses', window );">Initial public offering costs in accrued other expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating right-of-use assets and lease liabilities, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_InitialPublicOfferingCostsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering costs in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_InitialPublicOfferingCostsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_InitialPublicOfferingCostsInAccruedOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering costs in accrued other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_InitialPublicOfferingCostsInAccruedOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074827928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Organization and Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Longboard Pharmaceuticals, Inc. (the "Company"), formerly Arena Neuroscience, Inc., was incorporated in the state of Delaware on January 3, 2020, and is based in San Diego, California. The Company was organized and initially wholly-owned by Arena Pharmaceuticals, Inc. ("Arena"), until the closing of its Series A convertible preferred stock ("Series A Preferred Stock") financing in October 2020. The Company is a clinical stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The Company&#8217;s most advanced product candidate, LP352, is being developed for the treatment of seizures associated with developmental and epileptic encephalopathies and is currently in a Phase 1b/2a clinical trial ("the PACIFIC Study"). The Company&#8217;s preclinical product candidates include LP659 and LP143, which are potential therapies for multiple neurological diseases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On March 16, 2021, the Company completed the initial public offering (&#8220;IPO&#8221;) of its common stock. In connection with the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,298,360</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock, which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">298,360</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of its voting common stock issued pursuant to the option granted to the underwriters to purchase additional shares in April 2021, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Company raised $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">76.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds from the IPO after deducting underwriters&#8217; discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and issuance costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. Unless otherwise noted, all references in the financial statements and related footnotes to the Company's "common stock" refers to the Company's voting common stock.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the closing of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,630,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A Preferred Stock were exchanged for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of non-voting common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,970,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,098,600</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock. Following the IPO, there were no shares of Series A Preferred Stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Forward Stock Splits</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2020, the Company filed an amendment to the Company&#8217;s certificate of incorporation to effect a forward stock split of shares of the Company&#8217;s common stock on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,783</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-for-1 basis (the "October 2020 Forward Stock Split"). The par value of the common stock was not adjusted as a result of the October 2020 Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the October 2020 Forward Stock Split for the periods presented.</span></span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On March 5, 2021, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#8217;s common stock on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-for-1 basis (the "March 2021 Forward Stock Split"). Adjustments corresponding to the March 2021 Forward Stock Split were made to the ratio at which the Company&#8217;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March 2021 Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March 2021 Forward Stock Split for all periods presented.</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and applicable regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, the accompanying unaudited condensed financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The balance sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. The operating results presented in these unaudited condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. The Company&#8217;s unaudited condensed financial statements should be read in conjunction with the audited financial statements included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 3, 2022.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">its inception, the Company has devoted substantially all of its resources to research and development ("R&amp;D") activities, organizing and staffing, business planning, raising capital, in-licensing intellectual property rights and establishing its intellectual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">property </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">portfolio, and providing general and administrative ("G&amp;A") support for these operations and has funded its operations primarily with the net proceeds from the issuance of Series A Preferred Stock and common stock. The Company has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">51.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as of March 31, 2022, and December 31, 2021, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Management expects the Company will incur substantial operating losses for the foreseeable future in order to complete preclinical studies and clinical trials, seek regulatory approval, and launch and commercialize any product candidates for which it receives regulatory approval. The Company will need to raise additional capital through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic continues to evolve and has resulted in a significant disruption of global financial markets. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the pandemic. If the disruption persists or deepens, the Company could experience an inability to access additional capital.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, the Company had available cash, cash equivalents and investments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">96.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and working capital of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">93.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million to fund future operations. Management believes that its capital resources as of March 31, 2022, will be sufficient to fund the Company&#8217;s operations for at least 12 months after the date these unaudited condensed financial statements are issued.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074912584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Estimates are based on the Company&#8217;s historical experience, knowledge of current events and actions it may undertake in the future, and actual results may materially differ from these estimates and assumptions.</span></p></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.</span></p></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. government-sponsored enterprises. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">R&amp;D Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#8217;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;D expenses amounted to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, for the three months ended March 31, 2022 and 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based awards are measured at fair value and compensation expense is recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.</span></p></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease or contains lease components at inception. Lease terms are determined at the commencement date by considering whether renewal options and termination options, if any, are reasonably assured of exercise. For long-term operating leases, the Company recognizes a lease liability and a right-of-use (&#8220;ROU&#8221;) asset on its balance sheets and recognizes lease expense on a straight-line basis over the lease term. The lease liability is determined as the present value of future lease payments using the discount rate implicit in the lease or, if the implicit rate is not readily determinable, an estimate of the Company&#8217;s incremental borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. The Company does not have any financing leases.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.622%;"/>
          <td style="width:0.664%;"/>
          <td style="width:17.99%;"/>
          <td style="width:0.664%;"/>
          <td style="width:1.74%;"/>
          <td style="width:0.664%;"/>
          <td style="width:17.99%;"/>
          <td style="width:0.664%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,350,934</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,248,156</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock awards, issued but unvested</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101,635</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">348,450</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,452,569</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,596,606</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2016-13), to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance will become effective for the Company beginning January 1, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on its financial statements.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Potential impacts to the Company&#8217;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#8217;s ability to raise capital and conduct business development activities.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074946792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 3. Fair Value Measurements</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> &#8212; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> &#8212; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> &#8212; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.14%;"/>
        <td style="width:3.229%;"/>
        <td style="width:1.197%;"/>
        <td style="width:11.45%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.229%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.578%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.229%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.615%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.229%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.128%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements at <br/>Reporting Date Using</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Other Observable Inputs <br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Unobservable Inputs <br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22,904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22,904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,983</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,983</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29,647</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26,862</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,785</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">85,990</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">49,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36,014</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36,014</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,559</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,816</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">40,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30,820</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">76,393</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">45,573</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30,820</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074932056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 4. Short-Term Investments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes short-term investments:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.427%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.02%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.955%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.788%;"/>
        <td style="width:0.798%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.011%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,983</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,983</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">320</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,456</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27,925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">277</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27,648</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,683</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">597</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,087</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,117</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">40,543</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">40,379</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. As of March 31, 2022, the Company held </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> securities, with an aggregate fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">43.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, in an unrealized loss position. These securities have not been in a continuous loss position for more than 12 months and there were no individual securities that were in a significant unrealized loss position as of March 31, 2022. The Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the maturities of the Company's short-term investments at March 31, 2022:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.649%;"/>
        <td style="width:3.385%;"/>
        <td style="width:12.594%;"/>
        <td style="width:3.385%;"/>
        <td style="width:12.594%;"/>
        <td style="width:3.385%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.619%;"/>
        <td style="width:0.992%;"/>
        <td style="width:3.385%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.609%;"/>
        <td style="width:0.992%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42,878</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Due after one year through three years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,720</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,209</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,087</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632078596424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Other Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Other Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 5. Accrued Other Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued other expenses consisted of t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">he following:</span></p><p id="bkmk_281" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.945%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.869%;"/>
        <td style="width:22.617%;"/>
        <td style="width:0.803%;"/>
        <td style="width:3.236%;"/>
        <td style="width:1.869%;"/>
        <td style="width:22.065%;"/>
        <td style="width:0.803%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">As of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Insurance premium finance liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ebed43d0-0a92-4d67-8082-ae25c97d4cd4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued consulting fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">154</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued legal and accounting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued computer related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5a0988e8-75d5-4bd3-b7bb-e0565dc26350;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued recruiting fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_447350e3-6678-4d9f-8965-dfcca260ed3b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,536</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">352</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company entered into a premium finance agreement in March 2022 in connection with the renewal of its annual directors and officers insurance.  The total amount financed is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million which will be paid over nine months. The total finance charge for the premium finance agreement is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> which is recorded to interest expense monthly on a straight-line basis.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632076767768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders' Equity (Deficit)</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 6.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the Company amended and restated the Company&#8217;s certificate of incorporation to, among other things, increase the authorized shares of voting common stock, non-voting common stock and preferred stock to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">300,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Common Stock and Non-Voting Common Stock</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,484,315</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock outstanding, excluding </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101,635</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares subject to repurchase, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of non-voting common stock outstanding. As of December 31, 2021, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,440,761</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock outstanding, excluding </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">145,189</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares subject to repurchase, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of non-voting common stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series A Preferred Stock</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">56.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, including </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares purchased by Arena. The Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in issuance costs related to the Series A Preferred Stock financing. On March 16, 2021, immediately prior to the closing of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,630,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Series A Preferred Stock were exchanged for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of non-voting common stock. Upon the closing of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,970,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Series A Preferred Stock were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,098,600</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of voting common stock. Following the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A Preferred Stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reconciliation of Changes in Stockholders&#8217; Equity</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following tables document the changes in stockholders' equity for the three months ended March 31, 2022 and 2021 (unaudited):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.225%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.32%;"/>
        <td style="width:5.937%;"/>
        <td style="width:0.417%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:4.86%;"/>
        <td style="width:0.417%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.32%;"/>
        <td style="width:6.041%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:4.957%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.32%;"/>
        <td style="width:6.041%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:4.957%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:6.5%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:7.919%;"/>
        <td style="width:0.417%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:7.258%;"/>
        <td style="width:0.417%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:7.919%;"/>
        <td style="width:0.417%;"/>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Non-Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Additional<br/>Paid-in<br/>Capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Deficit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">13,440,761</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">145,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">42,197</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">103,323</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Vesting of restricted stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">43,554</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized loss on short-term investments, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">432</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">432</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">9,597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">9,597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">13,484,315</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">146,254</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">596</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">51,794</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">93,865</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Non-Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Additional<br/>Paid-in<br/>Capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Deficit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,600,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">55,795</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,840,540</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">11,708</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">14,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">2,692</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Conversion of Series A convertible preferred stock to common stock in connection with initial public offering</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,600,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">55,795</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">4,098,600</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">55,795</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">55,795</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock in initial public offering, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">71,848</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">71,849</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">333</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">333</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,699</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,699</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">12,939,140</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">139,684</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">20,099</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">119,586</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity and stockholders equity disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074931224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements with Arena Pharmaceuticals, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Agreements with Arena Pharmaceuticals, Inc.</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 7. Agreements with Arena Pharmaceuticals, Inc.</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company entered into a license agreement (the "License Agreement"), a services agreement (the "Services Agreement"), and a royalty purchase agreement (the "Royalty Purchase Agreement") in October 2020 with Arena. The Company amended the License Agreement in January 2022 to add an additional program. The following section summarizes these related party agreements.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the License Agreement, the Company obtained an exclusive, royalty bearing, sublicensable, worldwide license under certain know-how and patents of Arena to develop and commercialize LP352 for any use in humans, LP143 for the treatment of any central nervous system ("CNS") indication in humans (excluding the treatment, prevention or amelioration of pain or any gastrointestinal, non-CNS autoimmune or cardiovascular disorder), and LP659 for the treatment of selected CNS indications in humans (pharmaceutical products containing any such compounds, Licensed Products). As consideration for the rights granted to the Company under the License Agreement, the Company will be required to pay to Arena a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by the Company, its affiliates or its sublicensees, subject to standard reductions. The Company&#8217;s royalty obligations continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of the (i) tenth anniversary of the first commercial sale of such product in such country or (ii) expiration of the last-to-expire valid claim of the patents licensed by us under the License Agreement covering the manufacture, use or sale of such product in such country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Services Agreement</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the License Agreement, the Company also entered into a Services Agreement with Arena under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for the Company and receive service fees therefore on an hourly rate based on an annual full time equivalent rate agreed upon by the parties. Arena invoices the Company for services provided on a monthly basis, in arrears. The Services Agreement will continue until December 31, 2022, and will automatically renew for successive </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> terms. Either party may terminate the Services Agreement for any reason, subject to specified notice periods. Payments for services provided under the Services Agreement are recorded to research and development or general and administrative, on the statement of operations, as appropriate. The Company has been decreasing its activities under the Services Agreement, including as a result of its having hired employees or contracted with third parties with the requisite expertise, and the Company is no longer substantially dependent on such services from Arena.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the services expensed under the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Services Agreement:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.758%;"/>
        <td style="width:1.206%;"/>
        <td style="width:21.074%;"/>
        <td style="width:0.603%;"/>
        <td style="width:2.467%;"/>
        <td style="width:1.206%;"/>
        <td style="width:21.083%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">246</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">315</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">188,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of related party amounts related to the Services Agreement in accounts payable as of March 31, 2022, and December 31, 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty Purchase Agreement</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company entered into a Royalty Purchase Agreement with 356 Royalty Inc., a wholly owned subsidiary of Arena ("356 Royalty"), and Arena, pursuant to which it purchased the right to receive all milestone payments, royalties, interest and other payments relating to net sales of lorcaserin, owed or otherwise payable to 356 Royalty by Eisai Inc. and Eisai Co., Ltd., pursuant to the Transaction Agreement, dated December 28, 2016, as amended, by and among 356 Royalty, Eisai Inc. and Eisai Co., Ltd. The Company made a one-time payment to Arena of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expensed this amount to research and development expense on the statement of operations and comprehensive loss as lorcaserin is subject to regulatory approval and there are risks and uncertainties as to whether royalties will ultimately be paid and collected.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632077026456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 8. Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company&#8217;s board of directors and stockholders approved the 2020 Equity Incentive Plan ("2020 Plan"), which provided for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, and stock appreciation rights to its employees, members of its board of directors, and consultants. The Company&#8217;s board of directors determined the exercise price, vesting and expiration period of the grants under the 2020 Plan.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company's board of directors adopted the 2021 Equity Incentive Plan ("2021 Plan") in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan became effective on March 11, 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> additional awards may be granted under the 2020 Plan and all outstanding awards under the 2020 Plan remain subject to the terms of the 2020 Plan. As of March 31, 2022, the 2021 Plan authorizes and provides for the issuance of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,694,999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which amount will be increased to the extent that awards granted under the 2021 Plan are forfeited, expire or are settled for cash (except as otherwise provided in the 2021 Plan). The number of shares of common stock reserved for issuance under the 2021 Plan automatically increase on January 1 of each calendar year, through January 1, 2031, in an amount equal to (i) 5% of the total number of shares of common stock outstanding on December 31 of the fiscal year before the date of each automatic increase (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock), or (ii) a lesser number of shares determined by the Company&#8217;s board of directors prior to the applicable January 1. Recipients of stock options are eligible to purchase shares of the Company&#8217;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2020 and 2021 Plans (or collectively, the &#8220;Equity Plans&#8221;) is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and, in general, the options issued under the Equity Plans vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c95df60b-4fb8-4cd0-9d53-ee8d8e733b63;"><span style="-sec-ix-hidden:F_1f13ee31-05a2-420a-b85b-665c04190587;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one </span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> period from the vesting commencement date. There are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,344,065</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares available for grant under the 2021 Plan as of March 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Award Grants under the Equity Plans</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s Equity Plans stock option activity is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.726%;"/>
        <td style="width:1.075%;"/>
        <td style="width:0.706%;"/>
        <td style="width:12.302%;"/>
        <td style="width:0.97%;"/>
        <td style="width:1.075%;"/>
        <td style="width:1.444%;"/>
        <td style="width:11.311%;"/>
        <td style="width:0.643%;"/>
        <td style="width:1.075%;"/>
        <td style="width:0.706%;"/>
        <td style="width:12.239%;"/>
        <td style="width:0.643%;"/>
        <td style="width:1.075%;"/>
        <td style="width:1.444%;"/>
        <td style="width:9.92%;"/>
        <td style="width:0.643%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,421,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">997,900</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.62</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options forfeited/cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">68,722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.55</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,350,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.47</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,493</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Vested and expected to vest at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,350,934</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.47</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.2</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,493</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options exercisable at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">686,889</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,127</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options exercisable at March 31, 2022 included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">338,439</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> vested stock options and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">348,450</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> stock options that are subject to an early exercise provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the weighted-average assumptions used for the stock option grants for the three months ended March 31, 2022 and 2021, along with the related grant date fair value:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.077%;"/>
        <td style="width:1.334%;"/>
        <td style="width:1.694%;"/>
        <td style="width:15.232%;"/>
        <td style="width:2.831%;"/>
        <td style="width:1.334%;"/>
        <td style="width:1.694%;"/>
        <td style="width:15.974%;"/>
        <td style="width:2.831%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.62</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12.10</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.94</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">75.21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">73.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expected life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated grant date fair value per share of award granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Prior to the IPO, there was no public market for the Company's common stock, and therefore, the estimated fair value of common stock for option grants was determined by the Company&#8217;s board of directors as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third-party valuations of the Company's equity instruments were performed contemporaneously with identified value inflection points. These third-party valuations were performed in accordance with the guidance outlined in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ("Practice Aid"). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the common stock at each valuation date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition to considering the results of these independent third-party valuations, the Company&#8217;s board of directors considered various objective and subjective factors to determine the fair value of its common stock as of each grant date, including: the prices of the preferred stock sold to or exchanged between outside investors in arm&#8217;s length transactions and the rights, preferences and privileges of the preferred stock as compared to those of the Company&#8217;s common stock including liquidation preferences of the Company&#8217;s preferred stock; the progress of the Company&#8217;s research and development programs, including the status and results of preclinical and clinical trials for product candidates; the stage of development and material risks related to the Company&#8217;s business; external market and other conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; the Company&#8217;s business conditions and projections; the Company&#8217;s financial position and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#8217;s common stock and preferred stock; the likelihood of achieving a liquidity event for the Company&#8217;s securityholders, such as an initial public offering or a sale of the Company in light of prevailing market conditions; the hiring of key personnel and the experience of management; and the analysis of initial public offerings and the market performance of similar companies in the biopharmaceutical industry, as well as trends and developments in the biopharmaceutical industry.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">After the closing of the IPO in March 2021, the Company began utilizing the closing stock price of the common stock on the Nasdaq Global Market as both the exercise price and an input to the Black Scholes option pricing model to determine stock-based compensation expense.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Since the Company is a newly public company and does not have a trading history for its common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">life</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The expected life represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is equal to the contractual term.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Awards</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">348,450</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> restricted stock awards were granted to an employee under the 2020 Plan, which vest over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and had an estimated fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3.12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share at the time of grant. As of March 31, 2022, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101,635</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> restricted stock awards remained to vest.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.635%;"/>
        <td style="width:1.694%;"/>
        <td style="width:20.682%;"/>
        <td style="width:0.754%;"/>
        <td style="width:2.366%;"/>
        <td style="width:1.694%;"/>
        <td style="width:22.422%;"/>
        <td style="width:0.754%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">443</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">263</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">333</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, unrecognized stock-based compensation expense was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">which is expected to be recognized over a remaining weighted-average period of approximatel</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">y </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> y</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ears.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company's board of directors adopted the 2021 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) in February 2021, the Company's stockholders approved the ESPP in March 2021 and it became effective on March 11, 2021. As of March 31, 2022, the ESPP authorizes the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">525,492</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under purchase rights granted to our employees. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, through January 1, 2031, by the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on the last day of the fiscal year before the date of the automatic increase (determining on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock); and (ii) such number of shares of common stock that would cause the aggregate number of shares of common stock then reserved for issuance under the ESPP to equal </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,060,017</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares; provided that before the date of any such increase, the Company&#8217;s board of directors may determine that such increase will be for a lesser amount of shares. The ESPP permits eligible employees, who elect to participate in an offering under the ESPP, to contribute up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of their eligible earnings (as defined in the ESPP) towards the purchase of shares of common stock. Unless otherwise determined by the Company's board of directors, the price at which stock is purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the Company&#8217;s common stock on the commencement date of each offering period or the relevant purchase date, whichever is lower. There are certain service requirements for an employee to be eligible to participate in the ESPP, and no employee may purchase shares under the ESPP at a rate in excess of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> worth of common stock (as determined in accordance with the ESPP). Offering durations under the ESPP may not be longer than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and the Company may specify shorter purchase periods within each offering. The ESPP is considered a compensatory plan as defined by the authoritative guidance for stock-based compensation. As of March 31, 2022, the ESPP had not yet been implemented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632076743384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 9. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, the Company entered into a lease agreement for office space located at 4275 Executive Square, Suite 950, La Jolla, California 92037 where it occupies </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8,681</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> square feet. The lease became effective </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">July 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and continues through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Rent payments are approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per month for the first year and increase by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% in the second year. A security deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">33,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> was paid in June 2021 and is classified as a long-term asset on the unaudited condensed balance sheets.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Previously, the Company leased certain office space in San Diego, California under a month to month lease. Rent payments were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per month.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Rent expense totaled approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">95,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> for the three months ended March 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The below table provides supplemental cash flow information related to leases as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.267%;"/>
        <td style="width:71.243%;"/>
        <td style="width:1.206%;"/>
        <td style="width:22.681%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.341%;"/>
        <td style="width:72.375%;"/>
        <td style="width:1.364%;"/>
        <td style="width:19.898%;"/>
        <td style="width:2.022%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">350</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.25</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease commitments are as follows as of March 31, 2022 (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.267%;"/>
        <td style="width:71.227%;"/>
        <td style="width:1.206%;"/>
        <td style="width:22.503%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">279</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">189</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">468</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of March 31, 2022, and December 31, 2021, the Company is not a party to any litigation.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074844040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Benefits<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock', window );">Employment Benefits</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 10. Employment Benefits</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Effective in June 2021, the Company established a 401(k) salary deferral plan for its employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company provides a safe harbor contribution of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the employee's compensation, not to exceed eligible limits, and subject to employee participation. For the three months ended March 31, 2022, the Company incurred approximatel</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">y $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">57,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> in expenses related to the safe harbor contribution.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for postemployment benefits,  which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6410195&amp;loc=d3e80090-111668<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632077000888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and applicable regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, the accompanying unaudited condensed financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The balance sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. The operating results presented in these unaudited condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. The Company&#8217;s unaudited condensed financial statements should be read in conjunction with the audited financial statements included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 3, 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Estimates are based on the Company&#8217;s historical experience, knowledge of current events and actions it may undertake in the future, and actual results may materially differ from these estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. government-sponsored enterprises. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_ShortTermInvestmentsPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">R&amp;D Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">R&amp;D Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#8217;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;D expenses amounted to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, for the three months ended March 31, 2022 and 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based awards are measured at fair value and compensation expense is recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease or contains lease components at inception. Lease terms are determined at the commencement date by considering whether renewal options and termination options, if any, are reasonably assured of exercise. For long-term operating leases, the Company recognizes a lease liability and a right-of-use (&#8220;ROU&#8221;) asset on its balance sheets and recognizes lease expense on a straight-line basis over the lease term. The lease liability is determined as the present value of future lease payments using the discount rate implicit in the lease or, if the implicit rate is not readily determinable, an estimate of the Company&#8217;s incremental borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. The Company does not have any financing leases.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.622%;"/>
          <td style="width:0.664%;"/>
          <td style="width:17.99%;"/>
          <td style="width:0.664%;"/>
          <td style="width:1.74%;"/>
          <td style="width:0.664%;"/>
          <td style="width:17.99%;"/>
          <td style="width:0.664%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,350,934</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,248,156</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock awards, issued but unvested</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101,635</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">348,450</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,452,569</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,596,606</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2016-13), to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance will become effective for the Company beginning January 1, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on its financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Potential impacts to the Company&#8217;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#8217;s ability to raise capital and conduct business development activities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties Policy Text Block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632075017368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.622%;"/>
          <td style="width:0.664%;"/>
          <td style="width:17.99%;"/>
          <td style="width:0.664%;"/>
          <td style="width:1.74%;"/>
          <td style="width:0.664%;"/>
          <td style="width:17.99%;"/>
          <td style="width:0.664%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,350,934</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,248,156</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock awards, issued but unvested</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101,635</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">348,450</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,452,569</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,596,606</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074912584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Company's Financial Assets Recognized at Fair Value</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.14%;"/>
        <td style="width:3.229%;"/>
        <td style="width:1.197%;"/>
        <td style="width:11.45%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.229%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.578%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.229%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.615%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.229%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.128%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements at <br/>Reporting Date Using</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Other Observable Inputs <br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Unobservable Inputs <br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22,904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22,904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,983</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,983</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29,647</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26,862</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,785</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">85,990</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">49,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36,014</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36,014</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,559</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,816</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">40,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30,820</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">76,393</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">45,573</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30,820</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632075881496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Short-Term Investments</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes short-term investments:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.427%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.02%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.955%;"/>
        <td style="width:0.594%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.788%;"/>
        <td style="width:0.798%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.011%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,983</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,983</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">320</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,456</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27,925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">277</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27,648</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,683</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">597</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,087</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,117</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">40,543</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">40,379</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Maturity of the Short-Term Investments</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the maturities of the Company's short-term investments at March 31, 2022:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.649%;"/>
        <td style="width:3.385%;"/>
        <td style="width:12.594%;"/>
        <td style="width:3.385%;"/>
        <td style="width:12.594%;"/>
        <td style="width:3.385%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.619%;"/>
        <td style="width:0.992%;"/>
        <td style="width:3.385%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.609%;"/>
        <td style="width:0.992%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42,878</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Due after one year through three years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,720</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,209</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,087</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632077023352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Other Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Other Expenses</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued other expenses consisted of t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">he following:</span></p><p id="bkmk_281" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.945%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.869%;"/>
        <td style="width:22.617%;"/>
        <td style="width:0.803%;"/>
        <td style="width:3.236%;"/>
        <td style="width:1.869%;"/>
        <td style="width:22.065%;"/>
        <td style="width:0.803%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">As of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Insurance premium finance liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ebed43d0-0a92-4d67-8082-ae25c97d4cd4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued consulting fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">154</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued legal and accounting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued computer related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5a0988e8-75d5-4bd3-b7bb-e0565dc26350;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued recruiting fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_447350e3-6678-4d9f-8965-dfcca260ed3b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,536</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">352</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company entered into a premium finance agreement in March 2022 in connection with the renewal of its annual directors and officers insurance.  The total amount financed is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million which will be paid over nine months. The total finance charge for the premium finance agreement is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> which is recorded to interest expense monthly on a straight-line basis.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632075023944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholder's Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following tables document the changes in stockholders' equity for the three months ended March 31, 2022 and 2021 (unaudited):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.225%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.32%;"/>
        <td style="width:5.937%;"/>
        <td style="width:0.417%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:4.86%;"/>
        <td style="width:0.417%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.32%;"/>
        <td style="width:6.041%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:4.957%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.32%;"/>
        <td style="width:6.041%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:4.957%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:6.5%;"/>
        <td style="width:0.32%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:7.919%;"/>
        <td style="width:0.417%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:7.258%;"/>
        <td style="width:0.417%;"/>
        <td style="width:0.66%;"/>
        <td style="width:0.64%;"/>
        <td style="width:7.919%;"/>
        <td style="width:0.417%;"/>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Non-Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Additional<br/>Paid-in<br/>Capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Deficit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">13,440,761</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">145,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">42,197</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">103,323</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Vesting of restricted stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">43,554</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Unrealized loss on short-term investments, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">432</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">432</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">9,597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">9,597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">13,484,315</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">146,254</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">596</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">51,794</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">93,865</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Non-Voting Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Additional<br/>Paid-in<br/>Capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Deficit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,600,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">55,795</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,840,540</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">11,708</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">14,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">2,692</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Conversion of Series A convertible preferred stock to common stock in connection with initial public offering</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,600,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">55,795</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">4,098,600</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">55,795</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">55,795</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock in initial public offering, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">71,848</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">71,849</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">333</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">333</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,699</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">5,699</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:6.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">12,939,140</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">3,629,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">139,684</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">20,099</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">119,586</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632076765544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements with Arena Pharmaceuticals, Inc (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock', window );">Schedule of Services Expensed</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the services expensed under the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Services Agreement:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.758%;"/>
        <td style="width:1.206%;"/>
        <td style="width:21.074%;"/>
        <td style="width:0.603%;"/>
        <td style="width:2.467%;"/>
        <td style="width:1.206%;"/>
        <td style="width:21.083%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">246</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">315</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632071889560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s Equity Plans stock option activity is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.726%;"/>
        <td style="width:1.075%;"/>
        <td style="width:0.706%;"/>
        <td style="width:12.302%;"/>
        <td style="width:0.97%;"/>
        <td style="width:1.075%;"/>
        <td style="width:1.444%;"/>
        <td style="width:11.311%;"/>
        <td style="width:0.643%;"/>
        <td style="width:1.075%;"/>
        <td style="width:0.706%;"/>
        <td style="width:12.239%;"/>
        <td style="width:0.643%;"/>
        <td style="width:1.075%;"/>
        <td style="width:1.444%;"/>
        <td style="width:9.92%;"/>
        <td style="width:0.643%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,421,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">997,900</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.62</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options forfeited/cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">68,722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.55</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,350,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.47</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,493</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Vested and expected to vest at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,350,934</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.47</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.2</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,493</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Options exercisable at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">686,889</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,127</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Grant Date Fair Values and Weighted Average Assumptions used to calculate Fair Value of Options Granted</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the weighted-average assumptions used for the stock option grants for the three months ended March 31, 2022 and 2021, along with the related grant date fair value:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.077%;"/>
        <td style="width:1.334%;"/>
        <td style="width:1.694%;"/>
        <td style="width:15.232%;"/>
        <td style="width:2.831%;"/>
        <td style="width:1.334%;"/>
        <td style="width:1.694%;"/>
        <td style="width:15.974%;"/>
        <td style="width:2.831%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.62</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12.10</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.94</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">75.21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">73.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expected life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated grant date fair value per share of award granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.635%;"/>
        <td style="width:1.694%;"/>
        <td style="width:20.682%;"/>
        <td style="width:0.754%;"/>
        <td style="width:2.366%;"/>
        <td style="width:1.694%;"/>
        <td style="width:22.422%;"/>
        <td style="width:0.754%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">443</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">263</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">333</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632078488248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The below table provides supplemental cash flow information related to leases as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.267%;"/>
        <td style="width:71.243%;"/>
        <td style="width:1.206%;"/>
        <td style="width:22.681%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.341%;"/>
        <td style="width:72.375%;"/>
        <td style="width:1.364%;"/>
        <td style="width:19.898%;"/>
        <td style="width:2.022%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">350</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.25</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Commitments</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease commitments are as follows as of March 31, 2022 (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:4.267%;"/>
        <td style="width:71.227%;"/>
        <td style="width:1.206%;"/>
        <td style="width:22.503%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">279</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">189</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">468</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632070522632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Oct. 27, 2020</div></th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On March 5, 2021, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#8217;s common stock on a 1.38-for-1 basis (the "March 2021 Forward Stock Split"). Adjustments corresponding to the March 2021 Forward Stock Split were made to the ratio at which the Company&#8217;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March 2021 Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March 2021 Forward Stock Split for all periods presented.<span></span>
</td>
<td class="text">On October 27, 2020, the Company filed an amendment to the Company&#8217;s certificate of incorporation to effect a forward stock split of shares of the Company&#8217;s common stock on a 2,783-for-1 basis (the "October 2020 Forward Stock Split"). The par value of the common stock was not adjusted as a result of the October 2020 Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the October 2020 Forward Stock Split for the periods presented.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Forward stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.38<span></span>
</td>
<td class="nump">2,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,484,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net Proceeds from Initial Public Offering(IPO) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Number of shares Exchanged During Period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (51,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investment securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_WorkingCapital', window );">Working Capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,098,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_NumberOfCommonStockSharesIssuedAndSold', window );">Number of Common Stock Shares Issued and Sold | shares</a></td>
<td class="nump">5,298,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued | shares</a></td>
<td class="nump">298,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public Offering Price Per Share | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net Proceeds from Initial Public Offering(IPO) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDiscountOnShares', window );">Discount and Commissions Paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of Shares Converted | shares</a></td>
<td class="nump">2,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Number of shares Exchanged During Period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lbph_VotingMember', window );">Voting [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,098,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lbph_NonVotingMember', window );">Non Voting [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_NumberOfCommonStockSharesIssuedAndSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock Shares issued and sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_NumberOfCommonStockSharesIssuedAndSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187103-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lbph_VotingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lbph_VotingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lbph_NonVotingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lbph_NonVotingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074874744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 7,121<span></span>
</td>
<td class="nump">$ 4,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632069722632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="nump">2,452,569<span></span>
</td>
<td class="nump">1,596,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="nump">2,350,934<span></span>
</td>
<td class="nump">1,248,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_RestrictedStockAwardsIssuedButUnvestedMember', window );">Restricted Stock Awards, Issued But Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="nump">101,635<span></span>
</td>
<td class="nump">348,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_RestrictedStockAwardsIssuedButUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_RestrictedStockAwardsIssuedButUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074476024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">$ 61,087<span></span>
</td>
<td class="nump">$ 40,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">85,990<span></span>
</td>
<td class="nump">76,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">22,904<span></span>
</td>
<td class="nump">36,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_ShortTermInvestmentsAndCashEquivalents', window );">Short Term Investments And Cash Equivalents</a></td>
<td class="nump">29,647<span></span>
</td>
<td class="nump">12,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">14,983<span></span>
</td>
<td class="nump">13,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">18,456<span></span>
</td>
<td class="nump">14,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">49,766<span></span>
</td>
<td class="nump">45,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">22,904<span></span>
</td>
<td class="nump">36,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_ShortTermInvestmentsAndCashEquivalents', window );">Short Term Investments And Cash Equivalents</a></td>
<td class="nump">26,862<span></span>
</td>
<td class="nump">9,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">36,224<span></span>
</td>
<td class="nump">30,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">2,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">14,983<span></span>
</td>
<td class="nump">13,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">$ 18,456<span></span>
</td>
<td class="nump">$ 14,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ShortTermInvestmentsAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short Term Investments And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ShortTermInvestmentsAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074467864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Summary of Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 61,683<span></span>
</td>
<td class="nump">$ 40,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(597)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">61,087<span></span>
</td>
<td class="nump">40,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,983<span></span>
</td>
<td class="nump">13,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">14,983<span></span>
</td>
<td class="nump">13,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,775<span></span>
</td>
<td class="nump">14,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">18,456<span></span>
</td>
<td class="nump">14,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">27,925<span></span>
</td>
<td class="nump">12,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 27,648<span></span>
</td>
<td class="nump">$ 12,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074874744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Additional Information) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Securities</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value of unrealized loss position | $</a></td>
<td class="nump">$ 43.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_NumberOfSecurities', window );">Number of securities | Securities</a></td>
<td class="nump">27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_NumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_NumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632069752040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Fixed maturity securities, available for sale, due in one year or less, amortized cost</a></td>
<td class="nump">$ 42,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree', window );">Fixed maturity securities, available for sale, due after one year through three years, amortized cost</a></td>
<td class="nump">18,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">61,683<span></span>
</td>
<td class="nump">$ 40,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Fixed maturity securities, available for sale, due in one year or less, fair value</a></td>
<td class="nump">42,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree', window );">Fixed maturity securities, available for sale, due after one year through three years, fair value</a></td>
<td class="nump">18,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fixed maturity securities, available for sale, fair value</a></td>
<td class="nump">$ 61,087<span></span>
</td>
<td class="nump">$ 40,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632070554120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Other Expenses - Summary of Accrued Other Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrentAndNoncurrent', window );">Insurance premium finance liability</a></td>
<td class="nump">$ 1,191<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued consulting fees</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_AccruedLegalAndAccountingFeesCurrent', window );">Accrued legal and accounting fees</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_AccruedComputerRelatedExpenses', window );">Accrued computer related expenses</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_AccruedTaxes', window );">Accrued Taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_AccruedRecruitmentFeesCurrent', window );">Accrued recruiting fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,536<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedComputerRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued computer related expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedComputerRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedLegalAndAccountingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for legal and accounting fees received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedLegalAndAccountingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedRecruitmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for recruitment fees received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedRecruitmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632075004856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Other Expenses (Additional Information) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Total amount financed</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Monthly interest expense</a></td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074326824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,484,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,484,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock available for conversion</a></td>
<td class="nump">2,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="nump">2,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during conversion of convertible securities</a></td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,629,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,484,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,098,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="nump">4,098,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632069336520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,323<span></span>
</td>
<td class="num">$ (2,692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on short-term investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(432)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,597)<span></span>
</td>
<td class="num">(5,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,865<span></span>
</td>
<td class="nump">119,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, Beginning Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Beginning balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, Ending Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Ending Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
<td class="nump">3,840,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,098,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)</a></td>
<td class="nump">4,098,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,484,315<span></span>
</td>
<td class="nump">12,939,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,683<span></span>
</td>
<td class="nump">$ 11,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,254<span></span>
</td>
<td class="nump">139,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,197)<span></span>
</td>
<td class="num">(14,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,597)<span></span>
</td>
<td class="num">(5,699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,794)<span></span>
</td>
<td class="num">(20,099)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Gain/(Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on short-term investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (596)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632076023672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details) - Arena Pharmaceuticals Inc [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_RenewOfSuccessiveAgreementTerm', window );">Renew of successive agreement term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesNoncurrent', window );">Related party amounts related to accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 188,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments of related party</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_RenewOfSuccessiveAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Renew of successive agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_RenewOfSuccessiveAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632070448968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 7,121<span></span>
</td>
<td class="nump">$ 4,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,620<span></span>
</td>
<td class="nump">5,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember', window );">Arena Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632070599416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable, vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber', window );">Options exercisable, subject to early exercise provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,493,000<span></span>
</td>
<td class="nump">$ 1,272,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">997,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_PercentageOfSharesOfCommonStockOutstanding', window );">Percentage of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage', window );">Employee stock purchase plan, eligible earnings contribution, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue', window );">Employee stock purchase plan, shares purchase price as a percentage of market fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue', window );">Employee stock purchase plan, maximum shares purchased, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod', window );">Employee stock purchase plan, maximum offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,344,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,694,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member] | Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member] | Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock award, granted</a></td>
<td class="nump">348,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock award, Grant date fair value</a></td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares remained to vest</a></td>
<td class="nump">101,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, eligible earnings contribution, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, maximum offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, maximum shares purchased, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, shares purchase price as a percentage of market fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_PercentageOfSharesOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of common stock outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_PercentageOfSharesOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options subject to early exercise provision, exercisable number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074274280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options outstanding, beginning balance</a></td>
<td class="nump">1,421,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Options granted</a></td>
<td class="nump">997,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Options cancelled</a></td>
<td class="nump">68,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options outstanding, ending balance</a></td>
<td class="nump">2,350,934<span></span>
</td>
<td class="nump">1,421,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options exercisable</a></td>
<td class="nump">686,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Shares, Options Vested and Expected to Vest</a></td>
<td class="nump">2,350,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options outstanding, beginning balance</a></td>
<td class="nump">$ 6.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options granted</a></td>
<td class="nump">4.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options cancelled</a></td>
<td class="nump">10.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options outstanding, ending balance</a></td>
<td class="nump">5.47<span></span>
</td>
<td class="nump">$ 6.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options exercisable</a></td>
<td class="nump">4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options vested</a></td>
<td class="nump">$ 5.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in Years) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Options outstanding</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options exercisable</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options vested and expected to vest</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Intrinsic value</a></td>
<td class="nump">$ 2,493<span></span>
</td>
<td class="nump">$ 1,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">2,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Intrinsic value</a></td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632076022056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 4.62<span></span>
</td>
<td class="nump">$ 12.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.94%<span></span>
</td>
<td class="nump">0.84%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.21%<span></span>
</td>
<td class="nump">73.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated grant date fair value per share of award granted</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632072065496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632069480248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_PercentageOfIncreaseInRent', window );">Percentage of increase in rent by second year</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiry date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_EffectiveLeaseDate', window );">Effective lease date</a></td>
<td class="text">Jul.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="nump">8,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_PaymentsForRentHistorical', window );">Historical rent paid</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Future rent payment per month for first year</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Total rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EffectiveLeaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective lease date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EffectiveLeaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_PaymentsForRentHistorical">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Rent Historical</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_PaymentsForRentHistorical</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_PercentageOfIncreaseInRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_PercentageOfIncreaseInRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632076752696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632074604856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use lease liabilities, current</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use lease liabilities, noncurrent</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lbph_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632075100792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139632075003192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Benefits - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Company Provides Safe Harbor Contribution</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Expenses Related To Contribution Plan</a></td>
<td class="nump">$ 57,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>lbph-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lbph="http://www.longboardpharma.com/20220331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lbph-20220331.xsd" xlink:type="simple"/>
    <context id="C_2655fe60-4d25-4284-b79f-1967edee3839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_bdcd3f71-38fa-42e6-9add-cb16918179ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_31170f32-a22f-4352-849d-e35afea40908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_11b0fef0-018f-4b6f-ab46-c55488de2309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_29313d8d-0ffb-41be-8fa7-c20863221e1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e86bcfe1-5eb0-4d7b-989e-1f9935ce49ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0628a4d5-b09e-41bf-a2ee-edcd9f32b55b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0722e749-c954-4ce9-ab39-444c58dc2881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ffc4f5e6-0263-492e-ad25-dcc5b98597cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_03502668-69d3-4b66-87e8-922d0b9abce4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:RestrictedStockAwardsIssuedButUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_dec870ee-6073-4897-923d-80d2a6b03504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_02020b7d-b208-4c2c-a733-42569e5d08dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_fda728c6-7230-445d-bb2d-a1d2a175a4dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fdeeb5db-054e-4a0c-86cf-6ce2edf523ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_81e2be07-54b9-4bae-bda9-6422aa68dcac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lbph:NonVotingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_2a89fc91-d506-45f3-8bba-599c41b01b99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a8bb7596-5e83-40a5-bc09-180d4c07bdb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6f014e8f-22fe-4b60-8044-d462c1e03e5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_111122f4-280d-463c-9ab4-63bd2975497a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5471e841-ee26-4cc9-9b66-05a2aa664d47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_c0f2460f-20c4-446c-ac60-5e0355d60e9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c97da89c-c235-411e-8d1d-ca53c0034968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0e184fe9-70db-4b51-8f51-e7daee0646e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0898e6aa-40e5-4b23-a631-d1afea0062f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_44a745b1-8590-4c56-a3ed-0c09f28a94c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0af9bf0f-83d2-47dd-b34f-f5ff391ab8e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_ab26e8fc-4dd9-4f09-b2f7-0485e626668f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_3089195e-628b-4987-a83b-ebdfac8204f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_2ca15a2e-29d2-44a0-806a-b15a96250afe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_2e062ff4-cbda-4e3e-8fa7-05c3aade08b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_549ce4bd-686d-442f-bec8-cff814bcf0e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_22339958-3266-42a9-b2a0-2291d1710f50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_6986e0f3-27b9-4230-8099-f7546e5d6aec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_ec438a36-4ab4-4833-ab54-531b4294a419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_b7d798c6-2583-44f6-b7aa-21e646fcc6e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_3dac1763-1355-4e75-8a87-b645f330a7a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_8d514ad7-d0d1-4543-a8ee-033cdb99e31e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lbph:VotingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_81a29217-af44-4634-b86a-6f8e9b5cd41f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_d30731d9-ffd1-4fb3-a5cb-af59f3e75e1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_8c8296e4-a716-439c-9900-3c7b633eae24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_26a7cd1a-59b8-401c-a12e-bb0756e81c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_747a9757-4637-484e-8f82-bcf37809bb1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_8efd140d-3127-4cdd-8ac9-f08d5e61b9af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_a531a6b1-934f-48b8-b028-def438b4f83e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_3bcd0cd4-3850-4908-83de-d934090eb79e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_be132c83-e4b1-424e-8599-c831e7ef8f25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_72b0ea79-5b1c-4a38-a65e-54b9a5e8d3fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_b9cb68ea-1f8f-406a-aac6-ca4b08dfabf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0a879bf7-5305-4aed-a15a-0c23a2c40c3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="C_463e3347-cf52-4239-9f7a-da1011c1a577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_16281141-6238-424a-a692-584efe899d06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bb620d64-a9b5-4688-82e4-277ff6804f79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_efe47525-2ddf-4af4-b89b-dd45c135f753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_5569f3b9-e8d6-4f09-abb0-3e4cf23b60af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6ed6747a-4df3-4e56-9206-ca5d99f749b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6e96d89c-3510-4a01-bed8-8670aa664af7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_08f1e619-22db-4701-aac9-d440535be96c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2d24a6fd-40bc-4a7d-b253-daa51fdda1a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fd422146-05ed-41df-a129-56bc4396484d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_411fcc95-d2a3-4968-a6b9-3f43126c5687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_641c2769-ddbe-423d-9412-3a70a2e24ef9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_e77ce52b-d6f2-4eed-8fd9-5a23050d2e60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_ba57d460-9816-4359-a3ef-f6f9cb97b646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_02266e54-4c73-4ddd-a755-5e6bb9805b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_43c46d9e-b7fb-42d5-9413-a5ff23430785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_36111630-4e04-42da-b57e-0f75ad0cc30a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_36a1f79c-d3cd-46af-8004-96e6e76ca20d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_5f110eb6-6397-4682-9e46-c1939e77c0ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_839615d0-1a34-4d54-ab89-c7fcaed43c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_8b0cdbe2-b835-49c9-bc65-56f719043e55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_4eca72ce-0189-4f47-8a5c-532366ac8a15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_232f4315-8657-4869-b33e-7c126f32a8ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_1e80a750-d3a7-4459-84c3-c56a5568c616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_93010243-3fe5-453c-9416-305b5ced4e85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_5abf3b7d-dfe1-4131-b569-1ba2bbc191cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_506976c5-dd13-46a5-8cfa-503cc70a41d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="C_40e8580c-c3e8-4c87-a553-b371d230dd76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_f71add10-710e-4bf5-b5f6-4fff7c798c9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_eef36757-226e-47ff-beb4-5d13c0c46eab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_4ce3d74a-3f84-471d-9e5c-04ef7df96e27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2020-10-25</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_a030be25-78e1-4090-9c78-9f4811f1e055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2021-03-03</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="C_eaa76b6a-d6e8-4190-83d0-cdcd0bfea44e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7f8cf839-c503-41f8-9e31-ce86ee57e5b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_cf78c477-8c49-4b52-b598-45ec83827cde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_6903f08f-6a69-4542-a56f-570e58669425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_82778bab-76e7-48f5-8b9e-88f94d43736a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_93a82a9b-a4cd-49de-9617-b82cd4e5a356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b5a4e72f-cf27-46e2-ab49-3355ed77023e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_317bfead-8157-4725-b85c-7b445e78eecf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="C_20c59b03-2524-402d-b021-af6520d107e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_e2c10102-6c97-4154-85bb-f3bae871ff64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_151f28bf-56b2-4205-b6b7-87fdd9e3d327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="C_75d9b63f-7f04-4f56-b23d-3c79af44d34c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:RestrictedStockAwardsIssuedButUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_699a037f-4e23-4963-91de-5ec47a942247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_68129ee5-d5db-40e7-8ebc-9736893ecaab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_3dcaf53c-8e87-4231-9cdf-cbd59cbb3dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_56ad1eec-83c4-4eb6-9d05-df599a3ebed5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_8ab315bc-d0fd-45e4-8748-3fffcde6b7bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_84dde4dc-9258-407b-9e70-2284d1860ed8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_fca0cf8b-0c7e-4480-9275-35cb0b51c5ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_3500f45a-facc-48a9-b0ad-fc61707a95d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_c837c3fa-195b-40fa-9996-1c5976eb2157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_4f191f3e-5732-495f-a6d2-07b3bf590202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_6bf2e3e8-5766-4a8d-a320-22cfde28e6ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_447a2d48-43c5-47de-9129-d4546af4a637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_fb752fef-8648-4131-978b-8d72d633b477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Securities">
        <measure>lbph:Securities</measure>
    </unit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_c97da89c-c235-411e-8d1d-ca53c0034968"
      id="F_1f13ee31-05a2-420a-b85b-665c04190587">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_5ce25b0a-c8b6-4a6e-9441-b443568f228e">--12-31</dei:CurrentFiscalYearEndDate>
    <lbph:AccruedTaxes
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      id="F_5a0988e8-75d5-4bd3-b7bb-e0565dc26350"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccruedInsuranceCurrentAndNoncurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      id="F_ebed43d0-0a92-4d67-8082-ae25c97d4cd4"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_df5dbf7b-b950-49f3-abc4-43f13bddedd6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_bc658670-58ad-420e-91d0-3c0fdd6210c0">Q1</dei:DocumentFiscalPeriodFocus>
    <lbph:InitialPublicOfferingCostsInAccruedOtherExpenses
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_31aa28bf-c96d-414d-a22e-8d815c9560c0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      id="F_3e9290f2-0b2a-4695-a7d0-847c4bef8c92"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_02266e54-4c73-4ddd-a755-5e6bb9805b74"
      id="F_c95df60b-4fb8-4cd0-9d53-ee8d8e733b63">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_d22cadd7-b2aa-40bc-acf9-36f7dc858eea"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_552e6b6d-c6a6-46a7-bb88-6954cc69799d">0001832168</dei:EntityCentralIndexKey>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      id="F_6bdb1ba3-dfad-4058-a0be-7b7aed903997"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      id="F_9231d077-945d-410b-8307-6c7553574eee"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      id="F_95ed34e6-5f20-47df-b65f-8340f754d540"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_ebc61d5c-536a-481b-9217-70d9a5350593"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      id="F_bd9f2f72-a0af-4338-a21a-6b79219310b1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      id="F_1f0d255a-768e-477d-b6ea-fede3d5836b8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <lbph:InitialPublicOfferingCostsInAccountsPayable
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_4436940e-61d1-4fc1-835e-8100582ca39f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_7367b3af-9865-48bd-99a3-78098bb4ce66"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_1564051c-6da9-4837-b61b-5f6a25fdd6d3">false</dei:AmendmentFlag>
    <lbph:AccruedRecruitmentFeesCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      id="F_447350e3-6678-4d9f-8965-dfcca260ed3b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_764e77a5-513a-4fb3-9f05-eb63b1931457">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_31a5673b-c7b7-4bf4-84f3-a411f4eac832">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_92b391d2-5b75-429c-94d8-57576fab2463">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_21f572df-cf4f-4c5c-baf7-ed77fb0fb518">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_7cc8bdaa-81b0-4762-b67e-ae34d55636bf">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_81d464e5-861c-462f-b86e-96e634727458">001-40192</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_3e24cbf7-be56-48d0-a2f2-6cc4c5e26f89">Longboard Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_bf2cb209-02a8-4e26-94af-14b4c7ded830">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_e6b8df17-af22-4f59-ad2e-e065714d1261">84-5009619</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_4d08dda9-a3c8-4769-9dc1-324e13fb3a08">4275 Executive Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_1ccbc9f4-6cf7-4c2c-98bc-d93ea5d28036">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_bbd15cb3-3ac8-4146-b668-19bfe4400ce8">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_368c9157-a22d-4c9e-91d5-f3eea9534825">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_ee61252e-1507-4ac4-8ce0-a20b4f4fb49a">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_7785f77c-6638-4de8-8887-5800fffae3c8">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_d22da009-6a35-456d-b791-43428436fe60">592-9775</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_a3925b4a-da93-4fc1-8f0b-2eff96b65a13">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_f0aa17aa-aba4-4ed6-a449-c34f5124dea5">LBPH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_91a4718e-bab3-4f6d-8f1f-6f8a2e512233">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_2dc84b0d-09a9-4903-b83c-da0caab22c87">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_a846a6d1-7d64-4a11-adda-c6941991412b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_c08da267-c19b-4c62-8ffc-6cc30f1d06c4">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_4359f6fe-b364-4f76-8046-a69578ddcff6">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_9b83b82e-cdf0-490c-b99f-04c19047595f">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_d1ffeaab-b4c6-495d-b5fb-67f7aa4a3c2f">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_4959a3d3-4500-4334-bf2c-988f7ca8ddfa">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0a879bf7-5305-4aed-a15a-0c23a2c40c3f"
      decimals="INF"
      id="F_87c7f04a-3f98-4288-95d9-428ca13cefe3"
      unitRef="U_shares">17215350</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_54b88eea-9695-4ed9-a409-2510855eaa5e"
      unitRef="U_USD">35037000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_45452a93-2f1b-47b3-8ee5-cc37aa60d90f"
      unitRef="U_USD">66346000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_ca531450-8dc9-426b-9112-b28744f3704f"
      unitRef="U_USD">61087000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_a095c129-e981-4099-8fd5-8a6a8e68a56f"
      unitRef="U_USD">40379000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_b7708e90-3d99-49b8-883c-1300c045ab63"
      unitRef="U_USD">4035000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_ca1e5f66-3e37-4eac-b74c-5493bcf348bb"
      unitRef="U_USD">1659000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_0cd1bf50-4cac-4c30-a133-fdb8e700ceb8"
      unitRef="U_USD">100159000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_c33ebbde-7dc5-464c-8ed5-42e89c716523"
      unitRef="U_USD">108384000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_b19897a6-7a8d-4272-9d09-ed40ac0ad3b4"
      unitRef="U_USD">438000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_5015901e-82cb-4a14-9cfe-8758528d5662"
      unitRef="U_USD">521000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_fee2ed5c-710e-453f-a371-edd6a0d851f5"
      unitRef="U_USD">13000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_64d1f666-fcb2-403e-9f35-a4c352ae8a74"
      unitRef="U_USD">14000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherLongTermInvestments
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_bf759891-c4a6-4ba8-938d-9b557b6b3417"
      unitRef="U_USD">33000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_03cb9436-7f78-44ef-8a9a-5c96201533cc"
      unitRef="U_USD">33000</us-gaap:OtherLongTermInvestments>
    <us-gaap:Assets
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_4fd90f8b-934b-4e98-a108-eb3f758073d3"
      unitRef="U_USD">100643000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_40a6fe4f-83dc-44d4-90cc-10265a1a58f0"
      unitRef="U_USD">108952000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_a7d712c8-718c-41cf-9676-7441dfd87ba5"
      unitRef="U_USD">1357000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_4e99edcd-9ecf-48d3-8d82-ad737cbf7aa1"
      unitRef="U_USD">1028000</us-gaap:AccountsPayableCurrent>
    <lbph:AccruedResearchAndDevelopmentExpenses
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_7aec7d4b-565d-41dc-ac90-292daf4fb058"
      unitRef="U_USD">2998000</lbph:AccruedResearchAndDevelopmentExpenses>
    <lbph:AccruedResearchAndDevelopmentExpenses
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_646728b5-b62a-4a2e-ad3b-adb3acc9404f"
      unitRef="U_USD">2245000</lbph:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_a0bb330e-2964-4821-a778-84b6c8d8fda3"
      unitRef="U_USD">443000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_82f54535-866b-4297-8da8-f05b4157b69b"
      unitRef="U_USD">1480000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_10c6f502-e8d3-48e1-8c95-6262f730bfc2"
      unitRef="U_USD">1536000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_2cb92e02-1a00-4432-8164-5dc470c5ee64"
      unitRef="U_USD">352000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_9f4b2f4e-d9a2-4ae9-a3d4-62e512f9e771"
      unitRef="U_USD">350000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_7a727993-c95b-458a-bc92-5b4e0830397d"
      unitRef="U_USD">339000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_bd01dbe3-e34d-4844-ab70-2bf6b5a119e7"
      unitRef="U_USD">6684000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_7b936457-4d8e-4032-aaf7-477f8aad2c77"
      unitRef="U_USD">5444000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_bfaac795-ac19-4000-9d4e-2f3a5bc352ce"
      unitRef="U_USD">94000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_6d89d6df-50f6-4b76-8eb0-7cc8e99b0835"
      unitRef="U_USD">185000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_18fc72ed-d32e-4606-9a93-ee6ada8ca2ad"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_c5f0a5d2-d952-4805-ac9d-7320db3b6dd2"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_d29848e9-3ae9-4924-8132-689a440b14ad"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_49ac1a4d-56d0-49cc-b8e7-ebef97be8bfd"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_e85b4ce4-e29c-4978-9b46-e2f16dc6f675"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_8970246f-96a1-4401-b762-210115414ad5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_4d2f9361-3706-4e31-b876-acf8b86de34d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_0422d049-ee9d-48c5-85f7-df91145c5de1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_333a1558-1d50-4161-b02e-20c052064754"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_5c404260-139b-4f92-93b3-61a47072b2cb"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_812d2b52-94cf-4702-8dae-6546a9caa46a"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_bc0c51ea-0b27-4dc0-8282-7e025aa0f328"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_16a05661-6473-48e7-b64c-dc9992736e42"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_67e197ce-a518-4f65-9034-f3173d418857"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_852fb288-4b56-432c-b2fc-e1f05f2e917f"
      unitRef="U_shares">13484315</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_e8f7625d-5486-4340-82fd-2c68fa862af0"
      unitRef="U_shares">13484315</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_9f594b89-0f75-4e8e-b2b3-ff7c2a267f5e"
      unitRef="U_shares">13440761</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_e7db14d7-1e23-476b-b324-b0209fbd07f3"
      unitRef="U_shares">13440761</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_152c5055-cd1d-47bb-b652-24cde95b00c5"
      unitRef="U_shares">101635</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_fbe75a19-1a9d-4db9-8a6f-f34d7d3c82cb"
      unitRef="U_shares">145189</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockValue
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_60a50584-00f1-46d9-91ab-71e35b936e53"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_5498c207-b1d2-4b8c-90d8-46e79d096da7"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_31170f32-a22f-4352-849d-e35afea40908"
      decimals="INF"
      id="F_e0930587-58a0-422d-9946-1868eb161ddd"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785"
      decimals="INF"
      id="F_1f885dc3-241c-4fc7-9eb8-1b513cfbd0b6"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_31170f32-a22f-4352-849d-e35afea40908"
      decimals="INF"
      id="F_bd26ec26-aa85-4ff7-944d-4d2315193484"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785"
      decimals="INF"
      id="F_20ce6e0c-8f17-459e-9ceb-80c569e0f2ef"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_31170f32-a22f-4352-849d-e35afea40908"
      decimals="INF"
      id="F_afee300c-bac0-4f12-b1cf-5e5893c6035c"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_31170f32-a22f-4352-849d-e35afea40908"
      decimals="INF"
      id="F_19c24883-fd45-4699-b029-c2c4657bbd99"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785"
      decimals="INF"
      id="F_4a6a8cb0-96ad-4297-8e39-f3d49b25cc72"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785"
      decimals="INF"
      id="F_d254ef4f-6d2d-4ca8-a143-cbf0ba48cba6"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_31170f32-a22f-4352-849d-e35afea40908"
      decimals="-3"
      id="F_22d7620c-4f3a-4993-bec3-e26b8d06d8f2"
      unitRef="U_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785"
      decimals="-3"
      id="F_dd2d0ac8-843d-46c7-aad1-741be0abc3cf"
      unitRef="U_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_068e9439-cce4-4a7f-b1bc-7959fad7cbd4"
      unitRef="U_USD">146254000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_b83a06a3-770a-45de-a1b1-e62a73211eec"
      unitRef="U_USD">145683000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_ab45f0d9-92ed-406b-a049-44e16be563cd"
      unitRef="U_USD">-596000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_87af739d-f1fd-49d0-8432-193d055293bd"
      unitRef="U_USD">-164000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_72ac5d4b-ce43-42e7-8238-6260ce0e17a5"
      unitRef="U_USD">-51794000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_dd5ebbd1-63f5-4946-ad23-012063bba7db"
      unitRef="U_USD">-42197000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_b500b54e-6bb7-4b25-b4b7-5e9b0462baee"
      unitRef="U_USD">93865000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_11b859a9-a7ec-4e31-8431-05b5f80e90c5"
      unitRef="U_USD">103323000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_3d65a4d7-8c68-4955-a79b-49901d0137cf"
      unitRef="U_USD">100643000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_bf0c7ec9-992c-4c8d-962a-050d3bc7e01e"
      unitRef="U_USD">108952000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_b9ef8b3e-a970-41ad-a8d8-7ce0773162a4"
      unitRef="U_USD">7121000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_fe1e75be-2a30-44f1-bfb7-b55bee66dccc"
      unitRef="U_USD">4398000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_0549a859-6032-4f74-86a0-1e0fcbc40f94"
      unitRef="U_USD">2499000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_6da3711b-a0eb-482f-a30f-5d99bf7c0b87"
      unitRef="U_USD">1305000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_bfb6f579-b97d-4eb5-aecf-948e7c2d2b60"
      unitRef="U_USD">9620000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_5f213688-e17c-4a05-ac11-8da0c8baa5e2"
      unitRef="U_USD">5703000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_67297c67-9e5a-4095-826d-ffa05e6f4edf"
      unitRef="U_USD">-9620000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_9594741a-7c26-4f52-ae02-926d8531c2f3"
      unitRef="U_USD">-5703000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_86861c5e-1cff-4182-b2d5-bc60b1c9e67e"
      unitRef="U_USD">32000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_7e58f4b6-34d2-41d4-830b-7ffa131e524e"
      unitRef="U_USD">4000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_9484df02-2ae9-467f-a15d-b378e501c7de"
      unitRef="U_USD">-9000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_251770ba-4452-4318-b91f-5b53657f9d1d"
      unitRef="U_USD">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_ab4fe14d-ea4b-4b05-8e55-84f256b3d9a1"
      unitRef="U_USD">-9597000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_9dc6f280-c100-429d-ae11-a0ea63f476cc"
      unitRef="U_USD">-5699000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="2"
      id="F_af2e83d5-f703-46df-99e7-47b032ee2388"
      unitRef="U_USDollarShare">-0.56</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="2"
      id="F_19f89f61-2ddb-48e1-9742-605b675e541c"
      unitRef="U_USDollarShare">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="0"
      id="F_354475f1-5204-4b98-bb67-7ed6d9957512"
      unitRef="U_shares">17086615</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="0"
      id="F_f326b89e-a411-4c84-ad5b-59ca201cf724"
      unitRef="U_shares">6810407</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_b37d224f-6a51-4b88-9df6-6686910a5c32"
      unitRef="U_USD">-9597000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_2aff8e45-e10e-46da-bc20-c6d1c89b3cfb"
      unitRef="U_USD">-5699000</us-gaap:NetIncomeLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_079f94c1-4daf-4d7b-afb7-b5e903f6a0dd"
      unitRef="U_USD">-432000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_422298b6-1af7-4a55-8526-6c4906896ce5"
      unitRef="U_USD">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_f6b2d7e6-ef5e-4c1e-9c3f-b079e6044201"
      unitRef="U_USD">-10029000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_aaeb68fd-b57e-43f1-a977-479aa0766f9f"
      unitRef="U_USD">-5699000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_7f38b5aa-1288-48bb-9287-dc17af2c05fd"
      unitRef="U_USD">-9597000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_2ac01ca4-88aa-4393-91ac-1c5c0ad2cc6d"
      unitRef="U_USD">-5699000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_dd19c030-90f5-4274-ba4d-f1ad2ebe7231"
      unitRef="U_USD">571000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_38803ebc-8809-4b98-946f-e91937e0e0ff"
      unitRef="U_USD">333000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_240adac5-28ac-41e7-bfee-b3c23b685423"
      unitRef="U_USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_f9a8882d-b3fd-4596-b9b6-c3d5f0b8443b"
      unitRef="U_USD">145000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_65fc8cd0-8726-4bb7-8da9-55dfd7ea0e4a"
      unitRef="U_USD">2377000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_84e33b54-3745-45ac-8949-c8c4a95cf38c"
      unitRef="U_USD">2733000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_da608668-c510-4ccf-a7ae-e431bdd1270c"
      unitRef="U_USD">329000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_51d730f1-796e-44f9-adfb-8e75a363e938"
      unitRef="U_USD">275000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_588304c3-88a0-4445-ae9b-4c5e5c346eaf"
      unitRef="U_USD">-753000</lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_e8904c46-6a2f-4cb7-8dab-739c810556cb"
      unitRef="U_USD">-135000</lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_f0611029-6107-43fa-baff-a01b36dfb4af"
      unitRef="U_USD">-1036000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_3769833f-01e0-4010-92f6-49d5cb8ffdeb"
      unitRef="U_USD">115000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_496d4a26-f2cc-40cc-a2f3-1ca624e79988"
      unitRef="U_USD">1184000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_3182a4cd-2bb3-4bb2-99c5-3e6bda14890b"
      unitRef="U_USD">-172000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_001ca912-2a20-4c5d-8d55-b0f81c4eff4d"
      unitRef="U_USD">2000</lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_2f468bc6-0e4a-428f-905b-2f807ca15b94"
      unitRef="U_USD">-10025000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_ff80e552-252f-4336-9d58-b09b09b18321"
      unitRef="U_USD">-7746000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_6aeed1dd-a7df-4f13-aa50-80a1a805f833"
      unitRef="U_USD">21284000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_556f1389-8e40-4892-92ec-57600aa215b8"
      unitRef="U_USD">-21284000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_591d29fb-f896-4445-b4de-1949d109f15f"
      unitRef="U_USD">1000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_02acdbee-4a65-4ab9-8d57-0c9dbde62e49"
      unitRef="U_USD">80000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_a2140983-90f0-446a-aa50-1833ad7056c4"
      unitRef="U_USD">6718000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_d2c9e4af-bf75-46e6-b64b-c53334b674d8"
      unitRef="U_USD">73281000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_793e99af-879a-4e32-80c3-1335e16eb19d"
      unitRef="U_USD">-31309000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_c57bedab-3fa2-4f28-aba0-1e08254e4f46"
      unitRef="U_USD">65535000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_ff307f55-910a-4b13-af07-ec9423e29c57"
      unitRef="U_USD">66346000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f71add10-710e-4bf5-b5f6-4fff7c798c9a"
      decimals="-3"
      id="F_58cfccc1-3b9c-4f7b-9c8f-29917cbbfdd1"
      unitRef="U_USD">55316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_5d3cf4b2-3621-4dfb-a7fa-8ed6a9c730f3"
      unitRef="U_USD">35037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_cf78c477-8c49-4b52-b598-45ec83827cde"
      decimals="-3"
      id="F_4c27d11e-0f6c-4588-b596-4b1107e0fbe6"
      unitRef="U_USD">120851000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <lbph:InitialPublicOfferingCostsInAccountsPayable
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_d703a96f-77b6-47f8-8b5e-0e26997063f1"
      unitRef="U_USD">531000</lbph:InitialPublicOfferingCostsInAccountsPayable>
    <lbph:InitialPublicOfferingCostsInAccruedOtherExpenses
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_5d464ea6-72ff-4433-bc8c-eab2badea880"
      unitRef="U_USD">664000</lbph:InitialPublicOfferingCostsInAccruedOtherExpenses>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_ae2de305-fa63-4a5f-aa0b-34954ce802e5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 1. Organization and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Longboard Pharmaceuticals, Inc. (the "Company"), formerly Arena Neuroscience, Inc., was incorporated in the state of Delaware on January 3, 2020, and is based in San Diego, California. The Company was organized and initially wholly-owned by Arena Pharmaceuticals, Inc. ("Arena"), until the closing of its Series A convertible preferred stock ("Series A Preferred Stock") financing in October 2020. The Company is a clinical stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The Company&#x2019;s most advanced product candidate, LP352, is being developed for the treatment of seizures associated with developmental and epileptic encephalopathies and is currently in a Phase 1b/2a clinical trial ("the PACIFIC Study"). The Company&#x2019;s preclinical product candidates include LP659 and LP143, which are potential therapies for multiple neurological diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 16, 2021, the Company completed the initial public offering (&#x201c;IPO&#x201d;) of its common stock. In connection with the IPO, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,298,360&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of voting common stock, which included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;298,360&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its voting common stock issued pursuant to the option granted to the underwriters to purchase additional shares in April 2021, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The Company raised $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;76.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net proceeds from the IPO after deducting underwriters&#x2019; discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Unless otherwise noted, all references in the financial statements and related footnotes to the Company's "common stock" refers to the Company's voting common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Immediately prior to the closing of the IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,630,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series A Preferred Stock were exchanged for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of non-voting common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,970,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,098,600&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of voting common stock. Following the IPO, there were no shares of Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Forward Stock Splits&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 27, 2020, the Company filed an amendment to the Company&#x2019;s certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,783&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-for-1 basis (the "October 2020 Forward Stock Split"). The par value of the common stock was not adjusted as a result of the October 2020 Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the October 2020 Forward Stock Split for the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 5, 2021, the Company filed an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.38&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-for-1 basis (the "March 2021 Forward Stock Split"). Adjustments corresponding to the March 2021 Forward Stock Split were made to the ratio at which the Company&#x2019;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March 2021 Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March 2021 Forward Stock Split for all periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and applicable regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, the accompanying unaudited condensed financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The balance sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. The operating results presented in these unaudited condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. The Company&#x2019;s unaudited condensed financial statements should be read in conjunction with the audited financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 3, 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;its inception, the Company has devoted substantially all of its resources to research and development ("R&amp;amp;D") activities, organizing and staffing, business planning, raising capital, in-licensing intellectual property rights and establishing its intellectual&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;property &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;portfolio, and providing general and administrative ("G&amp;amp;A") support for these operations and has funded its operations primarily with the net proceeds from the issuance of Series A Preferred Stock and common stock. The Company has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;51.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of March 31, 2022, and December 31, 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Management expects the Company will incur substantial operating losses for the foreseeable future in order to complete preclinical studies and clinical trials, seek regulatory approval, and launch and commercialize any product candidates for which it receives regulatory approval. The Company will need to raise additional capital through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The COVID-19 pandemic continues to evolve and has resulted in a significant disruption of global financial markets. The Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the pandemic. If the disruption persists or deepens, the Company could experience an inability to access additional capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2022, the Company had available cash, cash equivalents and investments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;96.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and working capital of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;93.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to fund future operations. Management believes that its capital resources as of March 31, 2022, will be sufficient to fund the Company&#x2019;s operations for at least 12 months after the date these unaudited condensed financial statements are issued.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <lbph:NumberOfCommonStockSharesIssuedAndSold
      contextRef="C_84dde4dc-9258-407b-9e70-2284d1860ed8"
      decimals="INF"
      id="F_fc3333f2-e5e5-43e7-848d-4377346b6341"
      unitRef="U_shares">5298360</lbph:NumberOfCommonStockSharesIssuedAndSold>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_84dde4dc-9258-407b-9e70-2284d1860ed8"
      decimals="INF"
      id="F_d4236b36-becf-4015-a622-5612ef510e08"
      unitRef="U_shares">298360</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_84dde4dc-9258-407b-9e70-2284d1860ed8"
      decimals="2"
      id="F_64560fe5-8138-47ac-950d-55be13a893eb"
      unitRef="U_USDollarShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_5471e841-ee26-4cc9-9b66-05a2aa664d47"
      decimals="-5"
      id="F_978a6fdb-358e-4889-b861-6220da14dc0e"
      unitRef="U_USD">76200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockDiscountOnShares
      contextRef="C_40e8580c-c3e8-4c87-a553-b371d230dd76"
      decimals="-5"
      id="F_ef31dd85-aa2b-492e-ab6c-dab2afce1e95"
      unitRef="U_USD">5900000</us-gaap:CommonStockDiscountOnShares>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_5471e841-ee26-4cc9-9b66-05a2aa664d47"
      decimals="-5"
      id="F_0ce1b37d-e95e-4825-969f-47674f04e07f"
      unitRef="U_USD">2600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="C_eef36757-226e-47ff-beb4-5d13c0c46eab"
      decimals="INF"
      id="F_9dfb4f06-6d10-4127-8c8d-d8a83b090713"
      unitRef="U_shares">2630000</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_81e2be07-54b9-4bae-bda9-6422aa68dcac"
      decimals="INF"
      id="F_688c02cd-32a8-4afe-97f9-8ff8302a976c"
      unitRef="U_shares">3629400</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="INF"
      id="F_555bb312-1ca3-44ec-99eb-32e931ea4665"
      unitRef="U_shares">2970000</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_8d514ad7-d0d1-4543-a8ee-033cdb99e31e"
      decimals="INF"
      id="F_efddb313-dc17-4ca2-91bc-b6a7f6dbe47f"
      unitRef="U_shares">4098600</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="C_4ce3d74a-3f84-471d-9e5c-04ef7df96e27"
      id="F_7b53616e-77d0-47c8-b9eb-4a6c13e534fd">On October 27, 2020, the Company filed an amendment to the Company&#x2019;s certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a 2,783-for-1 basis (the "October 2020 Forward Stock Split"). The par value of the common stock was not adjusted as a result of the October 2020 Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the October 2020 Forward Stock Split for the periods presented.</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_4ce3d74a-3f84-471d-9e5c-04ef7df96e27"
      decimals="0"
      id="F_a4e7ce5f-3470-4531-b325-02ddce415423"
      unitRef="U_pure">2783</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="C_a030be25-78e1-4090-9c78-9f4811f1e055"
      id="F_bce0d40c-aae4-4f7f-aa7b-fa3aaef58776">On March 5, 2021, the Company filed an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a 1.38-for-1 basis (the "March 2021 Forward Stock Split"). Adjustments corresponding to the March 2021 Forward Stock Split were made to the ratio at which the Company&#x2019;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March 2021 Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March 2021 Forward Stock Split for all periods presented.</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_a030be25-78e1-4090-9c78-9f4811f1e055"
      decimals="2"
      id="F_379a9440-4385-4e7b-86fa-0dc68dd87b54"
      unitRef="U_pure">1.38</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_eaf22d25-1ab5-4b4b-bcc6-8185bed59c61">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and applicable regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, the accompanying unaudited condensed financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The balance sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. The operating results presented in these unaudited condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. The Company&#x2019;s unaudited condensed financial statements should be read in conjunction with the audited financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 3, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-5"
      id="F_b4e9a922-5596-4c28-a510-84ae94022fc0"
      unitRef="U_USD">-51800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-5"
      id="F_114970e9-d381-48fe-9da4-759dd17b1f40"
      unitRef="U_USD">-42200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-5"
      id="F_279cfe80-abad-4b67-9006-7fd82d8d0034"
      unitRef="U_USD">96100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <lbph:WorkingCapital
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-5"
      id="F_47cd4984-e381-43d2-92bb-08882fa4896e"
      unitRef="U_USD">93500000</lbph:WorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_040c8b52-3484-4cf6-b1ef-551e2147d136">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Estimates are based on the Company&#x2019;s historical experience, knowledge of current events and actions it may undertake in the future, and actual results may materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. government-sponsored enterprises. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;R&amp;amp;D Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;R&amp;amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#x2019;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;amp;D expenses amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based awards are measured at fair value and compensation expense is recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease or contains lease components at inception. Lease terms are determined at the commencement date by considering whether renewal options and termination options, if any, are reasonably assured of exercise. For long-term operating leases, the Company recognizes a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset on its balance sheets and recognizes lease expense on a straight-line basis over the lease term. The lease liability is determined as the present value of future lease payments using the discount rate implicit in the lease or, if the implicit rate is not readily determinable, an estimate of the Company&#x2019;s incremental borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. The Company does not have any financing leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.622%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:17.99%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:1.74%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:17.99%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,350,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,248,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock awards, issued but unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;101,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;348,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,452,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,596,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments - Credit Losses &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASU 2016-13), to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance will become effective for the Company beginning January 1, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potential impacts to the Company&#x2019;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#x2019;s ability to raise capital and conduct business development activities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_44f0cf70-5ca0-45ef-b2d6-7bd570d08280">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Estimates are based on the Company&#x2019;s historical experience, knowledge of current events and actions it may undertake in the future, and actual results may materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_fb7c8387-d6e9-4c29-b749-c017d3f65c3a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_ace3a6da-82d3-477b-a59a-52f0c1030b7d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_7a38135f-1947-4205-84ae-e4380f73067c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. government-sponsored enterprises. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <lbph:ShortTermInvestmentsPolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_99196370-2321-499b-b424-443961d24e17">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lbph:ShortTermInvestmentsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_97932192-fe40-4ace-93ea-ad824bcfdbea">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;R&amp;amp;D Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;R&amp;amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#x2019;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;amp;D expenses amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-5"
      id="F_efda0a7f-adfa-4993-ab05-86b976461e24"
      unitRef="U_USD">7100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-5"
      id="F_470eeeaf-499f-4148-8421-59f81c6fb05f"
      unitRef="U_USD">4400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_be872577-4f6f-4cbf-8def-6893fac7645b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based awards are measured at fair value and compensation expense is recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_f7599dc5-1298-4b35-9023-f554621edc53">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease or contains lease components at inception. Lease terms are determined at the commencement date by considering whether renewal options and termination options, if any, are reasonably assured of exercise. For long-term operating leases, the Company recognizes a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset on its balance sheets and recognizes lease expense on a straight-line basis over the lease term. The lease liability is determined as the present value of future lease payments using the discount rate implicit in the lease or, if the implicit rate is not readily determinable, an estimate of the Company&#x2019;s incremental borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. The Company does not have any financing leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_8192b82e-2b8e-41b4-8a38-6ead361f339b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.622%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:17.99%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:1.74%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:17.99%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,350,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,248,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock awards, issued but unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;101,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;348,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,452,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,596,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_22b0612f-c852-428a-a64f-36d300c8f763">&lt;p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.622%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:17.99%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:1.74%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
          &lt;td style="width:17.99%;"/&gt;
          &lt;td style="width:0.664%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,350,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,248,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock awards, issued but unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;101,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;348,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,452,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,596,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8b0cdbe2-b835-49c9-bc65-56f719043e55"
      decimals="INF"
      id="F_cb59130d-bdf9-4cd2-b671-fb89fdb81a8d"
      unitRef="U_shares">2350934</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ec438a36-4ab4-4833-ab54-531b4294a419"
      decimals="INF"
      id="F_fb7b44e8-12b5-48c9-868d-1a8c1582e0af"
      unitRef="U_shares">1248156</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_03502668-69d3-4b66-87e8-922d0b9abce4"
      decimals="INF"
      id="F_2776f918-e701-4e96-abca-d493f6296138"
      unitRef="U_shares">101635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_75d9b63f-7f04-4f56-b23d-3c79af44d34c"
      decimals="INF"
      id="F_37395533-6c95-42e8-b025-3c8fd460c9d2"
      unitRef="U_shares">348450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="INF"
      id="F_8c8c66ac-882b-49d6-904c-dd8088ee5fad"
      unitRef="U_shares">2452569</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="INF"
      id="F_55c0c26e-c0b9-4acb-9544-a3552651df8d"
      unitRef="U_shares">1596606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_44c01a0c-953d-4b8a-8063-e5dfbda691d3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments - Credit Losses &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASU 2016-13), to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance will become effective for the Company beginning January 1, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <lbph:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_92dc7851-fd93-4189-b9e9-55554e7cb637">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potential impacts to the Company&#x2019;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#x2019;s ability to raise capital and conduct business development activities.&lt;/span&gt;&lt;/p&gt;</lbph:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_7020939b-52f9-487b-bcb5-f7fa48a62eaa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 3. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2014; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2014; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2014; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.14%;"/&gt;
        &lt;td style="width:3.229%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:11.45%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.229%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.578%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.229%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.615%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.229%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.128%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements at &lt;br/&gt;Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant Other Observable Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant Unobservable Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;22,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;22,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;29,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;26,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;85,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;49,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;36,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;36,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;36,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;40,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;76,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;45,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_e7732527-320b-471b-aefa-82ffa360e788">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March 31, 2022, and December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.14%;"/&gt;
        &lt;td style="width:3.229%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:11.45%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.229%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.578%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.229%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.615%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.229%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.128%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements at &lt;br/&gt;Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant Other Observable Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant Unobservable Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;22,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;22,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;29,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;26,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;85,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;49,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;36,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;36,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;36,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;40,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;76,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;45,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="C_02020b7d-b208-4c2c-a733-42569e5d08dd"
      decimals="-3"
      id="F_866a8e51-99cc-4aed-ae49-8977d815185b"
      unitRef="U_USD">22904000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_8efd140d-3127-4cdd-8ac9-f08d5e61b9af"
      decimals="-3"
      id="F_4da00532-5d4e-4300-8802-2d14e6ca2fbc"
      unitRef="U_USD">22904000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_82778bab-76e7-48f5-8b9e-88f94d43736a"
      decimals="-3"
      id="F_be73908b-34af-4340-a6f2-9486c6372a37"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28"
      decimals="-3"
      id="F_a08ebc7d-09b0-450e-8519-93ca59fa70a4"
      unitRef="U_USD">14983000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_232f4315-8657-4869-b33e-7c126f32a8ca"
      decimals="-3"
      id="F_1008a247-2fbe-4007-b140-2d34e9d9c96f"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_72b0ea79-5b1c-4a38-a65e-54b9a5e8d3fc"
      decimals="-3"
      id="F_ced1e3e5-f0b5-4cea-8e5b-5e436cf1bef8"
      unitRef="U_USD">14983000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_5abf3b7d-dfe1-4131-b569-1ba2bbc191cf"
      decimals="-3"
      id="F_e7757150-88b7-4307-b9ce-c11c814c5a0a"
      unitRef="U_USD">18456000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_747a9757-4637-484e-8f82-bcf37809bb1b"
      decimals="-3"
      id="F_bde02af6-dd22-400c-9554-cb23774c6a5b"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_6986e0f3-27b9-4230-8099-f7546e5d6aec"
      decimals="-3"
      id="F_647b3ac4-7a4d-4905-bc79-29e8640241f3"
      unitRef="U_USD">18456000</us-gaap:ShortTermInvestments>
    <lbph:ShortTermInvestmentsAndCashEquivalents
      contextRef="C_a531a6b1-934f-48b8-b028-def438b4f83e"
      decimals="-3"
      id="F_80d19bc3-5417-47c5-a337-d6122843fcd9"
      unitRef="U_USD">29647000</lbph:ShortTermInvestmentsAndCashEquivalents>
    <lbph:ShortTermInvestmentsAndCashEquivalents
      contextRef="C_2ca15a2e-29d2-44a0-806a-b15a96250afe"
      decimals="-3"
      id="F_651de634-280c-4649-a065-2ab237ee76aa"
      unitRef="U_USD">26862000</lbph:ShortTermInvestmentsAndCashEquivalents>
    <us-gaap:ShortTermInvestments
      contextRef="C_81a29217-af44-4634-b86a-6f8e9b5cd41f"
      decimals="-3"
      id="F_bef0886e-aa68-4c04-9a5c-5ecff1d51e61"
      unitRef="U_USD">2785000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_d93ce9ac-a31d-4a71-bf03-dff5ebed0a43"
      unitRef="U_USD">85990000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_56ad1eec-83c4-4eb6-9d05-df599a3ebed5"
      decimals="-3"
      id="F_efbd2cca-bb5e-4864-81d9-0a0841e24998"
      unitRef="U_USD">49766000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_463e3347-cf52-4239-9f7a-da1011c1a577"
      decimals="-3"
      id="F_44687d33-dc97-4b68-817e-fb2c0cb62923"
      unitRef="U_USD">36224000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_eaa76b6a-d6e8-4190-83d0-cdcd0bfea44e"
      decimals="-3"
      id="F_6e602020-a127-436d-af2b-f8aba96885e0"
      unitRef="U_USD">36014000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_4f191f3e-5732-495f-a6d2-07b3bf590202"
      decimals="-3"
      id="F_442cc76f-1cab-4971-8f2d-47aa7667e439"
      unitRef="U_USD">36014000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_6ed6747a-4df3-4e56-9206-ca5d99f749b6"
      decimals="-3"
      id="F_b8114535-89fe-484e-a7c0-0cdfe0759fe6"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab"
      decimals="-3"
      id="F_2a3a747d-ca96-4d13-8eec-44326fff201f"
      unitRef="U_USD">13987000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0722e749-c954-4ce9-ab39-444c58dc2881"
      decimals="-3"
      id="F_4ba8a277-ea6f-479f-ac45-6e03cbb87e33"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_5569f3b9-e8d6-4f09-abb0-3e4cf23b60af"
      decimals="-3"
      id="F_080d1432-7bb7-4975-a661-684a96cb657d"
      unitRef="U_USD">13987000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_c0f2460f-20c4-446c-ac60-5e0355d60e9d"
      decimals="-3"
      id="F_f5998b3c-e160-4852-a582-afcb5d069b02"
      unitRef="U_USD">14017000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_6903f08f-6a69-4542-a56f-570e58669425"
      decimals="-3"
      id="F_0ec1b850-c0a1-4a8a-9a1e-8f0782dfafbe"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_b9cb68ea-1f8f-406a-aac6-ca4b08dfabf4"
      decimals="-3"
      id="F_904b85a1-a241-4126-96a7-6f96b0ccb746"
      unitRef="U_USD">14017000</us-gaap:ShortTermInvestments>
    <lbph:ShortTermInvestmentsAndCashEquivalents
      contextRef="C_111122f4-280d-463c-9ab4-63bd2975497a"
      decimals="-3"
      id="F_608276b2-349c-49a6-8003-d9f9c24f8308"
      unitRef="U_USD">12375000</lbph:ShortTermInvestmentsAndCashEquivalents>
    <lbph:ShortTermInvestmentsAndCashEquivalents
      contextRef="C_be132c83-e4b1-424e-8599-c831e7ef8f25"
      decimals="-3"
      id="F_ccab7d3e-6c13-47ba-8145-33c7bdb5efb3"
      unitRef="U_USD">9559000</lbph:ShortTermInvestmentsAndCashEquivalents>
    <us-gaap:ShortTermInvestments
      contextRef="C_44a745b1-8590-4c56-a3ed-0c09f28a94c7"
      decimals="-3"
      id="F_f188f641-5a13-421b-8012-9e383f392b97"
      unitRef="U_USD">2816000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_1c25c598-527e-4ced-9918-f79085ef2ad3"
      unitRef="U_USD">40379000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_11b0fef0-018f-4b6f-ab46-c55488de2309"
      decimals="-3"
      id="F_4b375f34-9985-4b04-aa93-b32644aaee22"
      unitRef="U_USD">9559000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_08f1e619-22db-4701-aac9-d440535be96c"
      decimals="-3"
      id="F_bac3a538-0ad0-45f6-beca-f697fc1e6e50"
      unitRef="U_USD">30820000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_a3ae066d-e30a-4ec8-9543-8cb28b669a96"
      unitRef="U_USD">76393000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_11b0fef0-018f-4b6f-ab46-c55488de2309"
      decimals="-3"
      id="F_4f518dd3-c6b0-4c4e-9245-ffca847042cb"
      unitRef="U_USD">45573000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_08f1e619-22db-4701-aac9-d440535be96c"
      decimals="-3"
      id="F_8b25d242-a2d2-4b0f-b2a8-6d6ebcdec9ee"
      unitRef="U_USD">30820000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_92c64068-09b5-49e9-b174-88ae6d857822">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 4. Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.427%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.02%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.955%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.788%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.011%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;27,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;27,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;40,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;40,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. As of March 31, 2022, the Company held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; securities, with an aggregate fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;43.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, in an unrealized loss position. These securities have not been in a continuous loss position for more than 12 months and there were no individual securities that were in a significant unrealized loss position as of March 31, 2022. The Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the maturities of the Company's short-term investments at March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.649%;"/&gt;
        &lt;td style="width:3.385%;"/&gt;
        &lt;td style="width:12.594%;"/&gt;
        &lt;td style="width:3.385%;"/&gt;
        &lt;td style="width:12.594%;"/&gt;
        &lt;td style="width:3.385%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.619%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:3.385%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.609%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due after one year through three years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_93aec26d-cf42-4196-b21f-d90a907ce136">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.427%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.02%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.955%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.788%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.011%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;27,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;27,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;40,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;40,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28"
      decimals="-3"
      id="F_3714981f-0b86-413d-9766-8920df8abd57"
      unitRef="U_USD">14983000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28"
      decimals="-3"
      id="F_3f540737-c294-4eec-ab44-d92a019381dc"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28"
      decimals="-3"
      id="F_43922153-4b18-4ce5-bb9b-320af9e359f0"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_839615d0-1a34-4d54-ab89-c7fcaed43c28"
      decimals="-3"
      id="F_8ea0ee2f-05f9-4d94-84d2-639cc388c774"
      unitRef="U_USD">14983000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5f110eb6-6397-4682-9e46-c1939e77c0ad"
      decimals="-3"
      id="F_716c429b-9531-4528-b774-6f8c95005d70"
      unitRef="U_USD">18775000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5f110eb6-6397-4682-9e46-c1939e77c0ad"
      decimals="-3"
      id="F_e5d1b940-8457-4775-8cb5-b4d3a7750c36"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5f110eb6-6397-4682-9e46-c1939e77c0ad"
      decimals="-3"
      id="F_9a2178df-3194-4f69-9a2d-221eb686f3aa"
      unitRef="U_USD">320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5f110eb6-6397-4682-9e46-c1939e77c0ad"
      decimals="-3"
      id="F_2c9f3c83-3569-4cfd-a0c4-d782ccaebc0a"
      unitRef="U_USD">18456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a"
      decimals="-3"
      id="F_46fc8c16-6770-4df1-9fde-885d46208f03"
      unitRef="U_USD">27925000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a"
      decimals="-3"
      id="F_c6f1b0d4-8035-45d5-8c24-390787bf1ab7"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a"
      decimals="-3"
      id="F_da4ba7af-de9c-4d1e-8f0b-c69b5dae3739"
      unitRef="U_USD">277000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_52d3063e-1c7f-4a95-a3d4-fe0870ea579a"
      decimals="-3"
      id="F_1634367b-ff1a-4b5e-8cc7-9c846cf320c1"
      unitRef="U_USD">27648000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_ad963d03-4981-4572-8182-0a2d3e5058e4"
      unitRef="U_USD">61683000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_091f6217-d8cb-4cfc-b610-4b78fd322d63"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_a38810a5-0868-4b20-83e8-034fb8342cbc"
      unitRef="U_USD">597000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_6087c072-942c-4806-8e71-56822aa8431d"
      unitRef="U_USD">61087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab"
      decimals="-3"
      id="F_dac25b9e-6b53-4051-bf08-30b7c200b947"
      unitRef="U_USD">13987000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab"
      decimals="-3"
      id="F_6592fff7-07be-45f0-ab5c-7e9943970a74"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab"
      decimals="-3"
      id="F_ac11e672-dbb4-4dc5-9f3a-1f759e19d167"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8f18a4d5-5287-4b5a-b5bf-905c84d295ab"
      decimals="-3"
      id="F_924f2733-2a64-44cf-987c-d0a2e7d91c31"
      unitRef="U_USD">13987000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2a89fc91-d506-45f3-8bba-599c41b01b99"
      decimals="-3"
      id="F_72b7a177-d742-4294-be00-3210bb03027c"
      unitRef="U_USD">14117000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2a89fc91-d506-45f3-8bba-599c41b01b99"
      decimals="-3"
      id="F_489b5e2b-9e3e-41fe-bda9-ca2f68452a9e"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2a89fc91-d506-45f3-8bba-599c41b01b99"
      decimals="-3"
      id="F_9d90714e-8cae-4400-81ca-142592468d93"
      unitRef="U_USD">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2a89fc91-d506-45f3-8bba-599c41b01b99"
      decimals="-3"
      id="F_5638b825-f728-458e-ad85-4374502fefc7"
      unitRef="U_USD">14017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3"
      decimals="-3"
      id="F_27046d40-bc63-48e7-9a8e-c02f2e88ce99"
      unitRef="U_USD">12439000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3"
      decimals="-3"
      id="F_e91416b5-82ec-465f-8225-e2a6d5191cde"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3"
      decimals="-3"
      id="F_9ad230b1-564d-4726-8e50-7e6950687a58"
      unitRef="U_USD">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9a5a9596-dc64-49ca-8e5d-1ff8aae844d3"
      decimals="-3"
      id="F_3394edd4-1646-4c3e-b670-f67ddb1260dc"
      unitRef="U_USD">12375000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_3be5a011-ed63-47bb-81ee-267cdfe50757"
      unitRef="U_USD">40543000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_2d23cdea-1698-4250-8d11-d4ce5dc7f984"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_6b1fe47f-da02-44aa-91fb-e42cebd54313"
      unitRef="U_USD">164000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_a84adb13-ad78-4014-a0c5-60cc3e7b3e6d"
      unitRef="U_USD">40379000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <lbph:NumberOfSecurities
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="INF"
      id="F_38c08b2f-519f-4d74-9e2a-61b518e5ba0d"
      unitRef="U_Securities">27</lbph:NumberOfSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-5"
      id="F_049847c5-119e-4b6a-bcb9-1bffe67792b4"
      unitRef="U_USD">43100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_55e92bcb-8a01-4670-a08b-d715015557a8">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the maturities of the Company's short-term investments at March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.649%;"/&gt;
        &lt;td style="width:3.385%;"/&gt;
        &lt;td style="width:12.594%;"/&gt;
        &lt;td style="width:3.385%;"/&gt;
        &lt;td style="width:12.594%;"/&gt;
        &lt;td style="width:3.385%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.619%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:3.385%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.609%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due after one year through three years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_7f5ae626-6e2a-4b03-81d8-acafb0b61b7f"
      unitRef="U_USD">42963000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_43cfd59d-bb15-451f-bee2-f91dff0b2957"
      unitRef="U_USD">42878000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <lbph:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_2c45700b-b793-4bdb-b8a5-457266210471"
      unitRef="U_USD">18720000</lbph:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <lbph:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_0c39cb58-9ba5-4a25-98ec-fc8a7f69a5fb"
      unitRef="U_USD">18209000</lbph:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_7638db67-5e77-4e21-8903-284ff8ccf4ee"
      unitRef="U_USD">61683000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_5a975d3f-c71a-4a4a-925e-55e1aaab7af7"
      unitRef="U_USD">61087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_859161a9-0aa6-4b36-aff9-c29a05a6fd1e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 5. Accrued Other Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued other expenses consisted of t&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;he following:&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_281" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.945%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.869%;"/&gt;
        &lt;td style="width:22.617%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
        &lt;td style="width:3.236%;"/&gt;
        &lt;td style="width:1.869%;"/&gt;
        &lt;td style="width:22.065%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Insurance premium finance liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ebed43d0-0a92-4d67-8082-ae25c97d4cd4;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued consulting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued legal and accounting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued computer related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5a0988e8-75d5-4bd3-b7bb-e0565dc26350;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued recruiting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_447350e3-6678-4d9f-8965-dfcca260ed3b;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company entered into a premium finance agreement in March 2022 in connection with the renewal of its annual directors and officers insurance.  The total amount financed is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million which will be paid over nine months. The total finance charge for the premium finance agreement is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; which is recorded to interest expense monthly on a straight-line basis.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_36d36dd2-dc55-4571-9eb3-feffeb7af329">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued other expenses consisted of t&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;he following:&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_281" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.945%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.869%;"/&gt;
        &lt;td style="width:22.617%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
        &lt;td style="width:3.236%;"/&gt;
        &lt;td style="width:1.869%;"/&gt;
        &lt;td style="width:22.065%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Insurance premium finance liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ebed43d0-0a92-4d67-8082-ae25c97d4cd4;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued consulting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued legal and accounting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued computer related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5a0988e8-75d5-4bd3-b7bb-e0565dc26350;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued recruiting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_447350e3-6678-4d9f-8965-dfcca260ed3b;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company entered into a premium finance agreement in March 2022 in connection with the renewal of its annual directors and officers insurance.  The total amount financed is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million which will be paid over nine months. The total finance charge for the premium finance agreement is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; which is recorded to interest expense monthly on a straight-line basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedInsuranceCurrentAndNoncurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_7e12c4ad-f47a-4fd8-9499-1663052df9f3"
      unitRef="U_USD">1191000</us-gaap:AccruedInsuranceCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_f8772cbc-f1d0-4600-ba4c-f23f79554421"
      unitRef="U_USD">154000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_0ce8d69b-bb50-4ca3-8064-b6bc81113175"
      unitRef="U_USD">97000</us-gaap:AccruedProfessionalFeesCurrent>
    <lbph:AccruedLegalAndAccountingFeesCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_090ca4ad-2442-44d2-92a1-123783db3760"
      unitRef="U_USD">104000</lbph:AccruedLegalAndAccountingFeesCurrent>
    <lbph:AccruedLegalAndAccountingFeesCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_89c1fe31-f3c8-49ee-b06b-40138995bd5c"
      unitRef="U_USD">7000</lbph:AccruedLegalAndAccountingFeesCurrent>
    <lbph:AccruedComputerRelatedExpenses
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_5d93b0c8-0752-415d-8513-64ff86292a9b"
      unitRef="U_USD">37000</lbph:AccruedComputerRelatedExpenses>
    <lbph:AccruedComputerRelatedExpenses
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_1a584be2-26da-4427-aecb-c5e12cb9b853"
      unitRef="U_USD">27000</lbph:AccruedComputerRelatedExpenses>
    <lbph:AccruedTaxes
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_9a857809-7fca-4a1f-ba5b-048f324cb7de"
      unitRef="U_USD">168000</lbph:AccruedTaxes>
    <lbph:AccruedRecruitmentFeesCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_3db574e9-84b4-4663-935c-b41339bbcb1d"
      unitRef="U_USD">30000</lbph:AccruedRecruitmentFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_64337406-e129-40d1-afbd-676fe815fb64"
      unitRef="U_USD">50000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_1060521b-3d0f-4bac-93ff-e85f72b3b531"
      unitRef="U_USD">23000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_b42a31b2-6207-4b57-b55f-b301dcdedd3c"
      unitRef="U_USD">1536000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_74a38960-e098-4500-9ee4-85e85b1abbd1"
      unitRef="U_USD">352000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-5"
      id="F_d6a8401a-9864-4032-8e2d-93259025db60"
      unitRef="U_USD">1200000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="0"
      id="F_841a70b6-1158-473d-bf3f-828af9f8fad0"
      unitRef="U_USD">15000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_1efc30c0-6e4c-4c5d-9193-b1468a519dd3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 6.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Amended and Restated Certificate of Incorporation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2021, the Company amended and restated the Company&#x2019;s certificate of incorporation to, among other things, increase the authorized shares of voting common stock, non-voting common stock and preferred stock to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Voting Common Stock and Non-Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2022, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,484,315&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of voting common stock outstanding, excluding &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;101,635&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares subject to repurchase, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of non-voting common stock outstanding. As of December 31, 2021, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,440,761&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of voting common stock outstanding, excluding &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;145,189&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares subject to repurchase, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of non-voting common stock outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2020, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series A Preferred Stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, resulting in gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;56.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares purchased by Arena. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in issuance costs related to the Series A Preferred Stock financing. On March 16, 2021, immediately prior to the closing of the IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,630,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Series A Preferred Stock were exchanged for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of non-voting common stock. Upon the closing of the IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,970,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Series A Preferred Stock were automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,098,600&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of voting common stock. Following the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reconciliation of Changes in Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables document the changes in stockholders' equity for the three months ended March 31, 2022 and 2021 (unaudited):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:21.225%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:5.937%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:4.86%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:6.041%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:4.957%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:6.041%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:4.957%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:6.5%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:7.919%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:7.258%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:7.919%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Non-Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands, except shares)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional&lt;br/&gt;Paid-in&lt;br/&gt;Capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Deficit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total Stockholders' Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,440,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;145,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;103,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vesting of restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;43,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrealized loss on short-term investments, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,484,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;146,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;51,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Non-Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands, except shares)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional&lt;br/&gt;Paid-in&lt;br/&gt;Capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Deficit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total Stockholders' Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,600,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,840,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;11,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Conversion of Series A convertible preferred stock to common stock in connection with initial public offering&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,600,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,098,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Issuance of common stock in initial public offering, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;71,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;71,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,939,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;139,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;20,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;119,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_36a1f79c-d3cd-46af-8004-96e6e76ca20d"
      decimals="INF"
      id="F_12f759bb-e356-4e0f-9756-9a2debfa9ca3"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_fd422146-05ed-41df-a129-56bc4396484d"
      decimals="INF"
      id="F_65dddaf3-b459-4e6a-8979-a68a37b4fef9"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_cf78c477-8c49-4b52-b598-45ec83827cde"
      decimals="INF"
      id="F_2b261a46-d960-4382-98f9-678e8faccb47"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df"
      decimals="INF"
      id="F_ba2c41a0-8d69-4641-a182-c46ed1e3ee0e"
      unitRef="U_shares">13484315</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df"
      decimals="INF"
      id="F_04bf6f32-e147-43c6-9322-afc10fdbb26d"
      unitRef="U_shares">101635</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_31170f32-a22f-4352-849d-e35afea40908"
      decimals="INF"
      id="F_75ce02b8-f624-4ebc-b597-948806f99578"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e2c10102-6c97-4154-85bb-f3bae871ff64"
      decimals="INF"
      id="F_87c206cc-72f4-4724-8573-762cc2b7727a"
      unitRef="U_shares">13440761</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_e2c10102-6c97-4154-85bb-f3bae871ff64"
      decimals="INF"
      id="F_b74e4b7a-90ea-433b-a71e-42683e12cc68"
      unitRef="U_shares">145189</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785"
      decimals="INF"
      id="F_18ff3e81-7cbd-41df-9291-58b391a5de08"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_7f8cf839-c503-41f8-9e31-ce86ee57e5b3"
      decimals="INF"
      id="F_0e30ccfe-070d-4424-86df-ff97a685a948"
      unitRef="U_shares">5600000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_7f8cf839-c503-41f8-9e31-ce86ee57e5b3"
      decimals="2"
      id="F_32017701-be78-4f48-8b32-8194d5f47b0d"
      unitRef="U_USDollarShare">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_8ab315bc-d0fd-45e4-8748-3fffcde6b7bb"
      decimals="-5"
      id="F_4e5dd951-b870-4e12-8df4-c7e5d85bc312"
      unitRef="U_USD">56000000.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_8ab315bc-d0fd-45e4-8748-3fffcde6b7bb"
      decimals="INF"
      id="F_ff06a88e-2fc7-4bbd-91db-c09649e8dea7"
      unitRef="U_shares">100000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_8ab315bc-d0fd-45e4-8748-3fffcde6b7bb"
      decimals="-5"
      id="F_8fe9f287-1d78-4937-9bf2-15e5d8d23a08"
      unitRef="U_USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_20c59b03-2524-402d-b021-af6520d107e6"
      decimals="INF"
      id="F_62b53b21-115d-4fae-bd63-977a6ebc5ca4"
      unitRef="U_shares">2630000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_317bfead-8157-4725-b85c-7b445e78eecf"
      decimals="INF"
      id="F_8c913013-a416-44aa-a218-2cadf58fb614"
      unitRef="U_shares">3629400</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_151f28bf-56b2-4205-b6b7-87fdd9e3d327"
      decimals="INF"
      id="F_625fde2a-a98e-4348-a564-77510e8e7713"
      unitRef="U_shares">2970000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_506976c5-dd13-46a5-8cfa-503cc70a41d0"
      decimals="INF"
      id="F_6701fc21-9213-4565-bd11-267d2bdbaacb"
      unitRef="U_shares">4098600</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ab26e8fc-4dd9-4f09-b2f7-0485e626668f"
      decimals="INF"
      id="F_4d93f70b-f4d3-41fc-bfa4-87ad8dceb1e5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_ea51d15a-6d65-42f6-ab2b-24b2e343f27f">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables document the changes in stockholders' equity for the three months ended March 31, 2022 and 2021 (unaudited):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:21.225%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:5.937%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:4.86%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:6.041%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:4.957%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:6.041%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:4.957%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:6.5%;"/&gt;
        &lt;td style="width:0.32%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:7.919%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:7.258%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
        &lt;td style="width:0.66%;"/&gt;
        &lt;td style="width:0.64%;"/&gt;
        &lt;td style="width:7.919%;"/&gt;
        &lt;td style="width:0.417%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Non-Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands, except shares)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional&lt;br/&gt;Paid-in&lt;br/&gt;Capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Deficit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total Stockholders' Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,440,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;145,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;103,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vesting of restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;43,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrealized loss on short-term investments, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,484,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;146,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;51,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Non-Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands, except shares)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional&lt;br/&gt;Paid-in&lt;br/&gt;Capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Deficit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total Stockholders' Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,600,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,840,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;11,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Conversion of Series A convertible preferred stock to common stock in connection with initial public offering&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,600,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,098,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Issuance of common stock in initial public offering, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;71,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;71,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:6.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,939,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;139,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;20,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;119,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_16281141-6238-424a-a692-584efe899d06"
      decimals="INF"
      id="F_ee16f5d0-9fd2-444f-b1ed-b5443ed8626b"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_16281141-6238-424a-a692-584efe899d06"
      decimals="-3"
      id="F_13c72c0e-2701-43a9-b213-5be6180f31d7"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_e2c10102-6c97-4154-85bb-f3bae871ff64"
      decimals="INF"
      id="F_d4a3bdd2-1d7a-4b8c-922f-b390a187a659"
      unitRef="U_shares">13440761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e2c10102-6c97-4154-85bb-f3bae871ff64"
      decimals="-3"
      id="F_9a094542-9661-45da-8a74-72b3f64e0aa1"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_43c46d9e-b7fb-42d5-9413-a5ff23430785"
      decimals="INF"
      id="F_e3cb197f-b2ef-417e-9ea4-3996e99a1f35"
      unitRef="U_shares">3629400</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ffc4f5e6-0263-492e-ad25-dcc5b98597cc"
      decimals="-3"
      id="F_7bcbd1a5-d5b1-4025-82fc-939c164d6bd0"
      unitRef="U_USD">145683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2d24a6fd-40bc-4a7d-b253-daa51fdda1a9"
      decimals="-3"
      id="F_1e83144f-1f11-427c-9eb7-d45b7e13fda4"
      unitRef="U_USD">-164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8c8296e4-a716-439c-9900-3c7b633eae24"
      decimals="-3"
      id="F_3d1b383d-9efe-4a00-8342-6241f858b638"
      unitRef="U_USD">-42197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_84b8cd24-88f1-4378-87c9-ef57e7101f3c"
      unitRef="U_USD">103323000</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_549ce4bd-686d-442f-bec8-cff814bcf0e1"
      decimals="INF"
      id="F_337be1fe-e735-4f3f-9c82-8c1e9aedf5bd"
      unitRef="U_shares">43554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_36111630-4e04-42da-b57e-0f75ad0cc30a"
      decimals="-3"
      id="F_a579db34-81d4-4d5d-ba5d-46487499678d"
      unitRef="U_USD">571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_f23ab182-0890-4327-a81b-928b136197ac"
      unitRef="U_USD">571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0628a4d5-b09e-41bf-a2ee-edcd9f32b55b"
      decimals="-3"
      id="F_0d85b60c-5708-477e-a805-dcbeba1ac084"
      unitRef="U_USD">-432000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_da6bcbfb-c7ea-4f8e-bd9a-b8a4b4636127"
      unitRef="U_USD">-432000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_699a037f-4e23-4963-91de-5ec47a942247"
      decimals="-3"
      id="F_d389d884-5f23-4e99-84d8-b5fc35d707c0"
      unitRef="U_USD">-9597000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_0022564a-f560-411c-8215-a4ebe8e8ec79"
      unitRef="U_USD">-9597000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_fca0cf8b-0c7e-4480-9275-35cb0b51c5ea"
      decimals="INF"
      id="F_8898faa5-4eaf-427b-a424-ba0939d9d4f6"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_fca0cf8b-0c7e-4480-9275-35cb0b51c5ea"
      decimals="-3"
      id="F_28023d26-b387-4f63-bf1a-a33242194a65"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df"
      decimals="INF"
      id="F_496b10ff-4571-4ddd-b5c0-9345bf9584d5"
      unitRef="U_shares">13484315</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_df442dc6-af70-4b61-a5a8-b9117dc2e5df"
      decimals="-3"
      id="F_794329b7-4fc5-44ca-bc4d-8632059e4227"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_31170f32-a22f-4352-849d-e35afea40908"
      decimals="INF"
      id="F_e2602960-1e98-4e6b-83a4-32445147c445"
      unitRef="U_shares">3629400</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2655fe60-4d25-4284-b79f-1967edee3839"
      decimals="-3"
      id="F_b0ef2fb6-2f56-4447-922e-c4c6066635c3"
      unitRef="U_USD">146254000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6bf2e3e8-5766-4a8d-a320-22cfde28e6ec"
      decimals="-3"
      id="F_b3510afe-4b8f-4099-9095-e43010c40962"
      unitRef="U_USD">-596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2e062ff4-cbda-4e3e-8fa7-05c3aade08b3"
      decimals="-3"
      id="F_57fcee95-4e0a-49e7-a1a7-161e4f584574"
      unitRef="U_USD">-51794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_be2ef4cb-2d2d-45b6-be80-d6c36342add8"
      unitRef="U_USD">93865000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0898e6aa-40e5-4b23-a631-d1afea0062f5"
      decimals="INF"
      id="F_acec0ae6-09a9-4589-992b-521710d805e1"
      unitRef="U_shares">5600000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_0898e6aa-40e5-4b23-a631-d1afea0062f5"
      decimals="-3"
      id="F_b443bdbe-91e3-4de9-87a0-ce9dd10d2828"
      unitRef="U_USD">55795000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_0e184fe9-70db-4b51-8f51-e7daee0646e2"
      decimals="INF"
      id="F_ce05f30d-fbee-4752-bf86-940e9037eeca"
      unitRef="U_shares">3840540</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0e184fe9-70db-4b51-8f51-e7daee0646e2"
      decimals="-3"
      id="F_bf4e4d28-e011-4d12-97c8-db3cd16e2b68"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_641c2769-ddbe-423d-9412-3a70a2e24ef9"
      decimals="0"
      id="F_6ca107e5-1b7b-49a8-851d-affc8f270b3c"
      unitRef="U_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6f014e8f-22fe-4b60-8044-d462c1e03e5f"
      decimals="-3"
      id="F_bcae0f27-292f-4d72-8020-9e50153f13d2"
      unitRef="U_USD">11708000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b5a4e72f-cf27-46e2-ab49-3355ed77023e"
      decimals="-3"
      id="F_3711acae-ba55-46e3-ae65-4272d3b6bddf"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_29313d8d-0ffb-41be-8fa7-c20863221e1e"
      decimals="-3"
      id="F_87596f74-021d-450e-a0cd-9a23993a82f7"
      unitRef="U_USD">-14400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f71add10-710e-4bf5-b5f6-4fff7c798c9a"
      decimals="-3"
      id="F_9dd4dfc1-dab5-4548-9ec3-b39f14ee7438"
      unitRef="U_USD">-2692000</us-gaap:StockholdersEquity>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_26a7cd1a-59b8-401c-a12e-bb0756e81c89"
      decimals="INF"
      id="F_7a778e1f-4279-43fc-9b48-c444460c0d0f"
      unitRef="U_shares">5600000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_26a7cd1a-59b8-401c-a12e-bb0756e81c89"
      decimals="-3"
      id="F_b1819a47-30d0-4c80-926b-13e69ac5c654"
      unitRef="U_USD">55795000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36"
      decimals="INF"
      id="F_f792b01e-8a53-403d-b8f5-b6c2f89f11a7"
      unitRef="U_shares">-4098600</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36"
      decimals="-3"
      id="F_662aca3a-c4d8-44e8-aa7a-5fc8df9dc92e"
      unitRef="U_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_fb752fef-8648-4131-978b-8d72d633b477"
      decimals="INF"
      id="F_a64e8f7d-b414-4c7f-8fa7-be8520c3c07a"
      unitRef="U_shares">-3629400</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_93010243-3fe5-453c-9416-305b5ced4e85"
      decimals="-3"
      id="F_3f5f0ded-51a9-4d36-8733-8f767be68ec8"
      unitRef="U_USD">-55795000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_fdeeb5db-054e-4a0c-86cf-6ce2edf523ed"
      decimals="-3"
      id="F_fc90ff12-afd2-4cb3-9629-0ddbbdb71321"
      unitRef="U_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_ba57d460-9816-4359-a3ef-f6f9cb97b646"
      decimals="-3"
      id="F_a3749ceb-1b82-4168-aef8-4c122b2ed4f6"
      unitRef="U_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_238a452d-06a5-4a36-9fce-68db1122acc4"
      unitRef="U_USD">55795000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36"
      decimals="INF"
      id="F_dd7597c5-bcad-4e32-a8c9-309bf9289b19"
      unitRef="U_shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_035a674b-77e9-4bc5-83ae-c3bbd601ad36"
      decimals="-3"
      id="F_937703e6-73b1-438d-b856-0ed823b79b5d"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_93010243-3fe5-453c-9416-305b5ced4e85"
      decimals="-3"
      id="F_28fc0e10-0cae-4235-b6de-a662d74a6d3c"
      unitRef="U_USD">71848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_bc21368e-ee7f-4a9d-af53-c3927127d799"
      unitRef="U_USD">71849000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_93010243-3fe5-453c-9416-305b5ced4e85"
      decimals="-3"
      id="F_1b3dd147-d51d-42ab-a98c-7940eabc3a23"
      unitRef="U_USD">333000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_c7412a31-11bc-4612-a1ef-0a6a49fe5b8d"
      unitRef="U_USD">333000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_ba57d460-9816-4359-a3ef-f6f9cb97b646"
      decimals="-3"
      id="F_d0ae51cd-0637-40ac-ba74-490046c53be2"
      unitRef="U_USD">-5699000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_0cec09f2-85aa-4d07-af0a-314b10ffaa20"
      unitRef="U_USD">-5699000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_22339958-3266-42a9-b2a0-2291d1710f50"
      decimals="0"
      id="F_322456e2-3e38-4e2c-afde-a541374993c6"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_22339958-3266-42a9-b2a0-2291d1710f50"
      decimals="-3"
      id="F_0705ef5c-3ee9-41a9-9a03-1b70734adaa4"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_36a1f79c-d3cd-46af-8004-96e6e76ca20d"
      decimals="INF"
      id="F_4f146fd3-30be-4baa-bf21-e58105f202d3"
      unitRef="U_shares">12939140</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_36a1f79c-d3cd-46af-8004-96e6e76ca20d"
      decimals="-3"
      id="F_9a88d479-fcfd-4c23-a6f2-20699dfc29b3"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_fd422146-05ed-41df-a129-56bc4396484d"
      decimals="INF"
      id="F_53e1ac2e-295d-4c0a-b35b-e38b0949f134"
      unitRef="U_shares">3629400</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c837c3fa-195b-40fa-9996-1c5976eb2157"
      decimals="-3"
      id="F_3a224d88-49d1-40ae-bb13-e270158fcb8b"
      unitRef="U_USD">139684000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_efe47525-2ddf-4af4-b89b-dd45c135f753"
      decimals="-3"
      id="F_cf1c189e-cf1a-4b08-a569-c598b0ade3b2"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4eca72ce-0189-4f47-8a5c-532366ac8a15"
      decimals="-3"
      id="F_44447a97-f0e7-4889-8949-c6b091d72586"
      unitRef="U_USD">-20099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cf78c477-8c49-4b52-b598-45ec83827cde"
      decimals="-3"
      id="F_81897685-e309-4ae5-9a6b-af082ec7030d"
      unitRef="U_USD">119586000</us-gaap:StockholdersEquity>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_374db6a7-9e0f-4a0e-8bf7-088319e406f5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 7. Agreements with Arena Pharmaceuticals, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company entered into a license agreement (the "License Agreement"), a services agreement (the "Services Agreement"), and a royalty purchase agreement (the "Royalty Purchase Agreement") in October 2020 with Arena. The Company amended the License Agreement in January 2022 to add an additional program. The following section summarizes these related party agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the License Agreement, the Company obtained an exclusive, royalty bearing, sublicensable, worldwide license under certain know-how and patents of Arena to develop and commercialize LP352 for any use in humans, LP143 for the treatment of any central nervous system ("CNS") indication in humans (excluding the treatment, prevention or amelioration of pain or any gastrointestinal, non-CNS autoimmune or cardiovascular disorder), and LP659 for the treatment of selected CNS indications in humans (pharmaceutical products containing any such compounds, Licensed Products). As consideration for the rights granted to the Company under the License Agreement, the Company will be required to pay to Arena a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by the Company, its affiliates or its sublicensees, subject to standard reductions. The Company&#x2019;s royalty obligations continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of the (i) tenth anniversary of the first commercial sale of such product in such country or (ii) expiration of the last-to-expire valid claim of the patents licensed by us under the License Agreement covering the manufacture, use or sale of such product in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Services Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the License Agreement, the Company also entered into a Services Agreement with Arena under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for the Company and receive service fees therefore on an hourly rate based on an annual full time equivalent rate agreed upon by the parties. Arena invoices the Company for services provided on a monthly basis, in arrears. The Services Agreement will continue until December 31, 2022, and will automatically renew for successive &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; terms. Either party may terminate the Services Agreement for any reason, subject to specified notice periods. Payments for services provided under the Services Agreement are recorded to research and development or general and administrative, on the statement of operations, as appropriate. The Company has been decreasing its activities under the Services Agreement, including as a result of its having hired employees or contracted with third parties with the requisite expertise, and the Company is no longer substantially dependent on such services from Arena.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the services expensed under the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; Services Agreement:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.758%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:21.074%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:2.467%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:21.083%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;31,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;188,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; of related party amounts related to the Services Agreement in accounts payable as of March 31, 2022, and December 31, 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Royalty Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2020, the Company entered into a Royalty Purchase Agreement with 356 Royalty Inc., a wholly owned subsidiary of Arena ("356 Royalty"), and Arena, pursuant to which it purchased the right to receive all milestone payments, royalties, interest and other payments relating to net sales of lorcaserin, owed or otherwise payable to 356 Royalty by Eisai Inc. and Eisai Co., Ltd., pursuant to the Transaction Agreement, dated December 28, 2016, as amended, by and among 356 Royalty, Eisai Inc. and Eisai Co., Ltd. The Company made a one-time payment to Arena of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company expensed this amount to research and development expense on the statement of operations and comprehensive loss as lorcaserin is subject to regulatory approval and there are risks and uncertainties as to whether royalties will ultimately be paid and collected.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <lbph:RenewOfSuccessiveAgreementTerm
      contextRef="C_3bcd0cd4-3850-4908-83de-d934090eb79e"
      id="F_da7a4966-d1bc-49c2-84c6-25948eb16552">P1Y</lbph:RenewOfSuccessiveAgreementTerm>
    <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_7c0b13fa-7d12-4f8c-9d2d-09e76083f59e">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the services expensed under the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; Services Agreement:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.758%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:21.074%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:2.467%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:21.083%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e"
      decimals="-3"
      id="F_7c203997-372d-4009-80c7-3bd57bea928b"
      unitRef="U_USD">87000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a8bb7596-5e83-40a5-bc09-180d4c07bdb0"
      decimals="-3"
      id="F_a494b1f1-dbe6-47c4-8885-0c019ce58454"
      unitRef="U_USD">246000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e"
      decimals="-3"
      id="F_88f99ddf-e5a2-415c-b16a-697a51b75f48"
      unitRef="U_USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a8bb7596-5e83-40a5-bc09-180d4c07bdb0"
      decimals="-3"
      id="F_c19e9cf8-e37e-4cc1-b069-dfd19b8e61a8"
      unitRef="U_USD">69000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e"
      decimals="-3"
      id="F_1425ed5a-0443-4e48-8251-cdb25dccba2f"
      unitRef="U_USD">87000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_a8bb7596-5e83-40a5-bc09-180d4c07bdb0"
      decimals="-3"
      id="F_535c0dad-0bae-42a4-8257-7c7d2c7d48cc"
      unitRef="U_USD">315000</us-gaap:OperatingExpenses>
    <us-gaap:AccountsPayableRelatedPartiesNoncurrent
      contextRef="C_d30731d9-ffd1-4fb3-a5cb-af59f3e75e1c"
      decimals="-3"
      id="F_c29b9931-244c-4c0f-b2a6-ec540cfc5df3"
      unitRef="U_USD">31000000</us-gaap:AccountsPayableRelatedPartiesNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesNoncurrent
      contextRef="C_fda728c6-7230-445d-bb2d-a1d2a175a4dd"
      decimals="-3"
      id="F_0dcbfb68-c4dd-493b-a142-e3a39ffd9732"
      unitRef="U_USD">188000000</us-gaap:AccountsPayableRelatedPartiesNoncurrent>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="C_3bcd0cd4-3850-4908-83de-d934090eb79e"
      decimals="-5"
      id="F_13f98f58-c264-4a66-bfe2-f5b7580fc594"
      unitRef="U_USD">100000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_b09ffe90-ed76-4352-9a01-8609aaf74083">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 8. Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2020, the Company&#x2019;s board of directors and stockholders approved the 2020 Equity Incentive Plan ("2020 Plan"), which provided for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, and stock appreciation rights to its employees, members of its board of directors, and consultants. The Company&#x2019;s board of directors determined the exercise price, vesting and expiration period of the grants under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's board of directors adopted the 2021 Equity Incentive Plan ("2021 Plan") in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan became effective on March 11, 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional awards may be granted under the 2020 Plan and all outstanding awards under the 2020 Plan remain subject to the terms of the 2020 Plan. As of March 31, 2022, the 2021 Plan authorizes and provides for the issuance of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,694,999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, which amount will be increased to the extent that awards granted under the 2021 Plan are forfeited, expire or are settled for cash (except as otherwise provided in the 2021 Plan). The number of shares of common stock reserved for issuance under the 2021 Plan automatically increase on January 1 of each calendar year, through January 1, 2031, in an amount equal to (i) 5% of the total number of shares of common stock outstanding on December 31 of the fiscal year before the date of each automatic increase (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock), or (ii) a lesser number of shares determined by the Company&#x2019;s board of directors prior to the applicable January 1. Recipients of stock options are eligible to purchase shares of the Company&#x2019;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2020 and 2021 Plans (or collectively, the &#x201c;Equity Plans&#x201d;) is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and, in general, the options issued under the Equity Plans vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c95df60b-4fb8-4cd0-9d53-ee8d8e733b63;"&gt;&lt;span style="-sec-ix-hidden:F_1f13ee31-05a2-420a-b85b-665c04190587;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;four year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; period from the vesting commencement date. There are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,344,065&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for grant under the 2021 Plan as of March 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Award Grants under the Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the Company&#x2019;s Equity Plans stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.726%;"/&gt;
        &lt;td style="width:1.075%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:12.302%;"/&gt;
        &lt;td style="width:0.97%;"/&gt;
        &lt;td style="width:1.075%;"/&gt;
        &lt;td style="width:1.444%;"/&gt;
        &lt;td style="width:11.311%;"/&gt;
        &lt;td style="width:0.643%;"/&gt;
        &lt;td style="width:1.075%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:12.239%;"/&gt;
        &lt;td style="width:0.643%;"/&gt;
        &lt;td style="width:1.075%;"/&gt;
        &lt;td style="width:1.444%;"/&gt;
        &lt;td style="width:9.92%;"/&gt;
        &lt;td style="width:0.643%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,421,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;997,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;68,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,350,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,350,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options exercisable at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;686,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options exercisable at March 31, 2022 included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;338,439&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; vested stock options and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;348,450&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options that are subject to an early exercise provision.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the weighted-average assumptions used for the stock option grants for the three months ended March 31, 2022 and 2021, along with the related grant date fair value:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.077%;"/&gt;
        &lt;td style="width:1.334%;"/&gt;
        &lt;td style="width:1.694%;"/&gt;
        &lt;td style="width:15.232%;"/&gt;
        &lt;td style="width:2.831%;"/&gt;
        &lt;td style="width:1.334%;"/&gt;
        &lt;td style="width:1.694%;"/&gt;
        &lt;td style="width:15.974%;"/&gt;
        &lt;td style="width:2.831%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;75.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;73.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimated grant date fair value per share of award granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Determination of Fair Value of Common Stock.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; Prior to the IPO, there was no public market for the Company's common stock, and therefore, the estimated fair value of common stock for option grants was determined by the Company&#x2019;s board of directors as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third-party valuations of the Company's equity instruments were performed contemporaneously with identified value inflection points. These third-party valuations were performed in accordance with the guidance outlined in the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; ("Practice Aid"). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the common stock at each valuation date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to considering the results of these independent third-party valuations, the Company&#x2019;s board of directors considered various objective and subjective factors to determine the fair value of its common stock as of each grant date, including: the prices of the preferred stock sold to or exchanged between outside investors in arm&#x2019;s length transactions and the rights, preferences and privileges of the preferred stock as compared to those of the Company&#x2019;s common stock including liquidation preferences of the Company&#x2019;s preferred stock; the progress of the Company&#x2019;s research and development programs, including the status and results of preclinical and clinical trials for product candidates; the stage of development and material risks related to the Company&#x2019;s business; external market and other conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; the Company&#x2019;s business conditions and projections; the Company&#x2019;s financial position and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#x2019;s common stock and preferred stock; the likelihood of achieving a liquidity event for the Company&#x2019;s securityholders, such as an initial public offering or a sale of the Company in light of prevailing market conditions; the hiring of key personnel and the experience of management; and the analysis of initial public offerings and the market performance of similar companies in the biopharmaceutical industry, as well as trends and developments in the biopharmaceutical industry.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;After the closing of the IPO in March 2021, the Company began utilizing the closing stock price of the common stock on the Nasdaq Global Market as both the exercise price and an input to the Black Scholes option pricing model to determine stock-based compensation expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Since the Company is a newly public company and does not have a trading history for its common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;life&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The expected life represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is equal to the contractual term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;348,450&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; restricted stock awards were granted to an employee under the 2020 Plan, which vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and had an estimated fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.12&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share at the time of grant. As of March 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;101,635&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; restricted stock awards remained to vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.635%;"/&gt;
        &lt;td style="width:1.694%;"/&gt;
        &lt;td style="width:20.682%;"/&gt;
        &lt;td style="width:0.754%;"/&gt;
        &lt;td style="width:2.366%;"/&gt;
        &lt;td style="width:1.694%;"/&gt;
        &lt;td style="width:22.422%;"/&gt;
        &lt;td style="width:0.754%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2022, unrecognized stock-based compensation expense was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;which is expected to be recognized over a remaining weighted-average period of approximatel&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;y &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; y&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;ears.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's board of directors adopted the 2021 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) in February 2021, the Company's stockholders approved the ESPP in March 2021 and it became effective on March 11, 2021. As of March 31, 2022, the ESPP authorizes the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;525,492&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock under purchase rights granted to our employees. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, through January 1, 2031, by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on the last day of the fiscal year before the date of the automatic increase (determining on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock); and (ii) such number of shares of common stock that would cause the aggregate number of shares of common stock then reserved for issuance under the ESPP to equal &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,060,017&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares; provided that before the date of any such increase, the Company&#x2019;s board of directors may determine that such increase will be for a lesser amount of shares. The ESPP permits eligible employees, who elect to participate in an offering under the ESPP, to contribute up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of their eligible earnings (as defined in the ESPP) towards the purchase of shares of common stock. Unless otherwise determined by the Company's board of directors, the price at which stock is purchased under the ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the fair market value of the Company&#x2019;s common stock on the commencement date of each offering period or the relevant purchase date, whichever is lower. There are certain service requirements for an employee to be eligible to participate in the ESPP, and no employee may purchase shares under the ESPP at a rate in excess of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; worth of common stock (as determined in accordance with the ESPP). Offering durations under the ESPP may not be longer than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;27 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and the Company may specify shorter purchase periods within each offering. The ESPP is considered a compensatory plan as defined by the authoritative guidance for stock-based compensation. As of March 31, 2022, the ESPP had not yet been implemented.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b7d798c6-2583-44f6-b7aa-21e646fcc6e0"
      decimals="INF"
      id="F_33c97270-89af-4f20-828d-1758150e34a5"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_1e80a750-d3a7-4459-84c3-c56a5568c616"
      decimals="0"
      id="F_4a547012-1cf2-4a74-abe6-00388f047446"
      unitRef="U_shares">3694999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_93a82a9b-a4cd-49de-9617-b82cd4e5a356"
      id="F_ee112f45-8957-46bc-ae6e-40b841015819">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_e77ce52b-d6f2-4eed-8fd9-5a23050d2e60"
      id="F_905b7d63-93b0-44ab-860b-5630722a3e69">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_93a82a9b-a4cd-49de-9617-b82cd4e5a356"
      id="F_5a499acb-1e14-47e2-bc5f-4b3f0f100084">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_e77ce52b-d6f2-4eed-8fd9-5a23050d2e60"
      id="F_46b4c2b5-d158-4dfd-8b81-38bf746a36f4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_3dcaf53c-8e87-4231-9cdf-cbd59cbb3dca"
      decimals="0"
      id="F_3f24c5a2-4de3-46bb-85ac-1672b59b589b"
      unitRef="U_shares">1344065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_ad84cba5-e628-48bb-9047-03024fbaf14a">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the Company&#x2019;s Equity Plans stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.726%;"/&gt;
        &lt;td style="width:1.075%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:12.302%;"/&gt;
        &lt;td style="width:0.97%;"/&gt;
        &lt;td style="width:1.075%;"/&gt;
        &lt;td style="width:1.444%;"/&gt;
        &lt;td style="width:11.311%;"/&gt;
        &lt;td style="width:0.643%;"/&gt;
        &lt;td style="width:1.075%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:12.239%;"/&gt;
        &lt;td style="width:0.643%;"/&gt;
        &lt;td style="width:1.075%;"/&gt;
        &lt;td style="width:1.444%;"/&gt;
        &lt;td style="width:9.92%;"/&gt;
        &lt;td style="width:0.643%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number of Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,421,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;997,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;68,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,350,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,350,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options exercisable at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;686,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="INF"
      id="F_3efd1d03-2767-4521-b6d7-d76f5b06c51f"
      unitRef="U_shares">1421756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="2"
      id="F_d6fef4f6-b665-4a7d-a3c2-a27850df8de9"
      unitRef="U_USDollarShare">6.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_e86bcfe1-5eb0-4d7b-989e-1f9935ce49ac"
      id="F_483861e8-79f4-4ff2-82c6-4df574225b9f">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239"
      decimals="-3"
      id="F_b2982688-ed54-43e9-a739-78af3de829a7"
      unitRef="U_USD">1272000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="0"
      id="F_1708bb3a-7e03-40f5-952a-a67df3eb8390"
      unitRef="U_shares">997900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="2"
      id="F_8e516a37-6bf9-4142-abe4-40a48f2a1c52"
      unitRef="U_USDollarShare">4.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="0"
      id="F_1fffa0b0-dcb0-42ef-a1a0-7d725c215f06"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="0"
      id="F_072504d8-94e1-49d4-86ca-40f952539f6e"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="0"
      id="F_0ce5651c-4c9b-4b3d-813c-1654f7ed3fa0"
      unitRef="U_shares">68722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="2"
      id="F_a1f74928-ea54-4369-afab-9d4fc70b3128"
      unitRef="U_USDollarShare">10.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_e2d8b8fc-419a-4290-b253-6efe6dde53f1"
      unitRef="U_shares">2350934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="2"
      id="F_0682ae12-23f4-4b9d-9697-20ac8c18f77b"
      unitRef="U_USDollarShare">5.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_99ff1c3b-8837-4238-b44d-9e6571942322">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_9650d453-a650-408f-b151-69dc0f8eae6f"
      unitRef="U_USD">2493000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="0"
      id="F_db55255f-a372-4a44-8d5b-0e93dbae09c2"
      unitRef="U_shares">2350934</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="2"
      id="F_67fa2ef7-7ab6-46d8-9933-1dba4323bde0"
      unitRef="U_USDollarShare">5.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_6aae6b14-44c3-4f56-be0d-6e5917f07450">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_098c3132-f4be-49ad-a080-24af1b71386f"
      unitRef="U_USD">2493000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_d1f22bf4-1b8e-44cb-8cbf-e387649febac"
      unitRef="U_shares">686889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="2"
      id="F_cc423b82-c1f5-48a5-9e9d-f76e4c588ead"
      unitRef="U_USDollarShare">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_c7cfea07-3b39-444e-8cec-1cbc67398aa6">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_b79adc72-b211-4861-9b88-c79a8195671f"
      unitRef="U_USD">1127000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_fbe4d8cc-6d39-4f4e-8b51-b3f1eff1c341"
      unitRef="U_shares">338439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <lbph:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="INF"
      id="F_2de2bc1b-34d9-4190-856e-2a798339a4be"
      unitRef="U_shares">348450</lbph:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_eb079f0e-f0b4-4632-8900-804a276adad1">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the weighted-average assumptions used for the stock option grants for the three months ended March 31, 2022 and 2021, along with the related grant date fair value:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.077%;"/&gt;
        &lt;td style="width:1.334%;"/&gt;
        &lt;td style="width:1.694%;"/&gt;
        &lt;td style="width:15.232%;"/&gt;
        &lt;td style="width:2.831%;"/&gt;
        &lt;td style="width:1.334%;"/&gt;
        &lt;td style="width:1.694%;"/&gt;
        &lt;td style="width:15.974%;"/&gt;
        &lt;td style="width:2.831%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;75.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;73.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimated grant date fair value per share of award granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="2"
      id="F_cce89ceb-f280-4d0e-b3c3-4e3121d329ec"
      unitRef="U_USDollarShare">4.62</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_cf78c477-8c49-4b52-b598-45ec83827cde"
      decimals="2"
      id="F_73c74836-74c4-49cb-8056-339570262565"
      unitRef="U_USDollarShare">12.10</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="4"
      id="F_f38cd22f-488a-43b7-8825-f66d968f4461"
      unitRef="U_pure">0.0194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="4"
      id="F_3af66033-f881-44bd-9d0c-128571f1cce0"
      unitRef="U_pure">0.0084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="4"
      id="F_6e676bc8-34b1-40b1-9a21-0b3435616ae1"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="4"
      id="F_340fec6d-602e-465c-ac42-4ca824f5e6b4"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="4"
      id="F_6e8cca87-f024-4f18-b232-6f950a805146"
      unitRef="U_pure">0.7521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="4"
      id="F_0a40a134-42cc-4927-94ab-286f51f95f48"
      unitRef="U_pure">0.7387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_416b8bfb-83d5-4137-84dc-9b17b0d3f9df">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      id="F_db1223d7-2cd8-4659-a598-df12a24cd364">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="2"
      id="F_7e1a729a-c186-443e-9bf2-809e18944a74"
      unitRef="U_USDollarShare">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="2"
      id="F_5e497a9f-e414-4a35-93db-100a843ec684"
      unitRef="U_USDollarShare">7.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4"
      decimals="INF"
      id="F_ea4d584d-9947-4923-8b19-0a23ca2c110d"
      unitRef="U_shares">348450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4"
      id="F_d5b6ddc0-3297-41b8-b59a-7e1bd295c6f9">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4"
      decimals="2"
      id="F_dacefc21-1797-4753-accb-e4dbb550a625"
      unitRef="U_USDollarShare">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_c6bd0fb6-08ea-41d5-9108-8951cd9211c4"
      decimals="INF"
      id="F_6f6a874c-0db6-4b74-91b2-65a50c45103d"
      unitRef="U_shares">101635</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_ded77d37-2ffb-487d-bd23-cc27def93e6b">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.635%;"/&gt;
        &lt;td style="width:1.694%;"/&gt;
        &lt;td style="width:20.682%;"/&gt;
        &lt;td style="width:0.754%;"/&gt;
        &lt;td style="width:2.366%;"/&gt;
        &lt;td style="width:1.694%;"/&gt;
        &lt;td style="width:22.422%;"/&gt;
        &lt;td style="width:0.754%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dec870ee-6073-4897-923d-80d2a6b03504"
      decimals="-3"
      id="F_ed20ba3d-9ba0-4418-813c-5a9904daaad1"
      unitRef="U_USD">128000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3089195e-628b-4987-a83b-ebdfac8204f0"
      decimals="-3"
      id="F_fbab596b-c929-4eb4-abce-830c1546bc8e"
      unitRef="U_USD">70000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_447a2d48-43c5-47de-9129-d4546af4a637"
      decimals="-3"
      id="F_f45e9b2d-035e-454a-b732-b4637a2608aa"
      unitRef="U_USD">443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bdcd3f71-38fa-42e6-9add-cb16918179ef"
      decimals="-3"
      id="F_642a03a1-4b73-49d4-bf4a-9188ffbfb69f"
      unitRef="U_USD">263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_af17078c-0662-42d9-965d-1265b3ec556e"
      unitRef="U_USD">571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="-3"
      id="F_ff2a7d73-f811-4562-be56-fe69c6d94806"
      unitRef="U_USD">333000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-5"
      id="F_5e449c51-7484-4776-a04e-418999898369"
      unitRef="U_USD">6800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_062bcbac-c94b-4462-ac86-6b0db5d392ae">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0af9bf0f-83d2-47dd-b34f-f5ff391ab8e2"
      decimals="0"
      id="F_8b51ee36-c6f9-434e-9d78-284bec5ef2db"
      unitRef="U_shares">525492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <lbph:PercentageOfSharesOfCommonStockOutstanding
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="2"
      id="F_d577bc74-1f92-49bd-9979-aefd0051edac"
      unitRef="U_pure">0.01</lbph:PercentageOfSharesOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="0"
      id="F_45a019a3-5f80-47fb-814a-31b7e446ddae"
      unitRef="U_shares">1060017</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lbph:EmployeeStockPurchasePlanEligibleEarningsContributionPercentage
      contextRef="C_bb620d64-a9b5-4688-82e4-277ff6804f79"
      decimals="2"
      id="F_9607cd62-dac6-4978-b837-9f35203fed9b"
      unitRef="U_pure">0.15</lbph:EmployeeStockPurchasePlanEligibleEarningsContributionPercentage>
    <lbph:EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue
      contextRef="C_bb620d64-a9b5-4688-82e4-277ff6804f79"
      decimals="2"
      id="F_2d1da700-9d3a-437b-8ef3-7d94193ef68f"
      unitRef="U_pure">0.85</lbph:EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue>
    <lbph:EmployeeStockPurchasePlanMaximumSharesPurchasedValue
      contextRef="C_bb620d64-a9b5-4688-82e4-277ff6804f79"
      decimals="INF"
      id="F_2e1ba75d-fe08-47c5-bff8-c220c7cf2ea2"
      unitRef="U_USD">25000</lbph:EmployeeStockPurchasePlanMaximumSharesPurchasedValue>
    <lbph:EmployeeStockPurchasePlanMaximumOfferingPeriod
      contextRef="C_bb620d64-a9b5-4688-82e4-277ff6804f79"
      id="F_5b99abd4-1acb-497b-99e6-813668cd15d9">P27M</lbph:EmployeeStockPurchasePlanMaximumOfferingPeriod>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_7af99f4e-3ccd-4c12-8679-20e0c0199c51">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 9. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2021, the Company entered into a lease agreement for office space located at 4275 Executive Square, Suite 950, La Jolla, California 92037 where it occupies &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,681&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet. The lease became effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;July 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and continues through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Rent payments are approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;29,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per month for the first year and increase by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% in the second year. A security deposit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;33,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; was paid in June 2021 and is classified as a long-term asset on the unaudited condensed balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Previously, the Company leased certain office space in San Diego, California under a month to month lease. Rent payments were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per month.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rent expense totaled approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;95,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The below table provides supplemental cash flow information related to leases as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:4.267%;"/&gt;
        &lt;td style="width:71.243%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:22.681%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:4.341%;"/&gt;
        &lt;td style="width:72.375%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:19.898%;"/&gt;
        &lt;td style="width:2.022%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease commitments are as follows as of March 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:4.267%;"/&gt;
        &lt;td style="width:71.227%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:22.503%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of March 31, 2022, and December 31, 2021, the Company is not a party to any litigation.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lbph:AreaOfOfficeSpace
      contextRef="C_68129ee5-d5db-40e7-8ebc-9736893ecaab"
      decimals="INF"
      id="F_c77a1416-44be-4013-91c4-f8aa22976270"
      unitRef="U_sqft">8681</lbph:AreaOfOfficeSpace>
    <lbph:EffectiveLeaseDate
      contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8"
      id="F_5d372964-aadd-4191-b9a5-a705a57c4f1d">2021-07-01</lbph:EffectiveLeaseDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8"
      id="F_df5818e3-7ba5-4c92-8245-59bf551a8d2c">2023-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8"
      decimals="0"
      id="F_da3dc98b-be09-4bfa-8cc4-f60326146e1b"
      unitRef="U_USD">29000</us-gaap:PaymentsForRent>
    <lbph:PercentageOfIncreaseInRent
      contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8"
      decimals="INF"
      id="F_f1d4feab-c51b-4480-ac36-56c2134f4fc4"
      unitRef="U_pure">0.045</lbph:PercentageOfIncreaseInRent>
    <us-gaap:SecurityDeposit
      contextRef="C_68129ee5-d5db-40e7-8ebc-9736893ecaab"
      decimals="0"
      id="F_4937ded1-9e61-469a-b734-ba494e74ba47"
      unitRef="U_USD">33000</us-gaap:SecurityDeposit>
    <lbph:PaymentsForRentHistorical
      contextRef="C_3dac1763-1355-4e75-8a87-b645f330a7a8"
      decimals="0"
      id="F_66e809fc-8701-4dba-b13c-e28239fa8ee2"
      unitRef="U_USD">1000</lbph:PaymentsForRentHistorical>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="0"
      id="F_a14eeef3-c770-4227-8025-9b8676de3f0f"
      unitRef="U_USD">95000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_411fcc95-d2a3-4968-a6b9-3f43126c5687"
      decimals="0"
      id="F_9f324392-782b-4fec-9469-8681d7084e17"
      unitRef="U_USD">3000</us-gaap:OperatingLeasesRentExpenseNet>
    <lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_eaff28f4-ed5e-4135-9c09-ca676196a3b4">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The below table provides supplemental cash flow information related to leases as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:4.267%;"/&gt;
        &lt;td style="width:71.243%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:22.681%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_4091559a-0d56-4f3a-a8fc-5b3435ff3c7f"
      unitRef="U_USD">90000</us-gaap:OperatingLeasePayments>
    <lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_e29a1c82-06d4-4f69-84cf-ad064872f351">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:4.341%;"/&gt;
        &lt;td style="width:72.375%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:19.898%;"/&gt;
        &lt;td style="width:2.022%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_3c75ab7e-8d0b-4ada-a04d-911b830540ef"
      unitRef="U_USD">438000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_a1fdda6d-2492-4d93-816e-18cd68c77905"
      unitRef="U_USD">350000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_98fa058b-3dd1-409c-9962-5d7b876f1610"
      unitRef="U_USD">94000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_c1c2c788-a443-481c-85c2-6408c95d0983"
      unitRef="U_USD">444000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      id="F_66c6591e-8b3b-4d9e-85bb-45114997d4cd">P1Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="3"
      id="F_78422ae4-1244-4124-8c7a-f3f919636dfd"
      unitRef="U_pure">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_03e7f79a-60cc-4690-b1e1-f061d6a23b54">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease commitments are as follows as of March 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:4.267%;"/&gt;
        &lt;td style="width:71.227%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:22.503%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_7928755f-bad2-493c-85b9-eb75de614e42"
      unitRef="U_USD">279000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_b66f57a0-1273-48e4-85d4-3f9f95ca7de1"
      unitRef="U_USD">189000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_ca32786f-5e6a-4ede-8638-e2a231c1118c"
      unitRef="U_USD">468000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_7c2f16c3-db1c-4a2d-b31b-7854bd724941"
      unitRef="U_USD">24000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3500f45a-facc-48a9-b0ad-fc61707a95d5"
      decimals="-3"
      id="F_2581b4aa-6dcc-4732-8b57-dc78cd0a9875"
      unitRef="U_USD">444000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PostemploymentBenefitsDisclosureTextBlock
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      id="F_3414b415-cb19-4330-ba0e-52bf253987d8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 10. Employment Benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective in June 2021, the Company established a 401(k) salary deferral plan for its employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company provides a safe harbor contribution of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the employee's compensation, not to exceed eligible limits, and subject to employee participation. For the three months ended March 31, 2022, the Company incurred approximatel&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;y $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;57,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; in expenses related to the safe harbor contribution.&lt;/span&gt;&lt;/p&gt;</us-gaap:PostemploymentBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="2"
      id="F_5241b343-336c-4983-a119-98f739c78685"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="C_6e96d89c-3510-4a01-bed8-8670aa664af7"
      decimals="-3"
      id="F_50278741-d3b4-4763-8fe3-00ff6a071523"
      unitRef="U_USD">57000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?@#OUU*:XXW]@;J+/?T?4$L#!!0    (  *$I50RGGON:@4  .(5   8
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MP/\'#E+>W>C7?/UKW?V_4$L#!!0    (  *$I51I"!I8+P,  ,T,   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG9?1DIHP%(9?)</T8G=F*P00=4>=
MZ;K3:2^VXZS3[46G%Q&.0A<2F@3=]NF; (NBB*@72N _A^\<$OXXWC+^*D(
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MW4[N\,W&]\R$:L1?G#VIDV=DJ&R%^&%>/B>W$\\@8AF+M3%!X<^1;5B6&4N
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MT%KDU6/*:,*D&0"_[X30+R_&07L]O_X/4$L#!!0    (  *$I51P7)?MU0L
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M5QAGX*]QI?YU<7$UX^5DE.:0PU[Q[^[@S1^=]9!I-$-%!U^_-<KT$NNV4CH
M0M:T XW645F,+B//Q.[.1PBI&SI^(!DPWL0P4;75A:UMM&D=\QG0%M(-3:YL
M*&L7.L]J*AVK#]*E%7C<>!$H@J8]K#$2%%KB@Y 56M@KD+G*U>@\MBWKKC*\
M#H;[#JM@[X]?ZV;]_,VNB "#\G9*&%0I6AAO6,\S];-N@:"TL3)WNNYD:4@Q
M;$0("(NT2T?"8!$+809/( /+RJY]T&@KB^T]?*MFH;PU,/Y$W;9N4YMJ*1KK
MO!<91BH0.]D(2VY5!R3PD4R:===%J'N2Q]+QX02 U,#C23@/S=9;&&>Q,%XM
MO&MH9OB"5\P@/:1KX^"'EW!<R/#1AEOUKK>7;1'KG1ALL[*PS!I6@MEYQ] 5
MOYOD5R./#*,H*_?W*64?3_O@);0<^;$.JPG_K\C/8:->0V$%AYWBF W$N<.9
M6)S9.#859=>(?P$)9^T"61;Z6Q@HDR7%FXXB<[%S,AN[I/P6-BM-X&BX/ZNV
MC4W"B 0\XV&Y)-PC![H5W&$E(;7RZL&86W(PZ E($(R_XY$0:JUKF+E<67@'
MMH06H*AMCOLA:()>F&6G/4X#;PD[SEV8FJ:GL!_;Q08*,')-1TZ\;Z:15:K.
MT.O=P&6ECB KJ=GY[3U-BI_$%?89K$'ALS)UU4-)J\6O);Y9(W@J<DS)7=HE
M$ F[T>S'7( .Y\V**!!T]I.# 7<?U?3(DE?@* 1Z I_E2@.WV.Q0+I1<=9Y$
MT(H"UU4IB+P&@*3X)+D=YOIQ\);6EUT#4(.3!YG4NG;J-BW&!==Y/!X?L6O!
M"VO[)R19LK<R8$)&P9]'CTEA04/YXNTH/L8QP-$$U\6J=0TX6J[@PN)']QT4
M2+6$<6L"$)R=T9I-ZXU1C; 2YU5-,;&!-M4:AUGIY#J%N1>J(RGO17'&<'YA
MB:OJRD(X?:=MK8N:#&)*#@LM61E:@Q"& MO?@GFSIP,?G$?V J+!H$5$+)5)
M=L%'5]1VJ<5>.,S-['JFEN[.^)9./@UKO' 4T+@S'E$73,*14GO/22AGQ3Y-
M)ACN6@T31DXL@.B6%%'HFA,\DTN8'_HJ']4!!0!E'G)"@L40)RE2]'KMW><$
MU MMO8Q#)F1W^$3N\'YDO^N'<4?@AM0ZAE77-,9+!&OX]E^J<%"7Y QD]W*K
M"L= ,_8V^((J:^040(BI4L(9RX/WO7VGT,TT0!.[^TDP\G-"1DK\XQ4HOQ4F
M V!%)X2*F?*PSW*R ;6I!?N: 0:)H$:S[$]%<6L@@]D7FR+E7FSTRU=LDL)L
M':\Q"HT$KC2 1,_!04?*.3Y1HN0_.TQG<*9=%YJI"V@6\-78KJ'P([Y%_@CO
ML8'=,PY[ =;@K3XRG."4AYA #,E$"5)+3HZ34?BYAF4#P='5[YV<EL9L+6%R
M%S+^DN*H3)L2F5:- 8HCK. 2_+:V"Y,3P, ,9CO>27X^<$Q6$SPZ,Y%JQ\%O
MO@"'M$["C4RHNZ:K>0W!X?(^TM,1^3FPH^4 8$JX<C7AXC\SVA/M)QHE>\]Z
M,ODVD\G[[!+2I)L>$B15[*0\ %:2FYP *[_]#!NTB1+R2CDXAW E_]%;T1Y,
M0JR:RBNB>4;#UG"$I6[MGP)LR(E=))SGE< #=4Y&HI6XLF &J# R <>P-E7X
M/379YZ[L9[#R=D+>5\+XS&,9R/H;XC I<@%8S)8JY,+:K4GV"<5?MR"**JET
M--R#K\!R1!8&08GZV)( ^)(8+R0=M+ZO-'&JTH&P_,E1DW@X_#G1^1$U@7!+
M3]*Q,@D>\MNP-B4Q'A5UN W)[6TKG1L:@ZEWMI+P&9.G8BLT1$3.PSRG2!J7
MW3N+4)->A.W)#*9CA#V%H5QJ/.TI 6) ^5+$D#@$*;,'')#SDDCVE?IN=JP:
M6]?<MH%&OU*GL]/\A/1-)R7*6<.BBR3D#H 9ZCB .9)_Y88!+X6+8Z0>KJ1>
MLYXO1Y54>B$&T!N04#%.8[1091QHB'!QH/'T=!["KI$]>X!AJ =?-(.J.<AF
MZIWS"V.),LJ&B2<0H.!X.Q$I<>B %WXW90WE$'/;04P8BJT0]@^7:[V,\TM/
M9'F R]>UQH3K$@!#_&F=G,B6-*!Q%9Q H&&G>+?MNA-PZG)I,"[.QH21U@)O
M<(@>JJFWV<&X3*PYF;#0$Z;NTP59N,=]RH$3Q#;Y*@S!6#_I"_N2O8E81%I3
MQ)^IGV#+W=8'XIP&(B4 41:<1;PG!LUIA/(0/)Y2$C$@EPHQ>=*#,>=,',R,
M=^']Q:#]%CEK"'?!!-Z$+5 ,))=.#E[*2()T:S;4%E@/5%T62[C0ZY5D1T0(
MG.C@6I"3+>N>?)?<X#.QI6#8X9!3VJ40+0?7XII$CH6UQO#0N_*@B=P%$<33
M, ]E5;>8=GCY#0'O_.CYQP\W?'7\_%NA"^1O!#1[S)*6&.TA.^10(@C8R]O<
MO!BE[5[5$@_[$G)]-&@_)!1%^H'B^PB11D2:W">L(19ZKL+DDF@9PB#FT,S^
MP4;@(,@#9+A4I[DPR.(0=YPPRN\!['X"@V-)B0PW*)SW;D-B><92.C(TG31L
MPVX;9T\9DT20$K!HX6-KC1J*^)A9&$KLY')Q%UPJ9^0,*TWAC">I>.Y]9J9^
MP?Y<I%[!,M<K<D- +/)1BQ=,8-:4&/D%Y$36+1/C*;82QUG9_00=H[=%%[F*
MDH374"4YHCTTF>9LN %OJBD$]&#*JNV: OL1$-&6(1<,>3XS#? +WC55R /,
MSM0;6W<DW"/20S'=_T]VBIEQKZHB80EIAPIDYWPY2^;#71-6[43Y2E,@]])3
M\X"21F8=B0VFN#% VH)M2X)4CVOJGMS>I*JH2;XK^BGH\U!F'N$OCT:>.*;/
M#*C)G\9MG,<%T]R3W+@.!4)!'AWM-._T_9-/3";&GR\&,O&$R001B2<?<A?:
M#77+SG'GDY.SH\FSDU-U/)F?/IT<GYT_^8AH1]XCN9).F&@ .@#4Y%#(GAV7
M'+@Y/CJ>G)^<J1-,/CT[>O+)$0;,<3V?G)T_P[)GS\XGYT?GZJ.A3N1.W]^[
M%M=E:JZ];]6/'>!S?G1\+@#_[N+Z==[UXOI&_>)F_'9Z?#(9=4G?C[JDT]Q)
M_4GJF&]H7IKS[215K+#BN+DVL+\B]_LX6&P# L?([]E'A_;IT#.JG=[I3BT>
M[-URZZW8/M;_'*;OU!HS-1)^E\,DPM>D,HOJZ)Y4[,I(@35LFZIB:06.OTAD
M[CN@\R,-]5Q?4Q_&#N+W^5Q89^C6M"K?4^%?ZB ]8R#3LK/YRPS$+@Q7QV:Q
M2%0L(T%/_LW2MBW)]R,J'.KH"E^&"W!!A2*-2$25Z1]EKABI^GLP/XB:I"F0
MYW T0C)&(^*=<!/)(WV#/W_#20SAH4\J,^[>BSIN<#ZNJA@-X-EOX/T,F3#G
MLXFZ_/#K^S=3N@*D.:I6F$)(B]XA+O2=]1UB;J-I,T]MA(H0A]LF&/=;M](H
M-2Y7$(0Z "G\H9<CB9W?G(>-?T"1#1U]&+D5<"B:)2Q+U#_+(:4[-%69QI9]
MUT:Q%%PYR3=UT@P3F^.C(\6![.UNCY5FW;3<7;DFU:2^559?TG3>:2C*:$=V
MB-K>&NFBP2FE%UX8+DJETX##-V11S466-/5=:0V1!V'[M*9\I$F]BR\L+>/X
M>\*H'P\RY;L!.^E,R]H5% J8[)HM=\\VIJ:( B &XN;Y,UBIUS9R:Y=ZIT2O
MH2=1YX:,,E-7.7LDM82]@K?G57GEG$LF#+Z4'LB5^;L(UZ0PN6FHKXCH2%\(
MY5N*+O.WP-3*OT,IXGR8[!S1$8D7T)=[<7(L6;NM,2')HS)C)6D]XJ.>[&N*
M25JMMYR?\\>\6A?4\J3^@R )A\MNKR-$N ]Y4O\D4M@QT[>^FE)'9;O7XR"0
MJ<<]C50F<+'!I*#7,Q@0Z$R*]14'12EE2/I,0$ENVW^\8W3KQ%_W!*)3+ES9
ML99Z-^;O;%Z*1P#&6+.#/J3*RR)F#L!M\G?.R;>9-[Y;JHL*Y-N&_K.=3^<;
M-W*ZN'+CSO%#[C.R%\"%<G]R36D,R!%['QMUDT;MH]E#/S,X'/V@HS%^R3];
M"0((\MN._FG_RY@+^4'(,%Q^5@/<6DJ]NL#4H]EW9P=2K>6;Z-;\\Y#"Q>@:
MOH0!P4YI -XO'*R<;FB#_O="K_X+4$L#!!0    (  *$I5101W("W04  $\.
M   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULI5?;<MLV$'WW5^RHF3:9
M870A=75MS]A)TV:F;MS<^M#I T2N1"0D0 .@9/7KNPM0%)U83CM]D0 2>[![
M]NR".-MJ\]GFB [NRD+9\U[N7'4Z&-@TQU+8OJY0T9N5-J5P-#7K@:T,BLP;
ME<4@'@ZG@U)(U;LX\\]NS,69KETA%=X8L'59"K.[PD)OSWNCWO[!6[G.'3\8
M7)Q58HWOT'VH;@S-!BU*)DM45FH%!E?GO<O1Z=68U_L%'R5N;6<,',E2Z\\\
M>9V=]X;L$!:8.D80]+?!%U@4#$1NW#:8O79+-NR.]^BO?.P4RU)8?*&+/V3F
M\O/>O <9KD1=N+=Z^PLV\4P8+]6%];^P#6N3<0_2VCI=-L;D02E5^!=W#0\=
M@_GPB$'<&,3>[["1]_*E<.+BS.@M&%Y-:#SPH7IK<DXJ3LH[9^BM)#MW\4I(
M Q]%42-<H["U06+<V;.!(W!>,D@;H*L %!\!2N!:*Y=;^$EEF-VW'Y!3K6?Q
MWK.K^%' :V'ZD(PBB(=Q_ A>TD::>+SDVY&^E#8M- =KX<_+I76&Q/'7(WN,
MVSW&?H_Q_V?S42 NQ5-;B13/>U1K%LT&>Q>_:8>0].'(+O ^1U)YJFOEI%K#
MNI:94"FR2 G>PHKM-FP7 5HGEH4DX5@0D&JJ,NL(!59&E,B5!%3Q4'I\1NL:
M"Y4!WE7T9R%KN?0&*-*<]/F)AL)::BJ\MI!B*0OI=I *AVMM=@TP9B!<!QJH
M3E&Z',F:2CZMC=^;P)16ASF5H;0-#\%.VB9* K1  .1?F@NU1JB,) Y<3AMM
M=5UDL$2&1FH&F7=9J,95&E="9N TD"*477DW#LX_I95X)UV ? 92^9UHIE)9
MB8(!2FTIYFPCE*.>IFM+9)C/!,X[\>IVJP,NX1"R-AF:8A>V%J%G+=%M$=4>
MHQ+&2=Z*LZW#[N5! 9 1NWVXM-1BTSSJ\BHYRP'E.3>Q[)Z=)\?F>W8R=&A*
M3V98JSU#=5FQ4S8L?\BEP&]MD4-BDCA977K;F+V7(B324^,52 2P!7O?W3 *
MQ#V@[/LJ=KE!?.XDI:T3>DYS8=)\%\$VEX1,CFDCG?P;@U*DJFIRON9(R>^'
M),^B6NF"3C!["K_B!@L8P???S>-1_"-\4"+[1)V:S&]KS7]>'];GU1\Z#5D-
M<\+X8-!:N2R0"^"A/'I6B!&*.!5%!#7IGQJ53)W7N&6X#J,2J2""9W'KV>_W
MW&% *TM9"+,'Z!:G?,CCZ.N0OHI%:==81>Q10V?@FM_K)?<ORA.WG5#<F:0*
M="1VOWX_BX*+-35DDI,4!5<#4;.JBP)8DJ!71VIH'WO2QGX3'-8A@\*7D\,T
M5_*VQL9[@[<U[;UWN8UHJ5U.5*V57!'Y7" Z.'(01#==S&*M#F'"4]G'?D21
M5)4VS-YR1ZXZ1Z]\*]L7CV>-O'_6][T[*(R5YSQ,^%!J=?I"EU1FNQ\HDU*1
M_(D@\IPT48?V?[RE=GMI*#G2,W%YS771GK&AK[^DUE@N*4?-XU'_Y-AY(]S)
M4]\#J<WQ6? ,WFM'3C6RNVDE<QDT==THA[/\>J]L:@1>BN\Z=+_Q(GES(/1U
M2%!WS8<NX>']R>4#49T$_-,3^CS!7=N-:SZ[G@!%O1B.NX.]?MK1"?%>HO%T
M5Z(BQT;C:#$_*.W^E)8;RCI7<(9+:JO,?*BNT3P:3Z8'NWO3DY_U!HUJ!46G
MATIW7?-X$4W',XBGT7P:0QS-YI/6.!#?5/41(3R!^21:+(8T&"^BV71*@V0:
MQ7$G[(;"KT3P.(N$,AR-NX-_P>(3&"5$W.S>ZB\?/<;FF/::=;/0F7Z;S5$<
M);,)+*+)9$%DSD?3+\BD\]"XY[[M2+6AWAM$/QZ2W:*Q2X;1/![^QRS,IE&R
M2#@+DV@RXT$#<R#BH4_10><CGYA<^ZN,!7\HAN_]]FE[6[H,EX3#\G#5H@I9
M4^>  E=D.NS/)CTPX?H2)DY7_LI C9 N('Z8TXT/#2^@]RM-%=Y,>(/V#GGQ
M#U!+ P04    "  "A*54DSLL='$%  #V#   &    'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;+57VV[C-A!]SU<0;M%F :UMR1<YV21 DKT"W6*QMSX4?:"E
ML45$(KTD9:_[]3U#:15Y$6<+%'VP19&<,S-G9CC4Q<[8.U<0>?&U*K6['!3>
M;\Y'(Y<55$DW-!O26%D96TF/5[L>N8TEF0>AJAPEX_%\5$FE!U<78>Z=O;HP
MM2^5IG=6N+JJI-W?4&EVEX-X\&WBO5H7GB=&5Q<;N:8/Y#]MWEF\C3J47%6D
MG3):6%I=#J[C\YLI[P\;/BO:N=Y8L"=+8^[XY4U^.1BS0512YAE!XK&E6RI+
M!H(97UK,0:>2!?OC;^@O@^_P92D=W9KR#Y7[XG*P&(B<5K(N_7NS>TVM/S/&
MRTSIPK_8-7LGZ4!DM?.F:H5A0:5T\Y1?6QYZ HOQ$8&D%4B"W8VB8.5SZ>75
MA34[87DWT'@07 W2,$YI#LH';[&J(.>O/A3&^J<?R5;BC=Z2\R#<NXN1!S;O
M&&4MSDV#DQS!F8BW1OO"B1<ZI_Q0?@2;.L.2;X;=)(\"OI5V*"9Q)))QDCR"
M-^D<G02\R1&\6^D*(74NPN#%EUIM9<F^BC^OE\Y;I,=?CZB9=FJF0<WT/_/Y
M* [7XKG;R(PN!R@V1W9+@ZO?C2<Q'8J'E8B/!8F5*5%G2J^%E\N2VF)3?Y,3
M+DAYEE+W4N<GUTZ8E0#?6=$1?O))H\1+R.4GITH+7YC:@3WW1%Q7@.$%<6N<
M%Z]0^$[\9IR#BA?.*U0*UEY*9<5G6=9T<FNJBFRF9"DV<D-6_"SB:72VF&#P
MRT^+)$Z>'8R:18C9C;$ 0Y$MO7"4U59Y!2WQ(DK3F8C%J9@D8_&$)Z:S^<DK
MLR6KV:L0:)PI.MOW!9,T.DMFG:I33*00Q_1\NCCY:#Q,?)@EF#6/HWFP.<;O
M5,S.6#1,CQ=I2^)SRJA:PL66Q_C_YG$"JM)C/(;%QWB<1G&<]NB(QX'-:32.
MTQ^S&2?1='+6$Y]/63J))NGL1V1.Q]%L>I@ 4!\ PN(D/0OI#)\W4N]Q_&_Y
M/!8*TGTD;X3*,5*K?;"24-0U^WJPJ9!>%')+V(*%7&4R= 0$; .^%=>)\079
MI]BI86[%A-F]4%"N+(,,$8C,&^M$9M"0<K*(#>*9$SNG-!?<KB &$5*40!7*
M'0'565GG!*M(X !:^X(-0;RI\>"K9\KAV*Y0J,@5)P![17#!B261AI@+7ND
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MXKLT 259*5'S*T5YJ[ULSEPL]8M4:(:BX8^Z*L.W6CE.;5FU"G\]UG79UL/
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ME]: PV:=;/.;VT6PCP9_2#SZDW\(F>RL_12$-_4ZR0(A5%A10!"\?,8[5"H
M,8V_!\QD"AD<3_]'])]C[IS+3GB\L^I/65.[3JX3J+$1G:)W]O@:AWR6 :^R
MRL<O''O;199 U7FR>G!F!EJ:?A4/0QU.'*Z_Y5 ,#D7DW0>*+%\*$IN5LT=P
MP9K1PD],-7HS.6G"H;PGQ[N2_6BSK2K780V_48L.7CWP87OTJY08.UBDU8!S
MV^,4W\ IX:TUU'IX96JLO_1/F=-$K!B)W19G =\*-X<ROX B*XHS>.64:!GQ
MRO](]!<I=E))DN@OX*YS#@W!7]N=)\<WY..92(LITB)&6OSODI['^=42PG(.
M7\>;U#:J<517EAO&4]AH@*!%:*SBUI-F?S/;>M;.?I0&J+6=%Z;VSX K7;53
MJ>$E5JAW##EH\MD;XSLG3(7 ?:]EIZ&1)LIJ*.8C? _Y1?X\Y_6'[ZZ+O'@Q
M&_D%0MPB'!\:9(+Y<@'/KZ9MA7NA@)EP@U:V,R>&V0*N3F#TH2.FY5")D-Z4
M<7D%Q9,=B0?6#20@O[R>=ASR*I_P1YLRFWU9RV4&13G[8(F)A;R6Y26OY;*
M#US..R8BS"/PO4''/M*0!?&OTHB]0]3A<G&U^Q+'\K+$%3'#4#I*:ODLD,D9
M/'(\/C1)GNMA.I9JR:3).A\+9)M&5LB"' ]D'AE19"ITJ-X8GWGY0'Y>\-10
M*L9J)9,XL@0[/DHA&?$SIVOXWH&.W7N*-R92M<+MPRURD>B9/&/ Y46694,L
MUC!_Z^IP+C94BBOF:3RZ/JAZA#"=(31@&*$_A3X(DU;Z^=>Z,3T9=AJ96ACI
MX=YS]OW<F[33J['MA^63>?_D\+'LN99\!QMVS>97RP1</\9[@>PACLZ=)1[$
M\;?EEP]=,.#]QG*/#D((,+VEFW\ 4$L#!!0    (  *$I50M6(-12@8  $83
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;.U86V_;-A1^]Z\@O&)+
M ,76U9<T">"D+19@38*D[1Z&/<@R;6F52)6DXF:_?A])29$3VVB*;D][2$Q2
MY_:=&X]TLN;BLTPI5>1KD3-YVD^5*H^'0YFDM(CE@)>4X<F2BR)6V(K54):"
MQ@O#5.1#WW5'PR+.6/_LQ)S=B+,37JD\8_1&$%D512P>SFG.UZ=]K]\<W&:K
M5.F#X=E)&:_H'54?RQN!W;"5LL@*RF3&&1%T>=J?><?GH:8W!)\RNI:=-=%(
MYIQ_UIO+Q6G?U0;1G"9*2XCQ<T\O:)YK03#C2RVSWZK4C-UU(_V=P0XL\UC2
M"Y[_GBU4>MJ?],F"+N,J5[=\_2NM\41:7L)S:?Z3M:4=!7V25%+QHF:&!47&
M[&_\M?9#AV'B[F#P:P;?V&T5&2O?Q"H^.Q%\382FAC2],% --XS+F [*G1)X
MFH%/G5UP=D^%RN8Y)3=P"!6"+LB=XLEG$K-ZE?)\087\A;S]4F7J@1R\H<LL
MR=3AR5#!!BUIF-3ZSJT^?X>^@+SG3*62O&4+NMCD'\+V%H#? #CW]PI\'XL!
M"3R'^*[O[Y$7M X)C+Q@A[P:XA^SN50".?/G'IEA*S,T,L/_S,E[]>E"/I9E
MG-#3/BI54G%/^V=77%$R&FPH^_FGB>^-7S<J9Z@V1,78=$NEBA4V%]IR6((-
MX4MRR1(N2BYB4U27C"  2:J]CQBHE)(+7I0Q>R!Q1YAHA'4(:MV2))L*L@T%
MBCN0Q-F*</ *",C82CJ:"CU(4B,QKE3*1?8W%,@TAC(MYYXKD)*$%V G4J-V
M"./L:,L#8V391L:>*4X"UW5<^U=+=HCW],@P/SMU-.B2FJ:3/PS()ZOUPFI]
MC/T5+-KV;&9 6.<VZ;WIX#2&VL ))Z$3>-%^Y 3]&"%@"SQP"/V:Y)5>PFS/
M&04MLZSF?\%D#5W0LH)NN-@Q=@;.R)\ZX2-J*-KES8ZR00WD#4UH,4< :RS>
M=BRAZXQ'WG=B"2/'FTS_32QW5&0@GSVK8M3!=:*X!@AP[B:X3,JJ+@2)NB.1
M,]I,(*C?*3E6)$9J9HDICE>(V ",)1099I-FN(&TW1DC*\&E!#E/*%U(RQ&-
M!BZNCCQ'/9G":6._843CH@69HQ,(RN(!^=!%P9+*V/6*N ._$:B5:GPQ@X$)
METK"H-S6.C=>V(ELF3%P&;]>-VW$&S79D14%7600E#]H^%PT\I*<2VT^L.GM
MY<TU6)#$3SVZ5_>:"JI3)XW9"H<8;EZ2% /RL=2]::<UT_'+K4$3XY@RT =S
M0$[LE0&2C %XZ+C3B4Z;_:4Q(.]XCCE+G[?FZ+Y)K0[&OR7E-E+^EL*4),LS
MVX_!=V&<)G7D]]PE.G66C\;$N/LD6?"DPK6@K.L>Y<B-"Y!:"3HHFDZE@E)2
MV+'!WBF;;=%4ELX:<E"Q&,D-MQT>]_;=NMLZ[HY.W#O(=*AY):%&FH9#2U7[
M\9!<5::M:7]:S\X*7@'A2\]G"]@-#\<YF27P4F6+Z-K<>KH&!4WU+'Q/R6^Z
MQKM$]:1 /G %]FW31.\\SDV)HIT\:\7$A,Y_C<IN5IU>C);3J8U7'6+=<$>3
M *L#%&Y(#LTJ]!UO.C8;SPV<P ]ZGW#]UT6B)P$T,]7>LHVXYC<,G"@*GQU_
MXV_/@#^:FSZ&RL"[B[2)^U*!T=C;=M;[R#!WY&;6R'4<=.EA^%!'BHH"N7P/
M@#K%D2D,[U3?B4/[,?#AQ"?[WA5D&KW?*_A1X-2)3)S:53=)GE38]@RI)X]]
M&3)R?$13YT4T'=49$GG.>&K391HXDU'T?ZE^8ZFZG=D!%WL$/T9P_02E&H7Z
MZ&A+I! &.-R=F,>F5D,3*!L,7)U3G5@V!++N\>W=D'0BLV5 WAB5X'R0L_I]
M>YVI%$?P%("6U3S/$DB& !VU@PX0G8$UE,/.1=>8_YA9;1E:XF?5:8Y[E\TT
M AA/S=MASO92C=J)_GDG&'MP^F3[\?3'-:$@"+:=_<@N@#A,IS8&=K6S"VR]
M)S#K!%/',\FWLPN 8C0)-\Z0>/"MT:SS$QUH,B+;7K6'G6\;!14K\P4'+XVZ
M$NUGCO:T_4@TL]]&'LGM%R:@665,DIPNP>H.QE&?"/O5QFX4+\V7DCE7F,7,
M,J4QBE,3X/F2XQVZWF@%[:>SLW\ 4$L#!!0    (  *$I51V@H+38 @  " 5
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;+58VW(;N1%]UU>@&%=*
MKJ)XT\5:KZ0JV>M--F5O5+*3/*3R ,XT.8@QP"R $<U\?4X#F.%0HK3.0U[(
MN0!]/7VZ,5<;Z[[ZBBB(;[4V_GI4A="\G4Y]45$M_<0V9/!F95TM V[=>NH;
M1[*,FVH]7<QF%]-:*C.ZN8K/[MS-E6V#5H;NG/!M74NW?4?:;JY'\U'WX%ZM
MJ\ /IC=7C5S39PI_:^X<[J:]E%+59+RR1CA:78]NYV_?G?'ZN.#OBC9^<"W8
MDZ6U7_GFE_)Z-&.#2%,16(+$WP.])ZU9$,SX+<L<]2IYX_"ZD_YS]!V^+*6G
M]U;_0Y6ANAY=CD1)*]GJ<&\W?Z;LSSG+*ZSV\5=LTMJSLY$H6A]LG3?#@EJ9
M]"^_Y3@,-ES.GMFPR!L6T>ZD*%KYDPSRYLK9C7"\&M+X(KH:=\,X93@IGX/#
M6X5]X>9V[8@0Y."A.%3BUI&1XJZ2\+B@-JA":C\6OYAB<C4-4,C;ID46_BX)
M7SPC_%1\LB947GPP)97[^Z<PM+=VT5G[;O&BP$_23<3I?"P6L\7B!7FGO?>G
M4=[I,_+N2<M I;B3+FS%%R>-EQ$M7OSS=NF#P]V_7M!SUNLYBWK._C]1?EGX
MKS:0>#,1_X,2\:4B\=[6C31;@1WD$ 1E@A52:%6@YDC(3IPX#E@]^IB?]VI&
MK\=8[LD]X(U_LOYS]V)_@RFQR=FMU(AXT[JBD@>4W><%=]V"@1 8*OY:!+LD
MQSB8#;S==TQB/7 G6.(3ZUG*7Z1IP40138*=+V&<X3_%()!:-,ZNG:R3W)75
MX#!EUG Z<4JB,O4?> DE$.\RH)H(J-XK/SE@ 'SSK<0%-!\T<1P?=][890#'
M4K20OA6Z]:"S<1_*)<$0LQ[#IF5*H5QJO <IZA*<0GUB6P3%B8(<RQ-?C=V<
M5( S9Z:!\8P?N\KH@6DE/8"ZF_B^L'5-KE!2PV?Q\>[T?(&H.,'VM1 ->55;
MHXK&>#D_.XTOV8F AA&BUQ#-JV$*JDL+ Y38U@N_]8%J<3QZ_^OGF.(2<(TQ
M[F6*X^AVR0G8DSE&FF"DB<O9FIJTLBYMA[Z&_<Q6KB6JV@+JY(-"AL?"6',"
MI4*VP:JZ;@WQVD*Z4MD'Z8M62R=*Y:U#V#*"/]Y=G/]PV+G4<) FEKESPP_]
M:/9JDD%6M@7"7H M82L[R+;ZMJ@XY(U%RCBD*8&@J[SA-8H^[O+(;_:W,\IQ
M._("Z#5L3<98!Z:$@>] W49I#6P!V+^URB5!C=SR7T*(1%<J3SQLUH0PK57H
M(0EK#,8*+S5%2#VQ/SYD$'6\@/+Z/E$25EG8Z9X*'8OE=NC"6"AHDJN5T@KP
M]IQ=?M+7"9&/5?-OY(W]\@'&(/WPF05R\O9XY8]_N%S,W_SH=\9!T#IGF5.H
M3$MLL7QBW,ER>_+X62ZL%O6PY??YDF<-Y9&HH'1TAXG%L>]\<ZQ>"R[5"KL-
M>,!YYK'\<J6<#X-:C6&+V&1 9;0Q'C/ DCZ$Y5A!+'UKU*YVDF8?3H(]B6](
M/*#Z8;&6JNY6=+RA.]^6S <OH0QJ8757RBB+=H5>VSHP%A,)C/D>HR?B:9=!
M@^,LF$S1L3E\!]#1&^WC5GA ^*"S)N\VE2JZ)Y'O4XF0XX&Y9UF'YB#1RF*R
M,Z-&>5W['(LU@0N1+%EBS%,\>_"\.EB (&%,WML5Q:4ZJ-O0HBJVG1']DHX0
M>D<-([N@@7"QHM3!,!%;E[ +MK*M@SS807'P+?-S( Z:Q*I%#08,Z(*I :!@
MP^+B;$';8'VN1>Z'BE!'*5#*/-AHW- P-K2W&@E_4&76*6H>(W6NB3&C0#J0
MKLN%>3!/L*XOQE1%/\'KFJ>&;H),M!.7,OMCQF<^9I^1BTTRJ"T@F%LM+*&3
M+92B\%P-S1]4#'QJ]35S(IZCIR "X;!17:N$Z=Z:?=)IJ% K!8>-#9P2($C9
M$FKNY#8-=8?CLZNQ PJE8^8NN'5%6#X+0XCN\<=,O(?!,2>!-8 9 W6-#N?"
M1!-(B 02&YC4.*;8_2D,XQL:"!GH*]AQKOG(R'P>4XR*%WW@;'==G]6P#SAQ
ML04LI9(/_*:*O8GJ1MLM)8[GY//\3F7' <J5'1!WM! ;FU=(&N@-U:H\)5@,
MH0DB-A;=R:R)(;'D%A%4A$I)#4^9')/,3;O*<[8>SJ6[^3'P;/9H>MSM8T,B
MB[X4E[='7RI<[IVPQ*>87,#[Z%AQRC!9P17_.DVX^)D?W3\'@5?B\@U^%F<7
M1W]Z%@HB-K_%C^+BAZ,O-F!-WG8Z/V<?@;<-__"#\6PVBR)>B?GE9;Q#TAY-
MR#43N>^?YC'E )2YYHLBK<8 $@,HXRS0.SVHZ<>ECE_@IJ'X#4"C;SQ_P.#^
M,3Q>[+>)1QWB!3$18:?G%_T:/GCQB6E360:.W? PSV!2I<K=.['C\6BPK3LT
MQ5=C/C'UAX;4>C E=<>H<C?YI6I/+,_#4JTP.050& <O\DEW=% 4&97=\F'0
M4+IU*3<1M79_"-/6%="*+@Z&V#!7N[1W@R+JDX1=PRB@(7Q07JIT#F5UZ?:]
M17 ^AG*R[R,[-#B7#WFAC(CI,[VXY$S/+Q(;I:-?G 4CBM%!UD,[QK]CQ1Z%
MU1+')QD;0&QX.32[(1C!>"5FDSF'&4</\^B W=4S*,AGR+_(QGG#[]!N=R+#
MX:?BKV3(M+;>L_N[S#!U#=J,HS7.,\$";I&P'W*5Q]Z?VH7R7Y/HUN3I)1(F
MI$;(401'#YW4/4'("MV3N$5S>%29C=/I,#0Y] UE.OAJA4EU';_-^33:I0]8
M_=/^\]]M^NJU6YZ^'8("U@H1T;3"UMGDS?DHE4%W$VP3OX$M;4"?CY<5(:N.
M%^#]RMK0W;""_J/HS7\!4$L#!!0    (  *$I53_9+U""!$  $,Q   9
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MOJVU]9RNE=6&*;4Z=! 1]NFL0HKOL?&?^^T[AS8[:XX>L^8H6!/&$C^IF6T
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M!4P]*U1GM8'XB(RPUHHPE39+4PX[K2KT4M,:4%DW"%)28&>P?8STM$9Q4^U
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M@./A!3>/<M=CP<_)_NTQW>U?N$"Y4^6DA;5Q'@5H'<71JLU0_(A*DUQR21U
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MSAO1T[KJS;/H(X/%6!,INE@7KT_TBA'(6(1#1IJ?HAA<<^_$KM%.&_J:R<*
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M2:B,/L#[A4$+'/Z@#=K_;^+U?P-02P,$%     @  H2E5(AW4\27!0  N P
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MI0)0#IZ$*>C2FJ#,0II<27\R"%#!A(.\%7>1Q&4_$#>FCQ"P]/36%++8Y1_
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M;JEN[*JR2YOIJE976>::JK;52KUSA<VL">J+].G+9Z<UEJ8)3K.XS$M99O[
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M^/YK,QRTRH.><0R?R6?%R/*6^'ATF#^U0HR T!^A:@<'NX5[M1(SB@>PN(U
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MX>D%/*=+A>D++=!>L7_Q/U!+ P04    "  "A*54W'@1.*0"  !M!0  &0
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MH<<;GL!;HV 64U@Q;9]AJYDTS/\U!GXL=L9JLGZ>X1EU/"//,SK!LR%-I;5
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M,ET3<%G*JI*@-=#>*JJCUM^>$K4;6;NI$I2VYZ;!=DG1DL"]K)&#B;!/4-4
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M =PW;T\W)^8+8?$9_/@_4$L#!!0    (  *$I52($ZF)< (  '0%   9
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M+TL:BZB= YWG2MF#X2[H!VWR!U!+ P04    "  "A*54D7#<:/D"  ","0
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MZ1NQ_D(Z0K'!RP13]A>M.U_/05FCM*BZ8*B@HKQ]XL>N$5L!@+,_(.@"@MV
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M'IBNI.)1YJPSB()X^Y_^R@I1<(#D@ /*'-"Q#CASP.E MYFEP[JBB@X'@F^
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M ?A\(:79#^QN6_U=Q7\ 4$L#!!0    (  *$I51X-!--& (  &@$   9
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;(5436_;, S]*X*Q0PH4=>(DW5 X
M!O*Q8056-&C6[3#LH-AT+%26/(F.TW\_2G:,8$TZ'RQ1(M][%"G%C38OM@!
M=BBELK.@0*SNPM"F!93<WN@*%.WDVI0<R32[T%8&>.:#2AE&P^%M6'*A@B3V
M:VN3Q+I&*12L#;-U67+SN@"IFUDP"HX+3V)7H%L(D[CB.]@ /E=K0U;8HV2B
M!&6%5LQ /@OFH[O%Q/E[AQ\"&GLR9RZ3K=8OSKC/9L'0"0()*3H$3L,>EB"E
M R(9?SK,H*=T@:?S(_H7GSOELN46EEK^%!D6L^!3P#+(>2WQ23=?H<MGZO!2
M+:W_LZ;UG9)S6EO491=,"DJAVI$?NG,X"8A&%P*B+B#RNELBKW+%D2>QT0TS
MSIO0W,2GZJ-)G%"N*!LTM"LH#I-YFIH:,O:(!1CV^4#%MF#98)YEPAT;E^Q>
MM;4GZXH-5H!<2'L5ATCT#B1,.ZI%2Q5=H'K@YH:-1]<L&D;1\V;%!A_^00E)
M?)]!U&<0>=CQ?S+X)OA62!(-]IHM:V- (?LUWUHT5/K?[S"->Z:Q9YI<8/JN
MD8Z#E[HFY%PHKE+(SIU#"W/K8=RMV"<CNB3TQ>'^#/^DYY^\R_^@%1;RE0F%
M8, B@[9<YR1,WDJ8OA40GC2.NX-4HIU0EDG(*6YX\W$:,-/V=6N@KGPO;352
M9_II04\!&.= ^[G6>#1<>_:/2_(74$L#!!0    (  *$I53\,'W6Z00  ,T6
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;)U847.;.!#^*QJF,]?.
M) $)C.V,[9G$=JY]2"_37'H/-_> 08YU >1*PF[OUY\$&' 0,G8>8K!W5]]*
MN]^W,-E3]L8W& OP,XE3/K4V0FQO;9N'&YP$_(9N<2I_65.6!$+>LE>;;QD.
MHMPIB6WD.+Z=!"2U9I/\NR<VF]!,Q"3%3PSP+$D"]NL>QW0_M:!U^.(;>=T(
M]84]FVR#5_R,Q<OVB<D[NXH2D02GG- 4,+R>6G?P]L%UE$-N\9W@/6]< Y7*
MBM(W=?,EFEJ.0H1C' H5(I ?.SS'<:PB21P_RJ!6M:9R;%X?HC_DR<MD5@''
M<QK_12*QF5HC"T1X'62Q^$;WGW&9T$#%"VG,\_]@7]HZ%@@S+FA2.DL$"4F+
MS^!GN1$-!^AU.*#2 ?5U<$L'MZ^#5SIX?1T&I<.@KX-?.OCYWA>;E>_T(A#!
M;,+H'C!E+:.IB_RX<F^YP215E?4LF/R52#\QF]-TAYD@JQB#)WFHF#$<@6=!
MPS<0I.75AL819OPWL/R1$?$+?%S@-0F)^ 2NP5T4$54C00R^I$6EJXJ1)B(@
M,5<F+\\+\/'#)_ !V(!O H8Y("EX28G@5_)+>?WGAF9<+L<GMI!)*6AV6"9P
M7R2 .A)X#-@-@/X50 Z"&O>YV?V/4-P %^;NCL9]T6/UTAUIW)?]W77@'\SN
M"QQVN=NR#JIB0%4QH#R>UUD,22+/CJLSOSH<59")#67D/QSIMJ<(.,@#*A;;
MS5RG_)O8NV8J?2R/4+L5:M>(NB[;<X"[+3A0BWO9U_"AA^%1?EZ5GW?^J4B1
MX$)V#$E?==EY;2RN-_)<.'@'6FOH.4,?ZD$/*M"#<T!GJW^EE !!I1IM,Q9N
MI!CH< \T>PA]]SUJC9DW@*.Q'K-?8?8O*B3">:8O(K^%XWU1F"R.0 XKD,.+
M0)H+8CX\A71QTN+!9'&4RZC*963,I9 9M;U!&F(04BYT"K P1E&SURW?!B&>
M6G*XXICML#4#.C(NXOC-LM$G,*X2&)_?FMWE,N[;E5I#0U="IY9[Q[SEF!&)
M\:XE]G\_XF2%V3\&&8&-H0*:5REVXM#INLV8ER':?-F18BUBT*QB9[?Q'+:U
M:>";L-32!,W:U!ROML>X0+"3 U*@?I%CDRQ^9:D&=NT,U!87Y+L&A+6X0+.Z
M_,XHER?%:(BQ=OZ:EP'\][O3L7*M$- L$3V[?UZ&::Z/.E>ON1Z>(GLB%]UB
M5I2'=F&_S1==Z];T#<W\_353;0;H^E"6Q<$+;67>PS;GHO'0<.XU]4(S]WZE
MZ?5W*J1<@)+%^O- 38_P GXTSV50PWWZP:RWY4,?R^.!N>939.;32X:S,N31
M*.RCL=<>F4\;'L.N"1J=(.BJ]R0=11E395 SD*K.L,%<'(?21$CAT-4H:A.Y
M&67C<<3,Y&?URA*U6?S:#*2F<72*QL_2>=1FZXX#/FUXC+BF=62F]0M;&]7L
MC<X:\'NT]A*UQ_83CX"HIG-DIO.+^K ]G'?,8WI+PT"&:CU 9CVX\$$)M85!
M^Z2DLS,\*J%:/] )_3BO-T?MWO2<\<CO//E:8] IC6G25L\6O4=M23#B<6M%
M<$],V&IIX^B[=-N\/M"V@=UXL:=>]#X&[)6D',1X+3V=FZ$,P8IWI\6-H-O\
M7=^*"D&3_'*#@P@S92!_7U,J#C?J]6'U!GOV/U!+ P04    "  "A*54<;A!
M73X&  "E(0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6S-FEUOVS84
MAO\*80Q8"L2U^"'9*AP#3=)M!=8N:-KL8M@%+=$Q44ET)3IN]^M'RHIHBQ0K
M;P&:7,22?'CT'I+G/"+E^4Z4GZLU8Q)\S;.BNABMI=R\FDRJ9,UR6KT4&U:H
M;U:BS*E4I^7]I-J4C*9UHSR;H""()CGEQ6@QKZ_=E(NYV,J,%^RF!-4VSVGY
M[9)E8G<Q@J/'"Q_X_5KJ"Y/%?$/OV2V3GS8WI3J;M%Y2GK.BXJ( )5M=C%[#
M5]<DT@UJBSO.=M7!,="A+(7XK$_>IA>C0"MB&4ND=D'5QP.[8EFF/2D=7QJG
MH_:>NN'A\:/W7^K@53!+6K$KD?W)4[F^&,U&(&4KNLWD!['[C34!A=I?(K*J
M_@]VC6TP LFVDB)O&BL%.2_VG_1KTQ$'#2#I:8":!FAH ]PTP$,;D*8!J7MF
M'TK=#]=4TL6\%#M0:FOE31_4G5FW5N'S0H_[K2S5MURUDXLK43RP4O)EQL"-
MZG)6EBP%MU(DGP$MFJ.UR%)65C^#-U^V7'X#9]=LQ1,N7X QN%4S,=VJUF(%
MKM:TN&<5X 7XGW[5D:0\J_0=/MU>@[.?7H"?M-^/:[&ME(-J/I$J?!W$)&E"
MO=R'BGI"?4?+EP!&YP %"#J:7PUHCF'='#F:7P]OWKG[1(U9.W"H'3A4^R,]
M_B[9/2\*7MR#2YK1(F'GX(YF6^8*;.\IJCWI0O"P@ '&",\G#X<!V&9C%,6H
MM3K2B5N=V*MS/Q'J,J%F2'(P+3;MM*CJ:2&%^CK/E>'^7(TVK2J1<%I7B!V7
M:W6-2TXSL-DN,YXHC\J#Z@/7<.QEA8?1A.$T#MWAD#8<X@WG;55M=6_O@S%J
M70J(I6 *9R1V"PA; :%70)TX8UWJ4BU U?^J[A_7N(>6@' *.X-NVV",W1*C
M5F+DE?BI4 3*^#]*X;TB#SC+1*4R67?56I1R+%F9JY%\8)54!)'5.2B8=.F/
M["$D&'4"L(T"M_QI*W_JE?]>T58K=BF:VHKB,)YV)#FLPBCN&?A9*VOFE?6F
M2(=E^\RZ>XQG4=C1:%M!&(>SR"TR;D7& [+=7?;_>L?R)2O_]A0_&!AL!=X;
M?63Y1I3J206PFAWGX)2"V#B/G).FJ>:VB:=\P />PH'"WUC"EX_";]>T9,X)
MV'AW3_=&N6T21H'^Z]%ND /]S/EAM1PZT.0;#0,G^ SH!,ZX+GUZ2%\XHW.A
MRCMBAE;0CRL[30:7D<:S-T=\)L>*#=Z@GV]V?G05>Y+#AIDEV6=R+-G@#OIY
M]UX4XSLAM<BK_1097O ,E*"?2E9Y ]Z>L!&$(Q23P.H/V["O/PRHH)]4SR.I
M;,!U>^ X/(,XZ&?<"?,Q'CH*WS<\7B083B(_)__CO$2&9\C/LY/6(=!>B'37
M(+9)7Q\<K)1.7"IY4Z=Q=O1DA D)II&EU;;$,Q*$I$^QP1+R8^E./1IKO2I]
ME$I9\D0^YHQ3L@T0@L.0],@P]$!^>OPPWJ/!8$$&+,@/EF=1E9"-'Q+$LZ@W
MT0V$D!]"SR&\2V0OQOSA&?PA/_Y.67<WKMQEYOC^AFG(S[2^^W]WP&T,A8'G
MT0X9#*'3,-1?=>/O5UV?R?&VCR$/]I-G."8;1YV*.R,8=A>M+DL4XQCVE5QL
M.(;]''N=IES/?S7I;RA/QWH/DVZX5.<#>(D-C/#3[=MAQ\8=":-9=^/.90>G
MP:RG3PZV[I[!ZLBY=V<#S;/<PP9H^.EV[[![^ZZO4PV'\--MX.$A.W@.H]XM
M/&QX@OT\&5Q>L%WS(8G0P=-'(]-AA^-HUO.4@@T:L!\-KY-DFV\SJA^1FA<(
M@U+6U'[LK_TGI:Q=[\<$06N+T&4'2>\#/S98P$-VX'Y$SMIKF)Y@B&$(\3/$
MMQ5+;!:X]F)=9OV;L<3P@OAY,3@_B+T=-P[A-.[FA\L.!4&O4D,<XB?.87[\
M(=>LU*M!-1G6^NWM P._4EY,SG[7>_2>="&&&L1/C5/2A3BVOF!D=8UMU3>U
M#M[C/-.U#;&YTA>,80KQ,^7)WK@0FR5'KUR.]1F8D">"2>/G>*,WCKKSP;;J
M=N'DX)6X_@'#.UJJ65F!C*U4F^#E5(58[G\3L#^18E._)5\**45>'ZX935FI
M#=3W*R'DXXE^\=[^,F/Q+U!+ P04    "  "A*546'W.(;\"  #\!@  &0
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M2N=R@&D390\O)XIO3!M<<H5-U0P3?/> T ;X?<6YVD^T@_HE-?D+4$L#!!0
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M0) E>?E/GZI M 3 4;, J03(:P&O0\"K!#SM:(E,NW5-%9V,!=\B4>P&;<5
MQT9+@S=)7J3Q3@EXFH"<FMPI'CU^N8) Q&C*,Z@.275\OZ"[,K.(SY'>A?Y:
MZ2>71>03]8S.KIFB22H_P^;[NVMT]NDS^H0<))=4,(F2'-WGB9+GL CC7TN^
MEC2/Y=A1 +PP[T05R*L2).D Z:$?/%=+B;[E,8L-\E.[/"86!0Y$K X;>0G;
M%;%J_$%%'WGX'!&7$!,@N_@UBVIQ;('CU5GTM#ZO0U^9&8G^N>5IBJ"^MU3$
M_UH4#VK% ZUXT*'XYSJ;,:%+0"?U'+V8@I8@%:0SR1?G:,8629[#$%ZIE.81
M,^6XM.1K2T5WV4SP@."1/QP[&P-$OX;HGPAQ(6BNC/5RY>]A"<-1Z+IF*,,:
MRO!$*.R)B2B19C##/3 =.$8UCM&).*(B.6EJQC':PS$,1D5YF[ $-9;@(RJ(
MZ7];^01[Z(CGNZ$WJ/&5;][^/FN9A;4?X?MR2V>I$7=HB.HP"$(S'.PVC=L]
M$= #DU#V"$*+OCVM@"]AHKA>-O9>]V!D=R&VN 5;V])O3:)@_7+#!!P* $[Y
M&J ;D43L^':%26.26*-RR.0-A$SSTWLZ684A:.>T[^&.<#5-''L?C=W2XBIC
M80ODH#_L>)MQ0PC8S@@G@+0V/[Q/"QW=#S>,@.V4< )&:V.LS+5#B=V^[W?@
M;.@"V_GBO<5ZN&E6 -K(_?Y@]*IE5KN.K.>&A;"=ADXOE:Y>6AG<K>FN3MHP
M%+93U DX-[K%&B$&>['<B?@NQH9]</BV5GK+BH^T(OU3.-H*^!Q:TQ3]8B)#
M9W#:_IM1 0?SHSLL:7B'V'GG#4B,96L*V@&3(7HNW$$$9>4Q'@[T,7TV?4E,
MCU2%2U5H:%"T&YB&[0C^^, <*/@#)H/*F\ :F%U_&BHE;Z328_S9-&</UCI[
M;#K.'@<@')?X7?\:NB5VNC6VU._@6)++)$(;FJ[-.2G5#MOGI4'HO>JIAEV8
MC#KHES3T2^ST>[E8"+:@BK60/A1(S]O'OJ-"OT^\.V[L FRXE]BYUU#8QT75
MWX\7!.P5'*=UTY$QL= 70,#>?)VK\M*C7JTOF2[UU8K3;"]OJ. 3'HYZ$J5L
M#J)N?P0 1'GI4TX47^E[DQE7BF=ZN&0T9J+8 ,_GG*N726&@OGJ;_ ]02P,$
M%     @  H2E5#@<K:-& P  C D  !D   !X;"]W;W)K<VAE971S+W-H965T
M-# N>&ULG59K;]HP%/TK5]$F;=*:A(3RF  )Z%[2IE6MVGV8]L%-;L"J$V>V
M@?+O=^VD&= T>WP!V[GG^)QK^]J3G53W>HUHX"$7A9YZ:V/*MT&@DS7F3/NR
MQ(*^9%+ES%!7K0)=*F2I ^4BB,)P$.2,%]YLXL8NU6PB-T;P B\5Z$V>,[5?
MH)"[J=?S'@>N^&IM[$ PFY1LA==H;LI+1;V@84EYCH7FL@"%V=2;]]XNQS;>
M!=QRW.F#-E@G=U+>V\ZG=.J%5A *3(QE8/2WQ24*88E(QL^:TVNFM,##]B/[
M>^>=O-PQC4LIOO'4K*?>R(,4,[81YDKN/F+MY]SR)5)H]PN[.C;T(-EH(_,:
M3 IR7E3_[*'.PP& >-H!40V(3@']9P!Q#8B=T4J9LW7!#)M-E-R!LM'$9ALN
M-PY-;GAA5_':*/K*"6=FUT8F]V<+2D0*2YG3YM#,Y?<,KJN%!9G!-Y<-"IEO
M4='BP@?%"G-&,R*\9US!+1,;U# OTJ>Q<TU;I+2D&F[L/$;"DHED(X[A=J*O
M=9SCI]!7%V@8%_HUZ7D! >@U4Z@G@2'KUD"0U#87E<WH&9LQ?)&%66MX5Z28
M'N,#2EF3M^@Q;XNHD_ +4S[$O3<0A5'4HF?Y]_!>AYRX6<;8\<7/+:/-"[0L
MXUQ1)E=(Y\[ 8@^'<9=L[X;G.Z92^/Z9*.&3P5S_Z!#4;P3UG:!^U[Z"4O$$
MVU:K H\<V!::[:SO#RB/V\,4/@WJ17ZO"3K2==[H.N_4=<7U_5FF$('3!J.]
M9$#1-FS3V$W4\\?]EVT+WPT+_=$I[,C'H/$QZ.2YX%N>(AVW/4>1MLGOQH=^
M&+;*_V?8D?QA(W_8R?/NH:0Z3IMP*ZD*<,'-OLU#-\GPW(]ZK2;^@(O]T;#+
MQ:AQ,?H[%X)G"*_VR)1^W>:CFV8 #MEFY#^ 1T[&C9-QMQ-M.-V)9&5E*R^D
MMC1GMC1O76DN456UUQ9IY@K&JBK1;7;'3PYN[(?#D]/]-&CHCTX.=W!PL>6H
M5NZ^UY#(36&J6MV,-D^*N;M)3\87]-2H7@:_::IW"E7B%:<;1V!&E*$_I/.K
MJKN_ZAA9NNOS3AJZC%US3<\E5#: OF=2FL>.G:!Y@,U^ 5!+ P04    "  "
MA*54I[RU;AL#   J"0  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6S-
M5DM/XS 0_BM6M >0@*1)7Z"V4A_L+A)HJW;9/: ]N,FTL7#B8#LM[*_?L9.&
M4$J7 P<NK1\SG[_YQIEQ;R/DO8H!-'E,>*KZ3JQU=N&Z*HPAH>I,9)#BSE+(
MA&J<RI6K,@DTLDX)=WW/:[L)9:DSZ-FUJ1ST1*XY2V$JB<J3A,JG$7"QZ3L-
M9[LP8ZM8FP5WT,OH"N:@;[.IQ)E;H40L@50QD1()R[XS;%R,&YYQL!:_&&Q4
M;4Q,* LA[LWD*NH[GF$$'$)M("C^K6$,G!LDY/%0@CK5F<:Q/MZB?[7!8S +
MJF L^&\6Z;CO=!T2P9+F7,_$YCN4 ;4,7BBXLK]D4]IZ#@ESI452.B.#A*7%
M/WTLA:@Y(,Y^![]T\'<=FF\X!*5#8 ,MF-FP)E3304^*#9'&&M',P&ICO3$:
MEIHTSK7$789^>C#7(KP_':$0$1F+!&^'HE;?RT<S!G)*YGAUHIP#$4OR7_,9
MA&*5LK^XCW>,4,[)Y4/.]!,9;JB,%*%IA$:9D!I-6$IT#(A*->#=T,J<\2,#
M:4$+8W.,A-C<G#60:Z$4.9J IHRK8V1W.Y^0HR_'Y(L!^QF+7*&3ZKD:Q3$A
MNF$IQ*@0PG]#B(#<B%3'BERF$40O_5T4M5+6WRH[\@\"WE!Y1H+&"?$]W]_#
M9_Q^]\8!.D&5Z,#B!6\E.J823A<V<U/Z9-0F0REINK+*GVPS&!6BTXQIRDT>
M3\@P$3E:WUTC)+G"3*D_!P@U*T)-2ZAY\.85A,+Z58*"R+X4%HAMBV@*U'K0
MZJ XZ[JLKVV"(*AL7E!M551;!ZG.0 &586REF< :BU]F!;R[@60!\I <[>J,
M]N?(3Z<BU/GP_!2(K9KV#;^[DY_7-AUO?WJZ%=/N0:;?(,6*P:TPPPB+)%/:
M5! L%^](T'EUROGG2%##>Z[=WH>GJ(2L?Q_-9K"3HSU&?GOW(W)K72<!N;+-
M6"$1C+4HD]5JU?"'MLWMK(_,0\!VLV>8XA6!17#%L ]P6"*D=];!:R.+QEQ,
MM,AL;UL(C9W2#F-\S( T!KB_%$)O)^: ZGDT^ =02P,$%     @  H2E5($[
MM;I3 P  X D  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULG5;;CM,P
M$'V&K[#"18L$S:WMMM!6Z@4$*Y!6+)<'Q(.;3%J+Q ZVL]U*?#QC)PT!4@OQ
M$E_B<^;,>#SV["#D-[4'T.2NR+F:>WNMR^>^KY(]%%0-1 D<_V1"%E3C4.Y\
M54J@J045N1\%P=@O*./>8F;GKN5B)BJ=,P[7DJBJ**@\KB 7A[D7>J>)]VRW
MUV;"7\Q*NH,;T!_+:XDCOV5)60%<,<&)A&SN+</GF] "[(I/# ZJTR?&E:T0
MW\S@33KW J,(<DBTH:#8W,(:\MPPH8[O#:G7VC3 ;O_$_LHZC\YLJ8*UR#^S
M5._GWL0C*62TRO5[<7@-C4,CPY>(7-DO.=1KQR./))72HFC J*!@O&[I71.(
M#B :G@%$#2#Z$Q"> <0-(/Y7P+ !#&UD:E=L'#94T\5,B@.19C6RF8X-ID6C
M^XR;?;_1$O\RQ.G%6A0%T[B16A'*4[(67#.^ YXP4.096:8I,QM$<_*&UVEF
MMNMB YJR7#V9^1I5&"X_:2RN:HO1&8LA>8<V]HJ\Y"FD/?BU&Q\[\#YZWX8@
M.H5@%3D)KRH^(''PE$1!%'Z\V9"+AT\R_?A!>#EYT2?/S?:.2F0++5O4L/6P
M;/Z=)>QE^<W5N-WMV-+&_[7;&Z:27*A* OFRW"HM\5!^=5@=ME:'UNKPC-4;
M2"K)]!'/8RD4TWTY4S.,+8.I5;>+. Z"8.;?]A@>M89'3L/7(!/T%>L7$1EA
M/,'*J  [6+&X)MLC49 (C,,1J.Q3Y:8?#D;!(T=\QJW,L9/GK54%=R63&".J
MH4^*F^*4P_?OW<.,B1VB+EM1ET[&EUD&MB:3W,H[I\O-<E7E Q(VLD*'K$DK
M:^(D7.(6FLT46<82(*JD^/U!'.=U51...JDU&4_"_LR:MC*F3AFO&59FR1(L
MBS:52LKZ2MEJ^E=:AV>S.@Q^U>S :?U5I<TA;2P?"]N")(4IC 2K-,F85/IL
M6C?T75G1]+RNSET2.G5]$/H4$,QF?!ST9<RZ(>E:GXZZUNL"V;.LIR+XG:NO
M +FS3PA%$E%Q75\![6S[3%G:R_F/^;5YOM@K]1=-_?;!6KQC7.$YR) R&%QB
M*LGZ.5$/M"CM!;L5&J]KV]WC$PRD68#_,R'T:6 ,M(^ZQ4]02P,$%     @
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M    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;'U4WV_:,!#^5TY1)[721D*
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M57OSOH27=TB,"WL%%\ 5O%2ZL4P5-HO)2?& \6I/.VUITQ.T WC2BBH+]ZK
MXF-\[%+H\D@/>4S3LX!/S/1@T/\*:9*FKXL[N+RX.@,[Z,HS"+"#$[!S;0D_
M*='OR=*2<4_JSQF284<R#"3#$R0S+6NFWF%N](87:&'!2H0'9I;:P,S5R?!E
MXR_@LSJ?AQ[VDN3+&8FC3N+H+,[]SDT!ZZ0]HV"$!;SH#\I@+MBG\EK8ZP#K
M!\0F']TD29+%FV,U\=$#EFC6H4TMK'2CJ'W+W6XW"29M _QW;\>(>PAKKBP(
M+%UHTKMQ"DS;FJU!N@[ML-3DFBLL*S?-T'@'=UYJ30?#$W3S,?\'4$L#!!0
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MGD8<P12 !@Q)$G<.[IQ'\?J<BC>_$8U^ U!+ P04    "  "A*54EXJ[',
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MC6M5-D=_UOW4FW\"4$L! A0#%     @  H2E5 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  "A*54
M7?IB;.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  "A*54F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  *$I52:IR;[@@4
M -$6   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  "A*54,IY[[FH%  #B%0  &               @('%
M#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @  H2E5&D(
M&E@O P  S0P  !@              ("!91,  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    (  *$I515IN8_X@,  -8,   8
M  " @<H6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  "
MA*54')K\];(%  "J%P  &               @('B&@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @  H2E5'!<E^W5"P  _1\  !@
M         ("!RB   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   (  *$I50;/J6G1PX  #LD   8              " @=4L  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  "A*544$=R MT%  !/#@
M&               @(%2.P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @  H2E5),[+'1Q!0  ]@P  !@              ("!94$  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  *$I51G,AT36@,
M %<'   9              " @0Q'  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @  H2E5"U8@U%*!@  1A,  !D              ("!
MG4H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  "A*54
M=H*"TV (   @%0  &0              @($>40  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    (  *$I53_9+U""!$  $,Q   9
M      " @;59  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @  H2E5(AW4\27!0  N P  !D              ("!]&H  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  "A*54 BD]S @#  "-!@
M&0              @('"<   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    (  *$I53S*#H0CQ   &XO   9              " @0%T  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @  H2E5-QX$3BD
M @  ;04  !D              ("!QX0  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  "A*54EOF0A+0#  "C"   &0
M@(&BAP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  *$
MI52(O\H3F@,  !\)   9              " @8V+  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @  H2E5,'C -EC P  3 <  !D
M         ("!7H\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  "A*54^=45OG\$  #W#   &0              @('XD@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  *$I51X?^#:G@(  &\%
M   9              " @:Z7  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @  H2E5 F$&2<A!0  #PP  !D              ("!@YH
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  "A*54#NG+
MD,,#  "H"0  &0              @(';GP  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    (  *$I517H=H3.0<  !(?   9
M  " @=6C  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M H2E5(@3J8EP @  = 4  !D              ("!1:L  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  "A*54D7#<:/D"  ","0  &0
M            @('LK0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    (  *$I52"7&AS&@4  ,8>   9              " @1RQ  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @  H2E5 N%)9SB P
M:A   !D              ("!;;8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  "A*54E)^U=&D"   Z!0  &0              @(&&
MN@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  *$I52A
M(+M^^ (  &L)   9              " @2:]  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @  H2E5*%5!/'[ @  :0D  !D
M     ("!5<   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M"  "A*54>#0331@"  !H!   &0              @(&'PP  >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  *$I53\,'W6Z00  ,T6   9
M              " @=;%  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!
M A0#%     @  H2E5'&X05T^!@  I2$  !D              ("!]LH  'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  "A*546'W.(;\"
M  #\!@  &0              @(%KT0  >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;%!+ 0(4 Q0    (  *$I51U=>97$0,  %4)   9              "
M@6'4  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @  H2E
M5&6W!SX^!@  :1\  !D              ("!J=<  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    "  "A*54^'V1&I8$  "&$P  &0
M        @($>W@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   (  *$I50X'*VC1@,  (P)   9              " @>OB  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @  H2E5*>\M6X; P  *@D
M !D              ("!:.8  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    "  "A*54@3NUNE,#  #@"0  &0              @(&ZZ0
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  *$I51A];;*
M7P(  .,$   9              " @43M  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @  H2E5"\:7C/K @  @P@  !D
M ("!VN\  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  "
MA*543H*YXG "  #@!0  &0              @('\\@  >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  *$I535W'_X5 (  "L%   9
M          " @:/U  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#
M%     @  H2E5"_J6H(> P  ,!(   T              ( !+O@  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  "A*54EXJ[',     3 @  "P
M    @ %W^P  7W)E;',O+G)E;'-02P$"% ,4    "  "A*54LL32S=L#  !8
M'P  #P              @ %@_   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @  H2E5/TLU:6N 0  P1L  !H              ( !:  ! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @  H2E5";ZAZ>U 0  W!L
M !,              ( !3@(! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ #8 -@"Q#@  - 0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>114</ContextCount>
  <ElementCount>238</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure -  Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Accrued Other Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpenses</Role>
      <ShortName>Accrued Other Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Agreements with Arena Pharmaceuticals, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc</Role>
      <ShortName>Agreements with Arena Pharmaceuticals, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Employment Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefits</Role>
      <ShortName>Employment Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure -  Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Accrued Other Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables</Role>
      <ShortName>Accrued Other Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpenses</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Convertible Preferred Stock and Stockholder's Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholder's Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Agreements with Arena Pharmaceuticals, Inc (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables</Role>
      <ShortName>Agreements with Arena Pharmaceuticals, Inc (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Short-Term Investments - Summary of Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails</Role>
      <ShortName>Short-Term Investments - Summary of Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Short-Term Investments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Short-Term Investments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails</Role>
      <ShortName>Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accrued Other Expenses - Summary of Accrued Other Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails</Role>
      <ShortName>Accrued Other Expenses - Summary of Accrued Other Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Accrued Other Expenses (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails</Role>
      <ShortName>Accrued Other Expenses (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails</Role>
      <ShortName>Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails</Role>
      <ShortName>Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lbph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Employment Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employment Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lbph-20220331.htm">lbph-20220331.htm</File>
    <File>lbph-20220331.xsd</File>
    <File>lbph-20220331_cal.xml</File>
    <File>lbph-20220331_def.xml</File>
    <File>lbph-20220331_lab.xml</File>
    <File>lbph-20220331_pre.xml</File>
    <File>lbph-ex10_2.htm</File>
    <File>lbph-ex10_3.htm</File>
    <File>lbph-ex31_1.htm</File>
    <File>lbph-ex31_2.htm</File>
    <File>lbph-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img8591006_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="426">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lbph-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 114,
   "dts": {
    "calculationLink": {
     "local": [
      "lbph-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lbph-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lbph-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lbph-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lbph-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lbph-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 397,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 12,
    "http://www.longboardpharma.com/20220331": 5,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 21
   },
   "keyCustom": 31,
   "keyStandard": 207,
   "memberCustom": 7,
   "memberStandard": 22,
   "nsprefix": "lbph",
   "nsuri": "http://www.longboardpharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Accrued Other Expenses",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpenses",
     "shortName": "Accrued Other Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Agreements with Arena Pharmaceuticals, Inc.",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc",
     "shortName": "Agreements with Arena Pharmaceuticals, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Stock-Based Compensation",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Employment Benefits",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefits",
     "shortName": "Employment Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure -  Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Short-Term Investments (Tables)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsTables",
     "shortName": "Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Balance Sheets (unaudited)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
     "shortName": "Condensed Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Accrued Other Expenses (Tables)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables",
     "shortName": "Accrued Other Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Convertible Preferred Stock and Stockholder's Equity (Deficit) (Tables)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables",
     "shortName": "Convertible Preferred Stock and Stockholder's Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Agreements with Arena Pharmaceuticals, Inc (Tables)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables",
     "shortName": "Agreements with Arena Pharmaceuticals, Inc (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_a030be25-78e1-4090-9c78-9f4811f1e055",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Organization and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_a030be25-78e1-4090-9c78-9f4811f1e055",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
     "shortName": "Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Short-Term Investments - Summary of Short-Term Investments (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails",
     "shortName": "Short-Term Investments - Summary of Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Short-Term Investments (Additional Information) (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
     "shortName": "Short-Term Investments (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails",
     "shortName": "Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedInsuranceCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Accrued Other Expenses - Summary of Accrued Other Expenses (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails",
     "shortName": "Accrued Other Expenses - Summary of Accrued Other Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedInsuranceCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Accrued Other Expenses (Additional Information) (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails",
     "shortName": "Accrued Other Expenses (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_cf78c477-8c49-4b52-b598-45ec83827cde",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_f71add10-710e-4bf5-b5f6-4fff7c798c9a",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3bcd0cd4-3850-4908-83de-d934090eb79e",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:RenewOfSuccessiveAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails",
     "shortName": "Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3bcd0cd4-3850-4908-83de-d934090eb79e",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:RenewOfSuccessiveAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
     "shortName": "Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_a2f497f1-e1f1-4e4e-943a-a2017e616b1e",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_a1f9e53b-02cf-4dd3-bfe9-54303f8cf239",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Statements of Operations and Comprehensive Loss (unaudited)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
     "shortName": "Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper",
     "shortName": "Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_68129ee5-d5db-40e7-8ebc-9736893ecaab",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_68129ee5-d5db-40e7-8ebc-9736893ecaab",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_3500f45a-facc-48a9-b0ad-fc61707a95d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Employment Benefits - Additional Information (Details)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails",
     "shortName": "Employment Benefits - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Statements of Cash Flows (unaudited)",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure -  Summary of Significant Accounting Policies",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Fair Value Measurements",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Short-Term Investments",
     "role": "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestments",
     "shortName": "Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20220331.htm",
      "contextRef": "C_6e96d89c-3510-4a01-bed8-8670aa664af7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 30,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lbph_AccruedComputerRelatedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued computer related expenses",
        "label": "Accrued computer related expenses",
        "terseLabel": "Accrued computer related expenses"
       }
      }
     },
     "localname": "AccruedComputerRelatedExpenses",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedLegalAndAccountingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for legal and accounting fees received.",
        "label": "Accrued Legal and Accounting Fees, Current",
        "terseLabel": "Accrued legal and accounting fees"
       }
      }
     },
     "localname": "AccruedLegalAndAccountingFeesCurrent",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedRecruitmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for recruitment fees received.",
        "label": "Accrued Recruitment Fees, Current",
        "terseLabel": "Accrued recruiting fees"
       }
      }
     },
     "localname": "AccruedRecruitmentFeesCurrent",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Taxes",
        "label": "Accrued Taxes"
       }
      }
     },
     "localname": "AccruedTaxes",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office space.",
        "label": "Area of Office Space",
        "terseLabel": "Area of office space"
       }
      }
     },
     "localname": "AreaOfOfficeSpace",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "lbph_ArenaPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arena Pharmaceuticals, Inc.",
        "label": "Arena Pharmaceuticals Inc [Member]",
        "terseLabel": "Arena Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ArenaPharmaceuticalsIncMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arena two thousand seventeen long term incentive plan.",
        "label": "Arena Two Thousand Seventeen Long Term Incentive Plan [Member]",
        "terseLabel": "Arena 2017 LTIP [Member]"
       }
      }
     },
     "localname": "ArenaTwoThousandSeventeenLongTermIncentivePlanMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Three",
        "terseLabel": "Fixed maturity securities, available for sale, due after one year through three years, amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three",
        "terseLabel": "Fixed maturity securities, available for sale, due after one year through three years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_DeferredFinancingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Costs Policy Text Block",
        "label": "Deferred Financing Costs Policy [Text Block]",
        "terseLabel": "Deferred Financing Costs"
       }
      }
     },
     "localname": "DeferredFinancingCostsPolicyTextBlock",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_DefinedContributionPlanArenaMatchingContributions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan Arena Matching Contributions",
        "label": "Defined Contribution Plan Arena Matching Contributions",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanArenaMatchingContributions",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_EffectiveLeaseDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective lease date.",
        "label": "Effective Lease Date",
        "terseLabel": "Effective lease date"
       }
      }
     },
     "localname": "EffectiveLeaseDate",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, eligible earnings contribution, percentage.",
        "label": "Employee Stock Purchase Plan Eligible Earnings Contribution Percentage",
        "terseLabel": "Employee stock purchase plan, eligible earnings contribution, percentage"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanEligibleEarningsContributionPercentage",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, maximum offering period.",
        "label": "Employee Stock Purchase Plan Maximum Offering Period",
        "terseLabel": "Employee stock purchase plan, maximum offering period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumOfferingPeriod",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, maximum shares purchased, value.",
        "label": "Employee Stock Purchase Plan Maximum Shares Purchased Value",
        "terseLabel": "Employee stock purchase plan, maximum shares purchased, value"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumSharesPurchasedValue",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, shares purchase price as a percentage of market fair value.",
        "label": "Employee Stock Purchase Plan Shares Purchase Price As Percentage Of Market Fair Value",
        "terseLabel": "Employee stock purchase plan, shares purchase price as a percentage of market fair value"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Increase Decrease In Accrued Research And Development Expenses",
        "negatedLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating right-of-use assets and lease liabilities, net.",
        "label": "Increase (Decrease) in Operating Right-Of-Use Assets and Lease Liabilities, Net",
        "terseLabel": "Operating right-of-use assets and lease liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_InitialPublicOfferingCostsInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering costs in accounts payable.",
        "label": "Initial Public Offering Costs In Accounts Payable",
        "terseLabel": "Initial public offering costs in accounts payable"
       }
      }
     },
     "localname": "InitialPublicOfferingCostsInAccountsPayable",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_InitialPublicOfferingCostsInAccruedOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering costs in accrued other expenses.",
        "label": "Initial Public Offering Costs In Accrued Other Expenses",
        "terseLabel": "Initial public offering costs in accrued other expenses"
       }
      }
     },
     "localname": "InitialPublicOfferingCostsInAccruedOtherExpenses",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_NonVotingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Voting Member.",
        "label": "Non Voting [Member]"
       }
      }
     },
     "localname": "NonVotingMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_NumberOfCommonStockSharesIssuedAndSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock Shares issued and sold.",
        "label": "Number of Common Stock Shares Issued and Sold"
       }
      }
     },
     "localname": "NumberOfCommonStockSharesIssuedAndSold",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lbph_NumberOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities.",
        "label": "Number of Securities",
        "terseLabel": "Number of securities"
       }
      }
     },
     "localname": "NumberOfSecurities",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lbph_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock [Member]",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_PaymentsForRentHistorical": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Rent Historical",
        "label": "Payments For Rent Historical",
        "terseLabel": "Historical rent paid"
       }
      }
     },
     "localname": "PaymentsForRentHistorical",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_PercentageOfIncreaseInRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in rent.",
        "label": "Percentage of Increase in Rent",
        "terseLabel": "Percentage of increase in rent by second year"
       }
      }
     },
     "localname": "PercentageOfIncreaseInRent",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_PercentageOfSharesOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares of common stock outstanding",
        "label": "Percentage of shares of common stock outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOfCommonStockOutstanding",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_PostSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post split.",
        "label": "Post Split [Member]",
        "terseLabel": "Post Split"
       }
      }
     },
     "localname": "PostSplitMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_PreSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre split.",
        "label": "Pre Split [Member]",
        "terseLabel": "Pre Split"
       }
      }
     },
     "localname": "PreSplitMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_RenewOfSuccessiveAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Renew of successive agreement term.",
        "label": "Renew Of Successive Agreement Term",
        "terseLabel": "Renew of successive agreement term"
       }
      }
     },
     "localname": "RenewOfSuccessiveAgreementTerm",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_RestrictedStockAwardsIssuedButUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards, issued but unvested [Member]",
        "label": "Restricted Stock Awards Issued But Unvested [Member]",
        "terseLabel": "Restricted Stock Awards, Issued But Unvested"
       }
      }
     },
     "localname": "RestrictedStockAwardsIssuedButUnvestedMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for lease obligations.",
        "label": "Right of Use Assets Obtained in Exchange for Lease Obligations [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and Uncertainties Policy Text Block.",
        "label": "Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental balance sheet information related to leases.",
        "label": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to leases.",
        "label": "Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Preferred Stock (on an as-converted to common stock basis) [Member]",
        "label": "Series A Preferred Stock On As Converted To Common Stock Basis [Member]",
        "terseLabel": "Series A Preferred Stock On As Converted To Common Stock Basis"
       }
      }
     },
     "localname": "SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options exercised in period, weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share based payment award, options forfeitures in period, weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remining Contractual Term, Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining contractual term, options granted",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Contractual Term",
        "verboseLabel": "Remaining contractual term, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining contractual term for option awards granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Remaining Contractual Term",
        "terseLabel": "Remaining Contractual Term, Options granted",
        "verboseLabel": "Remaining contractual term, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options subject to early exercise provision, exercisable number",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Early Exercise Provision Exercisable Number",
        "terseLabel": "Options exercisable, subject to early exercise provision"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years) [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_ShortTermInvestmentsAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short Term Investments And Cash Equivalents",
        "label": "Short Term Investments And Cash Equivalents"
       }
      }
     },
     "localname": "ShortTermInvestmentsAndCashEquivalents",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_ShortTermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Investments [Policy Text Block]",
        "label": "Short-Term Investments [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsPolicyTextBlock",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity and stockholders equity disclosure.",
        "label": "Temporary Equity And Stockholders Equity Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "TemporaryEquityAndStockholdersEquityDisclosureTextBlock",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Equity Incentive Plan member.",
        "label": "Two Thousand And Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_VotingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voting Member.",
        "label": "Voting [Member]"
       }
      }
     },
     "localname": "VotingMember",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term.",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.longboardpharma.com/20220331",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r203",
      "r212",
      "r237",
      "r239",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r397",
      "r433",
      "r434",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r203",
      "r212",
      "r237",
      "r239",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r397",
      "r433",
      "r434",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProFormaMember": {
     "auth_ref": [
      "r106",
      "r188",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro Forma [Member]",
        "terseLabel": "Pro Forma"
       }
      }
     },
     "localname": "ProFormaMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r203",
      "r212",
      "r227",
      "r237",
      "r239",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r397",
      "r433",
      "r434",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r203",
      "r212",
      "r227",
      "r237",
      "r239",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r397",
      "r433",
      "r434",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r102",
      "r106",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r102",
      "r106",
      "r188",
      "r238",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r144",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Other Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r365"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r87",
      "r357",
      "r410",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties.",
        "label": "Accounts Payable, Related Parties",
        "terseLabel": "Accounts payable includes related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Accounts Payable, Related Parties, Noncurrent",
        "terseLabel": "Related party amounts related to accounts payable"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of premiums on investments, net",
        "terseLabel": "Amortization of premiums on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r38"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and related expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrentAndNoncurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r405",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees.",
        "label": "Accrued Insurance",
        "terseLabel": "Insurance premium finance liability"
       }
      }
     },
     "localname": "AccruedInsuranceCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r11",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Payroll Taxes, Current",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r38"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued consulting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r49",
      "r50",
      "r51",
      "r423",
      "r442",
      "r446"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r48",
      "r51",
      "r58",
      "r59",
      "r60",
      "r90",
      "r91",
      "r92",
      "r301",
      "r437",
      "r438",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain/(Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r276",
      "r277",
      "r278",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r94",
      "r95",
      "r96",
      "r97",
      "r106",
      "r146",
      "r147",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r191",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r294",
      "r295",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r353",
      "r400",
      "r401",
      "r402",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r240",
      "r242",
      "r282",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r242",
      "r269",
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r86",
      "r130",
      "r138",
      "r141",
      "r162",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r297",
      "r302",
      "r326",
      "r363",
      "r365",
      "r404",
      "r421"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r47",
      "r86",
      "r162",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r297",
      "r302",
      "r326",
      "r363",
      "r365"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets",
        "totalLabel": "Total assets measured at fair value",
        "verboseLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r149",
      "r174"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Fixed maturity securities, available for sale, due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r153",
      "r154",
      "r416"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Fixed maturity securities, available for sale, due in one year or less, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r148",
      "r150",
      "r174",
      "r409"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Fixed maturity securities, available for sale, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r243",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r33",
      "r78"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and investment securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r72",
      "r78",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r107",
      "r108",
      "r109",
      "r111",
      "r113",
      "r118",
      "r119",
      "r120",
      "r162",
      "r192",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r210",
      "r211",
      "r213",
      "r214",
      "r326",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r187",
      "r411",
      "r427"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r189",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockConversionBasis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of basis for conversion of convertible common stock.",
        "label": "Common Stock, Conversion Basis",
        "terseLabel": "Common stock, conversion basis"
       }
      }
     },
     "localname": "CommonStockConversionBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDiscountOnShares": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.",
        "label": "Common Stock, Discount on Shares",
        "terseLabel": "Discount and Commissions Paid"
       }
      }
     },
     "localname": "CommonStockDiscountOnShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Voting Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common Stock Shares Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r365"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, value",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r62",
      "r413",
      "r432"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "verboseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r123",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "negatedTerseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering",
        "terseLabel": "Conversion of convertible preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "negatedTerseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)",
        "terseLabel": "Number of Shares Converted",
        "verboseLabel": "Number of shares converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)",
        "verboseLabel": "Conversion of stock, shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r22",
      "r23",
      "r215",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock available for conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r228",
      "r236",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r157",
      "r175",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Aggregate fair value of unrealized loss position",
        "totalLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r17",
      "r403",
      "r420"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred financing costs",
        "totalLabel": "Deferred Costs, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred financing costs",
        "totalLabel": "Deferred Costs, Current, Total"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Company Provides Safe Harbor Contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r76",
      "r129"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r58",
      "r59",
      "r60",
      "r90",
      "r91",
      "r92",
      "r95",
      "r103",
      "r105",
      "r117",
      "r166",
      "r217",
      "r221",
      "r276",
      "r277",
      "r278",
      "r294",
      "r295",
      "r316",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r437",
      "r438",
      "r439",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r320",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r204",
      "r228",
      "r229",
      "r234",
      "r236",
      "r320",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r228",
      "r229",
      "r234",
      "r236",
      "r320",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r320",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r178",
      "r179",
      "r206",
      "r216",
      "r307",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "negatedLabel": "Accrued compensation and related expenses",
        "terseLabel": "Accrued compensation and related expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r410",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Monthly interest expense"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Maturity of the Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiry date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r86",
      "r162",
      "r326",
      "r365",
      "r406",
      "r425"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and shareholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r86",
      "r162",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r298",
      "r302",
      "r303",
      "r326",
      "r363",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r52",
      "r54",
      "r60",
      "r61",
      "r77",
      "r86",
      "r94",
      "r99",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r110",
      "r130",
      "r137",
      "r139",
      "r140",
      "r142",
      "r162",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r318",
      "r326",
      "r412",
      "r431"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r106",
      "r116",
      "r146",
      "r147",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r191",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r294",
      "r295",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r353",
      "r400",
      "r401",
      "r402",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvotingCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors.",
        "label": "Nonvoting Common Stock [Member]",
        "terseLabel": "Non-Voting Common Stock [Member]"
       }
      }
     },
     "localname": "NonvotingCommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r130",
      "r137",
      "r139",
      "r140",
      "r142"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease Liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Right-of-use liabilities, current portion",
        "verboseLabel": "Right-of-use lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Right-of-use liabilities, net of current portion",
        "verboseLabel": "Right-of-use lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Total rent expense",
        "totalLabel": "Operating Leases, Rent Expense, Net, Total"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r38"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "verboseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r410",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred for employer-related costs classified as other.",
        "label": "Other Employee-related Liabilities",
        "negatedLabel": "Total amount financed",
        "terseLabel": "Total amount financed"
       }
      }
     },
     "localname": "OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAccruedOtherExpensesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r34",
      "r428"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountContributions": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners).",
        "label": "Partners' Capital Account, Contributions",
        "terseLabel": "Arena Pharmaceuticals, Inc. capital contributions"
       }
      }
     },
     "localname": "PartnersCapitalAccountContributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Future rent payment per month for first year"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.",
        "label": "Payments for Repurchase of Initial Public Offering",
        "negatedLabel": "Initial public offering costs"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Series A convertible preferred stock financing costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments",
        "terseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Expenses Related To Contribution Plan",
        "totalLabel": "Pension and Other Postretirement Benefits Cost (Reversal of Cost), Total"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r243",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PostemploymentBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for postemployment benefits,  which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.",
        "label": "Postemployment Benefits Disclosure [Text Block]",
        "terseLabel": "Employment Benefits"
       }
      }
     },
     "localname": "PostemploymentBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureEmploymentBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockDividendRatePerDollarAmount": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount per share used to calculated dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount",
        "terseLabel": "Dividend rate, per-dollar-amount"
       }
      }
     },
     "localname": "PreferredStockDividendRatePerDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r85",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Preferred stock, liquidation preference, value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23",
      "r365"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, value",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from contributed capital"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering",
        "verboseLabel": "Net Proceeds from Initial Public Offering(IPO)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r52",
      "r54",
      "r60",
      "r71",
      "r86",
      "r94",
      "r104",
      "r105",
      "r130",
      "r137",
      "r139",
      "r140",
      "r142",
      "r162",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r296",
      "r299",
      "r300",
      "r304",
      "r305",
      "r318",
      "r326",
      "r414"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentBasisOfValuation": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the basis at which an entity records its property, plant and equipment (for example at cost, fair value).",
        "label": "Property, Plant and Equipment, Basis of Valuation",
        "terseLabel": "Property and equipment, basis of valuation",
        "verboseLabel": "Property and Equipment Basis of Valuation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentBasisOfValuation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDepreciationMethods": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the methodology for computing depreciation for classes of depreciable assets.",
        "label": "Property, Plant and Equipment, Depreciation Methods",
        "terseLabel": "Property and equipment, depreciation method",
        "verboseLabel": "Property and Equipment Depreciation Method"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationMethods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r181",
      "r365",
      "r417",
      "r426"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r181",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life",
        "verboseLabel": "Property and Equipment Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r235",
      "r356",
      "r357",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r354",
      "r355",
      "r357",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Agreements with Arena Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "terseLabel": "Payments of related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r285",
      "r398",
      "r468"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "R&amp;D Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r221",
      "r279",
      "r365",
      "r424",
      "r441",
      "r446"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r90",
      "r91",
      "r92",
      "r95",
      "r103",
      "r105",
      "r166",
      "r276",
      "r277",
      "r278",
      "r294",
      "r295",
      "r316",
      "r437",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r348",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public Offering Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Other Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Short-Term Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r242",
      "r268",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r242",
      "r268",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Company's Financial Assets Recognized at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.",
        "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]",
        "terseLabel": "Schedule of Services Expensed"
       }
      }
     },
     "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r243",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r249",
      "r257",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Grant Date Fair Values and Weighted Average Assumptions used to calculate Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "verboseLabel": "Restricted stock award, Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock award, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock award, Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vesting of restricted stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of Shares, Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares, Options granted",
        "verboseLabel": "Number of shares, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Estimated grant date fair value per share of award granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r251",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Options outstanding, ending balance",
        "periodStartLabel": "Number of Shares, Options outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per share, Options outstanding, ending balance",
        "periodStartLabel": "Weighted Average Exercise Price Per share, Options outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable, vested stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r241",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r263",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, Intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of Shares, Options Vested and Expected to Vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Price per share",
        "verboseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance , Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r18",
      "r407",
      "r408",
      "r419"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term Investments",
        "totalLabel": "Short-term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r85",
      "r86",
      "r107",
      "r108",
      "r109",
      "r111",
      "r113",
      "r118",
      "r119",
      "r120",
      "r162",
      "r192",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r210",
      "r211",
      "r213",
      "r214",
      "r217",
      "r326",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r44",
      "r58",
      "r59",
      "r60",
      "r90",
      "r91",
      "r92",
      "r95",
      "r103",
      "r105",
      "r117",
      "r166",
      "r217",
      "r221",
      "r276",
      "r277",
      "r278",
      "r294",
      "r295",
      "r316",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r437",
      "r438",
      "r439",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r117",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r23",
      "r24",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares purchased"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r205",
      "r217",
      "r218",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Stock issued during conversion of convertible securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r217",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Share purchased"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the number of shares issued.",
        "label": "Stock Issued During Period, Shares, Period Increase (Decrease)",
        "terseLabel": "Number of shares Exchanged During Period",
        "totalLabel": "Stock Issued During Period, Shares, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r23",
      "r24",
      "r217",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Shares remained to vest",
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r217",
      "r221",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Number of Shares, Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r217",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Common stock, subject to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r28",
      "r29",
      "r86",
      "r145",
      "r162",
      "r326",
      "r365"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance, Value",
        "periodStartLabel": "Beginning Balance, Value",
        "totalLabel": "Total stockholder\u2019s equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.",
        "label": "Stockholders' Equity Note, Stock Split",
        "terseLabel": "Stock split, description"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Forward stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r41",
      "r86",
      "r162",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Temporary equity, Ending Balance, Value",
        "periodStartLabel": "Temporary equity, Beginning Balance, Value",
        "totalLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Temporary equity, liquidation preference, value"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Temporary equity, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Temporary equity, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary Equity, Ending Balance, Shares",
        "periodStartLabel": "Temporary Equity, Beginning balance, Shares",
        "terseLabel": "Temporary equity, Balance (in shares)",
        "verboseLabel": "Temporary equity, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r206",
      "r216",
      "r307",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r94",
      "r95",
      "r96",
      "r97",
      "r106",
      "r146",
      "r147",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r191",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r294",
      "r295",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r353",
      "r400",
      "r401",
      "r402",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r88",
      "r228",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r228",
      "r415",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Government and agency securities [Member]"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net",
        "totalLabel": "Unrealized Gain (Loss) on Investments, Total"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficitDeta",
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r121",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.longboardpharma.com/20220331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-07)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r469": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r471": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r472": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r473": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r474": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r475": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r476": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r477": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r478": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r479": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r481": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r482": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0000950170-22-007877-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-007877-xbrl.zip
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MXF'Z<16&*-U8?J37S#F[UK%8L.R\<[$-UM8,7T>=-)^C88@<-#T&B(*L]V.
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M^CGIJ6?4/0?7U1<\3T9XI<XR!V*;UO>S0*[UJ(V9GS YX/]05HXL-H\2\PW
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M14#ZW]XC_*\"7TGK?94'N>L./(7=*Z.E\J>P#.QHQKWUPP 0$PC)G^][Q@<
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MYPC?6_D,101A $)F.%3N2>*,G^7]C]5&+6\SN*P5?7XJ!L)NGK(LZ72R"JR
MPYT;;V>W^SK;BS=>EY]JNUD6&TF KZ$WQ@R@)N%QGY>#/(^BX7%IRY94CY@/
MCH)Y:VH?-C8DV1&ZC-\KL':3X4&4C\?#3% %<!D(?"+]#EB'27CM:  F5',D
MW>$Z4]5B03A9)A%(&KA+:V8JU5MV3:'B,:.WWN7'%6SM;.>;H0>Q]&O8M0$#
M."Q<0/F$K7DQ"0G6"!C2F#G6;7"^HEITQ=,F,GMC[\N*2"F_DVI;%Y&7F,*I
M-ONUOQJ03PK.& OQIM_7P1*-M@23C7./'C@%EE_L)Q;@[D_F-UEUW^L)/E8<
MHU=\.;'>NC CT IAD-PXD(C<5YYXV/UMYQ#($V)AFH[+1<UWD!T-W@2.BP12
MD+$(U78(L9?,H2O](]BW5)I;M</-R5PE>_0\#Z@+N1)*!V2ZS29CI]"S\\0(
MRC@)87('9I_"0NTB2U6[H]X<4S_K_4N\5O7/V>I;0?DFP*E<]$GSLL;.Y"($
MWR]L1:.BM@DAV?G).7U%9THPW-<P(>%>O%5\<,T&^S\T!ED49QWQ!1I+<WK5
M(?E&IO=O9Z!L!J9\[!5L?.:;5RPS,JLH:A#ZL&GF+P*O8P.L>1*]>[POONA*
M=+Z,&EK@3W"OX[#Z0!@TCA!>87C21/GMFSFRV!#]5;O+MI:4H+*Z)(L&4.-R
MT^"A7\M@.*]!L:^4/YUF>-(H^WXK;;"@?RVH:8GF0@+AM?O&W/&@CU@+)8KU
M(O5N/Z3N^OJCHBBF2K1%5R[]Y-CPO+):?I?*W&&>$-[T&4&R-_50RRL0-DNV
M&O2#MHYSU[E;@494F?VZGJ62'_BH;53!<.5,F,C)@FJRD6>9M)NZD_! .:2#
M!A1>$[*X^.-T^5-FM&6U1@B:8HMJ$\TSP3:IGSYKUFE/7EW9@TCZ0F%X,TXO
MBLM#?@B<IV<)02F=5S?2(T@[&OI?Z)H[3"NEO.\MF'TT7<6E7<,=I_B.KN(D
M)B3.0[-+=N5Y,P8(B_&36[CG)]@H76*^N;46/-G$Y8-7\5']'B(F@9@ ,?H!
M//'"./F190UE^[GP4E!=7*;QPGMS(NU -;VCPH?ZH.N</)=;9;C@8A1N*DIW
MES  DC<^[)#565!2$&PX\I@KZ#GTYNUJ]WTYOAY6SRKWE1CL4G%@("5=>YKR
M]O-<+F)VVDR]2E7B%A.7.I.1OES8!=E"[-XI?>^:YL"/HB(Q[4N _)O)@6#^
M\SJ4@/VR"I8 O-%0'N]M_5W2G!\R=[/%]NF4BWT7)?]+F<7$?B"(50U:Q;.S
M9+543D4NT-6$AP _66VQ?CC]L^B.](L'4?;OF :;1"VU_"P[Y71B)004[6\T
M1>F-_$R&&HO4&D:Z!;424*FL4FF8#1&R/V53&FYB1-[! !TFAX/?JK<E^Q[8
MS3UKRQ9&B+,!&& ['3D" 2-WCWZ8JW94.J7.,\'+,KTF&EQ>+.6QC-,_%R&P
M^]"7)KO.049FK(JU152(IF3O)1@E\M&D4=W'L:6QVW,3F62AN<]NW"H:R$DY
M6P\WA-DLQ"]0-C&@6))O(:2?<8Y*4NX0_S29RTI7GS8$K"HHS3^#)5I.;1:%
M0[TI(V$74+)+;_464S& 3L1*XLZ]:GNQ3^2Y(9KM%&V?MK[")Y])[#(Z2,G-
M)[L??99"7U9L_,X3_U5]E;4$C_UIJ9SR?[;]]\-Z-LN#M$CYI;)D_R56?7,!
MHS33NEJ:ZW2OZ$?4IE0(J.[E+Q.Z5T OG^>ETXM!3492;T&_?+ %#<6<9VY/
M-\4BC,.K+5E,3$R<4DD+9J;G- +)'G^5NLWF R'PZMUN+2W+6D\'4,V(M!T^
MQ.M6):&)1HC_2N'W^I'=JQ5)FEE1-M4NNI7H'S1B]>7O+R.USK3Z2; .-*G3
M+4-O,KP0]\3,DR7+BZA@#)"TMK)[1FD!VU@OGY2GN/9 *;%P9=3U!%48NK?0
MTHG,7S[;?6Y!B="(^RGHO</]0]#Y4/Z>38IS'Q/K-/=EO/GHXB2\=OLP[*H[
M3:J+2(U"L%C TYY"[8K\,@2EW)YSCW=DF!;S5R926],M12KO6A::Z#R1B 6;
M37@7D]+5C1U&1>S^I'\M7OW(2,RSI6W]Y^1WZ9WH<#3SW2[-$ Q06@OPKF*
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M"!Y]6U*BS/ENMFDY?F;4N*(""?*U]]@2VMUU7JZYKO[=V^V',@;P-MTO9\8
M81Y(J5,=>F1.YVW:]Z_I$T8OZN<_3FI\QDEX.%T1<PJF"_D.<>J#/(60>O<+
MWQE3NKIM<67TT,GQZM3 1%&N%),)EW.)B,HE7P5W2\/@S@I&#/"P^4(%@4(D
M8H8'LG<L!5$66!]$\K&C8BU(#J5\%2';V<994/;S+"@W7.#(''XM@^-CNM/9
MTS*3!>T*P\!7QCOZJ+/[(0;'UHI5(R_9[PU;2B ICX[@E#&2&Q+%9XK:[;&>
M''$"?2WQKDG!NC]*7PPRRFNR#LB6YS6?>X4()")#$:YM[*3.2:YT3D<-6HGW
MER.O6S@J;^ES$[ZD?.!45L;9G4F(NHR0-QNNT:'=)"Z^G5ORW)GNQ[SQ+DGR
M9S#EL0QYRBK6V/LC8S$ (<GPP:>@#$KXW'S1B(OF(?G=<[:IQ/$4AFN+[ET&
MJ'&L.V?<Z4H-M46Z%_J%=Y2ZN&" FN]A=#517^)DC'B?ZHIIG;PZX<H(0%@P
M8%MC&UT<+6EB;G=TIL\K@4Q?2&@+I0:?B@*\BUZ* J/-#QC;H 1<9"[C95JH
M'/:1 LK<@NSHA'_YDUYYMD:*A<&#W5TU.CQX]X[LLL[SA:JYKB=PU-V&B1\U
M5C)&07(7TB\^?ZC2PK'^%5RGVDV' ;[MWD5^0YRICA]JNT:7YJCESY(&)6T.
MWS*/COR1 TJ<A$0XP5JUM- =<)YSZ#QL@]IH$D6;J(RT67ZXT7VO*S!S5AU6
M^!Z<@C)%YB..C[P1WJ49-<MKX\XN].]K/IY=TS>=$PJVX^ABTN3"E^%T:VVE
M/]AM98]A@%2GM9&K?Y]819IV)*9]^/BQ6GG;6537R&'\M! L8^VFPK1(NXS=
MA^H+6G<X-I&,*G3*):0N;S^ B*G6,+B#*Q0A<Y)C6/== <49] XE/.']NB#]
M@K<3W%DO4KJ;QGE>\?E%=CC[365HW=F=6;_1-@CUH<Z%[0RY\48]1Y<*S5A/
M^=S'E>KEX1>7LV(65V0[@U] 16+:X9-M>LE)#6K9F6=[*2=+9]X%&"#RZ;B;
MR.VWA2N%Y]CUC#*8,,AJ>7>ZO96= "6^U,\/GWUTVCLJ^')J,]3TQV);'G3B
M(9Z8O,<<A2Q=R^G%:#@L'%8K'18L[!<FB,\K7"WXR/7PXFG8.^WPF!0-(X@(
M\(9*#I%^'->" 3)A$PF$?MT[E[%[ 0Q0=?0J/W+4=OPP5E.VII;FPK+A[:S&
M^/#05$; LS]0T<^R0R?<%2%]% ?ORB]SV(0M[K"H^TO?,>@47+EUO>.N[&/R
M^!Y^]_ WRR%*6#<PZBE4[<SWC02,XOQUYH&G,^06!@@<&'!//%=4>G7^&O9H
M1WBE>#!G_CXY0^?%H9/^QUQSY&V@, 3MOGLKOS\ -WT3P-XQ&(%F1G2'>-]F
MUQ]YC/[B?$F5(Y1N1D1?;T7FY/X='<;=J734^GF<T4ZSPR[XM<A7H_O3UXD,
M-([\59,WNS2P#L2Y;G9<.^H<9L+W+W]AP,CWZ<%9OZG*V+7J<[6#P.VG;#+"
M*S&:$S_501$*E]C\&4N9>4'[?4=/D'F(^$6=^,$HRV6UB5*"U$)?PLDICB<O
M?.S:KTZTDK-0Y%?L6B3"8:K(301LJ2ESN<_U.>Q;&/+KAV_][SLP@(=1?.JW
MK=CIQFXT"1_6F2Y7PP 5/NSG?/7EA3#K <A#5S#[*0H#C/1B@$&)EA/M#O;J
MJ&[A4 B5D(0.K1/5UJA)RH*S/X&KJSL3D[$6O1Z\_2/'>A@>8WF%Q%S [E$T
M4C)W6XD.P;H>9C]V(?&G<_;]M6<)E5H4C''2\8TBFJ 89N0^FH2R>&K+DJ7$
MN=3<KKYB>*FN8<K#<%K+[')W4%G4QOAAW8_GBV<+A"@\>/_['!;50(\D2X7'
M(GIV'ANB4S\$N@LE0I"T!N.-AOZ(D='V)FZ$4LZRK-<@]?L,VX:&I'O?<AKV
M^OBK6+,2[BAN'P8W\WMW/CPOKP'$M!!C(6[^D&GP=%,_,N?,#4F[-/!)Z;DS
MX>XSUQUXE=2;NS\0=5YBM$GM3>,<]DR+(2VG5Z/W7,-@U9/A:+E>;Z?LFO'(
MTL>1]R5VKDO>E\+'\^:_?S.LA<US-,YIPF^GGX-B/N-P'VNCSN[SM 3=&549
MK;;<<0[8^N;2;J95.\_X[:VQC])#6?5%YQ:.U:/32RN.I\:IV(N"T#ISI?8S
M@M3\[&INOY.K??9,I6L@M^'Y=H(Z*&W@P@;C?F\69<([["H7@=*L&3/2[F=H
MWW69N3=#>G]%7L?;AH^3LY[ >R6KO%()A'(;"5;PD]B6@U):^;KR) ;F?YU)
MG[\N)C+%\B).I7LMQICAS-D!S=:$)"VUV!:=>;ZMRGYDUQ[";1J9J#[&\X:>
M[,)F:,:L^P)<ISG*I/L)BK@<ZZA':FLJJ%P3M"<H#K-^9GG\\<#F,FCR@>*%
M(M#6-&]V[K_TK9;ZYJ=LK!-0O:6CBJ'&V])/=E&=[@6M+LD?]-Z4=2^&9[JD
MC.@ER>F"O]MW9$XSK/"TQ[,Y93!F=D\R)&W6Z;@(T4P0T(0>F[JTQX01,\G(
MEE?#[)LID)M>K.(=34*(U7DN<]-;T=XC&5]D.&L=KVOF?V47IZJW"-]EOXE=
MB3]@@.0H1/=YL# Z^N997R?DDA=VDA- !8*"GI?><;XZK2BO]0QK3#R6L:M)
MDRX-\6/WEM4$7I#&T0OD^GLH/9QP=L<-ML0Q=B6)7&A"3*&=SXSXC@;)J]D[
ME!P4AZN91%"F,V6HZM"[B48-Q)7=ME1?TH;I\>H-[OH$MI@OAC=LAFBTNE7&
MMJ%TYYF'Y2Q^)5 #9$.F$X*\BVNT6C9'Z?:3!VO2ES<T6.XB_073SIIUR58R
M;P+1$SQATXRK+P:O7"F^V4[8PWA-PUI'(6"L.J;5H(JU2/::'_M;/^$8R.-,
M\$;ZYZ[$I1ERTVZ3MQ^5/#:DT+;4*[)?H\KO%#&Z^1\ QPT"K4KTP=^:")&9
MR[Q>X#@,T)[>\?-*)*N^)'7_91GJXN)+4G[MA+TM3#ST$RAKY$D>BL[4_S">
MPB]9;W0M_FN0AE;%_=(L[MJ()/7$ZZ**GS= HP7EKP[B9[9;V3C&LD</FDF0
M@WI-+Q-92S/>NEXK#]'"N^BAQ>IW(+F- :B4KJG C]N,F,\'(QLUBE6\JX+>
MISRX^K&6+*)*[*)YB W!>F3+81;%]VCX;@1[S6"DDABRB)6R'<V*T'FYU#CS
M[8>UU$0+IXA8P\T9O)D0S2WEPW+W4Z]M948VN2%O2UH_E^5V-03!/..8>4JR
M?M@<CT/+ YV>62IE3D3YH.7S3%:T&)07^:P4><?UJ33#;O[-(J'4@0L=11N5
MG,[3/JLR@SQ3&36G=RV)H;>1!DHBZ-$%9B]-7:G"B^%.@?D5.^Z7C-0T4!<N
MZB!9@4#C'S:(-@RP @YQ=:[97JA%OM:LYU,8*"J5$*,9EC4$W/??M:#QMBU5
MS@7VDH\LD24+1&@1Q[K)N"%':?LSR%WU'E+:Q/W$;98(U^P/Y>,?9BIBI (\
MWYQ]?QO2CNA^7M((6CRWZ3!YCN?X?D;+H^\-P[08%:RZ&PA,M'S% *FE[.PK
M+K2S9#2[GB0O$RGOAU_ (Z_Q<S^$DGW5>**YYN$[7P2D*X,"*9K='SF^?EOC
M7JK2A^DNC_J=#%;$5@4&"&BB0BBE.>>B#,:K9^ZAB@6<'SGYV3!QJ%=5%APO
MZH,.(4L\82BKQ3.6]XBHV#5$RMQ(Q_5>.]9JGYAWQT_X^B)GZWD8IV28KC2I
MG3?4E#\U8J>O1NX(23[7H22]%_?Z")S(Z>\_[_'RZZN=,?*FQO.%PD=2ITIO
M?6&^')$3$SP9CA3!FD,7'\H0P/%0Q>N#M.CY9E(OF=G-.N:TI^\MJ!\_GI;D
M:3(Q_\A:B7>J"RZ!7DSK\&4G:11""]XW[M"Q8_RTWW)?FKWA'I52T"?/S.5^
MJ.69[3WH=:1I4/;SS&?3$W7Y3@N.5\:92FF$>=\;Y#K7I-$4,!V4UZ&9D<-*
M5_QH;R"N^;CF=Q?.D$;4)AY7@M[@NXEWUT#?8NTR+^A')N4=61K+1?3% [PM
MRP^_-C^!H[F]@MR'HZ(V23JOXE<)@X@MP&?D(1![5C"(?9/!\E1Q>[I1;?FV
M<%N XD!QR<+,9H-WY6[Z]Z4V_KC9C).6;EDNB@.\/#7H<"EZ+H.A=O]GM2NI
M7[+%L.""[6FC5)B >_C81=E+GI$D3B-*9,'#V%.W1K#YSNRV<^%,^2NE-.AS
MU@['!.D0II0T+K+P+G7W1&6V3#6/!1HE'C_/)4@4UZ2"3H%@1%)=ZDO]0:XG
M--1T9$G*/*PBE,K$Y318Q^_KYS&)M0D)V),,D;%&!5_V'4C5SO7F>?.B+QI@
M'A\B7M#FH[WFF(7J_' E<(.)TR2#^-:^Z?E[<JD!_+W&P%>J+EQ7PKYH"&90
M$)HB61 KUY&'67-; 8*E:Z^J$JWJPQ!T] _-8O/N15[R7CR-<_KUF=+%YGPG
M&./!U,$94MBV8D1_>L/T(^RJGD2)7L5PB%7BC 3><51;,QOELP7* U<ZP7#'
MYX7J(Z7%7[AX094QV.4@A/*.>'S UO;WP6]U6 _#G3)$ ;Q8@%+! /0\WSBJ
MSL!30N[KB<?2)Z;^7/MO B=KH3>0*4N#$1:LKTT15_-8(Z)9GWTBTLHD>#KL
MN2_:VL+V2H:) Y2?W619?5Y;!KW-NK;P))@.F=,1H%8HP/U#TX"/<?&)%B C
MV_4CM-\%RG5>@Z)&R)O4#?U<_ 0?J'!;YK5IGA[JPQK)DNA@A"*(]P>15A;E
M.]XRRV6>CEUR*-\0K0E"/5>B7TEKXAO7GH7^2&45?X1R_QO.H^XO_N6,-><-
M4,HRY(P*?#XT_U%Z;D/9.\*GC4F2=9$0*;5XO_F9.&E[ LI;0^#A ^,!"$VS
M2R:>'VD'[<:$T?$\=T/=9>Y,';XC.YE58F+"IT>,Z^4FNTK$Z.$,&N0.X<B&
MCJ=3H0E'TLJ=IABNGE>@KRS: D)WQ#/D5S@YV/+4A$]6W4=19Y/1J!OG)0HL
MB[>]JTEY#RD9_&*)U4<.&&_LL+CO??("OZ&2I@H(568;58,N+2[,Y+1,'S_E
M'/:>(;_;>ES2)2Y4R'Q"W>0&^BAK=EH9L9XD(K#QW:WH7D)A3*HL@#<1<C'Z
M9-?HO/* I9G*S"$##!_XA"!!S])R;ARM]]R=^=[J7(\6_!1$G-.267OUU;(E
MVY2?M!D\N'E),> D5>9!TQ,;]P%IHNG%2VX^S, I3;1B</6_\+7KOP58&$';
MSKS[7(*N"GX<;0^/.!VHA#F83G/WB4585=D@PC0A<&;43V3HF3K4%@Z./1PD
M'USI>_W,ZU.O('2M.L)(.3:VG6_V 5KRU-,R"59=ATI;8%V)1Z;W)RE5XQT1
MP(AA#L)4?OK=>M7(5EJSV9F\D>G>1QRD]2J&8E=HATYMXJ'Q!%%'U<A^>%K7
MI)S.LT.\(NU\G34+QX"4QGN/?6FN1'9=N!Q.Y9%/<,EX(^J)H14\XVF12+$=
MA;P-=31J_+P@%P-$Y)W=<?*Q8 BM,7V5%Z438R*THC#<45'/^N&"5<9+?0?0
M04YK!G\UHOO) 8SJ'MA4\,Z(_,=4G<:B+18PN&" <J3)Y[Q)DI)ILYGR0$M!
MDONP*?ZHD*)8,M3.KJT\N;%<R<)W_8W]0__.P$GL@@:N:\=NL2PNP5>3<BLW
M4T5-^Z_@T[\U %ME!!^Y6_BN#,[0+J6U[QCKC>Q*FA;/&>ND+-975E2DO.*Z
MKBJT3I*[/K0"SR)CG_(YZY)N)G9A[W0.Y*Z<_S"R-J;-9$(>[D/JT</"0;O
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MRYX:.TJ.D(^>/LQS'O9AUC[I=R>-DO]S>ML*28&RN@XA;,N%I)RYD,S^M//
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M7!X*DIV.WV5(\>P6$IFN&@-B>'V)3,L52W=S_TX)AF>%PFN3#(!1$ <J($8
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MVJ7 "!M?;-ZRI@*B_"OLJ8 S/=BO/ZME V<Z=\Z;.GSH;U.B7 0CL;&XUU1
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M+SEIH#!8;IAVD9F6D#W>#)O6E+ E!39RW)[H&E]=B\^S]ZB<6W1JSEH<N[T
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M:A)QQ$;""DXZA@(BF8S*PM4+;=QX/K@Q^TI:#(4>\*^9K2<;BNF09#[3<F2
MO?M-DA6>\:LBA.#4K#GHQT,%O!^HZ9%0V^OV"]NQF<^D47@^)@K/?LP!.WL4
MW^8$^8OW*MDM[)AIYQ\.V7F#I(QC>IN/*TIMWB>8%XY.,'XYF7>+,@+ON/@.
M#@X'G\@03FDXVH:OKN-)28B.<N,RY%EN_)7"4$FDX-G?'=V&>B%^!TUBBCN0
M=$:>UXT%-@@C/+I9&J+ZCV>N_^@X2V2$2Y\%P;P\>9?)E"^X.A]W0N"_1X8D
MA8:;G,!*Q]TM;3>Z?VD="BP8F/[B<$3=MD&J&#F-X6 18/U4XK(!Y>2%X_!+
MRPY00V.D9ZO@F<X6JKBKX?W6P^[2"TN"=P86RY-0^QI*(<:(4!(CGD'D*E%F
ML>4L2%'"[=:HIDB[D^_;601[PHEE-ZAQ+T\D#X_WQ&K.C]]O;$QZXK0G)[%,
MWR[)1?</TIE["?0VEPDN4;Z55+CS+\-?P>?%0ZSAG=W SCT#:7S5SP$2R!,+
MQ%PE.MA]W:EL??A2M>/<IV6/+^FV_F+!@<L8M F8B6B/9"2!<-$)_CEV<T69
M%[[K('8*@S0HK%8([I/>)?44*L#CUZT'NWKXDKXW+PBAX&W\^DXC#DL%+.44
MY_\EFAJ/>XG7?-AICN19\C(SO_,H_N\\%7"#?Q;AY0?EI/18CF,08_9\B=+7
M&V_.]5_EI_MH_6,1!$WGHM"/H1_ =:_&=)\6)'15?/V*R&1#.%%ZMBK.[L,>
M-N(JUA:JIJ^ !G)_A(+GR55@,2A<E2A8/N_FIUU9#,=OCMC>]1E]G2[?D1@I
MWG!A14C@I(K 38S!T6ZL+Q?[9H%S.]#:I#Y(^>&=J=N-?-R&8B8WZ!P'AG&H
MV_;_S@)@@2%!!.2$5+ATRM',S)NQZG"3D5[^Z@V&=-*P^TDC@6,"SOT:6^'8
M;2\S6O?F;'LUT?/Z\N/ZZ#N2QET&*06/PSL_AF4)1X<JHCWW^8A*_>A+RB&.
M7<&%E:4WJP]4F#W-0V<K/@U*Z9E,2E3=H__,?215%7M<Q87H4-RZ82A[FC<J
M5?]:T:CNT8.1@9Y$PX.D6.W3J1':+F E@5R4_6R(IKKA5K_-#([^FD>K#9R$
M*,U_)J8O>X"BT>S'* [;Z9#F?I.&RRH%4OJ?HL)#E?K WH4 ..>9.&4\@ZEC
M2,[1$'\^)4"N(5_#I#DJ7&(@4GXD,=Y29I:64DA%[3G5^.(N*@ CB#4-4YGC
M[,7U?R4&/EV/,<Z8[=6>2N=CI/O@M5O@LCI',L^L0O2@6<%2;H33R11OY-+K
M^@MFJYS&G_AB/N55KWY_QF3"5;(<1ZREA4-7FR4!2?R6(9=3,M7XGL_;_VS;
M_.; 3.S5P/7KG6E"H/L LAOA:/G@2SHP?:5_+>II8,)6C*BJCW;IT?_Q9 [+
ME;3=&_HDA6'A=4IX+1*R#JW(KT 8(L:^@I;7$W&O(/57;,_6F8Y_W0 7D"LS
ML9 H+?K/Q)ANQ-6)W58Y[8\\S0E111*W?CL^K!1^ NX_*Y:.[I<.XE_ F9IR
M$ZT-CCW/&<OW3?5N-F.%C9XIS<UD>>FL9^5MG:=C95=DKBK_ZB^GV4<%L+ST
MKS";\_+_]?A^]+5E;7X1CA&"A/KPRXND3OR+"*S"-&K94==3L[MDXY^1KV-0
M(XL?G;J>1'--]M?VPB@ HCYH.5Y$NWP%2;Q:A'($=4/8%PH+;LZSN3T_G+P!
M\M"])A&H%/^YZ@N8@V0\#KX! S[ RR?K#:5,:[<'J;1N=_?XS@H=QG.$:TR%
MTD!$3PJ$*X5K@LPPF!L2(S8_(24%C+E$:;-=XK6*8)JW=%4I'VPLN6EY5F*R
M*A_5<7I?.6ES3+ \S=RQYJE^:GG2^/6O?ZD ^)0+%<"P_1X4?HH]=L RQX)L
M/+QQE8>$AO%6NM>XHM>M(9($PLA/<*?VV_.[7O>SRWE@FJ'J;%$=DDFA.O1(
M1^Y:T^G^KN@!/79Y@>>?YM9"OCQ([4?PXF:@;(C18*&@W'K>V*,V <;LO6/8
M<B+?R(W7*\QM/AH4?":X6+W*DYP&YB(]^4[T%*E:'(Z]U2Z,HY1J53;X64LM
M]];_?''G:Z&C7^/[XJ1&Z?$9,) R@  1/;"6>!I=M(.A>ZLD?I'SX'D<DO"]
M@ ?5BD*YZ;';?5?I)TG2BR!V&/O\&I#=-5!#TI*M_4EUV'/V#A\3P# 3^L'4
M&G 7Y"FUORN'W8:!G,;=NZ[.2#I\NLH LETN5CEM:D$_GOI+23FQQ!\XHPA%
M>(GUZQE8)S*_$JF$?K\<.FVY%"G")B*,9-X\C !^/(U_?ZW]A42ZUGX[7VYF
M1&)W'(E(9&'KCZ("W$R9GW9>4[+Q*'TQIC"4<JC5N '[D4K:/H[9?^;/=#JU
M:MD54HOX@^&QH:=<#ND@4 &V!D5,FS$H+::E?9#KE^$>#>/V*H^7"VZ)@E$_
M"L(,6 ':B.?J53_WIP6[@TW?(;2)0493RF>>IL89FA^D*L:8$JH])>1O2ZNI
M01Y!RW@[,M4G7L$;^K1],6AYB*/V'6%50C(N8EA<5RC!#^ F"-*<,2A#FYT]
M"?X0!R"SX$'A_OLQ5,!%N(OW8L+E<;W6#\;-&5?]B7=M]K2B.;(4'K]O/;M(
M!!(>D//\D:$YHI,%DT?E[V;D+*[FJUHX/""<L2!9DE(T:_06$8^FA! IQ'S[
M=UT4@3_UZ4F%[XSK4O%C2M$R0B]WF/+$/-9+T<ZY4>@ZIFC_88&GFVGM/,U3
M<I,D*N#%[S)5M<$Y?M;0<)] NH5V-SIP*5YU";)[K12FB!GO'=W,Z(NMM'%O
M(#2F_F(=5W:A:$\,A@:1T+Z?2/E5WE\"V#2FS*LS?IQ."@X9?NR7:^MQ6 [0
MXG9V" =^K_JQC]%<E%VH78C_JDP,>%SZ=^$VH=PH.^=):33&_"/G@.0K-75"
MU3@D6M7R'YH-+NU;EAQ@Z)^IWRS[ZD$1E[QI^\[(>6CO0D2S0A_JH@WLC77J
MUHQ)^)9F->%RV<D]YXN*!0#=&S0+SN%,P_V1,0C^6APAPOWE4?F-(:XKEA_X
MG_\ZO"FYDAS\KP)S%;!EJ/W?G?+4\C\GJDU:T" ;Q$;9/^8NUQ&*^:\3NRU!
M_V7:VO^61567AT\8.JD NWY*^)^Q__)U@J[JO_;P/:G[7X<TN@(*E.NB0V_6
M XFD#SC*G7+S[/_/J+4)P*/^X*N?@5GM-R@_V]6)?UZ_]J@@/;+24E3(V>N^
M;\P.F3WX4?*[1L^VK)I??<,C!2>]8XK=C\048(HCVF79-!_E@,0M0ACY111O
M=P*52M7IF;RYC]'HX*OTFMT-P8FY2^1;,Y;M=H_-H^>5F]NM[M[!/ORLE<G$
M\N%#6$<%TZ 9UZ[CR!EAN4V.B^X V9/[=ZH/R5=5<0SB(9E%GQZ,*5S!7*WC
M3E1YL++\LGQ0VY"_3WTY<7T1VK$/@@O;R1A\Z"<T%T?*SK_0,!A+$=IGO_^U
M\!W=&DV9=)Q.M9R>C3ZX:/T;Y8R5$S\TFO <.S1MC5K,859JN.M\W1+/=+2<
M<<*(?I[+3U+ _R!^6-*/?[G+ZASIL\UO:?47/EK]Q#\E.&2Q=?&8OZIF8]L
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MA.YN _900"-.=7B7MUB\28&THS#)0L;MK**,^RE74HM8K#I%-K#R?W\G4ZF
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M2D0/\P3@J*YZ\]_X(W"2W58:@CAP#WOKN(QB?+$]%17%=8EH>KD( /#=WW3
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MUSB85FWE+7.@3PQZ*J?/>];2\EHG%<MQ>8IM9 H9\+3G-/FLX'FY RXPUA9
M\X([Y(7Y-&W3B.</RL476<+$CKGK\P&;MI :,M";>BK4'\O1BI8Y65(LAZS2
M=_-BS'462E"(X9CL%]Y:?&("*>#)K]_+<2DB?9B^6/NF(:;W$Z/T$\F0P&[O
MP@T^B8<1RNL.1WR*:JII*_S82@KT>U/<.1 9.&T+(PU<92Z/EF8S!U[)GM[M
MZ'6S?C,3'>35G8]RFIMYE[/P9B+T,O?828X0>O&\A4#LA>W*FVL80C?4!L#)
M3%ZVQ]=@8>\VT?:2:-V,E]/NT%M&YP;U$Z9M7:?L)P[%?"Z<9+VG,]VP :IC
M*@VK"J7$6I!*0_S*9K[=B!=M:<LHR=21^E;7)+V<O@RY0/J27\_910:2(!2D
MCW->+)=#PF@JO"2_&O%V*D[5'KO4$MEQ^W:UYJ 2K 3AW$!/4,-34H)P9Q]A
ML L1ZL8)BVT>F$WF4-6AF>LXT3JWHANO.S)7-%LG">7M=F2@MB#??4M59C)]
M=FJC,-,#W908LL8ZZ'@_S46-I8>&8E<)&>JC*4"P%A##W4F>G5(T,K0?N[L3
M<KS7!KWG%Z_Q_)9<6/E&?IFM>^-Y!^MO/0%N*G1G\CB9GISE9JA4.AW5R>\Q
MSXP_&_J9#+QKPA;?T2:8[+UU3KW/<*W_/I)[^461!CI"HPD[$R=/!MB7%'D^
M97COM<L=L#4W-J,&%G0ZV.^>I[HM@*ZO>*]Q(A#992/3F4_Q=1#-+S&M)Z]Z
MG%NX/?ZX]S'&8HZYNEYUC^%=1H,)@YKLO8,%7E4]TWZ%GNY()8S9V//X=ZD/
M7(]]9Y]M:5KOPGKICN;U$ZWW2HUY#%7/+B1J?'H=<U"MJ[ R38N/GIN)M^$+
M1L8H)'JZ&-^R^MAT-\-KHS:7W>L.\)E67UMP9[<P@N._49V.F36=<Z48M83$
MJ1D5!UH.K&>/5SD5H5Q KHAF/:%/X+;Y$YC0"P2M4 U<:4)U*/AEX,^,/-)W
MY^&YD_=<A:*Y+9Y]3([E1>IHU%,LC5H]A(1_@]!*^4'7MM&-.1YL'F52I8$4
M?7Q*5\\OJL;H4"C#["$"@4%M0F2 SF1O+)4H% .J)P/N09B^+3+0WEK:-)%2
M3_'9S('9B> 5R@L?R^Q4LQ-R\8Q$ATC&S0ZVU@)%C<:T[!N6668.MMIJ+,58
MO9>83$6&ZN+;YX7*3J>X'G.72&FHO!$(-<HW'=WTW%FE]YN1'ANMX/.&55PX
M"1Q,/%[);UCLFCHWYI74,M:;EO3"AI]I#461E#HM?_.\>L)\.!O%^E,K]5F$
M@"OHE+Q20RKCRCCJT_.SJ":.P=SS*Y4J%0$H38763_Z+>?5 I7'@SF!5*"_A
M3F =AO,=5[TV-('581DU:1RI+F.4>C601SW6U?=.6A,=&*ZQ:7!P&0EN:'HW
M$WN0VW*O"&W1 G^$#JS_<KOUY(L.1]3YZR=-ICX%"G%WP)Z"[VTFP>GQ/;,_
M;1=>MYOCH*RQI85ULLQU,?4!,G*HF8%&:Y%+;?8S[32<.E._[=3<#^%,_>]A
M&E/9UC?J^JZZ&\JJZZ_H[\)>D,Z%CPDH8)G7N8L"Z:]BGZK$)/N)M' 7IUSS
M]A6>?#MW\U)$3IRRY??@A .QK@!3-Q+]\&)SII+TW)OH^4S=$W&%LD_T9RGL
M[L (!D298;]$1NDVYY*9E8L3=&[4\!RQ2:Z^-3;)(*W(![K3@A'JZL'09)7G
M?;U'<:7#6YDX"(>:&+;4D"<V87?27H!F\&GM$^<L_DLZ;UW FJZ4;PKA_B-0
M+TC40?369./;D-M)'70;OC^NA.;1G6:A'3VQ7R%]:]!\^.;H>C4FRR3OE _[
M^^8O./9O?*"K)WTV-3F78,PXW?47V-AW+4^SPY")3FUO+UTF RZV P\B#H+B
M2O17/^>]J&C%>^*@[\"<]5^]B&+5DRLX[8=2WAOZCF)J:G<I98PQM+1L%";H
M_5AB0)7;+1,J_# SG9$70Y7@0+%N\ 1S4@'#>ERO%M7:O78E6,[/'';Y+&VV
MN,O=#F $SB2N@=%S-N'CK925.[+:[:7"A6%CA!<1L+KGEK<ENB0"3^_#'AW]
M):MY"B>U"\9)S>^2@:QR@-!L/GSB#S15XD\?G?_\^S.+#1E UD,V$C(+_\1O
M_ZE;N'B3_HL6]?Y.@UY4Y8H0W+[/4>2O$%SV%8J<&B3,C'ZF7K$Q^,>/#DAD
M5AV]QZ[#E=;K#5[X/="F*74/H3 S+7SIOV!$]?^ $XH(W*&Z0_D?#K__+=)>
MN_%$G'4#K]PF ^$P"WZQPZOYF_^ L5,)7@1^-^MPA%CN'K-)4G<^8I)D0 *X
MDW]4\]XD\(>Q[*K2HRZ4"TW=5K@3<4*\\/=%:3D4"2,>MWC_1\&4^MD?AC*O
M_G%D\_<?*>&_?.C7=-2(+5:*RJ#(GI^B*8U,=]_W]+G!^'&&'Q]?V3U"[K>]
M0JY",DB'DKLMI#&9RL7&C( >"3F5O&B]3O8?]AC8B<%9*+<'#^/[-T_>?9]C
MP%!/*%L=R#WN^C*Q_(W3YNQXX;Z_"UI#R'%1++8Z,V%U5P0/)0/'MP.[CGK^
MHXIU\!<:L[TBC_W(V=D\@D\2)M>%+R4<CR,#G2"ZT!OX$)=2MS1;ZQXJU9T<
M@CS5I>,8+J$' ABUW=4H2.Y7)'_%%-A%!J6R.N=YX-HR^L0.;QFPGNFAZ+3_
M.>!2D+/ O,_C\*@X.:+%/3L')J^\?).)T1_&'!_/WPA08]+(GJ_8:X%!9/IV
M9B*@M>J]B6@Z!1B?%D/,IUM2.[N.@GK7<9)YT2'1O2'Y!NL(UTV4W.1<6.)2
M-E_:-WQ>8/-2_^U']S=4&YDL3/@'N6A *,J]%R-M](4EL3'GUG>EPP\HI*Y=
M>J=75>B8)ND4<XO)(MAI0>TF*!JV2__"?"]DLG^^I:791ZKNZN3S+[F98N-M
M#*W2W8L9XZIR>,L!!)'YPT'2I%(G=H'[^_,+^]-;ZU -,O#XB"GQE,SO9Z7W
M^P7<7[!V>=ZD6J,L9?*ZG Q #%2V/)PZ2;S-N*R$^BJ64=ELTH+J_>LN-^\
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MZ5W,J$",H+*=>#= V*[B;Z6]BL]6!%,? X*6#/^=%OYO2<3_GR01EF"\%_O
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MY7AR,85!FG">2!:XWD-6!UM7-A[99Z0"#AY.&]1ZGATXT(3E C\O.2/0M#;
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MGX/;I'HOL1(RQJV*'[G<4RIF73*:*MLD!(&>OWXBRQT%*YJ7-5MQ$]>QM7?
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MWOJ0Q-44*V8I;R2MRRTWL7:Y;HZL!X[)("^QT!^@X2#X7#WJG39ZGXB)M7E
MN"SU;OHX7K)AOX!A&-)-L5PI)"2_>D7:(*<06SM1S W8I3&\K?ZS&,_+_1(,
MF?%'LCU5-<@F?+G$%%R?]'=AJ%MI<52#FRHWWJS40.M"%7&X&>GQ#D"T%E8V
MT_WJ<@KP3B.TNDA/11A3A 66J[[.GF%X+;R'26KK[T6ZMXU;S^+5YAM$XV_Y
M*\W3,52N\JJW1KP64-6OL4]YPTG"MJ$3<L^;'M! 4 $AI2BB63[3[5@'X5-
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MRDV8Y>3+.WXG1!+GHED.0!23KR=A%6UCDQ_!7T,*??G3DN'@YH#K<M/'IW0
M17+8_&22PSK\GNT"V]4'K.S6V!O[5]LFH(8[KM,*)Y_-JQ18X\1@@R$[U3$V
M^"=X02LM%%<5'M;H\TL--/=R=_SEM,>EN>?C\9!3C\20ONQGE5S?3_B^!<E^
MOLIO-BZ&R"]I1HE\N;6N%O!J%R5OX_I.B"7)+C=2U0][%#*9.1F+5L+>F5W*
M'UFI1WF5ESL$/JB/#U@=,>9Z_D.,Y]4:SY0$PZ=,!#O11>..ZH]Q7NH_^Z/$
M35965F&0CJ^<\@_::'M9[OK=)=5W5@4P7>@#I+?154P@JZTL%]*ZSNM"9SSV
MU# RXHC-H\WVT6PP:U7F,1#;&I\*5VJ^N5+4[+KTA;#SI:)9N&[E^W-SCH?2
MO1.UV:Z9@52'>AC*^X>:3 X@\D!Z6UM^?X4BDYJI4.4!5;U?,77?OOSN&7X@
M<E(7A.&G>>]/\17B2W/$.OJ.I5*?7/<0\7HNX+<0>OC6WC^'-.J.0Q&#.(!\
MG6OP/RXY;ZC]6_JP<5TX:H_F\MN_']QX3 KP*G []H&]PAT;)-H1Z>="IU%7
M^4XBQ'5(F^#\I/5MZTN9P;U///L]\5Q,/X>>=6R2^QZ[T!)-AYK:J-C6!=P_
MDC::%,WY.'Q:DP6SK'.N$H':PF:RP&17A1TF]SX[B6A]VJ^YW<OM/%7B"R_&
M,G]QKUL;(O070WEW.3[3&ZGN+]?*<[-N2=B+>+*:FE(_)!VS,=,2C>:]9%34
M);7I^=K/'7@H0RUVKC?VVVP<!U0)R*ALF>IM^1IGQ5M1?4FIUDVM)*WL(")0
MP/^.'VQJ>Q3#K*2^7+5Y-%26-7FE=3X @0JL&)329:BW,['4J1UCAA*E.2YO
MS[^(YH^45OXNYN<HR-3IYQ./ SHG<]]@.Z]'BS?A3H9.L]E$0=-L]N42T1GV
MA'2BTRNA3[BB4IX^S8=Q^369"D<=U9'GC]W?S34EDTG#ESQ@HM6I-X93'$XP
M78@,#MC50^ZOR'RO*+9>7 A#)O_-$0[C09WM@DOLO [GT9IZ]+7#RI5P+<8\
M7YZ0-8ZIX).*PI7PO1J;/)-!LZ6FVR?6,7N.JKN)MY0(OL70,)^_]+-T\\\,
MG#:]KS#R:<XN5&C@T=#JA>?0CJE>VC(Z-E]7L&J/ ]Z+EIZD:.?2).=T6"!V
M_KQRD9KB\\U>CYH^M+K6^\^^MJ%/0FEWQSC(2<G"U W;"[]CAH2^MT ]G..^
M@I5]331N>#+KJ0 Z"$!L$VWD^Q^M0"/IO?=N%FT.V\\\L\7R.Q0YYK2,M=DZ
MC<P]5B)<UQ:S,ES'3_"=W"3[8D,5&T,]W,T61GGO6U$KT2V@9.5=_UUD-?*$
MK?^QZ6>/L;IDMA!!?^X>G:[1[.H/]]?\I%IV&I]W%&H<G^3:'N?#!LAGGZ7[
MCA45X$.YY,_'*I5\@2/P##\868!Y2:CY _]Z!,O=H;>QPA V);39LB'Q 87=
MZ:37Q;M[:A2_\'1O"Y+ZD57F3CO,>)S2QU9[I[[BFV;Y9/7&1ISML$(,2\G?
M@<B$:+[  7#6GV6R;$1(N%[G8W^]T?GR\7-_$W+&RD6CMOH=9MW\P+--3V9:
ME%<\0D;FP,/X&9/J!/L3X>^B:R2 ^,52"'HR$SN237;"3VLK:0U;1F7?@P1N
M.9?3- ?=U5=JT5%>NIKSABDAASX<0PFG:E*C"]L*#)JS'.2=,EY7 M0]%0"F
MU'3RI\MHQ??Z4-VP?H?3(QG)*16+[\[D4?:'!K-PSTU(W7NP/?_MG48#O@8?
M''![H>;VK+>%;TP3HTN;(:UTW)< !5<<0"7+*]9=!L%?WNXOJMF!S9YH\B8Q
M0)[VK<8L)0C./VGM8_W9TPDB:>98:8)5;R\PC7D29[X=%*FJ_N#KU.UJD 5"
MML0O.YA6;5X89WUVSORT]^#-I&P>7A],E;:,],ZEK_"BY,2C22YH5GBL]"V[
MB,(3@Y/<W5-'CH')5=AX=+LL4QTR+?1XD'[,-42S-FZ:KO&[#C['W,G%9 )V
M"GZH]NY: QZ38X,?^K40BB2O:!)OR?)44AMT?:"/+:E/D'<)_BC02\C<G'Z$
MK,^VB(IC]9V>S_HM=?,DA@3YL;JQ2N(@$DKJ<1!E<B=9X2<>.]?#FH89XJ<"
M(.YX)Q<E.H*8F/5FAE-''/ A#!0ORUZ-4L8!D1-9";S6":N?;PASP9+/ZC@)
MO?W76\IBO8I:$5]+U+[:%5>(?D]]&:OUE7K0B^(LC'>VEF(KR]48XM_^VN7$
M951/V\ 'C);1E*)*5JSE"^,C3WT]LXX]5#LR)M[-^5B\2G\>K3+)<?4ID,6!
MFKZKO -"8=CHUZ^V ^DOKPXO^8Z?!=#NA!*0U1R?@NG+B^Q2TVO*4NMJA^=G
ME060OX-'PG,(0XRFI%_8NK\J9K95\ZS+-;'=&Q 0[!+7R94U2/".GO<I7!UB
M0O5T'WR820W=L$\S\(YX;F_ \,J>SW(^+JH,_OAB)><JP8/[BF8Y=&SQC4IA
M^7[NPXEFMXK1$5H$4:MG&Y?KMH#O/>.K\+8# COO]OW)]O07-$3>;.7?K#1+
M4#W+Q@GM00!BM+'4O$B)##GER2V:L1[0Q.YBYK;[NC*QQ^(A0Y=P@^[9?.W)
ML7A\[.*ALK3-SE6B)P[XEMZ,6'+N)K^Y"2(Z)F92ZO0-*)\3H$IZ_!#OXX$3
M>:']F;&:9NW$+A\/[*U:AMJ')VHD(5S;BD2)FPJN;$O\';O[US.E]F*HF36&
MCXWD^Q!YA#8:MC];TY@2UV9A%1LG= N19^3(?0:7[\-PE^K[*U\5Y4YB'L7,
MB&87?!(AWD0\9NK\(([/ 5MX89.\9O,MYHH[.(99P693EG&T6>@M3_47V5GU
M:D)6AC>IPD/NP0O5];(I_;&=/??$+T5LN]AA/]/<?_"T#MU452U+_CB;7!MU
M\,TX_E/RZZ:KSX$/'=2+#8; 0<U/W9QRF^MBOO_X'/GP#?F+Q&V=US$)"KX:
MA9<O,-)CQ_!:6 1K(^+QS6:GT<K=&XB0DRY?*^P7AQ*#/D<?9ZJ)YA"'+D%"
M7<)*PJ(*[:&EQ> R_M!Y^(?CB K*-6-'BC79W#@PT5XJ]YW(FA>O09(C]37E
M38O%ZQW\ P(:KY$B;+NSC=H:*+B#4Y/1X;5/02];@^)>4< !74QN?<>SU"&[
MOB*9'>1K[I=#!<1^]_>FB,[.V>\56[0')VN\F7C-">!U/T[3'3$Q['>6Y$GX
ME<_$D/N8EN62?JG+/+!&1[U409^]\>'PR7=Q_J)A%^WU#,?:B[X364^T8>ZT
MOQ.Z>.6 P?Y4]*(@\EIOIPV,]+3**JF,[B^_<>UFV.'VU3-$92\YAY\LAC?F
M^=*$'^^0FA-<JI?5ZD92QFS];GU-WBP(CW,8.P:1V;70C*5ICI;EC.TFI+YY
M:UQR1X(#5?Z(KI>-M7';6D>VDK[:4"LVR43M8GPI)VGT(F]SY?['#:\U)UB=
M,1GQ$C2>9H6C(X!#QTYL@>?9PA'M4&8V]WTII]:W,K1Z3RX-;RP2G#S=D:D#
MG4YSCV' R^IL[95S"KE;?R[>O>JU3I+RN%VV"ACBMP"8$LV[$*@Z2C'C85BY
M%>E5<HK->P^RO) $Y8O@<]V[G:_R8W2609Y2L\>27&]W)OM-[N>E2<56^)AV
M.H=QHVB6LKZ0IA/\>;>;T_P]1=Q9Q(+02>DL3*FR;<\0#F ?0MO[D:3EXQOT
M/[,O>#$!F G\]9Y<$I"Y\IY)I+,C57FUBSQ]#XGJO7M*1$ KX*NK&[XT3]/1
M&)834&"7^D?,(.0\3;LUP\"ZSW%PVVT@L"S OL1\POY^KI;I0K.IPWY$;FH_
M:508:[2*V^&@=^W0Y#%%MRIXF?S/>?>[ APP3 H1VYU V;3+4J$US0JW6UBJ
MOO^,LYM>2D'^(BE35!JC.@X8+--+/7HJR?/]5SY[;)C\8\80M!XI#B "+6/W
M>MHE]26&!(@FB2,ZE,BE91](B6:E;FW;Q+<A.&(*H]M5Q6(,SF"3PX?@*!!%
M-J(S<@D$Y-6E3O+%%N^04[ +/&<0IVN38$ON=@W.1!UKAAZ+2PLMSXLIUPQ-
MESDB:N-EO+Z%TIVUY@TW2^2AK0<,[.@=*SZ_DU1P(.J&)U 5U<1Q4Q$EQ!+=
M6_O@.:D[N_T[YM:-<J(?7>:%@]HJO,(J?!$&G-^:.^;^F91>_)]9]2K G=!#
M,3OH:3\.4*3?_:];XQ7./=F'=T*P3?%7-TOS_O-=$;[IM5HER(1?N5R;?$^I
MO(IM_TNXTG^F+^N6'L;?+-A8VTG7[/Y[SAL]EOJ)6($R+(@ZRGH;3 \$4,XX
M:9 "*@I"64)J8\+ ]N.F8HF_I\H_E@Z5 Y)_MW3I 4_*MG0R-;^_!\B/%*X+
MS5'9J/]V(/W_(B.?7FC@N.B.9ZD_@]*:4KSPV=:\MC6HB&J_9F6QNJ[=F0)C
M$-[FU4(WD?8T66,".^M:<DO6L>2VL7_O^%W]PSE B=U-<IBPR'Y!8+B:X=/2
M>$TY6#/]&95%8Z/RY\C? (FB)N&A2*&C*]/XO7[*2!Z-G-3G$KJ$.<P3AZG7
M0TVP@:3.M^!66>&G4"E320M07%E_K-8W_]F_1=&G>V^^3B\<PX=2BL$!%O 9
M^LEE;%UQ#0X(/2'^E /IIW!"O?#J\;R?I?7Q:DERSVJ#R!;_.$+[SZ,&!"]Y
M^]Z-'8.%C+SJ\\/4BWUQDD_=7OMLXKU;._JFR+IFTCAIA^4Y7QQ@WW8-@<.$
M\K#KJ2?7P@$P._ QA2D>M$T0NNJ#*KP*R<$!(P4MI^,PEG%I?F]W1V%OZC$#
MZ41UBEMZVA_""%R>,NT<@4\?((?B_-57XN_W+$'I>I;ZB]ZM.'Q>'3/_>930
MZ])D2>A$[BH'*AH/SX=0P3KXXQ,>Z\L*;]412LSSA_&V7?C74Z9EDP3*&G'>
MP]B/E4=LFR-_-@Q='6N>"^,=<>RJX0 .SY6AB]-Q^'$.]P$_G3]XS-_9;[DT
MXZQ><5A$>*)<]];+<D&V;^&_,BO8.6(8@X?LT12G5%$KBZ<E*$H]]^C2O$JX
M?N%MB@%7:;\,VR7+H^ =T[S74R0Q_O72%\>P(?YILGGP<DVS8TPPW80^%/E8
M[_P);(0(<WR5@ -63YJOS417YRMN [F JS*[A!U)X_TO+K2SQK-]!$V^>U8S
MKFB*F>;X%?)62A1'<" CA+GO#Y04XOVZ,A5M3R;='RUE^^6YC7VHM?MWQIN,
M62E[PF_)W@>QQE*+3^@\"\5[5M0*>,%^0]&<A"&\TG2H[ [9!\A=UG[=B>7+
MYY&V36I&72QW6/!S15\ES@N-3V[6K(V+BH[.&:FFGB)S?!XFOO_&2<>CL@1(
M8+@1\01H+].9IM.4M!6%B>9L9$4SU\J8DM!C8JCP"]6J]Q+&NY82&U<&F4=!
MY#]8Y]>*7<-;YPC+S=#]/5G,Z("\EL(5=>LAA4K3<T=O3CE-(T[IRE,ZD324
MWPHCB A+#PGO<H=E7'VV'^VYL\63%QI))M'F]32K=3(HL$^6V#1&DJFG"QIA
M#J:"A&@WI<I(FWY-7=2LBZU=H<W@^E ?*-?;PYC:2YAK!Z^U:2LW.'=D00V6
MJ!K:.F081K#M3/HGEB 6Q6%654WA+ZO#MF<@^XX%3]E?/5L>?<[VX&/<;995
M>A1XAO#4#@GOS [W7974_%#]J5GGU/U1MK<C@5?5>?^O4F6@5SI&C#$K//T$
M3K@)1\:B7RF.0G" W(^PR;6M0\72GC4YAO^E3S+_3HU@7&)0A_$C/RNZL7(U
MHJ8,]_@''^,-K7A[ TX\SIX:7DK@H_;(/V G>$N1,/^ZX!/SWZ([6OEE3P;9
MBRD=>#XM;'\5L@A.7LC_%G0_]1I/\_Y>Q'X]O?ZC $XH_];>FXGZ^\36XW^K
M@_>XZGFR8N]F18S KPZ6>'G-;T$LM95U5<]23U%R,6ZZPD3D:Z\<F3]6O[SQ
MUE=+30%X)%/TC^Y4_^U*C$64_?/$&%:NF-3V&#<-%8P*^(ML%/""3/Q;:A3P
M^+'M__T$,,;V@('\BW=Q:(Q#=Z!$X&@CN%U8E'JS$1XQ[Y;*=:G+HBBO"@V?
M]LV2Q$_?[C K-=_F>FWA]9O$28H\3<L3);@6)9,RQ<$>Q$W\$G46=FR^4P0)
M4:OD=&E?.13OO5A%F68N2*&7$9H1=:]$2RLT:JN@_;&EU;JM4&];L, &NBI@
MT,74 R\S;N+B%NC]MJI8I\Z/0STP1Q<Z5N.^ _&SG>8O\>.::*.%O[%9?\G\
MT<(A."#J&G5#!Y= %TP8F6M#4!F,+L$TYHK,8_-?XH#LH7VES]<+(1O5]3N#
MNIR^B,8!Q!FMX&,IM!\.N)4 1;V&MJ\CR:_(L,PXH"T/A-$)-+:.&?EW87D<
M$)$8A0.^0JYVKQ3^AX; R^X00FPXE!RZ-$J.Y8+S_5"TQ0':1="AC3.6?XG^
M2_1?HO\?$W5#WS[" 7?JPN.O.I=QP$KIX8ZPUK]K^[/_+"TUAGT"(:.=$XOU
MERYT!1]2_L6:4E-D P8?!\C#P^%(.T(<0&6:]OH_Y)_^"VG^)?HOT7^)_O]0
M- Z!X A*7Y"[]B/7$:!_H!VL?W=$Z2)%'@L%-Q!C616YL<&(LQ_'V"$$*&BE
M3L&9 0*YAP.TE&6@"\7P?VZZ:!"TK4-^CL&N@E#WGY@>DX-^9A?!D0W-_P4^
ME3!\S@ .&#Y8/L#07^-GE][:']O_D 2C(VEA%X3Q"T/CIO]F]RUV+/[#[,O%
MTH@%03>]D6=84I9_0W+K^!.N< P6ZD;^+\'_9P7E4=FM+#98"B@YV>(A9?BU
M9#F3U IA6$WJC8Y.2>,MF9L_YYPQL8$Z6E.^K_O?%QO.EQULOO97[C1=Z"CU
M$0UL5&*Q^G6$'OL#%V@F1I5VFY([/0A@,VJX%+8D_S[7:U7'-F8F#M)I.X/]
M:+F%'3-0ZLHW%CVG4$+15ZCG)#]V#>Z+C.=HF/%A\L$7.?R<1F9^N'FI<-#1
MN'4H>_ (04+F^%#5M"G;9G+=+Y2RZZ"OD-<_Y^S]_Y02Y>^Y(YE76!GHTK.*
M?[\(XNGX!XNZY3](U?_WT_7]1T@@[#^R.KZ\N?U_DF?R[F0;O(K@"0[HL/,W
M$ >Z&XL4>@"H;5=FH/P1K*%&W:!?L>Y2,<?G9FR+Z_J<:F5!@& GR>0&;#<4
MP?MH\K0%M9_C6CS385.B4%S^<V"L)&\6QI;@:.[S*\<>N"*:*!_=46L.4R!E
M3&B4S%HJ)@@L:'F  ]Z;=F=;H6,?C30%9N5= 'P.NU!Z=*D*\B#,DWA07J?Z
M>_AN56_2D$L1+0$'=Y+0;&&Y_[4M0S""XLO(741?=%^^K*W*VGO'?'O_T6O!
M73&\VI"SAD1?WRC@8NPT/?;1578@2R2-&PXPGZM;_1 _3G0(0C\ZQP'1Q,4V
MF0YGC+Z!*PL__4X_)5K\K2F42;YKF(C^R$(^$(6$HA\M1@IOME#L-$K7G:*V
M36='7]0.<472,2_<U*;,3/SH_"M(VED-11@IPH_FO-7D]W7FS2(DC$D#.S-*
M:FX3=;_2L(^<)R?B:O2^^#'L.[@N4";^/$7ZWB3V_1DX[2+]W/ T#VD3 ;>!
MSPCVKZQ'6DY*\LZO+$2ZO'#]K?<.J>QZZ!/B2GCU([[1]00:#'9P#LV2&&&!
M:]+8-?+\SLBK^E-Q?]0V8CM/"@@L41;&6P,3P_\>P=R"5M>CRU>DLLFGGDJ?
MO9JS\W4<J&JQ"D4 U!$D5A/Q(LL7IA'2*L6!BQ=K^\%V%@$KMSW5+AVD LR]
MK[O\E%UI78<]<(^!ECGE3.Q]BP1$<T4I:O]8D]A$K2*:DV32("7S89F9U,?;
M SUA;F1R1C&/^V Q8'O-6Y#H4[^K7)X6/MM47M=<XP7>@\_O+>+<FFS>*V)!
M D[7VE[M>J8!R!9CY]&GX/772"73"^(YK.FV0S^6&CO #![% 790M,$"6SWR
MZ@/%D*=,]^<"HW[N]3<F GBV0=WZAK!RW[K_V3B(#*.Y$6D?6M@A)3ORR)K=
MQH.I92%C>UU7ZJH/^T25YWE!O[TM;\X)Y/W-S29U;2F_R,#RPC_\K+$!G]\L
MW0:'5MX.I(.HBJSI*5=KH9^E')%C*'^H-3:B+9;]-G,3]W@]=?4_*]TV>#2C
M:?8K$3WYU9_\JD06!$EN:R$>X3WQ,>U,FC%\(YI,^O& 2Z.H9.,#6S\M+USJ
MV7N5/3D:J),EZ24?9#A!4+;SJ0Q\[&WN*5VLWJDQTN%FF[OOX,GE.\2%KM(>
M8L61;_(4@GJ4\BC?F3G?DS>]Q]I&BQL'Y'7C /=B6FU?KR+HVT5JNSK0CY:0
M B;%L;T_[B9W>%_TKW\[/WBDNB'>$9+M^]8'M%?C3(D#:O3:/9)$/!/?:8T'
MAYG6B1&.NT'.8,T*@5Z!L\S"HTY@NT4\DQG[U#.O1JORY#EU9\G&Y^V'2BP)
MRJ1UI,=L?^!/CP<->M[4'>WR\QZ8_9;NMWL>G?TB1)D\%.[,.0&VA87^X KF
M3P'FXUSX^ABQ'$>P/+##(L'VXMU  )VA//(@:4=[EO270:?@V.T"%;K7%LFA
M[&2K> LM%M?:'VJO90=G#&2::]JCKDW\O1??^&TK#BI_KC?;.!3+RRM-4^IP
M893H4&QF)3*C9,'5OT$[_%V!.S,YYGKZ1+'M(/IF$8ZV65/"[?2?62D5MNX:
MV58_4\SLS'P,Y+;J8Z<$!3/=!(3&*8(OC;]?Y4N;+9.'9]U(DO$][%Y7BWVE
M5=U9FWJ[[;5/4O',D["'[ED D,4]A"7'>*#5$$.4Z.0N. .O\ %:A<_Z=67H
M<7A]5=0X2>@=QG?&9Q2I'^_+ <S?6F*&H0XX8/JH_=2\7P%%&I?LD!GMQT2V
M37O4^OL^(&D>)'/T?/3M<+4?J>B4^<ROVWLK0R^+<I0VN?;<%XA0&^%85MO$
M'6;ZB;V:+Q)37],G?M2$"9:1<TWU_&IE!/ENZA66 SZ$/?$,_CK(V/6X;#)I
M.IN5>ILXQ6:'8E$?'J)=_+/B2=Z=T>:ZZY5U#SR$T=]CC[] XX#]J(ON*.!<
MZK\5XX#GWBHXH#4>NPE31(,0!]$+W"BJ$WBG)KX^1$\M;G*@KJ$VV37)>%L4
MM%"'3/+UVC&95@!8CX^+1,C1R 8<4*&.B7U38=BS(#G<3)>S+61_,1CWR:(Z
MZ6V=WAT&@9FI5G.AI-NT^YSXRT/H1YJ8>!,1'/#= WPA/+EI%?CN;] AQC0/
MXK"B%)DSX6DH([27;AX1."G9^= JQ8TR.29(I57Z9-?A^/WO?88=VWV6E$=A
M3QO88T.X\8??BX-# 373+_!*&"9+,Y;\2G "?%S,?;#GW44/#K/0%PDPZ5%5
MU&Z#56C?E>M6YE'"9\N:A@TN3N& '@/9C$L]!_J:TU([,[.2AQ==[IZL78RA
M:_=9YC0HOVLK22.BW@9F3"9A_^9-#?R;-]7];][4;(LB0_O48G<;=ZKYIHUW
MP\I,9&1DMQ%%;$C8S:M*63:(T^0I%!67??6SH"7?D\A0WHII1OAWMR7)#?SZ
M)1MI+^&@#>A2IIM/-N"L1WMX,IN" WI?9N^8OIKLSD9JP)EL)4W;KAQ4QT4R
M&$B?\3KI8X<\W1*;GB.?42%[$E3%>[%;L"JV1*M88UK![[U6$@2^(0M!H!?)
M,G'@(0/&K#GZ<]/3EJOR<BSU+#RD600"7>9NQ',Z>(#W.XT84 -<2+HT=%00
M+$GBO;?.>O@9'*#4_D\]D2'+$]W]#13.D34G!!WYAF)OGC)9NR96N]U2(G35
M?(LV1 [)HY66FD"DD,#%OJH:@NKX$/9#$)SG@Z<U&W()  !_3V3=Z0):!QG=
M[K)IP/^A6?F5:_KZ_I+<V/SOQ4#]-WU)JUAC0M4=RVNU_@0!65 BZR)(@E6(
M%N0(=RX'L!_Q.J%M\A]M_]);,.P(2BCKSMV8ZF76:76#HBXN]WSU^L%U9VWS
M\BMB'3)@DY&]F3-MY%R5.ON]"N.]/*WUQ)WJ;Z("$%*3[$M1C,UHH*#_DQ'G
M<MBW-/VZFC@F[2'(T;<OK[DK7[K71/"4#X<QM0'X'?"E N^G@0SH9[,NI(_*
M#F_N>[5WQ%_NZHUGDQX7#@<RH0U?)+Q+&E*MJ;62B7I6&C_:8H$>+.BZ?!DX
MTG(7F1K/NBU+B0S<F??%DDC?4+)\M A9SHR8<)%@F,,!=V#V5SFR8-MLP)]^
MYLNYX:#)JK"OTZ?RL(8$,A7L-I_B^AE^DMQ7?$1V=PAR4?/'R#&#$ R" XP>
MD=(H1#A9OV,<9!GJO^_)CBA\B4^5<RF-P3?]H$L?5EEN'.O>D[Z3$6NAZYKY
M0Q1!:1EW5XQ]R8F%$:^:/!E[-W!J@1AI75R,AG5)*OY<T03M$$3/JUM\4""0
MJJH]W;;\];R>>?70#V_; DMDNO1JK(.9A?V81<X'!\ _XIW>/ZX@1G!T[?$O
MG85>K\@PMJ1K!Z[1^<=6NL+W>5>H6^"J<BY',9WX$O,&<%@9.-Y"%;ZD#NMB
M4N 3GN=##C+E?YA5'SC,JWI>R4GP?L"<8Y@D.4C(E!U"<]J'+/67;T8'(P89
MWOS!:*6%J-56WV.089U-N']W](;E6[?1NY*9+PG'P4#+K>UTS8@:_DCHW72I
MOQPPDX-KP8V\7/<%6*)A S1$RKNB[P/-%] _Q;=,0="._F:BZ_%NYU\!_2(Y
MP@&.W NR>!BW,5DP6O&R4U(CV[O08&:;O/#<.U_L!X]KK^$:.UZD'(84\#7^
M7P_$?%P^/HQ?\CCO7FSGLI)!U.DA X,/'T>*69@(WZ%RF\YKDE3VTQLMS]%]
M*(0!N@$&;<=#[C\N?+_ZJ: Y8L\A> 39L_]<J-][:RSL&$D78.1_;I&GN[>;
MN&S=4$-2\66M;"W/O.X='#6&6,]'#-KZRZ(]JA8U/;J)H_M?#< 77CL% WTV
MTF\]>SA&6_"POWUMVOU$QIT[?=.BK(S4('K<MV6T>0X)2SW!+_ *D?Q+NBE(
M&WD;=Z:#"+Z/#/-R\3WF-@E!6([BW5M*G; 9KEGY)$>Q#CNFJUT;R[0DR[9[
MFUZ(@T0TN;M)F)! H4;:^'?)5X8M50&+:8E'G_RY<L%[[[95)OR4\OR3#M;]
M3!;;$Y3S$%Z:-?Y2%9#+3A/VQ+QQS]*^B3C__(]Y4+G28*RZ+V''M=++<DWR
M+$UDZZ=U#/_*67Y[2/?9-6&*1("\8= ?!W I!9"Q0'YE?K+G4QIOP'"O@6<=
M5O)_?[:S6OHB:W&G)7Y/,N2QQ!/+#_&; W? ^\$CI9O\-[<66(?W%OJ-QLW^
M6,A)1Z_),Y9).B;ZT!V_]1G2- T'.]1^:9&PQWIYE=?4QU\M\GA@O/7&D;_I
M:6/:N>PQQ?!TZ?TG/7\Z5O=?CT5GJ&&&&$!^P;M"Y]KNYUIG\?D$I[ YS-!Z
M;A':U"L5? _#[8*^0U;LP):Z2:F:E]VKM_WZ'9V;I-YJC) P!7>!_&."NR[N
MIH7PVQA7PD[^\ O9&HI2Z>'03'[D0+-XC_,G4 ?5.93>;,U79'1,YR+W%$;F
M^C*^KOWG?!Z<K?K;YV2T5R$1IO6JVN"ONR6OIB)'%\CR!X'$9DVZ=0EO,XMW
MN@09?YYC#4XBU&7:>=CL4MMBN+@EF9KF-$ Y-U>F^/ : SAW]=CC-)GSM% /
M\^([5$<4-E3K4D,MYFC\B#_UTLD(^DV0&H#OH@M?9*NEJ42KUC:^HIP4-"Z+
MJ<RB+0E=JUTE2<"3V* M<-$IUE+5"IGMW:Y1U^8%*3>-6\\-&SX;^ZZAHJ/=
M PHJU>IE#S6R(< ?,FA'79OE7:0KUUZ\!@4.V*PMH;[8B*3^(V)*DLOY$N_2
M]X:BY/'749U,FU^73-3QI?)ELRK"#][G';9ZDS"-]([4+:>(O.J2Y:A&9J5.
MGF4Y/*=E4:;QJ^2H.FLER+82^8+<5[%$[L8+![X8A$(,9)9/D]T?*2H14B57
M; _Y(#[,%IALU_J^>"[P0^<M'[O6I#O9<Z5:Z)]TDK4(UV]Y=3;>!'W"CUD%
M('/.NH0L(0N5-3#*@I3B#C/F+WY%\WUW/CW\UM/^_I:*M]9XU"^TC?]._IP=
M19NK'=_GQV'B3G+W S*/[HBSNWPRVBBA#^^D\?X#O5O.W-YQJ>B\VX>OM,%C
MJ#>HX>8[-JQ=L:8J%+>77UF7CZ[@5=,6%3(PL:O+("F^N6I/$G'[YL=2 9;[
M0B&)B5,37RPZJ7T94Q_[<08MJ*\^WY4U%7@OQ[%(RUPS"/%:.>CVK2FH<W_7
M^,X FGUCQB=G[2B2Z+)W":\Z2&I#)NP=>J:;5.\-<CY_3DVD>I*BAU7@UW?1
MT570T4PPUP^/3,2AI-]LK\>E!)]-BME[*KY#B?90?/;DXP+;QCSZTS1'J&/]
M[!R+QT*]^(4>K_.RC.JZ;;FGHYSI9BH/>XW&BSH"QL(L:'1_#VA!W**W=)%4
M$_.R451H  B9E/'Y^H?*7C4_KZS,&*495>;/S9275B#W8Z"2/[6I]HROHRI(
M4-/,4%7EI9]>^G9Z^.E&U(ENFB)\PF/'P6N,S4$GIF #^!UHS8CH-P$W3HQ@
M9"8XQJ4EJ'XN)8H0XY^JA7X*1 H&UV1D6B7DNEYM*WI4RHZ61OMZG-/[+D:4
M"X,?/A)4=Y=]+EJ[:9EJY-D>UR&=W#K$KN,HUD7JXY4ZMD6?FKE_1ZD^5)61
M)$&?[GTF^4JW?7RXA1J,&I*ZKTU_^OA;M8)39>L#)<"/QEL6!X1Z.IQ!LRD9
MGOXNA/OQ=3]J6/$8X2OG#4V9/QD<=F<4S1'ZT+WB716W\KD0G;YR@7K@2/BZ
M6I'=9^RV%Y^,5Z_FECZS8'U3#<H[W*KJ!\W8N9[<,ZM[J(BCOEN-ZM2'V%,:
MORMINT/\T*<":6R3+$26BFXI2@Q[JY*.)IR>?H[BX4<5#Y(\Q7_M*2HX!5;Q
M\N67=!0,FE$V]9L8!63)A(!%NP,#OH=5.>. U:^;YSC@:\ B-J:N -T/FF&F
M 9U0@2XT15CS=8H&3ZWC*LO5\L_->?DNM4C(#(:5/EP<>%X)O9:60O"C5:@7
MWG@$J"[\\5A(T[O!\N%M]K);QV%%E(:Y<[X[G+3%^<9F%MS:P")P;"8O/[^)
M/KKLF6?W:"7'#/6\DPK;VLR;HHU)EK&:6/,Q^1]B8LFWS0DX$0\_9=X$W%2D
M 0F)LC?7_2O0Q %O/^& 8X^/L\>&\(@+#SU\#]T_]XT,2SV.U$J$_!(*F=OE
M=YZ2E95S._M1/$4(L2>>-SZ".9/$4-DXO.T_X2HS5II0\'# JA/_NABS=*5/
M90=N:?AJ2[(6@F+G>EM0.BGA$675/G1=\Z.IQJ6'_ 1%%E.UDST5?\ICYS67
M390>3BPT%&S/A+9$%QN9FFJDI0>LVM&DEH)$YRU_C\4.]F"JS4R^+%^9@^[:
MUOI^ &WOLY'7-,(8B\\(62ZC;!Z2R)<^YKX@SG.XZT#L948F.^AR.E1OL6YD
MPSPWL2Y^,-,0#UP-0J#C!AOG45M3Z4HZCQO&U#-[49V"PDF&=HTI)YE.OYQY
M5U[1<2E+/74<P"-,T1:OB/N][%2>^UF,,E&^V(I+F4V&7'6U_.V$/Y7]B.$,
M#G#81%$_R>.X>D39)_4,<1]OV(T!(/\TJ5.P^+1XJLW;@770T26:QXU?49>.
M\%!82%(PV5%E9Z:KA/-;XO@_QY*X8MEP0&*3&@ZH-;T0F#0S@D9<3XO3-2[O
MI6%C1*;^*T6RT6(\>)6"\,H;=$&LI_*?[U[>:HG& 2Q^Y!?+(.Q[KCWM$>@J
MN=FU17K]^&$%X_^^8?@MV>5='*38CMP>.#] 4 UUQQ,O.F2Q#'LRL6H23[<[
ML55;WK**M>A?%71[2M)!.G2C)1 'A/U")V9&EX,YXM''H'Z1,YI.VPD,_HH"
MVX/JV2#HP:S>FLU;*68)V!C:.H[A2:Y(1"Y-O^.[P ?=.JC/BH\RVLT??=R?
M@:\&3"!#7J(G$,3EQ)V2M;EY3Y<=6NL$#<[-K"&JJXYXY!PLA^TMT3&K>AS(
M=#QG9%W[/0#LG6? OT8T:<"]].0DQ?ZPFE+;D3TE?J(J4ZACV<SGEY.*Z.I!
MJ;$4WC&,$0VW07E?^CA+DQ9MJ>0J.>67[8_[P#AY#),^O(W-/2 ++X1:%%7(
M"?0E8D3"F.N^%Q7^RE^=&)F,[;BR#RD<0/S9FLX&Q/9B46S[&>4RRDO[572$
M6]FF&\8;H=)^E\\PSX>_37J([V:K93X)37%,'I@9* .\V,T^QKF.MKQ%$:@V
M8@N"7/CR0>ASV/#BM D__Y)>F*";@80A6#\/_ >N,?1XV6V.5_*84_$P0"\1
MG4:JVV-#NUUOI/C(OU+39L-B?>@>=L24OH7!OKV_TXZTIENP<E[_40]S2:^+
MDLF'R7)_XJL*-G0H[.GRP?VIMOSM.@['FHEBV>=[5X-E*L_\+!-\+1GQAP.G
M NFJ_\B2V.N-/@L[4D_ECO8AOZF2J!460%2)&"=712NUCPTZK\0RJSU;M#6<
M,F#]Z1U.VX/07_H.83S@^Z*G\LRUL7'L=87CIW6Z;-+U\4VN_7P)_1F#S?F6
MHQ/M:X>B=G37R9EOW=#/T'9&OR!A68OR_H#F6V#0?QJA.9OQ;-29O0ZY'^U:
M06 .M\LR_:$X=_+R=27H)?<(#K"+OPLBQY"BV!NNU@8;9P R8I^*(J6KP^[F
M[&7-7;-OQA"3'BU4P.!N>LJXPY,?=<F_XFZ:)<2XIIK-(85:&2TQ!?KA_3F*
M;S+;]TSZ^'X.-?RN]/GY[H6 _C.5PR.5EB^)FNI7/^-G[MJ;D#]V>G,K:0$M
MA+=-^75H#'SEG"O+B'F%O+9WU)EJ2&\=#3U_\#!,3EOY4\SR1QSP(F3'E"-P
M9+%J(1LYV:&^XDPZ;R2;3?S-6']>P)W6FJ@B-DASX/7;C0IW?6BE1KZ/#<K7
MX8T:@V&YK&FUHE#U'I=.?#T'<.US!3C,=UOY6 OQ9TGQ-QOY!J9G\Z=M?/YM
MFO&J7\A0+1M6\7OSLBO;GF+.W?3Q-JCNY>A)Z0Y#/*& H7X6TU;Q#15=MIP(
MB\+R (-?=&_HT: V\ T+=!?JU0KIQ_2\=(.MQIA.89=(,:>LIW'*W:*3H8G+
M2!$=^T]K^UT<D\>RN9$HGRRFY2VKN+$,AX):I3QHAY\!=#@7C+U5A .FN1CB
M9U<$<GN1[Y(8C^!:Q#U7ER*.T+>#0KN[X&6>9B'FN-K(.I#ZXI]OIE-\0Q*R
M_-F@D]5F'( XV5=!]G#7'.  9Y!H;K=_GTJI?WS)WB.'Z#>6B=(-=/*"-N+B
M6UG<0[)<_H%(6+O(&T^'POKQ5>.1K=.WTIW,'U:#@A"E]_;2CR&(:5K0/"TL
M7-H0V7*)Z-D36=F14LO_4?DC]8FW1X=K['WA>"*I2BX721>'=<%,9A"5@5OG
MK_&5BJ$?0^XDUH2D&K3B1SI%XSI7(C:: 9=^ WSDT]*,!0!$R)[67'R;P!_4
M.>F /#L=1<*CG)<K)]^M(P>.!%YGV3VOG>:@M6GE/N$.'D_4UUO\GAUFJ.99
MC2(KI\ZI6TN%/EXFW0]^VE.[?4[>;4+5@@1'B?#B:[^LJZ6@M9SN=8T)8Q[(
M?V.3>2_]TI_/,-%Z)(7GX7C2T>4)6+3'>DXSX3=5Y:"XRKG(5D'/=K/SNE(]
ME013G()JMG<^Q&;7>V4'3N7/$L<]3:]?75KX79_Q<*2$K7"U@@:+;[)9<U[+
M3<[ST&=YK=DX?MIMU]*=Y*'T:]UD/>HHS@KYD7__?G._:!K:,S]TN3@^L?W?
MV1CE:(KM'MOBE>O3BT4=P^[:T]?$AJX,^>0911MN>E55WZ?](W?[K2!1/4L<
M.>Q6S6R-_QXJH\V4PO\A2A4484KT[EU-)/\[[1ZC$:>"-UU3L?%I_ ._Q+@J
M7\I;W@1NT$8!%VQC-?XBE_H0,RQ'X"0.(/47*E"T;J;V.C21M#A[R=N9).&L
M7E2VB'QX K,:P7+Z^Z >PJ<MT/(%$-^3>LF"<ECN3,[)H87IDW")):Q$1=,R
M31LM%K3M"X\\&51I5D?\= DIVA'LJGP6X_B>  >DN@*4%A)2BKX \ 0K'MB'
MI4)?K7 S670:=,,=>+]\KPE;5,^B729N^%3+3",5Z:3ARW6AEX$#.FIEZ;C)
MT5F0[Y<!5=?]3-S94<C%'PUZ<B!\&<#1+D8MFE#^,[\F69Z$4^ >M317_%L
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M_WC=#C\2"R)$C4.(G\C 0$CMV3^XM_PIV&5"X#,R4#Q_/.+9K?[I'1C[XTZ
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MTC^>S8B)ZV(!K+GDK=<7\7>5\'>@!@:C60,6&(*W[\R/=SS53X)@ 976=O,
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MJN4X6C[DM#25X[.SJ(?JTCOP\WZ#$!#<&G31=@TKV=+:=N7Z3NRG9EJ;3S?
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M7:I6>WTNMS.<ASW"]")JDD+$071KDI<J%'R_2AGLM+M8/NJ]UD'E<W^6UC*
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M094D-X,A/2\<^=N3/W<Y&4#:-$XQ"2K;'[MM _":FT;_Z6,8_\[RYR.1562
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M$JH@"!'IO1.1)EU 2@("4A-*""2$R^^<\Y[RC7N_<]\[?O?[[KCC_6..O4*
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M>F2 HEVNC3Y[Q(<JFG/&6FBQJ2JR\PF [VCA4'@]3#;,GUZ[YN7)&%%=:_Q
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MEQYL^>! M7M?V8MGZ5VA4/#E-=[2#U$%LT[*([%6DBHV2[Z9:K;QG!57T2K
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MOV6IJ<KP(+:D(]@J-/(D9$7 ,.I>E*^5Z*.#6\ !B$ A2F*DJ5L-%V#,8(<
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MTRF!.9I-U,%I?Z%8RXS;D:W2S>\-1'MVG^SW;IMP>+P^_0'%); -=VC:SHX
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MQL+64C#PSAF!QO$?1("V,JMPIMIGG=ND_E(;0-5==AP *$G=L8,(A'+C!(G
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M.8,9-S4OOE-3D/+E+*%CF)^]]H;>0I#*1^ES/'>F*+Q8R7:^A\$=&X6&38B
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MC]W3O0'>82\C D,B2^3;>O7D+=E>Z%S4QX=F!*;(,\$;ITG9PSAB/-#;-)'
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M$KSZH94(.!I3C=TPD\1TMM4BHE1H<U9/[80)A_[PR[E7/?1.H**&H>F< /D
M^8!G\;^S=;LHGPATIA! /:;)OS6-*5[_JO?.+_JU+,^_7J[\O['__(*O[ZK,
M/<]D,H)P:(Q9<Z,8!A)980&G7^Z'\U[TL1MY_?4FJE<G/#HRBEF#=F03H(K
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M)#M^XX6J%[;3-E@@&)1@=EUM:)LY-L/I6/Y4] +ZN7QY\B[F19PRE4DTA0*
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M;X!KQH^_OP((  'O8NO.M D/T'CB ZQ76R;%CK=YMGNV43GFLK.O]+5Q4[9
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M4;3]WB]P[ OPB*T;N'+Y -VD.;%HAA,9IZX?_O(N;&6Q:9:T4P;3[7E3K;:
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M] N4&=L9E0)L'@?IKOE*Y );8!A(H]I#W Z68E*MMJ8RS@ E4VH<VWUTWGZ
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MCCSSVG]LYIK\^V;N'NX?=WC_=O$*P'@LP*1R^GH-[7=.A4'@5>&!X&U*ZRM
MEG;=]]>(MOCZ15B@X!5 W@MR29TX=KAG^J+:<F04Q[XNE7*-N48LR92LS/=3
M5*K+P?07^M>=>UEV!3 KAZW;F;E?"&'SX#)WS\4N).HP9H'9V(]."D[),1Y!
M'!$G?5K)+,KS1.:R/ M[M%> [M$B&&I[_HQ)?^-D.^(ORL*%P;.3?]^1716<
M3K,O\4XRIGM\1/WY6KN2H1SN$/3>CG2!X;,"=ZT*%M:I<O**96/C-L@MY;F9
M/V5(P(+/D)#SH?CV_#GO!HQ06T/[>%$43OM:>:7'O>"YWJ;GC_L'@PSF/4@
M6?A)_S<7^FRK0\03UQ6N_8<67F,8D46=Z9Y:]7JYZP[Y![A_/6P.G%:*B=;<
M3$GY6C.PGJ7T#KQ7SG#!L]P\A5CB3,44+M'@V<=X5YOKJT97X9"R:FW3I4VE
MYZ^("*M7+'M:US\1MX!5KP"MREDPG/+%W4<J$YLKD+$L\U-0;T/Y,2&F/Z,6
MF[)[O$_SM:)12#WBTP)+7$6H'W+8$%FEZ"EBQ\PO+,-KE/[",_RSIT$K+A_K
MA6X8K2I#O';/;I/R:=_UE[:R'-V)85ZD]7V-O5SEP-@67*9=#S'(79QS9PHT
M BUK:F?9GAR74V^R25[G)68>%-,+_? :_>DCMEL6/B_'@5E-7YJGG+<ZRZEP
M\_0YU" ;ZO[F_\/KD%T26$:+.T)34E8'7AB76-G/F6\DET_=ZQ*GB?D.C@8;
M<4FYA];43+=W*57=^F'399<W>_F5N1BJ]]K;$ OW;V+W5JC&0+_+)DSO(L33
M)DK#'OF4J[UBOZ-V!2BR5Z)4NWR,T_^I7N@MB(DZ7"A"2<FFC=SP%'X:".\;
MO6##(-OFB&J::H<JI&6E5L_T4U;=L_M^";-TT$E*#"H. -^:^C 6P$7'!VWO
MAF1P*W1.7N1B[S6CMYA^9)J.>:LZ.(]SC.75*$LR+#27^-B.RI'@)UF%<';%
M1NW%-OJFG!BTA'J$>L^+\HZO*TN?'_II77#L2"") LRR\9R8IOBERWMKJA,5
MYS[J+VNU?QG/*C$8ST]&=SA1JETDX9 +@ACDDENHMT"<2*GUB?1;#SEL6(R,
MQ\GD[_BM-$?3=,:8CCQB9?/6CN'BY![=R)D7EPXCE>H0:JNDNJ"T0M>W/C<&
MR;YY_U+:),GLH#*#LXI@5I !#29%5FXJPX-Y)K\_]K;_DM3TV!0@&'3<,LMM
M_L77V8G:WEI UOU9Y:7.6CN/D G/#!ZJ##M7@/9(T75MM1;-F(KY+2G01R'8
M(_K"%^5/G^?'J ( ]'?D6Y8!/!&4VB*/U80F#[%?/-!<;3G@,!L+;_++T@NZ
M)<H;UD/N>29P)2QYP@VF,I]$PRFZ6Z_L0SX+5RR6QT:^R4P!?VR.2M'OHJ2W
M)EX\CMMZ-KR8Q+5G0L)[(*G#]N+ ]YY@-U#R&*&*.;FXF['HRI5JA@T$3VTJ
MN+N<ZQUPL(P)5]W="C[S]%C;*3//<H=TS3%C'$+LWI6-BLARJ_I3I?_JW48Z
M@CW" ]\AX^OJ?G8E5S?*OF1^50;3M?FERH*XN!O'P-29(?P%5J#.XV(^P[NM
M?ZB':-!KTK[632\<IQW=8E/E$O>2H%RU)S6U,B79_9]O=QI70!AFU'CA:_I\
M;MW/LD5U3^BM<OEHM%Z'_/B[G7SXGZ&_A>/_D>O EU][Y-]GS!O:PW\SJ D5
M_UEX2,_Z]R(G,(?O'V_[ZU]S]_K.% =_$>ET2X,D*Y$MGZ:/2<<CLQ*SK4KL
M889P#A<@BSOSQ#@-P>F@=<EF_KF]>$>^#,]2Z(7@,0ID@V^O>\(F%CRKNK+]
M)UJA2PCX$6OVC?4N5BD=K7$#93CR(\F6- YO/&C'5W]1I/4KKJ"F55M2:VND
M\ABNQNU;D5"A32 @RVV5Y4L=_K?PG+]B<OXOLY>MX-EPEOI8^^ D1O%P!V]V
MYS6@UQ;]@R3E2!Y"5@XB+H[\60&HU@!Q25;,$'!UK0U&ZZU6>5GD.D\Y8RN>
M(83Z:*8YLKWK^KN6O+)&>=K>0B'])ZWZQY?J J_];:<O7,^)YW%_[$7MU)<R
M:G^Z_WK1^Z0$K5MU(/ Y*.JE^>LX@1^^Q"TEP&/'^]!Y,VJ_^] 3?21JQ_8*
M@$(T*ML <)G';+A6-!,L=.XA3A>M\12MDZH1_:$Z:5>'-VF_]0&25V$FZ5D]
M^Z.H-%>$XF4^S"K*H26# S/?CB"ZK1PEH\PAF+/339&DRMOTRJX"TV<@;DI#
M%N,DB)Z_U0+":/$S$B#W7"DR%?"BW="1NS9TF=5)7^TH?DQS7 'L1XJW73G"
M.,561OA^!<(2=F)G I T!$<=F;\@OI6-@G<[J38S>,>[^Z:[\@M>IX8D[)L\
MK3$X72\ $!+>:A!?!'? J:&#5X"*Y7E@9;'37H<I=>/7!Z.<8QQ"_;:K2JQD
M@EMI@>_I3:;> &&N(&(\[S7,"MIPBX0-%>== ;"BO<KGS$WE6'5EG-_27BAC
M<NC1SI/-Z55Q.*2Z7'^?Q53TO4*DA;-?'#G@TWSUO50TXH:[&(S&X.(%*BAJ
MMZ J1*6::D;1@2R"_2;EO8DW]3<.XIP'(*)[X%\;"?C!#"+K]QX?XE^HFBR_
MZS,,,X_SD+7]?058R)H"EQ\U25P!POY4@X\'S+9,<\[Y8N;+F]OWI6 6[:?H
MS E?&=#QW*B,VP*,:-8]MWWI0QWO[I%H%1Y936Q+(]#]Z\[W)9*^6T-"'6O-
M1D>94^?JXS**YX]Q:J,0U.ZAR<NMEWHFIEPC'MF<VGWR,;0<D24J:$EZ"=&>
MOR@]OMX]]B(H);4Y;B&<77IV46X:>\XKU',NC0/\1)\_9L-%PM?D0?=PHYU-
MHCC+<S/K:<[L)1.OI3LC]@MB>MJO:<Y?E1L7*F68?GYB*I_CNT!V1G)(R8CO
M,Z,_X@]CI<%6U2^]QS+_LM6+\C'/_?WX22IQ MV^;FB?52WSFX4XA1[1Y*4M
M@SWP0JZ4B]-EJZ/M_;.2C!(P=L7H? MTZ0DX33V.OOPF.@,*-67%J2X0HRNQ
MIM4<ZFZ%4B'X@?!GK8KVI-MD:[)T]$2E/"A8^X,+Z;&*0WB'F&=R>*5&<].X
MJX_>IGH8J'Y9A?:E!X$\H>C^1.;/5#,<MXY& 6M=4<RC+Q#L9,4GUS-D^"45
M/5(-@*/LF)/#NFU+8[,&%>,-QV0@F!D=!6?RC!SN%)6W?)4='SU5&1A:VDK9
M[]_KO5S+FV\ML#X^J8KGZRSNL!415G(JB230 P[Y4Z+-&&"M+S\N.A#C&'?"
M(T+W[,UU=W6SGW; YDE/42-FY<6-XX@66 C6U/X ]:R"2%R757M'YY >% 3P
M+CR_AC ]A][OK@ U@_AT-D0VV(82/H0?Q -,M+FH3UXW)4QO5#E14RUW&<XS
M[RCT$!+%9;-+@B2AO;S@Q=HF 69XZKDYZ^G8HFCB%>"F1-P:GGKP1M=Y$_*8
M)Y[^40!;K#A>@OA,$]AT(7V9L83S6R0'F^(JO?+=D1V>/XA=^8K'MTNG#4),
MVN@7PI($?3^]I'CIV(I@O\QJ8MTR^V6ST22'TRTRVS"BJC7V>=9^,*OJ^"$H
M6+=*4E)IIN)$6]^: ;UC<FM_7GOH\+Q>H]DB8T[R[<RH.1</O"5\?W#Z>(!I
M;ZH>Z3C0&UKU0-, 1JT6F;U50X ; BIBQ)?&D[L0P77ZX1_1YR+QP>&;0U5H
M!REF*<N:74KM(G)WDHM76. .Z%S5UHQ"I-%^KQUZ$W/AW/2=,PFOL?IM6"7V
MUVG[JJ(06)&=BWA3Z2_*_HGJ6OC"2>B/9*?IGA)PPFV)V?LACJP-"U#:M>H,
M$)9NV^=<PQ8JUS#L( H)2>FHOH'6&D4+\36(4X=,7P%F+1+XR7U;WC"G:0+S
MO3TN8[R%K1=,C#OF;N*',?,1AQ&6C<&[\SHUL25$;\K9O[)$JP6W$K%,]HBN
M@<OU0_%BT*$,VK$,%)K0*D E0]HRV(YQSL-0[?WKWQ6"Z^VK/1(]HCMS4I??
MM[T]%GR>J>"L?]AF\*..;#UXBR\:.9>FI\?J$H7Z1;I#"VH'354((Y?MH;U7
M  +]!<IVEY'=#^KIGG@%MWP-JE.B5'FJ1^=<MX0\XY"1"X#W^!%32FPDF.*H
M^8Y5,[5K,8.++*,J'FE'PWW\]8&2I5NBIH0E(8@;P.JK#[H6TM88XF@O$,HQ
M=L3W=$N[,;6#N@M%YRQ2,F-7W"W])?["+,=+>8>L!D>,O8MOH9L_8]MJ;UY(
MV<GT2UD?@%QP.*]M'!L; ;;!5O!I.CV,0Z2,-&:^Y7CB1$X"2ZJ4[^PNKO"6
MJ4R+G6NSG6Q2!E#+]HN@& 'MF*/'CI>F=D$?8R%AKDB&>)V44QU;M_WOD]JB
M/1*OF3\T,'6DM([ %G*23AC# ^$[$Q/#(1*O5=^4=2D<S2Y<&C4KO'+<]+$B
M7,F<JEY\4HTQ0R.B9(2O ,04A47NVO.JU;6_U*L=>$5&7*?2F]Z%&KI19)<.
M\/Q$X4'NHVCE#OY[&W,<6(KJ10B!=9R"0ZZ1U1,^BW'QYPC>.+57Y???T1&N
M; T%9'J_H?N&7#03F,:/0)_@1K'/##&6;1&RG/,O1X3X9;2*@%\E[&J#.>XS
M5SU=3F^YZROYC9+[,JO9DESYV!G3>_$,YXR&W#&*DK+*;O#?/'%^7!^HIZ?Y
M/=E#D:O5;U;U48Z/SKF8MW8M#HEQD,>*7EBSY@DUT/D+W/B:[1398ND[\\R\
M:EL_"C_:3.8->8LA[#S+"VMZ:&OZ(&/Z]J3A,SL[\W>G&8('':&&9:T,T&S1
M<7P+M@#:=T:@%872M]PZ/R$\O.$K8XDG"4(M9EYV7 &.1YIV$('-"S^5^3!]
MA(,7+Z[1;XO1>1F]4##P_CXY0.K_)M\SB5@S]E+6M.#?ODQ$ !4ZGMIWJ].P
M?S'U!"PI[VAAMA:C.B:,HFOXCPRB09!1G<%$R(F!/Q6D7&#+E#__+_PF8N &
M^X 3PV_#**<1[+Z9/W6]];#?];R>+^9'M8]\3H"7K2-"KP"+R]?3_',,;&'O
M"E"[?@4(B0=?WFV] @0TX]>*Y0J-3U\T5Y0V]_G4*GHK7P$H.6%GCP*N $#8
MY:#RA<S7*\!Z!N7%M6TXD07I%E]\O\P)PIOO]/(L@7$>UZ-G6 :$D[X"['J"
M_[F:LV*'%<H=7OX#D+V6&=45H+TG$Q^V<-WJ^2N \_"_5#-N"^."6;^%?3EW
M"L?!\:POK@"'$"">X@IPG@'_YVK^:N^S<W72"^1,@GX'#+-O>07(<@=CW*ZM
MSR'LGVLY,IKO!4T;F*W*S68UL?]SQ[/_I9:"";PF?J3M"B!XO$*+!?U+Q_^Y
M&A^]ZOV0XR2Z4W@UUW\GX.S-RN8$\/_+\J7;N )@M)FXF2ZE6Y+O;0V*G:7T
M>7K2)S6"6F'5C]HA]U[$F)G,N=NL1(\S_I V?X2O8WM/^*=,&W-D7ACVPQ%G
M7<^=^7Q8]Z,KJ8_:!$^J>FC)3HX)MI\T1%EGR%^"?4-/T9FE)Z^T0DN1\'^2
M'?[_,-DAL2(?#4#;?#KIG]=GB7+^H0M_/QGP;Q?_*A!ELX[] R_!OT''?V,J
M^'MTMI;Z/Z+,_[:UNI4@W &L_32\_#]^ >+^GKFUDO9O"\'_R)1M:UD)D$J9
M+Q8Y9NC4'Q,E]7DR8EM?'[I3_%U[7X/GYG.MV?@6FI'5X;O<7+DK6;QER.KB
M3\U432+N^HM!)9>VVKIU[_L^"[Q=BU^O7?CD(<%Z=##8-3C#J,KJ VI91H*X
M.8L?>R-1OW6&8!4*9RZB^U7?\TVVZ.)-YF;5W5R%'>(,T^H%CSCV;?=^E= 6
MAJF5\.TCJ_7QRLNG:RQ:;=7/GKS>-[/-^UU[2-<!F7G6,7??FN]"DLCH9JS$
MW3L<-6^/9"A;'#=M6X\0=VWF'C2(2^5FN_Y\G?'K=>_ _%?1KXK0]*#?G[[0
M[P\%-9Q=KJ'IM]$L7]4S[^HVM_JT[9)W@:6>2KMF);[*")!M9AW?8)5(<Z.Q
MT"_TYKA,NX!@WVKOWD:I#QLL;(H_6_GH.MEH=@5@879%9^9=\)PSX.XJ5T-V
M1!LF=I7GK',%.7T2;TL<<Z#ZS7$1A,D]HVFU.5,V/M'Z;1X9UK3::9)OYXS,
MAG#9;4WB*&\J:/4T:YYSWFM^'=*8XG4&")D41H%U_-BAA7\Z!;5$,V0%?6!0
M<>E]4=H7<N=/IL(E"OQG;Z:T9,)A*GFQ8N@+//BM5N3[#XF05=8:$!V^LXFY
MQJP"9ZG=,.0P%!PI[5%V0Y(Y\XN/D^-&I_<':;&> ]??1A34&SS0S^O0D&2+
MU\]B5%^U:[P*,9B'J1_)P75BTU83#DL>+?JLA:(4&"W#=XZWQ,CN>W4/O&MX
MX1V7?\3N?QMX/PT@7S+EL=4/]=!F'; 7;X2CK/1T-PK"1*%PE^Z\#!YW(U4+
MJJ[L)'/?FW)SSU/8.#ZRT%L(2!)YHM*AP][>#%@Y\-HD;-W6"$SH@0,OH.?/
M'\]FGA_SY&U.M%U^N +8S <-B$8Z,&,^G\N@3B=WK2,_>:+#?3R2D8AP86]A
M3!%?;OMQHY?VUX^'Y]X67RFQYOF$T4#M5VY%5EH9#[)R()]=ELI>85S>FQ96
MO/.D[3QJ+)$Y':%*>S])DL209'#"?LNT+^]!D\<0[+U!@[H#:R&6TGBL\@_4
M]<_C(EPXM<=T@V7D<<LA;>P2[-96<SEIZY(9J4UR2G7 A**&LG)C#(C/P)?A
M-L!)A0%PQS&]7>(HB9!<V[0KRFLP-T5\"OR[]@ AAM0*F1"DM]6^ M N)W]N
M%MYDTYR=5;;7Z8O5<;8S03*8#^EJ4!I48BG@Y@6&JJO3ID^3[]3@.=X3@;I1
MD?C)9#JQ3+*/C\K=HG?Y](C9XL2FNQ<MV/RV%78E:=<6/_WJ6&(/]A3;]C*8
M=?GT11+-OL=5>):QUKVG67Q(;2):\_5%KY YF3BE-Y3] "&*H\)JX1^X0XWY
M=*$]2U'<^,&?TP(D,W[L?<CL-X?K"BR"KZL#/"Z+&VP@8"QWY+5AKSJJ'K-D
M&,_342::+YGQ67MT7"F54'IDM5D@TBBRM>XUO4QA]8$T+8W2TY95$N]Z\"'_
MISO\.!I[7/S=VK/BC-*OPAHZZ.ILX\BW[!LC+Q<"9"GS5^ @B+Y+>A0\F_.;
MOK#J"E \$-D..GI(W\9\D%KQKNX*$&=B>&CA&5011S^R]"C6LZ"4 TIKP;S:
M<./@6 I3=*_@C#._T.JLZ)F@&<?B%W%YE98K %+E#%5R(3=\!*?$O6QK-QN'
M556JZ%//?9QIS@ VW;J%[NF"<"*HE,EOYVL6]B^/?Z5_H226HPRA54XT=N5!
M//.TOD<_K<IBKLC BP00S.67-.8)F^\<3UT!2K(O;)-QLQW>[-@D('B*S@!\
MW%_8@:?"]^%O8^'M=G<-QM@;SEW''N98U+"G]PD!ATCFR0.S=2BPM*OHX@K]
M#6<XRY>EGTOHP+91;>^&@=UI4^288TVLTP^J37)^Z<;"-<34R.Y6.^R.C.V"
MBBNW:Q10V<56.LS8(T#6O!L]0\B<S4R&&LHXZHEL]]%#E#=.1($Y/27MI<^?
M410Z[==73)PAY+*$[=:^G10,;^J-OAS.Z8 \/I)'LV,0&=X*!>XAQX&XL *<
M\?-QSJ$+IBS5Y4WQJE/JV5[BFS1KL8EOH].HG1.!:FO'DI@TL3<;1DG%>39E
MSK3[ Z1 ENYI\ L?V^9-$2XN)*U^DH9ICREJ#Z^<>)D?T2&I3ABR%FA2\J>V
MN!$.U4$6<U)*7O*T0V_CSCO$6/G&Y9C=!V"5MD8N4->,;Q[GKYB=()\!^<!\
MIO+>E),GWSQ]; <[W^8%YF\OCVZF;&;TLPX F<A<0;8W[:-D1XV_#=QZ24?S
M6_JG SL_4;Z0)5.L'^V:685X--P72F^3K"G7_Q3C$SQHW>[QZX:0[/@S@2.>
MZ*,56+G$N!PM;EX'YX50#6ZJC- MW\[I)7B R$>#CCL;;4NBS1[7&"XY%$RY
MJ;OMR_2]=&26>PNY@7;E6YEJ#O(>_&G3.-ZG%_N5,_9!I*NE!.OL6/@\/Z+8
M';7C>.!-->Z!W"L.>0TZZGEM8 0V0)"(5PN7;9IC^8%!^:'A]>&-<#T3+XU8
M_YS+\J2%FXFJX"#3U]7L1%[Z@RF@[>0%/N-V*9^^6#-%T?XB)P;JY65JWV6+
M:P]\LS"SG*(^/V<PLH'= \99;+TX<P5X,'*LDV3U6Z5>>%VFX4CB3[2O?K;9
M306=M/573I_^B#KP43*1I[QKK'QL4*?VN.#$R&W#1VMW7R)*79 $L)SA7XX,
M=1G(G!;[<>91B!<U[JJ'+=Z9"&/H3)@_(T!\;2+ #^ I<6&8D=]&$VQU<7CK
M/&7WM<<4'._I0?(\,D_N1:G=19C:<XM4Z,_.@+Z\LUIZ&W0]>)TT-G?*C@)U
M>'L9& Q8-YT>O]\SXW./;ZO;VZYUM%T"DVWJIS3[7XS#-4?LT\3CBCZQ4 )<
M">_?H)C=92#<B*)[58T22=50&E$0+9Y5E=&FB(S\%G!*9?BN-#S27"^A]CM?
MQO2Q;;;4)\G ,IU$$LQR(?G$F6R*CY9G.!="XOCI_^>YDK6O_;($@CYO2*(=
MGMF]1%_B^4C)UR;_>YS-+'*59TCL00M4 !>_:+8-(L4%H]HG4&$<4A&#A"H'
MSWMO=;#O!AS8[RH0LJ==U%\!*%9030-%34*C%_M0"S$G.V2Y/3YQ\\UF6YSW
MH/.:L(SL1T65.L=&. )/(>@0""7FA3ILJ_->>@?VN_:UPU./$&%O+X/P;#-M
M,>U87D4:&RIV_1J2@EL @#B 1!T^J;]$.Z9!,T^M9S53H((BHUPPJOTCI5$]
M\!E)%1KY2O?1]XUI&+P2<A<_C3(BSRAS$>&C>_[6\2UMNT_ZZD*2!=#ZS0>M
M..%]N-J9&.3( M4W7P[93BVX(,<>[86*DG\>U(GVD5(7#9Y[I$<VHG0>)EO&
M ,(\WL*+>#_!I:/_>/5A,CO8%GW(BXDT+$IC5E]4K<UEN[&%0&_G)[Q9C?.D
M4]+-5M-.<W4P/^#OT+^![F!,*SRQJ$M$->L_.@N_E+R,LF\:/Y=P?[Z68/RE
M>U=LMA>X$7[ZIWDAS7-OJM6,P1K_&6K5GQJT-55M>5B":H7]&NR\!G<IGM9S
MK+C"6U_?1(_P_3(N[XC\HZ)'Y(S:&C3:[7B5IT?RV)CU)4F4MZREI,)4ING(
MJT_!^V/"]F\$D/.-JJ:21X\&YZO6?.UE'#$O-U=[V?EV0S[5A;YZ7:Y$&Z=P
M2+(R>)ZXC]CF69J!D5TXA4]LZH:)1A!_9+^V$A^T%1E.]D-/>'D.4Y8X4AY%
MC9L8W-$-5F#9ET9=-XP.]N8<O42':F*R$3"P3WA-+K2J'U0\>T?!7Q?(O$\P
M4PWR*CWDTH67N^2>R/!^8,VKCGX05Z\\32U4<,^\@J#G4=XI/O&4?8F4"1XQ
MSR+JY7-3;IP_5'0KN,*"F2;N\YNUH9O288=$9Z@Q?5.BR_R+MXNKF-7\PLE)
MZU'E98C+@7'1+R5WMHR'EDAF]$V_^VNB6Z#RYFU$EC?%@2CW+ITQ5B:_##$M
M&V:?5_ \3V+P?IGD??-H12GM:%8AMWJ+)>XQY !IXL\\-V=E]'RHZ%X ^ 9*
M$^,2RS%-7QEXF0L28?JD)R2X=2+D1798,KH([N1C6EKSW_96R'Y9$G__[LPN
MT\X'@$,8\MV/R]NM#$2Z\Z%SE'#D'"&J06*@M"3G/5]![U:-4E\@#[IIHK7+
M2[_=TV$['HM<A%:=R%&/?:>8YZX;J>3GD$)G%Z6ZN<K<D1>-DAC-I_285C8Q
M2OQTI!-I'%4'^E:N$M,UHK+%;"4N+-A".(9:&>SHJ+O,@EF;O/?FH6J0RME4
ML'L,C^\-%PGMFPNK%+<X/D%X0WR;*_@[2<';@TRX);Y'3V/+'&^HL:K2'-UD
MT]5G[<-MF#WUIL,1+IKY,ZH;KR?URWV7Z)S(=R%\#9EG -Q\C281D-CU*+;N
MI?>JV)T*LG%UG,U')O'4HG"@MJJ,FQ@H?/&<U<YE1F5'*[35IX# ?/>EZ@EG
M-7>C7.42C)X3AS9?>G %H$0/N?*1N,L3NW]_5/E)[IUAVBVREPJM&Y$4>5%/
MW IE#=4GD8I>GV7YD7-2PW@FG-&Y&>I)TBBD\FE'_('*GU@@5I@5P*(!M<>!
M6Z$/+XN;1#>E$F)5;R;^04V+,BT(LR2P4(N:M[XIH-+/GUG_ ?_^XS(!RN']
M;H*ODC("*J%?'AALPJ_6;D>_3)EH'E5_CV0*:73FU0*],=3$A'.:?XXY"OS,
MZ,U"Y6%IO[LS_N7DT4P53X%P,(LHT$/X=[Y2KIAUOU.KBU=R@^CB'W";Y\W@
MJ!SCXMQT<Y)6(NYA727@V G'OFJ_#8G@=%*-V]BQMI:>PC4J%?@_%;W;'X[A
MGR9%SM-#:=<]3\(/13"FWQ>C)#C\I_?G]G:RA'KS.-3*RHC6JEG@,!B"_;(H
M07Q[!3WT"H1+%ER[7/E&*7L)OP+8DD/0E[OU/]SC4!JC1X4TZH56AV/N(U;$
MTZ<4NVX\=@,4<HY(HLP\_5BS9,:)=-?SQ]YO<([H1B%NBH#"C<^>?E%"M!,J
M6@YL9Q<SONLRW9<\AP?*X\6B.YR#VJ7I]D4.;.H1'C$K%E%C0J7']P/D[PVN
MF$E )T&5M"?;IY;?IMVA\Y FU!&=1P:+(@LZ>NH6Z9WHO(>AK0,"Q6;/YTP4
MS6U%^SLBR.Y\CU-E7M22[WGG Z ]16+;IAW"S<@:O+!9^%O&=A"]RA$92>9O
MN]%M#/0,P+PO:+ FOH+@$+%]@)5&@[I@Y!M0WF;(3>L,IMI:"RNVRGIQ)T7F
M5 Z>\_U0J!YIVB%1)..9J*=^(+3]/JR=#\>3=]%T!=AP[?1*[]BP8U+GC:!1
M$1>6G"X :D/>RE,/FRH702= )"+28>\RN_3*OZ1:Q!DHB"ZK>&QBLKDVMDPR
M_?"<[F9+'S(<&O@1!EMZ/7YL%0G"2BK=%'FK3WWH20";5KD(M=]8_G 1.'##
M:=-S-<_VA_509&/_\F\:\R&+HT>EFUX?? 7D.*=PQP>0:K,;-D:LJ<XA!_-&
ME4EV2,(/_=$W#NJE USIF9T/Q+>?8=N19O1-[.[U>.H=)_7UG8_L E-%UC0"
M9<E$@?*2].R/'K%H>"4%G>M[<V!9LZKT3*5&Y4;ZJ*#C37_H8V,(>POR)-'
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M5/);PSPU/QK&A5Z*:)7'&2J/'\;P(#MLK:Z8=K,ES;T Q.%FUT[O*DA;.G/
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MON,F,?]YT\_DYV;_YG2WY4::06B(R_/G?K-R"PE?HH5Z%9/_8TCI/S)CU%\
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M!7$1_>>9.Y\=I;:DM',@:3<VT)5EV($)SO$+X&T;2_7^W4"'9N=<J[B!\5Z
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M0VUVH?"I8\8ERE;6+46Q42ZO* ^_W8?L(M<C],+W_=N-IV&#U:[D*_2B71<
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MZ&XTL9OJ'K3R[O^0L&#:VLL&>D(<&GU\7][?%?_.7@?I"T[?=GF@>_"D]H4
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MRR(SH.D=KL/T@EGF*W50\+ U3%T7B,&&X=)-QY38&AI\.&A/1+U1N0 ":)1
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MC>[)K-)Z<QH.0] Z">QS> 5<.@I&;+_C/JAB(/:59OY#D^-+6^+N +8H*K*
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MU>4*UY"U23<3[5-.,(H_D5_,B#[<"G58",8TY%3 5Y^[C#Q2\?=!,IDH94F
M&,8<+%Z,YU#W?\XI<!2H*(^VN6[\.%8U(_;I]>L"? %R?-$K7S3,N:NNMU7
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MXC&4S\T=+[0QM<-D@"BZ$&3R*B$YS72Z^DB0^H99I&6TT=B2GK,QMW]JUFR
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MBA:FP=;K?IL4G!2ONSMO]JZ3)<W+(\(RY<YOV9L!T^:1^R 4_@@1DZ609AQ
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MFN4-V=DUQ]A^5A;0O@ Z\WTCK%PQ;"M2%+,,UO"]H>(IZ1!18>'0 , 85G#
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M&H[1K>JH=)G6L7TFZK:](73HB3A3XFJU,(JSN58@B+/;1\RC \PM,G;YOE?
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M0>GNO&1E8T&/F*R0^M-@ZZ>( "S7,C8"O"E:0'4/!ZPK5C/"]PX;P.9*"W&
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MSOCH]'#X,EZO[&50/ ^=/_XID.7&O$'$1DN;;]Y<>\!H\8<[+Q9E95CN1(;
MY2.QVN#-@9 1\%($E::7;N^@<8)5VH"\E84=94;^U3MWZ^Z=O+P$C.D.5$\>
MB^[VN%,IO;'(6=K>9E:_&T+=>^O#H/V)^<.5D*P9G]!Q\">%!7,]'^4)[7M5
M0S8/5]B&/L"PYVL8FK<YT9YW_*\/%DP>+Q =^8P#1@%=Y$ZV?2%;2;!RAFL8
M74]5RRQ9BI.R3$514@'"TG6Z0*<Z/F3@-EKW?%W=R%LI5Z]7;U=Q@"DRQ/WD
M<I"KRB7LIMA]!,9'U-,*CKQ]H*52'K]:YU716Q8@'[GW8)JMTQS$)=M 5> *
MI@';Y<F<W[8#OW437&BG'QR,FY&O]:(.$S#TGI9;CFY==]RWP"CO:SS^;!,D
M_.%\^]2>:_LB1#=A'!V9H2/T<ID3V8*6[C]5=U&-Z@)TA-SAR<1>?)SG<UO=
MTPQ!)67N?2N:!IX/\YKJ>T#VBF80)VP+\MAM%"S ;(WC,_=!47Y*M-%KP2%7
M>="J[^0"V6R&S\8$[,&>P_+A;.L.V\$KUB/\T,=VJ<CNM];VG9^Y(GLP[Q26
M\GR&F^F+.I@O=7$STMFERBO=EF.X&'7HGO_%BB2A!FE>:1FE]7>Z,T8BRU,M
M8Q\09&N]CBY9RV=)7ANWK5:N1 O,=]?(6 _*<$$WB+<[,I-+%KC\1]\]Q+HL
M:8SX2[=OA[=CN) T1-U+;W# Y*+A:!TXDN5H)Y;.0Z=NOV'0MW2X-HE$LV'=
M7SN (M"X/M]Z6W_[F4QPFAWS]*/W94KGZ77HVXYB\B)Q0! Y"CW+<JH;O-I2
M!*5Z4%?-W[M&!J'=+(>ZRD+.!#;SN/<+V$LVQ^5 :O:8%8.EC=+0[6K>PV?4
M0S1+E2E4>2A?7P6.RU:P8D5GP256]34J30S'G^2A?:P:C$&5!HORJZPDIS56
MXS3%P>[,BYT8X7$9T-MM7HOG\RB;^"+.Q(ZAS%Z>RX>+%_W!%_NW5@U%\O+Y
MSFJGOAP\J&Z_449]:XFQ?B*Q.KYL==B+A7<,/AA>)[D2'UYH#*L3*[AR:?C3
M2!I?,Y. 3A,56Q9$PQ#6J!:N.*DC383:XNB)7.0?VE+CC6'TD&N=BKI_+[8;
M=*%5O,AQC;2>_QBZ<'%9LCS$9?C*+)VPZIV"LRQ)Q4]ULD(P_&EH_?ZE2MD$
MJTR#V?-22CJB[3F $[0KF)OXBM](I%A;J7+I.\1LZJ0:4:(IUX%.C?6^3)+R
MAN@N]]8Y%#S$#L,Q[BLL7]):WKV<5JY@GT][N75'QJ]T"ES&CXD9 N^37<4!
M*<K&J_<^FJ-CZ_;4PGGDXXMO'TFS+60_\9G5@D*(J+GH?#6&C_/31-J#Y#)W
MJU=1;WW-B*4Y>/GRH[PG(/5&4A,) >:=#I>5R4+M[-T".JZ3OIL<>GJR28Z-
M3:+HR$$2;/QLR&3[@V5IS8J^_,U[4)$0]I:3J=J^S:OVZL=7=C_ZZC$L:]QK
MEKN9<+G;K)_QELH%A>P.<LNJ8_OU+,M#QS;;Q0NK96]?%/>JL.'.X95&8%BR
MGH6UIAF<N7J&]/U%.V>8)\=N8="V^KN;ZY0^S>F+L=@/X!.BX92F?>/5QPJ&
M988SMJHM^@:O]MXB:@<H7.L"2/7WW$&1.CTB[U7U^U0,AJSME]/I/*PNS]5_
M9J%T-ED33/UX(]TSE;=O)-(SK5S@C0K-N$[$KJW<"+_K#")6VKT9Q(@]9:M_
MYEFND0WV[,D<:U[5[->Q;I(77V*R%N$%\ONL<^Y[_/7D634O$M0,AA54\CRF
MC3*>"S;1^DN/Q8EOT<D<+=RK']L)$*D:=X>.JYXG#Y**[NL4RNKUF$05-N+]
M2?'-PMQ/E2?KJR\Q7_N8N8NP;V6B,ZRBY;GC^*E584V53[MFQZ[&]SCGI#LF
MAHI^#P>8&\'F,HO$T8QK@6^]2.MJ#C5KK+$@H.X4A\W#E"];2 T%S@_6]&MV
M+Y=ZDX=S?Z*>Z1JGT*QG?5<9'9#N==)0"4V.VI="CE-W"Z\>32-_4,\C7#]!
M4\N]7[9LGV'VXM: F5G$VXKY,XS7#E8[UF%D"WT0:K M>S_F?,3@)43F8U'R
MN4DNYH;[XL0RV'4S:02W#(W5O"&%R3HW6 XU$S>>1&21/K\]:)<B<6*PH3C3
M^^GQK8RWFX6&]N?%0YL'\A2X.'R7JIX],3[BP:"I;?XT\_.S$EU?ZB6?AL2,
MT:7W:]SZ=M?Z/#&')\AC79FGJRV"GGY0OOC&RQRNF9MN'L#=Y0H>M!J?060<
ME/K(T?;3*_%.NL7!3<XP@0JYN_DW%XTT^U2@[ST*"Z88C;D>2KZ0>2 C[Q0/
M.X*AO.W#MXSA3)>_FW5QT1K!M<7DB-:]4WSKNFJN:<IN7V1C@=W(@=HE>K_;
M 4Y9]W) EL-=,>Z1^P:N@[,)&+K.K:)0"#4_]L)BO%KFIQ*066?^#!V,&S'B
M*V#P*<'^C2ZRE352!5%Y1%7"3%L]!2"ERS0RD/=TX*V>>WGUXB,7^XATD\ E
M:"!MZ%ZOMI3^Q5:.3KZ0HGMO?14" Q)$ANS*^]1R-HKJAAG>3[HWJIWQ&-(M
M+N\54;'"ONN:J(RTB,A]FD!6'R4PNMU;PUV [D2)U>_MU-?H\%+5#[H&%Y/Y
M9O89<"M-1J?+/?//!GE8P)BVB]0Z?*0RT9 ;!I07WS'+MAZS"#X\F!(; V/H
MNOUTRES7Z'I35A^;3KBMX$N55AA"JSTUIFLO?<Z4^M&L.Y=!WG+_U7MHT&0C
M.A0UI-2KK[J3=Z*\:AXA(:O#[C;L_\9+H-!JNTS3[]A"8)^W/7CYI6X6&E:7
MJ!AD5A&NV%VP.9?U\".[V]Q)O1:@C-2':/=F,BL*FS01*;HD"KW@L/0T3^14
MBBL[4R#<#/[N1?"Y9SRF14?W<T9&4SNU2(UK;Z'BV%]_MG-^AV7S$80\0))L
MSMWI./_*RH)R^GY.O6<>G903N%I()HK*=AA-NL:-/0WQM[//$N]=P@&=#I.K
M,]F@2S)T)OO4BK:;*M[6!79I 71]XJ;J#\+$U8\ Q%TO2\!'YFJ9>T3)EX6O
MEQ57]H ^5,:3#'9?4K%WT(HWVS);U-8ZG:<>QQ"&W9K8A[C(,Y7=NG-3D$9?
M)2$>6E/FATQ)%M+  4?]RMN$+<2P_M"W2,NB<-F3J*(Z;TJP]MKAN* EYQOM
M)$7!ZA:F0K*/B])6[$RKRQ./=5H$:W.QWQ&B5YH"U54XH/$."-6.O>S)KM8V
M3W^="D,%!G'/\;5C R6;Y6I:TGY4]-(6TL;4&M6F_35^M2'1&'7T4[R)R*X&
MH ]S5)>]=K%3N^7QY&PPZ\";MF.M3,G"$12S\.<^@JEOQQ''YROE"_W:S1R8
M2SP72VDNM-<>/A\T_I&S_I)IMU*WG<O[VUW<MW1$,?X%\OF.M[)OWK=6A_.P
M%5:6C>JXF C06FLG<]/*VL8HVSQ7=KG2*4\[PS+V@S5+]'T('D<L&PZ(KE+!
M 660/8'^V]_/3SC[2>. A]=!6Y]A<[Q&'-]=7F;8^V9"IE3E^_T#/VWU#O77
MH\MZ%](L\%ZM.W@5IG7Y3(X-US\_"'6N?CG&FVHG=_GWB9K+9[X$"Y'??Q[_
MT_C]_]ST[)C[K @#4],96B4#T/")1T5B#6HGZ8\P+K_DDPDT\?/7Y34.6EN4
MCU5 )^0(4\A[4,^ [[X/Q/LNW+K)?J7/P93-<MT-/9HC2_H7GC^I^\=G!+3F
MMX5MW?OZW!9KO4-/7^AQMV0EVDTD"YNQY79> 1.U;'BPU:\K-Q1D#<6SS(A^
MM"_0ZKJCJ]*US-,Q;3=^Z]ZV.NEF7EST?B/-Y VN57->&@VY%X25<?\+5\9]
MF[B^A"%J+N6E43^D^5?.&?EUYO&O_>-_8GE$9KG6Y>/9F0\5Q$X%,24&;Z\S
M,GKR<<;=#A;A6U=ZJWV3(IY]^U#M+^C6M5E]].LB6!T1:H4K*V#J<6;U@V7H
MO4Y4\\HOPN_=Y[N#MP3H?0U]EIG/E3N8P\E%/V9;N*SR6O&RT599AC2KP1,3
MX**IJ/WQKO>^,MUT?/R\:D(XP%.CDH28X^G:O7XFQ#4TZ;Z$#>+84K\&\N2"
M,5<<S-M#E_NX5[K>G.1T)2(3Z$*?07%>0XNFOGH=M=-PYAKE2HKB9+%PRV78
MJ9YM8LX)W65:N]362TGC)5'8;6&\NA<R>; IY;C3@B%]78BQO'WC&7_VF$AF
MN:_Y/I*?;58 K:T &QSHB<W=ABOM<HQ^V*Y)FP^3.Q<;.2#;BUIY/;EZTB-&
M(5:CKXA31V(]7C/ZX% AZ:[H'(@*>Q2=9_@J4,?7$D)U]6)(4&"+I47351.!
M-[*SHAN8'.9-\7N3%YUN9[\&:<ZBBA[A +NBL 1)BXR$ )?=B/-[X)(%BO2I
MQAAJ<)H ._X-(E4H2L&<R?((OUH>\]ZPYVR?!K#.'T?A]&*^M#\:H4#Z=%W&
MC_&@<- -/9VW.S!8UC<!WO$I[EX;AFC5BUN;"A_-R5O/Q%IO5#2##*AB);1N
M\-GQ;TC?\5TA[0;'<8+C0!Y[ZFJV!^T?L+:2\* =C4\8151!_1B[9$9)E$&*
MQL5X\,,#[JV+ERA>,W.O*] G'HOK/OLHX*BX1%'WZ'T_\<"),_4'(/W0WF3K
M*VUGT);&3&;E'ZC&PS#(2('U&H9YF]P#C7W=$/%LQ:%QXY4N2/2@QO56C)16
MD)^)WR#OKV?99J2G4"!/0!W1,#7H:]-$5RHF4_'+?!]63EYN)<X[OA4S(FX
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MN-#<Q<>58<=V9#YCM3^B1YL'0?4''%O,SNIA38=);:M\5GQIO8JW:3=((W&
MO4IXR^!HW:#8IU[TOF5J*+-?=$Z38M5)8POH))P('7B+ =G K-*8S%?3YO,H
M[ +O&^S<(:-/I"F::4,%OK*@X.)KO8(:-F[Z[S$)'] 1#@PFA7-CF4^1B?KR
M?OE+/I UMF90J=@#\#@S*BBBCX5)\9"EY<6*=BI'UC&O^_3SGR=J'Z*%46I7
MT;PI+R^_=\Z]GEKD*G$&JG2YC73GA)OA@9-GT444#E@.1?77)1I*ND6/1QK<
M> 4/"A[I(\'[N]&DG'T55*&CI>483HU:A(6-9Z;U[*KBNF<L#JB]>A>Y!&^J
M7'ML^*X&G'?[1=LSCNZ\#8><J=O.3&G$G/!&4VV?JXN=GO(N,J!)L6;2_O2D
MJZC-&1D!G]@1!25HLNS"R18UOX)D\3:?6T UT;T.76X<0,ZH9BS;[D*ZGX=W
M(#1A=<W=R-F16>PN!'NQ&K+$\Q[K\VK&\<DTCRO$3B?K^9R7V+VEY2T0_9Q.
MN2W#(/23IKQ]1%4SZ5#Y),0YB&Y,=R8?1IV?%FT>QE@:32?T<IE$0/ID.]/.
M5J,OY3AL*$TN1#& UUFIE[WGY)7JLM"34=>I:MY'G/KLEA,O_\0 S;.7S#Q!
M44Y.7U=Z,\D;H1G'4KJNMER#:IJ9W)=JVA80Z31HXMDZ+!<36O%X2GR)7 "L
MO6PDAA'3#0#/41;B@-'',/2RG.^^/9I<\U5BWZQ<7U99')DR4SSJI5!TP%$A
MIZ,MA9ARHB2+3]FF9Z_H.\QYTS?91%M^DABW"HVJDFU/7>/,EK%>-2IOL*DF
MSH8H>X[U](GT1)=?2LJ^"GKT9';'_N5IXHX3,![=4WO]2YNV^]87H_AX-[V$
M=[M/RM]>D'2,B5DI(]NA&D!,%J,-BLJ2<I66QS_*O4U@.DB^ 3PZ/IEB(L'&
M?)<(M2>3QV-Y.EXRO+Y/5VVO4NS]6N_ZYU\<Q=UM%/=>@?5+]A?M--NXDY1C
M)@8MJ)@Z7YB[LK$&2 ;JQ",OU=)@.Y*YT#=T1MI<:[O<3]M=FHMYFNSV%!,R
MWZ3<(KIIB=AW16L7L(D-LA11MLFZE)]4\M\7=.5<+VH6K!:$U_78/O*<'';8
M4-SD,V@:L!2*\0C=E]A2<XB537Q>:X\#@N=1:@=$6Z/[6Z0X@#D-RYCU%KQ)
MV@];[0%AW*I'?QT2*BLRB*TL#AR0\ABAU,6PB_S^+CC:'D&" SI 1C@ J0Y;
M&P2_>,6_N\9? >Y[FH -,/5&AHD\$2T0Y'WNJGCFTH:]W^,H<S=0#**M- ">
M7?04-EXI?0H'7/9UQQ[(X86Z-;Y2<]]6*NL@Y FL/=2W@8^S]=3,W@<UG[5+
MB7O-(:XRLN=O35>6QI-8SI&?55<K4S4NCZAW8* ^WDLLDS<+0=O#OZ_6CP5A
MZS\@9QMJQW" WLL;]@[Y3;/5'@XJL8K=LP&Z>O0KA9R'9=B??*8JI-.2YGRN
M_'S>@L\\RGLHU'AFQAJ[J#3+23\+W%9\&88J^J^6-&'6\(3=#MO-3.5:T3D#
MH=5?Z.LZQV906M!C][0E924RI++8KR;=5J=S2I8'KGV\]MJ :%%"VW)C[ZO-
MNO[[.*#>Q8,3ZS^X>K 7B .B.G$ 9>=8,N+3W@IX\=&7CEB2_K6WSNRU1F\U
M-'LGSYH]5\Y$)Z[L'=.^4_2<4II48J.?C!V2:P+:.8W(FUM?8&@*=2M,Y;&*
M4::M?-@I2>$]'>2AAA%3#(#-47UYP;+!Z&40:ICE&+[O+^&5KU\*#I@L@=V>
M@6Q,0.[RL;?T>.J<!WO+1CP\HBG5QQFRF51#7*=3Z>%AO#UR*.SS@QUGN(]N
M".RW>N]]5V_$'O$B<F>!"BNEN,V"5_"R'#LTZ"3V6&3?<^_^8!&-\8,C70VM
MLRH,*_%F?<JWXJ/;JP3-T#WJ<R_UT+F^"J21=H7+O7SG5BP4=IE@;_3NX0!7
M7^XZY-\;3&G[5$(X $&]'X1]91ZOLBC8L;UL5E].;1NHW66OTZZU?E_SF*Z/
MV-%C9PT/'66-#29E<USL>I99%,HPSZ@>JQHPX%PII<%6]10T<>?PV[=SSE&]
M>$_E+UOH!\9_C& <D._)*2;4R+$!F_)6#!6)U)S5[=KBY5^*4;5^Q:;HMN(?
M0MZ16ZY:&V=:YW"J]#/,KJPK9HC36\Z135;FWF6P/EZ9_%<'VS@,7Y9P#+XL
M'.#OG?# 16^UD&=UR?[TD-9+WNF27'V)D\$,8@#\T?@-1=9LV92>LLXM.[5;
MKVKZILN4EL*E3\=[ASTYRCTC)4!_5@4 WGSV6C,6_+'K,&+@7X4Q[+>A\LDS
M 8-.^"SAR*+,!5G4V,<!8R"%\H^,%-M;^>W';(2L91FZ-W>?L2>.T$8.@BN5
MF//>_MW7_VN/18+[?!*2DA8%909</'4;UQ=J37=YS>/K9-WMJ86MY@.5)_BI
M(F\7%+(^R]_B5N!W< FOR%2@OX8#J%^,%?D<$KC,]@\,CU"\4!!2$=UZO.!]
MDWMB@$-I)E8I^(2?]X-X14N6>\<!O(*&=Q5YI*F\[MN4>B8[8E$NQBK/'A)S
MCOV8X(K6798IW< _WM>_.^Z/.9Y7L4SFDMK% 6]D0\N#I3PTZ1ZQ6Q_*S1X#
MQ.GR"XCE$5>3M.1C+A4GSQ?:=3_K="!*UUI&.E/M% ]6\V,9$6]!FT?ZP7\(
MXQ^&QXN-7X5QT582>_=!IB3+:XL,=,+5RI[X=S)\$R,+*RHI_:=:(L0>.OH'
M5QJ R\J2$?8G&CWD*+=-C6@V HX!R8*#M7Y_M%/IGXHB[5L5\+OD.8>@-G_8
M:9HPB@. ;=WRM;M:]GPE.328YVL3T>8L,P+7\(;-(?H#;G>YKLF.36]564X;
MZD&.!THXP/.%),*YK]877] T2L4*RSZX0@5:2,6_3*6KQB?7F)'AU:*9BSJA
M[&[]'1P--@)$=2]:VH[1%_+<@(2];50YJ=HH.YN1,./I)YN>=K^@G;VTW_R.
MACSM+ N:X+[_.[OO=WNEOJQ;+U(GAND+JH1=.-F&CGWC!UIS0BS;G1]9N6[6
M9C[$RG*OB6K1D+E_J7F<._.\1"FWQL#M9TJ@G:[$K07!,'=QJ(E Z?!"MVJR
M* Z@>#5NA@,$><VP. #?I4US^!&IAT(>D)3"]_?/X #&(LOGX4]QP  =:'<3
M3O_C?].P]%9U.&"3N@^\N@3!V-<DAO&!!NBH"/?^K[J7*63;")5O3U_DJG<9
M>SI1&O1. )J+FGT[>@QM*A_3KQ2F]VA*U87B U7V\%-0ACM-B6%?LD%@!I^U
MIG*TO\QA:8T2ET9>MD[\0+P7].,79\)F@7_]9H%_6<JUA:PM8+Q@DN5_G++>
M<>@JXE5C<I*\!SP<!YBMDGB\A]3TSE3TB@RL3-M8A#598UY.Q7S<:&IFCVVZ
M*TED/&T+[OPU^&M%8?4E_I.!L?$L]KSSJ;-F0ICSMVDIC$1%JC9E'1P^Z;X9
MAI7Y7%$[<,=;%Q%XZX*">\P>.21[%J_Y4;"UQ+VKA\(V8>7"'*6>OK/1V'SS
MT4W*4[-4Z-L08EB'50-X!SOZ%0?;HT"'H)*IL,(0Q:[.@]=X<W77=QR;-X7<
M) =5[%9AZ73?C&[2KYTYP &!WZ.POP;G:(+.D^G#AIXD8'! P@AHH1:O42]W
MRG[Q,&E18@='?/"R%(;WM"9%D*BZVB-X:[G] 7(5 \)8UL*?PY<_O,?"WJ]2
M;4'.X_]SZZ"Y#?3#7? OU<;;-58-$$B)W)?RYO:X8/:6D TLQ .6NRMV0*RX
M(NOP:W%@M67$23-LU9=J?;'P:'ZMP-7?*R"Z&42# \J%P7ASB[\:W.N3A+UG
MZH-O"@JN[PA9__:L[Y"1-/@B87\6^0O>%\:W3#/63/;<[ZTNMT^&!F$#OU[O
M78E/V)[!*V[P]$[(7E$LK(/';W(&;\9_Y;.#Q3>[(D:@"._#S E/\..M9KR)
M15^4?B%MW_F+-;J^W_QK[WWIB5_+P\NTO]85X7]VQ07L9[P3@*G%^PLZ0@Y[
MA^&??V7X_7U_,I3_IFV^-FH>O=C!H>:OC?IM'\+J?R09!BX7YO^]12/P+6JV
M Q+#&\#?WP8>#_*APIM'B).P4308_='WK#SHSR'3I(H?,L7[\"0<\,-]7P8#
MZ;=#YN$W0\;L]R'S$>^'?7\;_(<VABAI*/[9%<7_O:ZH/[C5BIP[#7;<@/W%
M?6E_T3G]730:7]\F0A_^'^C#]#]:JOJ;U_[\X1\Y=N(Y#FV?0>$?^,&J@7W[
M (,W/SI%5V5/HJ:1]Z5%,^?BX>SQ?2<X2M0$#[_+?L/K?\0OH'0;?HT;?NJQ
MZ5JT1L--)Y77<R8OGQXWXI3FX#BR\Z)$0]YSMO!'5?NC@V((>X #INR[<,!R
M C9"]-/WR\T,1^'@J5.D!^Z@/7)=Y6^OU(_4XM4/JS?5WC@(&W!Q6?/[3;@_
M30.2Y%Z"K.TXXS6SJ-=7UZ7C\(+^-?U_:*OG?^LDE;][K.Z_+A$.F/TIZ7_S
M:37_LO2'J1GVZFL.B/GC"(%2VM\_R_WSIPO^1B+^(6# )$81!["Y)>" .\C-
MVX5UW_?R#,83+ZL>@Q<K\,))O_+:]]?^HIN07>)/L/ZC>"5Z4M<V_CO!]M.<
M' X-?%WA58@=9$Y>[]=@ O[\FEW_ T?O_B[ M <S\F#-+W" ES_?E^ !X3OR
M_[5H^O_,]$/0WZV?7TBDBE(/D<H?BPJRYW^7:C^_F?]<$:[UU9]6)Q;YNB"\
MU^X/AUKDYPL6&2VL#&SL2N$?&7^>>FP.>)AFSQR\$'O0J?;SE<37Q01%7Z6:
M^N&%?_%,WG>I(!O?(4E8T ?MQ*]9=9)XY-KRF?WG&=D%OR\-_^='\/@;B>D'
M$TSW^[.PO^]E7;')]ET2O*ENU(P-Z.WZ[K*'J @OHEM8ZK$5>&F8$E9UL^1;
MP?;3!#;1Q<@$C.]G'%!SH&K\U3X3(?**C_D?F,C]0X(5]O(:8&5"]GN('/$&
M63JD\G]@ OOOI$.17_;8Z.;^]I/]TXL@K)(BK)+Z!P),_&O2CZ98Q8]'#WW?
MUZ^1++"6\U1[*^#-TX4QWUZE4/J>P5[>!FW5@0](\);+][+MIXG?8U]/%[+=
M^M-$2R'O*7E4\L_OT=]D6*_;[V>.IY!_,<G.'73^:U72ET1C!YO<\ZJY^=O/
MSR^"\%WC/_B[1IXM>&T&!X1LT%I^S=(0<?RQXI,;@MX./^C\'W",_D8B_=X.
MH_W^2__W'?T1O8&5$X#U.^)E4ZE+W'>7 '3NNS/2>GF_%6L U[%&WK-['8<E
M2L,9]?2Y"L>CY!?RQTY>QP'W U5Q &(1MH^^&(0# N]L,;;:F\>,FS^<"K)H
MSG+4Q@'C1-TX8+:@_V 3B5$%\/*_3BX3![1O(0\P-+ _\[31..#H<00.D+%'
MKN+E\(0U_N&D^)&?7 [9P=N=:R)$13C@V)$D' #NPP$[*(WOKG04,:R2,,Q6
M)0ZHQ8OUT#3L"68PUFL8-JJ" QHZCB Q[ P.&!Q@@ -&WRI^>Z$'0OG/XX"-
MOD7L'@1['HZ^C#<I=A==<8 O/PXX=9D!!Z >VB W#AQP .PPZ)N\.:R.&&]M
MM!L4[<_#T(E@ E,"TW\;IJ 3O]X)WYN[^*SP=59&S]3(%2)ID  L4OM':DC4
MO5NP=NAOSP'ZOA4*%[Z]X&;[CE;GCTU&#,%24XIA804X8'4L[9M\_H^T?FBN
M%$H86DED=!=;C@.0 ?!O\B^_I_5]8_F+XJ43:S=L=F\4BR4#_YEM^9'A]TT%
M]!,H$B@2*!(H_I^BF)L8_SJKU?[0R)5FF:<LS2,Y>&7VMS0 _P.1S\[>  ZX
M!U_+(#0L@2*!(H$B@2*!(H'B5U9<OP.I]M'@II>POU;>X._E\1I *[U&;JA.
ML;K)FN  AJJ_\  O@?ZX^7?*RP2'E<"4P)3 ]'\]4S;HWA>D'/Z_\+5\Q-^1
MV.1>;J^SFAF#J_U]&@[6L*(.WXA[O&1LQ5,\4H_U-OJW4A7_ =J00)% \=^<
M8G:AZ[)$P12Y-Y$X%@WN>_47)I_-E[K._E97_D^+@T[Z307>@(G$>_A:WG^.
M/B P)3 E,/VW94JKJ]$OLLO;8M!R:\KEKFW"WZYLOA]K]R^VE$O$42N'I?[]
M5<1_@!8D4"10_#>GF#,*3?1N)3)H,8 ZAY#N]:K]5\"=?5]F @D]0J!(H$B@
M2*!(H$B@^'^28I%OX7R7?F7!$L\-P1#2BMR_<*I$L+5V[;]Y1C9#BX-.;^G$
M7ARBN6M(%OM#546^5-69T!L$B@2*!(H$B@2*_\<H#I7WYJ^R#QS^X%0K7,K$
M0HH#"@O"&KM\>*%IP[NH5F$)S8KH1U%^ 65!@!/+/QBXAPC;_""J.P"V&E\8
M\U):V[Q_D&<A)5ZCFJAGLF@^$2A]/KG/TLPL??_7>#WY(-(%<O?T]%_@EYA2
M(7?6]DX:_/RM>(1$2(3TLY,HO/8"<?3WX7 F)F/WW9NXS_GT;://UAS:Q '-
MD6XN0,FW^U/[LC0N,^ED90Y[6&)&/T4,G=K(,I&A*KUC@^4KKE;GB%UZN:,L
MZ>=:]BG?N_W8?'_^K?JI8NR%&^ ;CXC<]TWK?Y.HZS@@$C1T&K1Q8(<#8 D8
M* A[P@@OF3_#1J&_2V:^7R4S;+7T5\EL]AL4^?^-Q $$* %*@!*@!"@!2H 2
MH 0H 4J $J $* %*@!*@!"@!2H 2H 0H 4J $J $* %*@!*@!"@!2H 2H 0H
M 4J $J $* %*@!*@!"@!2H 2H 0H 4J $J $* %*@!*@_TE0'3MGM6"AIFT*
M]R%6LUVR65<(C4HNHM@FNJ5)[5%K!+5,32[&C[0[^J7Q^$$X?([;LEFUK#N-
MVX&L.3G]N%I/QV'^XW/0-'V3\170:ODF;8'*7SG@G*;D7W]V/2$1$B$1$B$1
MTG]((L4-_#]02P,$%     @  H2E5+M_GAG0O0( ;[XC !$   !L8G!H+3(P
M,C(P,S,Q+FAT;>R]>UO;2+8W^O_^%#K9M^[G4*3N4I'N?A\Z(3V\DX8,D)D]
MYY\\=05-&XN6;!+VIS^K)-N86R!@@PPU>W?P19:JUO6W5JU:]=/_^7H\R$Y]
MW935\.=79!V_ROS05JX<'O[\:G/_[?;VJ__SRT__#T+9N_?;.]F._Y)MVE%Y
MZM^5C1U4S;CVV0_[O_^8;0\'Y=!G__/KWH?L767'QWXXRE!V-!J=;+Q^_>7+
MEW47RF%3#<8C>%2S;JOCUQE"W;W?UE['C[-W>N2S#8HI15C _Q\0L<'9AI#K
M$A?\_\5X ^/S7U4G9W5Y>#3*?K _9O%'\.3AT \&9]G[<JB'MM2#;'_ZR#48
MHUW/-@>#;"_^JLGV?./K4^_6XRW_[:>C$= "Z#%L?GXU-^XO;+VJ#U\3I=3K
MK_&:5]U%&U]-/7#E[-KXMKV28BQ?=U]>N'1T[:6BNW0T?VEY80#S5[/70,01
M3,U/KP>R__&-R^/71C>SR[]>N?["_.*WTTO+KS?=E\1A1'Y'=D\O'U;#'6![
M7=KK?^9&]>O1V8E_#1>B87?E^:-&U__H_#&O1[4>-J&JCUM1B:, ":&(RKF;
MH,9??#J\7S^L3F^]3X$8F9&H*:\C$)"3O/Z?WS_LVR-_K-%E/CA_212FCX8O
MX+>4_,EG+#,G1Q>>,*B&AZ;2M3LYTC"N5CFB/&-V/JIQ@PZU/IG]+NC&M..:
M?-$^ V$R-Y&RJ3@E^;>$J;MB-H=1C2*+FELX"(_"\5%T]JBF'ET=&7QXS:C&
MH_K&$:G7\.VK7_XM^^G(:P=_LY]&Y6C@?R$8_>VGU]WK^.FQ'^G6N"#_Y[@\
M_?G5VVHX I.##F!\KS+;O?OYU<A_';WNE/9UO.WKR7U_,I4[:^_DRM.L&9T-
M_,^O7-F<#/19E&3_YM4O/Y5?-^+EONY>EL[Y8?OR7-2STOW\ZOUG$@CSGL%,
MA::(4ZR1*81!4@J+.5%8%$#DH3Z&ITSXM;$/O/:_@FJZM]7QB1\VK3QNUB">
MASZ:SU_/SB_YJ,_B1YM?0$C:?_[NFQ$8Z8\PB,J1R8R_CO9\ %I\MBIWNE 6
M6<H$XH1X5#CBD-6"66 \5[)X]<M'\L^?7E^8SO6S$]9386!.MC 2<2T]4IP3
M9#AG0A:!TL)/9P?2OO%V7-<PV/?@(O3@GU[76T,7+?OE44JOI(NC9 +XRS6(
MB?&N0(7,L=92<AWR5[\@1"B(SPTC?5]KV[J.R5 U5D7A"Y0+!Q,WCB&3&X,\
M%E(X2R43>#K4J(8;F];68^\.]%??7!X?7(L#%QH%;2WBA58(J.!0L)+D.-<*
MGO$J&P_+[@>?/G_:?P=2WI0;PW( L@<W!BEZ?7&@-PS<P\PY<Z!66H$$.9FC
M A<4:2!]Y":WCE^6H,G8MX?@AJ,IFM!]<^AVJJ'MWER>DR9!><$,F$X;X#F1
M0,$K)#C#+!0V4*86-2<7A#,A-\@H ?Q5@2%M+$><@;H8T";GY.4Y[?C16]T<
M?:RKTQ(N^/7L4Q-G./'GP\,6?92C\BJW[B1-]YW9184P5HIX6R0*$ =0=U (
M KP#W0HP)TJPQ?,*,05$G49T.OL>/KO?''[YVQV5@1&M:6$"LG!7L +<(4UI
M- 4% :$2<FZ8K3)L W$ ,WT<FT%I=T. >P\/WU;-J-D>3H1M=W3DZZVOT5X]
M,@LN3\XKJG  H&BH1EPJ@70./"AX;KGQ(,J*7IJ<!9C9^'>^^[L]W#WQM8Y6
MM,6#NP%$;;-I_*@!#?H0+_E0:E,.6FD#N;P\6S"KP0(9D:.:H6A2D99&(18X
M(U1:,(V+$CAXB@L2&\2#*1#8 HR4$PQY#[ST.6-&LL?T+X!-I/0"5-GF+%H1
MD*Q<""2\-$856)B<?\N_7#84E%KM7(Z E<!+;"S2-@ E9<B=+43AO;X\/; 0
MUGO7O*^KX^VF&4<#>*W\/J&=$(("04#WK-3@.*6&&9JB0""LW%JI<J7<O)W8
M&@+".7L+C*CU8'OH_->_^K/[V8@, UPM&"6RN!L/I'&&&!!D%Z)- \2"-#8>
MY2;7WBG,E+H"8:)-\*U4'5?UJ/S?5L)V0XP-J_&PU:./M3\NQ\=@0$Y!HJ*,
M7;$:2]6C2[-4E(&ASG, ,"*:1%"I@N$<20OBRT3.O?>79PGJ<UQV0X<)1: )
M4@51\C4^Z#$1@Q+>,>XE$@'0.,]=0$:* //A..2".\'Q%:7IU+PYJ#8MX.;:
M[Q\!XPY\?=P3_GAPK<0)BP238 D*8I""  7EV"G K@(+=<7032>U&_9'E?UC
M:@Q:O_64'LHX%6C( <-A#5"+,: ;)1I)D\.<% /A(W>$/QUWO@E_'I-+)&!'
M!8AY+@L/HI<[$#T/4N^=9TX43)KB 5KTF!@50ABI.  X$#L"[M424" !&(E@
M,('@EI@*WX.16KL'$JG-X'[QSH+FE3.9&P9RIPH)@5!A'%(*!",O($ RAELO
MKV#OJ2*]K^H]?S*N[1% @]W0-Z]*A 3W1"R2#NPK+QAX50F&0@2IJ8@ W+%Y
MK[H)DW(M_![H^XW[EZ 'C;^;'^4\!S/E&<3^.4 UL &H4, "!]JIJ<1@M,UU
M$>@>P-)QIR#OO6_>7A^^+<G!O+Z8WZ@],!ETTS>__!0S@AM-F_."6V9MAG C
M9H%^?M64QR=1RKO/CNKXQ#@E-,U=K7]M7'S<Q7MTCYM_1ONVJ4#BXKLV [HQ
MF7=+U;>?J10B> D< L,#$5?!(:X'TA(E<S ZGA5@$J8_]2V,FKX#.PKO0^GK
MK!V"OS9!^';[KZ]^F<=,EW\\O5WC#R./NK<.'O;U!-2B'/WNCPT\PI7P;9=-
MGP'QD1ZU@'L+7"[ .T#CU;"U@U_+YM4O,S#E7!FY 9JF2[#Y;_5).=*#[KX_
MO;[V<;],QSD;U>OK2'#2HO@90=K,Y>B7+LW.VMS*Q6^F[Z>_>WV!)==SR#CK
M6,@)8D4 SPW %RG ],@:(A4I2*Y\Z"N'(#2LCOV,3Q\JV\5*%_CSFQ]"N#@
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MVO^M.O7UL/UF4L*RF@HG R;<%P%1&GQ,'F (#SE'CDMJB<?,B]ZNV?8XO;/
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M1]MALJ0^AX$H$AC$UCFC$&J+@+1T( *Y80;@$W@-VE<.I<,'ORTD"\NX6FD
ML &JQO%8(TYB[QX23[E3X%^<HH38WN;!GZACW2VU"9>2>\\2(TH3J(\;9D0N
M)>*Z<$@S&C&B#<[3PDO?V_3NBI0$+-!5<YYKZB 6X\P*Q/-86A1[$3LN8@LA
MKB7KK:ON*#WCV8?*ZO-LR/2BW_P0S/, ',:F.RZ')2B@CMJ^]?4$[K<$/O4@
M,1),+FCP 14R<C9N"54YQ J%RZF3C!G>WY.V>EOG\2@+(N-AV3'QT^=/^^^J
MP4!W"T<S;KGR%*@\?_G.^!@$?%3-:'[<'K#I?RF;BE.2;\"-ID^;?C5]?^WO
MXX?O_+ ";;GNMA,*Q%$UW[KOA5N\OCCZN<NNF?G)>&["%Q\;O_K60Z^Y6_-G
M&%VYVWA4;\0OOO=>[:QO&-OM)+F>RU=N=T?&77.W\Q7%*S=M(=#Y]]^^\>OR
MZP;,I1K7UC?=VR.O7:M)P,-?_BW+?CK)FM'9 .Q#E%]4#J/N;^!U_)]O L@T
M:LK_]1L$WI^,WASK^K <HE%ULM%],"B''AWY\O!HM$'6B>A^$O1Q.3C;. "C
MT&0[_DNV5QWKX?37IAJ-JN/)#=IGZD%Y.-P8^#!Z ]-M3O1P.J0O1^7((_C$
M^@WPS.A+K4^N#NN;#X4G?BG=Z&@CE"/4:NDP/N:__IU(_.:GU_%I0(R3BZ0P
M50U$:B=*UZF AV2N&IN!?W.B(6 <'K9?D?,I)++U0((B_O?U96(8;?\XK"N(
M'F$>@ZK>J ^-_@&OM?_WXYLKGY$?W]Q,OR_=2$TU</.3*^Y-T$\[VP=;[[+]
M@\V#K?U$UX71=7_K[:>][8/MK?UL<^==MO4_;_^RN?/;5O9V]_??M_?WMW=W
M$K$O$9O>F]C_V-S_R_;.;P>[.VO9N_6WZQG%@JN;"#PA0#1<&[RE\!623ZWL
MA$CD?&0W\($]E ^RO<'$[L]X(W T_4TU*-WT^KJ]^]RXO\6V6PPQZX,=EL](
MA.]O+][O[OV>3>DY/^SONCM,&2#6L!JV8+RT+9Q[_SF7W.>Y%D@0IA$/AB$5
ML$#>2&:(8H2+_%4V"2'V?+CS87/94,?(SOERXUUEQ].==2M%>9C=WV:"?(%Z
MOR0+LA(6A*^+1P"UCR#%]Q?B'^(:1;8[]#]>HNA(0]1P*:R( P+9W,!OVF_1
M0)]5XQ'<\:MW;[J[$]Q2??(#&Q,()XW?:/R)CGMDX8EP<[A[/;WU:=F4IAR4
MH[.-Z=63B^ J-Y.F]N8\WAJH^WKD;KA"R4N7P(OZ\B.GO.ZX=_5AMS#L"\P-
MF=KK/S;:?U'\8*:WK6[#G0DNAV_:)62K!Q/I )F;7=<IT_1"&/%-(GR+^E\'
MY/#"9?B[8K ;G DC6LB<&61S$P\!#!P5/#"DXYEGW&M;,+HH9_*WL:[!* W.
M]OQ)58]>9:&JC_7HYU<E3+/Q%A2H&A@]&%0C4WU] K?SD$A6Y5R^N=WS7*LF
M2;:?PCX_@-U_^[2Y=["U]^&?V=[6Q]V]@^SCI[W]3YL[!]G!;@;!X@%$A!EA
MV>Y>1L0/[L=L]WUV\)>M;"Z.G,60FV\/XM< W/AU<C*UE? WFO<$S1_(NO=5
MG8V.?/;GU!AE7>X]\T!&=QMHO[>=5=0P11Q%PN0"<:IB>U47ET-%+H,VE$NV
M*#O[L9W05K?$<,'*;KBXC (/.7+Z[,SKV@]7BGF_QXJ*C)&UI?&)DB!R&BOS
M P^(6V&1 3*CN&T]&!R,(,6B^/2^;,!4_Q/8\!X^:5:*$W%I\C9O=[?P*]FP
M[R;^[EZ*"U82.UTGOOV,"W)K"^.T1@4Q8--R29&1N4?:,^Z$D$R:L+ D4]RS
MTM9-/M/ @+^(P.!QA+O?[#[8V]S9WV[A?XH,5LRK3B.#T<P<34.#4%?'V>?9
M_[)1-??N<P(V"V-!+-TJFUCZE;TO =& G32^WE@:VB^(XY+[>!8.L8A+&I I
MI&]/1V0\ISD7#T;[6VTU69Q.-YN58@C&L?4Q4;=B_;2FTN<UE<<J+#@? ^7W
MSDA[RJV!D-MX(1$O'$::AMAVQT(X[JD,A5J,3N[YP[;P=SB*>P(>7R_O0*.;
M9.-#-3PTE:Y==FE7]UJV/;3KRPS!GU.1ROT-XP];7[4=95%PLBIDYZ*4Z2;;
M/_$V%CR[K!QFY:C)WAZUR<;+RWG]-I<XF<NGK*N4BZ7$A131O+SI\:AZL[B<
MT069:._]H"R2P+>FD:Y<\FAII$M!=<?\&^+J:X2A-PMPMSGS^P-L$Z@U%"N$
MJ2YB!R>)%#AC1+CA-G?@HQE>C#./VWZZGM]EW/P!HO@6N#FJS]Y6SE_-*#7Q
MBI.Z.HWW6;%5D'=^H+_HN.7A\9)*2=1O$W4O3>$"R9$.E,8&=@II1SWR6(J<
M<$>H)(L1]0/]=7NRIZK;V[:"@67!$2 ))8GZ#BG^AF'/5\VNYT\EZX\@%_G]
M875KN;.JSJJXA3;[U[@N&U>V_:P 9\\+Q9-1.1<K3^9RWEFVU*X/];#\W_;]
MCROK0)).7:M3V^M[Z_OKV>0(A/HG4V>O?[GH0;*=:OU:OB<LO1ASL B$P1TN
MG-. *Y@MXIJL0LI9@ACEGK!@F,8+RE9O.E?[IIG\^0#D(2N%+CC-1;;UU=NV
MHVZV'XN];H/+JS.[Y54_$6N-58$C:4..N*46J2)VZ%/,:^%H@9E<EH31E9*P
M_3$\*E,"WP&^O@3;9(PCPAJ&F(ZVB7")C)0%(LH$SSG&UB_6-KV%E[OU0?5E
MM6+W#SK[OS'GE8S1[0M!LK J'DFC*75@C%1L0N,$"LQ[K03C!14+%:DV]MBM
M/];5*0#DI]CW]H"5\\WOD*@G'FNVL@'&BF>HO"144(^(P.#=M>6HL#XNKV+#
M P^&*[U0A?I8-2,]^/_*DS8'NTKJI"AF><I,I2CZ/(J>R'1<[3VIP3^4)WJ0
M^5F,406(I7V3DB?/C.U@O;)HOKZ9'7EX"29/514PU/,RBO_Z]Z\4$_6FR49^
MX$^.JJ'/ANTRQUH&RC<81\G/(*K7X+"<W\A^6!8,S?-"A#RW2$H&D8WSX/R*
M(D>BP#B$H#VS#XYL8C"S"7-9.3]Y^_K-ZLSEQZ5%,@X"&(VQ0E(S@;B08.)S
M11!GG!:<R>#E@U?!8Y_+P<>H)RNX&B@412K/Q7.H,GVV95-BG3'VV%[LL;:
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MJ+,%-]@AK+1"7&&&3,$LA#K8:FTHM<6##^;HZBO?CNL:YMBU2XQH9:1'C])
M=H$2_D_?/''IR"(72;-)!_@H7CO5Y"U/Z^I/9A*CJ0 K<5R.1F!7_ "L15T-
M(V8:G&4>\--9MAT1B;9M^>8[/=)=S[E+%O/\'O,K^'MCN))C,>G]$T_]C=9T
M'QUD/T38E[^AC*Y/+A@=E0V,6)_$%D#+-I_=>&=6T3<_+M7FZ8)++1U!N9,0
MDFE"D'9.(RL5)TH13JA95(./&;<BLR8F<+5$.-F\9/.6:// S.AL $3PF;86
M;%ZL)W&M&:@CB+KVTPRD$%WS10-S@!<3%!:-E*V.@7)G:Q$QPLT 9D5R'V9
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M<H:Q1J(+6(9G77>S\[QCO-M$YYO9HFW4^/8^[7IKK!*[6,<UCU"F>]N[;06
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MX*86',<_8$7ULEM*'1=?G!E)!$\$?]X$3XZRCXY2<%58X"HRQ%'$36&1PJX
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M5@J"YXC@GF"NA71 480 -8("99D&3!J%(3*^QG07NS)[0' ^$0A.*"PGP(_
M?F6ZK7)"&GBVR&81?HGC%X&?I,"+>2FS_20$7LXF'>YFQ\OV*CSCTLWZYKU+
MIY1>?+U!>Y1S<8 N=9[6K4C_X*2?DZQS095B<HY\TA?I/S.[.M9".;ESK*\K
MGGS$SDKNBGOD.:;32L++78FG>D1)D]IB3#W@BB% M1! 6L\!YX)+!!4S9"?I
M+ =2\KB8T;R.%IVTQO)D\4<L\-R72&$:A6D<+-/ RGOA* ,.01=+P"B@#8;
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M%-5DJYK"TG)D:=X36'O&@$10 :H1 <K#&C@C*28.RT#C[K(TA;QTC&@ L?&
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M#'LZIWK.25,GE8QU!9B,9Y:P "J&)0553M+@:WBS522;, @]92J,P!A A9)
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MAM+'@G,E'$- 2F, 5<X"Y:@$0M:U%8@AP?3=TL<P-J/6== \A@)0@PU0-2&
M8L:E8Q8*:[=*'U^VW?P7UUV]GKUW_3P5)OJF6LR:X::__O;KNU>!K899$[Y$
MOJFL,TUX]?ZOWX#P+Q_E,/_K-\T?02:+*]O.Q\^_^0^,)Q+29;/%Y=O]1S%,
M!0V*T$]6Z+D;XP+!!8*7$$RM@I 1#)BE#E "(1 "8H MHHX;A;TV=R%8.!\^
MA180A.L P=8"H8P$/F O<QQIJ7R!X P-4T&#(O33$'KNQKA <('@)01K5Q,)
MA0:$*A\@F$*@N,= 4L$-)S56I-Z"8%S70BL-:NX"! O/@-#2!>SVDEI*:L+5
MTT'POUS76M5?1A,T-,<J^%N@H B]"+W@[Y'A;^Z*7 -06879F+YRM.4HC.3F
MEO?+]NK*=:GKX+6Z=EU)N<IBI15Q'X.X#Y 7G(!?KJ!PVM060*DAH P&]YHA
M"20QBDFO:JCHEE].)$?,0H 4H8!:1H'20@)3>Z-<<,P-%L\6&D=T(@79H6M>
M;$G^MJ2(NXC[>,5=D#)'I$00"H5I#;#7#E (:Z 1A0!;0IVTTDCN[R(E)MA3
M@A@0G,4(-I= $^) ;1#FGF ES*%&L(LAR=^0%'$7<1^ON M,Y@B3QEGDB&/
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M/$:34G*U,YG\10/[UD!.\B[F)R-EG,+D+QHH!78.)2ZWRUS-X4C$BY+[?K"
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MF2D(]NVJ:M;<M&339+3JGE3HA:H<B7H.D+"<0( !&<P,DP(P7+M8\-0"*9$
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ML$E<V-P"[Q'7UB"';4#)2Z*PRB(QB%[L;I%D)'>:M&Q//@*Z$$ZD'!/<( A
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M9,LN9 OVT6.3*-+"6L0#5L@F;!$CW!&<DK44[R)]%,@6D"U/*5MVGG!JB,G
M]F%<UXS#3DS[@QW;J8^5G5?_L#-_5C$RJBBFY*D2NL&)YR=.G7<S>M(3*DKT
M#,W"C2-HTX.PRP'*TL%+/$8I%S)2Q"+3B$?JL\0+$5G!"5/<&.;EIL2CE#%C
MA$:,2EG*^QCDJ,6(4D,"45D9"KPI\3[&R7DSL[.+GWY?U/.++AEH^WXQ;^=V
M&NKIZ0W5UW;O7I=[^*;(^W><-<&V9]>7OYXWL^?7W>#@U-VPXA2 W2MO.!2R
M[GE0_U-_#0MLWS^VQPJ+F(3/;!\-XB0SM[&8(>(45HS;8"W? ]N_L;/912;Y
MUY.,5YGJ&2\*YW]H9J5MK^?S6>T6<YO[T,?F73,MWS]KQMG<IV]+QXGM_!MF
MA4 G '5M& B2G?7.)"#=>@KV<*3;T=H%E%?_E!=/A,L4&&+81<2=M<@E2E 4
MFF"1**9AJR0RDY8D93P*S ?$I4U(8\R1D5%&);VE.&PJKV^=6'G[[N<OKI\1
M.C+,C C'H)P@0@%-]P7LX=!TS\,YS+  SW\#SQNK=>#*H.13YFQ/&;(R442Q
M-"8D3XW;#<_/&__;63/.?:5=3K+LI$8: 98'XH&\>#W&?SC$?[1V =[N'V\+
M%HGU-")J1.%MG,?G3#@4F7;8<),(VUH928%3FH?U"(N8/T-"0I90@X1TGC,C
MN>9['Y^SD:1FQ#$,SR% P?"\-V /AZ5['LT'.3R'5!=[2G4!S#;$8 M@]\H;
M@-F V6  ^^0;^2VE/&B-N FDI)B(R#G"4*0*$Z&3=]IM#F"]9LJS9!$Q>:C+
M<?[-&",1\<(H&1TE8NNLYKXFGID92<UA% OT US?%["!ZX'K@>O[Q_4^$4^T
MB2C_8A%W6",KI$&9MK7#-D3FMM))Q12Y$E0@&D)"W":.G#8.A<"%)TPD)=B^
MN!ZVX0/U ,_W%VS@>>#Y ^3YGAO[.'-&\?P_98U""4>%N-8&:<.S-I$.&Q(4
M%7HKH0"/WBKJ(\)9U2">N$+:"H\$HTQ*Z[4E8I?:Y#Z)HVA&=*>9HT"G'(37
M/B+7)0@=$#K@12!T8$+C6T6#SKROI!8H,IP%@(T"&2M=R3:I:?0*L[(#?F/Q
M(BGMN<I2P6=YP9V@R FC$1?1:Z:I\B$^U>(%,:,L:T L#(5^KB>(S+^7S!1_
M75OWW6(29[7/?X?ZT_+5<MMZNK KHY?7\X?O!/:[;XXIY*F!)7AWR#X<"K)[
M+*Y"_I.SZ2,P)70#S[/+G*7G]C0N T2.EOG17MGQ9WO1?O^B^B_HA#=!RWZY
MS:CW^))+UEJY_GK%7?'@I%7(1%QFU'%$VB6%L-:,F,BQ3&*3M&0T,FCC$1,$
ME\\0Y&+02$N%K962V[2UXOY+'-MY#!_L;'[Q<6:G[9)=VA_KUH^;=C&+'_,7
M_##.U/:BBIF^SHNU9XOXA=C>!^L_08+91_2@=\T\5NJD>GTZBW&27VNKS_7\
MK'H]BU-;?3BSV;M]7'0TW(ZJMU-_<IU-+H%? 5, *)0LU7??/X<M5J\M4^"4
M=ICOOF:?9X]ZU0K0M3.?W]&?^0EA;*@]>I> ?CR+U9MFDEM\474\&$-53^=-
M9:MQG9FQC95==_?JY3Q?_1__A_'O_[YZ[](5NE?_/,H?:^/L4WZWO?5SOZ[?
MW/[@-.0/SYH+.YY?5.>+F3^S=WSY+ZN+/JPOVKA9?H#JO9\W+LY* FA\S4M/
MJNL/G&-J[BZA*G?>>J)RE_]KLX2;792[T*J $G(CI^6?NL1;.Z[.9\WIS$Z6
M]TW->-Q\KJ>G&83E6*9=3'*GR39JRY?DV\^6D;LZ+Z'[ZNG:^T0*1GL1*!@1
MPPD40'S7&KZ\N+3H53W/C?5WPKOE+=!]@>?ZS'.9*]J%S5$]1_%;P_VH>WG-
M#(V;VXQ8%^WC'WZ\:.M/<71)3R[FH#X]'>7X[I8T6>8#1M7G9C8.^>OC)7EF
M0#(+^3@K]ZM^FS:?T5GSN6.[<SOO-&235@HR-RW$3W'<G'?O^V:2QQ:^SJ#_
M.S?X Q.TS#A5I7V+?.M\O[-%?N8L-?_^@7#6O5D>8IZ'?O..PO*MR]5EA#O+
M9#7-[-LLVJJ]:.=Q4KWLZ/+-NU\O:3-DZ;J<@UO?NWK9/7XYEGKSWJ-,?;FQ
MT^[RTJI)'-?-;/GQ_+WGY7E7K3VU[7S69%D1VWF=67-4Y9$3RE]<V<6\J2>3
MQ326:[V=A;KY9%N_&-M9%>JVF[Y:J8._?Y#"W/Z0;1QGPLWF*O>\>HSV^G.<
MW]#GA;C#PF?X2Q_);2T/6-K:+OQ9@?Z\].4"[=*0H?JP^L"?\P"@^U2;[;QZ
MWG6CNAC35ED13$MK5GUMW:F6?>$>O>]S/1[G/I;%PN^+>K:\T;F]*/\L>XJM
M)G7(/C$]'<<,TVD]O^R:N373.*]:.XY=U]IJ?_=BZ4QKS94ER_UN97.KFMS.
MV?9-1Y6[N/X(HZK.WV13JL=U[N9ML6YYY=)?8FP[[_G?;+?R7-W9YVS^_,SE
MAL5X-[3:<I>8^;Z]:EV^T^G*S*O9MEB:;+=:A]P%VGQMY6&+[!@7Y?W5KY6S
M;=UF2\WK<?<\1:W-RL.7/U[6?ZZ*SY[E3T]S0)BU11RNWDSUK)U?<]H.MZYS
MEAZUZFZE0ZYZV/+[,BXOZWS;^,=Y?>4\RV]NYSF H^Z=6'VR)3>I']MZLKYB
M'4#&ZV=S)3!\J9OEK\VM7OMR]HM%LGZ^F.7052)*;LQ]&GV[5NVAJGK"R:1>
MXW!HZG)[E CS** O>ZTOWTX+"4U7P_YNPN$>1&_';;,Y[;+=^:_/,BZ#>WXT
MOWZEFT-82H0X*RN2EVIS%MO85<(J7+=2EMW]UE,TH^HT9DV8N<J&_&!U5FF9
M@C[%:Q?D9[:G\<:GNMLM=<!D,5]D57"Q;L3E)6M!=/F@T\+L/EZ[>97B<E9D
M%O/52^K.:JU9S/+]<CMBX>)\S^7KF7#S-U5ID37(/-ND*M(H<V)I6'?QJ@6+
M\WS]2HN4.98Z9AVQ!*J>?FJZQEUO6&GH9:LSWWVJP^H[JTDV[MEX)0E&A03M
M+(O.V4J8W&JGW+I++;(4$3_FIYZ4F:A5.;*5[.HN+>IW8CL]6IXYV^+SLD$+
MGV]<AAS5ES<,/GRE(EAEN9$2!>(\XL93I+F7B K#=71$"K%U7H Y'[ /'#$M
M<"E4K9%F(:)@&,<&1Z?,Y?+ZV)V?O?JE/-'[].OEXUQ"]3'.)C?6SU$;_:NP
MF)6U[#9.#\S[FQS\+G+7N*2IS77A;2/V_9&RT)U-<E?_J>X\?3E?.2F#D/QZ
M'L1EEYO?[@7K,6KVE;:9WE3YY]'7J<X>-FWF)0;DD%4W(7_-!WNQ7%&YW2&O
M-.TM7VAG9:CDRUBQBX-WQKU\Z\N 5X8^-X+>J'A]^88\%)G']<BR.5^-\7($
ML#GTG><FG<_*F.;F5/)9?M/%."T[1,J#%XW=#8$R(7RJ2QCZXC.4\+(>9I>O
M*<^P&'<M*'<YLY_*.V?=8#!.SL?-15P.JKK"&+8;^ZY(IYZ%=>2[XJ%N)-GF
M[E,&&F6G2!N7<>AZ+,P#GVF3AX/3TUABD"MCLGG=Q:80SV.G"*IF-1:X"O6S
M9K*:7/^J'NZ-G'C*D<&.UYB5QXZ4$]HJ$(IXTAZ90 /")BJ)-4NB1.''KS'_
MZL_R4'P<WZ?W)0*\7SK"]/1-T\Y?3\-/N1]E9?/#1>D].?Z5F/Y-2\Z]Z0M]
MC\0W5Y:ZG4<;ZTI7SAB75KD6, ^2>[8#Y"N(+;=O85GN'5QVBNUA<5&8ZTV
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M*'118XK]J7GT,<5:\*@O>+1259#8^FQKI?IPI9K&EFT[:4#L!-2BZWL1H=@
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M_\A!P-:(IXNET#4<.^BG#"P1W*%;Y/.Z"F/_;'.X)"]Y4[<HA+F4H@M6H_W
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M1S#SK4Z&/:=6OL>.\U?D7\$8GE65D"[ Z& 8"X30'6_4]K#KY2TWXA(,+&?
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MA<+KKD\0%B\X>\79@F+F7$\,42LFEWZQJPGR=<[S6 2M7_5K[&F%+._J1E/
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MH_69G7!K:GO#J=YL9BG_?$ZO(Z4L[L-3=W ^0_Y4!8MH9*@V]-!$/[$+3F^
M/O670'3=;DL)"^D1'7%K/6IU_$$Y#GRF?H:S$GA:*ZG&$Q=,=-4-^GMYX)[K
M)EXDYYRA0^49Y/(%H6O;E+G$LEV7N/!_$B8!)9F315;D.WZ:/;X_]EV',O\
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M(P%*B(0]$*( 4N*\6LPHW"=AK4CD$TY:H5LK4"PR&)*R:U94"Q2]904_3@R
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MZ$[.K[]\EF<%8% ;,Z !-WA2P _HAD'X!,*VN_;+Y[?]M4CBM^_^ZU</\U8
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M %RW M$C["PJSCOW><FN9-!":+*LJ&XZ,#JR87@N+!3 X/B#Q-0RR-CD2;Y
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M"BM7UXJ[AIHH@;T:^A4673(J.[WT_7&&:BQ4$256LAE7HITGUIV)<C=< NO
M .%1U$U]B5A7AR.\BIUO?A0EZ%SS@TFVP\-?C6XUN#WZYB^B+5"5[?[NWN#
M]@.(ACU]JLMD?V9G-AB-$TF*JAF<0:-D3]XF2(^I\;%KP]/]O7M^WH<B)D,5
M7PH:'DU1\68RH"(+RR1.[G%Q6HE;]C6.HEQNM7X!-NTUS0M9)SPN2>2X9?
M8F/%W?]_]MZUN6TK61?^*ZA]9DXENVAM7^(XF=0Y58KMS'B?7+SCS$R]GZ9
M8E%$# (,+I(YO_[MI[O7#00DV;$DRED?9B)+)+"PL/K>_3SXQ4EVBH,BKVKA
M1I)K QRC8=FAN8>1E'T/D#;+P8V(QPUUCIEK0W[R$*=F/;1<Z\'["E&K^;45
MHQ+/],Y_K'&YV]$_=ZY@WL-S.)I-.W:E_7<ZWBS8&QG2S;EP0D?4:Z>.GJU<
MDR*FPQUI*B?/E^@5F0Z^,(%LBZS9F==NPX+9N?%@"ZK5.JPRJ-I^C]\49ME[
M664E*BT.=CQ2)V=#0^,GK3ZP]RB8<E9]NT01B;41/0[#>D6ZA%ZVQC&]=%\T
MLL%RB_#2*!C7_/R&)SC7^3DMCR_,C56BZT@#BLH-4O4S=]75Y04ME^)UBIZV
M=(XTXO$[<='07[E]Y*QJEL!MIQ/1;+G1N)9+^E$ULL[0:Q1RMH.=;V[$<IXW
M%6TFKZFL911Y14:QE.X3WX$LELDE(O]>EUC2F]Z-Q-&"JH+.IU&MS;,(UAK.
M1FG^Q5W0;IQDOPBN&TFDF_^^,(=;90_+ 1 ?(D=WUD(</#YWTAB@-7PLZX($
MI-N4.^G -IW#TF.,N$U3%0"6LZ:0+XF9;YC%LAIZ&%LW="VO>ZVCU?Y6FC)B
M0#PZL,#CY./KC[Y@]"&,5GOJ7WZ^7@MF@-%NGRD(/5WG2?8B$BYI+)+=<+\4
M V]M\4(7QQ/V66[+IYV=O)=%(]5<<SMM1<+5:Y<%MJLMQ?\;5:'@JV4=:0LH
M'>ZQ96EE$<H[!3 9]?#B!6$Y;P410=XO>X;TD:$5?ZL@-S/G;U(X3V>-!(8<
MI+4_(R)#]EB,U87;\2DE,=GIH>J"00,@LTB@T8Z2RB/?;& YU_<"+W)&B>HL
MJ=6\M&TF%]7@.")YS%5_&=Z0\0Z]FJ,W+N?,P1/ Z:+C&*B=)ALZ6Q3 )UJ
M#XHSC#6;J1-D-Q%5O"OUHMW=>:4>Z,10XX8>-^>*%G*@%G:-G'1MR=#E?>QP
M1=Z9GZ@/'#01*3O0 =><=\Z_'+U$T TT\[Y@\.I,$EP7+.Y./ZFDSER.C_=4
MG(!B#! LCMU9S,J"W)VWV[?_>O3DRWOL.AY)ZN.^X;,Q+-MW@(TZ\G-Z?T_F
MT6S:L0<UOS"V6$6'D2-ZMD@=_$_H=W(B2-ENM\CJ6&,60)Y=EY>%=3>@CL?P
M*L?]ZFXYHZI[?U@SR8>^L21^6 UP:AY^PQ]_0+:]&7JZ_#M3?".W>O20U;)^
M@3VS76?^TAGRM<A,QH40OO9_C/G/S\NN%"?S+_;[WQRRH,OMOGQX\OA+E. F
M:0QU22=?/_[ZRL\\?GCE=9Z>?/WDV14?>GCR[.NOCGM!EW#.?\6'ZF8HYY4/
M<N+87XOK\:OKB.'OHWJ<KBA=(8A??3PY/!;JXEO8Z@_0>#>VT;2M^,O_^8\O
M_R.=]UOQ9S_\5?["UOX'L?8O8VM_BY)T[U[J'<C6W9J9F';XX<G3AW1+L%N4
MQ0=2A]^15CQJ<?R,\\3-T)&/W7U^9ZS2$Z_WPTFE_ZC6[_%-6+_KB^&]4ZE'
M+9@(?(];'._=^TYQ0-*$21/>1TWX*&G"^ZX)+PDF-!-ZW6CB\<-GB\=?/*3]
M?\P'\3KOEC;WVF_E>OGB^Q$G?,Q4/Y>=AHYA\&R''EH#'#+7APGIA[S.]S2#
M=_5&;[$"D#;\/HC0GV[]C4V:@J-YAUQ$NF\O\;-'=-?'3Y/PW;/W]H'9K4_X
MC27[E$0DV:=/SCX]6SS[XLLD>_?LM4V:IX\7-;]?+B3%RQ\Y7A92P(\1+]]H
MPCAY(FFK[\]6)^?AXSL/CQ\M'G_U19*7>_/&;K-IX]C?U2>DV])6)S-R?\V(
M0"E^D03F;@4F%5WONW7G(!)X,64AR +!U'@JO!Z3K-WHAG_\9NCT:F[]U20_
MX\C\C)M\ZQ_>OIXD,UFI^[GAR4I] J\F6:F/;J6>/5D\_NH#>YB3C;IKN4PU
MV/L;/O]H^NRSP@AA\.>..A@5648B8?A0_ #$J_.\ KY8RED=N1G\"&,=CT\>
M/X4R+)J!H>'NE7-R[$+W@5UD-_U:DV/S\:O%3QXMGCS\^JC>]_US:H[]+:<*
M<[*(Q_U6CEV"DD7\HUC$+Y\NGC[YP-F@9!"/(,JG_P(9\1.AH#H&5I_;VIY[
M8B/DPUC353B_/[D9Z].I4O_Q(Z#>N39.B+\WDU);704%D%WD7?8GW"7;@DRW
MJ3G5]J=G)\_<+]X?_Q?X\V KH+N8:G^276\IU[[/@E>]:TMZ:[0C63$8RQ90
MTYVJIF-6AS]]??*E?8A%EA=@G03O$MWF3P_]G_!1QNQ_ #Y/9BD">Y;BWS.3
MEO!H_8E.D=\4,'&L-B [Z$9/U#&N,KY1E<+A0$_WL3?AT74WX:E_DX>;\.3]
M-^'QR1<?O@E6*QZE\CDZWL5CUCK7MXZOW$35/;6.Q^";'<UF',OYN[;5FQKH
M$ZOW^%&@_Z"IZJ8V-V'M)I?PGM9.U7N\:"CM3=/V#T#RHK=A2I?=0%<@19XT
M[J=SXJ^O<;]SK<<?7>/^P?;\2BUS5<<WRR[K%7&KGP32^Q$US97+*(;6$H)?
MT[.$!]B6T&"D9>!1,GDL6 GA5<8/ C<0CN>KUS\ME(;5O&.J,P07)X_=)Z$,
MNVY@KL-5TS%I;,7LX[WPU-$5+$D=,V?M\K( PQG=<[Q(WM"'P<7I,_BZ>JM=
M<!V^"MV;OOCP6IQ1=Z%[[BG+]A>C_4PLV[>6C[O'ROC]:;=F!V] "@E&[-/5
MBM;(;M;KALRCI<Q^$W"U_O=0G DW(?[RDIRR+1CEYM[&O4TGW[E:2 F]C[^G
MH+OU_+$=F&+U++=,I+C+6XDW<I*$MF CRQ2<0EO,G.&KE=G!W.9>6,C*TQ5W
ME9GFHCW)0!TFEU>:56$(FUX*B94UZ479K:JF8ZI19:KL0*5)IGX+/E-CQ8^_
M]:L336%L#7A:#:C'L>@MULS.@.27%F%R::$>!9.TJ@_@V63]8O!UH3 _0Z@T
MG:GB;-;,0YYD_S09TF3\"?\4M#6;LNN;EM41EM"6X*!=9&_KYH*VM@6]JJSO
MW.W6>=Z6#>V*\*BNR6=K6L\"OS05,\[G3'>:=XUPB=(959KU5=FNABWXVU>6
MA%?H@GF;Q!<C1U-8@VG1I42>2@OK-SU?-H-L]RIOVSW^R.2FP6X?[)&\*%H9
M.%-I=07RD/D.YY V5KQ"88<5"FK>.,,\K_UX\W!MNLVP53IEA.09=K IRI4L
M7 F?5_U VVL?$DRH1;D&B:@E1^Z"HW7L#*%);7_R:ON?F[*2TQZRQH<*V'DK
M+6BUNU5;+D61;QO^39^7E=7-)&K&<2-/J^#=S@BEL^JPT[J&Q/S,:A2"]1WT
MP:.'#_Z?"T'W] V-!5^8E=DN29R"<-#K(1;Y/N*2G'N2E77,0* ,?04E55AR
MZT!3,B^Z$!"3P$-9Y:PU\X[OY"XJ=L5&BKPWT8Y"/RKU-NY"5\F%B5J&#[_^
MI@OU';2PTSXV4]=?W]1]G#@R13.?@+:X20YABFK:@0[GSY;8' ?W1<#>_5)=
MG63HDJ&[VST][3)2G#V4INC1AGP^]A]%I5K5/Z5-V<B(D^LI[:U^YF_E*@AM
M* @AC;W+^TFZT.3TF65><1C4;8SI,[#'(YPI.[<X,1=L7,Y+P_:LH<MP@-"2
MJRF&PI93,N[AXTACNQUJLCML]CC(PAK)?)&'7ANV>25.3[G>9YUIS\N5]9<W
M^3G,*=U#C1TRK&*HEV:35^O0--F<;87GY'*/7"OXK@UPR'EN:%-[+MYW/4:H
MAK;54C\^8+]ZL:%[TV[S0N"Y[VEK>$'8#/H$K:<5Q_VB[/@C9&(E#ZS.-P=:
M$AAN\U_)C/>.-]HM4#+2;6>OBL@/L2FM*6\E"'$;XYYFD4G[@7C_=&#)^3$M
M'3CZ7;?:F&* *]7*,]AWA!710:4M:VKU/;:FITL-&*+<NC.5Y<4YGX9=OO>!
MW"@4U<>PI^UZA\JZ#I/^F'NBM3M/4=!FH\,&.\3>%?Z/9.XD>[7F'Z!8.CQV
M<"KQD!0:\8N1.PP[ND?0C*$RV#>D&/#E;D4GFX/"IGV+VRU-N/$7>L']5&"&
MW<BK3C,+="HIT--WU-B"A 9IR0XE.W3' 5>8G;'R&]29Z.E,6TL.8=J4.,6D
MBCE2#X$NQ657ALZ^J&&S)F$BX>2;(I8BNX%B5X^[_C8T5IR\&+/E.*</NYP/
M_:T85OW\VB);(3K8JQTH2[M(-&R=M2;($7;#\E=.JC59;<Y(K7.0LT *:J^]
M7+HR?,3]C!4@S2(I%ZB6H48"R^K1;$V1H)@#:"7ZY!(:T:HW^KRDH:S:I8\4
MKE?-/OQ%62%GA@KCI,7K?(U3<HQV+;EX%[(2?3WZUDF!UJ*[8$>M95H;(^Z&
M<R^X*DJ'2_--67-N6EVSNSNO;SEE>-U*Y?6K9G5G@);(5D.N+3H=YEKL%MV6
M?0YUF7SX&SVZ6O#QG9 Z1">)YKW< XDSQ:U^>B]6W_8RDD9U?ED96CFOWY,B
M3XK\K@.*"HS'9QL<YZ)A7Q4GE512K)1%XO!S6W*90Q+"+@EMZP8B<_1WZQLO
M^$*CY)1J>'+@!E'77D8/'5:Q*_!^-"VE<GW=KT-;LOH]5+)2]N ,FZ[?Y=O[
MILDVM-TLT?0SZ5]6A?6>([!R-51YZS3.+PT[J5P<: ._GWU^?,?NG-LWK'%I
M^@M\X,#^=0.W=UB-8<./N3V^7WHD9<J.+%,VMYTOMP9/=);]M6TNR(EZWFQW
M.,M<\2<-5)$)_]E)D/WK&Q;+U OWD=UMZ"1:L.395]\8^V[.Y-VL9/?ES\4W
M0?7ROX?MCE0E^3(H[7T[=(AT.[RFMA]V'?H7H7+H:X^SS^SE__NG;]_@+_9Z
MGR^T>LBJB9V?%:VF1V#/(7^?G[$_E=?L^[-;1JYMW96<Y%>O;\T!]G97[5U.
MIZ:'I]\B-]3%17,V%WE;=#Z?1)_A1F+413J^U_0VP%(49#7VHC>+9F=+#5/7
M#Y)&WJH9+H[#ZA2LE;'TW;"LRI6DJ]KR''ZMW! N(JY*SN:FZ4QPZ8MFJ(H@
MTY/OZ.&QO(,+<*:$%V$JNK/$4?DYZE)D'SK#*32VG"7"'R-57+&^U]A$5Z9O
MS1IEG0LC_K98J3!N8=.<^YR.=@PTLH_7N1=G<K@JK3OF=RFJ9T^_O?+CE923
M^K#J@]_UBO&>Q)6[1'CH:++3(P%/S5G)<<GRRT56KNF";9]S]-56)?U1>RZ:
M%?DE"[@GU< .'WV4"YPKI ISI\3(@SKCT(E.?,NI@W5)/SDEAIY\L^;,)-WD
M9R0F'SU>/G@<:+<WAFXEK1(OWTEFSFJT1U\_^2+[#!^R]PL_$6@V3D9* 9=V
MHN-$M:G1EZ'!\I\>G3Q\EBUM#VR+AT&/K59(Z4S7_!G_D34:DO$&>% =[22%
M6?;6@>3VX =<$%8',IWWFS"75=<$IZU3E\4[_6.C&9\WG)SPQ&@J>Z^=38.3
MI&SVRBP0&7?FVN)+C5""KMA>(H'N3H?VU4J<#:%6>35J V.3P1U,M+RYE=G&
M39MRL9\_O*%DN2;NP]4%>1C6]T@T-1)+R9S/ _TG"CE-+:./V<94W$&/O^=K
M$O>2K2N9M I>B8C2XZ?AL.R6M-;02GZ?4S1Y1R;+^C%%'M1%D-DC'8+59K\-
MY. 84D.HM'@)5]D>W?'1P_".02?_%G4>9"#KOMJ+[V)$4?%-6(;QO!_S\9\]
M_'B/GUKQ/VXK_M/4BO_)M>)G9?%__J/\%VW!]LF]"M!?T8JS)U/CA\>][I/L
M?U"R*7M)ZT%ATB^BY^!70H_WKR?_(DU6Z4?ID[\%WZ27=>^>W3Y*]B*PI:?<
M&?Q#WKXU??9SV;V=5=N7CTM\<?+DR]O)\=U3_)VC28(>NZ'[.T=8;UX^S]JA
M,G;HX&RHN)[9<>?H98ZO\W;[J-U("XSLR)0U%^(XB^$^L]Q+@@.RGP:K?Y\Q
M^^+^&;,O[I]"/\F>-_6T[?KB7US@;ZJ.Q(?;X0JH^_MHMO@I6 N\=L^1VK-3
MT>E6P!9>RCR39M:\XP3)FSJ8=VHWKO]8U[(D1^.Q'(,$'<UF'(L,79(!W>9E
MS:E"F_\,QC-7H=QXP[2X)!-ZS43[DR]&67;ZQ>><NN^R1T_R!X^>?F8^Y]L^
M>EKHOUQ-J# 8-M(.PII7RG^;]!0E^:H/Y=<IKJB?[ER7TL[<#<MMV0>5@^@I
MR./\K/P<B3ZTGQ<+V[R.'[MA"_RW?[NV.!V51?E2;QITMG49FG6E:=ANW<OG
M?CS*N]-X)OGILY+NG:]6PW:0#DKI8+3][_*P2/'Y>:NPNL)M\3)AS$.Q]*9<
M7.U_[SL8F_6Z7"$SFO,D6]O0AW3JBRNKTA"]I]>QXGHK"B)G.?>L^>WWITEF
M1OW2>!?/:MHP6^ZK][,G#OEP>K-(D&_HSA>FJOPQX,3J3DI#"RXXV_BAJ:M]
M.*R+L=;6]O3EJTUISC6#6[99PZ7-\ESW/=[(K#9XT0+PA^HL3R;W?HZ-NPO5
M &E2F)O_EZ8F">FU.XEV:5/NN.&OZ3JN^,P\LFS7U<)X(!'VV:_[V'K=X/''
M;VHA)7ANB^2>)CHHX4S>U*'2PW/UX=K0Z;*#R-*_Y$KJM<ZL--?;B,\.ZX#S
MRF1:P#^? KAYO @KG-H<BC:%%;I3@V#T?R273@=$VEU.LF_].(#T:CD/9?%[
M=TYZ &@O&-RG$!&ZYDXQ$H_O7,CM</_$@9%&U]RWF_'DSKTRPL?@D22?_@.=
MW^=^BN95K<,"SZW&0G/X=TXP7(]9\NL_42DZFLTX%CF:VU*9_V U3XY3" M,
M!J*T<K0*Y<@;&)^E#0K<6B>>@<7TG7%!Z[?@QG!K=QNCINRSJGQKI,'MX N+
M]UMDRO[^$>KI7Z9Z^IW5T[^ZL4/(*7"$%/\JRWM5A'A]^O,OV:M7EDK]IU_^
M]O+^Y>I_SE[]^-U//_]P^LNKGWX\5GT55JND7/7H7IT4+E<]NG^'XR3[WIR1
MG46V?+IJ]>A?%3[Q+P6C)5-\+RM6NO14I$JN^(VX+M_Q2# 2O^B;I?\*O@./
M9G.?N^*><,[*(A"R9&6!9$FJM\K+K9N-*#L'=L&#PAA=7/$(B,V9N>Y/CS[-
M+<.VXX*G KEA->?$'OOCT13BP3I.*,I&CK?2U!S??>CQ($" [,LSR0PB"<OQ
M /TW+\AUQV*W.\RPTU\'S#2N\D&66IBUXS3I3-]7DG!E9)-%5I3XMF8;H^RQ
M0ADN,$$OO5(R1E+V>Z!S[X:>UT(/L,G;K>1T0V3'3SER^.,HHCO;BL 2YO\B
M:7S[+SU7]] _.3TT\>ILY??1II]P<V3VW4C.[P&F-"WCT=.$*?TI.PK73Q"?
M6KX:6U_LR)!Y8*QH8J24@O)0^5YI!ZB6"T)!88!!@V]#6YUD_U\S@+,&@Z<K
MNNYZJ'ATI>Y*6QK#Y[H !W5IJN:"Z\%<@%544#&J8?&=W9*)@MBX&CW4.?U#
M<-)P6CJ>F)G!LI82E12^:P?@8[L6?IB &$4'T-!UEE/HE%R!/5"7:0=\U> Y
MW5F&C_&9GSU@LU))TGZX=H>ES,2BX,W/<+$Q_.RHNBHNW2+;-!7#MG78(GUC
MFGD-WYC@!?$(),,\R%3TWCI5DUL/_XXNSNY,Z. M@EU;V>=9A.C3C7N8A1TB
MLWAAO(__A07S0=JU0.;! +;X9X<XSQB:%ICG('>KR#>8:L8!SFT5EC;L@OS%
M!U73O-7A7_M2+? =8Q#-'1E]];BNNLV,$K<>>]7Q<;:'F)86;JC#]/;[RO!U
M0=T^W%8_:KU%R[VT<K!'V^&YZ7J?_>?GNKCH\GYZF:0^^@N&S( @IWO$.S(L
M,1'-8FLS]0Y'J"M)A^38CK[L,5H77:VTQ=^/!2],$HU&F,(7_(-^'N9IL,7R
MYW242Y&MS[A[A[M7T,6SP(VU0*"D.;[I![>)ERE?NEM?_"/7[([$.S_B[;N&
MW_!!F_CXX;-[X3=\Q"0N],'/W%N$2EV3G9(UR;._Y=SA\RU@@TY7?FCB]9KN
MUZ9#G [QD6-M\RD&^5E^<'H7V:MZ=>*MS"-7AF8O#]_T/B!_7=%EX#W87!%@
ML30?A9ZI -61_**S-I=\4> 2G?QGDII;DIH4,EZ7ANA0!$1$@&) RP: =-D'
M< 1E'TL$^<8L+X'H<&:6X5<N*)*I]@^:"X9\)B^5@AXDF>E+<A?O'].+E^A-
MFAH;QDU= <:/49'"N._[UT^>TCJ_?_WETZ_YKM^_?O0%.8KL\@:+N>!HC[&-
M95UDVS:FVC&0,B"(T"%2 0)ID!0U13C]7MMLQ11B,6YENBIRZD^#%D^_<7(3
MQ@)!!-=ECY^<//JSC;6;H7>PA#X*OQK)86%;+]&2RY1+%IG#(Q &R+0Y^=OZ
MZU,+&,N[K)B+P*<&2HZ^94'K:;3W69QVP?;63;+=.Q^X5XL(P\0V%M,=0CC4
M*-[EF&4^2R%M^J1S+VHM16"_+WDX(,'/:>@./=2E*O.F#52[=!P)<695XCM\
M;@54S/2E18F$.$Q=F*%A<W32.MA>!\*H4))VD:85_%R!,M+?;B'IM"&&P;W5
M@OE.IC53;VU:!M2$>+6V*?P]MF^!8)'>*8(Q?)#SA_Q""K/. 5R)1 Q^LZRT
M*N.PR+^7%^W/&.]7+8F<J4=>N!>,*\H*%S9=(?"\J#'A%C9%,5?[X80"\U8I
M_!IO?Z@X-$H6L)+  *=R3?(*CF$;C]TK.!UG$97^ J-&Z ME0-MQP.B L.0K
MX0?4V'_J!_WCQ>0W'2#>CR/]<7,<G20Y9,0)XTG?EUNN'&B:GH[JWYC'C(R_
M3^Z_;CJ?V_\1&'W?D6TY+21#CNQ_OH.&^M3/]AW5_HYDRX[C=%_?*-JH*L_(
M>4*OO)STQIWTC3WI&BCQIQW+4-5T@ /O2JXJ<2\]J&:M&*#4P!-\Q@V_:ASA
M77V^5D3IIQ>U9034P<B_Y6$Q(0QT8(0@I&B5Z+8W["1:,+VFM4U/Y.K1,_/7
MFW:AP)\RF>C_R$ZB:Y=2!%H'63AT'$>5?<K,I-+]G8_1<R!(8M.TNT8P:NEL
M_G=>#X@\'S]\_#"2U:LD6T9&);#:-P.WTT5LO;ZU3](+4LF5P5U?Z^4 "U\)
MF,[:<BM#S.MF-2@=5M.>Y77Y;YO+(,%:KVTQ5)&:%O,T.+Z[<.'7M:OR&N5-
M^EY>=IP6$5.+7- #R30(,>ID9D*"6:5?(Y$O*4+6!4U_ Z7$=5.539AQ8<A4
M8=P6U5?0&Z0=;J5)HAMV7"A5I89JM]NZ$YNHXC%P#'(K95EQF-]:H/M"X8WW
MV8JD@<E4@SU:X%TJ]:PB7E^1)!MEQ_+6-7O2:7:W8(!M?2T=H%A]2L[2R15F
M2X_3MPH8$,;>&*EB;;P]:#S K9$_Y%Q5+]0VYK=!ND5-S5C>=O;90\7J"I=E
MLT./ LG>(+RSI%!(7<-B^6<<K67)VERQPR "##EPS@//PFXVWG1:]8!*^-"*
ME3GX2,8D3MLM/27WDP"<5H?16BYBX\7GZ#MH"]\ 6S3 JXVXG1;*^,:7[W*+
MS,!= 9(!="+@< +V@GP[K/#/]5#YY;D5E?_FLR;<2(7MVKAP.551#IZ]W"9R
M69KL$>C1@-$)SIK#!7Y.K]R^KH5NCBE*3=$(P3CS/QYP_4:FEEF(!C'CW.NS
M5Z!ZL$JM9:4%MQ>)UI(9<7U@1H9@";!Z)7QR_.[PG+@D;;+H=^.0IXE#.W'X
M+$T<IM&1NSV#KZ+FSUEM&3ECY(F@V9.4;]@.:J<MRCY#,:2L.M]V1A<:=NNV
MP<B%N&C*F%?V@B\#CS"(!+D#S0'V[!HLM@Q6X\TOAY5K,)-PHM_Y(63LR#CA
MAQCJQ:(D@>Y!/.B">7V%3"%G D$*9#D"[/*UZ?<2*L*JG\UY#UB^!IW>_M#V
MG)>X3N@O^?J#?-DX(AKG0>25M-8Z#\N&N444Y_:6YDM]_LM#ZWG'VDVL3'%G
MLB]9GS5*E.S\UE-X M*KN0CQ58.0VSW"=7(&HSCFA%-H_)Y 3T&^<=UONAE<
M@ OC<;!R<HTDCP _X4]?GWQIL>OCDFST;?8OZ@CT"A _JY(1Q?[T]-')5^XJ
M][<^=#0:\6BV*V4G/FIV0KD:E4KV=V3YG$JS5^2P6;\FEVR9/8AG!/XR.OQ%
M>3XU>_/%R=/'7TT,WQ1EMZOR_5_6E7D7OM8OIU\K2%;+]=X^.7_M 5.:?<,O
M[P$&FKJ_@) 8WYT>QG%[2(MZ<C58^7&_^VA'W7:6-6\=[^I[W>22#0[W[=G3
MQX^>??7E%U\_?O+LBV>/G_Z9O<-WT.G./PQ.0KRL^[7!__%_8WF"OV:;\:^5
M+_/I$$TOX,<PP]/U]&?3?>/M"&V=_G\2J212GZ!(*03KJQ]?.(YV"2Q&*:^U
M,C;I&+N I6I"ZR"[^DV2GZ-XO4E^;EY^T'<8Y*8U$A:!F4R4Z\1:E+NU3<."
M9!N)GD4]3C)U'*\\R=2-RY2K0H+-!@6@12AA->-<DVPL!TV9K-N<_CW8XE10
MQ@S*5EH5E2H8NX-VH#BOFIK;)70.TQ:H^$,<Q?E*RI2U8U&7\K%V3\S7U[C[
M@M3"-UAGDNBC.'!)HF]<HC=HR<]])^#.M%U3UT8SQD-9%3$0:0 XY*,V'?[V
M65D&-%AD:*]"V5_2MPRCM(B$#U/M^;L']IMNH"+ONF95YI8XP-$S6-*LJN0J
M+?_-V&%LTBM.$3$75\#(#00EBB?[1@E(%3V\K"W"-^WTMAR48D!"6/VLLG([
MY'J!9$I6_SB.<-(1-ZXCQ&@ND.PD>5@X8:3? .UD9;DS9"#M&LU)R<8>S^M-
M\G/S\J.#B=R<I-;$]BC-2,$Q-T_<^7ZFZM@-0.4WMCU 6)N@XX-:N;2?DVQ+
M=D3Z>D=];:CZ0^%+UB1J<7,M!9Q@<4WQ<?F?FP: !U5VTC.A_AN/B3)]5=!&
M2+?/,VE?;-9N!C1N0HSK"O,]@VR\#FH-GM;GL$55+*(P/!WV6OA&VHF05#HF
M@]AW'$)COE1^WOM]>X] UF&;,NN3[Y9%(R6CHW*'+#\>-_1*PRMJE3$\JA]B
M"%[Y^),9.P1X==H)632+J?$'?;L!)E3X[DW-,\ \)#PQ^W"2?>MA4O$T]4"G
M"P"Q<UVZX_#A6DU#KDUDJ.UTA>W[K%SGJ"4PXW83B@^V: '&NFS)M_!=*OS.
M3,UML^5ZX49,@O&-F>=]&6[HAPV$-*VO0D=?1$]O;HDL9&0\%R0J\GI*;9Y'
MN](@,]V7J07M@RT,[4XG,'AHSS?!V#:LG-8O\%%,0)?M>/P9S?'&M\:+HSG"
M=G,,?9=6%<UZ#4([!YB[WL\(,9Z;SZTK73;1T,!)=@J$.]@%*T23CR:/Q3.C
M<D8QJ$"/!)H] 5YK.6>%[^W%-[;M;*F]-\W;'=>\':NGVBC0B>V+#-)#MC62
M#KA@+8[%9J%F*M1,YZ1,9,8MZETD];,52 68A(H,UW=>ZZA]8S!$/TM@;\]P
MA5BG*?A.$H6*GU 8BA06,C> B^,VM%0R0A9S9&38)]0'0R]PSBI0"&F^+OGH
M1]+!AN/KW(RPWRP06W'^5DCF\L"+>$)ANRP[OAA00UMJX#4+N^4@@)O<P1;U
MRTU@E81VE1V$0V]:D/L//>_ UNO\G;0Z+_?9IN3:T%1V6KP4MP6LM^8V8<Z-
MGRGTCL;7?/>Q/HGT_HG!%Y?&WG=I]HT\$>VXA9H1C_7O)V_0,=P(2^N+=CC+
M3H,I/ <?^MV+4R4!=AHH=/&'?M,H#&D<'.GHTB7+YHA)=Y+18CEE;T>? PX$
M-Q<],Y#EFJ5S]ZS3'96AV4#&_, K]_.>4YF1[+NAQ0-L&_1;BC.L5N&PJN^Z
M8*:BM8NP\_.PVW.JJWPN0EL$<V]AK?-^48'>N29+UN$&\&XFAP<X5,F[S8+_
M/X/2('$Q%DV\(WW2/X"+%,0ERHS[IZ^_/'GDAQ/^"057(1!=(%+4D>F@\<R+
M,XS*PE/QFG=:F/N A6B\W THV)5&\.'6@[48?L9[+7YD19I8@O2:7F?VZ+%.
M9IQD?VLND)-8A%_4M;(/J47$W,^-*-7*W@%->RTYU(!I8T4Z=*X;7!(?HD&X
M_2A0@5@SF9RFJ1E5'NS<8GH7#@--%6##A,CG/!A$N]3O!<ULV5MX\_H,[0_H
MAG@@X[JX]D0F*6K&T&%?+88&V/5B)>CXDH_>."]>1I3.:#ED1+G8*N_)CZS'
M%]2>*E+>2SC;BJJHZ2(HZ7Q%/R<UF=3DG4\3\D'E9+5/R5EOZNJPUZ(E1/ 3
M@1X2?YG1+./&BL GCGSA.)DZ-_H?*5J1M=DFWX7W_BZ05QNM6CVU\<!<Y.Q=
MQ]U2M(0/]+H.YO\G_3![X7&SV6+4/W;@CX4I5#5;SH/UQN3^SLJE$?9KC[!_
ME4;8/S72L?MU JWU&$]J- YY)'9'.U?;&3N1]DKE6E6AY[GIN'2USL_)AQ,\
M,8=- I5'BAB:-_#K+#N,*W>@3G-X*XM;9#.C6!;75L28!%2$EJVE)&\UW]/[
M?T#_B1)+/C6L@+B.[7P.#Y?+BVC,U5'TQ:CG=SSX<JE=O%_>YS$(^-%LQK&+
M^&D<Z$%@/J@"<AI'GXACG__TCU<O'CSZ.D.>U&P1D=6%PYGN\[>&P] .Q%@,
M2TT/FW-4:;*SJEE"EE&[ULDP!PHJ"J03_>#1E9#3Z]$TFYTW:'AEB53WJAUV
M&AY>TOI;E>1*%_9;]M:R UJYANI!"1\_K '+NS*+S- _&CR>$',M*,8VVUW5
M[(7GU#NV[H.=+YB_DKW2>#FXL7W*PH"KBC'I!/K*! XR7I/3G(N,OZ8,6U H
MOO[$43@*QW(?%X]G6R9$*^%7,N $_QM93RFPZY^K 2 ?O-H+!V8OM>\I)5^'
M:0_I-.@"VER$%(AB - !U<LQ!Q8S!L^8<+5ME5Q[2A "3="I>;-D2<]BG+U[
MY"/<N89(]>N;KE__K)[*A"A!XIE^0-MV@BQ6UT$]+/=9V8GTC')NG6=^XRPA
M]WB(*$LAQ>'S@P&"G!J)XG4MDO6S";[*U(6-5J<3:7P/$C8*9-4I"E(+#',8
M5GW0U%6#QH1I#'>DP)GA06 CDW2F3-M=EZLOBV&L4.3CI+&FP<74Q'EPT&U*
M^OL@'^X#&^3$E4RDTUKMU1GLD^R71ER(=SU7&;0P.FN=[?*9JP2 6+1RKSIH
M%Q BE?#R1FID(6U@GO"$1ZN F&&+':Q=$.M8OE?V$WDSE>I2G2P'"F;!5 WM
MC^$GE3[+<92U#RA2N- 1*"YA8M7JKC*QXL@O:2F<Y)1>/W5. 3GM.A[7Y3L
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MF@>VC:9G%-J4TC3--*J.3L22/FA#1[1E$HE):&(O8#W3B1$Q_B"N-6JJ.+R
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MCVA^CZD<JG'1O?,58A>8)<ZNXWFQ27)N7'*8^7+*+N5UC%,..V6:';A0-J
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M"WNV^%%L&@.-7+039(+"-PM/&!:M@C3W.>VX5'CM.> 45R&C-H*C58B8K^E
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M&[JL!@Y$ABR;9K&T0CP AGW/5V6P;GM%+ JL1M[C%!H5YBVB!V.XKH"]:/2
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M7LE-*Y,7'8,BG&-+'6T"O3\!!46V<8(_F[:T:^K:5'8T77#3JKUB-M)3G1E
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M+#0Q0>%J9:CU]@RFMARO7IU629W#5#:'4')VG&[4&<1;'W<:S,*6KQ:TX*T
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MJ1%M*_ABEDF-'Q7:!&"[KQ0H*K!13C:E/#% 0M"BH>V:N@X'AT<>B!Q=M03
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MSDFP2"8CR^U%R),G&?#MT?;:VP#J7UCB% D\7[VHE;P ,4*>U6<*D7&&<KI
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MG(^>0Y9'8Q'APXX_SCL'U+TT<R#D%!%*Q5(X;76K$LAM"#_0\&O])SQ0V+?
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M*G+<&_PU4\TV&RE224/S2->HQ4J.YF: N(V"*^X9997+#%F7.&?MV SP*0^
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MHSSC0U!32 )6'?E/6R9>"UML9Q3_;> )I!B%K*VXS>/?Z+P@J#I?3DR,<N#
M3W&7IL=L!4"K \O\;8N86&@:Y0MH!14@AG--X5C,OGGX+((Y"?:[<[-YS50.
MH95)K>(TNK#J>&+;!-X65&VX9Z"U4^E^2VGU)'2@##A0OAS$HW'RQZ09[B3L
M:,)+?4PQHLI,<$#M<P++D&4N>3Y]BY_)(@O>QJ]M"H-N0+S2NE;;U($B[0P(
M\;&<',]JF"/,21$Q0G-5*N]"ZB+Q2!S$EM8P80L,OW'/9^7'K(L&7$3GLV3D
M[?4/CI9N4_'?=RSG0[_D\OE!3^6F/\-R8)NM0QW(!(AT-&+.X?92WJ#$.59O
M_0.@YM9OM2^\U>*CU-4J"0IIE7$UO:EY(0A50'7NXPN,_&8<5W.#I_0S8:TP
M\@#3@8!7+\O?:PY];.]).1"^=I\!9LJN:S;2US&L56\4M4Q[H#E6RJCDL@I2
MO9=,!2,9LEI)Y(W(!&A%H[;(_XJ-6LOJ$M)>NN%-6QY12W]F#@[SBHRJ#M&#
M&24R !T5;%HBFA(8F,HW[:M3AL_>A\,)9#GM+(^%4C$PB&=Q1A9GY)'GU%&;
MT#E')T35[0=]<G),#(".?%+2.A;82YFZQ-F>ZH%E[6;.%U$.ZXN2&-&Y7VZ1
MUF9B*;%? \:.U$"GB$B+ZNHH%KIBK-7V$CL\V%X6@Y,H"QS*(X=G_!<*')"Z
M=_PPB-X A(I<4M,GD7?.(N+%$U?YEM'97K<8Q"4;B60ZC^S0='U"OJ 7@_R<
M, 'R::U:BWPG7>W4TYO<K!B?P[;Z:.42J;U&@HL]V4IA%#LV$^Y;2Z[6@!W-
M&<$..!9&X[1"2TZGX^'229)3\MGLD]!LR9DG&5J[NQ00K&?/,>?,,\MJQ7SC
M9I5!?>*&+6CZI3_E"?6G?);7FZ)JW(Q+,*BNS>J)D*6.N#*U5<+ -$8Z-AJN
MM,:'%+A363'U/U>Q8-DOB^?Q8V%7<#KXO*D'H"1+5D(?]1HS\R3$W075L1$C
M;;_Z2DFQ2/A.0YLC>$F8<QYQ[)+)ZGQ2R=2(;737J=M)FF9ZGPMO*1W$$GO%
M5,U\+\JD!V(-*LQ_<+U#Y>I8R,S<[9M#D'/=P4D-5^LU3B2QH_#9AS2M1-Q;
M[%GQ1*#LS[A'2@BH(<4DHOI8_>:B,$/4O?>*6>#NGW/;!_>>$CVB D5B=PG\
MG31K/_^3WM.=8P,:]>C$*Q7#,0Z&D)[-5>#EXGD<O*-#I4-R2K,'3C0'..CQ
M\I,O?_ A6"E?/E^Q<?S31^__Z;UWPKOOO/?N\]5W U[<X2O+.LIV@W;T'XTM
M]["9(IM,FN,N'(J8\'ECO/E/AVUK8?]G@&Z[!QACMF<@/Y)#K2/"$T 9 8+D
M:1GEQ\VZ>=382L7*05]-?2FGLD2NNN<7=Y $8I"T]>!&X,?<#O*:QG7XVK+
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M*>K+8/;,C1-N^!]CUWZ*UL,2%2V9AE^H]V/>&\8.B^9%RP9#1BVK/$@OI#O
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MBI@(TS\:1E)/X=Q7B@Y:5Q V0,[3+Q],><PA]LRF?_VZ)FF0-!M^'#W#$_)
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MVU<N*MW.T6A&/0_7=B^\^ :4$Q88HU1O4MD1\*5"*:=YW[@-!3-$'>A7_ 8
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MC>"MH['R/H;:'F&=^K$ZW.WC^X2X0?>"K:_%:W!C:]O6:+ZAMV0OQW>B9C:
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M]^[U(( 1XWUMC/?3B/'^U*&7]W[(8O1T!T,&;)QC$Y8V;-CM,LSI;]OF&%\
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M)L[I3$."T\D4%E0]*GK1.3,$AZQ>Y*V29LS50'SP<^Q[# DE!=MXG65 H+G
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ME4)Y]XNRAVTAS4+Y9NG^1B&EH_G33H&WBASNVRDB8L;KV$:,C9W>)CV^]*+
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M*&>ZS2<S=D1*S$0W_+72$56A ,2;DD $$LI M!!K#-Z$<L 4O$'7(;N+ 15
M-&>*@\;E^H[UK 9\G%?I2,B;M3*:CJ6BZ>,OLC_M+Z. C.X1%E!-<PS7/+![
M3YJ'D2JL#-!XNQT:26G82R3EA1U*JD2"13:#T&&Q<D7E_-;Q'LO!(B>7 0'O
MBB( 61/-NS%UM=E /$+WQ8RZ_$^M#S3?3U1RL%UZ3IJ>%93)9C#V/S*>0IJG
M;MF:*]H[S;>Q<@4KC_S%@HI5?SKB,Y=/812%*9UE>;[VQ0:>P]$;R[5TP:P&
M:_\S8VT2,D;[IEB3A#>)F#<FKV#R6\K%+]3QV6?PHN'?NO/,M7 ^I<&@_\H8
M%-D0S8>D&37&*S<+',T]H103BSOW@4F5,IN!QF"P]QF#:2[M,; A*3Z-O2HT
M-NBTA ]"P!1%W#PMT6?);VNYA+LMUSW-6"[D0C0;$O%I+%<VW@*H%PI7J,'!
MF#(AT('UK&_@T.B_<\^QF9 W?_A<K3!F;7&5#:U486*P>#<GBA(70^)RB"Y
MNTKIHGX@06$8+='%-9YQI38]$RP8PG[E:MX3S*4#S<-BOHY#R#O7RF_DA7(:
M,)"-I"5LR2/P)9HQV> <[#QI#%[%2<8V!',.IH,8T*5NG_YL(368]#P[!".?
MMF9$TIP:^U6PWXXH=ZX1=]$;+/FV7)B[,6<%<]XLEHZWPAK]Q%P0<<OL)8?,
M8+QW&>,E/$C$I#'9T<(,!P@W% P[=+-!IN)1!_(F^M7X3\<#PYB"2[L/%$(&
M!B#L%7\B;X)"&AR4G&'E1I;2%B]&:K!MX5!48\<#QJ3RS;B#TF#%HO&IQHB'
M#E3MZ()WD.\VYUG1H%5CSN>,7N4WVGU8&6"P5R3K!YF)9#5PJ0B70C&I?'B4
MR6J PSY!K<;TAP]N[?*^=V4PF+EXH*LQZN$WBV[KY$T9#$8M&?-J+'O<;3D]
MV]9B4R>UAS[<'EMQR\Y.E@9T9(-JQ;;SX! 0%YL^#I#L]6T =+3H2VD0'8"M
M 4A[A>P:,+T@F)*C!#WX;G,\"__ 1LSR!<<#6#=/EN/;S+X5W@)] #^HV/[T
MA@H7^,@!$R,0C>T/P(.+8@!M-KQ8"K3I,Q!I@4DB,8E$)E.0F:2$QDR1V 3D
M)EKP!O$'#5K&L,.*I^Y*QI<^]*1D2@Z9Y8&5_V1V3\4,UG!\S (,Z"P>(%W#
M;2@)S,*3&RX"84@B#:$JS:U!W0%#K$E?EY.X!5R5^1@P5#@\N][U;0GA-B@Y
M'$K,/MP>^7>CXCP;Y=UF\7R_[,<&"D?I,#Y3A7X#_!K/<RFK]!Z%F1I DXT)
M%^E*HM+QMYJSIFMYKN6AV/YYB;M<]<K,#/C)"2+G+RVMX6?;\E.#EXH+"CD&
M+#,4E<YO0$4VYKS-XLU05(>ER#)8.7P!!C#EQ;KWV8#?!*;J ;HD+G0UI^Z,
MR3NW$A\TVD% >E"!#*#.ANCW!G4Z<!4J0+B[+]^F31S]W$KIP/_^7 WHS,;]
M2YQW:?K7E]DPDG1?(R8>N(61]9R)P<&Y&K"4#<>7V&:RWJM%$C0SAOTC%MCK
M3S9WE)0*7Y7G8$!*-C2^=:=*T\4\#R"2:#4F]Y?:Q'@3N/9V2N"B"",#/'*B
MWMOAD8Y[:U<G*))$939 .1)0?F5XQSJS>^!TTAG[65!7V50E"VVXXVF#J">E
MO]#VD5^![]B+;NA,<N'-5IJ@)-R.+LYNT+[-"<H7 FTD$@EE(EKRMKXH/UGB
MDP2DS]*F%""H 5$>B75(KQ#J"[P".LT?2)MV<=!V$7HJ*2]J%UFRE'OKB9[C
M!+.QWB.(@C@=,KSWFMEW+@;]-VY]*]8PGE$>0\O(67G8UC)":3:]01-Y:F$<
M' 1"'2>:W@8:Z.EOI -.E?521MGK[9KV<O!-L^7"D=78&-!9_N[4QB%]@1MX
M1_YR&;RJ0IWHCL-4[0\9CG@P@NO;:[?-@X]8D@%EV762,C?TID5*KF%<0U\H
M%CH @6 -'I\-C^D;>H^/R7*E&7!9]GC!#ERNW23<8/,%L5GD3O&C759N0ES>
M>L@Q[BIOD'60VU]*+UF49&% 2W9](N?6F/];G^Q#9^,=HO##VFM%^JVB\$4Z
M;3!\>^5W]"(&E.OIW@(WQ^,2@-[JKN=XJ?W)_:EN9?><3KBC=\7W)E():JG@
M425\9N40O()'6?1C;!?P#7J .YB?H;(M(GT@XTH_\_>S\/QE1,B!I$6"WS"#
MXYX]UFQL/YC-@8C<<?!(W&5+"1]8T;# \-^=[56DWQ#L3[]*%NR_[D\ 2RXJ
M=?-DZ6574%CKTY\X?!;,'C?K9D\FM:L4?<PA<T"U)P2JHEO]*B$94-U0]20\
M##]M1."&; '5 6IAIX\2^-3!W86;U?CLQ=:NXC<TP#X1F]H0/*O-RBI$6G<%
M8Q/IQI&'B1(9:J=LN$LN.%#$1.@A)Y?8!AJ:J-)J+3P7QCJQVD.QX!%(M4NO
M*77T4UXZ[R3P^"];EF P_!;0]Y[-J /^97(@ZY8Q>>4+?&AD0VL#[:O3?<C@
M3^"F;E=Z&]$KU%8R*JPY&/":/3#'6R+9%H";B%^=]F/ZE%$R_/:*=!&,]J?]
MZ91;;(0O9\8*91,"K>(GC2]@**;/H=4.\:_91"4G.7L/, ] 3N!NC:C#P%$5
M"E<,KCRIHE,./<?!-T9A2''M$70X#HM2<#FN-X4^^#\ U+[+QG-08S:'/RRN
MEF<LL"X@LMED-X9VUTER)O,9#'"PPEY1Y4]QJJ%]7'RQ'"0:0%Z]"PM4M>:1
M QPFRJ0B2V<\<*44\;$JULK-=,KT$_?:3T131VKGI:3UPNT$SZ+3+NEU^(,%
MB[X#'P9-$!6-<P.S1]SZ&QU*7S,>$Q8&-&:)JONRV>SPET%:;:OG,WW"B"$,
M6@S=_X$NV%@;6W*M@2(4N^Z:Z^FQC!)LW1,6U3\_;VV:O-F5V:K@NF8# 1Y-
M3R8XQ^.7XAM+SOX;:ZP\PYJV)"A)RH'P+,9LB3=VW$GI8WWKRQ+ WEKUJ#Z*
M4M<&,\9AXLX%6.$PP(*_=VZIF4WE[+6I(7.KRNH8[J)Q9YMA3]!V,_+[A:GM
ME56:46VJK0"P0&KJ#/R)PZUH9,%)@=08T?'S 5UAF4G]E,CRW=1$SMM.A:HC
M)]_KJ9,O_F+"Q%JO&0PIV*$&4Q7/B1V7HM1K\<^ X&4GYY'@R71M4Z5T2EI\
M[BHV8^*EA\=PC4'"Y'((?__-I?)$\(QSH,<.@MJ@T=S%ISV7J)>^<X>IP.4N
MBIJZ-FF1@^:RUH+ZOD* V]"IY"EIRG%XI0_1X, @[!$W$ED6D[BI-3Z;A2LE
M\6JE@:J.$Y]]EP9OGL! 7.*2;#"_*[A6>*BER>KE?X_6@.YRRCAN\I$O9(]]
M)/@>+1*>%SE2;6_C_AW7Y+$!;"SF>ZS;D3_Y+[/4V+NAPEE%?>I > ]<<CSF
MHC^@<(&#>:C*+E]N[7QQ?:?7>.-Z.M?&75UXBN:!.DR_AAQ56#'J5[-*\JLG
MOF$KH4NN$O=]\VM=U#&[[.D;P*'I2\_A=@!JUT[? =Z?QA>,)D>A[KFKESAB
M<Q^*6_UVX.3?@O"9I7L' ]&FJV][V.760;'QHS>>>[Z$2<F(/4 Z8^Z]Y\Z"
MAHOS$7#N=80_JV_IO+6LAB^>^XN'$<1U#3.?:RE\.+B,O6@A(3797->G"&4M
M51QX4HV6#E?K^F0^UU-XP?)DW_A:2]&'#+M?2T776^D#LD&X\).OONI!G=GK
MBI7+4TNU1\"/R=[6:[[6%2Y*76=5UR7NNST9JJ,O.DAZ"?U 2*[ZE3C4LDI2
M0QKX+>-'2%SU718<$M\Q'I;/5W?U QW**&[,44N5\\;^5S#P7X<M+G2FPV4M
M_6C%:LR>U"<GM>A>D'A3414EO?2<?\CE-YP[?@54"3P6HZ)'IK.Z%J.MK:I[
M3:/&Z;7@0W"J,!FSU<5\A4L9_D1/Z8XV>.UQYEEKET'.(3G6%E]5KR\H4V7E
MN=6WNG*"6%LZGD*DM55TS!9+3U 1CM_YE]G&QVLSRE?._N(5$IR$E0#D!?WX
M/U!+ P04    "  "A*54Z$HK94T+   &E   %0   &QB<&@M,C R,C S,S%?
M8V%L+GAM;.5=;7/;-A+^WE_!4[^TTY,EV4G:>.IT9#O.:,:V/))]U_N4@2C(
MPA0D5("TI?[Z6U"OI  2U(L!)C.9V):PBWT6NPOL$@!__V,:4.\%<T%8>%%K
MG31K'@Y]-B3A\T7MJ5]O]Z\ZG=H?GW[X_5_UNG=]T[GW[O&KU_8C\H*OB? I
M$S''WD_]NY^]/R][M]XM"?\:((&]:^;' 0XCK^Z-HVARWFB\OKZ>#$<D%(S&
M$70H3GP6-+QZ?<'^BF,D/_>N482]\]/FZ6F]^1[^/;;>G[][=]X\/?GU[,-O
MOS2;Y\WF!AF;S#AY'D?>3_[/GJ2"OL,04SKS;DB(0I\@ZO67G?[;ZX3^B=>F
MU.M)*N'UL,#\!0]/YCPI(#BG2QA30<Z%/\8!NF5^(MY%;0//=,#I">//C=-F
M\ZRQHM*VD'_5E\WJ\J-ZZ[1^UCJ9BF'-@]$(1=*W02?+YM.M]J]G2>O6QX\?
M&\FWJZ:"J!H"VU;CS[O;?H*S#B,4@=9P[=,/GC=7!V<4]_#(DS^?>IT4$\K"
MYP%#?#@9(QZ@9%#E*#3/SEJ-"$U9R()90U(V^A&,K#2**Q8.<2CP\!)1V55_
MC'$DGD(4#TF$I2:2;L<<CRYJ=# 9UY<<I:)^+,LGFDWP14V08$)QK7%P6&M'
MN&)!0"(IF6B'0Y N D\"CR)82.4.8XJ[HYLX@J9W)"1!'-QB&,H-LFL<(4+%
M:9$*CMGGD=6U/7JK3T1WU)U@GOC9'$TPX7@,C2#>W#*QCXGLT8E5A5PA,;ZA
M[/50V/7\WLQ-^F/&HPCSH!.^8#$WPGX<!(C/NB/5EPL+-7>*?7MP0Q5W"+R6
M1/#;XUC9\K!Z*=O=D974@_^^KD5O^SZ/\; ;C3'_/)U(NUZ+KOK24#D'[L:M
MN:8?3T .V0C1S3FR$XX8]"1#8 ]3" [#1Y9,"^5-ZFWD<$NM)M.IA1F\2%D^
MHGY,$VW+=7JJ-9Y&&&:+U60@U7+T=9X432%<F_LIV1#WEV+!KUN2I=?'BQ8-
M(9U6<JM#5\&2?L19<%&+1?T9H<G7MA @SU7,.0B[TAY;-Y"3I1P3^/'Y[YB\
M()J,4G2%.)_!*/T'T1A6XHP/,;^H0?KTBF52 ;E4S8L%B,DF4@1$Y\-@$VL_
M8OY?8T9!4B&Q1#,5X >P5@SJ&";-*P3OEJ !H20"IX$!,P.[0;.R@8IAS;%=
MF*Q8#-;Z@&9H0'&E$,X=4XDJ[;+5 9,S4LE:ZS&]UEI!:[D,S<S/Y$S%0D5$
M<1J;W@87Z6/XG,S#21FI.WH2.*&H!KC\$")7*U\7BUU9'@/.<AJ\QB^8LHFT
MS^7JMW)HC2>']" O.<SN6>AG@H_3T,W MH>P($LD?D!DV FOT(3 4GW#<5=H
M3UU&:SPS2LO.F?ZK M+8FG-RC&J UD?C!\[ 5:/9 Z08$8"32DABU#VNR( :
M^JCOQT&<),E) 2)5M^R$D(\EU4M W1T]HND*^IG+T',F68GQ%I).W<*H KAR
M8A D6A,(M8MY%,PVP:M>W3J-M%3(_1Q,*)MA?(E#/"(50ZJWU>M%TGS%Q(:!
MOG,9C%G,Z<G"4@CCAG@($X;8B$& F?@DJ@9:,R/5+/FR1EH5I,:+ U6KLE@I
M2P.D\G$YX^DJJ$0H &(";X3$(,&X$$-6$UL-3".Q_$063%OU9FOQ@/S'W.!*
MT0!370"V)JIA 5$)P8S6&C2];65P*!I:$UI9WU1*K6II36Q3K\Y@*"1S 5"^
M'RL:VHL[FHJJ.@"I&UL.FKG1TF(L459 U=%$U=1>?-\J;:I#>;:9-8$+:I=*
MZ?-IRD/9?AA:IN"8$K$$H2,J5U82#=2NHK,73 SJA>I 4TQH,[SKRH*Z"*]I
M;S4<:<M\VLBDH["X2LLKZ6F6:SDD-DVJ7,U.9VBEN-B+=-J:G3K Z9K;3 ^*
MJW*Z=*&0TG9DTU;?\L*;CL@:F$RQ32E[NHTU44W*9TKY#0A=6\[D&U,!T7R3
M6B-;-;N%O]]^^]I1]M9;KPMB"$58,PR0H\ZE72<PJ7U2>;1/X1#T)5-=,->I
M#TW;@?RK&GMS]E&+AJK\OH W+;R4!)PMQYB2NPE0;ZSET6IYN1:9RX5DMV+Q
M8<[QV(XR*U5GJQCI9VTYY8MJ1%-%8I)-;381W\L# ,OLI1H(,R+G3 I50Z84
M/ ??U@[ #71UA^'EN> 7R'$XHN"![6$ "SH129H7G'5"IW?\E73"IY!C1,D_
M>/@%4@XY[-VP<ON0"]VR [,T!TSS5HOQO(>)9FD6]U79N5L<@63A(>/-2\"[
M[(BSLH+1E/OU[2SF^+G3MB:]SZ.Q63TNBAS;U6,MA3482@_)")YN8]_>"P56
MM;0F=N$\J8101&4-3N$4J(131&4-CME<I\1D1&KW\4+.S*9_R* GJE"VJ[BY
MP8'%B)3J@;,7 CJXG#V!S)V%&X"ZDYN"DD>CRCW0BWK1(VO[?\=D<3V!;K^W
MV_F%>K/> ^:$@4)\+FLLUWC^4Y,+JS2Y,MQ-358AG2R#1V$9G(U(5)WD^4BC
MK_2CBB0I>XQ^'P(EO@15)34]B(-)=Y5&OKB)S#0B=D?)7IB.$+&\-R%]KJ#E
M="#<;^BO,>03/DDZ@=\I3F2'%6, ,P/Y)VT(3A_J.E)(4!I2%?2QIV-PYF,\
M%#? <^D5G1":(_H0#RCQNZ,1J#9\KK0R#)U$[LR8.\:&5W1'UXO'4?)AR /'
M 8D#47!PKCKQHV0 O6&\AR<Q]\?@7MU1OJE44B&&MI(--9UPL5-IN45&N6-)
M=?[G.U!-9L_^2@OOO[U8DFR<5FJ@Q*4/'[XWZ\CL]UTZS?I1^OJ[E9(^?C?&
MLZ+*'!&0>DIM,@!VJ><M3N=V1S*C/J*(IQ(Z)_<+E:_P;%?:31G8V_9K5HA2
MXC.C=>P :GX:8G0.5</"-4/-<5,S0U4QL'DP8E474UOCNH'%PWSJ\HU28$UC
MU\PH)_TP,R,5 ^OQ3EUFR@US2A*+9P%,RD5*0$:D-AW=M-ZABP.&]%8/I>Q2
MQ5#BW9&9=0\TJU/D>J01"XL/HW>K/V@>3^_$S"'P6Q4&0YQ9NH,=NMZY!) 2
M?"]6;@U/J13??/3*L#WBX)9.T4V&N2Q3]P9\G8R7&]$5G5/;2 [P'@S;19?V
M"X@A(QW,;J!DT/P@ZF-?OI]">L]\DI^?[X3D@:@?D^3S6!^I_,*3TR*;V[DN
M\8AQO'F-HMO;3VSJ2V:;V_IR^BG],=2UID]S<WO']:Z:R*Z_R[)Q%;!I5-A%
M"X:\*Z>:3  XJ&K2O)U1C=[9C=!KR:NXCC!^;]2W'_47JH"__DNB,0F[(?X?
MI#XIUM78T5C6X/?6T0TBO$+OF]G'EI(T*D.089=BL'2P-DU"'![*RQPAW:)X
M^8U\96I[!&XG-0D*?1QS%C^/X0>NR*G%7>S-0(\KJWIK'3HT;W_[:[A=@O .
M\[018T>5<N EBGL BZ>5PXWXFNG!2G5O.!ULE_3>KO,WTM?!PGY971VJ8Z?R
M@!X[S"M2K:\QBB[X5+RQ0FZHP$(D,_P-KMB+ HT IZ_0A1_SJ\M48-U>098%
M^XBF&]4YMU\]4A:;W$P30VQ9O%5W:^>NT^^P*(WV%C_/SY7/GY)"F%59K].[
MN$O%IOG#[<*WF'UP,EFI_BW+15-#'@X=T>%O45='\NT%33[!H>5:!%VM&//O
M#]VK-AQJY=!1'%JR@M"EE2^?SNX5#65=O(#(J;7PF[WXWO:$5'"9Y [OS7)Z
MJ;P_W'W>#%O16T(=$G__ZZ<= G.H5X-4-&B:W*AM/3X>[4+M)6T/!XC "'!0
M".@/45DGJD8P/;IN@/8>#/3Q%=,7? =6--[A8A1G;J7^YJ_=+C#IW2&K&;JM
M!*7M[C7J6^QR@__B<_G? !A^^C]02P,$%     @  H2E5(X]_FB7(@  ZW0"
M !4   !L8G!H+3(P,C(P,S,Q7V1E9BYX;6SM75MSVSB6?I]?H?6\S-2N8SOI
M=$]2DYF2;UE7.99*EKMGGU(P"4F<ID@-2-I6__H%2$J\ @0ED#A05-75L22
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MK+^')A=DO=7&PB"M&$BYN(V%H9TPE/&+&PO%/KN$T+=N+"+-^X/8&:^6\0_
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M$BV-$9G@3>UOP<T;L\VQR]B/%HFC1>)X*#T:5OJ%.,!4RB^&GGV-7[#KK^+
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MZJHLSCG:IE^S_[$#Y#_^'U!+ P04    "  "A*54)3RLR3I]  !G! 8 %0
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M(-Y\VH:!?2^=3N("6+2YK?:D,X7X5]W%WQX&:[0>3%CYE"99!IMCP?DR0U,
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MT!* T8(?^2I)^3QXL4FY@]">B,&T<<?7-CW:)\FNG \"^C;0Z%-#5]@_(/<
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MY1],0F1OX*N0Q%2>HP.@1&V?HXT3M 0^3*=.W8 3G$:H<:>4V6K;$>7O6_Y
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MZ,.9%WM.N"/:=E/ZX]A3&%59_PQ366_7M7?"[N_^Q/':"MEM0:S-G3R"2HN
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M+(#9.XX>B6C/T4D)\?465,RW6>#2?^B*-R/Z/,O#-=F?7*;>.N=(@X*Z#%^
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M (\ IWW"$ODY.IR $_W,L-C1]RACRY8A3BV(4&.[BL^"30B*0@_4N>J;7(Y
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M-SYLDYO ;?+I61)C]8^4!.3;,/OE#-3,,,=_.]@)IU%D2.B$":+R/\;$*G+
MIND0UWG%J@TEHV-A2E04%%6Q^A8>'UG:I1\,JKK%""=D#*N_(ZYV'!GR6MY1
MP=18[):"#^5PGG##!H%=J </<V]%<L!9U,*4).Z0.1U83-2]$A[12_C;H>]
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M;:'7%Z'_X:;JK_*7!-D&*4Y\ZM'.K(F88QW>$.)N$KCSH_\.-V?)\M"HE*H
M)V@R(,J0ZM2Y:))%G;,B2E[#*%24=1  3J0FBK.ZRLCN.5^Y;6B>1,8U#&C/
M^1I1=,6DAY]KEN9_F8<YPNU>@1CV%"ZW0=0CKX9HH:174G.683/8W/7%KF'@
M*&3UR26B&DKA:!FFDUG1NO)V2?V2.$8 Z.J)'\4%?WQL[FI, L1?UFQSJRPM
M.%]FB!*$T,ZH$E_%H*&! +B]C\+%;+7B:>_4:92YU5 B_$T.PL0H3 WSYNIF
M]OT1LFM&I.N,AI+1C6 TD0,<(8]1'7MJ!-L'=1H" )LL#T$;'3JG0"/-1LLO
M&)B?J)65$1S&W4-LQXLM/D9NJY8IPHC<9A+MJR:2>)SKA;!)T22$R;=4?7"0
M.T4CJZHV'@L_]G=@H3'EK%2C8JH9[<I,(+N1^&?#H/.L#(R[;1G4*J BY5C'
MS;G<M)W"FRN9=>SFFU@!_3[JM0S.3>-W"O1/E$E'C2V)4:;N88"0%==+6LX!
M/OI"9%O0IK2ZU!V1LWMYQ ^"('_RANYUE.OMP,K2"/>EL301&'.C_,X@F5M&
M 1Z'.5J#S%QN@$JU(Z?Q;J7?XI8_A#A,G".*4#^_2TG+$2314-.N<;0XGSO9
M_V?I0Q"'?Z.##><K2Z)P*2ZJ> FZ7J9\)QI^1O$<BCIW/5TR^@10P"UG0+?%
M1IN#B;E;0/%FKGPYXZ^-W+W&FA@C,QB:Z6.SV8J50"3E\#)!T)7;:/RE,0S5
M4UX?TQ:3T2*($GMKC" 6Q>]ZR4 E92I;JEEG-F9-6GQB%QH^(VKZ\ (EL!:T
M-@39/;IQ<=B%B>K61*+]"<+."PO?P8*!EC2@Q4U09*<>S&T#,F,D<ULX<ODD
M4S01V;/X>9 '_2+HY*NLT40@\L!=,-W0?-2(&#Z8D?$C9_"OLW2>/!]J.:F&
MHR!!EJ0,24YZ_DTQ-6Z9Z*V9%A#WH!ELUT*W*[13OYIF64B :9,[*;5-MPKC
M=);4V%Z*^2A<<?:&X/P=>$;Q<,S3 .,%[E[7]\FA%GQ)@PDB$YRG$8#C>+)E
MOB3EY-P$:?Y*H(=X7\,F*4MW]<4=D2,P&H+I8QCUP4;)R7;(K>EK2+G4 T@&
M/H57+V W<$+7P8)O\W 11!G%+SO0+5M<?67%.*?805J1O#&P@]PS&W7RYI9%
M\49&BFJ,^_D:+V6".5]>O"PP@XQ4EWXHG3@D"[%L%S'O.K3>+8<U6_I;Y"\J
M66N+5M.'9&),J?%.T>AS'<;\"OY];X?9K\1>>/#Z#&DSQ$DPFL4D#8<'K]'@
MQD.G"X5RZG6"$ R/2<Q[I<\2&49TG&6\#C%=XUH?8<Z[.!%W&/$,"EGV=8-%
M_#Z\>_^;=Q]Z&?$TR(B".!/4&9)_^^[#"/8\)QP:LO3=UQ'9<50S2W-!]]_
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M0N<_#Y_")8^7$R^!H*9YC 40^BRQ8256:_ :\FB*6(\B5$=S9=/!F(.Z9J!
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M.SR(IL]KJ5KR3(NYJY3QI;(6NAL$N*I [0Q#T>=RV.*(:)KH9:U[?_;KZ?L
MM)D+LQ9[X2>,[2G03P;/91]N>-\+'>"-0!<@1D+-5IK#V"[WMO?R#07"UYL$
MA.]7B6+>8@MK:.X;N(\FU"1/FBU\7DN55424E!T/3DL(0Q\ZWD60 F&KE"VH
MAI+%1FYI/<W8D^LZWWO7/KY5 0D@9K_/S!:^K^3Z6CRD\'[AS_3+/D5\S(Z^
MF:M]6;N_P;ZW4LHW0;B4&?5P,Y&!OA6ZND,W_XQI5N-SS,?C\5("(IPG412D
M]C"DSIU];[Y"!:K?7!J"=":#QCJ VO2G.LTKO]'<WM;'^W;>3;";K<Q]*AP#
M\ <./UJ+EQQ&R?=&[QEM,4JLTM2"DBQAI#7PWG6KT;WW!.148:Q%RP9:]&!V
MLL98-RCT?0CXOMI,6\[L/@_0SGD57[PL'G&?7B:I)7RV]M8[G)QO5P7)&O8(
MBJEXXJ[BS3;/KA&\J"&,M*&Y[YNWJ9"F+@DH(U!]M-S>5+RS+5WIC7KB;BO?
M#O?2I%MK9:CUNK?T\7W0K<9]S'Z6&(OP7W\,\\<PGL6$K&=4CJF])'I3G0#N
MV']M05KE:?1ZRS<PLVKTCZ795$[6;*5JD#0*YDWM?6_-^@" AFR!I@X>-Y3<
M_:_O/]P3A$UU)U5_]R_Q5>-QF[#=&IK[M"YK:O9VLXEHCP>1VN-7\2I)US)T
MA%33>2(BH^P*_(!D)R@^_;2?^/33-,2G@QUO]'\(NX[*>*O!U\4X7N-V4AX'
M\^=D_IALLP#AZ9]@PIS'UTG\@'[=*P)WA0.-<[:@AQU"9 +!2M?\(8C@:Y2Y
M91UBEAH[3>$0'))\3?_WLTAZ)54UDT$ZP8/=S3WT0%.Y"C^^[@9BTDUG0\[I
MUM.K@[4\F_-G6&WI(.URMKMW/=;-?_&R"05X=4MAG2&(3V63:P_X^_W>^_?3
M^-I-AHZZXK4DB6KUC?:VGG0A.CTQ]V,0H>/A[I$CP/R@HNXAI'U;=<UOV*5,
ME'\0G5*]2C&Z):]4?&A"5&SH,*TXJ^L0_B'2;DJ'6(> J]I^OJ^FGNXM,P20
MJGBX\*+5#.,]R4Z*T<)^)K >\EV4_Z:VOLN=%3F]I.E9!,;=5AYS+^] D M@
M"WR-LPU?A*L0'K\=];>QH><U_YS$_/5SD/["\\MMO&RX$.M;'NMUH03QHD <
MQ0;-'X.X2RPQ_8AU< L9;]!+9NC)><^=N6\ @-U!4]RCF^\PX4K!Z0[9HRU=
MO$M)17RLJLXSBX4$;XM)L#3W?2\40K=*XY<9C98S*8I=4UJ2S';\&QQ).EWH
M1LLZAJ(-/)AO/VT73'B1S++D*:9X8^$@]$'6>G /IN;;@=9>=:<1>JM;9^]W
MM(BLHPW8$%-;U\Z[V(BK6$8YR,-E=T,T=O!::"3EC75&C)^]KWH."F.6P\G%
ME[@KM$J';KX#$I/XB7#$M-?-?K[MK;W'XNX"DIQN\\<DQ=>FCI7F'KX?].'"
M7L<NL=MQ:*_FSYXL=H38MR;(CCR^1X/!9YC7>KO>O5!V?O2M"@09%K3$?Z Z
M^@0J5PL64',/W_>'# XZYQLL,5)[SLTFWH5O= "416X:%M[2U.>%@O5K,5#S
M*S1+,5P;5?@&];AS)]^ZP"$1F8U&HGX4IP4/42#3--3#W861/I".;S&1/VNE
M9M,DAG]=B""F67I&:0G$2-$BC!?AIL'<U8O@D1R+.YAXQ%7)>;11-F(V]:;J
M^]$9R0#LT_CL\P:RX"=11%T=>-+NW;,W!;^/J@F14YL(1<+ [#X*'P)K.FE_
M:K[Q+&NMB"@ME)4J&V$K]^COF]4^")L=2Y<,/897E*8D_04/[6[1Q9J?O<L0
M7;-7#RC$TD#%M]NLBY<$#6NBK (^2MD\P?P [7<T0'])\C_QO/2AU#K<7 TV
MA:H(6GSIJ0HQ!16A4X!J+T+>@UTNPXBG9W '/22ID3!H:>);0!8:#4A5VQ3C
M_KJ:R[OT\^X(0&_*/'CIX/VVM9U /@,>]VW.4QF!:=56FYM/(-^R])M>PE]V
MXK\LS7R?#SBQRS#:XBU3JGD@B$9;>-(0!40LN!1#JE$4UTWYST/1]JU,EDBB
M_1BR6B"&'<'W<@T:X3EN_-=11GG=<J$_JLV@13Z@EKVH-[JW]_+M1\50#=*$
MR YR Y)@RO-0H,Y_Y#%,4IDD:YVJW;L?LP.0=J.THY3^ML']?/7#>!=&+UX(
MC"NL3X-J:C>5C*92B6]4-9O:3RF J35RR:<'.'AI\ #K/WK?UV<<SUET%2_Y
MRW]RBYI5:>2USJFX)>;)S39=/,(=TAC"T['+%.280Y(GC=J4 NI-8B7:,V(&
M'F<"(0S5:(1X>?>8I+G(JR]*R#47UMN?S!1L0P.%+:'QH58 M0796&U,OB8T
M@5VX&Q;3I:!CEX[^C3_UOON[( I2"VAC:R?O3!4G^BP*LHRRM3Z^:MM*]S6W
M0]7VH>==!I@'+U=+-/^",B9LY;6ELAL;^_8WD!4;+YTDALG9 \-K&_K6/XVH
MW)L@G:7D>Q, X\KB4JMZ=NHY!?'FD$>A4$5.LVR[5B^$*+_]<Q(!&<PK033L
M04TSW8?UOF\L);4ZO#Q=^_K>.SLHD%^27"!!4YY$6>+A%C]O;4&J?6GXMI.+
MAQ)V)/2(X+JMA5QJ;^W[1G;EE!6"X662:C4+:[_[N#/P:&XX>PSY"D3G!1GS
M9RMXF7E:;WQH:.K[I!]Z79OZ:'/^R^"#^#2%7*Q6'.,^1*':\\HS:&ERK%_9
M,$'@>R4?Y'F"?_*8^M-O1KX_APKQLCL,C1:^ ^6,F+[6DGNUK\*^-+QK9QCC
MTJ20E;_[WDR'GJ3K1FCSWE0GYC1M M6J:SF%KRI+]M&5U:2/6AO[1M,"ZK/5
MZ3*A.]O^!>K:^58'RDK?('$V9)#8P)3V(N!;HY6QV;($IBH+9'7X-;7W_59A
M+$")[UN8!VO?)$M;[T;2&B,N;IU,IO9WMOSJG8Y!+VW%;VE\L@8>PG>6:IDZ
MH4)3FQ)5K:U]!P\4X0RSE?X=9'0G+?F.(-'L->Q)TK?3JDNUJ6;OU5X4?-_'
MW8M13:O0E,"%*5# 9RMUPU[!1JO!8;<WG<"&:P5;F5ILAK*OILF*9QF53+&
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MV:\X1$D>O9G-'13KBGII:8DB.8U:7%Y9#Y>,J&X[P"V'1TQ R_CF3P<P:45
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M2>MR,9%*4O%5"C%O\A_BYO33=T7-2;L+T2HZH0M*PK+,:#?_!WM6[*ZZ)[:
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M<@Q6[4G49!=CK#<K37M>L?>Y4J]U,^@1UOC49'GM_"[E4&*J,M/9>@W!VDG
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M+K.ECF68Y#XY\YK< 69ONGJ7@[QNINQ^/EIN$!D%6N*I:[F%9"Q@#Z>YY3:
ML? <Y^IK*Y!TM41I&LRG'-4P>[K3D/?K^^+*,\4H381IVZMT&&,>T/\J9:GR
M:AQ9I5(0@I6?6%0?81'%"6C/CVU]X'12%@ESC<8-0::A0O\IQ1#B@N)9^?$O
M3H*8OGABNOAE\\[<<1!];P&222VJP4 2M853=K[*?DE9K_[CZDND!V&,967H
MS9,-@)CS($C\/!"ZX#QV@3^9$73+:K'=>/#!=-@?EE\;Q %4N.<LOS'(8RJU
M:<>X'U"5B.(7^'^XNN1__G]02P,$%     @  H2E5(M_-3W0)0  &S<!  \
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MI'==]*Z+KRX&OJ[K(MLWU\4U4'(FB9S(<\ "SRIM]B!B3B@HTP[*  -NG!;
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MHZG( H'+UBIAT1-P#^=*U[98(F ?#"OI"R;#S7D;G:;M_"'"!U(\O7MQ=(\
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MQL[JZN*57RND&=;4*K<3M1)(FSX":=P$C)!8V-N!BV'"+Z0!88Q,Y4H8:BR
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M:TPN7!Q-+TH/+(13^(Z2;3$[&M8UB6! >%M"GK#(?$2&$>^DAF:B='BAJ-,
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M+8(T*))HQOCR"+_/\8#'RII-P+C55\?$J>4IN]I$MO3]FP[G9D=/PC!N?#^
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MXQ-VCL#UB'[MIE,OM+E^-M=BEVZ9-Z%-_W-3VOKZ6[SV5B[9(%P_0[C^RC3
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MKW^(T'H_W9KO?GSE5*NC%B(IE&JHE:G 2P4#X!HE?2DQXD)NO8_!#:1_7^"
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MW8JG8_%L+)Z/Q>D)_'L*_Y[Q%IX^]*1!YL)S)G0&T#UC6%$1JZ@PY*-,F42
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MM]?GPW,D'GP[_:5_\?<!ZY\.V>47UOS4/JI5*GDQE?1O6/_L\FHX.%NV>=*
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M&P-31N\PKV>ZB-:NQ6!O Q8-_!\"?%[#NR;EAM!-0QBHV3QR;W ./A?<6&+
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MO5=ZY](KRR*>)U%C.F+.-51I!##RJ)C2F;;I5._(O9BQ=V1?Z?@_4$L#!!0
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M*(4NA?6[)GD&X(>X==JVU3D]:9W9S4ZK8[</5>XQ"U]XX 2/#=HO: _.QZ"
M/'H$<P:AQ(.8P)1N2RUS\F5..9E!!Z&D(?(X9#6/,(0,CJSVD7]<RNE>^:7J
M<TU99\U6)LQ9&D9<%1M*=0&D^:-6V2^M,OMUJHQ&@1HQE8YZ!\,Z?#B:JJ:0
M(*8JG8,]0JFMIM[&C"'H1CC%#+0H$I"?J*6] AKAR%/'84"?ID.K= NMYBR5
M7)P0GDXI"GWF.=_<H+NU.S4#B&J=';H)]GT:34LIOK1]J\9U!WN[UQTDGC"R
M+C;AN8S=2<Q]PE-K "E04MK< ->-YZ "NH2PETUE-=+(E7< %V4X$<01),%
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MOY#T/U!+ 0(4 Q0    (  *$I53+GX5O+ET# .+L!0 0              "
M 0    !I;6<X-3DQ,# V7S N:G!G4$L! A0#%     @  H2E5+M_GAG0O0(
M;[XC !$              ( !7%T# &QB<&@M,C R,C S,S$N:'1M4$L! A0#
M%     @  H2E5)2O2W[<#P  "ZL  !$              ( !6QL& &QB<&@M
M,C R,C S,S$N>'-D4$L! A0#%     @  H2E5.A**V5-"P  !I0  !4
M         ( !9BL& &QB<&@M,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M  *$I52./?YHER(  .MT @ 5              "  >8V!@!L8G!H+3(P,C(P
M,S,Q7V1E9BYX;6Q02P$"% ,4    "  "A*54)3RLR3I]  !G! 8 %0
M        @ &P608 ;&)P:"TR,#(R,#,S,5]L86(N>&UL4$L! A0#%     @
M H2E5%6.ZFS4.P  'I$$ !4              ( !'=<& &QB<&@M,C R,C S
M,S%?<')E+GAM;%!+ 0(4 Q0    (  *$I52+?S4]T"4  !LW 0 /
M      "  203!P!L8G!H+65X,3!?,BYH=&U02P$"% ,4    "  "A*54D1C!
M7.DW  "8^P$ #P              @ $A.0< ;&)P:"UE>#$P7S,N:'1M4$L!
M A0#%     @  H2E5/2=3%6)"   S5$   \              ( !-W$' &QB
M<&@M97@S,5\Q+FAT;5!+ 0(4 Q0    (  *$I51]).+@D@@  -E1   /
M          "  >UY!P!L8G!H+65X,S%?,BYH=&U02P$"% ,4    "  "A*54
M/C,NL@0&  "75   #P              @ &L@@< ;&)P:"UE>#,R7S$N:'1M
64$L%!@     ,  P ^0(  -V(!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
